sorafenib has been researched along with Cancer of Liver in 2970 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 118 (3.97) | 29.6817 |
| 2010's | 1825 (61.45) | 24.3611 |
| 2020's | 1027 (34.58) | 2.80 |
| Authors | Studies |
|---|---|
| Ji, H; Lai, Y; Ling, Y; Peng, S; Tian, J; Ye, X; Zhang, Y; Zhang, Z | 1 |
| Abdel-Aziz, HA; Abou El Ella, DA; Abou-Seri, SM; Ali, MM; Aly, MH; Eldehna, WM; Fares, M; Ibrahim, HS; Zada, S | 1 |
| Chen, Y; Han, J; Lv, J; Song, Y; Wang, C; Yang, C; Zhang, L; Zheng, C; Zhou, Y; Zhu, J | 1 |
| Abraham, LJ; Callus, BA; Diepeveen, LA; Dwyer, BJ; Elsegood, CL; Finch-Edmondson, ML; Kampmann, SS; Kong, GS; Olynyk, JK; Passman, AM; Stewart, SG; Tirnitz-Parker, JE; Woo, K; Yeoh, GC; Yeung, SY | 1 |
| Danielli, M; Giri, GF; Marinelli, RA; Spanevello, RA | 1 |
| Chen, C; Feng, Y; Huang, L; Lan, J; Liu, Y; Lou, H; Ma, X; Pan, W; Wang, N | 1 |
| Huang, CF; Liu, HS; Ramesh, C; Su, CL; Tseng, CL; Yao, CF | 1 |
| Al-Tel, TH; Hersi, F; Omar, HA; Srinivasulu, V; Tarazi, H; Zaher, DM | 1 |
| Chen, D; Goh, WH; Soh, CK; Wang, H | 1 |
| Bai, M; Chen, JJ; Dong, SH; Huang, XX; Lin, B; Liu, QB; Song, SJ; Xu, W; Yao, GD | 1 |
| Chen, W; Gu, X; Guan, M; Huang, X; Li, X; Qiu, J; Zhang, Y; Zhao, Y; Zhou, Q; Zou, Y | 1 |
| Alach, NN; Anbar, HS; El-Gamal, MI; El-Gamal, R; Khakpour, MM; Mohamood, NA; Omar, HA; Sbenati, RM; Shehata, MK; Tarazi, H; Zaher, DM; Zaraei, SO; Zoghbor, MM | 1 |
| Andrewartha, N; Buyan, A; Corry, B; Nutt, MJ; Stewart, SG; Yee, YS; Yeoh, GCT | 1 |
| Banoglu, E; Çalışkan, B; Cetin-Atalay, R; İbiş, K; Kahraman, DC; Nalbat, E | 1 |
| Cao, B; Cao, Y; Hu, K; Li, F; Li, R; Li, Y; Ma, X; Peng, H; Peng, T; Sheng, Y; Sun, H; Wang, F; Wang, M; Xi, R; Xiao, W; Zhang, G; Zhang, H; Zhou, Z | 1 |
| Gong, C; Huang, J; Liu, Y; Tan, H; Zhang, J; Zhang, Q | 1 |
| Abd El-Meguid, EA; Awad, HM; El Kerdawy, AM; Moustafa, GO; Naglah, AM | 1 |
| Cui, S; He, Q; Lou, S; Qi, J; Tang, Y; Wang, J; Wang, W; Yang, B; Yuan, T; Zhu, H | 1 |
| Deng, X; Jiang, W; Li, Y; Liu, L; Luo, T; Wang, Z; Xie, L; Zhang, X | 1 |
| Chen, XG; Du, TT; Ji, M; Li, L; Liu, WQ; Liu, YC; Wang, R; Yang, BB; Yang, YD | 1 |
| Chen, D; Chen, L; Fan, T; Gao, Z; Jiang, Y; Li, Y; Liu, Z; Qiu, Z; Wai Wong, VK; Wu, W; Yang, M; Zhang, C; Zhou, Y | 1 |
| Abu Rabah, RR; Al Shamma, SA; Al-Tel, TH; Anbar, HS; El-Gamal, MI; Elgendy, SM; Omar, HA; Sebastian, A; Shehata, MK; Sultan, S; Tarazi, H; Vunnam, S; Zaraei, SO | 1 |
| Charoensuksai, P; Chuaypen, N; Limpachayaporn, P; Nuchpun, S; Sirirak, J; Suksamrarn, A; Tangkijvanich, P; Wongprayoon, P | 1 |
| Brzozowska, M; Gotlib, J; Małkowski, P; Panczyk, M; Śliwczyński, A; Straś, W; Tronina, O; Wasiak, D | 1 |
| Gao, L; Ikemoto, T; Miyazaki, K; Morine, Y; Saito, Y; Shimada, M; Takasu, C; Tokuda, K; Yamada, S | 1 |
| An, Q; Cao, X; Chen, J; Luo, Y; Niu, B; Qi, F; Qin, W; Shi, K; Xia, J; Yang, B; Yu, Z; Zhang, Y | 1 |
| Cai, M; Guo, Y; He, M; Huang, J; Huang, W; Lian, H; Liang, L; Lin, L; Zhou, J; Zhou, Z; Zhu, K | 1 |
| Hu, J; Huang, L; Lan, H; Lv, Y; Shen, X; Zhang, G; Zhou, M; Zhu, Y | 1 |
| Hsu, SJ; Kao, JH; Su, TH | 1 |
| Iwamoto, H; Kajiwara, A; Kamachi, N; Kawaguchi, T; Koga, H; Kuromatsu, R; Nakano, M; Niizeki, T; Noda, Y; Okamura, S; Shimose, S; Shirono, T; Tanaka, M; Torimura, T | 1 |
| Araki, M; Ikegami, T; Kamoshida, T; Ochi, M | 1 |
| Bargellini, I; Berg, T; Gasbarrini, A; Iezzi, R; Klümpen, HJ; Malfertheiner, P; Öcal, O; Pech, M; Peynircioglu, B; Ricke, J; Rössler, D; Sangro, B; Schulz, C; Schütte, K; Seidensticker, M; van Delden, O | 1 |
| Fox, C; Jemielita, T; Liaw, KL; Pettersson, A; Salomonsson, S; Widman, L | 1 |
| Abhilasha, A; Narayan, S; Pareek, P; Rakesh, A; Soni, S | 1 |
| Chen, J; Wang, J; Xie, F | 1 |
| Abdel Wahab, AHA; Abdulla, MS; Ashmawy, AM; Ayad, EG; Sharada, HM | 1 |
| Hu, HJ; Jin, YW; Li, FY; Lv, TR; Ma, WJ; Paudyal, A; Regmi, P; Sah, RB | 1 |
| Li, Q; Liu, GL; Mu, W; Zhang, JG; Zhang, X; Zhou, HM | 1 |
| Ben Khaled, N; De Toni, EN; Denk, G; Geier, A; Op den Winkel, M; Reiter, FP; Seidensticker, M; Ye, L; Zhang, C | 1 |
| Balcar, L; Bitzer, M; De Dosso, S; Dufour, JF; Ebert, MP; Finkelmeier, F; Fründt, TW; Heinzl, H; Himmelsbach, V; Hucke, F; Kirstein, MM; Kütting, F; Mandorfer, M; Meischl, T; Mertens, JC; Müller, C; Peck-Radosavljevic, M; Personeni, N; Pinato, DJ; Pinter, M; Pomej, K; Pressiani, T; Radu, P; Rahbari, NN; Reiberger, T; Rimassa, L; Scheiner, B; Schulze, K; Shmanko, K; Siebenhüner, AR; Spahn, S; Stadler, M; Teufel, A; Trauner, M; Trojan, J; Vogel, A; von Felden, J; Waidmann, O; Waldschmidt, DT; Wege, H; Weinmann, A | 1 |
| Buechel, D; Camargo, FD; Christofori, G; Coto-Llerena, M; Dill, MT; Ercan, C; Gao, R; Kalathur, RKR; Piscuoglio, S; Shuang, S; Tang, F | 1 |
| Liu, X; Yi, Y | 1 |
| Chan, BKC; Cheung, MSH; Choi, GCG; Chu, HY; Fong, JHC; Huang, Y; Ma, S; Mak, KH; Pardeshi, L; Tong, CSW; Tong, M; Wong, ASL; Wong, KH; Wong, TL; Xu, F | 1 |
| Bieniek, A; Czarnecka, J; Grzanka, D; Kloskowski, T; Nowacki, M; Roszek, K; Wierzbicki, J; Wiśniewski, M; Ziętek, M | 1 |
| Bargellini, I; Benito, A; Gebauer, B; Iezzi, R; Ingrisch, M; Loewe, C; Malfertheiner, P; Öcal, O; Pech, M; Peynircioglu, B; Ricke, J; Seidensticker, M; Sengel, C; Ümütlü, MR; van Delden, O; Vandecaveye, V; Zech, CJ | 1 |
| Dai, Z; Han, Q; Jiang, M; Lee, TH; Lin, J; Liu, H; Lu, KP; Peng, R; Wang, J; Wang, X; Zhang, B; Zheng, M | 1 |
| Chang, WI; Chie, EK; Jung, YJ; Kim, BH; Kim, YJ; Yoon, JH | 1 |
| Aino, H; Hiraoka, A; Itano, S; Iwamoto, H; Kajiwara, M; Kamachi, N; Kawaguchi, T; Kawano, H; Koga, H; Matsukuma, N; Nakano, M; Niizeki, T; Noda, Y; Noguchi, K; Ogata, K; Okamura, S; Shimose, S; Shirono, T; Suga, H; Tanaka, M; Tanaka, T; Torimura, T; Yamaguchi, T; Yokokura, Y | 1 |
| Liu, HF; Liu, YW; Song, CX; Xie, BH; Xie, YK; Yang, Y; Zhang, JH; Zhong, BY | 1 |
| Wen, J; Zhao, M | 1 |
| Ao, J; Aoyama, K; Chiba, T; Iwama, A; Jin, J; Kanayama, K; Kanda, T; Kaneda, A; Kaneko, T; Kanzaki, H; Kato, J; Kato, N; Kiyono, S; Kobayashi, K; Koide, S; Kusakabe, Y; Ma, A; Maeda, T; Maruyama, H; Mikata, R; Mimura, N; Muroyama, R; Nakagawa, R; Nakamoto, S; Nakamura, M; Ogasawara, S; Oshima, M; Otsuka, M; Rizq, O; Saito, T; Suzuki, E; Yasui, S; Zen, Y | 1 |
| Jiang, X; Li, L; Xie, S; Zhang, W | 1 |
| Gong, C; Han, L; Li, Z; Wang, R; Yang, G; Yuan, Y | 1 |
| Castet, F; Finn, RS; Heikenwalder, M; Llovet, JM; Maini, MK; Mazzaferro, V; Pikarsky, E; Pinato, DJ; Zhu, AX | 1 |
| Cai, L; Chen, K; Cheng, Y; He, G; Huang, W; Li, L; Liao, H; Lu, Y; Pan, M; Tang, Y; Zhang, D; Zhao, L | 1 |
| Fernández-Palanca, P; Fondevila, F; González-Gallego, J; Mauriz, JL; Méndez-Blanco, C; Payo-Serafín, T; van Pelt, J; Verslype, C | 1 |
| Chiba, T; Kanogawa, N; Kanzaki, H; Kato, N; Kiyono, S; Kobayashi, K; Kondo, T; Koroki, K; Muroyama, R; Nakagawa, R; Nakamoto, S; Nakamura, M; Ogasawara, S; Saito, T | 1 |
| Alisi, A; Balsano, C; Braghini, MR; Conti, AL; Crudele, A; de Billy, E; De Stefanis, C; Gnani, D; Leonetti, C; Levi Mortera, S; Marzano, V; Panera, N; Pastore, A; Pomella, S; Pompili, L; Porru, M; Putignani, L; Romito, I; Rota, R; Scarsella, M; Tartaglia, M; Vinciguerra, M | 1 |
| Chang, WT; Chen, KY; Chen, SC; Cheng, TS; Chuang, SC; Chuang, WL; Dai, CY; Hou, NJ; Hsieh, MH; Hsieh, MY; Hsu, CT; Hsu, PY; Huang, CF; Huang, CI; Huang, JF; Jang, TY; Ko, YM; Liang, PC; Lin, CC; Lin, YH; Lin, ZY; Tsai, YS; Wang, CW; Wei, YJ; Yeh, ML; Yu, ML | 1 |
| Chen, Q; Deng, CX; Feng, Y; Lei, JH; Lu, L; Lyu, X; Quan, Y; Sun, H; Wang, H; Xu, J; Xu, X; Zeng, J; Zhao, M | 1 |
| Frenette, C | 2 |
| Cai, J; Ding, J; Jin, Y; Xu, Q; Yang, R; Zhu, C; Zhu, F | 1 |
| Becker, D; Binder, H; Breuhahn, K; Castven, D; Czauderna, C; Galle, PR; Hajduk, J; Heilmann-Heimbach, S; Keck, T; Keggenhoff, F; Marquardt, JU; Pereira, S; Schmitt, J; Shah, V; Thorgeirsson, SS; Weinmann, A; Wörns, MA | 1 |
| Fujimoto, N; Furuta, Y; Kawasaki, T; Nagaoka, K; Naoe, H; Narahara, S; Oniki, K; Saruwatari, J; Sasaki, Y; Setoyama, H; Tanaka, K; Tanaka, M; Tanaka, Y; Tateyama, M; Tokunaga, T; Watanabe, T; Yoshimaru, Y | 1 |
| Fidelman, N | 1 |
| Abdel-Rahman, AA; Alswah, M; El-Adl, K; Omar, AM; Saleh, NM | 1 |
| Andrade, AC; Castro, ACG; Farias, JPF; Garicochea, B; Gil, RA; Jácome, AA; Lessa, MAO; Lima, FMT; Moraes, ED; Prolla, G; Silva, MHCR; Vasconcelos, JPS | 1 |
| Wu, G; Yang, Q | 1 |
| Fujihara, S; Fujita, K; Goda, Y; Iwama, H; Kobara, H; Masaki, T; Morishita, A; Nakahara, M; Nishiyama, N; Shi, T; Takuma, K; Tani, J; Yamada, M; Yoneyama, H | 1 |
| Dituri, F; Giannelli, G; Maruccio, G; Monteduro, AG; Piccinno, E; Rizzato, S | 1 |
| Breder, V; Cheng, AL; Ducreux, M; Finn, RS; Galle, PR; Ikeda, M; Kaseb, AO; Kim, TY; Kudo, M; Li, D; Li, L; Lim, HY; Ma, N; Merle, P; Nicholas, A; Qin, S; Verret, W; Wang, Y; Zhu, AX | 1 |
| Chen, QF; Deng, HJ; He, M; Lai, JF; Li, JB; Li, SL; Lyu, N; Mu, LW; Wang, X; Zhao, M | 1 |
| Hu, SH; Lien, RY; Lu, LC; Lu, SF; Tung, HH; Wu, SL | 1 |
| Abou-Alfa, GK; Assenat, E; Begic, D; Chen, G; Cheng, AL; Choo, SP; Edeline, J; El-Khoueiry, AB; Finn, RS; Furuse, J; Harding, JJ; Kelley, RK; Kudo, M; Mathurin, P; Melero, I; Merle, P; Neely, J; Park, JW; Rosmorduc, O; Sangro, B; Schott, E; Sieghart, W; Tschaika, M; Wisniewski, T; Wyrwicz, L; Yau, T; Zaucha, R | 1 |
| Reig, M; Sanduzzi-Zamparelli, M | 1 |
| Chang, HP; Chen, CJ; Hsu, WL; Huang, LY; Lee, PC; Tsai, HY | 1 |
| Chang, JC; Chen, D; Chen, MM; Chen, X; Deng, Y; Gan, B; Hang, Q; Liang, H; Liu, X; Ma, L; Martinez, C; Mei, Y; Rosato, RR; Su, X; Sun, Y; Teng, H; Wang, Y; Xie, D; Yao, F; Yap, S; You, MJ; Zhang, M; Zhang, Y; Zhao, Y; Zhu, H | 1 |
| Su, D | 1 |
| Cui, Z; Jiang, T; Li, C; Li, L; Li, S; Ma, J; Qin, T; Shi, H; Wang, H; Yu, G | 1 |
| Bi, T; Li, J; Li, T; Liu, J; Liu, Z; Lu, Z; Ma, C; Wang, Q; Wei, X; Xu, Z; Yang, H; Zhang, L; Zhang, Y | 1 |
| Fujii, Y; Goto, M; Hasebe, T; Horioka, K; Isozaki, S; Kamikokura, Y; Konishi, H; Nakajima, S; Nishikawa, Y; Ogawa, K; Sawada, K; Tanaka, H | 1 |
| Irvine, AF; Jones, RL; Liu, JKH; Samson, A | 1 |
| Cheng, BQ; Gao, YJ; Tao, ZW; Zhou, T | 1 |
| Ali, A; Altaf, S; Saleem, F; Sher, AA | 1 |
| George, J; Nguyen, R; Qiao, L; Zhou, K | 1 |
| Chan, YT; Chen, ZS; Feng, Y; Guo, W; Lu, Y; Sharma, R; Tan, HY; Wang, N; Xu, Y; Zhang, C; Zheng, YC | 1 |
| Chang, ML; Chen, WT; Lee, WC; Lin, CC; Lin, CL; Lin, SM; Shen, CH; Wu, TJ; Yeh, CT | 1 |
| Bargellini, I; de Toni, EN; Gasbarrini, A; Gebauer, B; Loewe, C; Malfertheiner, P; Öcal, O; Pech, M; Ricke, J; Sangro, B; Schinner, R; Schütte, K; Seidensticker, M; Sengel, C; van Delden, O; Vandecaveye, V; Zech, CJ | 1 |
| Alés, E; Castillejos, MC; Cepeda-Franco, C; de la Cruz-Ojeda, P; Flores, JA; Gutiérrez-Valencia, A; Khiar, N; Mena-Barragán, T; Muntané, J; Navarro-Villarán, E; Negrete, M; Romero-Ben, E; Rosales-Barrios, C | 1 |
| Chen, W; Dong, ZB; He, YC; Huang, ZT; Li, H; Liang, C; Weng, YH; Wu, HM; Yu, WM | 1 |
| Sidaway, P | 1 |
| Gai, L; Li, F; Li, H; Wu, Z | 1 |
| Chao, Y; Chen, MH; Chen, SC; Huang, YH; Hung, YP; Lee, RC; Shao, YY | 1 |
| Chen, F; Chen, L; Gong, D; He, Y; Xiang, D; Yan, J; Yang, D; Zeng, L; Zhang, S | 1 |
| Hua, Y; Liu, D; Qiao, J; Shi, G; Wang, S; Wei, H | 1 |
| Kong, H; Li, H; Sun, J; Zhang, H; Zhang, W | 1 |
| Chen, Y; Han, L; Li, X; Long, S; Sheng, H; Tang, Q; Wang, S; Wu, W; Yu, Y | 1 |
| Cho, EJ; Choi, NR; Jang, H; Kim, MA; Kim, YJ; Lee, JH; Lee, YB; Moon, H; Nam, JY; Park, MK; Yoon, JH; Yu, SJ | 1 |
| Hsieh, HP; Lai, YL; Wang, KH; Yen, WC | 1 |
| Bacigalupo, ML; Carabias, P; Elola, MT; Espelt, MV; Rabinovich, GA; Rojas, P; Rossi, JP; Rubin, A; Saffioti, NA; Sarrias, L; Troncoso, MF; Wolfenstein-Todel, C | 1 |
| Calvisi, DF; Chen, X; Evert, M; O'Farrell, M; Roessler, S; Shang, R; Stahl, A; Sticht, C; Wang, H; Wang, X; Xu, H; Zeng, Y; Zhang, Y; Zhou, Y | 1 |
| Aldrighetti, L; Antonucci, A; Baiocchi, GL; Baroni, GS; Bernasconi, DP; Biasini, E; Campani, C; Celsa, C; Chiarelli, M; Cipriani, F; Crespi, M; Donadon, M; Famularo, S; Ferrero, A; Ferri, S; Foschi, FG; Gasbarrini, A; Giuliante, F; Grazi, GL; Griseri, G; Jovine, E; Maestri, M; Mega, A; Memeo, R; Morisco, F; Pelizzaro, F; Raimondo, G; Rapaccini, GL; Romano, F; Ruzzenente, A; Sacco, R; Torzilli, G; Trevisani, F; Valle, RD | 1 |
| Ahmadpour, S; Ai, J; Alijani, M; Ebrahimi-Barough, S; Hajifathali, A; Hosseinzadeh, F; Komeili Movahed, T; Muhammadnejad, S; Seyhoun, I; Shirian, S; Verdi, J | 1 |
| Chuma, M; Kondo, M; Maeda, S; Morimoto, M; Moriya, S; Nozaki, A; Numata, K; Ogushi, K; Uojima, H | 1 |
| Chung, JW | 1 |
| Gulmez, A; Harputluoglu, H | 1 |
| Chen, SC; Chen, YL; Cheng, CC; Choi, HQ; Chou, YT; Gao, GL; Lin, CY; Su, JJ; Wei, KL | 1 |
| Cai, Y; Hu, L; Liu, H; Lu, X; Sun, J; Wang, B; Xie, S; Ye, L; Zhang, X; Zheng, L; Zheng, X | 1 |
| Chen, SC; Chuang, WL; Dai, CY; Huang, CF; Huang, CI; Huang, JF; Lin, ZY; Yeh, ML; Yu, ML | 2 |
| Chang, KH; Chang, PY; Chang, WC; Chen, PK; Chiu, SH; Huang, GS; Lin, HH; Lo, CH; Tsai, MT | 1 |
| Chen, W; Feng, X; Lan, J; Nan, T; Yu, J; Zheng, L; Zheng, X; Zou, B | 1 |
| Fidan, E; Fidan, S; Kazaz, N; Merev, E | 1 |
| Chen, A; Chen, M; Chen, W; Fang, S; Ji, J; Kong, C; Qiao, E; Shu, G; Weng, Q; Xu, S; Zhang, D; Zhao, Z; Zheng, L | 1 |
| Chang, YS; Chen, SC; Chen, YY; Liang, YJ; Su, CW; Wu, JC | 1 |
| Altayar, O; Chang, CY; Falck-Ytter, Y; Muir, AJ; Shah, R | 1 |
| Altayar, O; Estfan, B; Falck-Ytter, Y; O'Shea, R; Shah, R; Su, GL; Sultan, S; Wenzell, C | 1 |
| Abuhelwa, AY; Badaoui, S; Hopkins, AM; McKinnon, RA; Ruanglertboon, W; Shankaran, K; Sorich, MJ; Tuteja, A; Yuen, HY | 1 |
| Bai, M; Gong, S; Guo, T; Hao, X; Lei, C; Li, X; Si, M; Song, S; Tian, H; Yang, W | 1 |
| Chen, PS; Cheng, AL; Hsu, C; Lee, BS; Lin, LI; Ling, A; Ou, DL; Shao, YY | 1 |
| Du, FH; Li, YL; Li, ZD; Wu, J; Wu, LW; Zeng, LH; Zhang, C; Zhang, MM | 1 |
| Habiba, YH; Helmy, MW; Houssen, ME; Omran, GA | 1 |
| Chen, LT; Liu, YH; Shiah, SG; Tseng, CF; Wang, HD | 1 |
| Aly, A; Feinberg, B; Healey, MJ; Klink, AJ; Marshall, LZ; Seal, B | 1 |
| Ankathi, SK; Banavali, SD; Bhargava, PG; Daddi, A; Goel, M; Gota, V; Jadhav, S; Mandavkar, S; Nashikkar, C; Naughane, D; Ostwal, V; Patkar, S; Ramaswamy, A; Shetty, N; Shriyan, B; Srinivas, S | 1 |
| Baik, R; Cheng, R; Colman, S; Novick, D; Rajan, N; Szende, A; Wei, A | 1 |
| Agirrezabal, I; Brennan, VK; Chatellier, G; Colaone, F; Pereira, H; Shergill, S; Vilgrain, V | 1 |
| Byun, JK; Choi, YK; Kang, GW; Lee, J; Lee, S; Lee, YR; Park, KG; Park, SY; Song, IS; Yun, JW | 1 |
| Amoozgar, Z; Duda, DG; Huang, P; Inoue, K; Jain, RK; Kikuchi, H; Matsui, A; Morita, S; Ruan, Z; Staiculescu, D; Wong, JS; Yau, T | 1 |
| Anders, RA; Baretti, M; Kim, AK | 1 |
| Cao, Y; Li, H; Ma, A; Wang, X; Wang, Z; Yang, L; Zhou, T | 1 |
| Asahina, Y; Hayakawa, Y; Higuchi, M; Inada, K; Itakura, J; Izumi, N; Kaneko, S; Kirino, S; Kurosaki, M; Maeyashiki, C; Nakanishi, H; Okamoto, R; Osawa, L; Sekiguchi, S; Takahashi, Y; Takaura, K; Tamaki, N; Tsuchiya, K; Yamashita, K; Yasui, Y | 1 |
| Chen, J; Chen, T; Cui, Y; Ge, C; Geng, Q; Jin, W; Li, H; Li, J; Lin, H; Liu, T; Miao, C; Tian, H; Xiao, X; Xie, H; Yao, M; Yu, J; Zhao, F; Zhou, Q | 1 |
| Abdel-Hamid, NM; El-Shishtawy, MM; Eldomany, RA; Nawaya, RA; Zakaria, S | 1 |
| Cho, EJ; Cho, H; Choi, NR; Hong, JH; Hur, MH; Kim, J; Kim, JY; Kim, YJ; Lee, JH; Lee, YB; Park, MK; Yoon, JH; Yu, SJ | 1 |
| Johnson, PJ; Kalyuzhnyy, A; Pinato, DJ; Toyoda, H | 1 |
| Harris, WP; King, GG; Wong, KM | 1 |
| Chen, Y; Hou, X; Huang, X; Li, D; Moorhead, JF; Rao, Y; Ruan, XZ; Su, Y; Varghese, Z; Wei, L; Yao, Y; You, Z; Zheng, G | 1 |
| Cattan, S; Chan, SL; Cheng, AL; Daniele, B; Edeline, J; Fartoux, L; Finn, RS; Gurary, EB; Knox, J; Kudo, M; Ogasawara, S; Palmer, DH; Sarker, D; Siegel, AB; Verset, G; Verslype, C; Vogel, A; Wang, A; Yau, T; Zagonel, V; Zhu, AX | 1 |
| Deng, X; Guo, X; Huang, X; Li, X; Lin, J; Lu, Y; Tan, W; Wang, C; Xie, Y | 1 |
| Cai, L; Cai, X; Chen, J; He, J; Ji, T; Jiang, S; Li, B; Liang, X; Shao, H; Staiculescu, D; Xu, J; Zhao, J | 1 |
| Brown, ZJ; Choe, J; Gregory, S; Hewitt, DB; Iacono, S; Labiner, HE; Pawlik, TM | 1 |
| Cheng, AL; Liu, TH; Shen, YC | 1 |
| Badami, A; Dhanarajan, A; Elms, D | 1 |
| Bourhis, H; De Toni, EN; Kolligs, FT; Malfertheiner, P; Mayerle, J; Merz, J; Nagel, D; Öcal, O; Op den Winkel, J; Op den Winkel, M; Ricke, J; Seidensticker, M; Stecher, SS | 1 |
| Liu, C; Lv, H; Qin, C; Song, S; Xiao, F; Xie, X; You, Y; Yu, Z; Zhu, Q | 1 |
| Cheng, Z; Dai, W; Feng, J; Guo, C; Ji, J; Li, J; Li, Y; Wu, J; Wu, L; Xu, X; Yu, Q; Zhang, J; Zheng, Y | 1 |
| Abe, H; Endo, S; Ishii, S; Ishikawa, N; Kamimura, K; Ko, M; Koseki, Y; Ogawa, K; Sakai, N; Sakamaki, A; Shibata, O; Terai, S; Yokoyama, J | 1 |
| Cao, Y; Hu, H; Meng, R; Qiu, Y; Zhou, T | 1 |
| Chen, Z; He, Q; Lin, N; Xie, Q; Yan, F; Yang, B; Ye, S; Yuan, T; Zhang, B; Zhu, H | 1 |
| Kumar, AR; L, A; Mathew, B; Nair, B; Nath, LR; Sugunan, S | 1 |
| Imai, T; Kaneko, S; Okayama, Y; Oya, M; Sunaya, T; Tsujino, T | 1 |
| Chen, J; Guo, B; Huang, K; Jia, X; Wang, X; Xue, J; Yao, M | 1 |
| Feng, Y; He, G; He, S; Li, H; Liu, Y; Lu, G; Ren, L; Ren, X; Sun, H; Yin, Y; Zhang, D; Zhang, Z; Zhao, Y | 1 |
| Cui, M; Wang, L; Xiao, B; Zhang, B | 1 |
| Gui, S; Guo, J; He, N; Huang, Y; Li, Z; Liang, X; Tang, M; Tao, Y | 1 |
| Hsieh, CH; Huang, YH; Lai, MW; Yeh, CT | 1 |
| Bai, Z; Hu, H; Pan, X; Tang, W; Wei, J; Yin, Y; Zhao, M | 1 |
| Kuwano, A; Masumoto, A; Morita, Y; Motomura, K; Nagasawa, S; Tanaka, K; Yada, M | 1 |
| Claxton, L; Eastwood, A; Hodgson, R; Sharif-Hurst, S; Wade, R; Walton, M | 1 |
| Chu, T; Hu, M; Li, B; Li, S; Liu, R; Lu, Z; Meng, H; Nie, G; Qi, F; Qie, Y; Wei, J; Wu, S; Wu, Z; Xu, S; Yang, Z; Zhang, X; Zhao, G; Zhao, Y | 1 |
| Kudo, M | 9 |
| Li, W; Wang, H; Zhang, D | 1 |
| Fu, X; Li, Z; Lin, R; Lu, Y; Wang, H; Wei, T; Zhang, J; Zhang, W | 1 |
| Hu, J; Le, W; Li, M; Lu, H; Yuan, Y; Zhang, T; Zhou, L; Zuo, H | 2 |
| Brown, ZJ; Hewitt, DB; Pawlik, TM | 1 |
| Che, F; Huang, ZX; Li, Q; Shi, YJ; Song, B; Wang, LY; Wei, Y; Xu, Q; Yang, CW | 1 |
| Fukushima, M; Haraguchi, M; Honda, T; Miuma, S; Miyaaki, H; Nakao, K; Sasaki, R | 1 |
| Duan, J; Fan, L; Jiang, B; Liu, S; Tan, Y; Yin, H; Zhang, Y; Zhao, X | 1 |
| Djumhana, A; Gani, RA; Hasan, I; Lesmana, CRA; Loho, IM; Purnomo, HD; Setiawan, PB; Siregar, L; Sulaiman, AS | 1 |
| Bengtsson, B; Hagström, H; Ljunggren, G; Norén, S; Wahlin, S | 1 |
| Gu, J; Guo, B; He, G; Qi, K; Shao, M; Wang, L; Xu, X; Yang, X | 1 |
| Andersson, C; Blom, K; Brechot, C; Ek, F; Fryknäs, M; Jarvius, M; Larsson, R; Nygren, P; Rudfeldt, J; Selvin, T; Senkowski, W | 1 |
| Caterino, M; Ciardiello, F; Facchini, S; Fasano, M; Lo Giudice, G; Pirozzi, M; Rauso, R; Sica, A; Varriale, E; Zotta, A | 1 |
| Cao, W; Cui, C; Feng, W; Pi, X | 1 |
| Bai, L; Cao, D; Liu, H; Tang, H | 1 |
| Fan, M; Liu, W; Pan, Y; Qin, W; Tai, Y; Tian, H; Wang, L; Wu, X; Xiao, C; Yang, Y; Zhang, Q | 1 |
| Abdel-Hamed, AR; Abo-Elmatty, DM; Abulsoud, AI; Al-Noshokaty, TM; Mesbah, NM | 1 |
| Gao, L; Kong, Y; Liang, X; Liu, S; Ma, C; Sun, M; Wu, Z; Yue, X; Zhang, Y | 1 |
| Guan, H; Han, S; Wang, C; Zhao, Z | 1 |
| Bejjani, AC; Finn, RS | 1 |
| Fan, SY; He, LJ; Jia, YL; Li, S; Nan, X; Pei, XT; Wang, DX; Wang, HY; Wang, XK; Xi, JF; Xu, YC; Yue, W; Zeng, Q; Zhang, B; Zhang, M; Zhang, MM; Zhong, W; Zhou, JN; Zhou, XB | 1 |
| Chapin, WJ; Hwang, WT; Kaplan, DE; Karasic, TB; McCarthy, AM | 1 |
| Deng, WX; Huang, ST; Li, JX; Li, LQ; Liang, CF; Liang, SX; Lin, XF; Long, MY; Lu, HY; Pang, YD; Su, TS; Xiang, BD; Zhang, J; Zhou, HM | 1 |
| Al Kenawi, AA; Alghamdi, AS; Dahlan, YM; Sanai, FM; Shirah, BH | 1 |
| Fu, J; Hu, J; Liu, C; Qin, Y; Seeberger, PH; Wu, W; Yin, J | 1 |
| Fan, K; Huang, H; Xie, ML; Xie, T; Zhao, Y; Zhu, ZY | 1 |
| Hua, H; Ji, H; Lu, T; Ren, Y; Shan, K; Wei, Q; Yang, S; Zheng, X | 1 |
| Hou, Y; Jiang, H; Li, J; Li, Y; Li, Z; Wang, C; Yang, X; Zhang, A | 1 |
| Hsieh, SY; Lee, CW; Lee, YS; Lian, JH; Tsai, CL; Tsai, CN; Wu, TH; Yu, MC | 1 |
| Chen, Y; Fan, X; Hu, H; Yuan, X; Zhang, C | 1 |
| Alunni-Fabbroni, M; Benckert, J; Chow, PKH; Gasbarrini, A; Kuhl, C; Malfertheiner, P; Öcal, E; Pech, M; Ricke, J; Sangro, B; Schinner, R; Shuen, TWH; Toh, HC; Wildgruber, M | 1 |
| Chen, D; Chen, X; Chen, Y; Gu, J; Ling, F; Luo, H; Maimaiti, F; Qi, W; Tan, G; Wang, C; Xu, S; Yang, L; Yin, M | 1 |
| Baker, DM; Cybulski, JD; Ding, J; Lau, EYT; Lee, TKW; Lei, MML; Leung, CON; Leung, HW; Leung, KS; Lin, CH; Lindholm, D; Ma, S; Mok, EHK; Ng, IOL; Tong, M; Wong, TL; Yu, J; Yun, JP; Zhou, L; Zhu, HL | 1 |
| Chen, X; Guo, X; Liu, D; Liu, S; Sun, W; Wang, H; Yang, G; Zhang, J | 1 |
| Fujinaga, Y; Hokuto, D; Kawaratani, H; Kitagawa, K; Narita, H; Nishimura, N; Ozutsumi, T; Shibamoto, A; Sho, M; Takeda, S; Tsuji, Y; Yoshiji, H | 1 |
| Alonso, JC; Burgos, R; Casans, I; Espinoza, N; Fuster, D; González, FM; Oyagüez, I; Rodríguez, A; Sánchez, N; Williams, AO | 1 |
| An, J; Han, S; Kim, HI; Shim, JH | 1 |
| Fan, H; Fan, W; Li, F; Li, J; Lu, M; Qiao, L; Wang, H; Wu, Y; Xue, M; Yuan, G; Yue, S; Zheng, X; Zhu, B; Zou, X | 1 |
| Das, S; Ke, R; Kumar, S; Principe, DR; Rana, A; Rana, B; Singh, SK; Srivastava, P; Vishnoi, K; Viswakarma, N | 1 |
| Banerjee, K; Benzaghou, F; Borbath, I; Breder, V; Chan, SL; Cheng, AL; Fawcett, J; Gane, E; Hazra, S; Kaseb, A; Kelley, RK; Makharadze, T; Melkadze, T; Merle, P; Qin, S; Rangel, JDG; Rimassa, L; Ryoo, BY; Sukeepaisarnjaroen, W; Verset, G; Yau, T; Zhu, AX | 1 |
| Fan, B; Guo, S; Zhang, Y | 1 |
| Fang, S; Li, X; Liu, G; Ma, Y; Yang, J; Yang, X; Zhao, B | 1 |
| Chen, J; Ding, X; Li, L; Li, W; Li, X; Zhang, Y | 1 |
| Li, R; Li, S; Li, Y; Liang, P; Mao, X; Wang, C; Wang, J; Wang, X; Xie, X; Zhou, Q | 1 |
| Akutsu, N; Hirano, T; Ishigami, K; Kawakami, Y; Nakase, H; Numata, Y; Sasaki, S; Wagatsuma, K | 1 |
| Akita, T; Jomen, W; Kohgo, Y; Ohtake, T; Osawa, Y; Suto, D; Yagi, H | 1 |
| Azadbakht, A; Gharibzadeh, S; Hajighasemlou, S; Mirmoghtadaei, M; Muhammadnejad, S; Nikbakht, M; Pakzad, S; Seyhoun, I; Verdi, J | 1 |
| Han, H; Lin, T; Liu, C; Zhai, H; Zhu, W | 1 |
| Griffiths, CD; Meyers, BM; Serrano, PE; Tywonek, K; Zhang, B | 1 |
| Cao, Z; Chen, D; Deng, X; Ding, W; Dong, F; Han, M; He, X; Jin, L; Li, J; Liu, D; Liu, H; Luo, W; Mu, J; Mu, X; Pan, L; Pang, Y; Wang, T; Wei, Y; Wu, Z; Zhang, H; Zhang, Y | 1 |
| Goyal, P; Mouli, SK; Salem, R | 1 |
| Cho, SH; Kim, JA; Kim, JH; Kim, KM; Moon, B; Park, M; Seo, HR | 1 |
| Fang, X; Gong, L; Guan, XY; Lam, KO; Lam, RHW; Lee, AW; Liu, B; Luo, J; Ren, J; Tiu, YC; Yan, Q; Yang, Y; Zhang, Y | 1 |
| Kuppusamy, P; Nagalingam, A; Saxena, NK; Sharma, D; Siddharth, S; Wu, Q | 1 |
| Bruins Slot, AS; Coppens, BJP; de Bruijne, J; van Beers, MA; van Dijk, AM; van Erpecum, KJ; Verstraete, CJR; Vleggaar, FP | 1 |
| Amthauer, H; Bargellini, I; Bartenstein, P; Benckert, J; Berg, T; Gasbarrini, A; Gebauer, B; Iezzi, R; Klümpen, HJ; Loewe, C; Malfertheiner, P; Öcal, O; Pech, M; Philipp, A; Ricke, J; Sangro, B; Schütte, K; Seidensticker, M; Sengel, C; van Delden, O; Vandecaveye, V; Verslype, C; Zech, CJ | 1 |
| Chen, J; Huang, Y; Li, K; Liang, W; Liao, X; Liu, K; Qin, Y; Qiu, D; Qiu, X | 1 |
| Ardelt, M; Nickel, S; Settmacher, U | 1 |
| Bu, J; Chu, PK; Ding, X; Hu, X; Li, L; Li, Z; Ren, K; Zhou, H; Zhu, X | 1 |
| Choi, I; Kim, KM; Kim, N; Kim, S; Lee, JY; Lee, SY; Rhu, HC; Seo, HR; Song, Y | 1 |
| Feng, T; Huang, X; Lai, C; Li, Y; Shang, J; Shi, Y; Yang, Q; Yao, Y; Zhang, Z; Zhong, D | 1 |
| Liu, J; Nie, C | 1 |
| Abuduwaili, W; Dong, L; Huang, AT; Li, Y; Liu, TT; Liu, ZY; Shen, XZ; Sun, JL; Wang, F; Wang, X; Weng, SQ; Xu, RC; Zhang, GC; Zhu, CF; Zhu, JM | 1 |
| Gnocchi, D; Kurzyk, A; Lentini, G; Mazzocca, A; Mintrone, A; Sabbà, C | 1 |
| Cerniglia, M; Kim, SS; Klepadlo, M; Sheneman, D | 1 |
| Airoldi, C; Cortellini, A; D'Alessio, A; Demirtas, CO; Fulgenzi, CAM; Gennari, A; Pinato, DJ; Scotti, L | 1 |
| Li, N; Lv, S; Ma, X; Song, T; Sun, L; Yan, Y; Zhang, E; Zhao, X; Zou, Q | 1 |
| Bonney, GK; Chee, CE; Chow, EK; Chow, PK; Dan, YY; Hooi, L; Lim, JJ; Toh, TB; Zhou, L | 1 |
| Baradaran, B; Kheradmand, F; Nour, MA; Rasmi, Y | 1 |
| Cai, L; Chitakunye, AT; Guan, X; Hong, H; Li, Y; Shi, H; Sun, Y; Zhang, S; Zhang, T; Zhu, Q | 1 |
| Guo, F; Jin, X; Meng, J; Ren, D; Sun, Y; Wu, H; Zhang, H | 1 |
| Li, J; Tan, XP; Wang, SL; Xiong, BH; Zhang, YX; Zuo, Q | 1 |
| Feng, Y; Han, Q; Hu, R; Pan, Z; Song, Z; Wang, X; Yu, Y; Zhang, J; Zhao, H | 1 |
| Chen, CT; Chen, SC; Cheng, AL; Feng, YH; Hsu, CH; Lin, YT; Lu, LC; Shao, YY; Yen, CJ | 1 |
| Li, Y; Shen, J; Wu, Y; Yu, Y; Zhang, R; Zhu, J | 1 |
| Donne, R; Lujambio, A | 1 |
| Guo, J; Li, C; Lin, Y; Liu, X; You, H; Zhang, Y | 1 |
| De Giorgio, M; Di Costanzo, GG; Di Donato, MF; Fagiuoli, S; Giuffrida, P; Granito, A; Iavarone, M; Ielasi, L; Pallotta, DP; Piscaglia, F; Pressiani, T; Sacco, R; Sansone, V; Tovoli, F; Trevisani, F | 1 |
| Brandi, G; Carloni, R; Cusmai, A; Fanizzi, A; Federico, AD; Marco, MD; Massafra, R; Palloni, A; Palmiotti, G; Rizzo, A | 1 |
| El-Kholy, AA; Esawie, M; Hasanin, AH; L Louka, M; Said Ali, H | 1 |
| Chi, HC; Huang, PS; Huang, YH; Liao, CJ; Lin, CC; Lin, KH; Lin, YH; Liou, YS; Liu, YC; Yeh, CT; Yu, CJ | 1 |
| Fu, J; Hu, J; Liu, C; Qin, Y; Wu, W; Yin, J; Zhou, J | 1 |
| Chan, LL; Chan, SL; Feng, MY | 1 |
| Chakraborti, A; Dhiman, RK; Kanthaje, S; Kaur, R; Taneja, S | 1 |
| Byun, JK; Chin, J; Cho, SJ; Choi, YK; Jin, J; Kim, DH; Kim, J; Kim, MJ; Kim, NY; Lee, IK; Lee, J; Lee, S; Park, KG; Yun, JW | 1 |
| Chen, J; Jin, Z; Li, H; Xiong, Z; Zhang, B; Zhang, S; Zheng, Y; Zhu, X | 1 |
| Chang, B; Chen, Q; Deng, F; Li, L; Lu, X; Luo, J; Wang, D; Zhou, J; Zhu, Z; Zuo, D | 1 |
| Jiang, Y; Li, J; Lu, Z; Shao, Y; Sun, W; Yang, H | 1 |
| Cao, G; Chen, X; Dong, H; Fan, J; Han, X; Ji, H; Jiang, D; Li, Z; Liu, D; Liu, W; Qian, Y; Tan, X; Wei, Z; Xian, L; Yin, J; Yu, H; Zhao, J; Zhao, P; Zhou, X; Zhu, X | 1 |
| Chang, J; Chen, CY; Chen, YL; Cheng, CC; Ho, AS; Peng, CL; Sie, ZL; Wang, CL | 1 |
| Chai, MY; Chen, DX; Dou, SS; Fu, Z; Kou, BX; Liu, XN; Wei, FL | 1 |
| Chen, CT; Cheng, AL; Hsu, CH; Shao, YY | 1 |
| Cai, X; Hong, J; Zheng, W | 1 |
| Fukumoto, T; Kido, M; Komatsu, S; Ku, Y; Kudo, M; Kuramitsu, K; Toyama, H; Tsugawa, D; Ueshima, K; Yanagimoto, H | 1 |
| Cao, X; Du, X; Guo, M; Qi, Z; Xia, J; Xu, J; Yu, Z; Zhang, X | 1 |
| Ding, X; Liu, Y; Lo, WS; Ng, KK; Wan, HL; Wong, AM; Wong, N; Xu, M; You, W | 1 |
| Chen, SC; Chuang, WL; Dai, CY; Hsu, PY; Huang, CF; Huang, CI; Huang, JF; Liang, PC; Lin, ZY; Yeh, ML; Yu, ML | 1 |
| Boix, L; Bruix, J; Brüne, B; Castell, FJ; de la Cruz-Ojeda, P; Falcón-Pérez, JM; Ferrer, MT; Giráldez, Á; Gómez-Bravo, MA; Moreno, M; Muntané, J; Praena-Fernández, JM; Reig, M; Sapena, V; Schmid, T | 1 |
| Cui, Y; Dong, Z; Guo, C; Li, Y; Ma, Y | 1 |
| Attia, J; McKay, GJ; Oranratnachai, S; Rattanasiri, S; Raunroadroong, N; Sirachainan, E; Tansawet, A; Thakkinstian, A | 1 |
| Chang, SY; Chen, YC; Hsu, CS; Peng, TR; Wu, CC; Wu, TW | 1 |
| Hou, Y; Hu, W; Tan, K; Wang, Y; Yang, G | 1 |
| Cao, TS; Du, LJ; Fang, P; Li, H; Li, MJ; Tan, LJ; Xu, PY; Zhang, CF; Zhao, J; Zhong, XL | 1 |
| Fu, XL; Guo, SM; Li, QQ; Li, XM; Ma, JQ; Shi, XH; Sun, HM; Wang, X; Xu, FF; Ye, K; Ye, LH; Zhang, L; Zhang, WY | 1 |
| Cai, L; Chen, T; Cheng, Y; Fu, S; He, G; Huang, H; Huang, M; Pan, M; Wen, Y; Xu, Y; Zheng, Y; Zhong, K; Zhong, X | 1 |
| Chen, X; Ren, J; Shao, M; Yang, H; Yang, W; Zheng, J | 1 |
| Lai, Y; Lu, N; Luo, S; Wang, H; Zhang, P | 1 |
| Barsoum, M; Khan, U; Noginskiy, I; Pak, T; Singh, A; Usta, S; Zahid, S | 1 |
| Chen, Y; Jia, C; Li, G; Lu, X; Qiu, X; Tang, Y; Wang, T; Wu, D; Xiong, Z | 1 |
| Ang, C; Balcar, L; Bettinger, D; Cammarota, A; Cheon, J; Chon, HJ; Cortellini, A; D'Alessio, A; Fulgenzi, CAM; Gaillard, VE; Galle, PR; Huang, YH; Kudo, M; Marron, TU; Masi, G; Napolitano, A; Naqash, AR; Nishida, N; Personeni, N; Phen, S; Pinato, DJ; Pinter, M; Pressiani, T; Rimassa, L; Saeed, A; Salani, F; Scheiner, B; Schönlein, M; Schulze, K; Sharma, R; Singal, AG; Vivaldi, C; Vogel, A; von Felden, J; Wege, H; Wietharn, B; Wu, L | 1 |
| Duda, DG | 1 |
| Battiston, C; Citterio, D; Droz Dit Busset, M; Flores, M; Mazzaferro, V; Sposito, C; Virdis, M | 1 |
| Arrese, M; Debes, JD; Manica, M; Mattos, AA; Mattos, ÂZ; Pase, THS; Revelo, X; Vogel, A | 1 |
| Aikimbaev, K; Balli, HT; Burak, IG; Pehlivan, UA; Piskin, FC; Sozutok, S | 1 |
| Shen, C; Zhang, Z; Zhou, F | 1 |
| Hu, B; Ju, D; Liu, XJ; Ma, J; Mu, Q; Sun, ZL; Xu, Y; Yang, P; Yu, MC; Zhu, XF | 1 |
| Chen, Y; Dong, X; Li, M; Li, W; Lin, B; Wang, Q; Xu, J; Zhang, M; Zhu, M; Zou, Z | 1 |
| De Toni, EN; Finn, RS; Galle, PR; Goyal, L; Hsu, CH; Qin, S; Rao, S; Sun, F; Wang, C; Widau, RC; Yau, T; Zhu, AX | 1 |
| Meshari, AA | 1 |
| Aldrighetti, L; Arai, T; Atsukawa, M; Burgio, V; Cabibbo, G; Casadei-Gardini, A; Cascinu, S; Cheon, J; Chon, HJ; Claudia, F; D'Alessio, A; De Cobelli, F; Di Costanzo, GG; Foschi, FG; Fukunishi, S; Hatanaka, T; Hiasa, Y; Hiraoka, A; Hirooka, M; Iavarone, M; Iijima, H; Imai, M; Ishikawa, T; Itobayashi, E; Itokawa, N; Iwamoto, H; Joko, K; Kakizaki, S; Kang, B; Kariyama, K; Kawata, K; Koizumi, Y; Kudo, M; Kumada, T; Lonardi, S; Marra, F; Masi, G; Morishita, A; Nagano, T; Naganuma, A; Nakamura, S; Niizeki, T; Nishida, N; Nishimur, T; Nouso, K; Ochi, H; Ogawa, C; Ohama, H; Okubo, T; Pedica, F; Pinato, DJ; Piscaglia, F; Pressiani, T; Ratti, F; Rimassa, L; Rimini, M; Ryoo, BY; Sakamoto, N; Scartozzi, M; Shigeo, S; Shimada, N; Sho, T; Silletta, M; Soldà, C; Suda, G; Tada, T; Tajiri, K; Takaguchi, K; Tamburini, E; Tanaka, T; Tani, J; Toyoda, H; Tsuji, K; Tsutsui, A; Ueshima, K; Yasuda, S; Yoo, C | 1 |
| Aratake, Y; Azuma, Y; Harada, S; Higuchi, N; Kohjima, M; Koyanagi, T; Kuniyoshi, M; Kurashige, T; Motomura, K; Mutsuki, T; Nakamura, T; Nakamuta, M; Ohno, A; Ooe, M; Ooho, A; Satoh, T; Senju, T; Sugimoto, R; Tada, S; Tanaka, M; Tanaka, Y; Uchimura, K; Ueda, A; Yamashita, N; Yamashita, S; Yoshimoto, T | 1 |
| de Liguori Carino, N; Onafowokan, OO | 1 |
| Chao, TI; Chen, G; Chen, LJ; Huang, CY; Wang, CY | 1 |
| Abu-Gharbieh, E; Abushawish, KYI; Al-Hroub, HM; Alzoubi, KH; Bustanji, Y; El-Huneidi, W; Elgendy, SM; Giddey, AD; Mousa, M; Omar, HA; Semreen, MH; Soares, NC; Soliman, SSM | 1 |
| Cui, Y; Dong, Z; Fu, Y; He, X; Li, Y; Ma, Y; Xun, X | 1 |
| Jiang, L; Lv, T; Shi, Y; Wu, Z; Yan, L; Yang, J; Yuan, J | 1 |
| Chiang, IT; Hsu, FT; Liu, YC; Tsai, JJ; Weng, YS | 1 |
| Duda, DG; Jain, RK | 1 |
| Allaire, M; Blaise, L; Campion, B; Cluzel, P; Evain, M; Ganne-Carrié, N; Giudicelli, H; Larrey, E; Rudler, M; Sultanik, P; Thabut, D; Wagner, M | 1 |
| Cai, GX; Chen, GX; Chen, X; Deng, YF; Huang, HB; Kong, WY; Lei, QC; Liao, YN; Liu, Y; Shao, ZL; Sun, WS; Wang, R; Wu, SG; Yu, CF; Zhuang, XF | 1 |
| Chen, MY; Chu, YC; Hsieh, MS; Hsu, CH; Ma, HP; Ong, JR; Setiawan, SA; Tzeng, DTW; Tzeng, YM; Wu, ATH; Yeh, CT | 1 |
| Guo, J; Huang, D; Xu, Q; Zhao, J | 1 |
| Ding, X; Li, Y; Pang, Q; Xu, T; Zhang, L | 1 |
| Hafner, C; Madlener, S; Pinter, M; Rohr-Udilova, N; Samadaei, M; Senfter, D; Trauner, M; Uranowska, K | 1 |
| Jiang, J; Lai, L; Liu, X; Sun, B; Wang, X; Xiong, J; Yao, Y; Zhang, X | 1 |
| Tan, J; Xu, M; Zhong, Z | 1 |
| Aboulwafa, MM; Helmy, OM; Taha, AM; Zedan, H | 1 |
| Jantana, S; Kunwong, N; Nguyen, KT; Punnakitikashem, P; Punuch, K; Rodponthukwaji, K; Sirivatanauksorn, V; Sirivatanauksorn, Y; Somboonyosdech, C; Srisawat, C; Wongwan, C | 1 |
| Cheon, C; Kim, B; Kim, DB; Lee, DK; Ribeiro, RIMA | 1 |
| Miao, TG; Nan, YM | 1 |
| Ding, Y; Hui, N; Li, L; Su, B; Wang, X; Yang, M | 1 |
| Cai, J; Gan, H; Guo, H; Hu, X; Li, L; Pang, P; Xu, X; Zhang, H; Zhao, N | 1 |
| Aratake, Y; Harada, S; Higuchi, N; Hioki, T; Kohjima, M; Koyanagi, T; Kuniyoshi, M; Kuwano, A; Morita, Y; Motomura, K; Mutsuki, T; Nagasawa, S; Nakamura, T; Nakamuta, M; Nakashima, M; Ooe, M; Ooho, A; Satoh, T; Senju, T; Sugimoto, R; Tada, S; Tanaka, K; Tanaka, M; Tanaka, Y; Uchimura, K; Ueda, A; Yada, M; Yamashita, N; Yoshimoto, T | 1 |
| Chen, YM; Hu, YY; Huang, SC; Jia, HY; Kang, JL; Li, Z; Shen, G; Shi, YJ; Xiao, QW; Zhou, Q | 1 |
| Chirayil, TJ; Kumar, GSV | 1 |
| Aikata, H; Cheng, AL; Daniele, B; Dutcus, CE; Finn, RS; Han, KH; Ikeda, K; Kudo, M; Lencioni, R; López, CL; Meng, Z; Palmer, D; Park, JW; Pracht, M; Qin, S; Saito, K; Tamai, T; Tovoli, F; Ueshima, K; Vogel, A | 1 |
| Chan, YT; Feng, Y; Feng, Z; Huang, L; Lan, J; Liu, Y; Lu, Y; Pan, W; Wang, N | 1 |
| Hu, J; Jiang, X; Peng, W; Zhang, L; Zhang, W; Zhang, Y | 1 |
| Chao, Y; Chi, CT; Hou, MC; Huang, YH; Hung, YP; Lee, IC; Lee, PC; Su, CW; Wu, CJ | 1 |
| Bernards, R; Qin, W; Wang, C; Yang, C; Zhang, H; Zhang, L; Zhu, AX | 1 |
| Chen, SY; Chen, ZJ; He, S; Lei, J; Li, X; Li, XQ; Liao, SQ; Liu, HT; Mao, LH; Ran, T; Wang, QL; Zhou, L; Zhou, ZH | 1 |
| Chen, YT; Fang, YH; Hsiao, YW; Hsu, LW; Liu, PY; Liu, YW; Masbuchin, AN; Rohman, MS; Wang, JM; Wu, SN; Yen, CJ | 1 |
| Chen, PH; Dai, HQ; Feng, J; Hooi, SC; Liao, XW; Lu, G; Lu, GD; Lu, PZ; Peng, T; Shen, HM; Su, WJ; Wang, LM; Wu, Y; Ye, XP; Zhou, J; Zhu, GZ | 1 |
| Fey, D; Malik, IA; Rajput, M; Salehzadeh, N; von Arnim, CAF; Werner, R; Wilting, J | 1 |
| Alaimo, L; Moazzam, Z; Pawlik, TM | 1 |
| Li, SQ; Yang, Y; Ye, LS | 1 |
| Chao, YJ; Haung, LY; Hou, YC; Shan, YS; Wang, CJ; Wang, HC; Yen, CJ | 1 |
| Akbas, EM; Arslan, YK; Demirtas, L; Gürbüzel, M; Karatas, O; Tahirler, H | 1 |
| Cao, X; Cheng, Y; Kuang, Y; Li, H; Wang, J; Wang, Y | 1 |
| Bai, M; Chen, JJ; Liu, Q; Song, SJ; Yan, QL; Yao, GD | 1 |
| Pan, Q; Shao, Z; Zhang, Y | 1 |
| Brandi, G; Calabrò, C; Carloni, R; Cusmai, A; Laforgia, M; Oreste, D; Palmiotti, G; Ricci, AD; Rizzo, A; Sollitto, M; Ungaro, V | 1 |
| Chen, TL; Chien, CY; Chiu, WC; Liao, YJ; Suk, FM; Wu, CY | 1 |
| Abdu, S; Amin, A; Juaid, N; Miled, N; Moulay, M | 1 |
| Deng, ZJ; Li, L; Liu, HT; Ma, L; Su, JY; Teng, YX; Zhang, GL; Zhong, JH | 1 |
| Boleslawski, E; Canva, V; Dharancy, S; El Amrani, M; Goria, O; Lassailly, G; Lebuffe, G; Louvet, A; Lubret, H; Mathurin, P; Minoux, K; Nguyen-Khac, E; Ningarhari, M; Truant, S | 1 |
| Chen, J; Ding, X; Li, W; Li, X | 1 |
| Bao, H; Li, X; Liu, C; Yin, X | 1 |
| Liu, R; Xu, Y; Yu, H; Zhang, X; Zhao, G | 1 |
| Eguchi, H; Hatano, E; Ioka, T; Kanai, M; Kobayashi, S; Nagano, H; Ogawa, K; Seo, S; Takada, Y | 1 |
| Hayashi, Y; Kashii, Y; Kawai, K; Minemura, M; Motofuji, Y; Muraishi, N; Murayama, A; Shimizu, Y; Shinno, E; Tajiri, K; Takahara, T; Tokimitsu, Y; Yasuda, I | 1 |
| Ding, Z; Hao, L; Hu, S; Liu, J; Qi, G; Tian, H; Wang, L; Wang, Z; Wu, C; Yin, Q; Yu, J | 1 |
| Li, R; Liu, Y; Tang, B; Wang, W; Yang, X; Zhang, X | 1 |
| Hu, L; Lin, J; Shi, X; Wang, A; Zheng, Y | 1 |
| Lei, F; Lu, X; Sun, JY; Tan, H; Wang, J; Wu, R | 1 |
| Chen, J; Chi, H; Gu, T; Guo, L; Han, Y; He, K; Jiang, Y; Li, H; Su, K; Wang, P; Wu, Z; Xu, K; Zeng, H | 1 |
| Chen, H; Chen, X; Liu, Y; Shao, K; Shao, Z; Shen, H; Wang, Y; Wu, X | 1 |
| Bagheri, F; Hashemi-Najafabadi, S; Jamialahmadi, O; Mancina, RM; Motamedian, E; Romeo, S; Salehabadi, E | 1 |
| Acosta-Rivera, M; Bruix, J; Choo, SP; Cubillo Gracian, A; El-Khoueiry, AB; Eldawy, TE; Frassineti, GL; He, AR; Koopmans, P; Matilla, A; Neely, J; Piscaglia, F; Sangro, B; Santoro, A; Scheffold, C; Tschaika, M; Vaccaro, GM; Yau, T; Zagonel, V | 1 |
| Guan, Y; Huang, Z; Lan, R; Li, S; Long, Y; Song, X; Zhang, L | 1 |
| Gnocchi, D; Mazzocca, A; Sabbà, C | 1 |
| Fan, J; Gao, Q; Shi, J; Xie, D; Zhou, J | 1 |
| Abbadessa, G; Decaens, T; Kurma, K; Lerat, H; Macek Jilkova, Z; Marche, PN; Mercey-Ressejac, M; Roth, GS; Sturm, N; Yu, Y; Zeybek Kuyucu, A | 1 |
| Chen, MY; Gong, JX; Hsu, CH; Setiawan, SA; Tzeng, DTW; Tzeng, YM; Weng, PW; Wu, ATH; Yadav, VK; Yang, Z; Yeh, CT | 1 |
| Liu, Q; Wan, Y; Zhang, W; Zhang, Y; Zhu, X | 1 |
| Ahn, SH; Goh, MJ; Kang, W; Kim, BK; Kim, DY; Kim, SU; Kim, Y; Lee, HW; Lee, JS; Park, JY | 1 |
| Abu Hilal, M; Aldrighetti, L; Antonucci, A; Ardito, F; Baiocchi, GL; Bernasconi, DP; Chiarelli, M; Cipriani, F; Conci, S; Dalla Valle, R; Delvecchio, A; Dominioni, T; Donadon, M; Ercolani, G; Famularo, S; Farinati, F; Fazio, F; Ferrari, C; Ferrero, A; Frena, A; Fumagalli, L; Germani, P; Giuliante, F; Grazi, GL; Griseri, G; Hasegawa, K; Iaria, M; Jovine, E; Kawaguchi, Y; La Barba, G; Lai, Q; Maestri, M; Memeo, R; Molfino, S; Patauner, S; Perri, P; Pinotti, E; Piscaglia, F; Romano, F; Romano, M; Rossi, M; Ruzzenente, A; Tarchi, P; Torzilli, G; Valsecchi, MG; Zago, M; Zanello, M; Zanus, G; Zimmitti, G | 1 |
| Chakraborti, A; Dhiman, RK; Kanthaje, S; Kaur, R; Kumar, M | 1 |
| Qiu, R; Zeng, Z | 1 |
| Guan, XY; He, YT; Kong, FE; Li, GM; Li, MM; Liang, JK; Liu, M; Ma, NF; Xie, MB; Zhang, CY; Zhang, XF | 1 |
| Chen, B; Cheng, J; Lei, J; Li, Y; Lu, Y; Safadi, R; Si, T; Wu, T; Yang, X; Zhang, L; Zhang, R | 1 |
| Cheng, Z; Dai, W; Feng, J; Guo, C; Ji, J; Li, J; Li, Y; Wu, J; Wu, L; Xu, X; Yang, M; Yang, W; Zhang, J; Zheng, Y | 1 |
| Chen, Y; Dai, S; Fan, S; Ke, C; Li, Y; Xu, F; Yang, L; Yuan, J | 1 |
| Ding, J; Li, D; Lin, B; Luo, J; Shang, M; Wang, W; Xu, K; Zheng, S; Zhou, L | 1 |
| Kim, SK; Park, JS; Park, S; Park, SJ | 1 |
| Hayashi, Y; Ikehara, T; Kaneko, R; Kitajima, M; Matsuda, T; Nagai, H; Ogino, H; Uekusa, T | 1 |
| Chen, C; Huang, LY; Liu, Y; Shan, XF; Tang, N; Wang, K; Wu, XH; Xia, J; Xu, FL | 1 |
| Cai, M; Chen, J; Chen, Y; Guo, Y; Huang, J; Huang, W; Lai, M; Liang, L; Lin, L; Liu, M; Xie, L; Zhang, X; Zhang, Y; Zhu, K | 1 |
| Cawston, H; Dubois de Gennes, C; Gaugain, L; Le Dissez, C; Mazaleyrat, B; Nahon, P; Sanchez Alvares, J | 1 |
| He, X; Lee, LTO; Lu, L; Peng, L; Su, Y; Zhang, X; Zhang, Z | 1 |
| Li, D; Liu, M; Lu, T; Xu, M; Yang, C; Yuan, X; Zhang, J; Zhou, L | 1 |
| Bi, T; Li, J; Liu, Z; Sun, W; Wang, Q; Wang, W; Xu, Y; Yang, H | 1 |
| Chen, Y; He, K; Liu, X; Song, W; Wang, S; Yang, Y; Yang, Z | 1 |
| Brandi, G; De Luca, R; Fanizzi, A; Massafra, R; Ricci, AD; Rizzo, A | 1 |
| Deng, J; Gao, J; Liao, Z | 1 |
| Chen, LW; Chien, CH; Chien, RN; Hu, CC; Liang, KH; Lin, CL; Lin, YH; Yeh, CT | 1 |
| Blanc, JF; Edeline, J | 1 |
| An, N; Lan, H; Li, H; Yi, C; Zhang, M; Zhao, F | 1 |
| Liang, S; Tao, S; Yin, D; Zeng, T | 1 |
| Duan, B; Guo, P; Li, G; Li, P; Li, X; Liu, H; Liu, J; Liu, M; Ma, S; Rahman, NA; Ren, X; Song, R; Wang, Q; Wołczyński, S; Xu, J; Yin, F; Yu, L | 1 |
| Baylan, SM; Erdal, E; Fırtına Karagonlar, Z; Guven, K; Karpat, O; Kıpçak, A; Sarıyar, E; Sezan, S | 1 |
| Bianco, V; Caponnetto, S; Cortesi, E; Marrocco, GA; Mondera, F; Pappalardo, L; Sciortino, C; Silletta, M; Tonini, G; Viglialoro, V | 1 |
| Cai, W; Cao, N; Gao, J; Ma, Y; Song, L; Tang, X; Zhou, S | 1 |
| Bai, Y; Chu, F; He, X; Li, BA; Li, LX; Li, ZJ; Liu, ZW; Mao, D; Niu, XF; Wang, H; Zhang, DL; Zhang, P; Zhang, XF; Zhuang, YL | 1 |
| Ho, CM; Liu, CJ; Liu, TH; Su, TH; Wu, CH | 1 |
| Liu, K; Zhu, H; Zhu, Y | 1 |
| Du, XY; Feng, NN; Jiao, ZK; Wu, XH; Yang, BM; Zhang, YS | 1 |
| Cai, J; Fan, N; Guan, G; Huo, J; Li, Z; Qiu, W; Rao, W; Wang, S; Wu, L; Xin, Y; Zhu, Q | 1 |
| Atmodjo, WL; Irawan, A; Prabowo, E; Riwanto, I | 1 |
| Ji, M; Lan, W; Li, M; Lin, J; Wang, S | 1 |
| Akiyama, S; Fujino, Y; Furutani, A; Kajimoto, K; Mohri, K; Murata, K; Otsubo, D; Sawa, H; Suzuki, S; Tanaka, M; Tominaga, M; Yamagishi, T; Yamane, H; Yoshida, T | 1 |
| Chang, S; Chen, F; Li, G; Li, X; Liu, Q; Meng, F; Sun, L; Wang, H; Zhang, J | 1 |
| Chen, X; Guo, L; Han, Y; Hu, L; Su, K; Zeng, H; Zhou, C | 1 |
| Chen, Y; Jiang, X; Li, J; Li, X; Su, Z; Xiao, F; Zhao, D | 1 |
| Balcar, L; Finkelmeier, F; Himmelsbach, V; Mahyera, A; Mozayani, B; Pinter, M; Pomej, K; Scheiner, B; Shmanko, K; Trauner, M; Vogel, A; Weinmann, A; Welland, S | 1 |
| Deng, M; Guo, R; Li, S; Wei, W | 1 |
| Ahn, YE; Jung, YK; Kim, TH; Yim, HJ | 1 |
| Pan, B; Qiu, J; Tang, N; Wang, Z; Wu, X; Yao, Y; Zhang, X | 1 |
| Abbati, C; Chen, R; Granito, A; Ielasi, L; Stefanini, B; Tonnini, M; Tovoli, F | 1 |
| Bi, Z; Chen, T; Chen, W; Cheng, H; Jing, Y; Pang, L; Yao, S; Yin, X; Zhang, X; Zuo, H | 1 |
| Chen, R; di Carlo, A; Ielasi, L; Tovoli, F | 1 |
| Chen, L; Chen, M; Fei, L; Huang, C; Li, L; Tao, S; Xie, X; Yang, Q | 1 |
| Ci, H; Dong, Q; Du, W; Fu, Y; Jia, H; Shen, K; Wang, X; Zhou, J | 1 |
| Bhatt, LK; Desai, N; Desai, RM; Momin, M | 1 |
| Bissonnette, JP; Chen, J; Craig, T; Dawson, LA; Munoz-Schuffenegger, P; Tadic, T; Velec, M | 1 |
| Daneshgar, H; Farasati Far, B; Naimi-Jamal, MR; Rabiee, N | 1 |
| Babalghith, AO; El-Far, AH; El-Sewedy, T; El-Shehawy, AA; Elmetwalli, A; Gaber, M; Mahmoud, MA; Mohany, H; Mosallam, SAE; Salama, AF | 1 |
| Azemoto, R; Chiba, T; Fujita, N; Fujiwara, K; Iino, Y; Inoue, M; Ishino, T; Itobayashi, E; Iwanaga, T; Kanogawa, N; Kanzaki, H; Kato, J; Kato, N; Kiyono, S; Kobayashi, K; Kojima, R; Koma, Y; Kondo, T; Koroki, K; Maruta, S; Muroyama, R; Nakagawa, M; Nakagawa, R; Nakamoto, S; Nakamura, M; Obu, M; Ogasawara, S; Ogawa, K; Saito, T; Sakuma, T; Unozawa, H; Yumita, S | 1 |
| Ladekarl, M | 1 |
| Ahn, HR; Baek, GO; Cheong, JY; Cho, HJ; Eun, JW; Kang, TW; Kim, S; Kim, SS; Kim, YB; Lim, SB; Park, W; Son, JA; Weon, JH; Yoon, JH; Yoon, MG | 1 |
| Chen, S; Feng, R; Hu, Y; Li, J; Li, M; Li, X; Li, Z; Liao, X; Mo, S; Qian, W; Tang, M; Xie, C; Xu, Y; Yu, R; Yuan, S; Zhang, S | 1 |
| Huang, L; Li, W; Lin, C; Lv, L; Saw, PE; Xu, R; Xu, X; Yang, X; Yao, Y | 1 |
| Finn, RS; Rimassa, L; Sangro, B | 1 |
| Chen, LW; Chien, RN; Chu, YD; Lin, CL; Yeh, CT | 1 |
| Cai, J; Guo, H; Jiang, P; Ma, Z; Shi, S; Xu, Q; Zhai, D; Zhao, X; Zhou, X; Zhu, C | 1 |
| Coelho, JFJ; Faneca, H; Mendonça, PV; Santo, D; Serra, AC | 1 |
| Che, Y; Chen, G; Duan, Y; Feng, H; Guo, Q; Xia, Q | 1 |
| Yu, SJ | 1 |
| Leowattana, P; Leowattana, T; Leowattana, W | 1 |
| Hsueh, KC; Huang, PT; Lee, CC; Liang, CY; Yang, SF | 1 |
| Chen, X; Fang, Y; Fu, J; Li, Y; Liu, Y; Xiang, C; Xu, H; Yuan, L; Yuan, Y; Zhang, Q; Zhou, S | 1 |
| Ding, Y; Fan, S; Lu, J; Luo, C; Ni, D; Wan, W; Xiao, W; Xie, Y; Xu, P; Zhang, N; Zhang, R; Zhang, Y; Zhao, K | 1 |
| Chen, A; Chen, L; Dai, X; He, M; Li, S; Lian, J; Liao, Q; Liu, D; Shan, M; Sun, L; Xiang, L; Yang, M; Zhai, L; Zhang, Y | 1 |
| An, C; Fu, Y; Li, W; Wu, P; Zuo, M | 1 |
| Cao, GS; Chen, SQ; Gao, K; Guo, JH; Ji, JS; Lau, WY; Li, HL; Li, R; Li, YL; Lu, D; Lu, J; Lu, LG; Lv, WF; Min, J; Ren, WX; Shao, HB; Sun, JH; Teng, GJ; Wang, WD; Wang, WJ; Wu, FZ; Yang, P; Yin, GW; Zhang, FJ; Zhao, Y; Zhu, GY; Zhu, HD | 1 |
| Li, S; Liu, Q; Peng, Y; Qin, S; Tan, C; Wan, X; Wang, L; Zeng, X | 1 |
| Liu, R; Liu, Y; Wei, J; Wu, L; Zhang, F | 1 |
| Wang, D; Yang, J | 1 |
| Li, Y; Liu, J; Pu, H; Sun, W; Xu, C | 1 |
| Cao, Y; Chen, Z; Gao, Z; Li, M; Ling, C; Lv, D; Shen, H; Shi, C; Tang, Y; Wang, D; Yang, J | 1 |
| Chen, R; Deng, X; Peng, P; Wen, B | 1 |
| Li, C; Li, M; Wang, J; Wei, F; Wei, S; Yang, Y; Zhang, J | 1 |
| Yang, S; Zeng, L; Zhou, Y | 1 |
| Abo El-Magd, NF; El Gayar, AM; Yousef, EH | 1 |
| Alamri, ES; Albalawi, AN; Diab, T; El-Far, AH; El-Naggar, SA; Elmetwalli, A; Ghedan, AR; Salama, AF | 1 |
| Gu, L; Jin, X; Liang, H; Yang, C; Zhang, Y | 1 |
| Chen, S; Duan, T; Gao, C; Kuang, J; Liu, C; Lu, C; Min, L; Wang, W; Zhu, L; Zhu, LY | 1 |
| Huang, Y; Li, L; Shen, X; Xiao, X; Yu, Y | 1 |
| Ali, SA; Atya, HB; Elkateb, AS; Nofal, S | 1 |
| Du, C; Li, J; Liu, F; Meng, L; Sun, W; Xiong, Q; Zhu, J | 1 |
| Chen, Y; Huang, A; Liu, L; Luo, M; Pan, M; Qiu, J; Sha, Y; Xia, J | 1 |
| Hu, Z; Li, L; Mang, Y; Ran, J; Yu, L; Zhao, Y; Zhu, J | 1 |
| Eguchi, Y; Iino, S; Kageyama, R; Morimoto, M; Nakamura, S; Okusaka, T | 1 |
| Bi, QC; Deng, ZQ; He, YQ; Liu, Y; Lv, YF; Tang, Q; Xie, CS | 1 |
| Huang, L; Huang, Z; Li, R; Li, S; Shen, Q; Wei, C; Wu, G; Xu, L; Xu, X; Zhang, F; Zhang, L | 1 |
| Arabloo, J; Mohammadnezhad, G; Noqani, H; Rostamian, P; Sattarpour, M | 1 |
| Chai, Z; Feng, J; Gu, Z; Qian, C; Shan, J; Zhuang, N | 1 |
| Cao, M; Chen, YY; Gao, GB; Gao, X; He, QY; Huang, S; Li, N; Liu, L; Ouyang, L; Wang, Y; Wen, SY; Yu, NN; Zhang, J; Zhang, S; Zhao, Q; Zheng, YH | 1 |
| Cao, W; Chen, Q; Lu, J; Lv, S; Ma, H; Ma, W; Zhang, X; Zhang, Z | 1 |
| Camacho, J; García-Cuellar, CM; Mendoza-Garrido, ME; Pérez-Carreón, JI; Sánchez-Pérez, Y; Villarruel-Melquiades, F | 1 |
| Abdel-Reheim, MA; Aboregela, AM; Al-Ameer, AY; Alamri, MMS; Alfaifi, J; Cavalu, S; Hasan, AM; Hashish, AA; Khalid, TBA; Mohammed, OA; Saber, S; Saleh, LA; Senbel, A | 1 |
| Amthauer, H; Bargellini, I; Benckert, J; Berg, T; Gasbarrini, A; Gebauer, B; Hinnerichs, M; Iezzi, R; Klümpen, HJ; Loewe, C; Malfertheiner, P; Öcal, O; Omari, J; Pech, M; Ricke, J; Sangro, B; Schütte, K; Seidensticker, M; Seidensticker, R; Sengel, C; Surov, A; Thormann, M; van Delden, O; Vandecaveye, V; Verslype, C; Wienke, A; Zech, CJ | 1 |
| Wang, T; Wang, WT | 1 |
| Bu, H; Chen, M; Chen, Y; Shao, M; Shen, J; Shi, Y; Shu, Y; Tao, Q; Wen, T; Wu, Z; Xu, Q; Xu, Y; Yang, J; Zhou, Y | 1 |
| Dai, JY; Jiang, B; Liu, KC; Lu, D; Lv, WF; Tan, YL; Wang, GX; Yin, L; Zhu, XH | 1 |
| Cho, Y; Hur, MH; Hyun, D; Kim, DY; Kim, GM; Kim, HC; Kim, YJ; Lee, HA; Lee, IJ; Lee, JS; Park, JW; Seo, YS; Sinn, DH | 1 |
| El Gayar, AM; El-Magd, NFA; Yousef, EH | 1 |
| Feng, L; Jiang, X; Jin, H; Lu, K; Wang, W; Wang, X; Wei, Q; Zhu, L | 1 |
| Ao, YP; Feng, GY; Feng, X; Qi, SG; Shi, ZR; Tao, J; Wu, XH | 1 |
| Chen, MY; Cherng, YG; Fong, IH; Huang, TY; Yadav, VK; Yang, CK; Yeh, CT | 1 |
| Bergamini, C; Cescon, M; Coada, CA; Fato, R; Ferracin, M; Fornari, F; Galvani, G; Giovannini, C; Gramantieri, L; Leoni, I; Liparulo, I; Melli, M; Monti, E; Negrini, M; Piscaglia, F; Ravaioli, M; Rizzardi, N; Stefanelli, C; Valenti, F; Vasuri, F | 1 |
| Jing, M; Song, Q; Xiong, X; Yan, W | 1 |
| Nguyen, DH; Nguyen, DT; Nguyen, VTH | 1 |
| Jiang, H; Jin, C; Liao, J; Mo, J; Wang, L; Xiang, S | 1 |
| Dong, Y; Gao, Y; Hu, Z; Jiang, J; Li, L; Li, W; Mang, Y; Ran, J; Yang, C; Zhang, S; Zhao, Y; Zhu, J | 1 |
| Chiu, S; Chuai, X; Cui, Y; Gao, Z; Guo, Z; Li, J; Qiao, H; Wang, W; Zhao, B; Zhao, Y | 1 |
| Knox, JJ; Lim, HJ; Liu, DM; McLeod, D; Meyers, BM; Ramjeesingh, R; Tam, VC | 1 |
| Chen, B; Chen, G; Chen, J; Chen, Q; Ding, X; Jin, B; Li, Z; Lin, Z; Liu, F; Roberts, LR; Shan, Y; Shi, Z; Wang, L; Wang, Y; Yang, Z; Ye, W; Yu, Z; Zhang, B; Zhang, S; Zheng, J | 1 |
| Chen, JJ; Huang, ZY; Li, QH; Li, TZ; Ma, YB; Yan, JX | 1 |
| Chen, Y; Chen, Z; Chi, X; Hong, H; Lv, L; Yu, J | 1 |
| Türköz, Y; Üremiş, MM; Üremiş, N | 1 |
| Farinati, F; Pelizzaro, F; Pinto, E; Russo, FP | 1 |
| Amadeo, E; Aoki, T; Arai, T; Atsukawa, M; Burgio, V; Cabibbo, G; Campani, C; Casadei-Gardini, A; Cascinu, S; Cheon, J; Chon, HJ; Di Costanzo, G; Finkelmeier, F; Foschi, FG; Fukunishi, S; Hatanaka, T; Hiasa, Y; Himmelsbach, V; Hiraoka, A; Hirooka, M; Iavarone, M; Iijima, H; Imai, M; Ishikawa, T; Itobayashi, E; Itokawa, N; Iwamoto, H; Kaibori, M; Kakizaki, S; Kariyama, K; Kawata, K; Koizumi, Y; Kosaka, H; Kudo, M; Kumada, T; Lim, HY; Lonardi, S; Marra, F; Masi, G; Montes, M; Morishita, A; Nagano, T; Naganuma, A; Nakamura, S; Niizeki, T; Nishida, N; Nishimura, T; Nouso, K; Ochi, H; Ogawa, C; Ohama, H; Okubo, T; Persano, M; Presa, J; Rimini, M; Rossari, F; Sakamoto, N; Scartozzi, M; Shimada, N; Shimose, S; Sho, T; Silletta, M; Soldà, C; Stefanini, B; Steup, C; Suda, G; Tada, F; Tada, T; Tajiri, K; Takaguchi, K; Tamburini, E; Tani, J; Tovoli, F; Toyoda, H; Tsuji, K; Tsutsui, A; Vivaldi, C; Yasuda, S; Yoo, C | 1 |
| Chen, Z; Han, L; Hu, CW; Liang, XL; Mao, JZ; Song, F; Wang, CG; Wang, TL; Zhang, Y | 1 |
| Cheng, F; He, H; Li, H; Quan, Y; Zhou, J | 1 |
| Ding, Y; Shu, Y; Tang, Y; Zhang, Q | 1 |
| Guo, L; Luo, L; Wan, L; Wen, Z; Wu, Z; Xu, K | 1 |
| Chen, A; Chen, HA; Hsu, TW; Huang, CY; Liao, PH; Shen, SC; Shibu, MA; Su, YH; Tsai, KY; Wang, TH; Wang, WY | 1 |
| Cong, P; Jin, Z; Liu, L; Shi, G; Sun, D; Wang, J; Zhu, W | 1 |
| Chen, W; Dong, K; Gao, R; Liu, SM; Luo, C; Xu, S; Yang, Y; Zhou, Y | 1 |
| Deng, DF; Fang, M; Li, XP; Tang, YK; Xu, Z; Ye, ZM; Zhang, YY; Zhou, Q | 1 |
| Pan, S; Shi, C; Zheng, J | 1 |
| Fan, Y; Guo, H; Liu, X; Shang, Y; Tan, K; Wang, H; Wang, M; Zhang, B; Zhang, S | 1 |
| Fan, W; Hu, Q; Hu, X; Huang, P; Lu, X; Song, F; Xu, T; Zhang, Q; Zhang, Y | 1 |
| Chen, K; Chen, L; Jiang, D; Jiang, J; Li, Q; Li, S; Zhang, C; Zhang, T | 1 |
| Chen, M; Chen, W; Chen, X; Ding, J; Ding, Y; Fang, S; Guo, X; Ji, J; Ma, J; Tu, J; Yang, Y; Zhao, Z; Zheng, L | 1 |
| Jin, L; Kuzuya, T; Tanizawa, Y | 1 |
| Bai, Y; Chan, SL; Chen, C; Chen, Y; Chen, Z; Cheng, AL; Cheng, Y; Gu, S; Guo, Y; Hu, X; Jia, W; Jin, Y; Kaseb, A; Li, W; Liang, J; Liang, X; Lin, X; Melisi, D; Meng, Z; Osypchuk, Y; Pazgan-Simon, M; Pisetska, M; Ponomarenko, D; Qin, S; Ren, H; Ren, Z; Sinielnikov, I; Sultanbaev, A; Vogel, A; Wang, L; Xiong, J; Yang, F; Yang, TS; Zeng, Y | 1 |
| Albalawi, F; Fakurazi, S; Hussein, MZ; Masarudin, MJ | 1 |
| Cai, G; Cheng, J; Huang, H; Kong, W; Lei, Q; Liao, Y; Liu, Y; Sun, W; Yin, S; Yu, C; Yu, Y; Zhuang, X | 1 |
| Fu, Z; Gao, D; Lin, D; Liu, X; Wang, T; Yang, G | 1 |
| Aliberti, A; Buonaguro, L; Caputo, TM; Carriero, MV; Celetti, G; Cicatiello, P; Cusano, A; Cusano, AM; Micco, A; Minopoli, M; Principe, S; Ragone, C; Ruvo, M; Tagliamonte, M | 1 |
| Gao, F; He, H; Li, W; Lian, Z; Qiu, X; Su, R; Tan, Y; Wang, K; Xu, H; Xu, X; Zhang, Z; Zhuo, J | 1 |
| Firtina Karagonlar, Z; Sariyar, E | 1 |
| Cui, XJ; Dong, P; Ning, HF; Wang, GZ; Xing, H; Zhang, YL | 1 |
| Cao, Y; Jiang, C; Shi, W; Wang, Z; Wu, J; Wu, S; Xu, X; Zhang, G | 1 |
| Chen, TL; Fang, CC; Liao, YJ; Suk, FM; Wu, CY | 1 |
| Chen, D; Chen, X; Kang, M; Wang, Y; Zhu, L | 1 |
| El-Gazzar, MGM; El-Hazek, RMM; El-Sabbagh, WA; Fadel, NA; Zaher, NH | 1 |
| Abenavoli, L; Argenziano, ME; Giorgi, F; Montori, M; Ponziani, F; Scarlata, GGM; Scarpellini, E; Svegliati Baroni, G | 1 |
| Beier, D; Ben Khaled, N; Berger-Thürmel, K; De Toni, EN; Ehmer, U; Geier, A; Kubisch, I; Lange, CM; Mayerle, J; Mörtl, B; Munker, S; Pawlowska-Phelan, D; Philipp, A; Reiter, FP; Rössler, D; Schwade, DF; Teufel, A | 1 |
| Jiang, X; Kang, MJ; Liu, H; Liu, MR; Pei, DS; Shi, C; Song, QY | 1 |
| Deng, Y; Guo, S; Wang, H; Wang, L; Weng, C; Xia, Y; Zeng, H; Zhang, C | 1 |
| Al-Abdulla, R; Bantel, H; Bettinger, D; Briz, O; Del Carmen, S; Geier, A; Herraez, E; Macias, RIR; Marin, JJG; Serrano, MA; Soto, M | 1 |
| Greten, TF; Korangy, F; Ma, L; Ruf, B; Ruppin, E; Villanueva, A; Wang, XW; Yarchoan, M | 1 |
| Kong, S; Song, J; Wang, H; Yan, J; Yu, H | 1 |
| Beppu, T; Hayashi, H; Imai, K; Isiko, T; Karashima, R; Mima, K; Miyata, T; Nitta, H; Oda, E; Okabe, H; Ozaki, N; Yamamura, K | 1 |
| Allaire, M; Araujo-Goncalves, J; Charlotte, F; Couty, JP; Evain, M; Galy-Fauroux, I | 1 |
| Cai, J; Cai, X; Chen, T; Ji, L; Ruan, Y; Tao, L; Wang, Y; Xu, J; Zhao, H; Zheng, L | 1 |
| Androutsakos, T; Apostolidi, EA; Griniatsos, J; Karamouzis, MV; Papadakos, SP; Pergaris, A; Sarantis, P; Sougioultzis, S; Vallilas, C | 1 |
| Amer, MS; Borchard, G; Elshafeey, AH; Jordan, O; Qubisi, M; Sakr, OS; Zaitoun, MMA | 1 |
| Abdelhakim, HK; El-Khawaga, AM; Elfattah Mohammed, RA; Khafaga, DSR | 1 |
| Cui, M; Fang, Z; Lai, K; Liu, K; Song, M; Yin, M | 1 |
| Chen, Y; Huang, S; Jiang, J; Lü, M; Luo, B; Ren, W; Shi, L; Shi, X; Tang, X; Zhang, W; Zhong, X | 1 |
| Cai, WH; Chen, L; Ju, LL; Wang, F; Wang, HX; Yuan, LX; Zhang, P; Zhao, JH | 1 |
| Ponvilawan, B; Roth, MT | 1 |
| Feng, YP; Gou, JX; He, HB; Liu, BY; Liu, ZX; Tang, X; Wang, P; Wang, QQ; Wang, YJ; Yin, T; Zhang, Y | 1 |
| Liang, B; Lu, H; Xia, X; Zheng, C | 1 |
| Cardone, F; Cerreto, M; Cerrito, L; Gasbarrini, A; Pallozzi, M; Ponziani, FR; Santopaolo, F; Stella, L | 1 |
| Chan, YT; Feng, Y; Feng, Z; Lee, TK; Li, Q; Lu, Y; Tan, HY; Wang, N; Wu, J; Xing, T; Xu, L; Yuan, H; Zhang, C | 1 |
| Chen, W; Gong, H; Hua, X; Liang, J; Yin, Z | 1 |
| Abdelaziz, AO; Abou-Alfa, GK; Afihene, M; Agyei-Nkansah, AA; Alatise, OI; Ali, MM; Asombang, A; Atipo Ibara, BI; Balogun, F; Biachi de Castria, T; Bougouma, A; Bounedjar, A; Capanu, M; Chou, JF; Cunha, L; Diop, PS; El Baghdady, N; Elwakil, R; Fouad, M; Hammad, N; Jonas, E; Kimani, S; Kingham, P; Kurrimbukus, R; Li, Y; Makondi, PT; Mekonnen, HD; Ndlovu, N; Ndumbalo, J; Roberts, LR; Servais Albert Fiacre, EB; Sewram, V; Spearman, CW; Tzeuton, C; Yang, JD | 1 |
| Du, J; Ma, Z; Nie, W; Wang, C; Yang, D | 1 |
| Gao, Y; Li, M; Loh, JJ; Ma, S; Ng, KY; Tong, M; Wang, Z; Wong, TL; Xie, YN; Yu, H | 1 |
| Ahn, SH; Cheon, JH; Cho, KJ; Joo, DJ; Kim, BK; Kim, DY; Kim, MD; Kim, SU; Lee, HW; Park, HJ; Park, JY; Seo, SH; Yook, JI | 1 |
| Andrisani, O; Caron de Fromentel, C; Elzey, BD; Kazemian, M; Kim, W; Lanman, NA; Levrero, M; Li, Z; Sun, J; Utturkar, S; Wang, WH; Yan, B; Yeo, Y; Zhang, H | 1 |
| Bai, Z; Cai, C; Dai, Y; Jia, Y; Li, J; Li, P; Lin, E; Liu, X; Wang, B; Zeng, G; Zhao, J; Zhuo, W; Zou, B | 1 |
| Li, H; Li, Y; Liu, X; Liu, Y; Luo, M | 1 |
| Barbi, J; Hutson, A; Iyer, R; Kalathil, SG; Thanavala, Y | 1 |
| Duan, X; Wang, Z; Zhang, Y; Zhao, K; Zhao, Y | 1 |
| Abd Elwakil, MM; Harashima, H; Khalil, IA; Younis, MA | 1 |
| Akahane, T; Douhara, A; Furukawa, M; Kaji, K; Kawaratani, H; Kitagawa, K; Mitoro, A; Moriya, K; Namisaki, T; Saikawa, S; Sato, S; Sawada, Y; Shimozato, N; Takaya, H; Yamao, J; Yoshiji, H | 1 |
| Chen, D; Huang, Y; Lian, Y; Wang, J; Wei, H; Zeng, G | 1 |
| Amthauer, H; Bargellini, I; Bartenstein, P; de Toni, EN; Gasbarrini, A; Klümpen, HJ; Malfertheiner, P; Pech, M; Peck-Radosavljevic, M; Popovič, P; Ricke, J; Rosmorduc, O; Sangro, B; Schott, E; Seidensticker, M; Verslype, C | 1 |
| Arriaga, Y; Beg, MS; Dowell, JE; Mokdad, AA; Singal, AG; Yopp, AC; Zhu, H | 1 |
| Garten, A; Grohmann, T; Kiess, W; Kluckova, K; Lavery, GG; Penke, M | 1 |
| Chen, M; Cheng, CL; Chin, DW; Law, CT; Lee, D; Lee, JM; Ng, IO; Shen, J; Tsang, FH; Wei, L; Wong, CC; Wong, CM | 1 |
| Cetin-Atalay, R; Kahraman, DC; Kahraman, T | 1 |
| Casadei-Gardini, A; Foschi, FG; Granito, A; Ielasi, L; Negrini, G; Orsi, G; Piscaglia, F; Renzulli, M; Rovesti, G; Tovoli, F | 1 |
| Danilova, L; Fertig, EJ; Jafarnejad, M; Mirando, AC; Pandey, NB; Popel, AS; Sové, RJ; Tran, PT; Yarchoan, M; Zhang, Y | 1 |
| Guo, X; Li, X; Liu, K; Ouyang, Y; Pang, L; Qiao, L; Wang, W; Wang, Z; Xu, L; Yuan, C; Zhang, X | 1 |
| Chen, R; Li, L; Ma, H; Ren, Z; Tang, B; Xie, X; Yin, X; Yuan, J; Zhang, L | 1 |
| Jiang, P; Jiang, Y; Li, C; Wang, J; Wei, S; Xu, X; Xue, L | 1 |
| Dong, H; Jing, W; Jun, X; Min, M; Runpeng, Z; Shuo, L; Yingru, X | 1 |
| Bai, T; Lei, P; Liang, R; Sun, Y; Wang, W; Zhou, H; Zhou, L; Zhu, R | 1 |
| Bai, H; Hu, X; Phan, C; Tang, G; Wang, J; Wang, Q; Zheng, Z | 1 |
| Dehua, WU; Xiaohui, C; Xin, LI | 1 |
| Cao, Y; Feng, F; Li, Z; Wang, L; Wang, X; Yin, F | 1 |
| Airoldi, A; Antonelli, B; Cesarini, L; Donato, MF; Iavarone, M; Invernizzi, F; Lampertico, P; Maggi, U; Manini, MA; Mazza, S; Rossi, G; Sangiovanni, A; Saverio Belli, L; Zavaglia, C | 1 |
| Beijersbergen, RL; Bernards, R; du Chatinier, A; Gao, D; Jin, G; Jin, H; Lieftink, C; Qin, W; Wang, C; Wang, H | 1 |
| Fan, L; Liu, J; Lu, Q; Sun, G; Wang, H; Wang, Y; Wei, W; Zhou, B | 1 |
| Appelman, HD; Feng, S; Li, Z; Wang, TD; Zhao, L; Zhou, J; Zhu, J | 1 |
| Li, H; Li, X; Liu, J; Ma, Y; Peng, X; Yang, L; Yang, S; Zhou, Y | 1 |
| Pathania, YS | 1 |
| Fernández-Palanca, P; Fondevila, F; González-Gallego, J; Mauriz, JL; Méndez-Blanco, C | 1 |
| Jiang, Z; Li, X; Qiu, G; Wang, G; Wang, H; Wei, G; Zhao, W | 1 |
| Chakraborti, A; Kanthaje, S; Kaur, H; Kaur, R; Makol, A; Sharma, S | 1 |
| Belev, B; Bulimbašić, S; Kekez, D; Kocić, L; Pleština, S; Prejac, J | 1 |
| Likhitsup, A; Parikh, ND | 1 |
| Berhane, S; Bettinger, D; Blanc, JF; Bonnett, LJ; Cucchetti, A; De Man, RA; Edeline, J; Eskens, FALM; Johnson, PJ; Klümpen, HJ; Labeur, TA; Meyer, T; Takkenberg, RB; Ten Cate, DWG; Van Delden, OM; Van Vugt, JLA | 1 |
| Bai, XF; Barajas, JM; Elkholy, KH; Ghoshal, K; Hu, P; Jacob, ST; Khan, WN; Li, D; Lin, CH; Noonan, AM; Wani, NA; Yu, L; Zhang, X | 1 |
| Banz, V; Bouchez, LC; Candinas, D; Dommann, N; Gavini, J; Jakob, MO; Julio, MK; Karkampouna, S; Keogh, A; Medova, M; Schläfli, AM; Stroka, D; Tschan, MP; Zimmer, Y | 1 |
| Cabibbo, G; Cammà, C; Casadei-Gardini, A; Celsa, C; Cucchetti, A; Emanuele Maria Rizzo, G; Ercolani, G; Johnson, P | 1 |
| He, M; Li, Q; Shi, M | 1 |
| Coriat, R; Dermine, S; Palmieri, LJ | 1 |
| Nazari, M; Rosenblum, JS; Trumbo, S | 1 |
| Che, N; Chung, KPS; Ding, J; Lau, EYT; Lee, TKW; Leung, CON; Ma, S; Ng, IOL; Tang, KH; Tong, M; Zhou, L | 1 |
| Huang, J; Kong, H; Lu, Y; Rong, Y; Wang, C; Wang, Y; Xie, H; Yang, B; Yang, Y; Zhang, H | 1 |
| Aikata, H; Hatanaka, T; Hidaka, H; Ishibashi, T; Kobayashi, S; Kondo, M; Maeda, S; Matsunaga, K; Morimoto, M; Nakazawa, T; Numata, K; Ohkawa, S; Okuse, C; Suzuki, M; Taguri, M; Takizawa, D; Tanaka, K | 1 |
| Chin, DW; Law, CT; Lee, D; Ng, IO; Shen, J; Tsang, FH; Wei, L; Wong, CC; Wong, CL; Wong, CM; Zhang, A; Zhang, MS | 1 |
| Abdelgadir, AM; Alhaider, A; Korashy, HM; Saraswati, S; Tanwer, P | 1 |
| Argentiero, A; Brunetti, O; Delcuratolo, S; Gnoni, A; Licchetta, A; Longo, V; Memeo, R; Solimando, AG | 1 |
| Chapel, S; Lacy, S; Nguyen, L; Tran, BD | 1 |
| Argentiero, A; Brunetti, O; Calabrese, A; Casadei-Gardini, A; Delcuratolo, S; Gnoni, A; Licchetta, A; Longo, V; Silvestris, N; Solimando, AG | 1 |
| Che, CM; Fung, YME; Ko, FCF; Kwong, EML; Lai, CL; Leung, Z; Liu, BHM; Ma, APY; Mao, X; Ng, IO; Tey, SK; Wong, DKH; Yam, JWP | 1 |
| Achterbergh, R; Klümpen, HJ; Labeur, TA; Mathôt, R; Takkenberg, B; Van Delden, O | 1 |
| Lei, T; Liu, J; Lv, L; Song, Y; Wang, X; Wei, L; Xie, M; Xing, H; Yang, M; Zhang, N | 1 |
| Afifi, AM; El-Houseini, ME; El-Husseiny, AM; Khalil, MA; Tabashy, RH | 1 |
| Chang, YY; Ensslin, CJ; Hsieh, CH; Hsieh, SY; Kao, PH; Kuo, TT; Miller, LS; Wu, MY; Yang, CH | 1 |
| Cai, ZS; Chang, CW; Chen, MJ; Tang, TY | 1 |
| Duan, X; Lv, Y; Wang, Z; Zhao, Y | 1 |
| Chen, D; Fei, W; Li, C; Song, Q; Tang, H; Wu, X; Zhang, Y; Zheng, C | 1 |
| Li, Q; Li, Y; Liang, R; Lin, Y; Liu, Z; Luo, M; Ye, J; Zhang, J; Zhang, Y | 1 |
| Chang, CS; Lee, SW; Lee, TY; Peng, YC; Yang, SS; Yeh, HZ | 2 |
| Liu, J; Qiu, WC; Shen, XY; Sun, GC | 1 |
| Liu, C; Luna, A; Pham, K; Studzinski, GP; Wang, X; Wu, Q | 1 |
| Adhoute, X; Bourlière, M; Pénaranda, G; Raoul, JL | 1 |
| Fujishiro, M; Honda, T; Ishigami, M; Ishikawa, T; Ishizu, Y; Ito, T; Kuzuya, T; Muto, H | 2 |
| Aikata, H; Haruna, K; Ikeda, K; Ikeda, M; Inaba, Y; Izumi, N; Kawaguchi, Y; Kitamura, C; Kobayashi, M; Kudo, M; Kumada, H; Kuromatsu, R; Numata, K; Okita, K; Okusaka, T; Saito, K; Tamai, T; Tateishi, R; Wada, Y; Yamashita, T | 1 |
| Chen, SC; Chuang, WL; Dai, CY; Hsieh, MH; Hsieh, MY; Hsu, CT; Hsu, PY; Huang, CF; Huang, CI; Huang, JF; Liang, PC; Lin, YH; Lin, ZY; Wei, YJ; Yeh, ML; Yu, ML | 1 |
| Cui, YL; Ding, CH; Ding, J; Feng, JF; Huang, CK; Liu, JP; Lu, B; Xie, WF; Xu, WP; Yang, Y; Zhang, X; Zhou, WP; Zhu, CP | 1 |
| Dai, Z; Deng, Y; Dong, L; Liang, L; Zan, Y | 1 |
| Bangaru, S; Marrero, JA; Singal, AG | 1 |
| Chen, J; Jia, H; Lin, J; Lin, Z; Lu, L; Lu, M; Luo, M; Qin, L; Shao, W; Zhu, W | 1 |
| Chuang, YT; Hsu, MH; Liao, YJ; Liu, CL; Suk, FM; Wang, JP | 1 |
| Ahmed, AR; Alaaeldin, E; Allam, S; Elsadek, BE; Elsayed, MM; Mostafa, ME; Sarhan, HA; Shaykoon, MS | 1 |
| Ebrahim, HM; El-Rouby, MN; Ezz, MK; Morsy, ME; Said, MM | 1 |
| Christie, CF; Dang, Y; DeHart, DN; Fang, D; Gooz, MB; Heslop, KA; Hunt, EG; Lemasters, JJ; Maldonado, EN; Morris, ME; Rovini, A | 1 |
| Chang, TS; Chi, CC; Huang, YH; Kuo, YC; Lai, SC; Lan, PC; Lee, KF; Su, YT; Wu, YC; Yang, MH | 1 |
| Cen, B; Chen, K; Feng, T; Feng, Z; He, X; Jiang, G; Ling, S; Liu, J; Liu, P; Ma, J; Shan, Q; Song, P; Wei, R; Wen, X; Wu, Y; Xiang, J; Xie, H; Xu, L; Xu, S; Xu, X; Ye, Q; Zhan, Q; Zhang, C; Zhang, X; Zheng, S | 1 |
| Chatellier, G; Hawkins, NS; Palmer, DH; Pereira, H; Ross, PJ; Vilgrain, V | 1 |
| Chang, J; Duan, Y; Gao, JX; Gong, XQ; Hou, W; Liu, HS; Wang, HJ; Wei, D; Wu, XL; Yang, H | 1 |
| Aikata, H; Aino, H; Arai, Y; Furuse, J; Hino, K; Ido, A; Ikeda, M; Isoda, N; Izumi, N; Johnson, PJ; Kawabe, N; Kokudo, N; Kudo, M; Kuzuya, T; Nakao, K; Nojiri, S; Okita, K; Okusaka, T; Tanabe, N; Torimura, T; Tsumura, H; Ueshima, K; Wada, Y; Yamasaki, T; Yasui, K; Yokosuka, O; Yoshimura, K | 1 |
| Chu, Y; He, C; Hua, QM; Li, JZ; Liao, J; Mao, K; Wen, WP; Wu, Y; Xiao, Z; Zeng, DN; Zheng, L; Zhu, LY | 1 |
| Abo Elseud, Y; Albarrak, J; Mohanty, A; Salamah, R; Shaaban, A | 1 |
| Cheng, L; Guo, B; Li, F; Li, Y; Meng, F; Wei, J; Wei, Y; Zhong, Z | 1 |
| Jiang, J; Liu, W; Mei, F; Wu, M | 1 |
| Chen, D; Han, G; Li, L; Liu, L; Peng, K; Wang, E; Wang, M | 1 |
| Chuang, KL; Dao, AH; Hsu, WH; Huang, CF; Huang, ZY; Liao, SC; Lin, KT; Su, CL; Tsai, TH; Tseng, CL | 1 |
| Chen, T; Chen, X; Cui, Y; Ge, C; Huang, T; Jiang, Z; Li, H; Li, J; Tian, H; Yao, M; Zhang, L; Zhao, F; Zhou, Q; Zhu, M | 1 |
| Bai, W; Chen, H; Fan, D; Guo, W; Han, G; Han, N; He, C; Hu, J; Jiang, D; Li, K; Li, X; Liu, L; Luo, B; Lv, Y; Niu, J; Shi, J; Sun, Y; Tie, J; Wang, E; Wang, J; Wang, Q; Wang, Z; Xia, D; Yang, K; Yang, S; Yin, Z; Yu, T; Yuan, J; Yuan, X; Zhang, C; Zhang, Z; Zhu, Y | 1 |
| Ghanim, AMH; Saber, S; Younis, NS | 1 |
| Bock, T; Buechel, D; Christofori, G; Dazert, E; Gao, R; Hall, MN; Heim, MH; Hergovich, A; Hindupur, SK; Jeevan-Raj, B; Kalathur, RKR; Lim, DS; Matthias, P; Morini, MF; Ng, CKY; Nuciforo, S; Piscuoglio, S; Song, S; Tang, F; Terracciano, LM; Wyss, CB | 1 |
| Li, JX; Liang, GL; Liu, X; Tang, ST; Xiang, BD | 1 |
| Bruix, J; Reig, M; Sanduzzi-Zamparelli, M; Sapena, V | 1 |
| Chen, YC; Hsieh, YC; Huang, CH; Hung, CF; Jeng, WJ; Lin, CC; Lin, CY; Lin, PT; Lin, SM; Lui, KW; Sheen, IS; Teng, W | 1 |
| Chen, XP; Dong, HH; Dong, KS; Zhang, EL; Zhang, LW; Zhang, ZY | 1 |
| Ding, G; Dong, J; Fu, Z; Guo, W; Liu, F; Liu, H; Mao, J; Sha, Z; Song, S; Sun, K; Zhao, Y | 1 |
| Chen, ZQ; Dong, ZR; Li, T; Shi, K; Sun, D; Wang, XW; Wu, R; Yan, LJ; Yan, YC; Yang, YF; Yao, CY; Zhi, XT; Zhou, W | 1 |
| Han, L; Li, T; Lin, Y; Ma, D; Ma, X; Qin, Z; Qiu, Y; Shen, X; Sun, C; Zhao, Y; Zhu, L | 1 |
| Buonaguro, L; Cavalluzzo, B; Manolio, C; Mauriello, A; Petrizzo, A; Ragone, C; Tagliamonte, M | 1 |
| Bai, J; Kong, D; Liu, J; Liu, Z; Ren, L; Tian, Y; Zhang, S; Zhang, Y | 1 |
| Berhane, S; Johnson, PJ; Labeur, TA | 1 |
| Dai, W; Dong, L; Guo, C; Guo, H; Liu, H; Liu, T; Shen, X; Song, G; Weng, S; Xu, L; Yu, X; Zhang, G; Zhu, J | 1 |
| Fang, W; Hou, R; Li, L; Li, Y; Liu, C; Liu, S; Liu, Z; Luo, R; Peng, X; Zhang, Y; Zuo, S | 1 |
| Devi Padma, U; Keechilat, P; Prasanna Thankappan, A; Thomas, S | 1 |
| Cinnamon, E; Pikarsky, E | 1 |
| Cai, X; Liang, Y; Pan, Y; Xia, S; Xu, J | 1 |
| Lin, LS; Liu, TP; Yang, PM | 1 |
| Arai, M; Chiba, T; Kanayama, K; Kanogawa, N; Kanzaki, H; Kato, J; Kato, N; Kiyono, S; Kobayashi, K; Kondo, T; Koroki, K; Maruta, S; Nakamoto, S; Nakamura, M; Ogasawara, S; Ooka, Y; Saito, T; Suzuki, E; Tawada, A | 1 |
| Faivre, S; Finn, RS; Rimassa, L | 1 |
| Cervilla Sáez de Tejada, E; Díaz Alcázar, MDM; Ruiz Escolano, E | 1 |
| Baradaran, B; Derakhshani, A; Hajiasgharzadeh, K; Khaze Shahgoli, V; Mansoori, B; Mokhtarzadeh, A; Shanehbandi, D; Somi, MH | 1 |
| Gao, Y; Jiang, JD; Li, K; Li, ZR; Xue, ST; Yi, H; Zhao, LY | 1 |
| Cheng, Q; Hu, S; Li, Z; Wang, S; Wang, Y; Xiang, X; Xun, X; Zhang, C; Zhu, J | 1 |
| Chen, K; Dai, W; Feng, J; Guo, C; Ji, J; Kong, R; Li, J; Li, S; Mao, Y; Mo, W; Wu, J; Wu, L; Xu, X; Yu, Q; Zhang, J | 1 |
| Björnsson, B; Hemmingsson, O; Henriksson, M; Isaksson, B; Lindell, G; Rizell, M; Sandström, P; Sternby Eilard, M; Strömberg, C | 1 |
| Chen, J; Duda, DG | 1 |
| Fujishiro, M; Honda, T; Ishigami, M; Ishizu, Y; Ito, T; Kawashima, H; Kuzuya, T; Miyahara, R; Nakamura, M; Yamamoto, K | 1 |
| Battelli, N; Bianconi, M; Casadei Gardini, A; Cascinu, S; Demurtas, L; Falcone, A; Faloppi, L; Gadaleta, CD; Galizia, E; Giampieri, R; Lai, E; Loretelli, C; Marisi, G; Masi, G; Puzzoni, M; Scartozzi, M; Silvestris, N; Ulivi, P; Vivaldi, C; Ziranu, P | 1 |
| Cheng, Q; Gao, J; Li, Z; Wang, Y; Xiang, X; Zheng, SM; Zhu, J | 1 |
| Liu, M; Mou, T; Shen, A; Shi, J; Wang, Y; Wu, Z | 1 |
| Bae, SH; Cho, EY; Jang, BK; Jang, JY; Kim, BH; Kim, DY; Kim, HJ; Kim, IH; Kim, JH; Kim, KM; Kim, YJ; Lee, BS; Lee, HW; Lee, JI; Paik, YH; Seo, YS; Sinn, DH; Suh, KS; Yim, HJ | 1 |
| De la Cruz Lombardo, J; González Grande, R; Jiménez Pérez, M; López Ortega, S; Santaella Leiva, I | 1 |
| Busschaert, P; Cappuyns, S; Dekervel, J; Galle, E; Lambrechts, D; Roskams, T; Thienpont, B; Van Cutsem, E; Van Haele, M; van Pelt, J; Venken, T; Verslype, C | 1 |
| Cai, SH; Cho, WCS; Lau, EYT; Lee, TKW; Lei, MML; Leung, CON; Leung, HW; Ma, S; Ma, VWS; Mok, EHK; Ng, IOL; Yu, HJ; Yun, JP | 1 |
| Ichimura, Y; Imamura, R; Kojima, H; Komatsu, M; Mashino, T; Nagano, T; Ohe, T; Okabe, T; Takahashi, K; Yamamoto, M; Yasuda, D | 1 |
| Ahn, SH; Beom, SH; Byun, HK; Choi, HJ; Han, KH; Kim, BK; Kim, DY; Kim, SU; Lee, HW; Park, JY; Seong, J | 1 |
| Amano-Teranishi, Y; Dong, MP; Enomoto, M; Fujii, H; Hagihara, A; Hai, H; Hieu, VN; Hoang, DV; Iida-Ueno, A; Kawada, N; Odagiri, N; Tamori, A; Thuy, LTT; Uchida-Kobayashi, S | 1 |
| Baldan Ferrari, G; Berlofa Visacri, M; Coelho França Quintanilha, J; Cursino, MA; de Godoy Torso, N; de Oliveira Guarnieri, JP; Moriel, P; Oliveira Vaz, C; Passos Lima, CS; Pereira, TT; Sampaio Amaral, L | 1 |
| Aramaki, T; Fujii, H; Furukawa, M; Furuse, J; Homma, G; Kudo, M; Kudo, T; Morimoto, M; Motomura, K; Nadano, S; Ohkawa, K; Ohno, I; Okusaka, T; Sato, S; Seo, S; Takai, H; Wada, Y; Yamashita, T; Yoshikawa, R; Zhu, AX | 1 |
| Bian, Y; Guo, D | 1 |
| Guo, D; Hou, C; Liu, T; Wang, S; Yu, X | 1 |
| Bort, A; de Miguel, I; Diaz-Laviada, I; Mateos-Gómez, PA; Sánchez, BG | 1 |
| Aleixo, MJ; Fonseca, C; Fonseca, J; Nunes, G; Patita, M; Ramalho, M | 1 |
| Han, L; Li, T; Lin, Y; Ma, D; Ma, X; Qin, Z; Qiu, Y; Sun, C; Sun, Y; Zhao, Y; Zhu, L | 1 |
| Chon, HJ; Kim, C | 1 |
| Červinková, Z; de la Cruz-Ojeda, P; Del Campo, JA; Elkalaf, M; Gallego, P; Kučera, O; Maseko, TE; Muntané, J; Navarro-Villarán, E; Rodríguez-Hernández, MA; Staňková, P | 1 |
| Bertacco, A; Cillo, U; Mescoli, C; Vitale, A | 1 |
| Kim, JJ; McFarlane, T; Tully, S; Wong, WWL | 1 |
| Chen, CH; Chen, YY; Cheng, JY; Cheng, YF; Hu, TH; Lin, CC; Liu, YW; Wang, JH; Yen, YH; Yong, CC | 1 |
| Cheng, Z; Guo, G; Lei, Z; Luo, T; Si, A; Tang, X; Wang, L; Yang, P; Zhang, Q | 1 |
| Chang, UI; Choi, JY; Choi, SW; Jang, JW; Kim, CW; Kim, HY; Kim, SH; Kwon, JH; Lee, HL; Lee, SW; Nam, HC; Song, DS; Song, MJ; Sung, PS; Tak, KY; Yang, JM; Yoo, SH; Yoon, SK | 1 |
| Arai, K; Asahina, Y; Hashiba, T; Hayashi, T; Honda, M; Iida, N; Kaneko, S; Kawaguchi, K; Mizukoshi, E; Nio, K; Ohta, T; Okada, H; Sakai, Y; Shimakami, T; Takamura, H; Takatori, H; Terashima, T; Yamashita, T | 1 |
| Dufour, JF; Radu, P | 1 |
| El-Badawy, O; Eldin, AS; Fakhry, H; Hassan, EA; Hetta, HF; Rayan, A; Soliman, A; Zahran, AM | 1 |
| Aballay Soteras, G; Alvares-da-Silva, MR; Alves, R; Anders, M; Arenas, JI; Bruix, J; Chagas, AL; Coll, S; da Fonseca, LG; Delgado, M; Di Costanzo, GG; Díaz-González, Á; França, A; Gallego, A; García Juárez, I; Giannini, EG; Granito, A; Hernáez, T; Hernández-Guerra, M; Huertas, C; Iavarone, M; Ladekarl, M; Leal, C; Lledó, JL; Lozano, M; Lue, A; Marín, J; Matilla, AM; Mello, V; Menéndez, J; Mínguez, B; Nault, JC; Pascual, S; Pereira, G; Perelló, C; Piñero, F; Pinter, M; Reig, M; Rimassa, L; Rodríguez de Lope, C; Rojas, Á; Sacco, R; Sala, M; Sánchez-Torrijos, Y; Sanduzzi-Zamparelli, M; Sangro, B; Varela, M; Vergara, M; Wörns, MA | 1 |
| Borentain, P; Chopinet, S; Gerolami, R; Grégoire, E; Hardwigsen, J; Palen, A | 1 |
| Ba, Q; Gao, Z; Li, J; Li, X; Qiu, L; Sun, M; Wang, F; Wang, H; Wang, W; Yang, C; Yang, Y; Yao, W; You, R | 1 |
| Blessin, UB; Leineweber, CG; Pietzner, A; Rothe, M; Schebb, NH; Schott, E; Weylandt, KH; Zhang, IW | 1 |
| Carceller, F; Marshall, LV; Pearson, H | 1 |
| Li, X; Li, Z; Lian, D; Liu, J; Ye, L | 1 |
| Jiang, L; Jin, X; Lin, M; Qiu, Y; Wang, L; Wu, Z; Zhan, Y | 1 |
| Chen, X; Luan, C; Wang, T; Wu, J | 1 |
| Chen, CT; Chow, LP; Huang, YH; Liao, LZ; Lin, JH; Lin, YK; Lu, CH | 1 |
| Castello, A; Lopci, E; Personeni, N; Pressiani, T; Rimassa, L; Smiroldo, V | 1 |
| Deng, Y; Dong, L; Li, YH; Liu, J; Liu, TT; Shen, XZ; Yu, XN; Zhang, GC; Zhu, CF; Zhu, JM | 1 |
| abuTaleb, F; Ebian, H; El Shorbagy, S; Elbana, KA; Haggag, R; Harb, OA; Labib, HA; Mohammed, MS; Rashied, HA | 1 |
| Duan, XC; Feng, ZH; Guo, Y; Li, H; Li, ZY; Liao, A; Liu, M; Wang, GX; Wang, JR; Wang, SM; Xu, MQ; Yin, YF; Zhang, S; Zhang, SQ; Zhang, X | 1 |
| Gao, L; Teng, Y | 1 |
| Ho, CH; Huang, CI; Li, LC; Lin, CH; Que, J; Wu, HC | 1 |
| Fujishiro, M; Honda, T; Ishigami, M; Ishikawa, T; Ishizu, Y; Ito, T; Kuzuya, T | 1 |
| Beyer, S; Grammatikos, G; Jakobi, K; Koch, A; Pfeilschifter, J; Schwalm, S; Thomas, D; Zeuzem, S | 1 |
| Chen, Y; Jiang, L; Lei, J; Li, Y; Peng, J; Sheng, H; Wang, J; Wu, L; Xu, Y; Yu, H; Zhang, J; Zhang, X; Zhao, H; Zhou, Y | 1 |
| Cao, LP; Weng, XY; Wu, J; Xie, HY; Zhang, C; Zheng, SS | 1 |
| Briggs, A; Daniele, B; Dick, K; Evans, TRJ; Galle, PR; Hubner, RA; Lopez, C; Siebert, U; Tremblay, G | 1 |
| Hua, S; Li, W; Li, Y; Lu, L; Ma, F; Wang, H; Xu, H; Yang, X; Zhan, M | 1 |
| Abd-Elbaset, M; Abo-Youssef, AM; Ahmed, OM; Mansour, AM | 1 |
| Chao, Y; Chen, BB; Cheng, AL; Hsu, C; Hsu, CH; Huang, PH; Hung, YP; Lee, RC; Lin, ZZ; Shao, YY; Shen, YC | 1 |
| Ananth, S; Arora, SP; Gelfond, J; Ketchum, N; Mahalingam, D; Michalek, J | 1 |
| Cheng, S; Du, C; Fan, X; Fu, J; Gao, Y; Li, N; Ma, J; Markowitz, GJ; Qin, W; Wang, H; Yang, B; Yang, P | 1 |
| Han, J; Ji, Q; Liu, W; Liu, Y; Ma, L; Ma, Y; Shen, C; Tai, Y; Wang, T; Wang, Y; Xu, A; Zhao, C | 1 |
| Assenat, E; Borg, C; Brandi, G; Dadduzio, V; Daniele, B; Drove Ubreva, N; Finn, RS; Galle, PR; Jen, MH; Kudo, M; Llovet, JM; Merle, P; Morimoto, M; Motomura, K; Okusaka, T; Pracht, M; Shinozaki, K; Tomášek, J; Vogel, A; Widau, RC; Yoshikawa, R; Zhu, AX | 1 |
| Fang, WY; Li, AM; Li, YH; Lin, X; Liu, C; Liu, YY; Liu, Z; Luo, RC; Xie, YY; Zou, YJ; Zuo, S | 1 |
| Gao, JJ; Wang, K; Yao, X; Yin, H; Zhao, CR | 1 |
| de Liguori Carino, N; Hubner, RA; Kapacee, ZA; Lamarca, A; McNamara, MG; Valle, JW | 1 |
| Ding, HR; Liu, YX; Ma, B; Qu, L; Tian, ZH; Zhang, H | 1 |
| Chung, JI; Jo, H; Kim, J; Kim, KS; Kim, SY; Kim, T; Ko, HY; Lee, JS; Lee, M; Park, Y; Pyun, JC; Yun, M | 1 |
| Ahn, YE; Byun, KS; Jung, YK; Kang, SH; Kim, HR; Kim, JH; Kim, TH; Lee, YS; Seo, YS; Suh, SJ; Um, SH; Yeon, JE; Yim, HJ; Yim, SY; Yoon, EL | 1 |
| Cai, J; Chen, J; Cheng, Z; Pu, C; Shi, W; Suo, X; Tian, Y; Wu, T; Wu, X; Zhang, K | 1 |
| Arefian, H; Hartmann, M; Settmacher, U; Sieg, M | 1 |
| Kumar, A | 2 |
| Cao, F; Chen, G; Chen, S; Fan, W; Feng, Z; Mo, J; Qi, H; Shen, L; Shi, M; Wan, W; Wu, Y; Xie, L; Xu, L; Ye, D; Zhang, Y; Zhu, G | 1 |
| Chen, G; Gong, L; Hu, X; Jing, Z; Ma, X; Shi, J; Yang, W; Ye, X | 1 |
| Bresnahan, E; Lindblad, KE; Lujambio, A; Ruiz de Galarreta, M | 1 |
| Ding, J; Dong, W; Jin, GZ; Li, J; Li, SC; Liu, D; Liu, H; Pan, CZ; Sun, W; Ta, N; Wang, HY; Wang, ZG; Xu, L; Zhong, W | 1 |
| Chen, Y; Huang, M; Huang, Q; Sun, C; Sun, R; Tian, Z; Wang, J; Wei, H; Wu, Y; Xiao, W; Zheng, X | 1 |
| Brown, LM; Rajbhandari, P; Stockwell, BR; Werth, EG | 1 |
| Jiang, S; Liang, P; Lv, H; Wu, H; Zhang, Z | 1 |
| Wangensteen, KJ; Yin, D | 1 |
| Canbay, A; Chatellier, G; Chow, PKH; Donghia, R; Gandhi, M; Guerra, V; Leandro, G; Malfertheiner, P; Pech, M; Pereira, H; Ricke, J; Venerito, M; Vilgrain, V | 1 |
| Chen, Y; Ma, C; Shao, B; Zhang, F; Zhou, Y | 1 |
| Fang, W; Fu, Q; Han, S; Jiang, W; Jiang, Y; Liao, H; Pan, Y; Qi, Q; Shen, J; Tong, Z; Tu, X; Zhang, X; Zhao, P; Zheng, Y; Zhong, L | 1 |
| Bu, X; Chen, D; Chen, L; Chen, X; Cheng, C; He, W; Liang, H; Lin, Z; Niu, Y; Sun, L; Wan, A; Wan, G; Zhan, S; Zhang, X | 1 |
| Assaraf, YG; Baboci, L; Cecchin, E; Dal Bo, M; De Mattia, E; Mezzalira, S; Toffoli, G | 1 |
| Cheng, X; Fu, J; Huang, Z; Ji, YX; Jian, C; Li, H; Liao, R; Pan, S; She, ZG; Shen, LJ; Song, K; Tian, H; Tian, S; Wang, HP; Wang, X; Wang, Y; Zhang, X; Zhang, XJ; Zhu, L | 1 |
| Batuyong, E; Cheung, WY; Davies, J; Fung, AS; Knox, JJ; Ko, YJ; Lee-Ying, R; Meyers, DE; Samawi, H; Sim, HW; Tam, VC; Zaborska, V | 1 |
| Astara, G; Bertolini, G; Cabibbo, G; Caputo, F; Casadei-Gardini, A; Cascinu, S; Celsa, C; Cerma, K; Conti, F; Dadduzio, V; Delcuratolo, S; Faloppi, L; Fornaro, L; Granito, A; Lonardi, S; Marisi, G; Massa, V; Piscaglia, F; Rizzato, MD; Scartozzi, M; Silletta, M; Silvestris, N; Stornello, C; Tovoli, F; Vivaldi, C | 1 |
| He, C; Jaffar Ali, D; Kumaravel, S; Li, Y; Ma, J; Si, K; Sun, B; Xiao, Z; Xu, H | 1 |
| Goto, W; Hamano, G; Kanazawa, A; Kikuchi, T; Kinoshita, M; Kodai, S; Maeda, K; Miura, K; Murata, A; Nishio, K; Nobori, C; Shimizu, S; Shirai, D; Tashima, T; Yonemitsu, K | 1 |
| Cadenas, M; Chapresto-Garzón, R; Gómez-Bravo, MA; Muntané, J; Navarro-Villarán, E; Negrete, M; Padillo, FJ; Rodríguez-Hernández, MA; Victor, VM | 1 |
| Bárcena, JA; Choya-Foces, C; Cruz-Ojeda, P; González, R; Hueber, AO; Martínez-Ruiz, A; Miranda-Vizuete, A; Muntané, J; Negrete, M; Padilla, CA; Ranguelova, K; Rius-Pérez, S; Rodríguez-Hernández, MA; Rossin, A; Sastre, J | 1 |
| Chang, WT; Chen, LA; Chuang, SC; Huang, JW; Kuo, KK; Lee, KT; Lin, CS; Su, WL; Wang, SN; Wang, YC | 1 |
| Fujisawa, M; Kanda, T; Kuroda, K; Masuzaki, R; Matsumoto, N; Matsuoka, S; Moriyama, M; Ogawa, M; Sasaki, R | 1 |
| Amos, C; Cheng, C; Schaafsma, E; Weng, YL; Zhao, Y | 1 |
| Hopkins, AM; Rowland, A; Ruanglertboon, W; Sorich, MJ | 1 |
| Abou-Alfa, GK; Blanc, JF; Cheng, AL; Daniele, B; Guerra, I; Kelley, RK; Marteau, F; Mollon, P; Valcheva, V; Yau, T | 1 |
| An, Y; Cai, M; Huang, J; Huang, W; Li, B; Lin, L; Shuai, X; Wang, Y; Zhou, Z; Zhu, K | 1 |
| Hinrichs, JB; Kirstein, MM; Manns, MP; Marwede, T; Pinter, M; Scheiner, B; Semmler, G; Vogel, A; Voigtländer, T; Wacker, F; Wolf, C | 1 |
| Rimassa, L; Wörns, MA | 1 |
| Fujishiro, M; Honda, T; Ishigami, M; Ishikawa, T; Ishizu, Y; Ito, T; Kuzuya, T; Tanaka, T | 1 |
| Kommalapati, A; Mahipal, A; Tella, SH | 1 |
| Hopkins, AM; Logan, JM; Rowland, A; Ruanglertboon, W; Sorich, MJ | 1 |
| Kawagishi, N; Kimura, M; Kitagataya, T; Maehara, O; Mizokami, M; Morikawa, K; Nakai, M; Nakamura, A; Natsuizaka, M; Ogawa, K; Ohara, M; Ohnishi, S; Sakamoto, N; Shigesawa, T; Shimazaki, T; Sho, T; Suda, G; Sugiyama, M; Suzuki, K; Takeda, H; Umemura, M; Yamada, R; Yamamoto, K | 1 |
| Cho, EJ; Jang, H; Kim, MA; Kim, SW; Kim, TY; Kim, YJ; Lee, CH; Lee, JH; Lee, KH; Lee, YB; Oh, H; Yoon, JH; Yu, SJ | 1 |
| Gong, W; Hu, W; Shao, L; Wang, F; Xu, J; Xu, W; Zhou, Y; Zhu, Y | 1 |
| Chen, Y; Cheng, D; Jiang, Y; Jin, H; Ye, H; Zhou, L | 1 |
| Cheng, L; Li, H; Tang, X; Ye, Y; Yu, J; Zhang, M; Zhang, W; Zheng, S | 1 |
| Friedlaender, A; Thouvenin, L | 1 |
| Hanzel, J; Jansa, R; Kosir Bozic, T; Stabuc, B | 1 |
| Li, B; Li, L; Li, S; Wang, W | 1 |
| Nakamura, T; Sakamoto, K; Takada, Y; Tamura, K; Tohyama, T; Wakisaka, H; Watanabe, J | 1 |
| Kim, N; Seong, J | 1 |
| Adachi, T; Aibiki, T; Hiraoka, A; Iwasaki, R; Izumoto, H; Michitaka, K; Miyata, H; Mori, K; Nagamatsu, K; Ninomiya, T; Okazaki, H; Okudaira, T; Suga, Y; Tsubouchi, E; Tsuruta, M; Yamago, H; Yoshino, T | 1 |
| Chang, CS; Lee, SW; Lien, HC; Peng, YC; Tung, CF | 1 |
| Chen, B; Chen, SY; Cheng, SH; Huang, Z; Li, YX; Liu, JX; Pan, Y; Wang, WH; Wu, F; Xu, X; Zhao, YT; Zheng, X | 1 |
| Andreone, P; Cabibbo, G; Casadei-Gardini, A; Cascinu, S; Celsa, C; Cucchetti, A; D'agostino, D; Dadduzio, V; Guarneri, V; Lonardi, S; Orsi, G; Rizzato, MD; Rossi, M; Rovesti, G; Scartozzi, M; Vukotic, R; Zagonel, V | 1 |
| Benzaghou, F; Cheng, AL; Hazra, S; Kelley, RK; Rimassa, L; W Oliver, J; Yau, T | 1 |
| He, Z; Tian, H | 1 |
| Chen, MS; Guo, Z; Hua, Q; Huang, JH; Li, JQ; Liao, J; Lin, J; Liu, C; Liu, CQ; Liu, M; Luo, S; Sun, C; Weng, Y; Wu, C; Xu, J; Xu, L; Zeng, DN; Zheng, L; Zhou, J; Zhuang, SM | 1 |
| Ferreira, CPDC; Ribeiro, MA; Szutan, LA | 1 |
| Fletcher, P; Kunene, V; Ma, YT; Razak, RA | 1 |
| Cheng, Z; Jin, D; Wei-Qi, J | 1 |
| Abou-Alfa, GK; El Dika, I; Makki, I | 1 |
| Alghamdi, MA; Amaro, CP; Batuyong, E; Chan, KK; Cheung, WY; Knox, JJ; Ko, YJ; Lee-Ying, R; Romagnino, A; Samwi, H; Sim, HW; Swiha, M; Tam, VC | 1 |
| Ayuso, C; Belmonte, E; Bruix, J; Darnell, A; Díaz, A; Díaz-González, Á; Feu, F; Forner, A; Gomes da Fonseca, L; Iserte, G; Llarch, N; Reig, M; Rimola, J; Sanduzzi-Zamparelli, M; Sapena, V | 1 |
| Cheng, BB; Ling, CQ; Liu, H; Meng, YB; Shen, F; Wan, XY; Yang, YK; Yao, M; Yin, HX; Yu, SS; Zhai, XF; Zhao, HT | 1 |
| Chen, Z; Cheng, Y; De Toni, EN; Reiter, FP; Rong, D; Tang, W; Wang, Q; Wang, S; Wang, X; Wu, F; Zhang, B; Zhang, W | 1 |
| Dai, LJ; Guo, XR; Huang, Y; Ji, FY; Meng, ZJ; Ruan, XZ; Shan, MY; Tang, JM; Wang, J; Yuan, Y; Zhang, ZL; Zhou, XP | 1 |
| Chen, YJ; Hsieh, CH; Huang, HL; Huang, YC; Tai, HC; Tsai, TH; Wang, LY | 1 |
| Gao, ZQ; Li, DY; Shen, PC; Tang, Z | 1 |
| Chen, PH; Dai, HQ; Feng, J; Han, CY; Hooi, SC; Huang, XW; Li, ZJ; Lu, GD; Lu, PZ; Peng, T; Su, WJ; Wu, Y; Ye, XP; Zhou, J; Zhu, GZ | 1 |
| Abou-Alfa, GK; Boussayoud, C; Capanu, M; Chou, JF; Do, GK; El Dika, I; Ferrer, CS; Harding, JJ; Iyer, R; Kelley, RK; Khalil, DN; Kuhn, P; Muenkel, K; Rodriguez-Lee, M; Ruiz, C; Shia, J; Tan, B; Wilton, J; Yarmohammadi, H | 1 |
| Ding, W; Huang, G; Tao, T; Wang, M; Wang, Z; Xiong, J; Yang, Y; Zhang, H; Zhi, X; Zhou, W; Zi, X | 1 |
| Hikita, H; Hiramatsu, N; Imai, Y; Imanaka, K; Inada, M; Kegasawa, T; Kodama, T; Maesaka, K; Ohkawa, K; Oshita, M; Sakamori, R; Tahata, Y; Takehara, T; Tatsumi, T; Urabe, A; Yakushijin, T; Yamada, R; Yamada, Y | 1 |
| Endo, M; Fukuda, K; Hasegawa, N; Hattori, J; Hirose, S; Hyodo, I; Ishige, K; Komatsu, Y; Mizui, T; Nagase, M; Sato, M; Yamaura, M | 1 |
| Lei, L; Lin, H; Wu, W; Zhang, R | 1 |
| Feng, JQ; Fu, ZQ; Li, D; Li, H; Luo, H; Peng, JJ; Sun, FF; Wang, C; Wang, D; Wang, T; Zhang, T; Zhou, DJ | 1 |
| Chen, X; Liu, Z; Lu, W; Ouyang, G; Pan, G; Wu, Y; Xu, H; Yi, B | 1 |
| Chien, CY; Hsu, MH; Hsu, SM; Liao, YJ; Suk, FM; Wang, YH | 1 |
| Bamoharram, FF; Davoodnia, A; Hashemi, T; Razavi, SF; Shahrokhabadi, K | 1 |
| Han, BH; Huh, JD; Lee, SU; Seo, KI; Son, MY; Yun, BC | 1 |
| Iha, H; Ikeda, M; Ishibashi, S; Kanao, T; Kitagawa, M; Kurata, M; Muto, Y; Tatsuzawa, A; Yamamoto, K; Yanai, M | 1 |
| Andoh, A; Fujimoto, T; Hira, D; Iida, H; Ikeda, Y; Morita, SY; Noda, S; Osaki, R; Tanaka-Mizuno, S; Tani, M; Terada, T | 1 |
| Igarashi, Y; Ikehara, T; Kamada, K; Kaneko, R; Kimura, Y; Nagai, H; Sato, Y; Yano, Y | 1 |
| Cheung, KS; Ko, KL; Mak, LY; Yuen, MF | 1 |
| Chang, XF; Shen, D; Teng, GJ; Zeng, CH; Zeng, P | 1 |
| Liu, Y; Lv, P; Ma, L; Man, S; Yang, L; Yao, J | 1 |
| Bai, YD; Feng, JQ; Li, D; Li, H; Liu, Y; Peng, JJ; Shi, ML; Sun, FF; Wang, C; Wang, D; Wang, T; Zhang, T | 1 |
| Aramaki, T; Asakura, K; Endo, M; Itoh, Y; Iwai, K; Moriguchi, M; Sato, R; Seko, Y; Takahashi, A; Tsuchiya, S; Umemura, A; Ymaguchi, K | 1 |
| Braat, A; Lam, M; Reinders, M | 1 |
| Cheng, AS; Feng, H; Gao, Y; Huang, L; Jiang, Y; Le, F; Li, M; Sun, X; Yu, DY; Yu, Z; Zhang, X; Zheng, C; Zhou, Z; Zhu, X; Zhuo, Y | 1 |
| Chen, W; Li, H; Li, X; Li, Z; Liu, Y; Mao, J; Shen, J; Xu, Y; Xue, F; Yan, L | 1 |
| Dong, Y; Feng, Y; Gu, Y; Jiang, W; Lu, Z; Zhao, W | 1 |
| Han, S; Kim, DY | 1 |
| Cao, J; Chen, A; Chen, M; Hu, J; Juengpanich, S; Li, S; Shen, J; Topatana, W; Yao, Z; Yu, H | 1 |
| Ardelt, MA; Arnold, GJ; Fröhlich, T; Gerbes, AL; Huber-Cantonati, P; Kiemer, AK; Koeberle, A; Koenig, LM; Meßner, M; Müller, M; Ortler, C; Pachmayr, J; Pein, H; Rothenfußer, S; Schmitt, S; Vollmar, AM; Zischka, H; Zobel, L | 1 |
| Malfertheiner, P; Ricke, J; Sangro, B; Seidensticker, M; Todica, A | 1 |
| Capelletti, MM; Manceau, H; Peoc'h, K; Puy, H | 1 |
| Chen, PH; Dai, HQ; Deng, JH; Feng, J; Huang, XW; Li, ZJ; Liu, YJ; Lu, GD; Shi, H; Wang, JG; Wang, ZX; Wu, Y; Yang, XM; Zhou, J | 1 |
| Chen, Y; Dong, H; Huang, W; Zhang, T | 1 |
| Chuma, M; Fukuda, H; Komiyama, S; Maeda, S; Moriya, S; Numata, K; Ogushi, K | 1 |
| Aikata, H; Ando, Y; Chayama, K; Fujii, Y; Hiramatsu, A; Imamura, M; Kawaoka, T; Kosaka, Y; Morio, K; Murakami, E; Nakahara, T; Suehiro, Y; Takahashi, S; Tsuge, M; Uchikawa, S; Yamaoka, K | 1 |
| Athavale, D; Bhat, MK; Chouhan, S; Nair, BG; Nair, SS; Ramteke, P; Singh, S; Vanuopadath, M | 1 |
| Chen, Y; Fan, W; Huang, G; Jiang, S; Li, J; Miao, H; Song, Z; Wang, Y; Xie, W; Zhang, Y | 1 |
| Tian, H; Xiang, H; Xie, Y | 1 |
| Anugwom, CM; Bane, A; Braimoh, GA; Debes, JD; Sultan, A; Wondifraw, Z | 1 |
| Mancuso, A | 1 |
| Iavarone, M; Invernizzi, F | 1 |
| Hsu, C; Luu, S; Silberfein, EJ | 1 |
| Bampoh, S; Ha, Y; Harmsen, WS; Kim, KM; Lee, HC; Mady, M; Missula, VR; Mohamed Ali, MA; Petersen, MM; Prasai, K; Roberts, LR; Ryoo, BY; Therneau, TM; Valles, KA | 1 |
| Chang, SW; Chang, Y; Cho, SB; Hwang, SY; Jang, JY; Kim, JH; Lee, HW; Lee, MJ; Lee, YS; Seo, YS; Yim, HJ | 1 |
| Liang, Q; Liu, J; Shen, X; Sun, G; Yang, X; Yu, Y | 1 |
| Cai, X; Chen, J; Ji, L; Jiang, S; Liang, X; Liang, Y; Lin, C; Lin, Z; Pan, Y; Tao, L; Wan, Z; Xia, S; Xu, J | 1 |
| Deterding, LJ; Gao, X; Ji, M; Kang, K; Li, L; Li, X; Li, Y; Liu, J; Locasale, JW; Shats, I; Tong, L; Tong, X; Williams, JG; Xu, Q | 1 |
| Cao, B; Chen, DT; Kim, DW; Kim, R; Machado, C; Mahipal, A; Masawi, F; Tan, E; Wang, E; Yu, J | 1 |
| Jiang, Z; Li, H; Liu, X; Wang, C; Wang, P; Yu, K; Zhong, L | 1 |
| Chung, WY; Dennison, AR; Huang, A; Yang, XR; Zhou, J | 1 |
| Gu, W; Tong, Z | 1 |
| Aydin, C; Yilmaz, S | 1 |
| Isik, B; Sarici, B; Yilmaz, S | 1 |
| Abou-Alfa, GK; Capanu, M; Chou, JF; Do, RKG; El Dika, I; Harding, JJ; Hrabovsky, AD; Ly, M; Ma, J; Millang, B; O'Reilly, EM; Shia, J | 1 |
| Abou-Alfa, GK; Baron, AD; Bolondi, L; Cattan, S; Chan, SL; Cheng, AL; El-Khoueiry, AB; Kelley, RK; Knox, J; Lim, HY; Lougheed, JC; Merle, P; Meyer, T; Milwee, S; Park, JW; Parnis, F; Ryoo, BY; Yau, T | 1 |
| Aby, ES; Bane, A; Debes, JD; Sultan, A; Wondifraw, Z | 1 |
| Chen, X; Cheng, Y; Li, C; Li, F; Piao, JG; Tang, H; Zhang, Y; Zheng, H; Zhu, J; Zhu, Z | 1 |
| Basha, R; Ghabach, B; Narra, K; Neerukonda, L; Sankpal, UT; Sharma, I; Sridhar, S | 1 |
| Ang, AJS; Choo, SP; Lee, JJX; Ng, KYY; Tai, DW; Tan, SH; Wong, LWJ | 1 |
| Aikata, H; Aisaka, Y; Ando, Y; Azakami, T; Chayama, K; Fujino, H; Fukuhara, T; Hiramatsu, A; Honda, Y; Hyogo, H; Imamura, M; Kawaoka, T; Kodama, K; Kosaka, Y; Masaki, K; Mori, N; Morio, K; Moriya, T; Murakami, E; Naeshiro, N; Nakahara, T; Nonaka, M; Suehiro, Y; Takahashi, S; Takaki, S; Tsuge, M; Tsuji, K; Uchikawa, S; Yamaoka, K; Yamauchi, M | 1 |
| Card, PB; Knox, JJ; Lim, H; Liu, D; Meyers, BM; Ramjeesingh, R; Tam, VC | 1 |
| Cheng, DL; Gao, ZG; Hao, YH; Ji, CS; Jia, WD; Liu, KC; Lv, WF; Shi, CS; Su, MX; Xu, SB; Zhou, CZ | 1 |
| Chen, WC; Hartano, S; Ho, RZW; Huynh, H; Koh, TS; Le, TBU; Lee, P; Prawira, A; Teo, XQ; Thng, CH; Tran, A; Vu, TC | 1 |
| Cheng, Z; Guo, Y; He, L; Song, S; Song, Y; Zhang, L | 1 |
| Alexandrescu, ST; Croitoru, AE; Droc, G; Grasu, MC; Grigorie, RT; Popescu, I; Tomescu, DR | 1 |
| Chan, AC; Chan, LK; Cheung, ET; Cheung, TT; Chiu, EY; Chok, KS; Ho, DW; Kam, CS; Lee, TK; Lo, IL; Ng, IO; Tang, CN; Tang, VW; Wong, CC; Wong, CM; Yau, DT | 1 |
| Chai, H; Gu, Y; Li, F; Ren, Q; Wu, J | 1 |
| Pinato, DJ | 1 |
| Bai, XL; Chen, BW; Chen, W; Liang, TB; Ma, T; Ni, L; Shen, SC; Wang, Y; Wei, T; Wen, L; Zhang, J; Zhang, YB; Zhou, Y | 1 |
| Hou, ZH; Huang, P; Li, Z; Ni, CF; Sun, JH; Wang, WS; Yan, ZP; Yang, MJ; Zhang, L; Zhang, S; Zhong, BY; Zhou, GH; Zhu, XL | 1 |
| Aly, A; Benavente, F; Henriques, C; Kim, A; Malangone-Monaco, E; Noxon, V | 1 |
| Chen, M; Liu, L; Ma, D; Wang, J; Wang, Z | 1 |
| Hu, M; Ma, X; Yuan, Z; Zhang, J; Zhao, X | 1 |
| Deng, Y; Dong, L; Li, Y; Liu, J; Liu, TT; Shen, XZ; Sun, Y; Weng, SQ; Yu, XN; Zhang, GC; Zhu, CF; Zhu, JM | 1 |
| Acosta-Rivera, M; Anderson, J; El-Khoueiry, AB; El-Rayes, BF; Hou, MM; Hsu, C; Kang, YK; Kim, TY; Knox, JJ; Kudo, M; Lim, HY; Matilla, A; Melero, I; Neely, J; Ruth He, A; Sangro, B; Santoro, A; Shen, Y; Tovoli, F; Wisniewski, T; Yau, T | 1 |
| Alpdemir, Ş; Bayram, C; Denkbaş, EB; Haberal, E; Kara, G; Vural, T | 1 |
| Bruix, J; da Fonseca, LG; Reig, M | 1 |
| Liang, Q; Liu, J; Sun, G; Yang, X | 1 |
| Ayuso, C; Belmonte, E; Boix, L; Bruix, J; Brunet, M; Corominas, J; da Fonseca, LG; Darnell, A; Díaz-González, Á; Forner, A; Iserte, G; LLarch, N; Millán, O; Reig, M; Samper, E; Sanduzzi-Zamparelli, M; Sapena, V; Torres, F | 1 |
| Chen, SC; Chuang, WL; Dai, CY; Hsieh, MH; Hsieh, MY; Huang, CF; Huang, CI; Huang, JF; Kuo, HT; Liang, PC; Lin, IH; Lin, ZY; Yeh, ML; Yu, ML | 1 |
| Saboji, M; Salimi, A; Seydi, E | 1 |
| Ahn, HR; Cheong, JY; Cho, HJ; Cho, SW; Huh, J; Kim, B; Kim, JK; Kim, SS; Lee, JH | 1 |
| Cho, SB; Hong, YM; Hwang, SY; Jang, BK; Jang, ES; Jang, JY; Jung, YK; Kim, DY; Kim, HJ; Kim, JH; Kim, MY; Lee, HW; Lee, JH; Lee, YS; Seo, YS; Yim, HJ; Yoon, KT | 1 |
| Argentiero, A; Benevento, F; Brunetti, O; Cabibbo, G; Casadei-Gardini, A; Cascinu, S; Conti, F; Cucchetti, A; Dadduzio, V; Foschi, FG; Gramantieri, L; Granito, A; Ielasi, L; Lonardi, S; Marisi, G; Orsi, G; Pecora, I; Piscaglia, F; Rizzato, MD; Rovesti, G; Salani, F; Scartozzi, M; Teglia, F; Tovoli, F; Vivaldi, C; Zagonel, V | 1 |
| Liu, Z; Wang, N; Wang, T; Zhang, B; Zhang, Q; Zhao, Y | 1 |
| Hu, YT; Jiang, JH; Shu, ZY; Xie, QF; Zheng, SS | 1 |
| Draper, A | 1 |
| Chang, Y; Cho, EJ; Kim, YJ; Lee, JH; Lee, YB; Yoon, JH; Yu, SJ | 1 |
| Allara, E; Arizumi, T; Bettinger, D; Giordano, L; Hajiev, S; Kaplan, DE; Kudo, M; Motedayеn Aval, L; Park, JW; Personeni, N; Pinato, DJ; Pirisi, M; Pressiani, T; Ramaswami, R; Rimassa, L; Sharma, R; Taddei, TH; Thimme, R | 1 |
| Mandlik, DS; Mandlik, SK | 2 |
| Duda, DG; Jain, RK; Pinter, M | 1 |
| Luo, J; Si, Z; Tan, X; Tong, JS; Yao, H; Zhang, Z | 1 |
| Cao, X; Chen, H; Cheng, F; Gao, J; Gong, A; Liu, Y; Song, L; Tsai, HI; Wang, D; Wang, K; Wang, M; Xu, Z; Zhang, Z; Zhu, H | 1 |
| Dáša, S; Igor, A; Ján, T; Jana, V | 1 |
| Chao, Y; Chen, YT; Cheng, TY; Hou, MC; Huang, YH; Lee, PC | 1 |
| Wang, L; Wang, Y | 1 |
| Azzaroli, F; Golfieri, R; Impellizzeri, G; Marasco, G; Mazzella, G; Renzulli, M | 1 |
| Chapiro, J; Doemel, LA; Jaffe, A; Kucukkaya, AS; Laage Gaupp, F; Lin, M; Patel, T; Petukhova, A; Savic, LJ; Schlachter, T; Stein, SM; Strazzabosco, M; Tefera, J; Zeevi, T | 1 |
| Hendrikse, NH; Hoekstra, OS; Honeywell, RJ; Lammertsma, AA; Mammatas, LH; Meijerink, M; Menke-van der Houven van Oordt, CW; Peters, GJ; Schuit, RC; Schwarte, LA; Verheul, HMW; Yaqub, M | 1 |
| Breeta, RDIE; Grace, VMB; Wilson, DD | 1 |
| Harada, N; Iguchi, T; Iseda, N; Itoh, S; Kurihara, T; Mori, M; Morinaga, A; Nagao, Y; Shimagaki, T; Tomiyama, T; Toshima, T; Wang, H; Yoshizumi, T | 1 |
| Cho, EJ; Han, SW; Im, SA; Kim, H; Kim, TY; Kim, YJ; Lee, DW; Lee, JH; Lee, KH; Lee, Y; Oh, DY; Yoon, JH; Yu, SJ | 1 |
| Byrnes, J; Downes, M; Saiyed, M; Scuffham, P; Srivastava, T | 1 |
| Hou, Y; Wu, B | 1 |
| Du, J; Li, Y; Ren, X; Shao, F; Wu, H; Xia, J; Yu, J; Zhou, Y | 1 |
| Bai, Y; Li, D; Li, H; Li, J; Liu, J; Liu, W; Shi, M; Wang, X; Xu, C; Yan, X; Yang, T; Zhang, T; Zhang, Y; Zhao, R | 1 |
| Carvalhana, S; Cortez-Pinto, H; Freitas, LC; Gaio, R; Marinho, RT; Moura, M; Nogueira, PJ; Reis, D | 1 |
| Jeng, WJ; Lin, CY; Lin, PT; Lin, SM; Sheen, IS; Teng, W | 1 |
| Chen, GG; Gong, Z; Lai, PBS; Liu, L; Wang, N; Yang, S; Yu, J | 1 |
| Chan, LH; Che, N; Huen, MS; Kau, PW; Lee, TK; Ma, S; Ng, KY; Tong, M; Wong, TL; Yun, JP | 1 |
| Abada, P; Finn, R; Galle, PR; Kudo, M; Liang, K; Llovet, JM; Metti, AL; Reig, M; Schelman, WR; Wang, C; Widau, RC; Zhu, AX | 1 |
| Astara, G; Bernardini, L; Casadei-Gardini, A; Cascinu, S; D'Amico, FE; Dadduzio, V; Fornaro, L; Lai, E; Lonardi, S; Masi, G; Pretta, A; Rimini, M; Rovesti, G; Scartozzi, M; Vivaldi, C; Zagonel, V | 1 |
| Abdouni, A; Allende, DS; Apte, SS; Arechederra, M; Audebert, S; Bazai, SK; Daian, F; Dono, R; Gregoire, D; Hibner, U; Lozano, A; Maina, F; Mead, TJ; Richelme, S; Sequera, C | 1 |
| Dituri, F; Frusciante, M; Giannelli, G; Lupo, LG; Mancarella, S; Schmidt, TA; Scialpi, R; Villa, E | 1 |
| Fan, S; Hu, F; Li, X; Qian, B; Ren, H; Xu, L; Zhai, B; Zhu, Q | 1 |
| Chen, B; Chen, G; Hong, S; Li, T; Mo, X; Shi, Y | 1 |
| Cersosimo, RJ | 1 |
| Ahn, SH; Kim, BK; Kim, DY; Kim, KH; Kim, S; Kim, SU; Park, JY | 1 |
| Alvarez, ML; Angel, A; Carrillo, MC; Ceballos, MP; Comanzo, CG; Delprato, CB; Ferretti, AC; Livore, VI; Lucci, A; Mottino, AD; Quiroga, AD | 1 |
| Chen, Y; Ou, Q; Peng, L; Tang, N; Wang, X | 1 |
| Brennan, VK; Colaone, F; Evans, R; Mullan, D; Muszbek, N; Remak, E; Ross, PJ; Shergill, S | 1 |
| Cai, X; Cen, D; Gorshkov, K; Ji, L; Jiang, S; Liang, X; Lin, Z; Mao, Q; Tang, M; Wan, Z; Xia, S; Xu, J; Zheng, J | 1 |
| Gómez Zubiaur, A; Medina Montalvo, S; Vega Díez, D | 1 |
| He, CZ; Huang, ST; Li, HM; Liao, JJ; Lin, JY; Mo, S; Qin, YQ; Zhang, Z | 1 |
| Han, X; Li, Z | 1 |
| Alsebaey, A; Aly, RA; Badran, H; Elsabaawy, MM; Ragab, A; Sabry, A | 1 |
| Cai, X; Chen, W; Dong, Z; Li, H; Liang, C; Shen, J; Xu, Y; Yu, W; Zhang, M | 1 |
| Chen, B; Dong, L; Fu, Y; Huo, Z; Jiang, H; Li, X; Li, Y; Li, Z; Ma, P; Ma, Y; Pan, S; Shen, B; Wang, C; Wu, H; Wu, Y; Xu, Y; Zhang, B | 1 |
| Cao, M; Jin, G; Lang, J; Li, X; Liu, B; Liu, Y; Luo, X; Wang, B; Wang, T; Wu, C; Wu, H; Xu, C; Xu, S; Zou, H | 1 |
| Atenafu, EG; Barry, A; Brade, A; Brierley, J; Cho, C; Dawson, LA; Dinniwell, R; Kim, J; Kim, TK; Munoz-Schuffenegger, P; Ringash, J; Sapisochin, G; Wong, RKS | 1 |
| Abe, Y; Eguchi, H; Hayashi, Y; Hikita, H; Kodama, T; Maesaka, K; Mita, E; Motooka, D; Myojin, Y; Ohkawa, K; Sakamori, R; Sato, Y; Taguchi, A; Takehara, T; Tanaka, S; Tatsumi, T | 1 |
| Bai, C; Liu, B | 1 |
| Bullo, S; Buskara, K; Ebadi, M; Fakurazi, S; Hussein, MZ; Pastorin, G | 1 |
| Dong, Q; Fu, Y; Hu, B; Qin, L; Qin, W; Shen, X; Wang, S; Xu, J | 1 |
| Chen, L; Jiang, JL; Le, JQ; Luo, BY; Shao, JW; Wu, PY; Zhang, BC; Zhao, RR; Zou, JJ | 1 |
| Gryziak, M; Kraj, L; Stec, R; Woźniak, K | 1 |
| Han, JK; Kim, JH; Lee, HJ; Lee, S; Moon, H | 1 |
| Bonney, G; Chow, P; Dan, YY; Huang, DQ; Jumat, H; Kow, A; Lee, GH; Lim, SG; Lim, YT; Muthiah, MD; Pang, YH; Shridhar, I; Soon, G; Tan, WX; Wee, A; Zhou, L | 1 |
| Amaro, CP; Tam, VC | 1 |
| Kelly, D; O'Kane, GM; Perera, S | 1 |
| Galle, PR; Weinmann, A | 1 |
| Avanzato, F; Azzaroli, F; Bacchi Reggiani, ML; Baroni, GS; Benevento, F; Biasini, E; Brunetto, MR; Caturelli, E; Celsa, C; Colecchia, A; Dajti, E; Di Marco, M; Farinati, F; Festi, D; Foschi, FG; Gasbarrini, A; Giannini, EG; Marasco, G; Marra, F; Masotto, A; Mega, A; Morisco, F; Nardone, G; Raimondo, G; Rapaccini, GL; Ravaioli, F; Sacco, R; Trevisani, F; Vidili, G; Zoli, M | 1 |
| Cai, X; Chen, J; Gorshkov, K; Ji, L; Jin, RA; Liang, X; Liang, Y; Lin, H; Song, X; Sun, Q; Wan, Z; Xu, J; Zheng, W; Zheng, X | 1 |
| Cheng, X; Cheng, Z; Cui, X; Ding, J; Hui, L; Jiang, W; Li, L; Li, S; Li, X; Liang, X; Liu, J; Ning, B; Sun, W; Wang, H; Xiang, D; Zhang, C; Zhou, T | 1 |
| Han, JK; Kim, JH; Lee, S; Ryu, H | 1 |
| Ai, X; Dai, T; Han, L; Ho, L; Hua, Z; Huang, Y; Lin, Y; Lu, J; Xu, J; Yue, X; Zhou, Y | 1 |
| Chang, YH; Chen, CT; Chow, LP; Huang, BS; Li, NC; Liao, LZ; Lin, LC | 1 |
| Berry, S; Chan, KKW; Delos Santos, S; Doherty, M; Ko, YJ; Nguyen, A; Udayakumar, S | 1 |
| Chuang, PH; Hsieh, MH; Hsieh, TH; Kao, CC; Kao, JT; Kao, TY; Lai, HC; Peng, CY | 1 |
| Li, JR; Liu, QX; Tian, M; Wang, T; Wu, MJ; Xiang, XH; Zhang, YQ; Zhou, G | 1 |
| Achira, M; Aikata, H; Furuse, J; Hagihara, A; Ikeda, M; Inaba, Y; Kato, N; Kimura, A; Kondo, S; Kudo, M; Kuroda, S; Morimoto, M; Motomura, K; Numata, K; Tsuchiya, K | 1 |
| Feng, G; Guo, R; Liu, J; Su, Z; Zhai, Y; Zhang, H; Zhao, F; Zhu, J | 1 |
| Chen, P; Chung, RT; Dai, G; He, L; Hong, J; Hu, K; Jiang, Y; Li, J; Lin, W; Peng, S; Qu, C; Tu, M; Xie, P; Yuan, H; Zheng, D | 1 |
| Ang, C; Buckstein, M; Ferket, BS; Kim, E; Marqueen, KE; Mazumdar, M | 1 |
| Lan, Y; Peng, Y; Shuai, X; Su, Z; Wang, X; Wu, T; Xiao, H | 1 |
| Abdelghani, MB; Audemar, F; Blanc, JF; Bourgeois, V; Bronowicki, JP; Costentin, C; Deplanque, G; Edeline, J; Faroux, R; Khemissa, F; Locher, C; Mabile-Archambeaud, I; Manfredi, S; Monterymard, C; Obled, S; Perarnau, JM; Seitz, JF; Senellart, H; Villing, AL | 1 |
| Cai, H; Cao, MQ; Shen, J; Wang, D; Zhang, KW; Zhang, YY; Zhuang, PY | 1 |
| Chen, S; Feng, Y; Guo, L; Hu, Y; Huang, H; Lian, L; Wan, L; Wen, Z; Xu, K; Yan, X; Yang, Q; Zhang, M | 1 |
| Choi, HJ; Hong, HE; Hong, TH; Jeena, MT; Kim, KH; Kim, OH; Kim, SJ; Lee, KH; Ryu, JH | 1 |
| Casadei-Gardini, A; Di Costanzo, GG; Granito, A; Ielasi, L; Magini, G; Nardi, E; Piscaglia, F; Pressiani, T; Rimini, M; Sacco, R; Sansone, V; Tortora, R; Tovoli, F; Trevisani, F | 1 |
| Cheng, X; Li, Y; Yu, J; Zhao, H | 1 |
| Chen, YC; Chu, SS; Ho, CH; Kuo, YH; Liu, WS; Wang, SC; Wu, HC; Yang, CC | 1 |
| Cao, ZT; Chen, Y; Du, JZ; Li, JX; Ma, M; Shu, N; Wang, J; Zhao, ZB; Zheng, SJ; Zhou, Q | 1 |
| An, G; Cao, B; Dong, B; Han, H; Ma, B; Tang, J; Tian, Z; Wang, B; Zhao, W | 1 |
| Finn, RS; Kelley, RK; Koike, K; Lencioni, R; Llovet, JM; Pikarsky, E; Roayaie, S; Singal, AG; Villanueva, A; Zucman-Rossi, J | 1 |
| Haruna, Y; Kawamoto, S; Yakushijin, T | 1 |
| Elewa, YHA; Harashima, H; Khalil, IA; Kon, Y; Younis, MA | 1 |
| Guan, XY; Kong, FE; Lin, JX; Liu, M; Loong, JHC; Ma, NF; Ma, S; Qi, L; Xi, SY; Yan, Q; Yang, XD; Yuan, YF; Zhang, Y; Zhao, Y | 1 |
| Huang, D; Ning, Q; Shen, G; Tao, R; Yan, W; Yuan, W | 1 |
| Bae, SH; Choi, HJ; Choi, JY; Jang, JW; Kim, CW; Kim, HY; Kwon, JH; Lee, SK; Lee, SW; Nam, H; Song, DS; Song, MJ; Sung, PS; Yoon, SK; You, YK | 1 |
| Braghiroli, MI; da Fonseca, LG; Hoff, PM; Marta, GN; Moura, F; Sabbaga, J | 1 |
| Kinoshita, Y; Matsuda, Y; Osawa, M; Wakai, T | 1 |
| Aoki, K; Ikeda, A; Kawamura, M; Kokuryu, H; Yamaguchi, D | 1 |
| Cheng, W; Gong, YF; Guan, XY; Kong, FE; Li, GM; Li, HL; Li, MM; Liu, M; Loong, JHC; Ma, NF; Ma, S; Mo, JQ; Tang, H; Tang, YQ; Xi, SY; Xie, MB; Zhang, Y; Zhao, Y; Zhu, WJ | 1 |
| Devan, AR; Kumar, AR; Nair, B; Nath, LR | 1 |
| Burns, MC; Fenton, SE; Kalyan, A | 1 |
| Chen, J; Yao, R; Zeng, L; Zhang, C; Zou, Q | 1 |
| Edeline, J; Minot-This, MS | 1 |
| Atsukawa, M; Bang, Y; Casadei-Gardini, A; Cascinu, S; Cucchetti, A; Frassineti, LG; Fukunishi, S; Hiraoka, A; Itobayashi, E; Kim, HD; Koga, H; Kumada, T; Lonardi, S; Masi, G; Nicola, S; Piscaglia, F; Rimassa, L; Rimini, M; Scartozzi, M; Shimose, S; Soldà, C; Tada, T; Torimura, T; Toyoda, H; Tsuj, K; Vivaldi, C; Yoo, C | 1 |
| He, C; Jaffar Ali, D; Kumaravel, S; Liu, R; Sun, B; Xiao, Z; Xu, H; Zhou, Y | 1 |
| Li, Q; Liao, W; Wen, F; Zhang, P; Zheng, H; Zhou, K | 1 |
| Cao, S; Feng, F; Jia, H; Jiang, Q; Li, B; Lu, J; Wei, L; Zhang, Y | 1 |
| Abdel-Hamid, NM; Ansary, A; El-Shishtawy, MM; Zakaria, S | 1 |
| Cho, S; Ji, J; Kim, DH; Larson, AC; Lewandowski, RJ; Park, W | 1 |
| Adachi, Y; Endo, T; Hata, F; Ikeda, K; Ishii, Y; Iwata, N; Kato, Y; Kikuchi, T; Makiguchi, Y; Minami, T; Mita, H; Yoshida, Y | 1 |
| Bi, L; Chen, F; Chen, W; Du, L; Feng, M; Jiang, Y; Jiao, Q; Meng, P; Ren, Y; Tang, B; Wang, C; Wang, Q; Wang, Y; Zhou, F | 1 |
| Liu, X; Meng, X; Qi, X; Xu, K; Zhu, X | 1 |
| Battaglia, S; Busacca, A; Cabibbo, G; Cammà, C; Cannella, R; Celsa, C; Giuffrida, P; Grova, M; Rizzo, GEM; Spatola, F; Stornello, C | 1 |
| Shi, L; Su, D; Wu, B | 1 |
| Cerrito, L; Gasbarrini, A; Monti, F; Pompili, M; Ponziani, FR; Santopaolo, F | 1 |
| Chen, Q; Huang, XF; Li, S; Tang, Z; Wang, W; Wu, L; Zhai, L; Zhou, J; Zhou, W | 1 |
| Aliya, S | 1 |
| Bang, Y; Burgio, V; Casadei-Gardini, A; Cascinu, S; Frassineti, GL; Kim, HD; Lonardi, S; Massa, V; Park, SR; Rapposelli, IG; Rimini, M; Rizzato, MD; Ryoo, BY; Ryu, MH; Salani, F; Scartozzi, M; Valgiusti, M; Vivaldi, C; Yoo, C; Zagonel, V | 1 |
| Jiao, L; Mao, W; Peng, H; Sun, T; Wang, Q | 1 |
| Cheung, TT; Chiu, J; Kwok, GGW; Leung, R; Li, BCW; Tsang, J; Wong, JSL; Yau, T | 1 |
| Ao, J; Arai, M; Chiba, T; Iwama, A; Kanayama, K; Kanda, T; Kanogawa, N; Kanzaki, H; Kato, J; Kato, N; Kiyono, S; Kobayashi, K; Kondo, T; Koroki, K; Kusakabe, Y; Maeda, T; Maruta, S; Maruyama, H; Mimura, N; Muroyama, R; Nakagawa, R; Nakamoto, S; Nakamura, M; Ogasawara, S; Ohtsuka, M; Ooka, Y; Saito, T; Suzuki, E; Tawada, A; Yasui, S; Zen, Y | 1 |
| Bi, F; Tang, Q; Xu, H; Zhang, H | 1 |
| Aikata, H; Amioka, K; Ando, Y; Chayama, K; Fujino, H; Fukuhara, T; Hiramatsu, A; Honda, Y; Imamura, M; Kawaoka, T; Kikukawa, C; Kohno, H; Kosaka, Y; Kouno, H; Masaki, K; Mori, N; Morio, K; Murakami, E; Nakahara, T; Naruto, K; Ogawa, Y; Takaki, S; Tsuge, M; Tsuji, K; Uchikawa, S; Yamauchi, M; Yoshikawa, Y | 1 |
| Chu, H; Liang, Z; Liu, Y; Sun, R; Wu, C; Yang, K; Zhang, L; Zhang, Y; Zhao, B; Zhao, Q; Zhong, S | 1 |
| Bang, Y; Burgio, V; Casadei-Gardini, A; Cascinu, S; Catanese, S; Cucchetti, A; Kim, HD; Lonardi, S; Masi, G; Pellino, A; Rimassa, L; Rimini, M; Rizzato, MD; Ryoo, BY; Ryu, MH; Salani, F; Vivaldi, C; Yoo, C | 1 |
| Chang, CC; Chen, Y; Chou, MC; Dinh, TK; Huang, JK; Huang, KW; Jan, JJ; Ke, YY; Lee, CJ; Shia, KS; Shiue, TY; Song, JS; Sung, YC; Ta, YN; Wu, CH; Yeh, KC; Yeh, TK | 1 |
| Azzaroli, F; Benevento, F; Cabibbo, G; Caturelli, E; Cucchetti, A; Di Marco, M; Farinati, F; Foschi, FG; Gasbarrini, A; Giannini, EG; Guarino, M; Marra, F; Masotto, A; Mega, A; Missale, G; Morisco, F; Nardone, G; Oliveri, F; Pontillo, G; Raimondo, G; Rapaccini, GL; Rodolfo, S; Svegliati-Baroni, G; Trevisani, F; Vidili, G; Zoli, M | 1 |
| Bruns, CJ; Chen, W; Gao, D; Hu, B; Jiang, Y; Nelson, PJ; Raatz, L; Ren, N; Sun, J; Wang, Z; Zhang, X; Zhao, Y; Zhou, C; Zhou, H; Zhou, Q | 1 |
| Gayed, A; Yamada, R | 1 |
| Fang, C; Geng, X; Hou, H; Wang, W; Xie, H; Zhang, B; Zhao, J; Zhou, D | 1 |
| Hagiwara, H; Hikita, H; Inada, M; Kodama, T; Maesaka, K; Mita, E; Ohkawa, K; Oshita, M; Sakamori, R; Tahata, Y; Takehara, T; Tamura, S; Tatsumi, T; Yakushijin, T; Yamada, R | 1 |
| Ahlenstiel, G; Carlino, MS; Gao, B; George, J; Nagrial, A; Read, SA; Shek, D | 1 |
| Daniele, B; Li, Y; Lim, HY; Marteau, F; Martín, L; Mollon, P; Piscaglia, F; Sarker, D; Trojan, J; Venerito, M; Xu, Q; Zaucha, R | 1 |
| Assenat, E; Barone, C; Berghoff, K; Blanc, JF; Bruns, R; Decaens, T; Faivre, S; Fasolo, A; Grando, V; Iacobellis, A; Merle, P; Raymond, E; Scheele, J; Straub, J; Trojan, J; Villa, E; Wermke, M | 1 |
| Du, B; Fu, S; Jiang, H; Li, Y; Liu, X; Lu, T; Lv, J; Que, Z; Wu, T; Wu, W; Wu, Z; Xia, X; Yang, Y; Zhang, S; Zhang, Z; Zhong, Y; Zhou, Z | 1 |
| Dang, S; Jia, X; Shi, J; Wang, J; Wang, W; Zhang, X | 1 |
| Mao, J; Xie, F; Zhao, H | 1 |
| Bekaii-Saab, T; Riaz, IB; Sonbol, MB | 1 |
| Li, J; Liu, C; Lu, J; Wang, X; Xu, F; Yang, J; Zhong, X | 1 |
| Fan, H; Gong, P; Li, X; Li, Y; Liu, M; Qian, Y; Song, W; Su, H; Wu, H; Xu, Y; Zhang, Z; Zheng, C | 1 |
| Chen, YW; Ding, G; Hua, HW; Jia, L; Jia, YP; Jiang, F; Jiang, HS; Jiang, MW; Lu, DQ; Yao, YL; Zhou, Q | 1 |
| Afecto, E; Carvalho, J; Correia, J; Estevinho, MM; Fernandes, C; Gomes, AC; Silva, JC | 1 |
| Basu, B; Ben Khaled, N; Benckert, J; Berg, T; de Toni, EN; Gasbarrini, A; Jurkeviciute, G; Klümpen, HJ; Kupčinskas, J; Malfertheiner, P; Morkunas, E; Öcal, O; Palmer, D; Pech, M; Ricke, J; Sangro, B; Schütte, K; Seidensticker, M; Seidensticker, R; Sengel, C; Valle, JW; Wildgruber, M | 1 |
| Huang, SQ; Kong, FH; Liu, X; Miao, XY; Wen, Y; Xiong, L; Ye, QF; Zhang, ZJ | 1 |
| Chao, WT; Cheng, CC; Hsu, YH; Lai, YS; Liu, YH; Shih, JH | 1 |
| Beenet, L | 1 |
| Chen, J; Duan, D; Fu, R; Li, B; Li, C; Li, L; Li, Z; Liu, Y; Ming, Y; Ni, R; Song, H; Xiang, M; Xing, H; Xu, J | 1 |
| Chen, L; Chen, S; Du, Y; Jiang, Z; Li, Q; Xu, B; Yang, L; Zeng, Z | 1 |
| Cao, S; Chen, Q; Li, Z; Liu, S; Ren, Y; Wang, Y | 1 |
| Ahn, SH; Beom, SH; Choi, HJ; Han, KH; Han, S; Kim, BK; Kim, DY; Kim, HR; Kim, SU; Lee, H; Lee, HW; Lee, JS; Park, JY; Seong, J; Won, JY | 1 |
| Cheng, Q; Gao, J; Li, Z; Wang, Y; Xiang, X; Zheng, S; Zhu, J | 1 |
| Chen, ZH; Hong, YF; Huang, HQ; Jia, CC; Li, Y; Wang, TT; Wu, DH; Wu, XY; Zhang, Q | 1 |
| Chung, KPS; Keng, VW; Lau, EY; Lee, TK; Lei, MML; Leung, CON; Leung, HW; Leung, RWH; Ma, C; Ma, S; Mok, EH; Ng, IOL; Tong, M; Zhao, Q | 1 |
| Ishizaki, M; Kaibori, M; Kariya, S; Kosaka, H; Matsui, K; Matsushima, H; Sekimoto, M; Yoshii, K | 1 |
| Huang, X; Huang, Z; Li, W; Tang, X; Wang, Z; Yu, Y | 1 |
| Bin, C; Gao, Q; Huang, A; Tang, N; Wang, K; Wang, Q; Xue, Q | 1 |
| Adam, R; Baba, H; Cherqui, D; Coilly, A; De Martin, E; El-Domiaty, N; Karam, V; Maria Antonini, T; Nitta, H; Rosmorduc, O; Saliba, F; Samuel, D; Sobesky, R; Vibert, E; Younès, A | 1 |
| Guo, N; Li, B; Miao, H; Pang, C; Sun, D; Zuo, Y | 1 |
| Cho, IJ; Ki, SH; Kim, EO; Kim, JK; Kim, SC; Ku, SK; Park, SM | 1 |
| Deng, Z; Jiang, K; Jiang, S; Liu, L; Wang, T; Ye, Z; Zhang, Y | 1 |
| Chen, M; Cheng, AL; Dutcus, C; Finn, R; Han, KH; Hayato, S; Ikeda, K; Kobayashi, M; Kudo, M; Kumada, H; Mody, K; Okusaka, T; Piscaglia, F; Qin, S; Ren, M; Ren, Z; Sung, M; Tamai, T; Wyrwicz, L; Yoon, JH | 1 |
| Chen, B; Chen, J; Chen, X; Huang, S; Li, J; Peng, B; Tang, Y; Zheng, Y; Zhong, X; Zou, X | 1 |
| Borgmann, M; Hamm, S; Hermann, F; Kallus, H; Parnitzke, U; Schrepfer, S; Streubel, G; Wulff, T | 1 |
| Cai, L; Cai, X; Ji, L; Lin, Z; Pan, H; Pan, Y; Tao, L; Wan, Z; Xia, S; Xu, J; Zhao, J | 1 |
| Álvarez-Navascués, C; Álvarez-Velasco, R; Cadahía, V; Carballo-Folgoso, L; Castaño-García, A; Cuevas, J; González-Diéguez, ML; Lorca, R; Martín, M; Morís, C; Rodríguez, M; Varela, M | 1 |
| Kato, N; Kondo, T; Ogasawara, S | 1 |
| Liu, QQ; Liu, YW; Song, CX; Wang, JZ; Xie, BH; Xie, YK; Zhang, JH | 1 |
| Berghoff, K; Cheng, AL; Choi, HJ; Kim, JH; Kim, TY; Lim, HY; Pan, H; Park, JW; Qin, S; Rau, KM; Ren, Z; Ryoo, BY; Scheele, J; Straub, J; Yen, CJ; Zhou, D | 1 |
| Casak, S; Chuk, M; Davis, G; Donoghue, M; Fashoyin-Aje, L; Goldberg, KB; Lemery, S; Pazdur, R; Pelosof, L; Rodriguez, L; Saung, MT; Schotland, P; Theoret, MR; Yuan, M | 1 |
| Cai, JB; Dong, ZR; Fan, J; Ke, AW; Li, T; Shi, GM; Yang, YF; Zhou, W | 1 |
| Bardin, C; Blanchet, B; Desbois-Mouthon, C; Hamoudi, RA; Harati, R; Praz, F; Vandamme, M | 1 |
| Aikata, H; Aisaka, Y; Amioka, K; Ando, Y; Azakami, T; Chayama, K; Chihiro, K; Fujino, H; Fukuhara, T; Hiramatsu, A; Honda, Y; Hyogo, H; Imamura, M; Kawaoka, T; Kodama, K; Kohno, H; Kosaka, Y; Masaki, K; Mori, N; Morio, K; Moriya, T; Murakami, E; Naeshiro, N; Nakahara, T; Naruto, K; Nonaka, M; Ogawa, Y; Suehiro, Y; Takaki, S; Tsuge, M; Tsuji, K; Uchikawa, S; Yamauchi, M; Yoshikawa, Y | 1 |
| Cai, L; Cai, X; Ji, L; Liang, X; Lin, Z; Ruan, Y; Tao, L; Wan, Z; Wang, Y; Xia, S; Xu, J; Zheng, J | 1 |
| Cho, M; Hong, YM; Yoon, KT | 1 |
| Chen, YS; Chuang, WL; Dai, CY; Huang, JF; Jun, DW; Lin, CW; Lo, GH; Nguyen, MH; Roberts, L; Toyoda, H; Wu, TC; Yasuda, S; Yeh, JH; Yeh, ML; Yu, ML | 1 |
| Castellaneta, F; Cesari, G; Fiore, G; Gnocchi, D; Mazzocca, A; Sabbà, C | 1 |
| Abbott, DE; Anaya, DA; Anders, R; Are, C; Bachini, M; Benson, AB; Borad, M; Brown, D; Burgoyne, A; Chahal, P; Chang, DT; Cloyd, J; Covey, AM; D'Angelica, MI; Darlow, SD; Glazer, ES; Goyal, L; Hawkins, WG; Hochstetler, C; Iyer, R; Jacob, R; Kelley, RK; Kim, R; Levine, M; McMillian, NR; Palta, M; Park, JO; Raman, S; Reddy, S; Sahai, V; Schefter, T; Singh, G; Stein, S; Vauthey, JN; Venook, AP; Yopp, A | 1 |
| Boige, V; Boilève, A; Fuerea, A; Hollebecque, A; Smolenschi, C | 1 |
| Chang, YC; Chen, MJ; Cheng, SP; Huang, WC; Lin, CH; Lin, JC; Liu, CL; Wu, CY | 1 |
| Li, J; Liu, Y; Wang, Z; Wu, H; Xie, K; Zeng, Y | 1 |
| Ai, Y; Gong, N; Huang, Y; Ju, Z; Li, J; Lu, G; Wu, X; Wu, Y; Xiang, D; Yang, J; Yang, Z; Zeng, B | 1 |
| Heo, J; Kim, AR; Kim, S; Lee, M; Lee, SY; Seo, HR; Shum, D; Song, Y | 1 |
| Faneca, H; Farinha, D; Migawa, M; Sarmento-Ribeiro, A | 1 |
| Breder, V; Cheng, AL; Ding, B; Ducreux, M; Finn, RS; Galle, PR; Hernandez, S; Huang, C; Ikeda, M; Kaseb, A; Kim, TY; Kudo, M; Li, D; Lim, HY; Liu, J; Merle, P; Mulla, S; Qin, S; Verret, W; Xu, DZ; Zhu, AX | 1 |
| Marasco, G; Trevisani, F | 1 |
| Berhane, S; Hoare, M; Janowitz, T; Johnson, P; Kolamunnage-Dona, R; Potts, H; Tanner, J; Williams, EH | 1 |
| Hu, Y; Wu, L; Ye, Z; Zhang, X; Zheng, L | 1 |
| Chatellier, G; Durand-Zaleski, I; Mimouni, M; Pereira, H; Vilgrain, V; Zarca, K | 1 |
| Alahmadi, A; Bajor, DL; Barnholtz-Sloan, J; Cioffi, G; Jones, N; Lee, RT; Mangla, A; Mohamed, A; Opneja, A; Patil, N; Saltzman, JN; Selfridge, E; Tang, TY | 1 |
| Chan, A; Cheung, TT; Chiu, J; Kwok, GGW; Leung, R; Li, BCW; Lo, CM; Ma, KW; She, WH; Shing, K; Tang, V; Tsang, J; Yau, T | 1 |
| Kim, SH; Lee, HJ; Park, SC; Shin, NR; Son, Y | 1 |
| Cheng, Z; Ni, Q; Qin, L; Shi, Y | 1 |
| Bennett, L; Breder, V; Fartoux, L; Hudgens, S; Kudo, M; López, C; Meier, G; Mody, K; Ohtsuka, T; Qin, S; Simon, K; Su, Y; Sung, M; Tamai, T; Vogel, A; Yamashita, T; Yoon, JH | 1 |
| Chen, SJ; Huang, CK; Liu, F; Luo, C; Qian, H; Xiao, MC; Xie, WF; Yan, FZ; Zhang, X; Zheng, BN | 1 |
| Aikata, H; Chayama, K; Hashimoto, M; Kawaoka, T; Kobayashi, T; Kuroda, S; Ohdan, H; Yamamoto, M | 1 |
| Huang, S; Li, D; Sun, L; Wu, J; Zhuang, L | 1 |
| Kitamura, S; Maeda, T; Miyamoto, K; Yanagi, T | 1 |
| Abdelaziz, AO; Abdelhady, RSM; Abdelmaksoud, AHK; Elbaz, TM; Hamza, I; Lithy, R; Nabeel, MM; Shousha, HI | 1 |
| Luo, X; Luo, Z; Wang, C; Wang, Y; Zeng, J; Zhang, Y | 1 |
| Bai, Y; Cang, S; Chen, M; Chen, Y; Chen, Z; Cui, J; Du, C; Fan, J; Gao, Z; Gu, S; Guo, Y; Huang, M; Jia, W; Li, Q; Liu, B; Liu, C; Lu, Y; Mao, Y; Meng, Z; Qin, Y; Ren, Z; Shan, Y; Shao, G; Shi, X; Teng, G; Wang, J; Wang, Y; Wu, J; Xia, F; Xing, B; Xu, A; Xu, J; Yang, W; Yang, Y; Yin, G; Yin, T; Zhang, B; Zhou, H | 1 |
| Argentiero, A; Azzali, I; Brunetti, O; De Re, V; Fasano, R; Krebs, M; Leone, P; Nanni, O; Petracci, E; Racanelli, V; Silvestris, N; Solimando, AG; Susca, N; Vacca, A | 1 |
| Benevento, F; Forgione, A; Granito, A; Ielasi, L; Sansone, V; Tovoli, F | 1 |
| Gnetti, L; Negri, F; Pedrazzi, G; Porta, C; Silini, EM | 1 |
| Chen, CH; Hu, TH; Hung, CH; Kee, KM; Kuo, YH; Lee, YC; Lo, KC; Lu, SN; Wang, JH; Yen, YH | 1 |
| Gao, J; Jing, Z; Li, J; Liu, F; Nan, P; Niu, F; Sun, Y; Tian, L; Xie, X; Zhao, X; Zhao, Y; Zhou, L; Zhu, Y | 1 |
| Melisi, D; Pietrobono, S | 1 |
| Bai, Y; Bi, F; Chen, F; Chen, J; Chen, X; Chen, Z; Cui, C; Gu, S; Liu, X; Lu, Y; Meng, Z; Pan, H; Qin, S; Qiu, M; Ren, Z; Shan, J; Wang, J; Wang, Z; Wen, X; Wu, J; Wu, L; Xin, X; Xu, A; Xu, L; Yang, P; Ying, J; You, Z; Zhang, H; Zheng, Z; Zhu, B | 1 |
| Berchialla, P; Burlone, ME; Carucci, P; Gaia, S; Gesualdo, M; Martelletti, C; Mattalia, A; Okolicsanyi, S; Pirisi, M; Ricotti, A; Rolle, E; Tabone, M | 1 |
| Ding, B; Hernandez, S; Lencioni, R; Li, D; Salem, R; Sommer, N; Verret, W | 1 |
| Ambrosi, A; Bargellini, I; Chandan, S; Cotsoglou, C; Facciorusso, A; Mohan, BP; Paolillo, R; Ramai, D; Renzulli, M; Sacco, R; Tartaglia, N | 1 |
| Aikata, H; Ando, Y; Chayama, K; Fujii, Y; Fujino, H; Hiramatsu, A; Imamura, M; Kawaoka, T; Kobayashi, T; Kosaka, Y; Kuroda, S; Miyata, Y; Morio, K; Murakami, E; Nakahara, T; Ohdan, H; Okada, M; Saeki, Y; Suehiro, Y; Takahashi, S; Tsuge, M; Uchikawa, S; Yamaoka, K; Yamauchi, M | 1 |
| Bridle, KR; Cao, L; Crawford, DHG; Jayachandran, A; Shrestha, R | 1 |
| Jiang, H; Lv, W; Ning, G; Wang, Y | 1 |
| Ayuso, C; Belmonte, E; Boix, L; Bruix, J; Da Fonseca, LG; Darnell, A; Díaz-González, Á; Forner, A; Guedes, C; Iserte, G; LLarch, N; Muñoz-Martínez, S; Reig, M; Rimola, J; Sanduzzi-Zamparelli, M; Sapena, V; Torres, F | 1 |
| Ishizaki, M; Kaibori, M; Kariya, S; Kosaka, H; Matsui, K; Matsushima, H; Nakatani, M; Sekimoto, M; Yamaguchi, T; Yoshida, K; Yoshii, K | 1 |
| Chen, J; Ding, X; Guo, X; Li, W; Liu, X; Shen, Y; Sun, W; Teng, Y; Zheng, L | 1 |
| da Fonseca, LG; Piñero, F | 1 |
| Assenat, E; Bouattour, M; Bronowicki, JP; Chatellier, G; Dioguardi Burgio, M; Grégory, J; Pereira, H; Vilgrain, V | 1 |
| Chen, X; Gao, M; Jiang, X; Liu, Y; Ma, W; Wang, G; Xia, P; Xu, K; Yao, Y; Yuan, Y; Zhang, H; Zhang, Z | 1 |
| Dasanu, CA; Lerner, J; Michel, M; Qureshi, A | 1 |
| Gao, W; Luo, C; Ma, L; Man, S; Yan, M; Zhao, G | 1 |
| Furuse, J; Ikeda, M; Ueno, M | 1 |
| Chiou, SS; Hsu, SH; Huang, SK; Liu, KY; Wang, LT; Wang, SN | 1 |
| Li, X; Shi, D; Wang, F; Wang, J; Zhang, J | 1 |
| Campani, C; Casadei-Gardini, A; Catalano, M; Marra, F; Mini, E; Roviello, G; Vannini, G | 1 |
| Dahiya, M; Dureja, H | 1 |
| Chen, Y; Chen, Z; Pan, B; Qiu, J; Tang, N; Wang, X | 1 |
| Abrams, TA; Ahmed, M; Alsop, DC; Bockorny, B; Bullock, AJ; Faintuch, S; Goldberg, SN; Miksad, RA | 1 |
| Abou-Alfa, GK; Galle, PR | 1 |
| Bantel, H; Busche, S; Essmann, F; John, K; Lehmann, U; Schulze-Osthoff, K; Vondran, FWR; Wandrer, F; Wedemeyer, H | 1 |
| Augello, G; Azzolina, A; Cervello, M; Condorelli, L; Cusimano, A; Emma, MR; Giannitrapani, L; Iovanna, JL; McCubrey, JA; Puleio, R | 1 |
| Chen, A; Chen, L; Chen, S; Dai, X; He, F; Huang, C; Jiang, Y; Li, S; Li, T; Lian, J; Sun, L; Xiang, L; Xiao, H; Yan, X; Yang, M; Zhang, Y | 1 |
| Fang, J; Liu, J; Lu, Z; Ma, L; Ma, Q; Wang, Q; Xu, Q; Zhang, W; Zhao, J | 1 |
| Awasthi, BP; Chaudhary, P; Guragain, D; Jee, JG; Jeong, BS; Kim, JA | 1 |
| Du, WQ; Huo, FC; Li, TT; Liang, J; Mou, J; Pan, YJ; Pei, DS; Wang, Y; Zhang, LS | 1 |
| Khan, AA; Liu, ZK; Xu, X | 1 |
| Daniele, B; Lim, HY; López, B; Palmer, DH; Park, SR; Rimassa, L; Ryoo, BY; Steinberg, J | 1 |
| Bao, MH; Wong, CC | 1 |
| Cho, EJ; Cho, KH; Hwang, CY; Kim, YJ; Lee, JH; Lee, KB; Lee, S; Noh, H; Park, SM; Suh, KS; Won, JK; Yoon, JH; Yu, SJ | 1 |
| Chen, SJ; Chen, SX; Cui, RL; Dou, SY; Jiang, HQ; Jiang, XY; Liu, T; Shi, LP; Wang, SL; Wang, YJ; Xie, XL; Zhang, JN; Zhou, X | 1 |
| Chen, YT; Chu, XY; Xiang, D; Zhao, XY | 1 |
| Aballay Soteras, G; Amaddeo, G; Anders, M; Bhoori, S; Blanco Rodríguez, MJ; Bruix, J; Cesarini, L; Crespo, G; Czauderna, C; De Giorgio, M; Di Costanzo, G; Díaz-González, Á; Donato, MF; Fraile-López, M; González-Diéguez, ML; Iavarone, M; Invernizzi, F; Ivanics, T; Lampertico, P; Manini, MA; Mazza, S; Mazzaferro, V; Piñero, F; Pinter, M; Prince, R; Regnault, H; Reig, M; Romero Cristóbal, M; Sanduzzi-Zamparelli, M; Sapisochin, G; Scudeller, L; Tortora, R; Varela, M; Villadsen, GE; Weinmann, A; Wörns, MA; Yoon, PD; Yunquera, AF; Zavaglia, C | 1 |
| Andrikakou, P; Basu, B; Chee, CE; Cobbold, M; Elasri, N; Evans, J; Gabrilovich, DI; Habib, NA; Habib, R; Hashimoto, A; Huang, KW; Jarvis, S; Khan, S; Kossenkov, A; Ma, YT; Martirosyan, A; Meyer, T; Pai, M; Palmer, D; Pinato, DJ; Plummer, R; Raulf, N; Reebye, V; Reynaud, A; Rossi, JJ; Sanseviero, E; Sarker, D; Sharma, R; Sodergren, MH; Spalding, D; Vasara, J | 1 |
| Cai, Z; Liu, J; Tian, H; Xiang, B; Xiang, H; Xie, Y; Zhang, Y | 1 |
| Cao, Y; Chen, L; Kan, X; Liang, B; Ouyang, T; Xiong, F; Zheng, C | 1 |
| Iserte, G; Llarch, N; Muñoz-Martínez, S; Reig, M; Sanduzzi-Zamparelli, M | 1 |
| Hai, Y; Hu, Q; Li, L; Li, Y; Yu, S | 1 |
| Bilici, M; Büyükbayram, ME; Hannarici, Z; Şimşek, M; Tekin, SB; Yılmaz, A | 1 |
| Chen, TL; Chiu, WC; Liao, YJ; Liu, CF; Suk, FM; Wang, YH; Wu, CY | 1 |
| Amthauer, H; Bargellini, I; De Toni, EN; Gasbarrini, A; Iezzi, R; Malfertheiner, P; Pech, M; Peynircioglu, B; Ricke, J; Sangro, B; Schinner, R; Seidensticker, M; van Delden, OM | 1 |
| Babajanyan, S; Bruenderman, E; Cohn, A; Foreman, P; Geschwind, JF; Gholam, P; Goldenberg, A; Mantry, P; Martin, RC; McGuire, B; Miksad, R; Piperdi, B; Sanyal, A; Zigmont, E | 1 |
| Baglioni, M; Baron Toaldo, M; Bolondi, L; Cescon, M; Giovannini, C; Gramantieri, L | 1 |
| Haga, Y; Kanda, T; Nakamoto, S; Nakamura, M; Sasaki, R; Takahashi, K; Wu, S; Yokosuka, O | 1 |
| Ahn, SH; Han, KH; Kang, JH; Kim, BK; Kim, DY; Kim, SU; Lee, S; Park, JY | 1 |
| Mu, S; Olerile, LD; Wang, T; Yu, X; Zhang, J; Zhang, N | 1 |
| Chen, L; Wang, HY; Zheng, B; Zhu, YJ | 1 |
| Bie, P; Chen, X; Dou, K; Liu, F; Liu, L; Yang, J; Yang, X; Ye, SL; Yip, CS; Zhang, S; Zhou, J | 1 |
| Hu, XG; Huang, DS; Li, T; Xu, QR; Yang, HM; Yang, L; Ye, S; Zhao, XY | 1 |
| Cao, XH; Lu, AQ; Lv, B; Qiu, F; Wang, XY | 1 |
| Chang, Y; Cho, EJ; Cho, H; Cho, YY; Jo, A; Kim, JB; Kim, YJ; Lee, JH; Lee, M; Lee, S; Nam, JY; Yoon, JH; Yu, SJ | 1 |
| Cho, HJ; Cho, HR; Choi, JW; Chung, JW; Kim, DD; Kim, HC; Park, JH | 1 |
| Chaudhary, D; Goel, M; Patkar, S; Shrikhande, SV | 1 |
| Chen, C; Chu, X; Geng, J; Han, D; Huang, M; Lei, Z; Wang, C; Wang, L; Wang, T; Wang, Y; Xie, T | 1 |
| Chao, Y; Chen, SC; Yang, MH | 1 |
| Karasawa, Y; Kawamura, S; Kojima, K; Kondo, M; Maeshima, S; Ohki, T; Seki, M; Shioda, Y; Tagawa, K; Toda, N | 1 |
| Chang, HH; Chen, JS; Chia-Hsun Hsieh, J; Chou, WC; Hou, MM; Huang, CY; Lee, CL; Lin, YC; Teng, W; Tseng, YT; Yang, TS | 1 |
| Chen, CP; Liao, XH; Liu, H; Lu, KP; Lu, W; Wang, J; Wang, L; Xu, H; Yang, D; Zhang, AL; Zheng, M; Zhou, XZ | 1 |
| Best, J; Dechêne, A; Gerken, G; Lohmann, G; Schotten, C | 1 |
| Friedman, T; Kishore, S; Madoff, DC | 1 |
| Chen, J; Cheng, Y; Li, A; Liu, D; Liu, Y; Luo, R; Wang, B; Xu, W; Zheng, H; Zhu, Y | 1 |
| Huachuan, Z; Jianhua, H; Li, R; Rongjian, S; Wubin, H; Yanjiao, G; Yue, W; Zhidong, L | 1 |
| Braiteh, F; Burris, H; Cohn, AL; Foster, P; Kelley, RK; Lee, Y; Spira, A; Su, WC; Van Cutsem, E; Verslype, C; Vogelzang, N; Yang, TS | 1 |
| Galle, PR; Wörns, MA | 3 |
| Cho, EJ; Cho, H; Cho, KH; Cho, SH; Choi, WM; Hwang, CY; Jang, JJ; Kim, CY; Kim, K; Kim, YJ; Lee, JH; Lee, KB; Park, SM; Suh, KS; Won, JK; Yoon, JH; Yu, SJ | 1 |
| Cho, E; Cho, SB; Choi, SK; Jun, CH; Kim, HJ; Kim, HS; Park, CH; Rew, JS; Shin, SS; Yoon, JH | 1 |
| Mancuso, A; Maringhini, A | 1 |
| Lujambio, A; Molina-Sánchez, P | 1 |
| Dhungel, B; Jayachandran, A; Mir, N; Shrestha, R; Steel, JC | 1 |
| Chen, CH; Hu, TH; Hung, CH; Kee, KM; Kuo, YH; Lu, SN; Rau, KM; Wang, JH; Wu, IP | 2 |
| Chen, T; Cui, M; Cui, Y; Ge, C; Huo, Q; Li, H; Li, J; Sun, J; Tian, H; Xie, H; Yao, M; Zhao, F | 1 |
| Caraglia, M; Cervi, C; Di Biase, S; Lo Re, O; Panebianco, C; Pazienza, V; Porto, S; Rappa, F; Vinciguerra, M | 1 |
| Giordano, L; Personeni, N; Rimassa, L; Santoro, A | 1 |
| Jackson, R; Johnson, PJ; Psarelli, E | 1 |
| Abe-Chayama, H; Aikata, H; Chayama, K; Daijo, K; Fujino, H; Hiramatsu, A; Imamura, M; Kan, H; Kawakami, Y; Kawaoka, T; Kobayashi, T; Makokha, GN; Masaki, K; Masuda, K; Miki, D; Morio, K; Nagaoki, Y; Nakahara, T; Nakamura-Inagaki, Y; Nelson Hayes, C; Ochi, H; Ono, A; Teraoka, Y; Tsuge, M; Uchida, T; Zhang, Y | 1 |
| Chen, B; Cui, X; Hu, B; Hua, L; Liu, J; Shen, C; Shen, Y; Yan, D; Zhao, F | 1 |
| Chen, HM; Chen, PJ; Cheng, AL; Hsu, CH; Lai, MS; Lu, LC; Shao, YY; Yeh, YC | 1 |
| Guo, Z; Li, T; Pu, J; Wei, X; Wu, Z; Zhu, D | 1 |
| Lee, SJ; Lim, HY | 1 |
| Chang, Y; Dusetzina, SB; Lund, JL; O'Neil, BH; Sanoff, HK | 2 |
| Badrinath, N; Heo, J; Woo, HY; Yoo, SY | 1 |
| Chang, Y; Cho, EJ; Chung, GE; Kim, HY; Kim, YJ; Lee, DH; Lee, JH; Lee, JM; Nam, JY; Yoo, JJ; Yoon, JH; Yu, SJ | 1 |
| Casadei Gardini, A; Ercolani, G; Foschi, FG; Frassineti, GL; Ulivi, P | 1 |
| Cho, EJ; Cho, Y; Kim, YJ; Lee, DH; Lee, JH; Lee, KW; Suh, KS; Yi, NJ; Yoon, JH; Yu, SJ | 1 |
| Bruix, J; Cleton, A; Drenth, HJ; Fiala-Buskies, S; Keunecke, A; Meinhardt, G; Ploeger, B; Reinecke, I; Solms, A | 1 |
| Cho, EJ; Cho, Y; Cho, YY; Jun, J; Kim, H; Kim, Y; Kim, YJ; Lee, DH; Lee, JH; Lee, S; Park, T; Yeo, I; Yoon, JH; Yu, SJ | 1 |
| Aoki, Y; Arai, T; Atsukawa, M; Doi, H; Fukai, M; Itokawa, N; Kanto, T; Kimura, K; Mano, Y; Mizokami, M; Osawa, Y; Shoji, H; Sugiyama, M; Taketomi, A; Yoshio, S | 1 |
| Abeni, E; Arici, B; De Petro, G; Marchina, E; Salvi, A; Traversa, M | 1 |
| Beukhof, CM; Bins, S; Chaker, L; de Herder, WW; de Rijke, YB; Mathijssen, RH; Peeters, RP; van Doorn, L; van Heerebeek, R; van Kemenade, FJ; Visser, TJ; Visser, WE | 1 |
| Personeni, N; Pressiani, T; Rimassa, L; Santoro, A | 1 |
| Franzesi, CT; Ippolito, D; Okolicsanyi, S; Querques, G; Sironi, S; Strazzabosco, M | 1 |
| Choi, YK; Ham, HJ; Jang, SY; Jeon, HJ; Kim, BG; Kim, JG; Kim, JH; Kim, MJ; Lee, IK; Lee, JY; Park, KG; Park, SY | 1 |
| Abada, PB; Baron, AD; Blanc, JF; Borg, C; Bowman, L; Chau, I; Chung, HC; Cui, ZL; Girvan, AC; Kudo, M; Malfertheiner, P; Okusaka, T; Park, JO; Pastorelli, D; Peck-Radosavljevic, M; Poon, R; Ryoo, BY; Seitz, JF; Yang, L; Yen, CJ; Zhu, AX | 1 |
| Abou-Alfa, GK; Bass, M; Blanc, JF; Bradley, M; Cebon, J; Ganten, T; Gupta, C; Hollywood, E; Liem, AK; Lipton, L; Litten, J; Ma, J; Miles, S; Saltz, LB; Trojan, J; Wu, B | 1 |
| Murata, K; Nitta, N; Nitta-Seko, A; Ohta, S; Sonoda, A; Tomozawa, Y; Tsuchiya, K; Watanabe, S | 1 |
| Eggert, T; Greten, TF | 1 |
| Adam, R; Amaddeo, G; Bricault, I; Calderaro, J; Cherqui, D; Costentin, CE; Decaens, T; Duvoux, C; Ganne-Carrié, N; Laurent, A; Letoublon, C; Luciani, A; Mallat, A; Nault, JC; Paule, B; Roudot-Thoraval, F; Samuel, D; Vibert, E | 1 |
| Itoh, K; Matsueda, S; Morita, M; Muroya, D; Sasada, T; Shichijo, S; Shirahama, T; Yamada, A; Yamaguchi, R; Yutani, S | 1 |
| Altamura, E; Azzariti, A; Cutrignelli, A; Denora, N; Di Fonte, R; Franco, M; Iacobazzi, RM; Laquintana, V; Lopalco, A; Lopedota, AA; Porcelli, L | 1 |
| Ji, B; Liu, J; Liu, K; Liu, Y; Meng, L | 1 |
| Byun, KS; Jung, YK; Kang, SH; Kim, BH; Kim, JH; Kim, TS; Lee, YS; Seo, YS; Suh, SJ; Yeon, JE; Yim, HJ; Yoo, YJ | 1 |
| Cheng, Z; Ke, X; Li, C; Li, H; Li, X; Liu, S; Qu, Y; Shen, Y; Wu, G; Xie, N; Xu, X; Yang, N; Yuan, X; Zhang, W; Zhou, J; Zu, X | 1 |
| Cheng, LKW; Copland, JA; Ding, J; Ho, NPY; Lau, EYT; Lee, TKW; Leung, DHW; Lin, CH; Lo, J; Lo, RCL; Ma, MKF; Ma, S; Ng, IOL | 1 |
| Collins, P; Cunningham, D; Evans, TRJ; Fox, R; Hacking, N; Hubner, RA; James, MW; Johnson, PJ; Ma, YT; Meyer, T; Palmer, DH; Primrose, JN; Ross, PJ; Stocken, DD; Stubbs, C; Sturgess, R; Wall, L; Watkinson, A | 1 |
| Chai, W; Jiang, T; Tian, G | 1 |
| Ahn, SH; Han, KH; Heo, JY; Jang, SK; Jang, SY; Jeon, MY; Kim, BK; Kim, DY; Kim, HS; Kim, SU; Lee, HW; Lee, SH; Lee, YR; Park, JY; Park, SY; Tak, WY | 1 |
| Galle, PR; Huber, Y; Koch, S; Labenz, C; Marquardt, JU; Prenosil, V; Schattenberg, JM; Weinmann, A; Wörns, MA | 1 |
| Abdel-Wahab, R; Abdelsalam, ME; Al-Shamsi, HO; Aloia, TA; Amin, HM; Avritscher, R; Chun, YS; Conrad, C; Dahbour, I; Das, P; Hassan, MM; Kaseb, AO; Koay, EJ; Krishnan, S; Lacin, S; Mahvash, A; Murthy, R; Odisio, BC; Rashid, A; Shalaby, AS; Vauthey, JN; Yao, JC | 1 |
| Dai, X; Ding, J; Fu, X; Geng, M; Huang, M; Huang, X; Liu, H; Shen, A; Sun, D; Wei, R; Yan, J; Zheng, X | 1 |
| Bruix, J; Cheng, AL; De Sanctis, Y; Llovet, J; Meinhardt, G; Nakajima, K | 1 |
| Bansal, P; Fekrazad, HM; Lee, FC; Patt, Y; Rojas-Hernandez, C | 1 |
| Barbera, MA; Biasco, G; Brandi, G; Frega, G; Garajova, I; Lorenzo, S; Palloni, A; Pantaleo, MA; Tovoli, F | 1 |
| Narasimhan, G; Reddy, MS; Rela, M; Scott, JX; Shanmugam, N; Valamparampil, JJ; Vij, M | 1 |
| Buder, R; Galle, PR; Ganten, TM; Gerken, G; Göhler, T; Koschny, R; Malfertheiner, P; Schott, E; Stauber, RE; Walther, M | 1 |
| Bouarioua, N; Bourmaud, A; Clavel, L; Merle, P; Phelip, JM; Roblin, X; Verot, C; Williet, N | 1 |
| Chen, C; Chen, SZ; Cheng, Z; Cong, WM; Ding, J; Lee, TKW; Li, XF; Lu, XY; Ning, BF; Qu, L; Shen, WF; Sun, W; Wang, HY; Wen, W; Xia, MY; Xiang, DM; Yang, W; Zhou, TF | 1 |
| Huang, X; Li, G; Li, W; Mu, X; Qian, X; Qin, J; Sun, B; Tan, S; Tan, Z; Wang, X; Xu, X; Zhang, W; Zhu, Z | 1 |
| Yao, CA | 1 |
| Chao, Y; Chen, YT; Hou, MC; Huang, YH; Huo, TI; Lee, FY; Lee, MH; Lee, PC; Li, CP; Lin, HC; Su, CW | 1 |
| Ba, Q; Duan, X; Li, H; Li, J; Li, X; Wang, F; Wang, H; Yao, W; Yuan, Y; Zhang, S; Zhang, W | 1 |
| Kollmann, D; Selzner, M; Selzner, N | 1 |
| Fan, L; Jiang, K; Li, T; Shao, J; Zhao, R; Zheng, G | 1 |
| Bai, T; Sun, Y; Wang, S; Wang, W; Zhao, Y; Zhu, R | 1 |
| Brunetti, O; Casadei Gardini, A; Cascinu, S; Di Costanzo, GG; Ercolani, G; Faloppi, L; Foschi, FG; Granata, R; Marisi, G; Palmieri, VO; Scartozzi, M; Silvestris, N; Tortora, R | 1 |
| Arizumi, T; Hagiwara, S; Kamata, K; Kudo, M; Minaga, K; Minami, Y; Nishida, N; Sakurai, T; Takenaka, M; Watanabe, T; Yada, N | 1 |
| Choi, HJ; Han, Z; Joo, Y; Kang, D; Oh, GH; Song, JJ | 1 |
| Bavari, S; Brahms, A; Kehn-Hall, K; Kota, K; Mudhasani, R; Nasar, F; Pinkham, C; Zamani, R | 1 |
| Bettinger, D; Boettler, T; Brunner, TB; Buettner, N; Gkika, E; Glaser, N; Maruschke, L; Neumann-Haefelin, C; Schultheiss, M; Spode, R; Thimme, R | 1 |
| Akhoundova, D; Aparicio, J; Bruixola, G; Caballero, J; Diaz-Beveridge, R; Giménez, A; Lorente, D; Rodrigo, E; Segura, Á | 1 |
| Chen, BB; Cheng, AL; Hsu, C; Hsu, CH; Lin, ZZ; Ou, DL; Shao, YY; Wang, MJ | 1 |
| Bardia, A; Chandrakala, L; Dhayal, M; Habeeb, MA; Khan, AA; Raju, N; Sastry, BVS; Sharmila, P; Sravani, G; Vishwakarma, SK | 1 |
| Appella, D; Avram, MJ; Chen, Z; Green, R; Gupta, P; Huang, M; Huang, S; Kandela, I; Liu, Y; Lou, G; Mazar, A; Norton, JT; Shank, NI; Tang, S; Wang, C | 1 |
| Hoshino, T; Ishihara, H; Kakizaki, S; Kudo, T; Naganuma, A; Sato, K; Suzuki, Y; Takagi, H; Uehara, D; Yamada, M | 1 |
| Borgia, F; Cannavò, SP; Franzè, MS; Lentini, M; Saitta, C; Vaccaro, M | 1 |
| Ballarin, R; Berretta, M; Di Benedetto, F; Guerrini, GP; Magistri, P; Pecchi, A; Tarantino, G | 1 |
| García Carretero, R; Rebollo-Aparicio, N; Romero Brugera, M; Vazquez-Gomez, O | 1 |
| Beveridge, DJ; Brown, RM; Candy, P; Chaturvedi, V; Epis, M; Ganda, C; George, J; Kabir, TD; Kalinowski, F; Kopp, C; Leedman, PJ; Richardson, KL; Stuart, LM; Wintle, L; Yeoh, GC | 1 |
| Li, W; Sun, X; Tan, G; Wang, P; Zhai, B; Zhu, M | 1 |
| Chen, K; Dai, W; Fan, X; Feng, J; Guo, C; Li, J; Li, S; Liu, T; Lu, J; Lu, X; Mo, W; Wang, W; Wu, L; Xia, Y; Xu, L; Xu, S; Yu, Q; Zhang, Q; Zhou, Y | 1 |
| Zhang, H | 1 |
| D'Addeo, K; Kaplan, DE; Mamtani, R; Mehta, R; Reiss, KA; Taddei, TH; Wileyto, EP; Yu, S | 1 |
| Arai, M; Chiba, T; Inoue, M; Kanda, T; Kato, N; Kiyono, S; Kobayashi, K; Maeda, T; Maruyama, H; Nakamoto, S; Nakamura, M; Ogasawara, S; Ooka, Y; Saito, T; Suzuki, E; Tawada, A; Wakamatsu, T; Yasui, S; Yokosuka, O; Yokoyama, M | 1 |
| Ayuso, C; Bruix, J; Castroagudin, J; Darnell, A; Delgado, M; Díaz-González, Á; Gonzalez, C; Hernandez-Guerra, M; Huertas, C; Matilla, A; Minguez, B; Pons, F; Reig, M; Rimola, J; Rodriguez de Lope, C; Sala, M; Sangro, B; Varela, M | 1 |
| Bai, T; Chen, J; Li, LQ; Li, ZH; Qi, LN; Wu, FX; Yang, TB; Ye, JZ; Zhu, SL; Zou, L | 1 |
| Barbera, MA; Brandi, G; Cescon, M; Cucchetti, A; De Lorenzo, S; De Pace, V; Del Gaudio, M; Frega, G; Maroni, L; Neri, F; Palloni, A; Pantaleo, MA; Pinna, AD; Ravaioli, M; Ripoli, MC | 1 |
| Ahmad, J; Ali, A; Awan, FM; Ikram, A; Janjua, HA; Naveed, AK; Naz, A; Obaid, A | 1 |
| Chang, CS; Chao, Y; Chen, CY; Lee, TY; Lin, CC; Lo, GH; Wang, TE | 1 |
| Azzolina, A; Balasus, D; Cervello, M; Emma, MR; Giammona, G; Loria, GR; Pitarresi, G; Porsio, B; Puleio, R; Puleo, S; Volpe, AB | 1 |
| Bitzer, M; Horger, M; Kaufmann, S; Lauer, U; Nikolaou, K; Schulze, M; Thaiss, WM | 1 |
| Cheng, H; Dong, J; Hu, F; Sun, W; Xu, J; Zhai, B | 1 |
| Eguchi, R; Enomoto, H; Honda, M; Iijima, H; Imanishi, H; Iwata, Y; Kaneko, S; Nishiguchi, S; Nishikawa, H; Sato, A; Tao, L; Tsujimura, T | 1 |
| Chow, PK; Gandhi, M; Gebski, V | 1 |
| Chen, HM; Cheng, AL; Hsu, CH; Lee, YH; Li, YS; Lin, H; Shao, YY | 1 |
| Gao, L; Lv, F; Shay, C; Teng, Y; Wang, X | 1 |
| Aprile, G; Brunetti, O; Casadei Gardini, A; Cascinu, S; De Matteis, S; Ercolani, G; Faloppi, L; Foschi, FG; Frassineti, GL; Granato, AM; Marisi, G; Negrini, G; Palmieri, V; Passardi, A; Perrone, G; Santini, D; Scartozzi, M; Silvestris, N; Tamburini, E; Tovoli, F; Valgiusti, M; Vespasiani-Gentilucci, U | 1 |
| Blanc, JF; Campillo-Gimenez, B; Edeline, J; Faluyi, O; Ghazi, S; King, J; Ma, YT; Mathurin, J; Meyer, T; Palmer, DH | 1 |
| Chen, KF; Li, B; Li, Q; Liu, F; Wei, YG; Zhao, RC; Zhou, J | 1 |
| Chan, KKW; Earle, CC; Jembere, N; Qiao, Y; Sapisochin, G; Thein, HH; Yoshida, EM; Zaheen, A | 1 |
| Cai, X; Chen, J; Jin, RA; Liang, X; Lin, H; Sun, Y; Tang, M; Xu, J; Zheng, L | 1 |
| Cai, X; Chen, J; Dai, Y; Ji, T; Liang, X; Liang, Y; Lin, H; Xie, Y; Xu, J; Yu, Q; Zhang, B | 1 |
| Cillo, C; di Tommaso, L; Lanzafame, M; Matter, MS; Ng, CK; Novello, C; Pallante, P; Piscuoglio, S; Pressiani, T; Quagliata, L; Quintavalle, C; Rimassa, L; Roncalli, M; Terracciano, LM; Tornillo, L | 1 |
| El-Serag, HB; Johnson, MS; Zhu, AX | 1 |
| Kudo, M; Nishida, N; Ueshima, K | 1 |
| Deguchi, A; Hiasa, Y; Hiraoka, A; Hirooka, M; Imai, M; Ishikawa, T; Joko, K; Koizumi, Y; Kudo, M; Kumada, T; Michitaka, K; Ochi, H; Shimada, N; Tada, T; Tajiri, K; Toyoda, H; Tsuji, K | 1 |
| Chen, GG; Lai, PBS; Liu, L; Niu, L; Ren, J; Yang, S | 1 |
| Arai, J; Goto, K; Ito, S; Kaise, Y; Kato, N; Lim, LA; Matsubara, Y; Morimoto, S; Muroyama, R; Nakagawa, R; Stephanou, A; Tanoue, Y; Yoshida, H | 1 |
| Andersen, JB; Beguinot, F; Condorelli, G; Heim, MH; Hindupur, SK; Matter, MS; Ng, CKY; Nigro, C; Pallante, P; Piscuoglio, S; Quagliata, L; Quintavalle, C; Roth, W; Tagscherer, KE | 1 |
| Bruix, J; Lii Cheng, A; Llovet, J | 1 |
| Berhane, S; Jackson, R; Johnson, PJ; Psarelli, E | 1 |
| Fang, C; Gao, P; Geng, P; Guo, L; Hu, C; Li, E; Liu, Y; Sun, M; Tang, L; Wang, C; Wang, J; Wang, Y; Xu, G; Yin, P; Yu, J; Zeng, J; Zhuang, Z | 1 |
| Cheng, SB; Huang, CC; Jan, YG; Lin, HC; Lin, YL; P'eng, FK; Shen, CH; Teng, CJ; Wu, CC; Yang, YS | 1 |
| Fu, C; Gu, H; Han, Z; Lin, J; Lu, F; Yang, S | 1 |
| Cai, M; Cao, Z; Chen, X; Lin, L; Shuai, X; Sun, W; Wang, Y; Zhu, K | 1 |
| Adam, R; Allaham, W; Assenat, E; Aubé, C; Barraud, H; Bouattour, M; Brenot-Rossi, I; Bronowicki, JP; Castera, L; Chatellier, G; Costentin, C; Couturier, O; Dinut, A; Gerolami, R; Guiu, B; Ilonca, AD; Itti, E; Laurent, V; Lebtahi, R; Lewin, M; Luciani, A; Mathias, E; Mundler, O; Oberti, F; Pageaux, GP; Perdrisot, R; Pereira, H; Raoul, JL; Ronot, M; Samuel, D; Sarran, A; Seitz, JF; Sibert, A; Silvain, C; Tasu, JP; Vidal, V; Vilgrain, V | 1 |
| Chen, X; Shao, J; Shen, Z; Xu, A; Zhao, R; Zheng, G | 1 |
| Arima, K; Baba, H; Beppu, T; Chikamoto, A; Hashimoto, D; Hayashi, H; Higashi, T; Imai, K; Ishiko, T; Kaida, T; Nakagawa, S; Nitta, H; Okabe, H; Sasaki, Y; Takeyama, H; Taki, K; Tanaka, M | 1 |
| Cai, R; Liao, Y; Ma, H; Pang, P; Song, R; Sun, H; Wang, H; Wang, S; Yan, Y; Zhang, H; Zhou, C; Zhou, X | 1 |
| Bae, WK; Kim, DY; Kwon, SY; Min, JJ | 1 |
| Cen, J; He, Q; Hu, C; Hu, J; Hui, L; Ji, Y; Jiang, K; Kienast, Y; Li, W; Liu, X; Qiu, Z; Tian, F; Wang, Z; Zhang, H | 1 |
| Bae, SH; Choi, JY; Hwang, S; Jang, JW; Park, HL; Song, MJ; Sung, PS; Yang, K; Yoo, IR; Yoon, SK | 1 |
| Abdel-Rahman, O; Eissa, M; El Gewaity, M; Farag, K; Ghonaim, A; Nada, Y; Rashad, N; Saadawi, I; Sheha, A | 1 |
| Abou-Alfa, GK; Dika, IE | 1 |
| Fei, Z; Lu, M; Zhang, G | 1 |
| Liu, H; Ming, L; Sun, T | 1 |
| Chakraborti, A; Chawla, YK; Dhiman, RK; Kalra, N; Kanthaje, S; Makol, A | 1 |
| Ahmed, B; Ghaffar, A; Jalal, F; Kamran, SK; Kiran, S; Munir, B; Oranab, S; Shehzadi, S; Zahoor, MK | 1 |
| Chang, PY; Huang, YK; Lee, SW; Lee, TY; Shiu, SI; Yeh, HZ; Yen, CL | 1 |
| Chen, D; Chen, YT; Jiang, XY; Kong, J; Luo, JH; Ni, JY; Sun, HL; Wang, WD; Xu, LF | 1 |
| Auriola, S; Bunch, L; Gynther, M; Han, L; Hansen, JC; Hansen, KB; Ishchenko, Y; Kayser, S; Larsen, Y; Malm, T; Nielsen, B; Petsalo, A; Pickering, DS; Proietti Silvestri, I | 1 |
| Liu, LX; Liu, QX; Luo, JJ; Ma, JQ; Wang, JH; Yan, ZP; Zhang, W; Zhang, ZH | 1 |
| Ciani, O; Rognoni, C; Sommariva, S; Tarricone, R | 2 |
| Fan, XG; Fu, Y; Hu, X; Huang, Y; Li, N; Quan, J; Sun, L; Xiao, Y; Zhou, P; Zhou, R | 1 |
| Barbera, MA; Bernardi, M; Brandi, G; Casadei Gardini, A; De Lorenzo, S; Di Costanzo, GG; Foschi, FG; Garuti, F; Granito, A; Inghilesi, AL; Marra, F; Sacco, R; Tortora, R; Tovoli, F; Trevisani, F | 1 |
| Arizumi, T; Kudo, M | 1 |
| Ando, M; Deguchi, A; Kokudo, Y; Kubo, A; Kudo, M; Masaki, T; Matsunaka, T; Minami, Y; Morishita, A; Morita, M; Moriya, A; Nagano, T; Nishida, N; Noda, T; Ogawa, C; Omura, A; Sakurai, T; Senoh, T; Shibatoge, M; Takaguchi, K; Tamaki, H; Tani, J; Tsutsui, A; Ueshima, K; Yoneyama, H | 1 |
| Arai, K; Asahina, Y; Hara, Y; Hayashi, T; Honda, M; Kaneko, S; Mizukoshi, E; Nio, K; Okada, H; Sakai, Y; Suda, T; Sunagozaka, H; Takatori, H; Terashima, T; Yamashita, T | 1 |
| Bosserhoff, AK; Dietrich, P; Fritz, V; Hartmann, A; Hellerbrand, C; Koch, A | 1 |
| Arakawa, Y; Bando, Y; Ikemoto, T; Imura, S; Ishikawa, D; Iwahashi, S; Morine, Y; Saito, YU; Shimada, M; Takasu, C; Teraoku, H; Yoshimoto, T | 1 |
| Matsumura, T; Matsushima, H; Ryu, T; Saitsu, H; Takami, Y; Tateishi, M; Wada, Y; Yoshitomi, M | 1 |
| Lee, JS; Park, IY; Shin, JH; Sohn, BH; Yim, SY | 1 |
| Baldassarre, M; Bolondi, L; Fornari, F; Giannone, FA; Giovannini, C; Gramantieri, L; Marinelli, S; Negrini, M; Patrizi, C; Pollutri, D; Porretti, L; Quarta, S; Trombetta, E; Van Vlierberghe, H; Vandewynckel, YP; Vandierendonck, A | 1 |
| Arnold, AW; Kiritsi, D | 1 |
| Ai, S; Fu, H; Pan, T; Tang, L; Wang, F; Zhang, J | 1 |
| Abe, S; Fujisawa, K; Furutani-Seiki, M; Goto, R; Inoue, R; Kamimura, K; Koyama, N; Nagoya, T; Nishina, H; Nozawa, Y; Ogawa, K; Sakai, N; Sakaida, I; Sakamaki, A; Shinagawa-Kobayashi, Y; Sugitani, S; Terai, S; Yanagi, M; Yokoo, T | 1 |
| Benoukraf, T; Chow, EK; Fong, ELS; Hooi, L; Huynh, TH; Lin, QXX; Liu, Z; Mohd Abdul Rashid, MB; Toh, TB; Yu, H | 1 |
| D'Addeo, K; Kaplan, DE; Mehta, R; Taddei, TH; Valderrama, A | 1 |
| Cao, S; Cao, Y; Chai, Y; Feng, F; Jiang, Q; Li, BA; Li, R; Li, X; Liang, E; Liu, G; Shen, L; Sun, H; Sun, L; Wang, T; Xin, S; Yang, R; Yang, Y; Yang, Z; Zhu, H | 1 |
| Bazaz, R; Denning, DW | 1 |
| Bi, Y; Casak, S; Goldberg, KB; Jiang, X; Keegan, P; Lemery, S; Liu, J; McKee, AE; Patel, A; Pazdur, R; Pelosof, L; Pierre, V; Rodriguez, L; Zirkelbach, JF | 1 |
| Antoniewicz, MR; Au, J; DeWaal, D; Guzman, G; Hay, N; Jeon, SM; Long, CP; Nogueira, V; Patra, KC; Terry, AR | 1 |
| Chen, M; Chen, S; Jiang, C; Kuang, M; Li, B; Li, J; Lin, M; Mei, J; Peng, Z; Qian, G; Wang, Y; Wei, M; Xie, X | 1 |
| Cai, MY; Chen, BH; Guo, YJ; Huang, JJ; Huang, WS; Meng, XC; Zhou, JW; Zhu, KS | 1 |
| Finn, RS; Llovet, JM | 1 |
| Hasegawa, K; Kokudo, N; Kokudo, T | 1 |
| Campillo-Gimenez, B; Edeline, J; Garin, E; Rolland, Y | 1 |
| Chatellier, G; Dinut, A; Pereira, H; Vilgrain, V | 1 |
| Aikata, H; Aisaka, Y; Chayama, K; Hatooka, M; Hiramatsu, A; Honda, Y; Hyogo, H; Imamura, M; Inagaki, Y; Kawakami, Y; Kawaoka, T; Kimura, T; Kodama, K; Kohno, H; Masaki, K; Mori, N; Morio, K; Moriya, T; Murakami, E; Nagata, Y; Nakahara, T; Nishida, Y; Nonaka, M; Takaki, S; Tsuge, M; Tsuji, K; Uchikawa, S | 1 |
| Baron, A; Blanc, JF; Cheng, AL; Dutcus, C; Evans, TRJ; Finn, RS; Guo, M; Han, G; Han, KH; Ikeda, K; Jassem, J; Komov, D; Kraljevic, S; Kudo, M; Lopez, C; Park, JW; Piscaglia, F; Qin, S; Ren, M; Saito, K; Tamai, T; Vogel, A | 1 |
| Dong, X; Li, L; Li, Z; Lu, H; Shi, X; Sun, P; Yu, X; Zhong, J; Zhou, W | 1 |
| Dai, B; Li, J; Liu, Y; Shi, XL; Wu, PW; Zhang, PF; Zhang, YH; Zhou, Y | 1 |
| Chan, KK; Ho, DW; Lee, TK; Leung, CO; Lo, RC; Ng, IO; Wong, CM | 1 |
| Bi, F; Dai, X; Fan, Z; Gong, Q; Tang, Q; Wei, G; Xia, H; Yu, H; Zhou, S | 1 |
| Abdel-Rahman, O | 1 |
| Cheng, S; He, B; Hu, W; Shen, X; Sun, W; Wen, X; Wu, J; Xiao, H; Xie, H; Yang, B; Yang, Z; Zheng, S; Zhou, L | 1 |
| Carella, N; Carr, BI; Cavallini, A; D'Alessandro, R; Lippolis, C; Messa, C; Refolo, MG | 2 |
| Cai, X; Deng, H; Guo, R; Kong, Y; Li, J; Li, S; Lin, Y; Liu, Y; Lyu, N; Mu, L; Shi, M; Wu, P; Xie, Q; Xu, L; Zhang, Z; Zhao, M; Zheng, L | 1 |
| Chen, J; Chen, L; Chen, Y; Chu, X; Wang, R; Zhang, B; Zhang, C; Zhang, K; Zhi, Y; Zhou, H | 1 |
| Aramaki, T; Asagi, A; Furuse, J; Hosokawa, A; Ikeda, M; Ishii, H; Kaneko, S; Kato, N; Okusaka, T; Sano, K; Sato, T; Sugimoto, R; Suzuki, E; Yamaguchi, K; Yasui, K | 1 |
| D'Addeo, K; Gade, TP; Kaplan, DE; Mehta, R; Taddei, TH | 1 |
| Thomas, H | 1 |
| Ahn, SH; Baek, SE; Han, KH; Jeon, MY; Kim, BK; Kim, DY; Kim, HS; Kim, SU; Lee, HW; Park, JY; Park, MS | 1 |
| Bae, SH; Bartlett, A; Cheow, PC; Choo, SP; Chotipanich, C; Chow, PKH; Cua, IHY; Gandhi, M; Gebski, V; Goh, ASW; Goh, BKP; Han, HS; Hung, CF; Jong, YW; Khasbazar, A; Khin, MW; Kim, YH; Kok, KYY; Law, CS; Lee, RC; Lekurwale, G; Lesmana, LA; Liang, PC; Liew, WM; Lim, K; Lo, RHG; Lobo, RR; Low, AS; Mak, KSW; Manuaba, TW; Ng, DCE; Ong, J; Peng, CY; Raj, A; Soo, KC; Tan, SB; Tay, KH; Teh, CSC; Thng, CH; Yoon, HK; Yoong, BK | 1 |
| Bie, P; Chen, X; Chen, Y; Deng, X; Dou, K; Fu, Z; Hao, C; Liu, F; Liu, L; Liu, Y; Lv, Z; Nakajima, K; Shao, G; Xia, Q; Yang, J; Ye, SL; Yuan, Y; Zhang, S; Zhou, J | 1 |
| Chen, ZH; Cheng, SQ; Guo, WX; Wang, K; Zhang, XP | 1 |
| Dore, GJ; Gomaa, A; Waked, I; Waziry, R | 1 |
| Jian, W; Li, C; Sun, X; Xie, F; Zhang, K | 1 |
| Bahary, N; Blanchard, S; Chen, H; El-Khoueiry, AB; Gandara, DR; Jiang, Y; Lenz, HJ; Mack, P; O'Donnell, R; Semrad, TJ; Wright, J; Yen, Y | 1 |
| Deng, M; Li, L; Li, W; Yuan, S; Zhao, J | 1 |
| Meyer, T | 2 |
| Costentin, CE; Farsad, K; Zhu, AX | 1 |
| Chen, Y; He, C; Lee, RJ; Li, M; Lu, Y; Wang, Y; Xiang, G; Yang, T; You, J; Zhang, X; Zhao, P | 1 |
| Cho, EJ; Cho, YY; Kim, HY; Kim, YJ; Lee, DH; Lee, JH; Yoon, JH; Yu, SJ | 1 |
| Deptala, A; Fartoux, L; Graham, J; Hocke, J; Loembé, AB; Ma, YT; Meyer, T; Palmer, DH; Peck-Radosavljevic, M; Ross, P; Schnell, D; Studeny, M | 1 |
| Bolondi, L; De Lorenzo, S; Granito, A; Tovoli, F | 1 |
| Dank, M; Padányi, P | 1 |
| Fu, Y; Liang, J; Lin, L; Wei, X; Xu, W | 1 |
| Das, K; Eason, JD; Helmick, RA; Kocak, M; Nair, SP; Satapathy, SK; Vanatta, JM | 1 |
| Agazzi, R; Colledan, M; Conte, G; De Giorgio, M; Fagiuoli, S; Iegri, C; Lucà, MG; Nani, R; Nicora, C; Pinelli, D; Sala, F; Sarti, D; Schranz, M; Sironi, S; Virotta, G | 1 |
| Costentin, C; Durot, C; Hoeffel, C; Luciani, A; Mulé, S; Rahmouni, A; Thiefin, G | 1 |
| Chen, CW; Hsu, FT; Kuo, YC; Pan, PJ; Tsai, JJ | 1 |
| Burgmans, MC; Chen, L; Coenraad, MJ; Farina-Sarasqueta, A; Gray, PC; Grosjean, J; Karkampouna, S; Klima, I; Kruithof-de Julio, M; Osanto, S; Schaapherder, AF; Snaar-Jagalska, EB; Stroka, DM; Terracciano, L; Thalmann, GN; van der Helm, D; van Hoek, B; Verspaget, HW | 1 |
| Almeida-Carvalho, SR; D'Ippolito, G; Loureiro-Matos, CA; Miziara-Gonzalez, A; Pereira-Lanzoni, V; Salzedas-Netto, AA; Souza-Silva, I; Szejnfeld, D; Tannus, RK | 1 |
| Chi, H; Meng, Z; Wang, H; Zhang, C | 1 |
| Chen, S; Cheong, M; Dai, Z; Kuang, M; Liu, W; Mei, J; Peng, Z; Wang, H; Wei, M; Zhang, H | 1 |
| Gold, LS; Harris, WP; Hebert, PL; Kwan, SW | 1 |
| Li, Y; Lu, L; Ren, L; Song, W; Su, Y; Tian, J; Wang, K; Xin, Y; Zhao, W | 1 |
| Andreone, A; Badea, RI; Benevento, F; Brocchi, S; Ferrarini, A; Golfieri, R; Mastroroberto, M; Morselli-Labate, AM; Negrini, G; Piscaglia, F; Renzulli, M; Tovoli, F | 1 |
| Chen, L; Cheng, Y; Feng, L; Fu, S; Guan, F; Jiang, Z; Lam, W; Lu, H; Tian, A; Zhang, J | 1 |
| Aikata, H; Aisaka, Y; Chayama, K; Hatooka, M; Hiramatsu, A; Honda, Y; Hyogo, H; Imamura, M; Inagaki, Y; Kawakami, Y; Kawaoka, T; Kodama, K; Kohno, H; Masaki, K; Mori, N; Morio, K; Moriya, T; Murakami, E; Nakahara, T; Nonaka, M; Takaki, S; Tsuge, M; Tsuji, K; Uchikawa, S | 1 |
| Asabe, S; Asano, T; Mashima, H; Matsuura, K; Tsuboi, R | 1 |
| Chen, CL; Chung, CL; Kao, YC; Shiao, MS; Shu, CW; Sun, WC; Wang, SW | 1 |
| Imam, SZ; Maqbool, MA; Zahid, MF | 1 |
| Cai, M; Chen, J; Guo, Y; Huang, J; Huang, W; Lai, L; Zhou, J; Zhu, K | 1 |
| Gu, FM; Guo, XG; Hou, GJ; Liu, H; Pan, ZY; Xu, QG; Yang, F; Yang, Y; Yu, J; Yuan, SX; Zhou, WP | 1 |
| Cai, L; Luo, L; Meng, X; Tang, Z | 1 |
| Bamodu, OA; Chang, HL; Chen, HA; Lee, KF; Lee, WH; Tsai, JT; Tzeng, YM | 1 |
| Kang, MK; Lee, HJ; Park, JG | 1 |
| Baumhauer, A; Bodoky, G; Bruix, J; Cabrera, R; Caparello, C; Chang, C; Finn, RS; Gerolami, R; Granito, A; Huang, YH; LeBerre, MA; Meinhardt, G; Merle, P; Pracht, M; Rosmorduc, O; Sun, W; Yokosuka, O | 1 |
| Chuang, PH; Ho, JC; Hsieh, ML; Hsieh, VC | 1 |
| Chai, ZT; Jia, QA; Ma, DN; Qin, CD; Ren, ZG; Sun, HC; Tang, ZY; Wang, CH; Zhang, N; Zhang, SZ; Zhu, XD | 1 |
| Asha, VV; Isaac, R; Jiji, SG; Philip, S; Praseetha, PK; Tom, G | 1 |
| Ahn, CS; Ha, TY; Hwang, S; Jung, DH; Jwa, EK; Kim, KH; Kim, N; Kwon, JH; Lee, KJ; Lee, SG; Moon, DB; Park, GC; Ryoo, BY; Song, GW; Tak, E | 1 |
| Lewandowski, R; Riaz, A; Salem, R | 1 |
| Anderton, K; Anis, M; Baron, A; Bendell, J; Bentz, T; Brisendine, A; Duddalwar, V; Edwards, A; El-Khoueiry, A; Garrett-Mayer, E; Siegel, AB; Thomas, MB; Weiss, G | 1 |
| Bae, MH; Choi, JH; Chung, T; Im, JY; Kim, DY; Kim, HC; Kim, HH; Kwon, JH; Lee, EJ; Park, YN; Wang, HJ; Woo, HG; Yoon, S | 1 |
| Goto, H; Hayashi, K; Hirooka, Y; Honda, T; Ishigami, M; Ishikawa, T; Ishizu, Y; Kuzuya, T; Nakano, I | 1 |
| Aprile, G; Brunetti, O; Bruno, D; Calvetti, L; Caparello, C; Cascinu, S; Chessa, L; Corbelli, J; Dadduzio, V; Ercolani, G; Faloppi, L; Farella, N; Foschi, FG; Frassineti, GL; Gardini, AC; Gentilucci, UV; Lanzi, A; Leonetti, A; Marisi, G; Masi, G; Negri, FV; Pagan, F; Santini, D; Scarpi, E; Scartozzi, M; Silletta, M; Silvestris, N; Stefano, G; Tamburini, E; Tassinari, D; Vivaldi, C; Zagonel, V | 1 |
| Chen, D; Chen, X; Chen, Y; Cui, T; Kabir, N; Ma, J; Mao, J; Pan, P; Yang, H; Yang, Y | 1 |
| Edeline, J; Finn, RS; Galle, PR; Kudo, M; Raoul, JL; Reig, M | 1 |
| Chu, YD; Huang, YH; Hung, CF; Lee, WC; Lin, CC; Lin, KH; Yeh, CT; Yeh, TS | 1 |
| Zhang, HM; Zheng, H; Zheng, WP | 1 |
| Bu, J; Chen, Y; Dai, Z; He, W; Ke, H; Lin, D; Lin, Q; Xie, L; Zeng, Y; Zheng, M | 1 |
| Bettinger, D; Fichtner-Feigl, S; Schultheiß, M; Thimme, R | 1 |
| Chen, Y; Jiang, R; Lu, S; Shao, Q; Sun, J; Xu, G; Yao, Y; Zhang, Y; Zhou, C | 1 |
| Bruix, J; Sanduzzi-Zamparelli, M | 1 |
| Choi, GH; Jang, SJ; Jung, Y; Kim, JS; Kim, KM; Lee, HC; Yu, ES | 1 |
| Chen, K; Li, M; Su, Y; Wang, W; Xu, L; Xu, X; Zhang, F; Zhou, J | 1 |
| Aikata, H; Amano, H; Awai, K; Chayama, K; Hatooka, M; Hiramatsu, A; Imamura, M; Inagaki, Y; Katamura, Y; Kawakami, Y; Kawaoka, T; Kohno, H; Masaki, K; Morio, K; Moriya, T; Murakami, E; Nagaoki, Y; Nakahara, T; Tamura, T; Tsuge, M; Waki, K | 1 |
| Chen, X; Li, J; Xu, FJ; Yang, M; Zhang, Q; Zhao, N | 1 |
| Personeni, N; Rimassa, L | 1 |
| Cattan, S; Chan, SL; Cheng, AL; Daniele, B; Ebbinghaus, SW; Edeline, J; Fartoux, L; Finn, RS; Knox, J; Kudo, M; Ma, J; Ogasawara, S; Palmer, D; Sarker, D; Siegel, AB; Verset, G; Verslype, C; Vogel, A; Webber, AL; Zagonel, V; Zhu, AX | 1 |
| Chai, S; Che, N; Ding, J; Kau, PW; Lee, TK; Lo, CM; Luk, ST; Ma, S; Man, K; Ngan, ES; Tong, M; Zhou, L | 1 |
| Babiker, HM; Borad, MJ; Tenneti, P | 1 |
| Abaza, MSI; Al-Attiyah, RJ; Bahman, AA; Khoushiash, SI | 1 |
| Enomoto, N; Higuchi, M; Itakura, J; Izumi, N; Komiyama, Y; Kubota, Y; Kurosaki, M; Nakanishi, H; Okada, M; Takada, H; Takahashi, Y; Takaura, K; Tamaki, N; Tsuchiya, K; Wang, W; Yasui, Y | 1 |
| Heo, YA; Syed, YY | 1 |
| Cai, S; Chen, L; Jiang, Z; Li, A; Liang, Y; Liu, X; Ma, D; Tang, X; Zhang, Y | 1 |
| Duo, J; Ma, X; Zhao, Y; Zhu, H | 1 |
| Dong, H; Gao, W; Ma, L; Man, S; Yang, L; Yao, J | 1 |
| Abo, D; Inaba, Y; Kodama, Y; Matsuo, K; Nakatsuka, A; Nishiofuku, H; Okubo, H; Sato, Y; Takaki, H; Yamakado, K; Yasumoto, T | 1 |
| Chu, PS; Ebinuma, H; Fukasawa, M; Ikeda, M; Kanai, T; Kato, N; Koda, Y; Murakami, Y; Nakamoto, N; Ojiro, K; Saito, H; Saito, K; Saito, Y; Sugiyama, K; Suzuki, T; Taniki, N; Teratani, T | 1 |
| Abbati, F; Barbera, MA; Brandi, G; De Lorenzo, S; Frega, G; Garajovà, I; Garuti, F; Golfieri, R; Palloni, A; Pantaleo, MA; Saccoccio, G; Venturi, M | 1 |
| Azahaf, H; Bart Takkenberg, R; de Man, RA; Eskens, FALM; IJzermans, JNM; Klümpen, HJ; Labeur, TA; Ten Cate, DWG; van Delden, OM; van Oijen, MGH; van Vugt, JLA | 1 |
| Aquino, D; Balbi, E; Barbosa, D; Carvalho, B; de Tarso Pinto, P; Leal, CRG; Magalhães, C; Pacheco, L; Perez, R; Setubal, S | 1 |
| Blanc, JF; Childs, BH; Choo, SP; Dao, T; Dufour, JF; Gane, EJ; Gérolami, R; Kocsis, J; Krissel, H; Lamlertthon, W; Lim, HY; Llovet, JM; Ma, YT; Mazzaferro, V; Merle, P; Peck-Radosavljevic, M; Reis, D; Ross, P; Roth, K; Ryoo, BY; Sukeepaisarnjaroen, W; Teufel, M; Thongsawat, S; Weiss, KH; Yau, T; Yen, CJ; Yeo, W | 1 |
| Balderramo, D; Barreyro, F; Carrera, E; Carrilho, F; Debes, JD; Diaz-Ferrer, J; Diehl, F; Ferreiro, MR; Gonzalez-Ballerga, E; Leathers, JS; Mattos, AZ; Prieto, J; Singh, D | 1 |
| Giménez-Manzorro, A; Herranz-Alonso, A; Matilla-Peña, A; Revuelta-Herrero, JL; Sanjurjo-Sáez, M | 1 |
| Chai, Y; Feng, F; Jia, H; Jiang, Q; Li, X; Li, Z; Rong, G; Sun, H; Zhang, Y | 1 |
| Abraham, IE; Dudek, AZ; Liu, LI; Schmidt, TM; Uy, AB | 1 |
| Bae, SH; Cho, SB; Choi, JH; Chung, WJ; Jung, YK; Kim, DY; Kim, SU; Kim, YS; Park, JY; Song, DS; Song, MJ; Suh, SJ; Yim, HJ | 1 |
| Das, M | 1 |
| Benhadji, KA; Ikeda, M; Inoue, K; Lahn, MMF; Morimoto, M; Sakai, D; Tajimi, M | 1 |
| Álvares-da-Silva, MR; de Freitas, LBR; Grivicich, I; Longo, L; Santos, D | 1 |
| Gu, C; Huang, Y; Liu, S; Mai, W; Nie, Y; Wang, K; Yang, H; Yu, G; Zhao, D; Zhong, Y | 1 |
| Bai, W; Cai, H; Chen, H; Fan, D; Guo, W; Han, G; Han, N; He, C; Li, C; Li, K; Li, X; Liu, L; Luo, B; Lv, Y; Niu, J; Tie, J; Wang, E; Wang, Q; Wang, W; Wang, Z; Xia, D; Xia, J; Yin, Z; Yu, T; Yuan, J; Yuan, X | 1 |
| Beijersbergen, RL; Bernards, R; Evers, B; Gao, D; Jin, G; Jin, H; Lieftink, C; Qin, W; Wang, C; Wang, L; Xue, Z | 1 |
| Cai, S; Chen, L; Gan, H; Li, A; Liang, Y; Liu, X; Sui, X; Tang, X; Wang, D; Wu, B; Zhang, Y; Zou, S | 1 |
| Ardelt, MA; Arnold, GJ; Atzberger, C; Cantonati, P; Fröhlich, T; Gerbes, A; Kanitz, V; König, L; Lehr, T; Martini, E; Mayr, D; Meßner, M; Müller, M; Pachmayr, J; Parazzoli, D; Posselt, L; Rothenfußer, S; Scita, G; Ulrich, M; Vollmar, AM; Wojtyniak, JG; Zahler, S | 1 |
| Duan, W; Liu, Y | 1 |
| Peck-Radosavljevic, M; Pinter, M | 1 |
| Chen, Z; Deng, L; Feng, G; Liu, K; Xiang, X; Xiao, D; Xiong, R; Yang, F | 1 |
| Finn, RS; Llovet, JM; Montal, R; Sia, D | 1 |
| Hosoi, H; Ikeda, M; Kojima, Y; Kondo, S; Saito, K; Saito, Y | 1 |
| Chang, WT; Huang, CS; Lee, KT; Lu, SN; Rau, KM | 1 |
| Hirai, S; Kakinoki, N; Kamoshida, T; Ochi, M; Ohkawara, A; Ohkawara, H; Yanaka, A | 1 |
| Cheng, B; Du, J; Fan, Y; Li, J; Li, X; Lin, W; Ling, C; Liu, D | 1 |
| Chen, A; Ding, H; Shao, J; Wang, L; Yao, Z; Zhang, F; Zhang, Z; Zheng, S | 1 |
| Attardo, S; Bargellini, I; Bresci, G; Buccianti, P; Cabibbo, G; Granito, A; Marchi, S; Marinelli, S; Marzi, L; Rossi, M; Sacco, R; Saitta, C; Tapete, G; Tovoli, F; Urbani, L; Zolfino, T | 1 |
| Piao, J; Poddar, N; Sochat, MM | 1 |
| Cho, EJ; Cho, YY; Kim, YJ; Lee, JH; Lee, S; Yoon, JH; Yu, SJ | 1 |
| Feng, Y; Guo, X; Huang, X; Li, X; Luo, X; Wu, M; Wu, S | 1 |
| Bassaganyas, L; Bruix, J; Camps, J; Chau, GY; Cillo, U; Croitoru, AE; de la Mata, M; Gane, E; Kokudo, N; Lee, HC; Llovet, JM; Lupo, L; Mazzaferro, V; Meinhardt, G; Moeini, A; Montal, R; Park, JW; Pena, C; Pinyol, R; Roayaie, S; Rodriguez-Carunchio, L; Sia, D; Solé, M; Strasser, S; Takayama, T; Thung, SN; Torrecilla, S; Verslype, C; Villanueva, A; Zhang, Z | 1 |
| Cao, Y; Chai, Y; Dai, W; Feng, F; Guo, Y; Jia, H; Jiang, Q; Li, X; Li, Y; Shao, Z; Sun, H; Yang, R; Zhang, Y | 1 |
| Ang, C; Feferman, Y; Gany, F; Heskel, M; Sarpel, U; Spivack, JH | 1 |
| Han, G; Jang, HJ; Kim, S; Lee, SA; Seong, S | 1 |
| Huang, W; Huang, XY; Ke, AW; Liu, D; Wang, F; Wu, J; Wu, Y; Zhang, PF; Zhang, XM | 1 |
| Chandra, N; Jayal, P; Karande, AA; Mishra, M | 1 |
| Dong, J; Gao, J; Huang, Y; Meng, X; Rong, Y; Shi, P; Wang, X; Wu, C | 1 |
| Ippolito, D; Lombardi, S; Okolicsanyi, S; Orsini, E; Pecorelli, A; Querques, G; Sironi, S; Strazzabosco, M; Talei Franzesi, C | 1 |
| Arafa, EA; Chen, PS; Hung, JH; Jeng, J; Omar, HA; Pan, HW; Wu, WD | 1 |
| Chai, CY; Chiang, CM; Chiou, SS; Hsu, SH; Huang, SK; Liu, KY; Wang, LT; Wang, SN; Yokoyama, KK | 1 |
| Chan, SL; Chen, GG; Cheng, CL; Chong, CCN; Hu, BG; Lai, PBS; Li, MY; Niu, LL; Ren, J; Yang, SL | 1 |
| Abdel-Rahman, O; Cheung, WY | 1 |
| Lin, B; Nie, J; Wu, L; Zheng, T; Zhou, M | 1 |
| Annicchiarico, E; Basso, M; Biolato, M; Carchesio, F; Cerrito, L; De Gaetano, A; Garcovich, M; Gasbarrini, A; Giuliante, F; Iezzi, R; Manfredi, R; Pompili, M; Ponziani, F; Posa, A; Rapaccini, G; Rinninella, E; Siciliano, M; Zocco, MA | 1 |
| Enomoto, M; Fujii, H; Hagihara, A; Iida-Ueno, A; Kawada, N; Morikawa, H; Murakami, Y; Tamori, A; Teranishi, Y; Thuy, LTT; Uchida-Kobayashi, S | 1 |
| Hu, J; Li, L; Liu, L; Wang, E; Wang, M; Zhao, W; Zhao, Y | 1 |
| Chiu, YF; Hsieh, YH; Lin, CL; Lin, CY; Liu, CJ; Wu, MH; Wu, PL; Wu, WJ | 1 |
| Meng, Q; Xu, X | 1 |
| He, XX; Li, QT; Qiu, MJ; Shi, LL; Wang, MM; Xiong, ZF; Yang, SL | 1 |
| Andrikou, K; Cascinu, S; Gelsomino, F; Orsi, G; Riggi, L; Rimini, M; Spallanzani, A | 1 |
| Jiang, C; Li, XX; Wang, HY; Xu, R; Xu, XY; Yang, Y; Zheng, XFS; Zhou, YF | 1 |
| Chen, J; Chen, RX; Cui, JF; Gao, DM; Lin, XH; Liu, HH; Ma, M; Ren, ZG; Zhang, R | 1 |
| Dong, W; Guo, XG; He, XD; Liu, FC; Liu, H; Wang, ZH | 1 |
| Inayat, F; Lodhi, HT; Ullah, W; Zafar, F | 1 |
| Ganesan, T; Mahajan, V; Muhrerkar, K; Ramakrishnan, A; Sunil, BJ; Tiwari, P | 1 |
| Lu, XJ; Wang, JC; Xia, AL; Xu, Y | 1 |
| Ikeda, M; Kaneko, S; Kobayashi, M; Tahara, M | 1 |
| Cabibbo, G; Canale, M; Casadei Gardini, A; Cucchetti, A; De Matteis, S; Ercolani, G; Foschi, FG; Frassineti, GL; Marisi, G; Scartozzi, M; Solaini, L; Ulivi, P; Valgiusti, M | 1 |
| Hu, Y; Li, X; Lou, L; Tu, J; Wan, J; Wu, S; Wu, Z | 1 |
| Fu, QH; Hu, QD; Huang, BF; Jin, PP; Que, RS; Shao, SY; Wu, WT; Zhao, XY | 1 |
| Chen, H; Dai, N; Guo, P; He, Q; Ye, R; Zhang, Q | 1 |
| Abada, PB; Finn, RS; He, AR; Kim, R; Morse, MA; Mynderse, M; Sun, W | 1 |
| Chen, Z; Dai, C; Dai, J; Huang, Q; Li, Y; Niu, K; Tao, K; Wang, B | 1 |
| Fondevila, F; García-Palomo, A; González-Gallego, J; Mauriz, JL; Méndez-Blanco, C | 1 |
| Kan, SY; Kang, H; Kim, BM; Kim, GH; Kim, JH; Kim, YS; Lee, YM; Lim, JH; Oh, TI; Shin, DH; Yim, WJ | 1 |
| Cho, E; Cho, SB; Choi, SK; Jun, CH; Kim, DH; Kim, S; Koh, YI; Sim, DW; Yu, J | 1 |
| Annicchiarico, BE; Cerrito, L; Garcovich, M; Gasbarrini, A; Pompili, M; Ponziani, FR; Siciliano, M; Tortora, A | 1 |
| Ai, J; Alizadeh, AA; Hajighasemlou, S; Hosseinzadeh, F; Mirmoghtadaei, M; Muhammadnejad, S; Nikbakht, M; Seyhoun, I; Seyhoun, SM; Verdi, J | 1 |
| Choi, S; Kim, S; Kim, Y; Lee, S; Park, T; Yoon, JH | 1 |
| Futsukaichi, Y; Kobayashi, S; Minemura, M; Nagata, K; Tajiri, K; Takahara, T; Yasuda, I; Yasumura, S | 1 |
| Abe, M; Hiasa, Y; Hiraoka, A; Hirooka, M; Imai, Y; Joko, K; Koizumi, Y; Michitaka, K; Ochi, H; Watanabe, T; Yoshida, O; Yukimoto, A | 1 |
| Amir, E; Frizziero, M; Hubner, RA; Knox, JJ; Lamarca, A; McNamara, MG; Nuttall, C; Pihlak, R; Slagter, AE; Tariq, N; Valle, JW | 1 |
| Amini, N; Borbath, I; dʼAbadie, P; Goffette, P; Lhommel, R | 1 |
| Boland, P; Wu, J | 1 |
| Benevento, F; De Lorenzo, S; Granito, A; Ielasi, L; Sansone, V; Tovoli, F | 1 |
| Cho, EJ; Cho, H; Kang, SH; Kim, YJ; Lee, JH; Lee, KW; Suh, KS; Yi, NJ; Yoon, JH; Yu, SJ | 1 |
| Kim, BH; Park, JW | 1 |
| Guo, XL; Li, QH; Wang, HB; Yong, JK; Zhong, J | 1 |
| Adachi, T; Dohi, C; Fujioka, SI; Hagihara, H; Ikeda, F; Iwadou, S; Kobashi, H; Miyahara, K; Nakamura, S; Nouso, K; Okada, H; Onishi, H; Oyama, A; Shiraha, H; Takabatake, H; Takaguchi, K; Takaki, A; Takeuchi, Y; Takuma, Y; Uematsu, S; Wada, N; Yasunaka, T | 1 |
| Goldstein, DA; Leshno, M; Shlomai, A | 1 |
| Allaham, W; Koulakian, H; Ronot, M; Vilgrain, V | 1 |
| Liu, M; Su, M; Wu, X; Xu, X; Yang, B; Zhou, R | 1 |
| Funahashi, Y; Hori, Y; Ichikawa, K; Ito, J; Kato, Y; Kimura, T; Kodama, K; Matsui, J; Nomoto, K; Ozawa, Y; Tabata, K; Takase, K; Yamada, K | 1 |
| Avritscher, R; Bankson, JA; Cortes, AC; Ensor, JE; Kingsley, CV; Maldonado, KL; Minhaj, AA; Mitchell, JM; Muñoz, NM; Polak, U; Rashid, A; Taghavi, H | 1 |
| Cury-Martins, J; Domingues, RB; Macarenco, R; Sanches, JA; Sato-Sano, M; Vasconcelos, R | 1 |
| Chimeh, U; Kumar, D; Niture, S; Tricoli, L | 1 |
| Cai, H; Chen, C; Li, S; Ma, W; Wang, R; Zhang, L | 1 |
| Carapinha, J; Hamdy Elsisi, G; Nada, Y; Rashad, N | 1 |
| Kim, DY; Kim, YJ; Lee, SJ; Lim, HY; Lim, TS; Park, JW; Ryoo, BY; Yoo, C; Yu, SJ | 1 |
| Casadei Gardini, A; Foschi, FG; Frassineti, GL; Maltoni, M; Marisi, G; Scarpi, E | 1 |
| Chen, D; Gao, Y; Liu, D; Liu, X; Shi, Y; Wang, Y; Wu, J; Yang, T | 1 |
| Bae, SH; Cheong, JY; Han, SY; Hwang, J; Kim, BH; Kim, DY; Kim, HY; Kim, YJ; Kwon, OS; Lee, HC; Lee, YJ; Paik, SW; Park, JW; Yeon, JE | 1 |
| Cao, L; Cen, C; Shen, X; Shu, Z; Tang, X; Yang, W; Yu, J; Zhang, M; Zhang, W; Zheng, S | 1 |
| Han, Z; He, Z; Wang, C; Wang, Q | 1 |
| Braghiroli, MIFM; Carrilho, FJ; Chagas, AL; da Fonseca, LG; Hoff, PM; Marta, GN; Sabbaga, J | 1 |
| Cai, H; Dong, Y; Dong, Z; Feng, ST; Huang, K; Huang, M; Jia, Y; Li, ZP; Liao, B; Luo, Y; Xu, L; Zhou, X | 1 |
| Deguchi, A; Hiasa, Y; Hiraoka, A; Hirooka, M; Imai, M; Ishikawa, T; Joko, K; Koizumi, Y; Kumada, T; Michitaka, K; Ochi, H; Shimada, N; Tada, T; Tajiri, K; Tanaka, J; Toyoda, H; Tsuji, K | 1 |
| Bao, MH; Chan, CY; Chan, DF; Cheung, TT; Chin, DW; Chiu, DK; Chok, SH; Lai, RK; Lee, D; Leibold, J; Lowe, SW; Ng, IO; Tse, AP; Wong, CC; Wong, CM; Xu, IM; Yuen, VW | 1 |
| Barbare, JC; Bodeau, S; Coriat, R; François, C; Galmiche, A; Godin, C; Louandre, C; Saidak, Z; Sauzay, C | 1 |
| Escudier, B; Kudo, M; Worden, F | 1 |
| El-Masry, M; Hanna, RM; Hasnain, H; Saab, S; Selamet, U; Wallace, WD; Wilson, J; Yanny, B | 1 |
| Huang, C; Ji, Y; Shen, X; Sun, H; Tang, M; Wu, D; Zeng, M | 1 |
| Al-Abdulla, R; Andersen, JB; Avila, MA; Banales, JM; Briz, O; Geier, A; Lozano, E; Macias, RIR; Marin, JJG; Martinez-Chantar, ML; Monte, MJ; O'Rourke, CJ; Serrano, MA | 1 |
| Cao, J; Chen, X; Chen, Y; Li, W; Luo, X; Shang, C; Tan, W; Zhong, J; Zhou, R; Zhu, S | 1 |
| Couri, T; Pillai, A | 1 |
| Hong, EK; Kim, BH; Kim, JS; Lee, SK; Park, JW | 1 |
| Fulda, S; Hinrichs, TM; Lange, M; Liese, J | 1 |
| Wang, M; Wu, M; Yang, T | 1 |
| Chen, PS; Chiu, CF; Hong, CC; Lai, HH; Li, CW; Ou, DL; Sun, HY | 1 |
| Abete, L; Briz, O; Di Giacomo, S; Di Sotto, A; Lozano, E; Marin, JJG; Mazzanti, G; Monte, MJ; Sanchez-Vicente, L | 1 |
| Hinrichs, JB; Ivanyi, P; Kirstein, MM; Koch, S; Manns, MP; Marhenke, S; Pinter, M; Rodt, T; Scheiner, B; Schulte, L; Schweitzer, N; Vogel, A; Voigtländer, T; Weinmann, A | 1 |
| Chen, MS; He, X; Hu, C; Huang, YM; Li, Y; Liang, H; Lu, LG; Xiang, QF; Xiao, J; Xin, YJ; Zhan, MX | 1 |
| Guan, L; Liang, N; Liu, H; Wang, M | 1 |
| Abou-Alfa, GK | 4 |
| Abada, PB; Assenat, E; Borg, C; Brandi, G; Daniele, B; Finn, RS; Galle, PR; Gerken, G; Hiriart, JB; Hsu, Y; Kang, YK; Kudo, M; Lim, HY; Llovet, JM; Merle, P; Morimoto, M; Motomura, K; Ohno, I; Okusaka, T; Pracht, M; Rau, KM; Shin, DB; Yen, CJ; Zhu, AX | 1 |
| Jahanian, A; Raghami, F; Rostami, M; Varshosaz, J | 1 |
| Beasley, JM; Brinster, NK; Lederhandler, M; Nagler, AR | 1 |
| Abdolahi, S; Ai, J; Ghazvinian, Z; Hajighasemlou, S; Hosseinzadeh, F; Mirmoghtadaei, M; Parseh, B; Seyhoun, I; Seyhoun, SM; Shadnoush, M; Verdi, J | 1 |
| Broglia, C; Negri, F; Porta, C | 1 |
| Bruix, J; da Fonseca, L; Díaz-González, Á; Forner, A; Iserte, G; LLarch, N; Reig, M; Ríos, J; Sanduzzi-Zamparelli, M; Sapena, V; Torres, F | 1 |
| Chen, LC; Chen, YJ; Chien, PH; Hsiang, YP; Hung, YJ; Pan, HL; Wei, CT | 1 |
| Goh, KY; Huynh, H; Lee, LY; Mumberg, D; Ong, R; Politz, O; Puehler, F; Scholz, A; Ziegelbauer, K | 1 |
| Cai, H; Chen, W; Chen, X; Sun, D; Yang, J; Zhang, Y | 1 |
| Aboagye, EO; Beaumont, J; Brown, MW; Coley, HM; Mauri, FA; Pinato, DJ; Sharma, R; Trousil, S; Zhang, H | 1 |
| Geng, P; Liu, Y; Qin, J; Sun, M; Sun, X; Wu, C; Wu, Y; Yin, Y; Zhan, X; Zhang, S; Zhuang, Z | 1 |
| Chang, RH; Chen, HY; Hu, JT; Huang, CC; Hung, CS; Liao, PA; Lien, HH; Yang, SS | 1 |
| Azuma, M; Copher, R; Ikeda, S; Ishii, M; Izumi, N; Kaneko, S; Kobayashi, M; Kudo, M; Meier, G; Pan, J | 1 |
| Luo, P; Meng, H; Zhang, J; Zhu, W; Zou, J | 1 |
| Chacon, E; Cornea, V; Eman, P; Garcia, C; Gedaly, R; Jiang, J; Liu, C; Marti, F; Spear, B; Turcios, L; Watt, DS | 1 |
| Choi, SH; Kim, JH; Kim, PH; Park, SH | 1 |
| Chai, W; Du, X; Ye, J; Zhang, R | 1 |
| Fan, HK; Fan, J; Gao, Q; Ren, ZG; Xie, DY | 1 |
| Choi, MS; Gwak, GY; Kang, W; Kim, J; Koh, KC; Lee, JH; Paik, SW; Paik, YH; Sinn, DH | 1 |
| Yang, X; Yi, C; Zhang, C; Zhu, H | 1 |
| Cho, EJ; Cho, YY; Kim, K; Kim, YJ; Lee, JH; Lee, YB; Na, J; Yoo, JJ; Yoon, JH; Youn, H; Yu, SJ | 1 |
| Fan, L; Guo, Z; Li, X; Liu, J; Sun, G; Yu, H; Zhang, J | 1 |
| Ba, Q; Chen, P; Chen, S; Ge, Y; Li, J; Mu, W; Wang, H; Wang, X | 1 |
| Fang, Q; Lu, J; Lu, Y; Wu, H; Xie, C; Xiong, Y; Yin, Z | 1 |
| Egawa, C; Inatome, J; Kagawa, Y; Katsura, Y; Kawai, K; Masuzawa, T; Mori, R; Murakami, K; Murata, K; Naito, A; Nose, Y; Ohmura, Y; Sakamoto, T; Takeda, Y; Takeno, A | 1 |
| Hatanaka, T; Hosonuma, K; Kakizaki, S; Naganuma, A; Nagashima, T; Namikawa, M; Saito, S; Sato, K; Suzuki, H; Takagi, H; Uehara, D; Ueno, T; Uraoka, T | 1 |
| Cho, M; Heo, J; Hong, YM; Hwang, TH; Woo, HY; Yoon, KT | 1 |
| Du, Y; Liang, Q; Liu, S; Ma, H; Tian, J; Zhu, X | 1 |
| Di Martino, V; Prati, C; Verhoeven, F; Weil-Verhoeven, D; Wendling, D | 1 |
| Cho, EH; Im, HS; Jang, JH; Kang, J; Kim, HJ; Kim, MK; Kong, SY; Lee, J; Oh, CR; Park, SR; Ryoo, BY; Yoon, KA | 1 |
| Cheng, X; Huang, Y; Li, T; Song, Z; Sun, P; Zheng, Q | 1 |
| Hosseini, K; Hussein, UK; Jang, KY; Kessler, SM; Kiemer, AK; Kim, KM; Laggai, S; List, M; Schultheiß, CS; Schulz, MH | 1 |
| Amanuma, M; Daido, Y; Higai, K; Igarashi, Y; Kobayashi, K; Matsui, D; Matsui, T; Matsukiyo, Y; Momiyama, K; Mukozu, T; Nagai, H; Ogino, YU; Shinohara, M; Wakui, N; Yoshimine, N | 1 |
| Forner, A; Sanduzzi-Zamparelli, M | 1 |
| Bort, A; Díaz-Laviada, I; Mateos-Gómez, PA; Rodríguez-Henche, N; Sánchez, BG; Vara-Ciruelos, D | 1 |
| Ebert, MP; Schlitt, HJ; Sollors, J; Steinebrunner, N; Stroszczynski, C; Teufel, A; Weiss, KH; Zhan, T | 1 |
| Boisserie, F; Ducreux, M; Finn, RS; Hou, J; Kudo, M; Li, X; Macarulla, TM; Meyer, T; Qin, S; Song, J; Tomasello, G; Vogel, A; Zhu, AX | 1 |
| Liu, Y; Wang, T; Yao, Y; Zhang, N | 1 |
| Chen, J; Chen, X; Guo, Y; Hong, J; Li, J; Li, M; Liu, J; Ma, Q; Qi, Y; Qian, C; Shan, J; Shen, J; Wang, M; Wu, H; Xu, H; Xu, Y; Yang, Z; Yao, C; Zhang, Q; Zhao, W | 1 |
| Chen, L; Chen, LJ; Chen, Y; Guo, J; Meng, S; Tan, ZR; Tang, J; Xiao, J; Xu, Y; Zhang, W; Zhao, Q; Zheng, B | 1 |
| Duan, Z; Liu, L; Long, Q; Song, Y; Zou, X | 1 |
| Al-Salama, ZT; Scott, LJ; Syed, YY | 1 |
| Bie, P; Fang, L; Jiang, P; Li, G; Lin, X; Wu, D; Xie, CM; Yang, Z; Yin, L; Zhang, J; Zhang, L; Zhong, C | 1 |
| Bissinger, S; Hage, C; Hoves, S; Kiessling, F; Pöschinger, T; Prinz, Y; Ries, CH; Strauss, L | 1 |
| Bonafede, MM; Cai, Q; Cappell, K; Jariwala-Parikh, K; Korytowsky, B; Parikh, ND; Sill, B; Singh, P | 1 |
| Cecener, G; Egeli, U; Eryilmaz, IE; Guney Eskiler, G; Tunca, B; Yurdacan, B | 1 |
| Bai, W; Cai, H; Fan, D; Han, G; Li, X; Liu, L; Niu, J; Wang, E; Xia, D; Xia, J; Yin, Z; Yuan, J | 1 |
| Dong, X; Feng, J; He, C; Jiang, H; Jiang, X; Li, W; Li, Z; Liu, C; Sun, X; Tan, G; Zhai, B | 1 |
| Chen, KH; Huang, CC; Jeng, KS; Lin, CC; Lin, CK; Teng, CJ | 1 |
| Hu, HT; Li, W; Lu, MD; Xie, XH; Xie, XY; Zhuang, BW | 1 |
| Chen, M; Fang, W; Guo, R; Guo, Y; He, M; Le, Y; Li, Q; Shen, J; Shi, M; Tan, G; Wei, W; Wu, X; Xu, L; Zhao, M; Zhou, Y; Zhou, Z; Zou, R | 1 |
| Goyal, L; Qadan, M; Zhu, AX | 1 |
| Li, B; Li, HY; Liu, D; Wang, D; Yang, P | 1 |
| Di, S; Jiang, H; Li, H; Li, Z; Liu, Y; Luo, H; Shi, B; Su, J; Sun, R; Wu, X | 1 |
| Cai, J; Shen, Z; Wu, B; Zhang, W | 1 |
| Bouattour, M; Hulin, A; Stocco, J | 1 |
| Yang, X; Yi, C; Zhao, Y; Zhu, H | 1 |
| Chen, X; Liu, Y; Liu, Z; Ma, S; Sakurai, K; Song, W; Tang, Z; Wang, G; Wang, Y; Yu, H; Zhang, D | 1 |
| Chen, J; Chen, K; Dai, W; Feng, J; Guo, C; Ji, J; Mao, Y; Wang, F; Wu, J; Wu, L; Xu, L; Yu, Q; Zhang, J | 1 |
| Ahn, SH; Han, KH; Kim, BK; Kim, DY; Kim, SU; Lee, JS; Park, JY; Seong, JS | 1 |
| Burki, TK | 2 |
| Cheng, Z; Cui, X; Ding, J; Fu, G; Hou, C; Hou, G; Jiang, W; Jin, GZ; Li, H; Li, SC; Liu, H; Sun, W; Wang, H; Wang, R; Xiang, DM; Zhang, C; Zhou, T | 1 |
| Barbier, E; Bouché, O; Bronowicki, JP; Debette-Gratien, M; Denis, J; Faroux, R; Jouve, JL; Khemissa Akouz, F; Lecomte, T; Legoux, JL; Manfredi, S; Nguyen Khac, E; Ollivier-Hourmand, I; Phelip, JM; Ramee, JF; Riachi, G; Seitz, JF; Vergniol, J; Villing, AL | 1 |
| Abo-Ali, EM; Barot, S; Dukhande, VV; Palaguachi, C; Zhou, DL | 1 |
| Gani, RA; Hasan, I; Jasirwan, COM; Kalista, KF; Kurniawan, J; Lesmana, CRA; Nababan, SH; Sulaiman, AS | 1 |
| Deng, H; Dong, N; Gao, Y; Kuang, Z; Li, JL; Li, M; Li, Y; Shi, X; Wang, S; Wu, Y; Xie, Q | 1 |
| Chen, M; Chen, S; Chen, Z; Feng, S; Kuang, M; Li, J; Mei, J; Peng, S; Peng, Z; Qian, G; Wang, Y; Xiao, H; Zhou, Q | 1 |
| Malloy, PC | 1 |
| Cheng, Y; Dong, H; Jia, L; Li, B; Liu, J; Liu, W; Nie, H; Wang, J; Zheng, N | 1 |
| Chen, Z; Kong, LC; Wei, P; Wu, SS; Xu, J; Zhang, R | 1 |
| Chai, ZT; Chen, ZH; Cheng, SQ; Cong, WM; Ding, J; Gao, YZ; Guo, WX; Lau, WY; Shi, J; Wang, K; Xie, D; Zhang, XP; Zhou, TF | 1 |
| Arai, M; Atsukawa, M; Azemoto, R; Chiba, T; Haga, Y; Inoue, M; Itobayashi, E; Itokawa, N; Kanayama, K; Kanda, T; Kanzaki, H; Kato, N; Kiyono, S; Kobayashi, K; Kusakabe, Y; Maeda, T; Maruta, S; Maruyama, H; Mizumoto, H; Nakamoto, S; Nakamura, M; Obu, M; Ogasawara, S; Okabe, S; Ooka, Y; Saito, T; Seki, A; Sugiura, N; Suzuki, E; Tawada, A; Yasui, S; Yokoyama, M | 1 |
| Cui, Z; Li, Q; Li, Y; Liu, L; Liu, X; Wang, J; Wang, L; Zhang, Y | 1 |
| Anderson, J; Chao, Y; Choo, SP; Chopra, A; Cruz, CD; Hou, MM; Hsu, C; Ikeda, M; Kang, YK; Kim, TY; Kudo, M; Kuromatsu, R; Moriguchi, M; Numata, K; Yau, T; Yeo, W; Zhao, H | 1 |
| Berhane, S; Cucchetti, A; Fox, R; García-Fiñana, M; Johnson, P | 1 |
| Andersson, M; Bennet, W; Cahlin, C; Eilard, MS; Geronymakis, C; Lindnér, P; Naredi, P; Rizell, M | 1 |
| Hidaka, I; Hisanaga, T; Ishikawa, T; Iwamoto, T; Maeda, M; Matsumoto, T; Saeki, I; Sakaida, I; Takami, T; Yamasaki, T | 1 |
| Cao, R; Kuang, S; Liu, G; Peng, Q; Sun, C; Wang, J | 1 |
| Chen, T; Huang, X; Li, C; Lin, W; Lin, X; Yang, F; Zheng, L | 1 |
| Aguiar, PN; Chavarri-Guerra, Y; Cordón, ML; Lopes, GL; Soto-Perez-de-Celis, E | 1 |
| Personeni, N; Pressiani, T; Rimassa, L | 1 |
| Dai, B; Dong, Z; Geng, L; Lu, J; Sui, C; Xu, M; Yang, C; Yang, J; Zhang, M | 1 |
| Hu, S; Lai, JM; Lin, H; Luo, H; Luo, YB | 1 |
| Celine, J; Couvreur, K; Frederic, D; Marlies, B; Philippe, D; Randal, D; Sylvie, R | 1 |
| Chen, YS; Hsiao, P; Hsieh, KC; Hsieh, PM; Hsu, CC; Li, YC; Lin, CW; Lin, HY; Lo, GH; Wu, TC; Yeh, JH | 1 |
| Cai, W; Chen, L; Dai, X; He, F; Li, T; Lian, J; Sun, L; Yan, D; Yan, X | 1 |
| Guo, Y; Jin, J; Liu, Y; Sun, S; Wang, Z; Yang, X | 1 |
| Ankoma-Sey, V; Balogh, J; Boktour, M; Divatia, MK; Duchini, A; Egwim, C; Gaber, AO; Galati, J; Ghobrial, RM; Graviss, EA; Heyne, K; Lunsford, K; McFadden, R; Mobley, C; Monsour, HP; Nguyen, DT; Saharia, A; Victor, DW | 1 |
| Baiocchi, G; Crosatti, M; De Petro, G; Faranda, T; Grossi, I; Manganelli, M; Marchina, E; Portolani, N; Salvi, A | 1 |
| Fujishiro, M; Honda, T; Ishigami, M; Ishikawa, T; Ishizu, Y; Ito, T; Kuzuya, T; Yoshioka, N | 1 |
| Chen, J; Chen, T; Cui, Y; Ge, C; Li, H; Li, J; Liu, T; Song, Z; Tian, H; Yao, M; Zhao, F; Zhu, M | 1 |
| Badarau, IA; Caruntu, C; Constantin, C; Didilescu, AC; Mihai, GL; Neagu, M; Scheau, C | 1 |
| Cheng, AL; Dutcus, CE; Evans, TRJ; Finn, RS; Han, KH; Ikeda, M; Kraljevic, S; Kudo, M; Piscaglia, F; Ren, M; Sung, MW | 1 |
| Bu, Y; Chang, F; Jia, F; Jia, Q; Jiang, S; Liao, X; Ning, P; Song, G; Xiao, X; Zhang, M | 1 |
| De Toni, EN; Denk, G; Gerbes, AL; Hohenester, S; Itzel, T; Mayerle, J; Munker, S; Ofner, A; Reiter, FP; Schiergens, TS; Spampatti, M; Teufel, A; Wimmer, R; Ye, L; Ziesch, A | 1 |
| Li, Z; Zhu, JY | 1 |
| Chen, SC; Chuang, WL; Dai, CY; Hou, NJ; Hsieh, MH; Hsieh, MY; Huang, CF; Huang, CI; Huang, JF; Liang, PC; Lin, IH; Lin, ZY; Tsai, YS; Yeh, ML; Yu, ML | 1 |
| Bhargava, S; Kulhari, H; Kuncha, M; Pooja, D; Sistla, R; Tunki, L; Vadithe, LN | 1 |
| Beraza, N; Musso, O | 1 |
| Amir, E; McNamara, MG | 1 |
| Chen, J; Han, X; Li, Y; Li, Z; Liu, J; Yao, Y; Zhou, X | 1 |
| Du, Y; Kong, L; Liang, Q; Tian, J; Zhu, X | 1 |
| Axelsson, R; Brismar, TB; Haji, M; Karalli, A; Seth, E; Stål, P; Teiler, J; Wahlin, S | 1 |
| Aspord, C; Decaens, T; Granon, A; Kurma, K; Macek Jilkova, Z; Marche, PN; Sengel, C; Sturm, N | 1 |
| Assenat, E; Benhadji, KA; Cleverly, A; Faivre, S; Galle, PR; Gane, E; Giannelli, G; Gueorguieva, I; Hourmand, IO; Kelley, RK; Lahn, M; Merle, P; Siebler, J; Zhao, Y | 1 |
| Bandyopadhyay, D; Bose, P; Deng, X; Dent, P; Gordon, SW; Kmieciak, M; Lee, HM; Matherly, SC; McGuire, WP; Nguyen, T; Poklepovic, AS; Roberts, JD; Ryan, AA; Shafer, DA; Shrader, EE; Sterling, RK; Tombes, MB | 1 |
| Gao, L; Han, B; Hu, J; Jiao, M; Liu, H; Qi, M; Su, P; Sun, F; Wu, Z; Xiang, L; Zhang, J | 1 |
| Hou, T; Wang, T; Yin, X; Zhang, J; Zhang, N | 1 |
| Chen, F; Chen, Z; Fang, Y; Huang, R; Le, J; Shao, J; Zhang, B; Zhao, R | 1 |
| Ding, GH; Fan, J; Guo, W; Hu, B; Li, H; Li, YX; Qiu, SJ; Sun, YF; Tang, WG; Tang, XY; Xu, Y; Yang, LX; Yang, XR; Zhang, X; Zhou, J | 1 |
| Chen, X; Deng, L; Liu, L; Sun, J; Wu, D | 1 |
| Heczey, A | 1 |
| Cai, L; Gu, X; He, S; Qi, G; Zeng, Z; Zheng, JF | 1 |
| Deng, M; Huang, F; Jia, C; Liang, H; Lin, N; Xiong, Z; Xu, J; Yao, Z | 1 |
| Baker, SD; Chen, M; Frisch, F; Hu, S; Koepsell, H; Laufer, S; Neul, C; Nies, AT; Schaeffeler, E; Schwab, M; Sparreboom, A; Winter, S | 1 |
| Li, A; Liang, Y; Lyu, Y; Tang, X; Xie, D; Zheng, D | 1 |
| Berbis, P; Buono, JP; Chambelland, A; Delaporte, E; Desmedt, E; Fongue, J; Koeppel, MC | 1 |
| Barzakova, E; Bruners, P; Isfort, P; Kuhl, CK; Pedersoli, F; Schulze-Hagen, M; Thüring, J; Zimmermann, M | 1 |
| Amaddeo, G; Anders, M; Bhoori, S; Bruix, J; Crespo, G; Cristóbal, MR; Czauderna, C; Donato, MF; Giorgio, M; González-Diéguez, ML; Iavarone, M; Invernizzi, F; Lampertico, P; López, MF; Manini, MA; Mazzaferro, V; Piñero, F; Pinter, M; Regnault, H; Reig, M; Rodríguez, MJB; Sanduzzi-Zamparelli, M; Soteras, GA; Varela, M; Villadsen, GE; Weinmann, A; Wörns, MA | 1 |
| Cai, X; Chen, C; Chen, Y; Gao, Q; Hu, Y; Huang, A; Lei, C; Liang, L; Tang, H; Tang, N; Wang, K; Xia, J; Yang, Y; Zhang, G; Zhang, W; Zheng, Y | 1 |
| Chok, KSH; Chu, KKW | 1 |
| Ameigeiras, B; Anders, M; Bermúdez, C; Colombato, L; D'Amico, C; Fernández, N; Gadano, A; Gaite, L; Marciano, S; Piñero, F; Reggiardo, V; Ridruejo, E; Romero, G; Silva, J; Silva, M; Zerega, A | 1 |
| Mirian, M; Rostami, M; Sadri, F; Taymouri, S; Varshosaz, J | 1 |
| Cen, J; Chen, X; Fu, Y; Gu, Y; He, S; Huang, X; Hui, L; Ji, Y; Li, C; Li, H; Li, Y; Lv, H; Meng, Z; Min, L; Qin, J; Qiu, Z; Shi, X; Shu, Y; Sun, L; Wang, C; Wang, P; Wang, W; Wang, X; Xie, F; Zhang, H; Zhang, Z; Zhou, H; Zhu, Z; Zhuang, L; Zou, K | 1 |
| Hwang, SG; Kim, JS; Kim, MN; Lee, SM | 1 |
| Bai, L; Chunyang, Z; Dan, W; Guangliang, H; Huanling, G; Jie, L; Manxia, L; Ming, X; Wei, W; Xiangzi, S; Xiaoyan, X; Yang, T; Zhong, C | 1 |
| Cheng, SQ; Davidson, JC; Lau, WY; Lu, J; Madoff, DC; Qi, X; Teng, GJ; Zhang, XP; Zhong, BY | 1 |
| Luo, J; Wang, J; Yang, J | 1 |
| Biasco, G; Brandi, G; Calzà, L; Caraceni, P; Cirignotta, F; de Rosa, F; Girolamo, SD; Ricci, CS; Tufoni, M | 1 |
| Bu, Y; Chai, ZT; Jia, QA; Kong, LQ; Lu, L; Sun, HC; Tang, ZY; Wang, L; Wang, M; Wang, WQ; Wu, WZ; Zhang, KZ; Zhang, QB; Zhu, XD | 1 |
| Ambe, CM; Anderson, AJ; Avital, I; Burka, D; Chen, JQ; Goldsmith, PK; Hari, DM; Herrmann, MA; Koizumi, T; Langan, RC; Miller, TC; Mullinax, JE; Ray, S; Rudloff, U; Stojadinovic, A; Thorgeirsson, SS; Wiegand, GW; Xin, HW | 1 |
| Chen, L; Gu, J; He, H; Liu, H; Liu, J; Liu, W; Liu, Y; Pan, D; Wang, S; Wu, Q; Xu, J; Xu, L; Zhang, H; Zhu, Y | 1 |
| Ackermann, K; Friess, H; Galle, PR; Hartmann, D; Heikenwalder, M; Otto, G; Protzer, U; Puschnik, A; Reisinger, F; Ringelhan, M; Schiemann, M; Schuchmann, M; Sprinzl, MF; Weinmann, A | 1 |
| Addeo, R; Cennamo, G; Del Prete, S; Iodice, P; Montella, L; Palmieri, R; Russo, P; Sperlongano, P; Sperlongano, R; Vincenzi, B | 1 |
| Kim, DY; Kim, YH | 1 |
| Jiang, W; Zeng, ZC | 1 |
| Grønbæk, H; Køstner, AH; Ladekarl, M; Lassen, U; Olesen, RK; Sorensen, M | 1 |
| Cai, JP; Hao, XY; Hou, X; Lai, YR; Liang, LJ; Yin, XY; Zhai, JM; Zhang, LJ | 1 |
| Vogel, W | 1 |
| Kim, BK; Kim, DY; Kim, EH; Kim, SU | 1 |
| Ding, ZB; Fan, J; Gu, CY; Hui, B; Liu, WR; Peng, YF; Qiu, SJ; Shi, YH; Yang, H; Zhou, J | 1 |
| Chao, Y; Feng, G; Han, G; Liu, Z; Lu, L; Shao, G; Teng, G; Wang, J; Wang, M; Yang, J; Yang, R | 1 |
| Hui, KM; Ooi, LL; Xia, H | 1 |
| Chen, KF; Cheng, AL; Hsieh, CY; Huang, CY; Lin, CS; Shiau, CW; Tai, WT | 1 |
| de Gramont, A; Dos Santos, C; Faivre, S; Raymond, E; Riveiro, ME; Serova, M; Slimane, K; Tijeras-Raballand, A | 1 |
| Berasain, C | 1 |
| Bhoori, S; Bongini, M; Flores Reyes, M; Germini, A; Grossi, G; Mariani, L; Mazzaferro, V; Sposito, C | 1 |
| Barbare, JC; Chauffert, B; Ezzoukhry, Z; Galmiche, A; Godin, C; Louandre, C; Mazière, JC | 1 |
| Bai, W; Fan, DM; Guan, S; Han, GH; Li, HL; Li, HP; Liu, JS; Wang, WJ; Wu, JB; Xu, RC; Yin, ZX; Zhang, ZL; Zhao, Y | 1 |
| Benson, AB; Bergsland, EK; Grabowsky, JA; Huang, Y; Hwang, J; Kelley, RK; Ko, AH; Korn, WM; Kuhn, P; Li, CM; Luttgen, MS; Mulcahy, MF; Munster, PN; Nimeiri, HS; Stucky-Marshall, L; Venook, AP; Vergo, MT; Yeh, BM | 1 |
| Kudo, M; Ueshima, K | 2 |
| Banales, JM; Briz, O; Bujanda, L; Herraez, E; Lozano, E; Macias, RI; Marin, JJ; Vaquero, J | 1 |
| Bulavina, I; Burdaeva, O; Cassidy, J; Chang, YL; Cheporov, S; Davidenko, I; Garcia-Carbonero, R; Gladkov, O; Köhne, CH; Lokker, NA; O'Dwyer, PJ; Potter, V; Rivera, F; Salazar, R; Samuel, L; Sobrero, A; Tabernero, J; Tejpar, S; Van Cutsem, E; Vladimirova, L | 1 |
| Harada, M; Honma, Y; Shimizu, S; Takehara, T | 1 |
| Villanueva, A | 1 |
| D'Angelo, S; De Cristofano, R; Secondulfo, M; Sorrentino, P | 2 |
| Salem, R; Weintraub, JL | 1 |
| Piscaglia, F; Salvatore, V; Venerandi, L | 1 |
| Katano, M; Kiyota, A; Koya, N; Morisaki, T; Onishi, H; Tanaka, H; Umebayashi, M | 1 |
| Barbare, JC; Chatelain, D; Chauffert, B; Dupont, S; Ezzoukhry, Z; Galmiche, A; Godin, C; Henaut, L; Louandre, C; Maziere, JC; Regimbeau, JM; Sabbagh, C | 1 |
| Grözinger, G; Horger, M; Plentz, R | 1 |
| Majno, P; Mentha, G; Toso, C | 1 |
| Bozzarelli, S; Carnaghi, C; Destro, A; Di Tommaso, L; Giordano, L; Ligorio, C; Personeni, N; Pressiani, T; Rimassa, L; Roncalli, M; Santoro, A; Tronconi, MC | 1 |
| Suh, SJ; Yim, HJ | 1 |
| O'Neil, B; Sampat, KR | 1 |
| Bargellini, I; Bartolozzi, C; Battaglia, V; Bertini, M; Bresci, G; Faggioni, L; Ginanni, B; Romano, A; Sacco, R | 1 |
| Boni, C; Bozzarelli, S; Carnaghi, C; Chiara Banzi, M; Chiara Tronconi, M; Cortesi, E; Fagiuoli, S; Fanello, S; Foa, P; Giordano, L; Personeni, N; Pressiani, T; Rimassa, L; Romano Lutman, F; Rota Caremoli, E; Salvagni, S; Santoro, A | 1 |
| Akiba, J; Kusano, H; Nakayama, M; Ogasawara, S; Ueda, K; Yano, H | 1 |
| Bay, JO; Blay, JY; Bompas, E; Chaigneau, L; Chevreau, C; Cioffi, A; Clisant, S; Fournier, C; Gauthier, E; Isambert, N; Italiano, A; Le Cesne, A; Penel, N; Ray-Coquard, I; Robin, YM | 1 |
| Chong, DQ; Choo, SP; Tan, IB; Toh, HC | 1 |
| Cho, JY; Choi, MS; Gwak, GY; Kim, YG; Koh, KC; Lee, JH; Lim, HK; Lim, HY; Min, YW; Paik, SW; Paik, YH; Yoo, BC | 1 |
| Gong, F; Ma, J; Shen, J; Zhang, F; Zhang, L; Zhang, P | 1 |
| Hou, JN; Jiang, MD; Wang, Z; Weng, M; Wu, XL; Xu, GS; Xu, H; Zeng, WZ | 1 |
| Duan, W; George, J; Hu, Z; Lam, V; McLeod, D; Qiao, L; Tian, A; Wang, XM; Wilson, GS | 1 |
| Aparo, S; Bakalarski, P; Berz, D; Charpentier, KP; Dubel, G; Eng, Y; Espat, J; Faricy-Anderson, K; Kaubisch, A; Luppe, D; Mantripragada, K; Martel, D; Miner, T; Perez, K; Plette, A; Rosati, K; Safran, H; Victor, J; Wingate, P | 1 |
| Fujiyama, Y; Hira, D; Morita, SY; Noda, S; Shioya, M; Terada, T | 1 |
| Dent, P; Fisher, PB; Grant, S; Hamed, HA; Yamaguchi, Y | 1 |
| Dekervel, J; van Pelt, J; Verslype, C | 1 |
| Dai, XF; Ding, J; Ma, CM; Ren, JH; Wu, G; Zhang, RG | 1 |
| Aloia, TA; Boktour, M; Burroughs, SG; Frenette, CT; Gaber, AO; Galati, J; Ghobrial, RM; Kaseb, A; Monsour, H | 1 |
| Abecassis, M; Atassi, R; Baker, T; Ganger, D; Hickey, R; Kulik, L; Lewandowski, RJ; Memon, K; Miller, FH; Mulcahy, M; Nayar, R; Salem, R; Vouche, M; Yaghmai, V | 1 |
| Bioulac-Sage, P; Blanc, JF; Carteret, T; Laumonier, H; Poullenot, F; Saric, J | 1 |
| Shen, HJ; Wang, YH; Xu, J | 1 |
| Bargellini, I; De Maria, N; De Simone, P; Dufour, JF; Goulis, I; Marinho, RT | 1 |
| De Vita, F; Di Marco, V; Koskinas, J; Semela, D; Toniutto, P; Verslype, C | 1 |
| Barbier, L; Belghiti, J; Faivre, S; Fuks, D; Le Treut, YP; Muscari, F; Pessaux, P | 1 |
| Chai, ZT; Gao, DM; Kong, LQ; Lu, L; Sun, HC; Tang, ZY; Wang, L; Wang, WQ; Wu, WZ; Xu, HX; Zhang, JB; Zhang, W; Zhu, XD; Zhuang, PY | 1 |
| Fiel, I; He, X; Savić, R; Schuchman, EH | 1 |
| Harada, M; Honma, Y | 2 |
| Ao, JY; Chai, ZT; Kong, LQ; Li, JQ; Lu, L; Sun, HC; Tang, ZY; Wang, L; Wang, WQ; Wu, WZ; Zhang, KZ; Zhang, QB; Zhang, W; Zhang, YY; Zhu, XD | 1 |
| Carithers, R; Halldorson, J; Jia, N; Lin, EH; Liou, I; Perkins, J; Rao, S; Reyes, J; Stohr, E; Yeh, M | 1 |
| Chen, JW; Guo, YJ; Huang, WS; Meng, XC; Pang, PF; Shan, H; Zhou, B; Zhu, KS | 1 |
| Stein, SM | 1 |
| Lu, J; Qiu, Y; Shen, N; Wang, Z; Wei, Y; Yang, G; Yang, N; Yi, B | 1 |
| Aziz, K; Cades, JA; Chettiar, ST; Cosgrove, D; Gajula, RP; Gandhi, N; Geschwind, JF; Hales, RK; Herman, JM; Kumar, R; Maitra, A; Menon, S; Pawlik, TM; Taparra, K; Torbenson, MS; Tran, PT; Velarde, E; Wild, AT; Williams, RD; Wong, J; Zeng, J | 1 |
| Angulo, P; Chen, C; Cohen, DA; Daily, MF; Evers, BM; Galuppo, R; Gedaly, R; Hundley, J; Musgrave, Y; Shah, M; Spear, BT | 1 |
| Rombolà, F; Spinoso, A | 1 |
| Azzolina, A; Bachvarov, D; Cervello, M; Cusimano, A; Lampiasi, N; McCubrey, JA; Montalto, G | 2 |
| Choi, KY; Joh, JW; Kang, KJ; Kim, DS; Kim, G; Kim, JP; Kwon, JH; Lee, N; Moon, YH; Park, JY; Shin, JH; Wang, HJ; Yu, YS | 1 |
| Ayuso, C; Bruix, J; Darnell, A; Forner, A; Llarch, N; Reig, M; Rimola, J; Ríos, J; Rodriguez-Lope, C; Torres, F | 2 |
| Arai, Y; Ikeda, M; Kondo, S; Kuwahara, A; Mitsunaga, S; Morizane, C; Ohno, I; Okusaka, T; Okuyama, H; Satake, M; Shimizu, S; Takahashi, H; Ueno, H | 1 |
| Chan, C; Felsher, DW; Gamrekelashvili, J; Greten, TF; Hewitt, S; Kapanadze, T; Kapoor, V; Korangy, F; Ma, C; Manns, MP; Zender, L; Zhao, F | 1 |
| Joo, J; Kim, CM; Kim, H; Kim, HY; Lee, WJ; Park, JW; Woo, SM | 1 |
| Fukunishi, S; Higuchi, K; Nishikawa, T; Nouda, S; Sanomura, M; Sasaki, Y; Takahashi, Y; Umegaki, E | 1 |
| Cao, D; Chen, C; Chen, SZ; Ding, J; Feng, GS; Han, T; Huang, L; Sun, W; Tang, L; Wang, HY; Wang, X; Wen, W; Wu, MC; Xiang, DM | 1 |
| Gong, K; Li, J; Li, W; Liu, T; Mei, L; Wan, J; Yu, C | 1 |
| Aikata, H; Awai, K; Chayama, K; Fujino, H; Fukuhara, T; Hiramatsu, A; Ishikawa, M; Kakizawa, H; Kan, H; Kawaoka, T; Kobayashi, T; Masaki, K; Miyaki, D; Naeshiro, N; Nakahara, T; Takahashi, S; Urabe, A | 1 |
| Ainora, ME; Annicchiarico, BE; Caracciolo, G; Di Stasio, E; Garcovich, M; Gasbarrini, A; Landolfi, R; Lupascu, A; Pompili, M; Ponziani, F; Rapaccini, GL; Riccardi, L; Roccarina, D; Siciliano, M; Zocco, MA | 1 |
| Biolato, M; Grieco, A; Lombardo, A | 1 |
| Chang, YC; Cheng, AL; Hsu, C; Lee, BS; Lin, LI; Liou, JY; Ou, DL | 1 |
| Abdel-Rahman, O; Abdel-Wahab, M; Abdel-Wahab, S; Elbassiony, M; Ellithy, M; Shaker, M | 1 |
| Beil, W; Holstein, A; Kovacs, P | 1 |
| Chen, D; Li, SQ; Liang, LJ; Peng, BG; Xiao, WK; Yin, XY; Zhao, P | 1 |
| Hashida, T; Inokuma, T; Kanamori, K; Kitada, N; Konishi, A; Suginoshita, Y; Tanaka, S | 1 |
| Enomoto, M; Fujii, H; Hagihara, A; Iwai, S; Kawada, N; Kawamura, E; Morikawa, H; Tamori, A; Teranishi, Y | 1 |
| Donnellan, F; Gill, S; Haque, M; Hashim, AM; Shingina, A; Suen, M; Weiss, AA; Yoshida, EM | 1 |
| An, JZ; Dou, KF; Gong, ZB; He, Y; Li, JJ; Li, QJ; Li, XL; Wang, DS; Wang, S; Yang, F; You, N; Zhou, L | 1 |
| Natori, T; Yamaguchi, M | 1 |
| Choi, GH; Kang, YK; Kim, KM; Kim, MJ; Lee, HC; Lim, YS; Ryoo, BY; Ryu, MH; Shim, JH; Shin, YM | 1 |
| Bian, X; Bie, P; Cui, Y; Liu, C; Liu, L; Qian, C; Shan, J; Shen, J; Wu, L; Xia, F; Xu, Y; Yang, Z; Zhang, Q; Zhang, X | 1 |
| Hargreaves, S; Hull, D; Hussain, SA; Johnson, PJ; Ma, YT; Palmer, DH; Ross, PJ; Smith, AJ | 1 |
| Finn, RS; Gish, RG; Marrero, JA | 1 |
| Fan, WZ; Huang, YH; Li, JP; Wang, Y; Yang, JY; Zhang, YQ | 1 |
| Deng, L; Jia, Q; Ren, Z; Shen, H; Wang, Y; Wu, W | 1 |
| Moroni, M; Zanlorenzi, L | 1 |
| Chen, KF; Chen, PJ; Chu, PY; Huang, HP; Huang, JW; Liu, CY; Shiau, CW; Tai, WT | 1 |
| Di Fiore, A; Di Fiore, F; Drieux, F; François, A; Kermiche-Rahali, S; Scotté, M | 1 |
| Cha, J; Han, KH; Kim, JW; Lee, IJ; Seong, J | 1 |
| Chen, CL; Dooley, S; Feldman, D; French, SW; Jeong, JH; Kashiwabara, C; Liu, JC; Machida, K; Mishra, L; Petrovic, L; Sher, L; Tsukamoto, H | 1 |
| Brandt, U; Bruix, J; Chen, LT; Finn, RS; Gomez-Martin, C; Kang, YK; Kim, TY; Klümpen, HJ; Kunz, T; Paquet, T; Poon, RT; Rodriguez-Lope, C; Sellami, D; Yau, T | 1 |
| Cucchetti, A; Dietrich, CF; Piscaglia, F; Salvatore, V | 1 |
| Lang, H; Ricke, J; Schlaak, J | 1 |
| Boucher, E; Chao, Y; Cheng, AL; Decaens, T; Ezzeddine, R; Han, KH; Heo, J; Hsu, CH; Hu, TH; Jeng, LB; Johnson, PJ; Komov, D; Kudo, M; Liu, D; Lu, L; Paik, SW; Park, JW; Philip, PA; Poon, RT; Qin, S; Raoul, JL; Robles-Aviña, J; Sobhonslidsuk, A; Tak, WY; Walters, I; Xu, J; Yan, L | 1 |
| Kelley, RK | 1 |
| Assenat, E; Blanc, JF; Boige, V; Boucher, E; Bruix, J; Chang, C; Chao, Y; Decaens, T; Ezzeddine, R; Fartoux, L; Finn, RS; Kang, YK; Kudo, M; Lim, HY; Lin, DY; Liu, D; Llovet, JM; Mathurin, P; Park, JW; Poon, RT; Raoul, JL; Sherman, M; Tak, WY; Walters, I | 1 |
| Ding, LM; Guo, J; Kang, XS; Li, LJ; Qiu, YQ; Shen-Tu, JZ; Tan, FL; Zhou, J | 1 |
| Angarano, G; Bronte, E; Bronte, F; Bronte, G; Cicero, G; Cusenza, S; Di Marco, V; Fiorentino, E; Firenze, A; Fontana, T; Rolfo, C; Russo, A | 1 |
| Büning, H; Decker, G; Gonzalez-Carmona, MA; Lukacs-Kornek, V; Meumann, N; Raskopf, E; Sauerbruch, T; Schmidt-Wolf, IG; Sievers, E; Strassburg, CP; Vogt, A | 1 |
| Cai, J; Mallick, R; Wogen, J | 1 |
| Ardisson, V; Audrain, O; Boucher, E; Clement, B; Edeline, J; Garin, E; Lenoir, L; Lepareur, N; Pracht, M; Raoul, JL | 1 |
| Tan-Shalaby, J | 1 |
| Columbano, A; Giordano, S | 1 |
| Byun, KS; Kang, K; Kang, SH; Kim, JH; Lee, HJ; Lee, SJ; Suh, SJ; Yeon, JE; Yim, HJ; Yoo, YJ; Yoon, EL | 1 |
| Hagihara, H; Honda, M; Ikeda, F; Iwadou, S; Kaneko, S; Kariyama, K; Kobayashi, Y; Kuwaki, K; Miyahara, K; Miyake, Y; Morimoto, Y; Nakamura, S; Nouso, K; Obi, S; Onishi, H; Sato, S; Sato, T; Shiraha, H; Takabatake, H; Takaguchi, K; Takaki, A; Takeuchi, Y; Takuma, Y; Yamamoto, K | 1 |
| Abdel-Rahman, O; Elsayed, ZA | 1 |
| He, X; Hu, BS; Huang, JW; Li, Y; Liu, B; Lu, LG; Zhao, W; Zheng, YB | 2 |
| Lee, YJ; Shin, SY | 1 |
| Cheng, AL; Chung, HC; Kang, YK; Kudo, M; Lanzalone, S; Lechuga, MJ; Lin, DY; Omata, M; Park, JW; Pitman Lowenthal, S; Poggi, G; Qin, S; Raymond, E; Song, X; Xu, J; Yang, L | 1 |
| Aucejo, F; Menon, KV; Murali, AR; Romero-Marrero, C | 1 |
| Bolon, B; Grever, MR; Kinghorn, AD; Kogure, T; Lucas, DM; Patel, T; Yan, I | 1 |
| Ganten, TM; Hoffmann, K; Koschny, R; Mehrabi, A; Pfeiffenberger, J; Radeleff, B; Schemmer, P; Schmitz, A; Stremmel, W | 1 |
| Barletta, E; Cannella, L; Daniele, B; Germano, D; Tinessa, V | 1 |
| Baglioni, M; Baron Toaldo, M; Bolondi, L; Chieco, P; Cipone, M; D'Adamo, S; Giovannini, C; Gramantieri, L; Ventrucci, C | 1 |
| Asahina, Y; Enomoto, N; Hosokawa, T; Itakura, J; Izumi, N; Kurosaki, M; Kuzuya, T; Matsuda, S; Muraoka, M; Nakanishi, H; Nakata, T; Nishimura, T; Suzuki, S; Suzuki, Y; Takahashi, Y; Tamaki, N; Tsuchiya, K; Ueda, K; Yasui, Y | 1 |
| Berardi, R; Burattini, L; Cascinu, S; Conti, A; De Giorgi, U; Iacovelli, R; Muzzonigro, G; Pantano, F; Santini, D; Santoni, M | 1 |
| Chiba, T; Fukudo, M; Hatano, E; Ito, T; Kamba, T; Matsubara, K; Mizuno, T; Ogawa, O; Seno, H; Shinsako, K; Uemoto, S; Yamasaki, T | 1 |
| Ahn, SH; Chang, S; Chon, CY; Han, KH; Kim, BK; Kim, DY; Kim, SU; Lee, S; Park, JY; Park, Y | 1 |
| Bae, JS; Chung, MJ; Jang, KY; Kim, DG; Kim, KM; Moon, WS; Noh, SJ | 1 |
| Chen, L; Qin, J; Wang, GL; Wei, YZ; Xu, YY; Zhang, YX; Zhou, JM; Zhu, YY | 1 |
| Adjei, AA; Kissel, M; Miner, JN; Mumberg, D; Neuhaus, R; Puehler, F; Schmieder, R; Scholz, A; Ziegelbauer, K | 1 |
| Bai, F; Belli, LS; Mancuso, A; Puoti, M; Zavaglia, C | 1 |
| Chen, W; Deng, J; Li, X; Wu, XY; Zhang, L; Zhang, YN; Zhong, CJ; Zhong, N | 1 |
| Chang, YL; Cheng, AL; Hsu, CH; Huang, CY; Shao, YY | 1 |
| Igarashi, Y; Ishii, K; Kanayama, M; Kanekawa, T; Kobayashi, K; Matsui, D; Matsui, T; Momiyama, K; Mukozu, T; Nagai, H; Shinohara, M; Sumino, Y; Wakui, N | 1 |
| Bamias, A; Bearz, A; Bellmunt, J; Imarisio, I; Melichar, B; Paglino, C; Porta, C; Procopio, G; Sabbatini, R; Schmidinger, M; Tinelli, C | 1 |
| Cabibbo, G; Cammà, C; Craxì, A; Maida, M | 1 |
| Agostini, V; Andreone, P; Biasco, G; Bolondi, L; Brandi, G; Cucchetti, A; de Rosa, F; di Girolamo, S; Golfieri, R; Gramenzi, A; Pinna, AD; Sama, C; Serra, C; Trevisani, F | 1 |
| Hu, BS; Li, Y; Liang, HY; Lu, LG; Shao, PJ | 1 |
| Chen, Y; Duda, DG; Duyverman, AM; Hiddingh, L; Huang, P; Huang, Y; Jain, RK; Koppel, C; Lauwers, GY; Reiberger, T; Roberge, S; Samuel, R; Zhu, AX | 1 |
| Cheng, NS; Chow, AK; Lam, CS; Ng, L; Pang, RW; Poon, RT; Wan, TM; Wong, SK; Yau, TC | 1 |
| Hatano, E; Ishii, T; Seo, S; Taura, K; Uemoto, S; Yasuchika, K | 1 |
| Chen, KF; Chen, PJ; Chen, YL; Chu, PY; Hsu, CY; Hsu, YC; Huang, JW; Li, YS; Shiau, CW; Tai, WT | 1 |
| Bronowicki, JP; Chen, XP; Dagher, L; de Guevara, LL; Furuse, J; Geschwind, JF; Heldner, S; Kudo, M; Lehr, R; Lencioni, R; Nakajima, K; Papandreou, C; Sanyal, AJ; Takayama, T; Ye, SL; Yoon, SK | 1 |
| Agnello, F; Brancatelli, G; Cabibbo, G; Furlan, A; Genco, C; Giannitrapani, L; Lagalla, R; Marin, D; Midiri, M; Salvaggio, G | 1 |
| Cho, T; Emura, M; Igarashi, S; Kobayashi, Y; Nakamura, T; Nomizo, T; Nomura, N; Seto, R | 1 |
| Cha, SW; Cho, YD; Jang, JY; Jeong, SW; Kim, BS; Kim, HS; Kim, JH; Kim, KH; Kim, SG; Kim, YS; Lee, SH; Shim, KY | 1 |
| He, XD; Liu, H; Qin, SK; Tao, L; Tong, XH; Wang, ZS; Wu, Q; Yang, Y; Zheng, RS | 1 |
| Chen, MS; Gao, HJ; Xu, L; Zhang, YJ | 1 |
| Abeni, E; Arici, B; Barlati, S; Conde, I; De Petro, G; Grossi, I; Portolani, N; Salvi, A; Specchia, C | 1 |
| Ahmad, S; Khattak, J; Murad, S; Naqi, N | 1 |
| Cho, JY; Choi, MS; Gwak, GY; Koh, KC; Lee, JH; Paik, SW; Paik, YH; Park, HC; Sohn, W; Yoo, BC; Yu, JI | 1 |
| Chen, K; Janssen, HL; Man, K; Metselaar, HJ; Pan, Q; Peppelenbosch, MP | 1 |
| Barbare, JC; Chauffert, B; Galmiche, A | 1 |
| Chen, CH; Chen, LC; Chen, YJ; Chien, PH; Chien, YF; Hsieh, YL; Hsu, SC; Huang, WC; Hung, CM; Lin, YM; Tu, CY | 1 |
| Kanazawa, A; Kawasaki, Y; Kioka, K; Kodai, S; Komatsu, H; Nakai, T; Nakajima, T; Ohira, G; Shimizu, S; Tsukamoto, T; Yamazoe, S | 1 |
| Doki, Y; Eguchi, H; Hama, N; Kawamoto, K; Kobayashi, S; Mori, M; Mukai, R; Nagano, H; Tomimaru, Y; Umeshita, K; Wada, H | 1 |
| Bae, SH; Choi, JY; Lee, JE; Lee, MA; Yoon, SK; You, YK | 1 |
| Dong, S; Gao, J; Gu, F; Ke, S; Kong, F; Kong, J; Pan, B; Shen, Q; Sun, H; Sun, W; Zhang, Q; Zheng, L | 1 |
| Baudin, E; Bonichon, F; Borget, I; Brassard, M; Chougnet, CN; Claude-Desroches, M; de la Fouchardière, C; Do Cao, C; Giraudet, AL; Leboulleux, S; Massicotte, MH; Schlumberger, M | 1 |
| Hagihara, A; Ikeda, M; Imanaka, K; Inaba, Y; Katayama, K; Kato, M; Kojima, Y; Kondo, S; Mitsunaga, S; Morizane, C; Nakachi, K; Okusaka, T; Sato, Y; Shimizu, S; Suzuki, E; Tamai, C; Ueno, H | 1 |
| Abdel-Rahman, O; Fouad, M | 1 |
| Balakan, O; Berk, V; Bilici, A; Buyukberber, S; Cinkir, HY; Demirci, U; Erdogan, B; Gumus, M; Kaplan, MA; Oflazoglu, U; Oksuzoglu, B; Ozdemir, N; Ozkan, M; Ozturk, T; Tastekin, D; Tonyali, O; Turkmen, E; Unal, OU; Uyeturk, U; Yasar, N | 1 |
| Choi, DJ; Jung, YK; Kim, JH; Kim, YS; Kwon, OS; Shin, SK; Yoon, HH | 1 |
| Bangen, JM; Gassler, N; Liedtke, C; Sonntag, R; Trautwein, C | 1 |
| Dong, X; He, C; Jiang, H; Jiang, X; Ma, L; Pan, S; Qiao, H; Sun, X; Tan, G; Wei, Z; Zhai, B; Zhao, D | 1 |
| Li, Y; Meng, Q; Shen, J; Sun, H; Yin, Q; Yu, H; Zhang, Z | 1 |
| Arizumi, T; Hagiwara, S; Inoue, T; Kitai, S; Kudo, M; Minami, Y; Nishida, N; Osaki, Y; Sakurai, T; Takeda, H; Takita, M; Ueshima, K; Yada, N | 1 |
| Behnke, M; Bornstein, K; Cotterell, A; Fisher, RA; Fulcher, A; Lee, DD; Posner, MP; Ramanathan, R; Sharma, A; Stravitz, RT; Sydnor, M | 1 |
| Bearzi, I; Benedetti, A; Bianconi, M; Bitetto, D; Bolondi, L; Cascinu, S; Colombo, M; D'Errico, A; De Minicis, S; Facchetti, F; Faloppi, L; Fava, G; Gemini, S; Giampieri, R; Granito, A; Iavarone, M; Loretelli, C; Mandolesi, A; Marinelli, S; Piscaglia, F; Scartozzi, M; Svegliati Baroni, G; Toniutto, P; Vavassori, S; Venerandi, L | 1 |
| Chiba, T; Kanogawa, N; Motoyama, T; Ogasawara, S; Ooka, Y; Suzuki, E; Tawada, A; Yokosuka, O | 1 |
| Chen, CH; Chen, CS; Chen, MC; Liou, JP; Pan, SL; Teng, CM; Tsai, AC; Wang, JC | 1 |
| Bruix, J; Gores, GJ; Mazzaferro, V | 1 |
| Benedetti, A; Bianconi, M; Bitetto, D; Cascinu, S; D'Anzeo, M; De Minicis, S; Del Prete, M; Faloppi, L; Giampieri, R; Loretelli, C; Scartozzi, M; Svegliati Baroni, G; Toniutto, P | 1 |
| Liu, LL; Pan, YH; Yun, JP; Zhang, CZ; Zhang, MF | 1 |
| Abdel-Rahman, O; Abdelwahab, M; Abdelwahab, S; Elbassiony, M; Ellithy, M; Shaker, M | 1 |
| Karagoz, E; Tanoglu, A | 1 |
| Antonuzzo, L; Arena, U; Boni, L; Colagrande, S; Di Costanzo, F; Fani, B; Forte, P; Gallori, D; Gianni, E; Inghilesi, AL; Laffi, G; Marra, F; Pradella, S; Tomcikova, D | 1 |
| Brose, MS; Frenette, CT; Keefe, SM; Stein, SM | 1 |
| Grande, C; Walko, CM | 1 |
| Chen, LF; Liang, SN; Liu, J; Shao, HB; Su, HY; Xu, K | 1 |
| de Man, RA; Schrier, GH; van der Geest, LG; van Erpecum, KJ; van Meer, S; Verheij, J; Verhoef, C | 1 |
| Arai, K; Chiba, T; Kanai, F; Kaneko, S; Ogasawara, S; Ooka, Y; Suzuki, E; Tawada, A; Yamashita, T; Yokosuka, O | 1 |
| Ikeda, M; Kuwahara, A; Mitsunaga, S; Ohno, I; Okusaka, T; Okuyama, H; Shimizu, S; Takahashi, H | 2 |
| Liang, JY; Lü, MD; Pan, FS; Xie, XY; Xu, M; Zheng, SG; Zheng, YL | 1 |
| Choo, SP; Chow, PK; Gandhi, M; Goh, AS; Han, HS; Khin, MW; Lai, HK; Lim, TG; Lo, RH; Poon, DY; Singh, H; Soo, KC; Tan, SB; Tay, KH | 1 |
| Carbotti, M; Coppola, R; De Florio, L; Galati, G; Graziano, A; Panasiti, V; Rinati, MV; Zanframundo, S | 1 |
| Deng, DF; Ding, LM; Kang, XS; Qiu, YQ; Tan, FL; Yu, W; Zhou, J | 1 |
| Chen, C; Geng, ZM; Huanchen, S; Jha, RK; Li, B; Li, WZ; Wang, L; Zheng, JB | 1 |
| Lazarevich, NL; Makarova, AS | 1 |
| Chen, CL; Chen, WY; Honda, K; Kawasaki, K; Masuda, M; Miyanaga, A; Nakamura, Y; Ono, M; Sakuma, T; Yamada, T | 1 |
| Bae, SH; Song, MJ | 1 |
| Cai, G; Chen, H; Han, G; Liu, L; Qi, X; Wang, M; Zhao, Y | 1 |
| Belghiti, J; Bouattour, M; Bruno, O; Castera, L; Dreyer, C; Faivre, S; Larroque, B; Raymond, E; Ronot, M; Vilgrain, V; Wassermann, J | 1 |
| Chen, SW; Chiou, JF; Kuo, CC; Kuo, YC; Liang, JA; Lin, LC | 1 |
| Abecassis, M; Al-Saden, P; Baker, T; Cotliar, J; Ganger, D; Habib, A; Karp, J; Koppe, S; Kulik, L; Lacouture, M; Lewandowski, RJ; Mulcahy, MF; Salem, R; Vouche, M | 1 |
| Andreozzi, M; Angel, P; Ben-Neriah, Y; Breuhahn, K; Finkelstein, R; Ganten, T; Grunewald, M; Hess, J; Horwitz, E; Kanarek, N; Koschny, R; Mogler, C; Nemeth, J; Pappo, O; Pikarsky, E; Porat, RM; Quagliata, L; Reuter, H; Schirmacher, P; Schweitzer, N; Shibolet, O; Shoham, A; Stein, I; Terracciano, L; Tornillo, L; Vogel, A; Zreik, F | 1 |
| Fukuda, H; Ishii, T; Kondo, M; Maeda, S; Morimoto, M; Morita, S; Moriya, S; Nozaki, A; Numata, K; Sakamaki, K; Shimoyama, Y; Tanaka, K | 1 |
| Chen, C; Daily, MF; Galuppo, R; Gedaly, R; Maynard, E; Shah, M; Spear, BT | 1 |
| Belli, LS; Mancuso, A; Mazzarelli, C; Perricone, G; Zavaglia, C | 1 |
| Daniele, B; Germano, D | 1 |
| Fan, JG; Li, GM; Pan, Q; Sun, C; Wang, J; Wang, YG | 1 |
| Geng, CX; Ji, YX; Lan, KT; Liu, SC; Nie, KK; Sun, L; Zhang, L; Zhang, ZC; Zhang, ZF; Zhuang, XJ; Zou, X | 1 |
| Chen, W; Chen, Y; Deng, DY; Ren, M; Shang, C; Wang, J; Xiang, Q; Zhang, H; Zhang, L | 1 |
| Dong, X; Hu, F; Jiang, H; Jiang, X; Liu, B; Pan, S; Qiao, H; Sun, X; Tan, G; Wei, Z; Xu, J; Zhai, B; Zhao, D | 1 |
| Cai, M; Chen, J; Huang, W; Lai, L; Meng, X; Shan, H; Zhou, B; Zhu, K | 1 |
| Choi, HS; Kim, SW; Lee, B; Nam, SW; Park, KC | 1 |
| Chen, J; Kim, DH; Larson, AC; Lewandowski, RJ; Li, W; Omary, RA; Shea, LD; Sheu, AY; Zhang, Z | 1 |
| Chiba, T; Kanai, F; Kanogawa, N; Motoyama, T; Ogasawara, S; Ooka, Y; Suzuki, E; Tawada, A; Yokosuka, AO | 1 |
| Beveridge, RD; Campos, GB; Daroqui, JC; Esparcia, MF; Estellés, DL; Huerta, ÁS; Imedio, ER; Ortiz, AG; Salcedo, JM; Urtasun, JA | 1 |
| Adachi, T; Akutsu, N; Hamamoto, Y; Hirayama, D; Igarashi, M; Kaneto, H; Motoya, M; Sasaki, S; Shinomura, Y; Shitani, M; Takagi, H; Wakasugi, H; Yamamoto, H; Yawata, A; Yonezawa, K | 1 |
| Bernardi, M; Bolondi, L; Cappelli, A; Cucchetti, A; Erroi, V; Fiumana, S; Golfieri, R; Gramenzi, A; Granito, A; Marinelli, S; Mosconi, C; Pettinato, C; Trevisani, F | 1 |
| Raza, A; Sood, GK | 1 |
| Miyahara, K; Nouso, K; Yamamoto, K | 1 |
| Bai, XL; Chen, YW; Fu, QH; Hu, QD; Liang, TB; Su, RG; Su, W; Zhang, Q | 1 |
| Aigner, B; Artl, M; Niederkorn, A; Richtig, E; Schwantzer, G; Wackernagel, W | 1 |
| Chen, LJ; Chen, YZ; Cheng, C; Fu, XY; Li, LL; Tang, Y; Wei, YQ; Xiang, R; Yang, J; Yang, LL; Yang, SY; Zhong, L; Zhou, S; Zou, C | 1 |
| Mu, H; Song, TQ; Wang, M; Wei, K; Zhang, W | 1 |
| Chen, W; Guo, E; Liu, Z; Lu, L; Peng, X; Wang, Y; Yan, T; Yang, X; Ye, L; Zhou, F | 1 |
| Bargellini, I; Bartolozzi, C; Masi, G; Mismas, V; Sacco, R; Scionti, A; Vivaldi, C | 1 |
| Bodoky, G; Fassan, M; Gyöngyösi, B; Járay, B; Kiss, A; Schaff, Z; Székely, E; Végh, É | 1 |
| Chiang, IT; Hsu, FT; Hwang, JJ; Lin, WJ; Liu, RS; Liu, YC; Wang, HE | 1 |
| Burra, P; Castelli, G; Cillo, U; Farinati, F; Giacomin, A; Senzolo, M; Vitale, A | 1 |
| Imagawa, DK; Reataza, M | 1 |
| Srimuninnimit, V; Sriuranpong, V; Suwanvecho, S | 1 |
| Fu, SR; He, X; Hu, BS; Huang, JW; Li, JP; Li, Y; Lu, LG; Zhan, MX; Zhang, YQ | 1 |
| Duan, Z; Hertzanu, Y; Hu, H; Liu, S; Long, X; Shi, H; Yang, Z | 1 |
| Aoyagi, Y; Fujimaki, S; Hirose, Y; Kobayashi, T; Kubota, M; Matsuda, Y; Osawa, M; Sakata, J; Takamura, M; Wakai, T; Yamagiwa, S | 1 |
| Beaune, P; de Waziers, I; Favre, A; Figg, WD; Kiehl, P; McMullen, J; Montemurro, M; Narjoz, C; Rochat, B | 1 |
| Llovet, JM | 1 |
| Cui, LJ; Li, AJ; Ma, SL; Wu, B; Wu, MC; Yin, L; Yuan, H | 1 |
| Izumi, N; Joko, K; Nishikawa, H; Ogawa, C; Orito, E; Osaki, Y; Takeda, H; Taniguchi, H; Tsuchiya, K; Uchida, Y | 1 |
| Bella, A; Guerra, JR; Lolo, D; Suelves, AM | 1 |
| Shouval, D | 1 |
| Chen, D; Chen, M; Kuang, M; Lencioni, R; Peng, B; Peng, H; Peng, S; Shen, S; Wang, Y | 1 |
| Antonucci, M; Cabibbo, G; Gadaleta-Caldarola, G; Galati, G; Lombardi, G; Mazza, G; Sacco, R; Tremosini, S | 1 |
| Ai, DL; Fu, JL; Li, J; Liu, CZ; Peng, XM; Wang, HM; Wang, JY; Yang, B; Yu, Q; Zhang, LZ; Zhao, Y; Zhou, L | 1 |
| Akasaka, K; Hisamichi, K; Kondo, Y; Maejima, T; Maekawa, M; Mano, N; Matsuura, M; Mori, M; Okawa, H; Shimada, M; Shimosegawa, T; Suzuki, H; Tsuchiya, M; Yanagi, T | 1 |
| Carella, N; Carr, BI; Cavallini, A; D'Alessandro, R; Giannuzzi, G; Lippolis, C; Messa, C; Refolo, MG | 1 |
| Hidaka, H; Koizumi, W; Kokubu, S; Minamino, T; Nakazawa, T; Okuwaki, Y; Shibuya, A; Takada, J; Tanaka, Y; Watanabe, M | 2 |
| Feng, GS; Luo, X | 1 |
| Luo, J; Shao, G; Zheng, J | 1 |
| Chapiro, J; Duran, R; Geschwind, JF | 1 |
| Abou-Alfa, GK; Harding, JJ | 1 |
| Bruera, G; Cannita, K; Carducci, S; Coletti, G; Ficorella, C; Giordano, AV; Iapadre, N; Manetta, R; Ricevuto, E; Saltarelli, P; Vicentini, R | 1 |
| Baron Toaldo, M; Bolondi, L; Croci, L; Diana, A; Marinelli, S; Milazzo, M; Palamà, C; Pecorelli, A; Piscaglia, F; Salvatore, V; Venerandi, L | 1 |
| Koyakutty, M; Malarvizhi, GL; Nair, S; Retnakumari, AP | 1 |
| Bao, LF; Cao, XQ; Dai, YC; Gan, MF; Li, ZY; Liang, XD; Lu, HS; Ma, SL; Wang, DD; Zhang, LM; Zhang, SR; Zheng, BJ | 1 |
| Bulla, K; Kolligs, F; Malfertheiner, P; Peck-Radosavljevic, M; Reimer, P; Ricke, J; Sangro, B; Schott, E; Schütte, K; Verslype, C; Walecki, J | 1 |
| Bie, P; Chen, X; Hu, P; Zhang, L | 1 |
| Alsaied, OA; Banerjee, S; Chugh, R; Jensen, EH; Krosch, TC; Saluja, A; Sangwan, V; Vickers, SM | 1 |
| Chen, YF; Liao, MB; Peng, HS; Wang, HY; Xie, Y; Xu, L; Zhang, MY; Zhang, YJ; Zheng, XF | 1 |
| Ady, JW; Belin, LJ; Chen, CT; Chen, NG; Fong, Y; Heffner, J; Johnsen, C; Klein, E; Love, D; Mojica, K; Pugalenthi, A; Szalay, AA; Yu, YA | 1 |
| Döring, C; Filmann, N; Hansmann, ML; Hartmann, S; Herrmann, E; Mertens, A; Peveling-Oberhag, J; Piiper, A; Trojan, J; Welker, MW; Zeuzem, S | 1 |
| Cheung, FY; Chiang, CL; Chong, M; Jolivet, J; Kwok, C; Kwong, P; Lai, M; Lee, C; Lee, FA; Leung, KC; Siu, SW; Tung, S; Zee, BC | 1 |
| Bogaerts, E; Colle, I; Descamps, B; Devisscher, L; Geerts, A; Janssens, S; Lambrecht, BN; Laukens, D; Libbrecht, L; Paridaens, A; Van Steenkiste, C; Van Vlierberghe, H; Vandewynckel, YP; Vanhove, C; Verhelst, X | 1 |
| Alsina, AE; Arrobas, J; Franco, E; Kemmer, N; Makris, A; Nenos, V; Sucre, E | 1 |
| Gandhi, S; Grewal, H; Sengodan, P | 1 |
| Altekruse, SF; Dickie, LA; Duffy, AG; Greten, TF; Kish, JK; McGlynn, KA; McNeel, TS; Rahma, OE; Ulahannan, SV | 1 |
| Andoh, A; Bamba, S; Fujiyama, Y; Inatomi, O; Nishida, A; Nishimura, T; Sasaki, M; Shioya, M | 1 |
| Liu, C; Liu, L; Long, J; Ni, QX; Sun, HC; Tang, ZY; Wang, WQ; Wu, CT; Xu, HX; Xu, J; Yu, XJ; Zhang, W; Zhu, XD | 1 |
| Kim, SW; Lee, B; Nam, SW; Park, KC; Yang, KJ | 1 |
| Bae, SH; Cho, SB; Chung, WJ; Jang, JY; Kim, YS; Lee, SH; Park, JY; Park, SY; Song, DS; Song, MJ; Yang, JM; Yim, HJ | 1 |
| Bhargava, P; Bhosale, P; Choi, JI; Imagawa, DK; Lall, C; Seery, TE; Tirkes, T | 1 |
| He, C; Liu, J; Mao, K; Sun, J; Tan, C; Wang, J; Wu, G; Xiao, Z; Xu, K; Zeng, Y; Zhang, J | 1 |
| Augello, C; Barberis, M; Bosari, S; Carnaghi, C; Di Tommaso, L; Fagiuoli, S; Faversani, A; Labianca, R; Maggioni, M; Pressiani, T; Rimassa, L; Roncalli, M; Rota Caremoli, E; Santoro, A; Spagnuolo, G; Vaira, V | 1 |
| Chen, IT; Chen, KF; Hsu, CY; Li, YS; Liu, CY; Shiau, CW; Su, JC; Tai, WT; Tseng, PH; Wu, SH | 1 |
| Cao, Y; Chen, W; Ding, Y; Jiang, C; Shi, H; Wang, Z; Wu, J; Zhang, G | 1 |
| Anak, O; Assenat, E; Blanc, JF; Cattan, S; Chen, CL; Chen, LT; Daniele, B; Dorval, E; Furuse, J; Jappe, A; Kang, YK; Kudo, M; Lim, HY; Peck-Radosavljevic, M; Perraud, K; Poon, RT; Santoro, A; Sellami, DB; Vogel, A; Zhu, AX | 1 |
| Gottesman, MM; Lavi, O; Skinner, J | 1 |
| Baron Toaldo, M; Bolondi, L; Cipone, M; Croci, L; Marinelli, S; Milazzo, M; Palamà, C; Piscaglia, F; Salvatore, V; Venerandi, L | 1 |
| Bruix, J; Forner, A; Gilabert, M; Raoul, JL | 1 |
| Bai, M; Han, GH; Yang, M; Yuan, JQ | 1 |
| Guo, QQ; Wang, QD; Yang, GR; Zhao, YL | 1 |
| Ji, B; Liu, K; Liu, S; Liu, Y; Wang, Y; Zhang, W | 2 |
| Chao, Y; Chung, YH; Han, G; Kim, BI; Lee, TY; Shao, GL; Wang, J; Yang, J; Yoon, JH | 2 |
| Akarsu, S; Çarsanbali, S; Fetil, E; İlknur, T; Lebe, B | 1 |
| Anand, BS; Fitzmorris, P; Shoreibah, M; Singal, AK | 1 |
| Chang, CJ; Cheng, AL; Gandhi, AK; Hsu, C; Huang, ZM; Jeng, YM; Liao, SC; Lin, YJ; Lin, ZZ; Ou, DL | 1 |
| Bitzer, M; Blondin, D; Dollinger, M; Erhardt, A; Gog, C; Häussinger, D; Kolligs, F; Lammert, F; Ohmann, C; Schott, E; Schuchmann, M; Walter, C; Wege, H | 1 |
| Tan-Shalaby, JL | 1 |
| Daoudaki, M; Fouzas, I | 1 |
| Fu, SR; He, X; Hu, BS; Huang, JW; Li, Y; Liu, B; Lu, LG; Zhan, MX; Zhao, W; Zhao, Y; Zheng, YB | 1 |
| Bianco, V; Francini, E | 1 |
| Chen, S; Dong, L; Fang, Y; Hu, T; Huang, X; Ji, L; Liu, T; Shen, X; Tang, W; Wang, Y; Weng, S; Wu, J; Xue, R; Zhang, S | 1 |
| Braeuning, A; Kirschnick, M; Muche, S; Schwarz, M | 1 |
| Dauch, D; Eilers, M; Geffers, R; Hohmeyer, A; Kang, TW; Laufer, S; Leibold, J; Longerich, T; Lowe, SW; Malek, NP; McJunkin, K; Pesic, M; Powers, S; Rudalska, R; Schirmacher, P; Sipos, B; von Thun, A; Weiss, KH; Wuestefeld, T; Zender, L; Zuber, J | 1 |
| Cheong, J; Jung, HU; Kim, HY; Park, BS; Yoo, KS; Yoo, SH; Yoo, YH; Yun, I | 1 |
| Dong, X; Jiang, X; Li, G; Li, J; Ma, L; Ni, S; Qiao, H; Sun, X; Zhao, D; Zhu, H | 1 |
| Jeong, KY; Lee, EJ; Seong, J; Yang, SH | 1 |
| Bonekamp, S; Corona-Villalobos, CP; Cosgrove, D; Geschwind, JF; Halappa, VG; Kamel, IR; Pawlik, TM; Reyes, D | 1 |
| Chiba, T; Kanai, F; Kanogawa, N; Motoyama, T; Ogasawara, S; Ooka, Y; Suzuki, E; Tawada, A; Yokosuka, O; Yoshikawa, M | 1 |
| Endo, M; Izumi, N; Joko, K; Nishikawa, H; Ogawa, C; Orito, E; Osaki, Y; Takeda, H; Taniguchi, H; Tsuchiya, K; Uchida, Y | 1 |
| Gores, GJ | 1 |
| Hsieh, SC; Hsieh, YH; Tang, MJ; Tsai, JP; Yang, SF | 1 |
| Hamilton, G; Rath, B | 1 |
| Koyanagi, T; Masumoto, A; Morita, Y; Motomura, K; Senju, T; Suzuki, H; Tajiri, H; Yada, M | 1 |
| Rupasinghe, HP; Sudan, S | 1 |
| Erlacher, M; Hertrampf, A; Herz, C; Kleinhans, C; Lamy, E; Mersch-Sundermann, V; Platz, S; Rohn, S; Schüler, J; Stetter, N; Wagner, M; Zimmermann, S | 1 |
| Bruix, J; Di Donato, R; Gazzola, A; Reig, M | 2 |
| Alencar, RS; Alvares-da-Silva, MR; Alves, VA; Campos, PB; Carrilho, FJ; Chagas, AL; Diniz, MA; Kikuchi, L; Oliveira, CP; Ratziu, V; Santos, GR; Stefano, JT; Tani, CM; Vezozzo, DC | 1 |
| Choi, GH; Han, S; Kang, YK; Kim, KM; Lee, HC; Lim, YS; Ryoo, BY; Ryu, MH; Shim, JH | 1 |
| Ahn, SH; Han, KH; Kim, BK; Kim, DY; Kim, HJ; Kim, JK; Kim, SU; Kweon, YO; Lee, HW; Lee, JI; Lee, KS; Lee, S; Park, JY; Park, SY; Tak, WY | 1 |
| Barroso-Sousa, R; Bento, Ada S; Blanco, BP; da Fonseca, LG; Hoff, PM; Pfiffer, TE; Sabbaga, J; Valente, GL | 1 |
| Fan, W; Huang, Y; Ke, S; Li, J; Ran, H; Wang, W; Wang, Y; Yang, J; Zhang, F; Zhang, Y | 1 |
| Choi, HJ; Heo, J; Hsieh, WS; Hsu, C; Jeffers, M; Kappeler, C; Krissel, H; Lim, HY; Lin, CY; Park, JW; Poon, RT; Rajagopalan, P; Rau, KM; Tak, WY; Tay, MH; Yen, CJ; Yeo, W; Yoon, JH | 1 |
| Ames, E; Borys, D; Canter, RJ; Chen, M; Grossenbacher, SK; Li, CS; Mac, S; Monjazeb, AM; Murphy, WJ; Sayers, TJ; Smith, RC; Tellez, J | 1 |
| Li, W; Li, XS; Pan, T; Wang, JP; Wu, PH; Xie, QK; Zhao, M | 1 |
| Albines, GS; Fernández-Molina, J; Fuentes-Martínez, N; Mesa, A; Pérez, R; Rodríguez, M; Varela, M | 1 |
| Chen, KF; Chiang, HC; Chu, PY; Hsu, CY; Huang, JW; Ko, CH; Li, YS; Lin, MW; Liu, CY; Shiau, CW; Su, JC; Tai, WT; Tseng, PH | 1 |
| Bie, P; Huan, HB; Lau, WY; Ma, KS; Xia, F | 1 |
| Binder, H; Elsäßer, A; Schmidtmann, I; Weinmann, A | 1 |
| Bolondi, L; Boni, C; Bruzzi, P; Cammà, C; Colombo, M; Craxi, A; Danesi, R; Daniele, B; Di Costanzo, GG; Fagiuoli, S; Santoro, A; Spandonaro, F; Trevisani, F | 1 |
| Li, H; Liang, Q; Liu, B; Ma, Y; Mei, X; Wang, Y | 1 |
| Arizumi, T; Chishina, H; Hagiwara, S; Inoue, T; Kitai, S; Kono, M; Kudo, M; Minami, Y; Nishida, N; Sakurai, T; Takita, M; Ueshima, K; Yada, N | 3 |
| Chen, WT; Jeng, WJ; Lin, CC; Lin, CY; Lin, SM; Sheen, IS | 1 |
| Chen, KF; Hung, MH; Shiau, CW; Tai, WT | 1 |
| Dou, K; Du, X; Feng, X; Guo, C; Jia, W; Liu, T; Ma, K; Qin, X; Wang, Z; Xu, J; Xu, R; Yang, S; Zhao, H | 1 |
| Bianco, V; Fiaschi, AI; Francini, E; Laera, L; Mazzaroppi, S; Pellicelli, AM; Petrioli, R; Pira, T; Roviello, G | 1 |
| He, C; Jiang, H; Jiang, X; Ma, L; Sun, X; Xu, L; Zhai, B; Zhao, D | 1 |
| Dill, MT; Djonov, V; Heim, MH; Hlushchuk, R; Makowska, Z; Quagliata, L; Rothweiler, S; Semela, D; Terracciano, L | 1 |
| Fujii, Y; Hatano, T; Horie, S; Kawata, N; Kimura, G; Kondo, T; Kume, H; Morita, M; Murakami, M; Nakajima, K; Nakazawa, H; Ohno, Y; Okegawa, T; Oya, M; Saito, K; Takahashi, S; Wakumoto, Y; Yamaguchi, R | 1 |
| Hiraoka, A; Ikeda, M; Izumi, N; Kadoya, M; Kudo, M; Matsui, O; Minami, T; Miyayama, S; Ogasawara, S; Okusaka, T; Tsuchiya, K; Ueshima, K; Yamakado, K; Yamashita, T | 1 |
| Seong, J; Yoon, HI | 1 |
| Kudo, M; Shimada, M; Tanaka, K | 1 |
| Bazzica, M; Di Gion, P; Fucile, C; Lantieri, F; Marenco, S; Marini, V; Martelli, A; Mattioli, F; Picciotto, A; Pieri, G; Robbiano, L; Savarino, V; Stura, P; Zuccoli, ML | 1 |
| Barbare, JC; Bouhlal, H; Chatelain, D; Chauffert, B; Debuysscher, V; François, C; Galmiche, A; Godin, C; Lachaier, E; Louandre, C; Marcq, I; Saidak, Z | 1 |
| Armeanu-Ebinger, S; Dewerth, A; Fuchs, J; Nagel, C; Warmann, SW | 1 |
| Cai, H; Kong, WT; Tang, Y; Wang, WP; Yuan, HX; Zhang, XL | 1 |
| Seino, S; Tsuchiya, A; Watanabe, M | 1 |
| Bresci, G; Caparello, C; Felder, M; Fornaro, L; Granito, A; Masi, G; Mismas, V; Musettini, G; Sacco, R; Vivaldi, C | 1 |
| Chao, CC; Lin, YT; Lu, HP | 1 |
| Dai, C; Jia, C; Peng, S; Xu, F; Xu, Y; Zhao, Y | 1 |
| Ackermann, K; Esposito, I; Galle, PR; Heikenwälder, M; Lang, H; Protzer, U; Puschnik, A; Schad, A; Schlitter, AM; Sprinzl, MF; Weinmann, A | 1 |
| Abdel-Rehim, M; Castéra, L; Chatellier, G; Lebtahi, R; Ronot, M; Sibert, A; Vilgrain, V | 1 |
| Gong, W; Liu, DJ; Liu, J; Sun, P; Xu, YT; Yu, GS; Zheng, SZ | 1 |
| Boucher, E; Brunot, A; Cattenoz, C; Crouzet, L; Edeline, J; Gédouin, D; Guillygomarc'h, A; Larible, C; Latournerie, M; Le Roy, F; Le Sourd, S | 1 |
| Chiba, T; Kanogawa, N; Kobayashi, K; Motoyama, T; Ogasawara, S; Ooka, Y; Saito, T; Suzuki, E; Tawada, A; Yokosuka, O | 1 |
| Narang-Master, J; Rizzolo, D | 1 |
| Cainap, C; Carlson, DM; Chen, PJ; Cheng, Y; Chung, IJ; El-Nowiem, S; Eskens, FA; Gorbunova, V; Huang, WT; Kang, YK; Kudo, M; McKee, MD; Pan, H; Qian, J; Qin, S; Ricker, JL; Toh, HC | 1 |
| Fukuda, H; Hidaka, H; Ishii, T; Kobayashi, S; Kondo, M; Maeda, S; Morimoto, M; Morita, S; Nakazawa, T; Nozaki, A; Numata, K; Ohkawa, S; Okuse, C; Sakamaki, K; Shibuya, A; Suzuki, M; Tanaka, K | 1 |
| Artaza Varasa, T; de la Cruz Pérez, G; Gómez Rodríguez, R; González de Frutos, C; Muñoz López, D; Romero Gutiérrez, M; Ruano Díaz, L; Sánchez Ruano, JJ | 1 |
| Fischer, K; Göke, B; Kolligs, FT; op den Winkel, M; Paprottka, PM; Rauch, B; Schmidt, L; Straub, G | 1 |
| Ikeda, M; Kuwahara, A; Mitsunaga, S; Ohno, I; Okusaka, T; Okuyama, H; Senda, S; Shimizu, S; Takahashi, H | 1 |
| Chen, J; Chen, S; Wu, B; Xi, W; Yu, H | 1 |
| Ahn, JM; Cho, JY; Choi, MS; Gwak, GY; Koh, KC; Lee, JH; Lim, HY; Paik, SW; Paik, YH; Sinn, DH; Sohn, W; Yoo, BC | 1 |
| Colombo, M; Sangiovanni, A | 3 |
| Bardeesy, N; Chen, Y; Duda, DG; Fan, C; Hato, T; Huang, P; Huang, Y; Jain, RK; Kitahara, S; Ng, MR; Ochiai, H; Ramjiawan, RR; Reddy, TP; Reiberger, T; Unan, EC; Zhu, AX | 1 |
| Fang, Q; Liu, S; Sun, J; Xu, H; Zhan, C; Zhang, S; Zhang, Y; Zhao, L | 1 |
| Bruix, J; Carrilho, FJ; Evans, TR; Jensen, M; Kang, YK; Leberre, MA; Llovet, JM; Meinhardt, G; Qin, S; Rosmorduc, O; Ross, PJ; Santoro, A; Thuluvath, PJ; Zhu, AX | 1 |
| Duan, F; Fan, QS; Fu, JX; Liu, FY; Wang, MQ; Zhang, L | 1 |
| Liu, C; Meng, FD; Pang, Q; Qu, K; Wang, ZX; Wei, JC; Wu, QF; Zhang, LQ | 1 |
| Boige, V; Ducreux, M; Ferté, C; Hollebecque, A; Malka, D | 1 |
| Ardizzoni, A; Campanini, N; Dal Bello, B; Fanello, S; Maria, SE; Missale, G; Negri, FV; Poggi, G; Porta, C; Rossi, S; Salvagni, S; Tinelli, C | 1 |
| Karakurt Eryılmaz, M; Kıvrak Salim, D; Musri, FY; Mutlu, H; Şenol Coşkun, H; Tural, D; Ünal, B | 1 |
| Albares, MP; Berbegal, L; Blanes, MM; de León, FJ | 1 |
| Chan, SY; Cheng, AL; Hsu, CH; Lu, LC; Shao, YY; Shau, WY | 1 |
| Andrade, R; Arenas, J; Bustamante, J; Castells, L; Díaz, R; Espinosa, MD; Fernández-Castroagudín, J; Gómez, M; Gonzálvez, ML; Granizo, IM; Hernandez-Guerra, M; Polo, BA; Rendón, P; Sala, M; Salgado, M; Serrano, T; Turnes, J; Vergara, M; Viudez, A | 1 |
| Choi, HJ; Han, J; Han, KH; Kim, GM; Lim, S | 1 |
| Chung, YH; Jung, J; Kang, YK; Kim, GA; Kim, JH; Kim, KM; Lee, D; Lee, HC; Lee, YS; Lim, YS; Ryoo, BY; Ryu, MH; Shim, JH; Yoon, SM | 1 |
| Chan, JK; Chung, AY; Endaya, BB; Gnecchi, M; Ho, IA; Hui, KM; Huynh, H; Iyer, NG; Lam, PY; Leong, HS; Lim, KH; Newman, JP; Sia, KC; Toh, XY; Yulyana, Y | 1 |
| Colquhoun, S; Hata, K; Hoon, DS; Hoshino, H; Huang, SK; Iida, Y; Ohta, K; Ono, S; Wang, J | 1 |
| Chen, M; Gao, H; Huang, J; Li, S; Wang, H; Xu, L; Zhang, Y; Zhou, Z | 1 |
| Kong, D; Li, Q; Ma, W; Song, T; Wei, K; Wu, Q; Zhang, Q; Zhang, T; Zhang, W; Zhao, G | 2 |
| Belli, L; Cabibbo, G; Cammà, C; Enea, M; Galvano, A; Mancuso, A; Mazzola, A; Perricone, G; Zavaglia, C | 1 |
| Coy, DH; Sun, G; Sun, L; Yu, Y | 1 |
| Hsia, CY; Hsu, CY; Huang, YH; Huo, TI; Lee, RC; Lee, YH; Lin, HC; Liu, PH; Su, CW | 1 |
| Barbara, M; Basso, M; Biolato, M; Cabibbo, G; Cammà, C; Colombo, M; Craxì, A; Della Corte, C; Grieco, A; Iavarone, M; Maida, M; Vavassori, S | 1 |
| Chen, CY; Chen, SC; Feng, CW; Feng, YM; Lee, MY; Lu, CL | 1 |
| Feng, X; Hu, Y; Liu, A; Liu, D; Peng, J | 1 |
| Li, CS; Liu, QY; Qi, HL; Zhuang, BJ | 1 |
| Aguilar, G; Chan, YC; Chen, CL; Kabiling, CS; Pillai, VG; Wang, CC | 1 |
| Bai, Y; Guo, X; Kang, H; Lu, L; Lu, M; Qu, Z; Ren, Z; Shi, L; Song, T; Wang, H; Wang, X; Yang, W; Yang, Y; Ye, SL; Zhou, W; Zhu, K | 1 |
| Liu, J; Zhang, B; Zhang, X; Zhou, T | 1 |
| Bi, F; Hao, P; Li, J; Li, Q; Wen, F; Xia, F; Yan, W; Yang, Y; Zhang, P | 1 |
| Boucher, E; Boudjema, K; Breton, M; Clement, B; Edeline, J; Garin, E; Icard, N; Laffont, S; Lenoir, L; Mesbah, H; Raoul, JL; Rohou, T; Rolland, Y; Sulpice, L | 1 |
| Rupasinghe, HV; Sudan, S | 1 |
| Kirstein, MM; Klöpper, A; Lehmann, U; Manns, MP; Ringe, KI; Schmidt, S; Schweitzer, N; Vogel, A; Wedemeyer, H | 1 |
| Ishijima, N; Kanki, K; Shimizu, H; Shiota, G | 1 |
| Han, M; Jing, Y; Kan, X; Liu, KH; Pan, JC; Wan, QY; Wang, Q; Yang, Y; Zhu, M | 1 |
| Fu, Q; Liu, J; Liu, Y; Ouyang, H; Qiao, K; Shen, Z; Tao, S; Wang, W; Wu, J; Wu, Y; Xie, Y; Yang, X; Ye, X; Zhang, J; Zhang, JB | 1 |
| Ali, LA; Elmashad, N; Elmashad, W; Farouk, M; Ibrahim, WS; Mayah, WW; Taha, A | 1 |
| Duan, Z; Hertzanu, Y; Hu, H; Liu, S; Long, X; Shi, H; Tong, X; Xu, X; Yang, Z | 1 |
| Cen, J; He, X; Hu, C; Hui, L; Li, C; Li, Y; Mu, W; Qiu, Z; Qu, Z; Ren, H; Shi, X; Zhang, H | 1 |
| Bellentani, S; Biasco, G; Brandi, G; De Lorenzo, S; Di Girolamo, S; Saccoccio, G | 1 |
| Li, K; Liu, Y; Ma, N; Qiao, L; Wang, F; Wang, J; Xu, S; Yue, H | 1 |
| An, L; Chen, Y; Feng, F; Gao, X; Lu, Y; Qu, J; Sun, H; Wang, C; Wang, F; Yang, Y; Zeng, Z; Zhang, C | 1 |
| Jin, Y; Lin, L; Lin, Y; Tan, Y; Wang, D; Zhang, Y; Zheng, C | 1 |
| Doi, Y; Kikkawa, H; Kitayama, T; Nakaba, H; Oguchi, Y; Sasaki, M; Tamagawa, H; Taniguchi, E; Watanabe, Y | 1 |
| Hosoda, Y; Kakita, N; Kim, Y; Nagai, K; Nishino, M; Okano, M; Tsujinaka, T; Yamada, Y; Yamasaki, M; Yasui, M | 1 |
| Lee, HW; Park, JG; Park, SY | 1 |
| Barbare, JC; Barget, N; Bodeau, S; Chauffert, B; Conte, MA; Diouf, M; Galmiche, A; Ganne, N; Godin, C; Louandre, C; Saidak, Z; Trinchet, JC | 1 |
| Colao, A; Faggiano, A; Marotta, V | 1 |
| Addario, L; Caporaso, N; Cordone, G; de Stefano, G; Di Costanzo, GG; Farella, N; Imparato, M; Lampasi, F; Lanza, AG; Tortora, R | 1 |
| Arias, A; Catania, VA; Ceballos, MP; Ciriaci, N; Ghanem, CI; Luquita, MG; Mottino, AD; Rigalli, JP; Ruiz, ML; Villanueva, SS | 1 |
| Kawai, K; Minemura, M; Nakajima, T; Sugiyama, T; Tajiri, K | 1 |
| Bussom, S; Cheng, YC; Guan, F; Hu, R; Huang, X; Jiang, Z; Lam, W; Liu, SH; Wang, J; Yen, Y; Zhao, H | 1 |
| Hoshida, Y; Kishikawa, T; Koike, K; Kojima, K; Kondo, Y; Noyama, T; Ohishi, M; Ohno, M; Ota, S; Otsuka, M; Sato, M; Shibata, C; Soga, T; Sun, X; Takata, A; Takehana, K; Tan, PS; Yoshikawa, T | 1 |
| Delire, B; Stärkel, P | 1 |
| Azuma, K; Esaki, M; Kitazono, T; Matsumoto, T; Nakamura, S; Ooho, A; Yanai, S | 1 |
| Kim, YH; Lee, EW; Quirk, M; Saab, S | 1 |
| Choi, SJ; Gu, HR; Han, CJ; Jeong, JH; Kim, J; Kim, YC; Kim, YJ; Lee, JC; No, SH; Noh, GY; Park, SC; Yang, KY | 1 |
| Choi, HS; Hahm, JS; Jun, DW; Kim, JO; Lee, HL; Lee, KN; Lee, OY; Tae, HJ; Yoon, BC | 1 |
| de Man, RA; Ijzermans, JN; Klümpen, HJ; Schrier, JG; van der Geest, LG; van Erpecum, KJ; van Meer, S | 1 |
| Chow, LP; Feng, WC; Ho, WC; Hsu, CH; Shao, YY; Tsai, MH; Yeh, CC | 1 |
| Chao, Y; Chen, YT; Huang, YH; Huo, TI; Lee, FY; Lee, IC; Li, CP; Lin, HC; Su, CW | 1 |
| Chiba, T; Kanai, F; Kanogawa, N; Motoyama, T; Ogasawara, S; Ooka, Y; Saito, T; Suzuki, E; Tawada, A; Yokosuka, O | 3 |
| Benevento, F; Bolondi, L; Granito, A; Marinelli, S; Piscaglia, F; Renzulli, M; Terzi, E; Venerandi, L | 1 |
| Ha, TY; Hong, HN; Hwang, S; Kim, N; Moon, KM; Ryoo, BY; Song, GW; Tak, E; Won, YJ | 1 |
| Choi, YI; Ha, TY; Hong, HN; Hwang, S; Kim, N; Ryoo, BY; Song, GW; Tak, E; Won, YJ; Yoon, SY | 1 |
| Higai, K; Igarashi, Y; Matsui, D; Matsui, T; Momiyama, K; Mukozu, T; Nagai, H; Ogino, YU; Sumino, Y; Wakui, N | 1 |
| Chen, C; Cheng, Z; Cong, WM; Ding, J; Feng, GS; Han, T; Li, HY; Liu, N; Shen, WF; Sun, HL; Sun, W; Wang, HY; Wang, RY; Wang, X; Wen, W; Wu, MC; Xiang, DM | 1 |
| Abbattista, MR; Gu, Y; Guise, CP; Jamieson, SM; Nickel, JE; Patterson, AV; Pullen, SM; Wilson, WR | 1 |
| Bruckner, T; Ganten, MK; Ganten, TM; Koschny, R; Schuessler, M | 1 |
| Abei, M; Danjoh, I; Hyodo, I; Nakamura, Y; Shirota, R; Yamada, T; Yamashita, T | 1 |
| Chae, HB; Kang, HY; Kang, YW; Kim, AN; Kim, HS; Kim, SB; Kim, SH; Ko, SY; Lee, BS; Lee, ES; Lee, HY; Lee, JD; Lee, SH; Lee, TH; Noh, R; Song, IH | 1 |
| Dong, M; Kong, FM; Li, YJ; Zhou, JP | 1 |
| Abe, Y; Aiura, K; Ei, S; Hibi, T; Itano, O; Kishida, N; Kitagawa, Y; Kitago, M; Masugi, Y; Sakamaoto, M; Shinoda, M; Tanabe, M; Tanimoto, A; Ueno, A; Yagi, H | 1 |
| de Stefano, G; Farella, N; Iodice, V | 1 |
| Dou, H; Feng, K; Jiang, X; Li, Z; Wang, T; Zhang, Y; Zhou, F | 1 |
| Cho, M; Choi, CW; Heo, J; Hong, YM; Kang, DH; Kim, HW; Lim, W; Park, SB; Woo, HY; Yoon, KT | 2 |
| Chen, Y; Ding, J; Ding, R; Dou, K; Gao, Y; Guo, X; Liu, D; Lv, X; Ruan, B; Zhou, T | 1 |
| Cheng, BY; Ching, RH; Lau, EY; Lee, TK; Lo, J; Ma, MK; Ng, IO | 1 |
| Chen, E; Kerbel, RS; Kuczynski, EA; Lee, CR; Man, S | 1 |
| Barone, M; Carr, BI; Di Leo, A; Facciorusso, A; Licinio, R | 1 |
| Du, Z; He, X; Li, Q; Tang, R; Wen, F; Yang, Y; Zhang, J; Zhang, P; Zhou, J | 1 |
| Kalyan, A; Kulik, L; Nimeiri, H | 1 |
| Cho, JY; Choi, MS; Gwak, GY; Koh, KC; Lee, JH; Paik, SW; Paik, YH; Sinn, DH; Yoo, BC | 1 |
| Hanai, T; Ideta, T; Imai, K; Kochi, T; Miyazaki, T; Shimizu, M; Shiraki, M; Suetsugu, A; Takai, K | 1 |
| Bos, MM; De Santis, M; Eichelberg, C; Fischer von Weikersthal, L; Flörcken, A; Freier, W; Goebell, PJ; Gottstein, D; Hauswald, K; Indorf, M; Lerchenmüller, C; Los, M; Michel, MS; Pahernik, S; Schenck, M; Schirrmacher-Memmel, S; Staehler, M; van Arkel, C; Vervenne, WL; Zimmermann, U | 1 |
| Büchler, MW; Ganten, T; Gotthardtp, D; Hoffmann, K; Jäger, D; Karapanagiotou-Schenkel, I; Kollmar, O; Nadalin, S; Radeleff, B; Schemmer, P; Settmacher, U; von Kalle, C | 1 |
| Bhak, J; Hong, SH; Hwang, JA; Kim, BC; Kim, BH; Kim, JS; Lee, JA; Lee, SH; Lee, YS; Nam, S; Park, JW; Shin, A | 1 |
| Labgaa, I; Villanueva, A | 1 |
| Chan, SY; Cheng, AL; Hsu, CH; Huang, CY; Lin, TH; Shao, YY | 1 |
| Ku, CY; Lin, HY; Lin, JY; Lu, SC; Wang, YR | 1 |
| Chapiro, J; Duran, R; Geschwind, JF; Schernthaner, RE | 1 |
| Hu, X; Li, Q; Li, Y; Liang, R; Liao, S; Liao, X; Lin, Y; Liu, Z; Lv, Y; Yuan, C; Zhang, J | 1 |
| Amoroso, D; Angelico, M; Attili, A; Barni, S; Benedetti, A; Buonadonna, A; Burlone, ME; Calvani, N; Cascinu, S; Cengarle, R; Cillo, U; Crocè, LS; Cuttone, F; D'Angelo, S; Di Costanzo, F; Erminero, C; Fava, G; Gasbarrini, A; Germano, D; Giannitrapani, L; Giovanis, P; Lencioni, R; Lorusso, V; Magini, G; Marenco, S; Marignani, M; Massa, E; Montesarchio, V; Noto, A; Palmieri, V; Picardi, A; Poggi, G; Proserpio, I; Saitta, C; Sansonno, D; Tumulo, S; Villa, E; Zolfino, T | 1 |
| Altomonte, J; Braren, R; Dworniczak, J; Ebert, O; Esposito, I; Feuchtinger, A; Groß, C; Heid, I; Heß, J; Rummeny, E; Sayyed, S; Schlitter, AM; Schwaiger, M; Settles, M; Steiger, K; Steingötter, A; Unger, K; Walch, A; Zitzelsberger, H | 1 |
| Baba, H; Beppu, T; Chikamoto, A; Hayashi, H; Imai, K; Ishiko, T; Nakamura, K; Nitta, H; Okabe, H; Sasaki, M | 1 |
| Chen, J; Harris, KR; Kim, DH; Larson, AC; Lewandowski, RJ; Li, W; Shea, LD; White, SB; Yap, JW | 1 |
| Huang, A; Shi, Y | 1 |
| Bao, J; Che, S; Hao, C; Li, Z; Liu, J; Qian, Z; Shang, H; Wang, H; Zhang, H; Zhang, X; Zhao, H | 1 |
| Calucci, L; Cappello, V; Ciofani, G; de Julian Fernandez, C; Forte, C; Gemmi, M; Grillone, A; Innocenti, C; Mattoli, V; Mondini, A; Moscato, S; Riva, ER; Ronca, F; Sacco, R | 1 |
| Fujie, S; Fukubayashi, K; Izumi, K; Kawasaki, T; Kikuchi, K; Naoe, H; Sasaki, Y; Setoyama, H; Tanaka, M; Tateyama, M; Watanabe, T; Yoshimaru, Y | 1 |
| Jia, B; Jin, Z; Liu, K; Liu, S; Liu, Y; Tan, L; Zhang, W | 1 |
| Li, S; Liu, R; Liu, Y; Shen, H; Wang, P; Yin, L | 1 |
| Izumi, N; Joko, K; Nishijima, N; Nishio, K; Orito, E; Osaki, Y; Sakai, K; Takeda, H; Uchida, Y | 1 |
| Albuquerque, M; Benhadji, KA; de Gramont, A; Dos Santos, C; Faivre, S; Neuzillet, C; Paradis, V; Raymond, E; Serova, M; Tijeras-Raballand, A | 1 |
| Cosgrove, DP; Feng, AL; Geschwind, JF; Kamel, IR; Pawlik, TM; Reyes, DK | 1 |
| Austin, T; Beckman, RA; Cheng, AL; Greenberg, J; He, AR; Hung, CH; Izumi, N; Kang, YK; Kudo, M; Lim, HY; Ryoo, BY; Sheen, IS; Shiratori, S; Wang, Q | 1 |
| Guo, XL; Li, WB; Lu, YY; Wang, JJ; Zhang, XK | 1 |
| Guo, WH; Lu, J; Wang, XZ; Zhang, JX; Zheng, JF | 1 |
| Fan, W; Fu, S; Huang, J; Huang, Y; Li, J; Lu, L; Wang, Y; Yang, J; Yao, W; Zhang, Y; Zhu, K | 1 |
| Abada, PB; Baron, AD; Blanc, JF; Chang, SC; Chau, I; Chung, HC; Kubackova, K; Kudo, M; Okusaka, T; Park, JO; Pastorelli, D; Pfiffer, TE; Poon, R; Ryoo, BY; Sastre, J; Schwartz, JD; Trojan, J; Yang, L; Yen, CJ; Zhu, AX | 1 |
| Trojan, J; Waidmann, O | 1 |
| Chen, MS; Li, SP; Pawlik, TM; Spolverato, G; Xu, L; Zhang, YJ; Zhao, J; Zhou, DS | 1 |
| Aikata, H; Chayama, K; Fukuhara, T; Hatooka, M; Hiramatsu, A; Hyogo, H; Imamura, M; Kawakami, Y; Kawaoka, T; Kobayashi, T; Kohno, H; Miyaki, D; Morio, K; Morio, R; Moriya, T; Naeshiro, N; Takahashi, S; Tsuji, K; Waki, K | 1 |
| Huang, YH; Siao, FY; Yen, HH | 1 |
| Azmi, AN; Chan, WK; Goh, KL | 1 |
| Aedo, V; Cristina, V; Faivre, S; Raymond, E | 1 |
| Heo, J; Woo, HY | 2 |
| Igarashi, Y; Ikehara, T; Ishii, K; Kikuchi, Y; Kogame, M; Makino, H; Matsui, T; Nagai, H; Okano, N; Shiozawa, K; Sumino, Y; Watanabe, M | 1 |
| Bu, W; Chen, H; Cong, N; Li, J; Shi, C; Song, J; Wang, L | 1 |
| Bodoky, G; Bronowicki, JP; Croitoru, A; Daniele, B; Mathurin, P; Papandreou, C; Ratziu, V; Serejo, F; Stål, P; Turnes, J | 1 |
| He, D; Liu, R; Lu, X; Sun, C; Tang, C; Wei, X; Wu, Z; Zheng, D; Zhou, M | 1 |
| Abbate, I; Brandi, M; De Rose, F; Divella, R; Ferraro, E; Filippelli, G; Gadaleta-Caldarola, G; Infusino, S; Mazzocca, A | 1 |
| Heikenwalder, M; O'Connor, T; Weber, A | 1 |
| Cai, X; Chen, J; Huang, D; Jin, R; Liang, X; Liang, Y; Lin, H; Liu, J; Yan, H; Ying, H; Yu, H; Zhao, J; Zhou, S | 1 |
| Cheng, AL; Fan, HH; Feng, ZR; Hsu, C; Lee, BS; Lin, LI; Liou, JY; Ou, DL; Shyue, SK | 1 |
| Chen, L; Liang, S; Liu, J; Shao, H; Su, H; Xu, K | 1 |
| Bettinger, D; Brunner, TB; Neeff, HP; Schultheiß, M; Thimme, R | 1 |
| Albiges, L; Escudier, B | 1 |
| Chun, HG; Chun, HJ; Hong, SH; Hwang, SW; Jung, ES; Lee, JE; Lee, JM; Lee, MA; Lee, SH | 1 |
| Hijikawa, T; Ishizaki, M; Kaibori, M; Kitade, H; Kon, M; Matsui, K; Yamada, M; Yanagida, H; Yokoigawa, N; Yoshioka, K | 1 |
| Llovet, JM; Torrecilla, S | 1 |
| Chen, DS; Chen, KF; Chen, PJ; Lin, WH; Shiau, CW; Teng, YC; Tsai, TF; Wang, SH; Yeh, SH | 1 |
| Costentin, C; Decaens, T; Diao, G; Duvoux, C; Katsahian, S; Laurent, A; Luciani, A; Mallat, A; Nault, JC; Nelson, AC; Pigneur, F; Tselikas, L | 1 |
| Angarano, G; Brunetti, O; Faloppi, L; Gnoni, A; Guarini, A; Licchetta, A; Lorusso, V; Lupo, L; Memeo, V; Palasciano, G; Palmieri, V; Pisconti, S; Russo, A; Santini, D; Scartozzi, M; Silvestris, N | 1 |
| Chang, CC; Chen, Y; Chiang, WH; Gao, DY; Lin, TsT; Liu, JY; Liu, YC; Sung, YC | 1 |
| Berretta, M; Di Francia, R; Tirelli, U | 1 |
| Arencibia, JM; Augusto, EA; Groner, B; Ibrahim, AA; Kakoschky, B; Köberle, V; Korf, HW; Korkusuz, H; Kronenberger, B; Piiper, A; Pleli, T; Schmithals, C; Vafaizadeh, V; Vogl, TJ; Waidmann, O; Zeuzem, S | 1 |
| Fujimoto, Y; Hatano, E; Kaido, T; Kitajima, T; Minamiguchi, S; Mitsunori, Y; Mizumoto, M; Okajima, H; Taura, K; Uemoto, S | 1 |
| Dong, X; Li, J; Li, T; Liu, F; Wang, F; Wang, X; Wang, Y; Wei, H; Xiu, P; Xu, Z; Zhong, J | 1 |
| Kim, JK; Seo, MS; Shim, JY | 1 |
| Bao, WD; Chen, TW; Cheng, SQ; Deng, YZ; Feng, YY; Guan, DX; Koeffler, HP; Li, JJ; Long, LY; Qiu, L; Shi, J; Xie, D; Zhang, EB; Zhang, XL; Zhang, Y; Zhao, JS | 1 |
| Abbate, I; Brandi, M; Daniele, A; Divella, R; Ferraro, E; Filippelli, G; Gadaleta-Caldarola, G; Infusino, S; Mazzocca, A; Sabbà, C | 1 |
| Antonucci, M; Bargellini, I; Cabibbo, G; Marceglia, S; Mismas, V; Sacco, R | 1 |
| Chen, Y; Chern, GG; Chiang, T; Gao, DY; Lin, TT; Liu, CH; Liu, JY | 1 |
| Abastado, JP; Chew, V; Ho, V; Kaldis, P; Lee, J; Lim, TS; Steinberg, J; Szmyd, R; Tham, M; Yaligar, J | 1 |
| Fu, Y; Sima, H; Yang, G; Yang, N; Zhang, H; Zhu, N | 1 |
| Dong, D; Dong, X; He, C; Jiang, H; Jiang, X; Li, B; Sun, X; Xu, S; Zhai, B | 1 |
| Choi, HG; Choi, JY; Gupta, B; Hiep, TT; Kim, JO; Pathak, S; Poudel, BK; Thapa, RK; Yong, CS | 1 |
| Igarashi, Y; Ikehara, T; Kikuchi, Y; Kogame, M; Matsukiyo, Y; Okano, N; Shiozawa, K; Sumino, Y; Watanabe, M | 1 |
| Chen, L; Chen, T; Cui, Y; Fang, T; Ge, C; Jiang, G; Li, H; Li, J; Li, M; Liu, J; Tian, H; Xie, H; Yao, M; Zhang, L | 1 |
| Guo, W; Li, J; Qiu, X; Yan, B; Zhang, S | 1 |
| Finn, RS | 4 |
| Gish, RG | 1 |
| Gholam, P | 1 |
| Bose, SK; Di Bisceglie, AM; Kwon, YC; Meyer, K; Ray, R; Ray, RB; Steele, R | 1 |
| Chua, MS; Lu, WJ; So, SK; Wei, W | 1 |
| Berre, MA; Bolondi, L; Bruix, J; Cai, J; Chau, GY; Han, KH; Kudo, M; Lee, HC; Lee, KS; Llovet, JM; Makuuchi, M; Mazzaferro, V; Meinhardt, G; Poon, RT; Roayaie, S; Song, T; Souza, F; Tak, WY; Takayama, T; Yang, J | 1 |
| Choi, BI; Choi, WS; Han, JK; Kim, J; Kim, JH; Kim, YJ; Yoon, SH | 1 |
| Fang, T; Hu, F; Jin, X; Pan, S; Sun, X; Xu, L; Yan, H; Zhai, B; Zhao, D | 1 |
| Fukunaga, K; Iwasaki, K; Kohno, K; Kurokawa, T; Murata, S; Ohkohchi, N; Zheng, YW | 1 |
| Cabibbo, G; Cammà, C; Maida, M; Petta, S | 1 |
| Cheng, AL; Hsu, CH; Shao, YY | 1 |
| Goto, H; Hayashi, K; Hirooka, Y; Honda, T; Ishigami, M; Ishikawa, T; Ishizu, Y; Katano, Y; Kuzuya, T; Nakano, I | 1 |
| Ito, D; Kawanishi, K; Kojima, K; Ohki, T; Sato, K; Seki, M; Tagawa, K; Toda, N; Yamada, T; Yamagami, M | 1 |
| Fan, W; Fu, S; Huang, Y; Li, J; Lu, L; Wang, Y; Yang, J; Yao, W; Zhang, Y | 1 |
| Dorsch-Vogel, K; Gabrielson, A; He, AR; Jha, R; Marshall, JL; Pishvaian, MJ; Smaglo, B; Tesfaye, AA; Wang, H | 1 |
| Adhoute, X; Blanc, JF; Boucher, E; Boudjema, K; Campillo-Gimenez, B; Clément, B; Crouzet, L; Edeline, J; Garin, E; Guillygomarc'h, A; Lenoir, L; Pracht, M; Rohou, T; Rolland, Y | 1 |
| Kanda, M; Kodera, Y; Sugimoto, H | 1 |
| Ekser, B; Fridell, JA; Klingler, KR; Kubal, CA; Maluccio, MA; Mangus, RS; Nagai, S; Tector, AJ | 1 |
| Heaton, N; Karani, J; Peddu, P; Quaglia, A; Satyadas, T; Sharma, R; Suddle, A | 1 |
| Chubachi, S; Nakagawa, T | 1 |
| Ajiki, T; Fukumoto, T; Fukushima, K; Gon, H; Kido, M; Kinoshita, H; Ku, Y; Kuramitsu, K; Matsumoto, I; Shinzeki, M; So, S; Takebe, A; Tanaka, M; Urade, T | 1 |
| Aino, H; Iwamoto, H; Koga, H; Kuromatsu, R; Nagamatsu, H; Nakano, M; Niizeki, T; Okamura, S; Satani, M; Shimose, S; Shirono, T; Tajiri, N; Tanaka, M; Torimura, T | 1 |
| Chen, L; Sun, J; Yang, X | 1 |
| Cao, G; Li, J; Li, X; Qin, C | 1 |
| Hisamichi, K; Jin, Y; Kataoka, Y; Kondo, Y; Maejima, T; Maekawa, M; Mano, N; Matsuura, M; Mori, M; Okawa, H; Shimada, M; Shimosegawa, T; Suzuki, H | 1 |
| Carr, BI; D'Alessandro, R; Messa, C; Refolo, MG | 1 |
| Anders, RA; Fan, J; Gao, YB; Hu, B; Maitra, A; Sun, C; Sun, D; Sun, HX; Sun, YF; Tang, WG; Xu, Y; Yang, XR; Zhu, QF | 1 |
| Kitano, M; Kudo, M; Nishida, N; Sakurai, T | 1 |
| Arizumi, T; Chishina, H; Hagiwara, S; Ida, H; Inoue, T; Iwanishi, M; Kitai, S; Kitano, M; Kono, M; Kudo, M; Minami, Y; Nishida, N; Sakurai, T; Takita, M; Ueshima, K; Yada, N | 1 |
| Azoulay, D; Carra, MC; de'Angelis, N; Landi, F | 1 |
| Zhong, JH | 1 |
| Hidaka, H; Kobayashi, S; Koizumi, W; Kondo, M; Matsunaga, K; Morimoto, M; Nakazawa, T; Numata, K; Ohkawa, S; Okuse, C; Takada, J; Tanaka, K | 1 |
| Brunetti, O; Casadei Gardini, A; Cascinu, S; Faloppi, L; Foschi, FG; Frassineti, GL; Marisi, G; Masi, G; Nanni, O; Ricca Rosellini, S; Scarpi, E; Scartozzi, M; Silvestris, N; Tamberi, S; Tamburini, E; Tenti, E; Ulivi, P; Vivaldi, C | 1 |
| Chen, Z; Liu, Y; Lou, G; Song, X; Wang, J; Wu, S; Yang, F | 1 |
| Alkhatib, A; Allam, N; Gomaa, A; Rewisha, E; Waked, I | 1 |
| Chao, CC; Lin, YT | 1 |
| Park, JG | 1 |
| Chen, L; Ge, N; Li, J; Liu, H; Qian, H; Shi, L; Sun, B; Wu, M; Yang, X; Yang, Y; Yin, Z; Zhang, X | 1 |
| Barbare, JC; Bochereau, F; Chauffert, B; Degonville, J; Drullion, C; Fournier, E; François, C; Galmiche, A; Gicquel, A; Godin, C; Houessinon, A; Louandre, C; Nyga, R; Pluquet, O; Saidak, Z | 1 |
| Adjibade, P; Coudert, L; Fournier, MJ; Khandjian, EW; Mazroui, R; Quevillon Huberdeau, M; Savard, A; St-Sauveur, VG | 1 |
| George, J; Hebbard, L; Qiao, L; Wilson, G; Wu, G; Zhou, G | 1 |
| Gao, JJ; Inagaki, Y; Shi, ZY; Tang, W; Xia, JF | 1 |
| Chen, L; Ge, C; Li, H; Li, J; Li, M; Liu, J; Tian, H; Wang, T; Yao, M; Zhang, L; Zhao, F | 1 |
| Cheng, AL; Cheng, YC; Feng, ZR; Hsu, C; Lin, LI; Ou, DL; Shao, YY | 1 |
| Chen, J; Jia, H; Lu, L; Lu, M; Pei, Y; Qin, L; Zhu, W | 1 |
| Chen, L; Dong, S; Gao, J; Ji, L; Kong, F; Kong, J; Pan, B; Sun, W; Zheng, L | 1 |
| BelHadj, N; Ben Nejma, H; Bougassas, W; Cheikh, M; Elleuch, N; Ennaifer, R; Hefaiedh, R; Romdhane, H | 1 |
| Grieco, A; Mazzoccoli, G; Miele, L; Oben, J; Vinciguerra, M | 1 |
| Huang, J; Liu, L; Luo, Y; Ma, L; Qian, C; Shan, J; Shen, J; Xu, Y; Yang, Z; Yao, C | 1 |
| Alsinet, C; Cabellos, L; Cornella, H; Desbois-Mouthon, C; Domingo-Domenech, J; Hoshida, Y; Llovet, JM; Lozano, JJ; Martinez-Quetglas, I; Moeini, A; Peix, J; Sia, D; Solé, M; Torrecilla, S; Tovar, V; Vidal, S; Villanueva, A | 1 |
| Abou-Alfa, GK; Ang, C; Gamblin, TC; Gatalica, Z; He, R; Millis, SZ; Miura, JT; Reddy, SK; Xiu, J; Yee, NS | 1 |
| Bai, XL; Chen, ZL; Fu, QH; Li, GG; Liang, TB; Lou, Y; Sun, X; Zhang, JY; Zhang, Q | 1 |
| Ali, FR; Griffiths, CE; Yiu, ZZ | 1 |
| Chang, MJ; Chao, TI; Chen, KF; Chen, MH; Hung, MH; Shiau, CW; Tai, WT; Tsai, MH | 1 |
| Adhoute, X; Bayle, O; Beaurain, P; Blanc, JF; Bourlière, M; Bronowicki, JP; Castellani, P; Conroy, G; Edeline, J; Monnet, O; Muller, C; Pénaranda, G; Perrier, H; Pol, B; Raoul, JL | 1 |
| Axelrod, JH; Divon, MS; Galun, E; Lanton, T; Peretz, T; Salmon, A; Sonnenblick, A; Zahavi, T | 1 |
| Arai, T; Atsukawa, M; Itokawa, N; Iwakiri, K; Kondo, C; Nakagawa, A; Okubo, T; Tsubota, A | 1 |
| Bhoori, S; Bongini, M; Facciorusso, A; Flores, M; Gasbarrini, A; Germini, A; Mazzaferro, V; Ponziani, FR; Sposito, C | 1 |
| Cao, L; Chen, L; Ge, N; Li, J; Qian, H; Sun, B; Yin, Z; Zhai, B; Zhang, X; Zhao, L | 1 |
| Jian, C; Pei-hua, L; Xiao-chun, Y; Xu, L; Yuan-run, Z | 1 |
| Ayav, A; Bronowicki, JP; Claudon, M; Gavanier, M; Laurent, V; Orry, X; Sellal, C | 1 |
| Bie, P; Chen, X; Chen, Y; Deng, X; Dou, K; Fu, Z; Hao, C; Liu, F; Liu, L; Liu, Y; Lu, Z; Nakajima, K; Shao, G; Xia, Q; Yang, J; Ye, SL; Yip, CS; Yuan, Y; Zhang, S; Zhou, J | 1 |
| Bronowicki, JP; Chen, XP; Dagher, L; Furuse, J; Geschwind, JF; Heldner, S; Kudo, M; Ladrón de Guevara, L; Lehr, R; Lencioni, R; Marrero, JA; Nakajima, K; Papandreou, C; Sanyal, AJ; Takayama, T; Venook, AP; Ye, SL; Yoon, SK | 2 |
| Mikagi, K; Ryu, T; Saitsu, H; Takami, Y; Tateishi, M; Wada, Y | 1 |
| Mokdad, AA; Singal, AG; Yopp, AC | 1 |
| Cao, M; Cui, Y; Fang, F; Gao, J; Guo, Z; Li, H; Li, Q; Song, T; Sun, H; You, A; Zhang, T; Zhang, W; Zhou, H; Zhu, X | 1 |
| Gwon, DI; Han, K; Kim, JH; Ko, GY; Sung, KB | 1 |
| Chun, G; Dua, S; Hiensch, R; Meinhof, K; Nandedkar, D | 1 |
| Fujimoto, S; Kimura, T; Miyamoto, H; Muguruma, N; Okamoto, K; Takayama, T; Takeishi, S; Tanaka, H; Tanaka, T; Taniguchi, T; Tomonari, T | 1 |
| Adametz, D; Boldanova, T; Colombi, M; Dazert, E; Hall, MN; Heim, MH; Jenoe, P; Moes, S; Quagliata, L; Roth, V; Terracciano, L | 1 |
| Atabey, N; Erdal, E; Firtina Karagonlar, Z; Iscan, E; Koc, D | 1 |
| Bazin, I; Bondarenko, I; Ciuleanu, T; Deptala, A; Ding, M; Egger, J; Fox, NL; Giantonio, B; Gribbin, M; Humphreys, R; Kalyani, RN; Lungulescu, D; Miron, L; Rodriguez-Torres, M; Sun, W; Wissel, P | 1 |
| Kakisaka, T; Kamachi, H; Kamiyama, T; Orimo, T; Shimada, S; Taketomi, A; Tsuruga, Y; Wakayama, K; Yokoo, H | 1 |
| Matoba, H; Seta, S | 1 |
| Asaoka, T; Doki, Y; Eguchi, H; Kawamoto, K; Marubashi, S; Mori, M; Mukai, Y; Nagano, H; Tomimaru, Y; Tomokuni, A; Umeshita, K; Wada, H | 1 |
| Deguchi, S; Inoue, T; Kanazawa, A; Murata, A; Nakajima, T; Nishiguchi, Y; Sakae, M; Shimizu, S; Tachimori, A; Tamamori, Y; Tsukamoto, T; Yamamoto, A; Yamamoto, S; Yamashita, Y | 1 |
| Deguchi, S; Kanazawa, A; Kawasaki, Y; Kioka, K; Kurihara, S; Murata, A; Nakai, T; Sakae, M; Shimizu, S; Tashima, T; Tsukamoto, T | 1 |
| Bruix, J; Chau, GY; Del Arbol, LR; Guglielmi, A; Han, G; Kim, DY; Leberre, MA; Lencioni, R; Llovet, JM; Luca, A; Meinhardt, G; Nicholson, K; Niu, W; Paik, SW; Reig, M; Tak, WY; Yang, J | 1 |
| Cai, Z; Chiu, DK; Koh, HY; Lai, RK; Law, CT; Lin, SH; Ng, IO; Tse, AP; Wong, CC; Wong, CM; Xu, IM | 1 |
| Guo, GH; Hu, MD; Jia, LH; Liu, HB; Zhang, KH | 1 |
| Moriyasu, F; Saito, K; Shirota, N; Sugimoto, K; Takara, K; Tokuuye, K | 1 |
| Bai, W; Cai, H; Chen, H; Fan, D; Guo, W; Han, G; He, C; Jia, J; Liu, L; Niu, J; Xia, J; Yang, M; Yin, Z; Yuan, J; Zhang, L; Zhao, Y | 1 |
| Chen, KF; Chen, LJ; Chen, YL; Chu, PY; Huang, JW; Hung, MH; Shiau, CW; Tai, WT; Tsai, MH | 1 |
| Brekken, RA; Cheng, X; Huang, X; Li, L; Thorpe, PE; Yopp, AC | 1 |
| Liu, Y; Qiu, P; Wang, G; Wen, J; Wen, P; Xiao, X; Xu, L; Zhou, SF | 1 |
| Duda, DG; Hato, T; Zhu, AX | 1 |
| Brade, AM; Brierley, J; Cho, C; Dawson, LA; Dinniwell, R; Kim, J; Knox, J; Ng, S; Ringash, J; Wong, RR | 1 |
| Darstein, F; Galle, PR; Grimm, D; Hoppe-Lotichius, M; Koch, S; Lautem, A; Lieb, J; Schad, A; Schattenberg, JM; Vollmar, J; Weinmann, A; Weyer, V; Wörns, MA; Zimmermann, T | 1 |
| Chen, KF; Chen, YL; Chu, PY; Hung, MH; Shiau, CW; Shih, CT; Tai, WT; Yu, HC | 1 |
| Bodoky, G; Buehlmann, M; Demeter, G; Dufour, JF; Feilchenfeldt, J; Horber, D; Koeberle, D; Lakatos, G; Li, Q; Montemurro, M; Peck-Radosavljevic, M; Rauch, D; Ribi, K; Roth, AD; Saletti, P; Samaras, P; Tschanz, B; Wagner, AD | 1 |
| Chen, C; Hu, H; Li, H | 1 |
| Bisulli, M; Casadei Gardini, A; Cascinu, S; Corbelli, J; Donati, G; Faloppi, L; Foschi, FG; Frassineti, GL; Gardini, A; Giampalma, E; La Barba, G; Marisi, G; Scarpi, E; Scartozzi, M; Silvestris, N; Tamberi, S; Veneroni, L | 1 |
| Alonso López, S; Burgos, Rde L; Fernandez Cebrián, JM; Fernández Rodríguez, C; Gutiérrez Garcia, ML; LIedó Navarro, JL; Loinaz Segurola, C; Martel Villagrán, J; Martín Ríos, D; Ochando Cerdán, F | 1 |
| Abdel-Rahman, OM; Elsayed, Z | 1 |
| Han, KH; Han, SY; Heo, J; Kim, DY; Kim, HJ; Kim, YH; Kweon, YO; Lee, BS; Lee, HC; Lee, WS; Lim, HY; Ryoo, BY; Um, SH; Woo, HY; Yoon, JH; Yoon, SK | 1 |
| Arenas, JI; Buades-Mateu, J; Bustamante, FJ; de la Rosa, PA; de la Torre, MA; Gil, C; Iñarrairaegui, M; Lorente, S; Lué, A; Sangro, B; Serrano, MT; Testillano, M | 1 |
| Gao, M; Hua, H; Jiang, Y; Kong, Q; Luo, T; Wang, J; Yin, Y | 1 |
| Cao, Y; Chen, EB; Dai, Z; Fan, J; Hu, ZQ; Huang, XW; Wang, Z; Zhou, J; Zhou, SL; Zhou, ZJ | 1 |
| Furuse, J; Ikeda, K; Inuyama, L; Ito, Y; Kaneko, S; Matsuzaki, Y; Minami, H; Okayama, Y; Okita, K; Sunaya, T | 1 |
| Cai, X; Chang, C; Jin, RA; Li, G; Lin, H; Ma, WL; Shi, L; Sun, Y; Xu, J; Yeh, S | 1 |
| Abrantes, AM; Botelho, MF; Brito, AF; Casalta-Lopes, JE; Gonçalves, AC; Laranjo, M; Mamede, AC; Ribeiro, M; Sarmento-Ribeiro, AB; Tralhão, JG | 1 |
| Ammendola, AS; Bitzer, M; Cillo, U; Dollinger, MM; Ganten, TM; Gerken, G; Giannini, EG; Hauns, B; Henning, SW; Hentsch, B; Herz, T; Holzapfel, J; Horger, M; Lauer, UM; Mais, A; Malek, NP; Montesarchio, V; Pegoraro, S; Santoro, A; Scheulen, ME; Siveke, JT; Trevisani, F; Wege, H; Wörns, MA; Zagonel, V | 1 |
| Cao, M; Cui, Y; Fang, F; Gao, J; Guo, Z; Li, H; Li, Q; Song, T; Sun, H; Yin, H; You, A; Zhang, T; Zhang, W; Zhou, H; Zhu, X; Zuo, B | 1 |
| Boo, YP; Chen, KF; Chen, LJ; Chen, MH; Chen, YL; Chu, PY; Hung, MH; Shiau, CW; Tai, WT; Tsai, MH | 1 |
| Chan, HF; Chen, M; Hu, J; Liang, G; Skibba, M; Zhang, J | 1 |
| Chen, D; Chen, W; Lai, J; Liang, L; Xiao, W; Yin, X; Zhang, K | 1 |
| Brierley, JD; Brock, KK; Coolens, C; Dawson, LA; Dinniwell, R; Kassam, Z; Kim, J; Knox, JJ; Swaminath, A; Wong, R | 1 |
| Hao, J; Lei, J; Li, B; Liu, Z; Wang, W; Wen, T; Wu, L; Yan, L; Zeng, Y; Zhang, P; Zhong, J; Zhu, J | 1 |
| Cheng, KS; Chou, JW; Huang, CW | 1 |
| Chen, MS; Cheng, SQ; Cong, WM; Guo, WX; Lau, WY; Mao, YL; Meng, Y; Shi, J; Sun, BC; Wang, K; Wu, MC; Yang, YF; Zhang, YJ | 1 |
| Chen, KH; Chou, YH; Hsieh, CH; Lu, YF; Weng, MT | 1 |
| Bugiantella, W; Carnelutti, A; Leo, CA; Lorenzin, D; Pravisani, R; Risaliti, A; Soardo, G; Umberto, B | 1 |
| Li, H; Liu, D; Yan, D; Yao, X; Zeng, H | 1 |
| de Gramont, A; Faivre, S; Raymond, E | 1 |
| Chen, D; Chen, R; He, W; Kang, R; Niu, X; Sun, X; Tang, D | 1 |
| Antony, AN; Bisetto, S; Doria, C; Hoek, JB; Levine, M; Monti, DA; Newberg, A; Rouleau, L | 1 |
| Bai, W; Duran, R; Fan, D; Gu, S; Guan, S; Guo, W; Han, G; Li, H; Liu, J; Lv, W; Ma, Y; Mu, W; Qin, X; Ren, W; Sahu, S; Wang, W; Wang, Y; Yin, Z; Zhang, Z; Zhao, Y | 1 |
| Chauhan, AK; Choi, SM; Choi, WY; Chung, WJ; Hwang, JS; Jang, BK; Kang, KJ; Kim, BS; Kim, YH; Kweon, YO; Lee, CH; Lee, JM; Lee, YJ; Park, SY; Tak, WY | 1 |
| Bai, T; Chen, J; Chen, JZ; Li, LQ; Lu, Z; Ma, L; Peng, YC; Qin, HG; Xiang, BD; Xie, ZB; Ye, HH; Ye, JZ | 1 |
| Amadori, D; Casadei Gardini, A; Cascinu, S; Corbelli, J; Della Corte, C; Facchetti, F; Faloppi, L; Foschi, FG; Frassineti, GL; Iavarone, M; Lauletta, G; Marisi, G; Nanni, O; Neri, LM; Scarpi, E; Scartozzi, M; Tamberi, S; Tenti, E; Ulivi, P; Valgiusti, M | 1 |
| Bar-Zion, A; Butz, H; Daley, F; Foster, FS; Kerbel, RS; Kuczynski, EA; Lee, CR; Man, S; Reynolds, AR; Vermeulen, PB; Yin, M; Yousef, GM | 1 |
| Igarashi, Y; Ikehara, T; Kikuchi, Y; Kogame, M; Matsukiyo, Y; Shinohara, M; Shiozawa, K; Sumino, Y; Watanabe, M | 2 |
| Bucci, L; Camelli, V; Garuti, F; Spinardi, L; Trevisani, F | 1 |
| Balsara, B; Chan, SL; Chao, Y; Cheng, AL; Han, G; Ikeda, M; Kang, YK; Kudo, M; Lim, HY; Numata, K; Pan, H; Poon, RT; Rodriguez, AM; Sukeepaisarnjaroen, W; Thongprasert, S; Wang, Y; Wu, CC; Yang, TS; Zhang, Y | 1 |
| Abd El-Fattah, EE; El-Ashmawy, NE; El-Bahrawy, HA; Khedr, EG | 1 |
| Fujiwara, T; Kagawa, S; Katsube, R; Kimura, F; Matsukawa, A; Ninomiya, T; Noma, K; Nouso, K; Ohara, T; Shirakawa, Y; Tazawa, H; Tomono, Y; Urano, S; Yamamoto, K | 1 |
| Cao, Y; Feng, F; Hou, MX; Jia, H; Jiang, QY; Ma, HD; Sun, HW; Wang, T; Yang, Q; Yang, YP | 1 |
| Chen, GG; Ho, RL; Hu, B; Lai, PB; Lee, CG; Leung, BC; Liu, Y; Lu, G; Ren, J; Su, X; Wang, Y; Yang, S | 1 |
| Cai, XB; Hou, Y; Li, J; Liu, B | 1 |
| Chan, TH; Chen, L; Chow, RK; Fang, S; Guan, XY; Jiang, L; Li, Y; Liu, M; Ma, NF; Song, Y; Xi, S; Yang, X; Yuan, YF; Zeng, TT | 1 |
| Cai, JB; Dong, ZR; Fan, J; Gao, DM; Gao, PT; Hu, ZQ; Huang, XY; Ke, AW; Li, KS; Shen, YH; Shi, GM; Tian, MX; Zhang, C; Zhang, PF | 1 |
| Chen, W; Dan, Y; Li, M; Li, W; Liu, K; Mo, P; Qin, L; Tong, Z; Wang, W; Yu, C | 1 |
| Furuse, J; Ikeda, M; Ito, Y; Izumi, N; Kadoya, M; Kokudo, N; Kudo, M; Numata, K; Okusaka, T; Takayama, T; Yamashita, S | 1 |
| Chen, SH; Chen, YY; Cheng, KS; Chou, JW; Chuang, PH; Feng, CL; Hsiao, WD; Kao, JT; Lai, HC; Peng, CY; Su, WP; Yu, CJ | 1 |
| Fu, P; Li, Q; Wen, F; Wheeler, J; Yang, Y; Zhang, P | 1 |
| Asaoka, T; Doki, Y; Eguchi, H; Gotoh, K; Kawamoto, K; Mori, M; Noda, T; Ogawa, H; Umeshita, K; Wada, H; Yamada, D; Yamashita, M | 1 |
| Cai, X; Cang, Y; Chen, J; Huang, D; Ji, T; Jin, R; Li, G; Liang, X; Lin, H; Liu, J; Liu, X; Xie, A; Zhang, J; Zhao, J | 1 |
| Bae, SH; Cho, YY; Chung, JW; Gwak, GY; Heo, J; Kim, do Y; Kim, HC; Kim, YH; Kim, YJ; Lee, M | 1 |
| Chen, Y; Ding, J; Fang, T; Guo, LN; Li, T; Liang, D; Lv, GS; Lv, HW; Tan, YX; Tang, L; Tang, SH; Wang, CZ; Wang, HY; Wu, FQ; Yang, W; Yu, LX | 1 |
| Aycart, SN; Berger, Y; Edwards, MP; Heskel, M; Kim, E; Labow, DM; Sarpel, U; Spivack, JH; Sweeney, R | 1 |
| Chen, J; Cho, S; Kim, DH; Larson, AC; Na, K; Park, SJ; Park, W | 1 |
| Arachchi, N; Bell, S; Dev, A; Doyle, A; Fink, MA; Gill, R; Gow, PJ; Hong, T; Kemp, W; Knight, V; Kronborg, I; Lubel, J; Marsh, P; Mohsen, W; Nicoll, A; Roberts, S; Rodov, M; Ryan, M; Strasser, SI; Varma, P | 1 |
| Guo, X; Han, G; Li, H; Qi, X; Zhao, Y | 1 |
| Cui, SX; Gao, ZH; Qu, XJ; Shi, WN; Song, ZY; Wang, SQ; Yu, XF | 1 |
| Fan, XX; Huang, YC; Li, ZY; Liu, ZW; Pan, WT; Wang, YJ; Wu, ZM; Yang, P; Yao, K; Ye, YL; Zhou, FJ | 1 |
| Barbare, JC; Barget, N; Bodeau, S; Chauffert, B; Coriat, R; François, C; Galmiche, A; Ganne, N; Godin, C; Gutierrez, L; Houessinon, A; Louandre, C; Mongelard, G; Régimbeau, JM; Saidak, Z; Sauzay, C; Takahashi, S | 1 |
| He, J; Sun, J; Sun, T; Zeng, M; Zeng, Z; Zhang, S | 1 |
| Chan, AL; Leung, HW; Liu, CF | 1 |
| Campana, D; Chang, YH; Kamiya, T | 1 |
| Deng, YR; Hou, X; Li, X; Lian, ZX; Liu, WB | 1 |
| Ducerf, C; Golse, N; Mabrut, JY; Merle, P; Radenne, S; Rode, A | 1 |
| Blanc, JF; Campillo-Gimenez, B; Collins, P; Darby, S; Edeline, J; Evans, J; Hubner, RA; Iwuji, C; Johnson, P; King, J; Ma, YT; Meyer, T; Muazzam, I; Palmer, DH; Patel, K; Ross, P; Sumpter, K; Swinson, D | 1 |
| Abe, H; Baba, H; Kamimura, H; Kamimura, K; Kawai, H; Kobayashi, Y; Ogawa, K; Shinagawa, Y; Suda, T; Terai, S; Yamagiwa, S; Yokoo, T | 1 |
| Evans, TR; Gane, E; Jeffers, M; Kang, YK; Meinhardt, G; Peña, CE; Rosmorduc, O; Ross, P; Santoro, A; Vogel, A; Zhu, AX | 1 |
| Grünwald, V; Kalanovic, D; Lin, X; Simantov, R | 1 |
| Arai, K; Honda, M; Horii, R; Kaneko, S; Kawaguchi, K; Kitamura, K; Mizukoshi, E; Sakai, Y; Terashima, T; Yamashita, T | 1 |
| Althouse, SK; Chiorean, EG; Clark, RS; Loehrer, PJ; Shahda, S; Spittler, AJ | 1 |
| Andreoli, JM; Baker, T; Gabr, A; Hickey, R; Kallini, JR; Kircher, S; Kulik, L; Lewandowski, RJ; Salem, R | 1 |
| Abdelmaksoud, AH; Attar, IE; Aziz, AO; Elbaz, TM; Nabeel, MM; Omran, D; Shousha, HI | 1 |
| Chapiro, J; Duran, R; Gebauer, B; Geschwind, JF; Gorodetski, B; Lee, H; Lenis, D; Lin, M; Nonyane, BA; Pawlik, TM; Pekurovsky, V; Schernthaner, R; Schlachter, T; Stuart, EA; Tamrazi, A | 1 |
| Fu, CX; Gao, DM; Han, ZH; Lin, J; Liu, H; Lu, F; Lv, P; Yang, SH | 1 |
| Amantea, MA; Chen, Y; Nickens, DJ; Pithavala, YK; Valota, O; Zierhut, ML | 1 |
| Cui, X; Hua, L; Liu, J; Lu, C; Ni, R; Qu, L; Shen, Z; Wu, M | 1 |
| Gong, X; Liu, Y; Wang, T; Yang, S; Zhang, B; Zhang, N | 1 |
| Macaluso, FS; Maida, M; Valenza, F; Virdone, R | 1 |
| Furlan, A; Marsh, JW; Patchett, N | 1 |
| Augello, G; Bachvarov, D; Cancila, V; Candido, S; Cervello, M; Emma, MR; Gulino, A; Iovanna, JL; Libra, M; Loria, GR; McCubrey, JA; Montalto, G; Puleio, R | 1 |
| Lv, L; Mei, ZC; Zeng, J | 1 |
| Bie, P; Huan, HB; Lau, WY; Li, XW; Ma, KS; Wen, XD; Wu, LL; Xia, F | 1 |
| Borentain, P; Gerolami, R; Gregoire, E; Louis, G | 1 |
| Aikata, H; Aisaka, Y; Chayama, K; Hatooka, M; Hiramatsu, A; Honda, Y; Hyogo, H; Imamura, M; Kawakami, Y; Kawaoka, T; Kobayashi, T; Kohno, H; Mori, N; Morio, K; Moriya, T; Murakami, E; Nonaka, M; Takaki, S; Tsuji, K; Waki, K | 1 |
| Bhatia, S; Dinh, VY; Feun, L; Martin, P; Narayanan, G; O'Brien, C; Savaraj, N; Yrizarry, J | 1 |
| Chen, LZ; Dai, ZY; Li, CL; Li, WW; Pan, J; Wan, HG; Wang, XJ; Yao, LZ; Zhu, J | 1 |
| Cai, XF; Chen, J; Chen, K; Chen, X; Cheng, ST; Huang, AL; Huang, LX; Li, WY; Liu, B; Ren, JH; Tang, H; Tao, NN; Yang, QX; Zhang, WL; Zhou, HZ; Zhou, L | 1 |
| Blaziene, A; Chomiciene, A; Linauskiene, K; Malinauskiene, L; Vitkauskaite, E | 1 |
| De Velasco, MA; Haji, S; Iida, H; Ishizaki, M; Kaibori, M; Kanazawa, A; Kitade, H; Kubo, S; Kwon, AH; Matsui, K; Matsushima, H; Nagano, H; Nishio, K; Sakai, K; Takeda, Y; Takemura, S; Tsukamoto, T; Wada, H | 1 |
| Azumi, J; Sakabe, T; Shiota, G; Tsubota, T | 1 |
| Casadei Gardini, A; Chiadini, E; Delmonte, A; Dubini, A; Faloppi, L; Frassineti, GL; Loretelli, C; Lucchesi, A; Marisi, G; Oboldi, D; Scartozzi, M; Ulivi, P | 1 |
| Itoh, Y; Moriguchi, M; Umemura, A | 1 |
| Cheng, AL; Feng, WC; Hsu, CH; Lin, HH; Lu, LC; Shao, YY | 1 |
| Hong, TH; Kim, DG; Na, GH; You, YK | 1 |
| Cao, M; Liu, C; Lu, Z; Nelson, D; Ren, Y; Wang, T; Zhao, X | 1 |
| Li, LQ; Liao, YY; Peng, NF; Tong, TJ; Zhong, JH | 1 |
| Cao, J; Cao, X; Li, D; Peng, Y; Quan, M; Ren, K; Sheng, X; Song, Z; Xiao, Q; Zeng, W; Zheng, Y; Zou, H | 1 |
| Iwamoto, H; Koga, H; Kuromatsu, R; Nagamatsu, H; Nakano, M; Niizeki, T; Noda, Y; Okamura, S; Satani, M; Shimose, S; Shirono, T; Tanaka, M; Torimura, T | 1 |
| Chen, X; Cui, T; Diao, X; Huang, S; Sun, J | 1 |
| Addeo, R; Del Prete, S; Montella, L; Palmieri, G | 1 |
| Bronowicki, JP; Chen, XP; Dagher, L; de Guevara, LL; Furuse, J; Geschwind, JH; Heldner, S; Kudo, M; Lehr, R; Lencioni, R; Marrero, JA; Nakajima, K; Papandreou, C; Sanyal, AJ; Takayama, T; Venook, AP; Ye, SL; Yoon, SK | 1 |
| Jia, HL; Qin, LX | 1 |
| Chang, LL; Chen, Y; Chen, ZB; He, QJ; Hu, Y; Lin, WK; Lou, JS; Wan, ZQ; Wang, DD; Yang, B; Ye, S; Ying, MD; Zhou, TY; Zhou, YL; Zhu, H; Zhuang, LH | 1 |
| Farinati, F; Murer, F; Peserico, G; Pozzan, C | 1 |
| Cao, J; He, HG; Huang, JL; Liu, F; Lu, JH; Shen, YN; Shi, CF; Shi, Y; Wang, ZC; Wei, YP; Yang, GS; Yuan, JY; Zhu, N | 1 |
| Baulies, A; Fernández, A; Fernández-Checa, JC; Garcia-Ruiz, C; González-Gallego, J; Mauriz, JL; Méndez-Blanco, C; Ordóñez, R; Prieto-Domínguez, N | 1 |
| Li, Q; Wen, F; Zhang, P | 1 |
| Han, KH; Jung, I; Seong, J; Yoon, HI | 1 |
| Chapiro, J; Geschwind, JF | 1 |
| Chung, YH; Ha, Y; Kang, YK; Kim, KM; Lee, D; Lee, HC; Lee, YS; Lim, YS; Park, SR; Ryoo, BY; Ryu, MH; Shim, JH | 1 |
| Burgoyne, AM; Durden, DL; Garlich, JR; Ikeda, S; Joshi, S; Kono, Y; Morales, GA; Sicklick, JK; Singh, AR | 1 |
| Addario, L; Caporaso, N; Cordone, G; Di Costanzo, GG; Falco, L; Guarino, M; Morisco, F; Tortora, R | 1 |
| Finkenstedt, A; Zoller, H | 1 |
| Lange, N; Loscher, C; Mkounga, P; Nkengfack, AE; Sass, G; Tiegs, G; Tontsa, AT; Wegscheid, C | 1 |
| Chen, HA; Kuo, TC; Ma, JT; Su, JL; Sung, SY; Tseng, CF; Yang, CY; Yang, ST; Yen, CJ | 1 |
| Bins, S; El Bouazzaoui, S; Eskens, FA; Lenting, A; Mathijssen, RH; Oomen-de Hoop, E; van Doorn, L; van Schaik, RH | 1 |
| Chiba, T; Inoue, M; Ogasawara, S; Ooka, Y; Suzuki, E; Tawada, A; Wakamatsu, T; Yokosuka, O | 1 |
| Abdel-Rahman, O; Hubner, RA; Lamarca, A; McNamara, MG; Salu, I; Valle, JW | 1 |
| Abhari, BA; Fulda, S; Hinrichs, TM; Lange, M; Liese, J | 1 |
| Brizzi, MP; Di Maio, M; Pignataro, D; Scagliotti, GV; Tampellini, M | 1 |
| Abada, PB; Fujii, H; Furuse, J; Hatano, E; Ikeda, M; Ishii, H; Kaneko, S; Kawazoe, S; Kudo, M; Kudo, T; Masumoto, A; Morita, S; Obi, S; Ohkawa, S; Okusaka, T; Osaki, Y; Shimada, M; Sugiyama, G; Tateishi, R; Tsuji, A; Ukai, K; Wada, Y; Yang, L; Yokosuka, O; Zhu, AX | 1 |
| Azoulay, D; Calderaro, J; Compagnon, P; Costentin, C; de'Angelis, N; Feray, C; Lahat, E; Landi, F; Lim, C; Luciani, A; Nencioni, M; Palen, A; Salloum, C | 1 |
| Li, J; Shen, F; Wan, X; Wang, K; Wu, D; Xia, Y; Yan, Z; Yang, P; Zhai, X | 1 |
| Baroni, GS; Bernardi, M; Biasini, E; Borzio, F; Cabibbo, G; Caturelli, E; Ciccarese, F; Di Marco, M; Farinati, F; Felder, M; Foschi, FG; Garuti, F; Gasbarrini, A; Giannini, EG; Gramenzi, A; Lenzi, B; Masotto, A; Morisco, F; Pecorelli, A; Piscaglia, F; Rapaccini, GL; Sacco, R; Trevisani, F; Virdone, R; Zoli, M | 1 |
| Furuse, J; Hagihara, A; Ikeda, M; Inaba, Y; Ishii, H; Kaneko, S; Kojima, Y; Kudo, M; Morimoto, M; Nakamori, S; Ohmura, T; Okusaka, T; Sato, K; Sato, T; Shimizu, S; Sugimoto, R; Tahara, T; Yasui, K | 2 |
| Bruix, J; Reig, M; Ribeiro de Souza, A | 1 |
| Abdelmageed, MM; El-Demerdash, E; El-Naga, RN; Elmazar, MM | 1 |
| Casadei Gardini, A; de Stefano, G; Ercolani, G; Faloppi, L; Foschi, FG; Frassineti, GL; Marisi, G; Negri, FV; Santini, D; Scarpi, E; Scartozzi, M; Silvestris, N; Valgiusti, M | 1 |
| Alsinet, C; Dauch, D; Esteller, M; Llovet, JM; Lujambio, A; Martinez-Quetglas, I; Moeini, A; Pinyol, R; Portela, A; Rodriguez-Carunchio, L; Solé, M; Thung, S; Torrecilla, S; Tovar, V; Villanueva, A; Zender, L | 1 |
| Brower, V | 1 |
| Garg, M; Guha, C; Kaubisch, A; Ohri, N | 1 |
| Al-Khadimi, G; Allen, N; Chowdhury, R; Heaton, N; Korantzis, I; O'Grady, J; Papadatos-Pastos, D; Ross, PJ; Sarker, D; Suddle, A; Thillai, K; Ziogas, DC | 1 |
| Azzariti, A; Caligiuri, A; Dituri, F; Giannelli, G; Lupo, L; Mancarella, S; Porcelli, L; Quatrale, AE | 1 |
| Aburas, S; Colagrande, S; Inghilesi, AL; Marra, F; Nardi, C; Taliani, GG | 1 |
| Bai, W; Cai, H; Fan, D; Han, G; Liu, L; Niu, J; Wang, E; Wang, W; Xia, D; Xia, J; Yang, M; Yin, Z; Zhang, L; Zhang, Z; Zhao, Y | 1 |
| Choo, SP; Goh, BC; Hartano, S; Huynh, H; Koh, TS; Lim, C; Lim, KT; Low, LS; Ng, QS; Tai, WM; Tham, CK; Thng, CH; Toh, HC; Wang, LZ; Wang, WW; Yong, WP | 1 |
| Cai, X; Chang, C; Chen, J; Li, G; Lin, H; Shi, L; Sun, Y; Xu, J | 1 |
| Dong, X; Han, P; Jiang, H; Jiang, X; Qiao, H; Sun, X; Tan, G; Tang, S; Zhai, B | 1 |
| Ding, Y; Jiang, C; Luo, D; Qu, Z; Wu, J | 1 |
| Chen, B; Chen, Y; Hu, B; Hua, L; Liu, J; Wu, M; Yan, D; Zhang, C; Zhang, X; Zhao, F; Zhou, H | 1 |
| Delgado-Fernández, M; Galindo, MJ; García, MA; Garcia-Deltoro, M; Ibarra, S; Merchante, N; Merino, E; Mínguez, C; Montero-Alonso, M; Pineda, JA; Revollo, B; Rivero-Juárez, A; Rodríguez-Arrondo, F; Romero-Palacios, A; Téllez, F | 1 |
| Cai, Z; Han, Y; Liu, N; Liu, P; Shen, P; Wang, C | 1 |
| Balkrishnan, R; Lok, AS; Marshall, VD; Nathan, H; Parikh, ND; Shahinian, V; Singal, AG | 1 |
| Chen, X; He, L; Huang, Y; Liang, C; Liu, Z; Ma, Z; Shi, C; Zhang, Z | 1 |
| Amendola, F; Calvanese, A; Coppola, C; DI Sarno, A; Gatti, P; Giorgio, A; Giorgio, V; Matteucci, P; Merola, F; Merola, MG; Montesarchio, L; Santoro, B | 1 |
| Boucher, E; Brunot, A; Crouzet, L; Duval, M; Edeline, J; Guillygomarc'h, A; Laguerre, B; Le Roy, F; Le Sourd, S; Lelievre, N; M'Sadek, A; Ventroux, E | 1 |
| Cheow, PC; Choo, SP; Chow, PK; Gandhi, M; Goh, AS; Goh, BK; Liew, WM; Lo, RH; Low, AS; Ng, DC; Soo, KC; Tan, SB; Tay, KH; Thng, CH; Wong, JS | 1 |
| Arachchi, NJ; Bhullar, A; Bhullar, M | 1 |
| Arase, Y; Hirose, S; Kagawa, T; Mine, T; Okabe, H; Shiraishi, K; Shomura, M; Takahira, S; Tsuruya, K | 1 |
| Heo, J; Woo, HY; Yoo, SY | 1 |
| Bian, CB; Bollard, J; Hoshida, Y; Llovet, JM; Lujambio, A; Miguela, V; Molina-Sánchez, P; Nakagawa, S; Nguyen, CB; Roberto, MP; Ruiz de Galarreta, M; Sia, D; Tovar, V; Venkatesh, A | 1 |
| Han, C; Ungerleider, N; Wu, T; Yao, L; Zhang, J | 1 |
| Chen, JC; Chen, YC; Chien, YC; Chuang, HY; Hsu, FT; Hwang, JJ | 1 |
| Cai, X; Chen, G; Chen, L; Fu, T; Jin, W; Ma, D; Yu, F; Yu, Z; Zhang, J; Zhang, Y | 1 |
| Bi, XY; Cai, JQ; Han, Y; Huang, Z; Li, H; Li, MX; Li, ZY; Yao, XS; Zhang, YF; Zhao, DB; Zhao, H; Zhao, JJ; Zhou, JG | 1 |
| Abdel-Rahman, O; Lamarca, A | 1 |
| Wu, CH; Wu, X; Zhang, HW | 1 |
| Kerbel, RS; Kuczynski, EA | 1 |
| Bouattour, M; de Gramont, A; Faivre, S; Soubrane, O | 1 |
| Cao, D; Fu, GB; Guo, LN; Huang, S; Liu, J; Qin, CJ; Tang, L; Wang, HY; Wang, MD; Wu, H; Yan, HX; Zeng, M; Zhang, HL; Zhao, LH; Zhou, X | 1 |
| Amikura, K; Kageyama, Y; Kokudo, T; Miyazaki, Y; Sakamoto, H; Takahashi, A; Takano, M | 1 |
| Chen, PT; Chen, SC; Grevel, J; Hu, CT; Jeng, LB; Le Berre, MA; Lin, SM; Liu, X; Lu, SN; Meinhardt, G; Mitchell, DY; Peña, CA; Prins, K; Yang, SS | 1 |
| Chen, S; Fu, S; Li, Y; Liang, C; Liu, Z; Lu, L; Zhu, Y | 1 |
| Bergheim, D; Branchi, V; Dietrich, D; Dietrich, J; Fischer, HP; Goltz, D; Kalff, JC; Kristiansen, G; Matthaei, H; Semaan, A | 1 |
| Forgez, P; Galmiche, A; Liu, J; Paradis, V; Segal-Bendirdjian, E; Stadler, N; Wendum, D; Wu, Z | 1 |
| Chen, XW; Han, JH; Hong, D; Ma, TC; Niu, M; Sun, J; Xu, K | 1 |
| Baumhauer, A; Bodoky, G; Breder, V; Bronowicki, JP; Bruix, J; Cheng, AL; Finn, RS; Gerolami, R; Granito, A; Han, G; Huang, YH; Kudo, M; LeBerre, MA; Llovet, JM; Masi, G; Meinhardt, G; Merle, P; Ollivier-Hourmand, I; Pracht, M; Qin, S; Rosmorduc, O; Ross, PJ; Song, T; Yokosuka, O | 1 |
| Chuang, WL; Lin, ZY | 1 |
| Ghoshal, K; Jacob, ST; Motiwala, T; Reyes, R; Wani, NA | 1 |
| Alberts, SR; Borad, M; Gatalica, Z; Hubbard, JM; Kumar, S; Loui, WS; Mahoney, MR; Roberts, LR; Smyrk, TC | 1 |
| Anderson, DG; Conte, D; Fischer, A; Hough, S; Kennedy, Z; Li, Y; Moore, J; Mou, H; Park, A; Pomyen, Y; Song, CQ; Thorgeirsson, S; Wang, XW; Weng, Z; Xue, W; Yin, H; Zender, L | 1 |
| Fan, N; Feng, T; Hou, Z; Huang, Q; Li, Y; Ling, S; Liu, L; Liu, Y; Shi, L; Song, L; Tian, Y; Wang, M; Xu, F; Yang, X; Zhao, F | 1 |
| Blesing, C; Braconi, C; Collins, P; Darby, S; Hubner, RA; Iwuji, C; Johnson, P; King, J; Kirkwood, A; Meyer, T; Muazzam, I; Nash, S; Nobes, J; Palmer, DH; Patel, K; Ross, P; Sumpter, K; Swinson, D | 1 |
| Arihara, Y; Hayasaka, N; Kamihara, Y; Kato, J; Kikuchi, S; Kobune, M; Miyanishi, K; Murase, K; Nakamura, H; Okagawa, Y; Osuga, T; Takada, K; Usami, M | 1 |
| He, D; Liu, F; Meng, Z; Shao, G; Wang, J; Wang, Z; Yang, J; Yip, CS | 1 |
| Caraglia, M; Castiello, F; Ferri, C; Giordano, A; Mosca, N; Panella, M; Potenza, N; Russo, A; Stiuso, P; Vanacore, D; Zappavigna, S | 1 |
| Dai, XJ; Fan, JH; Liu, C; Liu, Q; Shen, YJ; Sun, WD; Sun, Y; Wang, J; Yang, H; Zhang, YQ; Zhao, JX | 1 |
| Katare, DP; Mishra, S | 1 |
| Bargellini, I; Fornaro, L; Lorenzoni, G; Masi, G; Vivaldi, C | 1 |
| Brauner, J; Dudeck, O; Jürgens, J; Kalinski, T; Nass, N; Powerski, M; Ricke, J; Schulz, N; Seidensticker, M; Streit, S; Wybranski, C | 1 |
| Chen, PC; Guo, L; Huang, Y; Kwok, HF; Li, B; Li, L; Lin, Y; Meng, C; Neves, H; Xiao, Y; Yan, W | 1 |
| Berhane, S; Jackson, R; Johnson, P; Khan, H; Psarelli, EE | 1 |
| Torjesen, I | 1 |
| Byun, KS; Je, JH; Kang, SH; Kim, JH; Ko, E; Lee, HJ; Seo, YS; Suh, SJ; Yeon, JE; Yim, HJ; Yoo, YJ; Yoon, EL | 1 |
| Calvisi, D; Eferl, R | 1 |
| Chen, J; Fang, H; Jiang, B; Kang, M; Tang, Z; Wu, Y; Ye, Q; Zhang, B | 1 |
| Cheng, AL; Hocke, J; Loembé, AB; Meyer, T; Palmer, DH; Yen, CJ | 1 |
| Gao, L; Hu, CA; Huang, S; Tang, Y; Teng, Y; Wang, X | 1 |
| Baglioni, M; Baldassarre, M; Baron Toaldo, M; Bolondi, L; Callegari, E; Casadei Gardini, A; Cescon, M; Fornari, F; Galassi, M; Giovannini, C; Gramantieri, L; La Bella, T; Marinelli, S; Marisi, G; Negrini, M; Patrizi, C; Pollutri, D; Ravaioli, M; Salvatore, V | 1 |
| Li, Y; Liu, L; Lu, L; Tong, X; Wang, F; Wang, X; Wu, G; Xie, J; Xue, Q; Zheng, A; Zhou, H; Zhu, X | 1 |
| Arizumi, T; Bettinger, D; Burlone, ME; Kudo, M; Pinato, DJ; Pirisi, M; Ramaswami, R; Sharma, R; Thimme, R; Ward, C; Yen, C | 1 |
| Abou-Alfa, GK; Agajanov, T; Beylergil, V; Boisserie, F; Carrasquilo, JA; Chen, YC; Cheng, AL; Di Laurenzio, L; Frenette, C; Gansukh, B; Hsu, CH; Larson, SM; Lee, R; Lin, ZZ; Lyashchenko, SK; Ma, J; Maki, Y; Morikawa, H; O'Donoghue, J; O'Neil, B; Ohishi, N; Ohtomo, T; Pandit-Taskar, N; Ruan, S; Schwartz, L; Shao, YY; Smith-Jones, PM; Tanaka, T; Wan, P; Yen, CJ | 1 |
| He, J; Liu, P; Lv, X; Wang, L; Xu, X; Yan, Y; Zhang, L; Zhang, Y | 1 |
| Hasegawa, J; Hirota, M; Kameda, C; Kawabata, R; Koga, C; Matsumura, T; Murakami, M; Noura, S; Shimizu, J; Shuto, T; Yasuyama, A; Yoshikawa, M | 1 |
| Akahori, T; Hokuto, D; Kanehiro, H; Kawaguchi, C; Kinoshita, S; Nagai, M; Nakajima, Y; Nishiwada, S; Nomi, T; Obara, S; Sho, M; Yamada, T; Yamato, I; Yasuda, S; Yoshikawa, T | 1 |
| Chen, B; Chen, W; Dao, H; Huang, Y; Li, N; Liu, N; Yang, J | 1 |
| Galmiche, A; Giacobbi, AS; Louandre, C; Mammeri, Y; Saidak, Z; Sauzay, C | 1 |
| Ding, W; Wang, B; Xu, L | 1 |
| Han, P; Jiang, H; Jiang, X; Li, H; Liu, B; Qiao, H; Sun, X; Tan, G; Zhai, B; Zhao, D | 1 |
| Dutta, R; Mahato, RI | 1 |
| Cheng, S; Wang, K; Wang, M; Wu, M; Yang, G; Ye, X; Zhang, X | 1 |
| Gao, C; Herr, I; Hoffmann, K; Lin, S; Petrulionis, M; Schemmer, P | 1 |
| Al-Abdulla, R; Bantel, H; Bettinger, D; Geier, A; Jahn, D; Macias, RI; Marin, JJ; Weiss, J | 1 |
| Acosta, LF; Butterfield, DA; Gedaly, R; Marti, F; Mitov, M; Poyil, P; Turcios, L; Vilchez, V | 1 |
| Harada, N; Harimoto, N; Ikegami, T; Itoh, S; Kawasaki, J; Maehara, Y; Motomura, T; Nagatsu, A; Soejima, Y; Uchiyama, H; Yoshizumi, T | 1 |
| Atkin, C; Earwaker, P; Ma, YT; Pallan, A; Punia, P; Shetty, S | 1 |
| Brade, AM; Brierley, J; Cho, C; Craig, T; Dawson, LA; Dinniwell, R; Goody, RB; Kassam, Z; Kim, J; Knox, JJ; Ringash, J; Wang, L; Wong, RKS | 1 |
| Arizumi, T; Black, J; Burlone, ME; Ferrari, C; Gibbin, A; Guaschino, G; Howell, J; Kudo, M; Pinato, DJ; Pirisi, M; Ramaswami, R; Sellers, L; Sharma, R; Toniutto, P | 1 |
| Liang, J; Liu, CQ; Meng, YM; Xu, J; Xu, L; Yan, J; Yu, XJ; Zheng, L; Zhuang, SM | 1 |
| Aikata, H; Chayama, K; Hatooka, M; Hiramatsu, A; Honda, F; Imamura, M; Inagaki, Y; Kawakami, Y; Kawaoka, T; Kobayashi, T; Morio, K; Morio, R; Nagaoki, Y; Nakahara, T; Teraoka, Y; Tsuge, M | 1 |
| Aihara, A; Akiyama, Y; Arii, S; Ban, D; Kudo, A; Matsumura, S; Mitsunori, Y; Mogushi, K; Nakao, K; Ochiai, T; Ohata, Y; Shimada, S; Tanabe, M; Tanaka, S | 1 |
| Arizumi, T; Bettinger, D; Black, J; Burlone, ME; Ferrari, C; Gibbin, A; Guaschino, G; Howell, J; Kudo, M; Park, JW; Pinato, DJ; Pirisi, M; Ramaswami, R; Sellers, L; Sharma, R; Thimme, R; Yen, C | 1 |
| Chiba, N; Hikita, K; Kawachi, S; Okihara, M; Ozawa, Y; Sano, T; Takano, K; Tomita, K | 1 |
| Cheong, JY; Cho, HJ; Cho, SW; Hwang, JC; Kang, DR; Kim, B; Kim, JK; Kim, SS; Lee, JH; Lee, KJ; Lee, KM; Lim, SG; Nam, JS; Oh, MJ; Shin, SJ; Yang, MJ; Yoo, BM | 1 |
| Chen, L; Ni, CF; Teng, GJ; Zhong, BY; Zhu, HD | 1 |
| Cao, J; Chen, Y; Li, W; Liu, K; Shang, C; Tan, W; Zhang, L; Zhong, J; Zhu, S | 1 |
| Bardeesy, N; Benes, CH; Chang, CC; Chang, CF; Chen, Y; Dima, S; Duda, DG; Duyverman, AM; Flaherty, KT; Gao, DY; Hsu, FF; Huang, P; Jain, RK; Jeng, KS; Kitahara, S; Lin, TT; Liu, CH; Liu, YC; Popescu, I; Ramjiawan, RR; Sung, YC; Zhu, AX | 1 |
| Chao, WT; Cheng, CC; Hsu, YH; Lai, YC; Lai, YS; Liao, CC; Liu, YH; Tseng, YH | 1 |
| Davidson, BR; Gurusamy, KS; Majumdar, A; Roccarina, D; Thorburn, D; Tsochatzis, E | 1 |
| Butte, AJ; Chen, B; Chua, MS; Gill, RM; Ma, L; So, S; Wei, W; Yang, B | 1 |
| Bonhomme-Faivre, L; Cailliez, V; Farinotti, R; Mhiri, A; Noé, G; Paule, B; Saffroy, R; Tandia, M | 1 |
| Keating, GM | 1 |
| Gerami, P; Guitart, J; Lacouture, ME; Reilly, LM | 1 |
| Chung, CY; Wu, SS; Yen, HH | 1 |
| Brouwers, AH; Hospers, GA; Mulder, NH; Siemerink, EJ | 1 |
| Pár, A; Pár, G | 1 |
| Blanc, JF; Bolondi, L; Borbath, I; Bruix, J; de Oliveira, AC; Forner, A; Galle, PR; Gane, E; Giannaris, T; Greten, TF; Häussinger, D; Hilgard, P; Llovet, JM; Mazzaferro, V; Moscovici, M; Porta, C; Raoul, JL; Ricci, S; Santoro, A; Schwartz, M; Seitz, JF; Shan, M; Voliotis, D; Zeuzem, S | 1 |
| Roberts, LR | 1 |
| Fan, J; Huang, XW; Qiu, SJ; Tang, ZY; Wang, Z; Yu, Y; Zhou, J | 1 |
| Alexandrescu, DT; Dasanu, CA; Farzanmehr, H; McClure, R | 1 |
| Palmer, D | 1 |
| Chaparro, M; González Moreno, L; Medina, J; Moreno-Otero, R; Trapero-Marugán, M | 1 |
| Chen, FS; Cui, YZ; Luo, RC; Wu, J; Zhang, H | 1 |
| Bruix, J; Llovet, JM | 4 |
| Choi, JI; Kim, CM; Park, BJ; Park, JW; Shim, JH | 1 |
| Chen, Q; Huang, WX; Li, XF; Ye, YB | 1 |
| Evans, TR; Roxburgh, P | 1 |
| Greten, TF; Korangy, F; Malek, NP; Manns, MP | 1 |
| Kelley, RK; Venook, AP | 1 |
| Chan, P; Epstein, R; Poon, RT; Yau, T | 1 |
| Carroll, S; Dale, P; Knox, J; Maroun, J; McDonald, H; Muszbek, N; Shah, S | 1 |
| Büchler, MW; Glimm, H; Heining, C; Hoffmann, K; Jaeger, D; Radeleff, B; Richter, G; Schemmer, P; Schenkel, I; Schirrmacher, P; Schmidt, J; von Kalle, C; Zahlten-Hinguranage, A | 1 |
| Aburatani, H; Hamakubo, T; Ishiguro, T; Kinoshita, Y; Kodama, T; Miyazaki, Y; Nakano, K; Ohizumi, I; Sugimoto, M; Sugo, I; Tsuchiya, M; Tsunoda, H; Yamada-Okabe, H | 1 |
| Paggi, S; Spinzi, G | 1 |
| Copur, MS | 1 |
| Palmer, DH | 1 |
| Chen, CK; Chen, YJ; Hsieh, CH; Jeng, KS; Lin, CC; Lin, CP; Liu, CY; Shueng, PW; Tai, HC; Wang, CH | 1 |
| Burock, K; Chen, Z; Cheng, AL; Feng, J; Guan, Z; Kang, YK; Kim, JS; Liang, H; Liu, J; Luo, R; Pan, H; Qin, S; Sun, Y; Tak, WY; Tsao, CJ; Voliotis, D; Wang, J; Xu, J; Yang, TS; Ye, S; Zou, J | 1 |
| Bellot, P; Llanos, L; Pérez-Mateo, M; Such, J; Zapater, P | 1 |
| Adamietz, IA; Brendel, E; Christensen, O; Grubert, M; Hilger, RA; Kupsch, P; Ludwig, M; Richly, H; Schultheis, B; Strumberg, D | 1 |
| Chan, P; Cheung, TT; Chok, SH; Fan, ST; Ng, KK; Poon, RT; Yau, T | 1 |
| Billingham, L; Johnson, P | 1 |
| Booth, B; Chattopadhyay, S; Farrell, AT; Justice, R; Kane, RC; Madabushi, R; Pazdur, R; Sridhara, R | 1 |
| Graziadei, I; Königsberg, R; Kornek, G; Maieron, A; Peck-Radosavljevic, M; Pinter, M; Plank, C; Sieghart, W; Vogel, W; Weissmann, A | 1 |
| Clark, JW; Zhu, AX | 1 |
| Greten, TF; Malek, N; Manns, MP | 1 |
| Befeler, AS; Gogia, S | 1 |
| Antonucci, M; Cabibbo, G; Craxì, A; Latteri, F | 1 |
| Apostolidis, L; Horstmann, S; Jäger, D; Kahlert, C; Lordick, F; Siegmund, A; Thom, R | 1 |
| Keating, GM; Santoro, A | 1 |
| Ayuso, C; Bru, C; Bruix, J; Buti, M; de la Mata, M; Forner, A; Isabel Real, M; Llovet, JM; Martí-Bonmatí, L; Robles, R; Sangro, B; Sastre, J; Tabernero, J; Varela, M | 1 |
| Desmedt, E; Digue, L; Milano, G; Mortier, L; Ravaud, A | 1 |
| Dreyer, C; Faivre, S; Raymond, E | 1 |
| Di Micoli, A; Frigerio, M; Santi, V; Trevisani, F | 1 |
| Bhat-Nakshatri, P; Maluccio, MA; Nakshatri, H; Saxena, R; Sheng, H; Skill, NJ; Wu, JM; Yu, M | 1 |
| El-Serag, HB; Hussain, K | 1 |
| Eskens, FA; Verheul, HM; Verhoef, C; Witjes, CD | 1 |
| Rosmorduc, O | 1 |
| Asemissen, AM; Keilholz, U; Knoedler, M; Miller, K; Schmittel, A; Steiner, U; Thiel, E; Zimmermann, K | 1 |
| Oseini, AM; Roberts, LR | 1 |
| Cao, MR; Li, AM; Lü, CW; Luo, RC; Su, N; Wei, L; Yan, X; Zheng, DY | 1 |
| Ball, SA; Plowman, PN; Reznek, R; Richards, TM | 1 |
| Chiang, D; Llovet, JM; Mínguez, B; Tovar, V; Villanueva, A | 1 |
| Ye, SL | 1 |
| De Roover, A; Delwaide, J; Detry, O; Honoré, P; Lamproye, A; Meunier, P; Polus, M; Van Daele, D | 1 |
| Jansen, PL; Kuiken, SD; Richel, DJ; van Delden, OM | 1 |
| Cui, YZ; Huang, N; Li, AM; Lü, CW; Luo, RC; Wei, L; Yang, L; Zheng, DY; Zheng, H | 1 |
| Rimassa, L; Santoro, A | 2 |
| Burkemper, NM; Chappell, JA; Semchyshyn, N | 1 |
| Chen, MS; Li, P; Lin, XJ; Xu, L; Yuan, YF; Zhang, YQ | 1 |
| Berg, CP; Bitzer, M; Claussen, CD; Gregor, M; Horger, M; Koppenhöfer, U; Lauer, UM; Schraml, C | 1 |
| Dai, Z; Fan, J; Yu, L; Zhou, J | 1 |
| Barbaro, B; Gasbarrini, A; Lauritano, EC; Novi, M; Piscaglia, AC; Pompili, M; Zocco, MA | 1 |
| Mendizabal, M; Reddy, KR | 1 |
| Dudley, AC; Klagsbrun, M | 1 |
| Qin, LX; Sun, HC; Tang, ZY; Wang, L; Wu, WZ; Xiong, YQ; Zhang, JB; Zhang, W; Zhu, XD; Zhuang, PY | 1 |
| Li, M; Li, N; Wu, T; Zhang, Y | 1 |
| Alsinet, C; Bruix, J; Cabellos, L; Chiang, DY; Deniz, K; Fiel, MI; Friedman, SL; Hoshida, Y; Lim, KH; Llovet, JM; Mazzaferro, V; Melgar-Lesmes, P; Minguez, B; Newell, P; Peix, J; Roayaie, S; Savic, R; Schwartz, M; Thung, S; Toffanin, S; Tovar, V; Villanueva, A; Yea, S | 1 |
| Christensen, O; Chu, QS; Das, S; Meza-Junco, J; Rajagopalan, P; Sawyer, MB; Stefanyschyn, R | 1 |
| Cascinu, S | 1 |
| Zhu, AX | 5 |
| Daniele, B; Di Maio, M; Perrone, F | 1 |
| Balabanov, S; Benten, D; Braig, M; Brummendorf, TH; Gontarewicz, A; Keller, G; Lohse, AW; Moll, J; Quaas, A; Schrader, J; Wege, H | 1 |
| Bai, S; Datta, J; Ghoshal, K; Hsu, SH; Kumar, P; Kutay, H; Nasser, MW; Nuovo, G; Wang, B; Yadav, A | 1 |
| Cheng, AL; Fan, HH; Hsu, C; Liang, JD; Liou, JY; Lu, YS; Ou, DL; Shen, YC; Wang, DS; Yu, SL | 1 |
| Huang, WS; Yang, CH | 1 |
| Bitzer, M; Claussen, CD; Horger, M; Lauer, U; Martirosian, P; Schraml, C; Schwenzer, NF | 1 |
| Chiou, JF; Jen, YM; Liu, TZ; Shiau, CY; Tai, CJ; Wang, YH | 1 |
| Song, IH | 1 |
| Bruera, G; Giordano, AV; Lapecorella, M; Lucchesi, A; Mariani, G; Napolitano, M; Ricevuto, E; Tudini, M | 1 |
| Printz, C | 1 |
| An, J; Chang, YJ; Chiou, JF; Huang, MT; Liu, TZ; Tai, CJ; Wang, YH; Wei, PL; Wu, CH | 1 |
| Escudier, B; Fizazi, K; Gross-Goupil, M; Massard, C; Szczylik, C; Zonierek, J | 1 |
| Coupe, P; Fournier, P; Gautier, S; Gerard, R; Marks, AB | 1 |
| Dumortier, J; Guillet, M; Lombard-Bohas, C; Scoazec, JY; Vial, T; Walter, T | 1 |
| Bruix, J; Reig, M | 1 |
| Choo, SP; Chow, P; Chung, A; Goh, BC; Huynh, H; Koong, HN; Ngo, VC; Ong, HS; Poon, D; Smith, PD; Soo, KC; Thng, CH; Toh, HC | 1 |
| Chen, KF; Chen, PJ; Cheng, AL; Lee, SS; Liu, TH; Yu, HC | 1 |
| Montalvo, RO; Moretti, LV | 1 |
| Cabrera, R; Nelson, DR | 1 |
| Mayor, S | 1 |
| Bolondi, L; Greten, TF; Lammer, J; Peck-Radosavljevic, M; Rosmorduc, O; Sangro, B; Santoro, A | 1 |
| Ajani, JA; Cheng, H; Gusani, NJ; Jiang, Y; Kimchi, ET; Staveley-O'Carroll, KF | 1 |
| Ahmed, A; Balfe, P; Bicknell, R; Farquhar, MJ; Harris, HJ; Hu, K; Maurel, P; McKeating, JA; Mee, CJ; Ramma, W | 1 |
| Brade, AM; Chung, C; Dawson, LA; Joshua, AM | 1 |
| Saif, MW | 1 |
| Aksoy, S; Altundag, K; Arslan, C; Dede, DS; Dogan, E | 1 |
| Cheng, P; Ding, X; Gao, H; Liu, H; Su, X; Wang, D; Wei, D; Zhang, T | 1 |
| Finn, RS; Saab, S; Yeganeh, M | 1 |
| Liu, ZZ; Piao, Y; Xie, XD | 1 |
| Duan, F; Liu, FY; Song, P; Wang, MQ; Wang, ZJ | 1 |
| Bitzer, M; Claussen, CD; Hartmann, JT; Horger, M; Maksimovic, O; Pintoffl, J; Schraml, C | 1 |
| Bruix, J; Navasa, M | 1 |
| Aracil, C; Bruix, J; Bustamante, J; de la Mata, M; Del Val, A; Matilla, A; Pascasio, JM; Pascual, S; Reig, M; Rodríguez, M; Turnes, J; Varela, M | 1 |
| Addeo, R; Bianco, M; Capasso, E; Caraglia, M; Cennamo, G; D'Agostino, A; Faiola, V; Febbraro, A; Guarrasi, R; Maiorino, L; Mamone, R; Montella, L; Montesarchio, V; Palmieri, G; Piai, G; Pisano, A; Prete, SD; Sabia, A; Savastano, C; Tarantino, L; Vincenzi, B | 1 |
| Braillon, A | 1 |
| Addeo, R; Caraglia, M; Colucci, G; Del Prete, S; Frezza, AM; Giuliani, F; Montella, L; Rizzo, S; Russo, A; Santini, D; Tonini, G; Venditti, O; Vincenzi, B | 1 |
| Forner, A; Llovet, JM; Minguez, B; Reig, M; Villanueva, A | 1 |
| Hasskarl, J | 1 |
| Adham, M; Boschetti, G; Cassier, P; Dumortier, J; Hervieu, V; Lombard-Bohas, C; Scoazec, JY; Walter, T | 1 |
| Hayashi, N; Hosui, A; Ishida, H; Kohga, K; Miyagi, T; Takehara, T; Tatsumi, T | 1 |
| Braconi, C; Croce, CM; Gasparini, P; Huang, N; Nuovo, G; Patel, T; Suzuki, T; Taccioli, C; Valeri, N | 1 |
| Smilde, T; Toonen, F | 1 |
| Akriviadis, E; Dedes, I; Drevelegas, A; Papalavrentios, L; Sinakos, E | 1 |
| Yen, Y; Zhou, W | 1 |
| Aitini, E; Cengarle, R; Costa, P; Fibbia, GC; Morandini, B; Perboni, G; Scalzini, A; Tagliani, A | 1 |
| Chen, Z; Gu, K; Jiang, GL; Li, WT; Liu, J; Liu, LM; Ren, ZG; Xu, ZY; Zhao, JD; Zhou, ZH | 1 |
| Bruix, J; de Lope, CR; Forner, A; Reig, ME | 1 |
| Chevreau, C; Dielenseger, P; Ederhy, S; Goldwasser, F; Grange, JD; Mortier, L; Neidhardt-Berard, ME; Robert, C; Rosmorduc, O; Scotté, F; Seitz, JF | 1 |
| Bouattour, M; Castelnau, C; Degos, F; Farges, O; Ozenne, V; Paradis, V; Pernot, S; Valla, D; Vullierme, MP | 1 |
| Bang, YJ; Han, SW; Im, SA; Kim, JW; Kim, TY; Lee, JO; Oh, DY | 1 |
| Byrnes, A; Pancoast, JR; Rixe, O; Verma, S; Wang, SX | 1 |
| Bali, MA; Devière, J; Maréchal, R; Van Laethem, JL; Verset, G | 1 |
| Ikeda, M; Kondo, S; Mitsunaga, S; Morizane, C; Nakachi, K; Okusaka, T; Ueno, H | 1 |
| Doki, Y; Hayashi, N; Hikita, H; Hosui, A; Ishida, H; Kodama, T; Miyagi, T; Mori, M; Nagano, H; Noda, T; Shimizu, S; Takehara, T; Tatsumi, T | 1 |
| Bhoori, S; Germini, A; Lampis, A; Mazzaferro, V; Pellegrinelli, A; Sposito, C; Toffanin, S | 1 |
| Kriener, S; Mönch, C; Trojan, J; Welker, MW; Zangos, S; Zeuzem, S | 1 |
| Chen, PJ; Cheng, AL; Ding, YH; Hsu, C; Hsu, CH; Lin, ZZ; Shao, YY; Shen, YC | 1 |
| Balsom, SM; Bekaii-Saab, TS; Bloomston, M; Li, X; Patel, T; Rose, J; Trolli, E | 1 |
| Carr, BI; Wang, M; Wang, Z | 1 |
| Saadati, H; Saif, MW | 1 |
| Hirose, R; Vagefi, PA | 2 |
| Crea, F; Landolfi, R; Leo, A; Miele, L; Pompili, M; Porto, I | 1 |
| Fehér, J; Lengyel, G | 1 |
| Ahn, CS; Hwang, S; Kang, YK; Kim, KH; Kim, TW; Lee, HC; Lee, SG; Moon, DB; Ryoo, BY; Ryu, MH; Suh, DJ; Yoon, DH | 1 |
| Bayliss, S; Connock, M; Greenheld, W; Moore, D; Round, J; Tubeuf, S | 1 |
| Ichijo, T; Joshita, S; Kamijo, A; Kobayashi, S; Komatsu, M; Matsumoto, A; Morita, S; Sano, K; Sekiguchi, T; Tanaka, E; Umemura, T; Yoshizawa, K | 1 |
| Ikeda, K | 1 |
| Bechstein, WO; Engels, K; Gog, C; Herrmann, E; Lubomierski, N; Trojan, J; Vogl, TJ; Welker, MW; Zeuzem, S | 1 |
| Cheng, AL; Hsu, C; Shen, YC | 1 |
| Brown, RS; Magun, A; Olsen, SK; Siegel, AB | 1 |
| Burak, KW; Thomas, MB; Zhu, AX | 1 |
| Abou-Alfa, GK; Geschwind, JF; Krishnan, S; Salem, R; Schwarz, RE; Venook, AP | 1 |
| Beck, J; Bellmunt, J; Escudier, B | 1 |
| Barbare, JC; Belghiti, J; Castaing, D; Chirica, M; Farges, O; Paradis, V; Soubrane, O; Vullierme, MP | 1 |
| Fischer, L; Herden, U; Nashan, B; Schäfer, H; Sterneck, M; von Baehr, V | 1 |
| Han, KH; Lee, JM | 1 |
| Barbaro, D | 1 |
| Aucejo, F; Kim, R; Menon, N | 1 |
| Kudo, M; Lencioni, R; Marrero, J; Venook, A; Ye, SL | 1 |
| Barbare, JC; Chatelain, D; Descamps, V; Duverlie, G; Ezzoukhry, Z; François, C; Galmiche, A; Godin, C; Joly, JP; Louandre, C; Mazière, JC; Nguyen-Khac, E; Regimbeau, JM; Sabbagh, C; Trouillet, N | 1 |
| Agaimy, A; Hartmann, A; Ocker, M; Strobel, D; Wich, C; Wissniowski, TT | 1 |
| Spinzi, G; Terreni, N | 1 |
| Armstrong, C; Hull, D | 1 |
| Arrivé, L; Fartoux, L; Lewin, M; Menu, Y; Rosmorduc, O; Vignaud, A | 1 |
| Dawson, LA; Horgan, AM; Knox, JJ; Swaminath, A | 1 |
| Duerden, M | 1 |
| Billemont, B; Blanchet, B; Coriat, R; Dauphin, A; Faivre, L; Goldwasser, F; Gomo, C; Mir, O; Ropert, S; Tod, M | 1 |
| Chan, P; Pang, R; Poon, RT; Yau, T | 1 |
| Aucejo, F; Kim, R | 1 |
| Merle, P; Mornex, F | 1 |
| Dank, M | 1 |
| Hayashi, N; Hikita, H; Hiramatsu, N; Hosui, A; Ishida, H; Iwase, K; Kanto, T; Kodama, T; Li, W; Miyagi, T; Shigekawa, M; Shimizu, S; Takehara, T; Tatsumi, T | 1 |
| Berardi, R; Cascinu, S; Del Prete, M; Di Pietro Paolo, M; Faloppi, L; Maccaroni, E; Scartozzi, M | 1 |
| Chamalidou, E; Chelis, L; Deftereos, S; Kakolyris, S; Maltezos, E; Ntinos, N; Souftas, V; Xenidis, N | 1 |
| Rowe, IA | 1 |
| Kan, HP; Tan, YF; Wang, Y; Zhou, J | 1 |
| Beck-Peccoz, P; Fugazzola, L; Iavarone, M; Perrino, M; Viganò, M | 1 |
| Bustamante, J; Castells, L; de La Mata, M; Delgado, M; Forner, A; Matilla, A; Moreno, JM; Reig, M; Varela, M | 1 |
| Josephs, DH; Ross, PJ | 1 |
| Huang, Z; Li, C; Wu, P; Zhang, F; Zhang, L; Zhang, W | 1 |
| Jeske, S; Kung, S; Lehrer, D; Matulich, D; Mazumdar, M; Milowsky, MI; Nanus, DM; Selzer, J; Sung, M; Tagawa, ST; Wright, JJ | 1 |
| Chen, KF; Chen, PJ; Cheng, AL; Huang, HP; Li, PK; Lin, YC; Liu, TH; Shiau, CW; Tai, WT | 1 |
| Bitzer, M; Claussen, CD; Fenchel, M; Gregor, M; Horger, M; Lauer, UM; Spira, D | 1 |
| Heinz, WJ; Helle-Beyersdorf, A; Kahle, K; Keller, D; Klinker, H; Langmann, P; Lenker, U; Schirmer, D | 1 |
| Frederick, RT; Frenette, CT; Gish, RG | 1 |
| Duffy, A; Greten, T | 1 |
| Audrain, O; Boucher, E; Leroux, C; Pracht, M; Raoul, JL; Vauléon, E; Zoheir, Y | 1 |
| Malek, NP; Manns, MP; Vogel, A | 1 |
| Hagymási, K; Tulassay, Z | 1 |
| Arai, K; Kaneko, S; Yamashita, T | 1 |
| Hoshida, Y; Newell, P; Villanueva, A | 1 |
| Hu, BS; Huang, GM; Huang, JW; Li, Y; Lu, LG; Shao, PJ; Wei, ZG; Zhang, L | 1 |
| Borner, M; Candinas, D; Dufour, JF; Heim, MH; Helbling, B; Hoppe, H; Kickuth, R; Maurhofer, O; Saar, B; Szucs-Farkas, Z | 1 |
| Carr, BI; Carroll, S; Gondek, K; Muszbek, N | 1 |
| Izumi, N; Kuzuya, T; Tsuchiya, K | 1 |
| Aucejo, F; Byrne, M; Chang, YD; El-Gazzaz, G; Elson, P; Kim, R; Tan, A | 1 |
| Düber, C; Galle, PR; Otto, G; Schuchmann, M; Weinmann, A; Wörns, MA | 1 |
| Abou-Alfa, GK; Capanu, M; Davidenko, I; Gansukh, B; Johnson, P; Knox, JJ; Lacava, J; Leung, T; Saltz, LB | 1 |
| Halff, G; Speeg, KV; Wang, Y; Washburn, WK | 1 |
| Jung, O; Kang, M; Kim, H; Kim, HJ; Kwak, TK; Lee, JW; Lee, MS; Lee, SA; Park, KH; Ryu, HW | 1 |
| FENG, FL; JIANG, XQ; LAU, WY; LIU, C; LUO, XJ; QIU, YH; Qiu, ZQ; RAN, RZ; TAN, WF; WANG, JH; WU, MC; YAN, PN; YI, B; YU, Y; ZHANG, BH | 1 |
| Hofmann, WP; Trojan, J; Waidmann, O; Zeuzem, S | 1 |
| Chen, XP; Dagher, L; Lencioni, R; Venook, AP | 1 |
| Büchler, MW; Franz, C; Hoffmann, K; Mohr, E; Schemmer, P; Serba, S; Xiao, Z | 1 |
| Chen, H; Chen, Z; Lin, JH; Liu, LM; Meng, ZQ; Xu, LT; Zhou, ZH | 1 |
| Chen, Y; Gan, YH; Ge, NL; Ren, ZG; Wang, YH; Xie, XY; Ye, SL; Zhang, BH; Zhang, L | 1 |
| Busuttil, RW; Finn, RS; McTigue, M; Saab, S | 1 |
| Di Stefano, G; Fiume, L; Manerba, M; Vettraino, M | 2 |
| Bozorgzadeh, A; Grossman, S; Piperdi, B; Rawson, AP; Saidi, RF; Shah, SA | 1 |
| Chung, YH; Jin, YJ; Kang, YK; Kim, KM; Ko, GY; Lee, HC; Lee, JL; Lee, YS; Lim, YS; Shim, JH; Suh, DJ; Sung, KB; Yoo, DJ; Yoon, HK | 1 |
| Angulo, P; Chen, C; Daily, MF; Evers, BM; Gedaly, R; Hundley, J; Koch, A | 1 |
| Azzariti, A; Colucci, G; Fratto, ME; Galluzzo, S; Maiello, E; Santini, D; Silvestris, N; Tommasi, S; Tonini, G; Vincenzi, B; Zoccoli, A | 1 |
| Bouattour, M; Faivre, S; Raymond, E | 1 |
| Chen, HL; Chen, KF; Chen, PJ; Cheng, AL; Feng, WC; Hsu, CH; Tai, WT | 1 |
| Aramendi, T; Balbin, E; Diaz-Sanchez, A; Rodriguez-Salas, N | 1 |
| Aomatsu, K; Arao, T; Fujita, Y; Furuta, K; Kaneda, H; Kimura, H; Kudo, K; Kudo, M; Matsumoto, K; Nagai, T; Nishio, K; Saijo, N; Sakai, K; Tamura, D | 1 |
| Amano, R; Hirakawa, K; Ishikawa, T; Kubo, N; Maeda, K; Muguruma, K; Nakata, B; Noda, E; Ohira, M; Onoda, N; Sawada, T; Takashima, T; Tanaka, H; Yamada, N; Yashiro, M | 1 |
| Ishizaki, M; Kaibori, M; Kwon, AH; Matsui, K; Nakatake, R; Yanagimoto, Y | 1 |
| Guan, YS; He, Q | 1 |
| Lord, R; Ross, PJ; Suddle, A | 1 |
| Girard, N; Mornex, F | 1 |
| Peck-Radosavljevic, M; Pinter, M; Reisegger, M; Sieghart, W; Wrba, F | 1 |
| Altomare, E; Bargellini, I; Bartolozzi, C; Battaglia, V; Bertini, M; Bertoni, M; Bozzi, E; Bresci, G; Capria, A; Gianluigi, G; Romano, A; Sacco, R | 1 |
| Donaldson, MR; Smith, JL; Stetson, CL | 1 |
| Baek, YH; Cho, JH; Han, JS; Han, SY; Kim, BG; Kim, SO; Lee, SW; Nam, KJ | 1 |
| Ahn, SH; Choi, HJ; Han, KH; Kim, DY; Lee, S; Park, JY; Yoon, SH | 1 |
| Beljanski, V; Lewis, CS; Smith, CD | 1 |
| Borg, C; Curtit, E; Di Martino, V; Heyd, B; Nguyen, T; Pivot, X; Thiery-Vuillemin, A | 1 |
| Cheng, SQ; Deng, YZ; Feng, YX; Guan, DX; Li, JJ; Li, N; Qin, Y; Wang, H; Wang, HY; Wang, T; Wang, XF; Wu, MC; Xie, D; Yang, P; Yao, F; Zhu, YQ | 1 |
| Eskens, FA; Mathijssen, RH; Peeters, RP; van der Lugt, A; van Doorn, L; Visser, TJ | 1 |
| Choi, BI; Kim, KW; Lee, JM | 1 |
| Bornschein, J; Csepregi, A; Malfertheiner, P; Ricke, J; Rühl, R; Schütte, K; Zimmermann, L | 1 |
| Cabrera, R; Cao, M; Gabrilovich, D; Liu, C; Nelson, DR; Xu, Y; Youn, JI; Zhang, X | 1 |
| Chen, BB; Cheng, AL; Hsu, C; Hsu, CH; Hsu, CY; Hu, FC; Shen, YC; Shih, TT; Wei, SY; Yu, CW | 1 |
| Prasad, SR; Sahani, DV; Shanbhogue, AK; Takahashi, N; Vikram, R | 1 |
| Blanchet, B; Chaussade, S; Coriat, R; Goldwasser, F; Gouya, H; Legmann, P; Mir, O; Pol, S; Ropert, S; Sogni, P; Vignaux, O | 1 |
| Lanzuela, M; Lao, J; Pazo Cid, RA | 1 |
| Borentain, P; Durieux, O; Garcia, S; Gérolami, R; Gregoire, E; Hardwigsen, J; Le Treut, YP | 1 |
| Carr, BI; Hyslop, T; Wang, M; Wang, Z; Wei, G | 1 |
| Alpini, G; Cleary, JP; DeMorrow, S; Francis, H; Glaser, SS; Han, Y; Hubble, L; Kumar, P; Liu, CG; Liu, X; Meng, F; Passarini, JD; Priester, S; Sharma, J; Staloch, D; Stokes, A; Venter, J | 1 |
| Chen, KF; Chen, PJ; Cheng, AL; Huang, HP; Huang, JW; Shiau, CW; Tai, WT | 1 |
| Adams, DR; Lynch, MC; Straub, R | 1 |
| Choi, JI; Kim, MJ; Lee, JS; Park, JW | 1 |
| Bruix, J; Sherman, M | 1 |
| Jin-hui, T; Ke-hu, Y; Li, M; Ling-lin, Z | 1 |
| Akladios, CY; Aprahamian, M; Balboni, G; Bour, G; Marescaux, J; Mutter, D | 1 |
| Dahut, WL; Figg, WD; Gardner, ER; Giaccone, G; Jain, L; Kohn, EC; Kummar, S; Mould, DR; Venitz, J; Woo, S; Yarchoan, R | 1 |
| Kim, DY | 1 |
| Bell, JC; Breitbach, CJ; Falls, T; Heo, J; Hickman, T; Hwang, TH; Kim, CW; Kim, MK; Kirn, DH; Lee, YK; Moon, A; Oh, SY; Parato, K; Patt, R; Rhee, BG; Rintoul, J; Woo, HY | 1 |
| Chang, HM; Kang, YK; Kim, JE; Kim, KM; Lee, HC; Lim, YS; Ryoo, BY; Ryu, MH; Suh, DJ | 2 |
| Belghiti, J; Chopin-Laly, X; Faivre, S; Irtan, S; Paradis, V; Ronot, M | 1 |
| Abbass, K; Baumann, MA; Dewani, S; Kaplon, MK; Markert, R | 1 |
| Chen, YJ; Liang, CP; Shen, JL; Yang, CS | 1 |
| Boeykens, E; Rutsaert, R; Stappaerts, I; Van Loo, S | 1 |
| Choi, JI; Kim, CM; Kim, HB; Kim, HK; Kim, HY; Kim, TH; Nam, BH; Park, JW | 1 |
| Abbruzzese, A; Addeo, R; Caraglia, M; Giuberti, G; Marra, M; Montella, L; Murolo, M; Naviglio, S; Prete, SD; Sperlongano, P; Stiuso, P; Vincenzi, B | 1 |
| Fernández-Contreras, ME; Hinojar-Gutiérrez, A; Mendoza, J; Mera-Menéndez, F; Moreno, R; Nieto-Llanos, S | 1 |
| Hua, SC; Li, Y; Liu, J; Liu, L; Ma, CY; Yang, M; Yuan, Q; Zhang, X; Zhou, C | 1 |
| Aucejo, F; Byrne, MT; Kim, R; Tan, A | 1 |
| Burak, KW | 1 |
| Gores, GJ; Razumilava, N | 1 |
| Chao, CC; Kuo, TC; Lu, HP | 1 |
| Chong, LW; Huynh, H; Jong, CT; Lam, IW; Lee, SS; Li, PY; Luu, DA; Ong, RW; Yang, S | 1 |
| Hashemolhosseini, S; Hellerbrand, C; Klinger, N; Neureiter, D; Ocker, M; Sass, G; Sirma, H; Tiegs, G; Wege, H | 1 |
| Chen, M; Orsini, LS; Qiao, YL; Therneau, T | 1 |
| Flaig, MJ; Prinz, JC; Rübsam, K; Ruzicka, T | 1 |
| Abou-Alfa, GK; Carter, WD; Chan, SL; Chiorean, EG; Gutheil, JC; Holcombe, RF; Lin, CC; Melink, TJ; Mulcahy, MF; Patel, K; Tsao, CJ; Wilson, WR | 1 |
| Abou-Alfa, GK; Gish, RG; Tong, MJ | 1 |
| Caja, L; Campbell, JS; Fabregat, I; Fausto, N; Fernández-Rodriguez, CM; Fernando, J; Lledó, JL; Sancho, P | 1 |
| Cabrera, R; Caridi, J; Clark, V; Firpi, RJ; George, TJ; Morelli, G; Nelson, DR; Pannu, DS; Soldevila-Pico, C; Suman, A | 1 |
| Cohen, L; Gao, Y; Gu, K; Li, HX; Meng, ZQ; Wang, P; Xu, LT; Xu, LY; Yang, PY | 1 |
| Belghiti, J; Botti, M; Boussaha, T; Dubreuil, O; Housset, M; Landi, B; Rougier, P; Taieb, J; Trouilloud, I; Williet, N | 1 |
| Abbadessa, G; Carrillo-Infante, C; Cucchi, E; Pressiani, T; Rimassa, L; Santoro, A | 1 |
| Betlloch, I; Cuesta, L; Latorre, N; Monteagudo, A; Toledo, F | 1 |
| Boers-Doets, C; Chrysou, M; Edmonds, K; Hull, D; Koldenhof, J; Molassiotis, A; Spencer-Shaw, A | 1 |
| Airoldi, A; Mancuso, A; Pinzello, G; Vigano, R | 1 |
| He, JT; Zhang, D | 1 |
| Chida, N; Furuse, J; Hayashi, N; Hori, T; Imanaka, K; Kaneko, S; Kudo, M; Kumada, H; Matsui, O; Meinhardt, G; Nakachi, K; Ohya, T; Okita, K; Okusaka, T; Suh, DJ; Tak, WY; Takayama, T; Tanaka, K; Tsubouchi, H; Wada, M; Yamaguchi, I; Yoon, JH | 1 |
| Dai, Z; Fan, J; Hu, J; Huang, XW; Qiu, SJ; Tan, CJ; Wang, Z; Zhou, J | 1 |
| Dai, Z; Ding, ZB; Fan, J; Gu, CY; Hui, B; Ke, AW; Peng, YF; Qiu, SJ; Shi, GM; Shi, YH; Wang, XY; Zhou, J | 1 |
| Kang, WK; Lee, J; Lee, SJ; Lim, HY; Park, JO; Park, SH; Park, YS; Yim, DS | 1 |
| Spicák, J; Suchánková, G | 1 |
| Baek, KK; Kang, WK; Kim, JH; Lee, J; Lim, HY; Park, JO; Park, SH; Park, YS; Uhm, JE | 1 |
| Boucher, E; Edeline, J; Le Roux, C; Perrin, C; Pracht, M; Raoul, JL; Rolland, Y; Vauléon, E | 1 |
| Desbois-Mouthon, C; Rosmorduc, O | 1 |
| Ahn, HK; Kang, WK; Lee, J; Lee, S; Lim, HY; Park, JO; Park, SH; Park, YS; Sun, JM | 1 |
| Abdulghani, J; Allen, JE; Dicker, DT; Dolloff, NG; El-Deiry, WS; Gallant, JN; Hong, B; Katz, SI; Navaraj, A; Smith, CD; Wang, W | 1 |
| Huang, C; Nan, K; Suo, A; Yao, Y; Zhang, L; Zhang, M; Zhang, W | 1 |
| Hong, SH; Jeon, EK; Jeong, HK; Ko, YH; Lee, SL; Roh, SY; Shin, OR; Won, HS | 1 |
| Ahn, SH; Choi, HJ; Han, KH; Kim, DY; Lee, JD; Lee, JH; Park, JY; Seo, HJ | 1 |
| Aubourg, A; Bacq, Y; Lucas, E; Perarnau, JM | 1 |
| Al-Osaimi, AM; Argo, CK; Caldwell, SH; Northup, PG; Schmitt, TM; Shah, NL; Truesdale, AE | 1 |
| Broneshter, R; Iancu, TC; Manov, I; Pollak, Y | 1 |
| Budak, K; Pestalozzi, B; Weisshaupt, Ch | 1 |
| Bareford, MD; Burow, ME; Cruickshanks, N; Dent, P; Fisher, PB; Grant, S; Hamed, HA; Moran, RG; Nephew, KP; Tang, Y | 1 |
| Hu, ML; Huang, CS; Lyu, SC | 1 |
| Kim, HY; Park, JW | 1 |
| Chung, H; Hagiwara, S; Inoue, T; Ishikawa, E; Kitai, S; Kudo, M; Minami, Y; Nagai, T; Sakurai, T; Takita, M; Tatsumi, C; Ueda, T; Ueshima, K; Yada, N | 1 |
| Choo, SP; Chow, PK; Chung, AY; Huynh, H; Ong, R; Soo, KC; Tai, WM; Toh, HC | 1 |
| Fujita, N; Hayashi, N; Hikita, H; Hiramatsu, N; Hosui, A; Ishida, H; Kanto, T; Kodama, T; Miyagi, T; Shimizu, S; Takehara, T; Tatsumi, T; Tsunematsu, H; Yoshimori, T | 1 |
| Anders, RA; Bai, H; Chenna, V; Fan, J; Hu, C; Khan, M; Maitra, A; Sun, HX; Sun, YF; Xu, Y; Yang, XR; Zhu, QF | 1 |
| Buder, R; Graziadei, I; Grünberger, B; Hucke, F; Königsberg, R; Kornek, G; Maieron, A; Matejka, J; Müller, C; Peck-Radosavljevic, M; Pinter, M; Schöniger-Hekele, M; Sieghart, W; Stauber, R; Vogel, W; Weissmann, A | 1 |
| Chan, P; Fan, ST; Pang, R; Poon, RT; Wong, H; Yao, TJ; Yau, T | 1 |
| Cabibbo, G; Cammà, C; Colombo, M; Grieco, A; Iavarone, M; Piscaglia, F; Villa, E; Zavaglia, C | 1 |
| Hasegawa, Y; Itou, N; Nitta, H; Takahara, T; Takahashi, M; Wakabayashi, G | 1 |
| Bhagat, N; Cosgrove, D; Geschwind, JF; Kamel, IR; Pawlik, TM; Reyes, DK | 1 |
| Fukumoto, M; Ichida, T; Matsuda, Y | 1 |
| Albert, MH; Corbacioglu, S; Fröhlich, B; Graf, N; Häberle, B; Kammer, B; Kontny, U; Leuschner, I; Scheel-Walter, HG; Scheurlen, W; Schmid, I; von Schweinitz, D; Werner, S; Wiesel, T | 1 |
| Bustamante, J; Castroagudin, JF; Garralda, E; Gomez-Martin, C; Herrero, I; Matilla, A; Salcedo, M; Sangro, B; Testillano, M | 1 |
| Ciampi Dopazo, JJ; de Artaza Varasa, T; de la Cruz Perez, G; Gómez Moreno, AZ; Gómez Rodríguez, R; González de Frutos, C; Lanciego Pérez, C; Romero Gutiérrez, M | 1 |
| Kong, D; Ma, W; Song, T; Wu, Q; Zhang, W | 1 |
| Li, XH; Liu, Y; Yang, DH; Zhong, KB; Zhou, J | 1 |
| Boleslawski, E; Cattan, S; Dharancy, S; Ernst, O; Hebbar, M; Hollebecque, A; Louvet, A; Mathurin, P; Mourad, A; Pruvot, FR; Romano, O; Sergent, G; Truant, S | 1 |
| Bihari, C; Gupta, NL; Jain, D; Rastogi, A; Sarin, SK | 1 |
| Asghar, U; Meyer, T | 1 |
| Altomare, E; Bargellini, I; Bartolozzi, C; Battaglia, V; Bertini, M; Bozzi, E; Bresci, G; Di Biase, M; Ginanni, B; Romano, A; Sacco, R; Tumino, E | 1 |
| Jirillo, A; Mazurek, M; Palozzo, AC; Trojniak, MP | 1 |
| Galle, PR; Gamstätter, T; Niederle, IM; Schadmand-Fischer, S; Schuchmann, M; Spies, PR; Weinmann, A; Wörns, MA | 1 |
| Chen, TJ; Cheng, AL; Hsu, C; Hsu, CH; Lin, ZZ; Shao, YY; Shen, YC | 1 |
| Hara, F; Hirano, N; Iida, K; Ishii, K; Kikuchi, Y; Shiozawa, K; Sumino, Y; Wakui, N; Watanabe, M | 1 |
| Han, KH; Kim, DY | 2 |
| Hagihara, H; Ikeda, F; Kobayashi, S; Kuwaki, K; Miyahara, K; Miyake, Y; Nakamura, S; Nouso, K; Onishi, H; Shiraha, H; Takaki, A; Tomoda, T; Toshimori, J; Yamamoto, K | 1 |
| Fan, J; Gao, Q; Gu, FM; Huang, XY; Jiang, JH; Li, QL; Pan, JF; Zhou, J | 1 |
| Ferlitsch, A; Peck-Radosavljevic, M; Pinter, M; Reiberger, T; Rohr-Udilova, N; Sieghart, W | 1 |
| Bartolozzi, C; Iannopollo, M; Lencioni, M; Oliveri, F; Orlandini, C; Petrini, I; Ricasoli, M; Ricci, S | 1 |
| Lachenmayer, A; Mínguez, B | 1 |
| Cabibbo, G; De Giorgio, M; Genco, C; Pressiani, T; Rolle, E; Sacco, R; Spada, F | 1 |
| Adenis, A; Antonescu, CR; Blay, JY; Bompas, E; Bui, B; Casali, P; Cioffi, A; Coco, P; Coindre, JM; Debiec-Rychter, M; Duffaud, F; Isambert, N; Italiano, A; Keohan, ML; Le Cesne, A; Maki, RG; Rutkowski, P; Schöffski, P; Toulmonde, M | 1 |
| Amiand, MB; Bard, JM; Bobin-Dubigeon, C; Bouché, O; Heurgue-Berlot, A; Le Guellec, C | 1 |
| Bernardo, G; Cornalba, G; Delmonte, A; Di Cesare, P; Greco, G; Melchiorre, F; Montagna, B; Poggi, G; Quaretti, P; Riccardi, A; Sottotetti, F; Stella, MG; Tagliaferri, B; Villani, L; Zorzetto, M | 1 |
| Asahina, Y; Hoshioka, T; Hosokawa, T; Itakura, J; Izumi, N; Kato, T; Kurosaki, M; Kuzuya, T; Nakanishi, H; Suzuki, Y; Takahashi, Y; Tamaki, S; Tanaka, K; Tsuchiya, K; Ueda, K; Yasui, Y | 1 |
| Chan, AC; Chan, P; Cheung, TT; Chiu, J; Fan, ST; Leung, R; Pang, RW; Poon, R; Tang, YF; Wong, H; Yao, TJ; Yau, T | 1 |
| Lencioni, R | 1 |
| Chen, HC; Chen, YL; Hsu, HC; Jeng, YM; Yuan, RH | 1 |
| Kim, H; Lim, HY | 1 |
| Fukumoto, M; Matsuda, Y | 1 |
| Chen, KF; Chen, PJ; Cheng, AL; Ko, CH; Lin, MW; Liu, CY; Shiau, CW; Tai, WT | 1 |
| Hatano, E; Iida, T; Ishii, T; Isoda, H; Kitamura, K; Machimito, T; Shibata, T; Taura, K; Uemoto, S; Yamanaka, K; Yasuchika, K | 1 |
| Ishizaki, M; Kaibori, M; Kwon, AH; Matsui, K; Matsushima, H; Nakatake, R; Sakaguchi, T | 2 |
| Egawa, C; Kato, T; Miki, H; Nakahira, S; Nakata, K; Okamura, S; Okishiro, M; Suzuki, R; Takatsuka, Y; Takeda, Y; Takeno, A; Tamura, S | 1 |
| Baba, H; Beppu, T; Chikamoto, A; Horino, K; Ishiko, T; Masuda, T; Mima, K; Nakahara, O; Okabe, H; Takamori, H; Tanaka, H | 1 |
| Sia, D; Villanueva, A | 1 |
| Lee, IJ; Seong, J | 1 |
| Bae, SH; Guan, S; Lim, HY; Park, HC; Seong, J; Tak, WY; Tanaka, M; Zeng, ZC | 1 |
| Choi, JY | 1 |
| Henmi, S; Inuzuka, T; Kimura, T; Kita, R; Kudo, M; Nishikawa, H; Osaki, Y; Saito, S; Sakamoto, A; Sekikawa, A; Takeda, H | 1 |
| Gadaleta, CD; Gadaleta-Caldarola, G; Goffredo, V; Mangia, A; Patruno, R; Ranieri, G; Rizzo, A; Sciorsci, RL | 1 |
| Ba-Ssalamah, A; Lammer, J; Müller, C; Peck-Radosavljevic, M; Pinter, M; Reisegger, M; Sieghart, W | 1 |
| Chen, Z; Cheng, AL; Fang, F; Guan, Z; Kang, YK; Kim, JS; Lentini, G; Pan, H; Qin, S; Tak, WY; Tsao, CJ; Voliotis, D; Xu, J; Yang, TS; Yu, S; Zou, J | 1 |
| Bruix, J; Dominguez, S; Germanidis, G; Greten, TF; Hilgard, P; Llovet, JM; Mazzaferro, V; Moscovici, M; Nadel, A; Raoul, JL; Ricci, S; Scherubl, H; Scheulen, ME; Sherman, M; Voliotis, D | 1 |
| Galle, PR; Marquardt, JU; Teufel, A; Wörns, M | 1 |
| Angulo, P; Chen, C; Daily, MF; Evers, BM; Gedaly, R; Hundley, J | 1 |
| Düber, C; Galle, PR; Heise, M; Hoppe-Lotichius, M; Koch, S; Niederle, IM; Otto, G; Schuchmann, M; Weinmann, A; Wörns, MA | 1 |
| Aoyagi, Y; Fujimaki, S; Kubota, M; Matsuda, Y; Ohkoshi, S; Sanpei, A; Takamura, M; Wakai, T; Yamagiwa, S; Yano, M | 1 |
| Caravetta, A; Guarino, R; Mollo, F; Peluso, L; Rombolà, F; Spinoso, A | 1 |
| Gong, RY; Li, XF; Shi, LH; Wang, K; Wang, M; Yan, ZL; Yuan, B | 1 |
| Kondo, M; Maeda, S; Morimoto, M; Morioka, Y; Moriya, S; Nozaki, A; Numata, K; Tanaka, K | 1 |
| Han, SH; Kang, H; Park, H; Park, K | 1 |
| An, S; Choi, JI; Kim, HB; Kim, HY; Koh, YH; Nam, BH; Park, JW; Woo, SM | 1 |
| Ayuso, C; Barrufet, M; Bruix, J; Burrel, M; de Lope, CR; Forner, A; Llovet, JM; Real, MI; Reig, M; Tremosini, S | 1 |
| Chang, C; Hsu, CL; Huang, CK; Hung, YC; Jeng, LB; Lin, TY; Ma, WL; Wu, MH; Yeh, CC; Yeh, S | 1 |
| Alsinet, C; Cabellos, L; Friedman, SL; Hoshida, Y; Lachenmayer, A; Llovet, JM; Minguez, B; Thung, S; Toffanin, S; Tsai, HW; Villanueva, A; Ward, SC | 1 |
| Conteduca, V; Dammacco, F; Lauletta, G; Russi, S; Sansonno, D; Sansonno, L | 1 |
| Chang, KH; Chen, YJ; Cheng, SB; Hwang, WL; Teng, CL | 1 |
| Bruix, J; Forner, A; Llovet, JM | 1 |
| George, S; Hornick, JL; Jagannathan, JP; Ramaiya, NH; Shinagare, AB | 1 |
| Bruix, J; Lathia, CD; Llovet, JM; Meinhardt, G; Peña, CE; Shan, M | 1 |
| George, J; Nguyen, V; van der Poorten, D | 1 |
| Dufour, JF | 1 |
| Hidaka, H; Kaneko, T; Koizumi, W; Minamino, T; Nakazawa, T; Okuwaki, Y; Shibuya, A; Takada, J; Tanaka, Y; Watanabe, M | 1 |
| Chan, P; Cheung, TT; Fan, ST; Pang, R; Poon, RT; Wong, H; Yao, TJ; Yau, T | 1 |
| Bozzarelli, S; Carnaghi, C; Giordano, L; Pedicini, V; Personeni, N; Pressiani, T; Rimassa, L; Santoro, A; Sclafani, F; Tronconi, MC | 1 |
| Cillo, U; Lombardi, G; Ramirez Morales, R; Vitale, A | 1 |
| Artéaga, C; Brardjanian, S; Coton, T; Fabries, P; Guisset, M; Pauleau, G | 1 |
| Boudou-Rouquette, P; Cessot, A; Chaussade, S; Coriat, R; Durand, JP; Goldwasser, F; Mallet, V; Mir, O; Pol, S; Ropert, S; Sogni, P | 1 |
| Chan, SL; Ma, BB; Mok, T | 1 |
| Graziadei, I; Grünberger, B; Hucke, F; Kölblinger, C; Königsberg, R; Maieron, A; Müller, C; Peck-Radosavljevic, M; Pinter, M; Sieghart, W; Stauber, R; Vogel, W | 1 |
| Spechler, SJ; Wang, DH; Xie, B | 1 |
| An, L; Bai, W; Chang, X; Chen, Y; Lou, M; Lu, Y; Lv, J; Qu, J; Wang, C; Yang, Y; Zeng, Z; Zhou, L | 1 |
| Espat, NJ; Falanga, V; Katz, SC; Kurniali, PC; O'Gara, K; Somasundar, P; Wang, LJ; Wang, X | 1 |
| Cohen, RA; Feusner, JH; Lo, L; Marsh, AM | 1 |
| Barbare, JC; Chauffert, B; Diouf, M; Dupont, S; Ezzoukhry, Z; Galmiche, A; Godin, C; Louandre, C; Mazière, JC; Trécherel, E | 1 |
| Chan, AC; Chan, P; Cheung, TT; Chiu, J; Fan, ST; Leung, R; Pang, R; Poon, R; Tang, YF; Wong, A; Wong, H; Yao, TJ; Yau, T | 1 |
| Chan, SL; Johnson, P | 1 |
| Duan, F; Liu, FY; Song, P; Wang, MQ; Wang, Y; Wang, ZJ | 1 |
| Cha, SW; Cho, YD; Jang, JY; Jeong, SW; Kim, BS; Kim, HS; Kim, KH; Kim, SG; Kim, YJ; Kim, YS; Lee, JE; Lee, SH | 1 |
| Ahn, SH; Han, KH; Kim, BK; Kim, DY; Kim, EH; Kim, SU; Lee, DY; Park, JY; Park, MS; Seong, J | 1 |
| Byrne, M; Estfan, B; Kim, R | 1 |
| Cho, M; Heo, J; Kang, DH; Kim, GH; Song, GA; Woo, HY; Yoon, KT | 1 |
| Lucas, LM | 1 |
| De Luca, M; Di Costanzo, GG; Iodice, L; Lampasi, F; Lanza, AG; Mattera, S; Picciotto, FP; Tartaglione, MT; Tortora, R | 1 |
| Hagiwara, S; Inoue, T; Kudo, M; Nagai, T; Nishida, N; Sakurai, T; Ueshima, K; Watanabe, T | 1 |
| Cheng, AL; Hsu, CH; Huang, CC; Lin, SD; Shao, YY | 1 |
| Duan, F; Gu, J; Jia, D; Liu, X; Ren, S; Ruan, Y; Sun, L; Sun, Z; Wang, L; Zhou, L | 1 |
| Dauser, B; Dienes, HP; Dufour, JF; Hayden, H; Peck-Radosavljevic, M; Piguet, AC; Pinter, M; Prager, G; Rohr-Udilova, N; Sieghart, W | 1 |
| Aiello, RA; Alì, M; Caruso, M; La Rocca, R; Licciardello, P; Sanò, MV; Scandurra, G; Taibi, E; Todaro, FM | 1 |
| Igarashi, Y; Iida, K; Ishii, K; Kanayama, M; Kanekawa, T; Matsui, D; Momiyama, K; Mukozu, T; Nagai, H; Shinohara, M; Sumino, Y; Wakui, N | 1 |
| Blanchet, B; Boudou-Rouquette, P; Chaussade, S; Coriat, R; Durand, JP; Goldwasser, F; Michels, J; Mir, O; Pol, S; Ropert, S; Vidal, M | 1 |
| Spârchez, Z | 1 |
| Chatzimichail, K; Gkoutzios, P; Kalokairinou, M; Karagiannis, E; Kiltenis, M; Kornezos, I; Malagari, K; Moschouris, H; Papadaki, MG; Stamatiou, K | 1 |
| Du, H; Li, H; Lin, A; Peng, C; Qiu, W; Seewoo, V; Shen, B; Wang, J; Yang, W | 1 |
| Bronowicki, JP; Chen, XP; Cihon, F; Dagher, L; de Guevara, LL; Furuse, J; Geschwind, JF; Heldner, S; Kudo, M; Ladrón de Guevara, L; Lencioni, R; Marrero, JA; Nakajima, K; Papandreou, C; Sanyal, AJ; Takayama, T; Ye, SL; Yoon, SK | 1 |
| Endo, Y; Kai, K; Kawai, T; Koujima, T; Matsumoto, Y; Miyamoto, M; Nobuhisa, T; Sato, S; Toda, K; Watanabe, N; Watanabe, T; Watanabe, Y | 1 |
| Bockisch, A; Ertle, J; Lauenstein, TC; Müller, S; Schlaak, JF; Schlosser, TW; Theysohn, JM | 1 |
| Chen, CS; Chen, JM; Gong, GQ; Liu, LX; Liu, QX; Liu, R; Luo, JJ; Qian, S; Qu, XD; Wang, JH; Yan, ZP | 1 |
| Beaugrand, M; Bolondi, L; Bruix, J; Craxi, A; Galle, PR; Gerken, G; Llovet, JM; Marrero, JA; Mazzaferro, V; Moscovici, M; Nadel, A; Porta, C; Raoul, JL; Sangiovanni, A; Santoro, A; Shan, M; Sherman, M; Voliotis, D | 1 |
| Bae, SH; Chung, YH; Kim, BI; Kim, JA; Koh, KC; Lee, D; Lee, HC; Lee, JH; Park, NH; Shim, JH; Shin, ES; Yoon, JH | 1 |
| Fujimoto, K; Gemma, A; Horiuchi-Yamamoto, Y; Inoue, Y; Johkoh, T; Kudoh, S; Sakai, F; Taniguchi, H | 1 |
| Bargellini, I; Bartolozzi, C; Battaglia, V; Bertini, M; Bertoni, M; Bozzi, E; Bresci, G; Faggioni, L; Federici, G; Ginanni, B; Metrangolo, S; Neri, E; Parisi, G; Romano, A; Sacco, R; Sodini, E; Tumino, E | 1 |
| Angulo, P; Chen, C; Creasy, KT; Daily, MF; Evers, BM; Gedaly, R; Hundley, J; Shah, M; Spear, BT | 1 |
| He, X; Hu, BS; Li, Y; Lu, LG; Luo, XN; Shao, PJ; Yu, XY | 1 |
| Cao, L; Li, B; Li, YM; Sui, CJ; Yin, ZF; Zhang, XF; Zhou, YM | 1 |
| Gao, H; Hu, S; Jiang, H; Kong, J; Li, Z; Shi, B; Yang, Y; Yao, M; Zhang, P | 1 |
| Hidaka, H; Kobayashi, S; Kondo, M; Matsunaga, K; Morimoto, M; Numata, K; Ohkawa, S; Okuse, C; Okuwaki, Y; Shibuya, A; Suzuki, M; Takada, J; Tanaka, K | 1 |
| Alsinet, C; Barretina, J; Bruix, J; Cabellos, L; Friedman, SL; Hoshida, Y; Lachenmayer, A; Llovet, JM; Mazzaferro, V; Minguez, B; Newell, P; Savic, R; Schwartz, M; Thung, S; Toffanin, S; Tsai, HW; Villanueva, A; Ward, SC | 1 |
| Singal, AG; Subramanian, M; Yopp, AC | 1 |
| Feng, M; Liu, X; Wang, Q; Wang, Z; Yu, T; Yuan, Y; Zhuang, H | 1 |
| Barbero, C; Campisi, P; Centofanti, P; Giorgi, M; Molino, F; Rinaldi, M; Salizzoni, S | 1 |
| Altomare, E; Bargellini, I; Bartolozzi, C; Bertini, M; Bertoni, M; Bresci, G; Faggioni, L; Federici, G; Ginanni, B; Metrangolo, S; Parisi, G; Romano, A; Sacco, R; Scaramuzzino, A; Tumino, E | 1 |
| Amigo, G; Antón, A; Esquerdo, G; García-Otín, AL; Lanzuela, M; Martín-Duque, P; Pazo-Cid, RA; Pérez-Gracia, JL; Trufero, JM | 1 |
| Kaneko, S; Yamashita, T | 1 |
| Matsui, O | 1 |
| Yamashita, T | 1 |
| Hatano, E; Kokudo, N; Nakajima, J; Numata, K | 1 |
| Furuse, J; Ikeda, K; Ikeda, M; Izumi, N; Kokudo, N; Kudo, M; Matsui, O; Tateishi, R; Yamashita, T | 1 |
| Díaz-Rubio, E; Ladero, JM; Manzano, A; Puente, J; Sastre, J; Zugazagoitia, J | 1 |
| Fischer, L; Nashan, B; Seegers, B; Staufer, K; Sterneck, M; Vettorazzi, E | 1 |
| He, XS; Hu, AB; Huang, JF; Ju, WQ; Ma, Y; Tai, Q; Wang, DP; Wang, GD; Wu, LW; Zhu, XF | 1 |
| Aikata, H; Chayama, K; Hiramatsu, A; Honda, Y; Kawaoka, T; Miyaki, D; Murakami, E; Naeshiro, N; Nagaoki, Y; Nakahara, T; Takahashi, S; Takaki, S; Tanaka, M; Waki, K | 1 |
| Arao, T; Arii, S; Hagiwara, S; Haji, S; Hakamada, K; Hiasa, Y; Hidaka, H; Hirooka, M; Hisai, H; Iso, Y; Izumi, N; Kanazawa, A; Kimura, H; Kubota, K; Kudo, M; Kumada, T; Kuzuya, T; Matsumoto, K; Nagai, T; Nishio, K; Sakurai, T; Sato, S; Shimada, M; Toyoda, H; Toyoki, Y; Tsuchiya, K; Ueshima, K; Utsunomiya, T; Yasui, K | 1 |
| Caccialanza, R; Ganini, C; Imarisio, I; Magnani, L; Paglino, C; Porta, C | 1 |
| Alexandre, J; Batteux, F; Chaussade, S; Chéreau, C; Coriat, R; Goldwasser, F; Mir, O; Nicco, C; Ropert, S; Weill, B | 1 |
| Bitzer, M; Föller, M; Jilani, K; Lang, E; Lang, F; Lupescu, A; Pasham, V; Plate, A; Qadri, SM; Shaik, N; Zbidah, M; Zelenak, C | 1 |
| Fínek, J | 1 |
| Kong, LQ; Li, Q; Song, TQ; Sun, HC; Tang, ZY; Wang, L; Wang, WQ; Wu, WZ; Xiong, YQ; Xu, HX; Zhang, QB; Zhang, W; Zhu, XD; Zhuang, PY | 1 |
| Anmarkrud, JA; Huitfeldt, HS; Line, PD; Liu, SZ; Scholz, H; Shi, JH; Wierød, L; Zhang, SJ | 1 |
| Chen, GG; Ho, RL; Lai, PB; Liu, LP | 1 |
| Krzemieniecki, K; Sowa-Staszczak, A; Zygulska, AL | 1 |
| Dogan, E; Koca, D; Olmez, A; Yalcin, S | 1 |
| Abou-Alfa, GK; Ang, C; O'Reilly, EM | 1 |
| Chen, D; Chen, W; Liang, LJ; Yang, D; Yin, XY; Zhao, P | 1 |
| Brümmendorf, TH; Gambacorti-Passerini, C; Wege, H | 1 |
| Allensworth, JL; Devi, GR; Diehl, AM; Lyerly, HK; Morse, MA; Rangwala, F; Smith, GR; Thomas, Z; Williams, KP | 1 |
| Boni, C; Bracarda, S; Caserta, C; Cinquini, M; Cortesi, E; De Angelis, V; Di Costanzo, F; Falcone, A; Gasparro, D; Labianca, R; Mucciarini, C; Paglino, C; Pazzola, A; Porta, C; Santoro, A | 1 |
| Ebert, MP; Schott, E; Trojan, J | 1 |
| Ma, YT; Palmer, DH | 1 |
| Boccagni, P; Burra, P; Cillo, U; D'Amico, F; Kertusha, X; Lodo, E; Lombardi, G; Pastorelli, D; Ramirez Morales, R; Senzolo, M; Vitale, A; Zanus, G | 1 |
| Chen, HL; Chen, KF; Chen, PJ; Cheng, AL; Chu, PY; Ichikawa, K; Liu, CY; Shiau, CW; Tai, WT | 1 |
| Boedi, P; Ganggaiswari, A; Gani, RA; Hasan, I; Lesmana, LA; Luwia, MS; Waspodo, A | 1 |
| Anai, H; Kichikawa, K; Maeda, S; Masada, T; Nishiofuku, H; Sueyoshi, S; Tanaka, T | 1 |
| Bechstein, WO; Trojan, J; Welker, MW; Zeuzem, S | 1 |
| Cserepes T, M; Döme, B; Rényi-Vámos, F; Török, S | 1 |
| Fang, D; Gao, J; Liu, J; Rao, Z; Zhang, A; Zhang, B; Zhang, Y; Zhao, J; Zhao, Y | 1 |
| Arma, D; Balabaud, C; Bexiga, MG; Bioulac-Sage, P; Blanc, JF; Castain, C; Chevet, E; Higa, A; Le Bail, B; Marza, E; Rosenbaum, J; Simpson, JC; Taouji, S; Yi, P | 1 |
| Banzi, M; Boni, C; Carnaghi, C; Ceriani, R; Cortesi, E; Covini, G; De Giorgio, M; Fagiuoli, S; Fanello, S; Ferrari, D; Giordano, L; Labianca, R; Latini, L; Locopo, N; Lutman, FR; Mucciarini, C; Naimo, S; Porta, C; Pressiani, T; Rimassa, L; Salvagni, S; Santoro, A; Tommasini, MA; Torzilli, G; Tronconi, MC | 1 |
| Airoldi, A; Belli, LS; Cordone, G; Gentiluomo, M; Mancuso, A; Vangeli, M; Viganò, R; Zavaglia, C | 1 |
| Allemeersch, J; Carmeliet, P; Casteleyn, C; Colle, I; Coulon, S; Geerts, A; Heindryckx, F; Libbrecht, L; Stassen, JM; Terrie, E; Van Vlierberghe, H | 1 |
| Bandeali, S; Brammer, JE; Lulla, PD; Lynch, GR | 1 |
| Fan, J; Huang, XW; Qiu, SJ; Shi, RY; Wang, WM; Wang, Z; Xu, Y; Yang, XR; Zhang, X; Zhou, J | 1 |
| Ganten, TM; Gotthardt, D; Jaeger, D; Koehler, C; Koschny, R; Stremmel, W | 1 |
| He, L; Hu, Y; Li, Q; Liu, M; Xi, M; Zhao, L | 1 |
| Addeo, R; Calvieri, A; Caraglia, M; Del Prete, S; Montella, L; Picardi, A; Santini, D; Silletta, M; Tonini, G; Vespasiani, U; Vincenzi, B | 1 |
| Cabrera, R; Clark, V; Firpi, R; Horne, P; Limaye, AR; Mills, R; Morelli, G; Nelson, DR; Soldevila-Pico, C | 1 |
| Cabrera, R; Cao, M; Liu, C; Nelson, DR; Ogunwobi, OO; Puszyk, WM; Tian, C; Wang, T; Zhao, X | 1 |
| Dekervel, J; Nevens, F; Van Cutsem, E; van Malenstein, H; van Pelt, J; Verslype, C; Windmolders, P | 1 |
| Duffy, A; Greten, TF; Wilkerson, J | 1 |
| Cabibbo, G; Campisi, G; Compilato, D; Genco, C | 1 |
| Inagaki, Y; Ito, M; Kasai, C; Kusagawa, S; Nobori, T; Nojiri, K; Ogura, S; Shiraki, K; Sugimoto, K; Takei, Y; Tameda, M; Yamamoto, N; Yoneda, M | 1 |
| Gu, K; He, M; Jiang, GL; Lai, S; Ma, N; Ren, Z; Shao, C; Yu, W; Yu, Z; Yuan, D; Zhang, X; Zhao, J | 1 |
| Fouzas, I; Klein, CG; Kykalos, S; Nowak, KW; Paul, A; Sotiropoulos, GC; Vernadakis, S | 1 |
| Aino, H; Fukuizumi, K; Iwamoto, H; Kajiwara, M; Koga, H; Kurogi, J; Kuromatsu, R; Matsugaki, S; Matsukuma, N; Nagamatsu, H; Nakano, M; Niizeki, T; Ono, N; Sakai, T; Sakata, K; Sata, M; Satani, M; Sumie, S; Tajiri, N; Takata, A; Tanaka, M; Torimura, T; Yamada, S; Yano, Y | 1 |
| Hernandez-Gea, V; Llovet, JM; Villanueva, A | 1 |
| Kikuchi, Y; Kudo, T; Maruyama, K; Shiozawa, K; Sumino, Y; Watanabe, M | 1 |
| Carr, BI; Cavallini, A; Correale, M; D'Alessandro, R; Di Carlo, A; Iacovazzi, PA; Lippolis, C; Messa, C; Refolo, MG | 1 |
| Hu, ZH; Huang, PY; Huang, Y; Lin, SJ; Liu, JL; Liu, LZ; Ma, YX; Pan, JJ; Song, XQ; Wu, JX; Wu, X; Xu, F; Xue, C; Yu, QT; Zhang, J; Zhang, JW; Zhang, L; Zhao, HY; Zhao, LP; Zhao, YY | 1 |
| Arkadopoulos, N; Dimitriadis, G; Psyrri, A; Smyrniotis, V; Vassilakopoulou, M | 1 |
| Galle, PR; Gamstätter, T; Koch, S; Marquardt, JU; Nguyen-Tat, M; Niederle, IM; Schuchmann, M; Schulze-Bergkamen, H; Weinmann, A; Wörns, MA | 1 |
| Hoekstra, R; Honeywell, RJ; Peters, GJ; van Erp, NP; Verheul, HM; Westgeest, HM | 1 |
| Chang, AY; Wang, M | 1 |
| Guo, H; Lv, Y; Nan, KJ; Ruan, ZP; Tian, T; Wang, WJ; Xu, R | 1 |
| Bearz, A; Berretta, M; Cacopardo, B; Dal Maso, L; De Re, V; Di Benedetto, F; Facchini, G; Fiorica, F; Garlassi, E; Lleshi, A; Nasti, G; Spina, M; Tirelli, U | 1 |
| Chen, CL; Cheng, YF; Hsu, HC; Kuo, YH; Lu, SN; Wang, CC; Wang, JH | 1 |
| Ararat, M; Atkinson, MA; Brusko, T; Cabrera, R; Chang, LJ; Liu, C; Nelson, DR; Wasserfall, C; Xu, Y | 1 |
| Shlomai, A | 1 |
| Dai, X; Ganten, MK; Ganten, TM; Höh, K; Schlemmer, HP; Schmidt, B; Xu, K | 1 |
| Flaherty, KT; Heitjan, DF; Kang, HC; Keefe, SM; O'Dwyer, PJ; Rosen, MA; Siegelman, ES; Tan, KS | 1 |
| Goertz, RS; Knieling, F; Strobel, D; Waldner, MJ | 1 |
| Armeanu-Ebinger, S; Dewerth, A; Eicher, C; Ellerkamp, V; Fuchs, J; Hildenbrand, S; Thomale, J; Warmann, SW | 1 |
| Chang, CY; Cheng, AL; Hsu, C; Lin, CY; Lin, KL; Liu, SH; Ou, DL; Shen, YC | 1 |
| Arizumi, T; Kudo, M; Ueshima, K | 1 |
| Bernatik, T; Goertz, RS; Knieling, F; Neurath, MF; Strobel, D; Waldner, MJ; Wildner, D; Zopf, S | 1 |
| Brunello, F; Brunocilla, PR; Cantamessa, A; Carucci, P; Castiglione, A; Ciccone, G; Gaia, S; Rizzetto, M; Rolle, E | 1 |
| Hara, J; Hasegawa, A; Kametaka, H; Koyama, T; Makino, H; Seike, K; Takagi, Y | 1 |
| Frampas, E; Koscielny, S; Lassau, N; Vilgrain, V; Vullierme, MP; Zappa, M | 1 |
| He, ZY; Hua, XD | 1 |
| Bruno, R; Cabibbo, G; Cammà, C; Colombo, M; Craxì, A; Enea, M; Gasbarrini, A; Grieco, A; Iavarone, M; Petta, S; Villa, E; Zavaglia, C | 1 |
| Bar-Yehuda, S; Benjaminov, O; Ciuraru, NB; Cohen, S; Farbstein, M; Fishman, P; Fishman, S; Harpaz, Z; Kerns, WD; Medalia, G; Patoka, R; Silverman, MH; Singer, B; Stemmer, SM | 1 |
| Fang, X; Jiang, H; Liang, Y; Liu, H; Liu, J; Liu, L; Meng, X; Song, R; Tian, L; Wang, J; Wang, L; Yin, D; Zheng, T | 1 |
| Furuichi, Y; Imai, Y; Kamiyama, N; Moriyasu, F; Rognin, N; Saito, K; Sugimoto, K | 1 |
| Ahn, SY; Kweon, YO; Lee, HS; Park, SY; Tak, WY | 1 |
| Ascione, A; Cordone, G; De Luca, M; Di Costanzo, GG; Galeota Lanza, A; Imparato, M; Lampasi, F; Mattera, S; Picciotto, FP; Tartaglione, MT; Tortora, R | 1 |
| Duan, X; Wang, J; Ye, W; Zhang, M; Zhou, S | 1 |
| Ding, ZB; Fan, J; Huang, XY; Ke, AW; Qiu, SJ; Shi, GM; Shi, YH; Wang, XY; Xiao, YS; Yan, J; Zhang, C; Zhang, X; Zhou, J | 1 |
| Bai, W; Fan, DM; Han, GH; He, CY; Li, RJ; Qi, XS; Wang, YJ; Wu, KC; Xia, JL; Yin, ZX; Zhao, Y | 1 |
| Chen, B; Chen, W; Huang, YH; Li, JP; Yang, JY | 1 |
| Amarapurkar, D; Chao, Y; Chen, PJ; Cheng, AL; Geschwind, JF; Goh, KL; Han, KH; Kudo, M; Lee, HC; Lee, RC; Lesmana, LA; Lim, HY; Paik, SW; Park, JW; Poon, RT; Tan, CK; Tanwandee, T; Teng, G | 1 |
| Chen, HL; Chen, KF; Chen, PJ; Cheng, AL; Lin, CS; Liu, CY; Shiau, CW; Tai, WT | 1 |
| Bolondi, L; Burroughs, A; Dufour, JF; Galle, PR; Mazzaferro, V; Piscaglia, F; Raoul, JL; Sangro, B | 1 |
| Grubert, M; Hilger, RA; Kredtke, S; Kupsch, P; Passage, K; Richly, H; Scheulen, ME; Seeber, S; Strumberg, D; Voliotis, D | 1 |
| Brendel, E; Christensen, O; Grubert, M; Haase, CG; Hilger, RA; Kupsch, P; Passage, K; Richly, H; Schwartz, B; Strumberg, D; Voigtmann, R | 1 |
| Awada, A; Brendel, E; Faghih, M; Haase, CG; Hilger, RA; Korfee, S; Richly, H; Scheulen, ME; Schleucher, N; Schwartz, B; Seeber, S; Strumberg, D; Tewes, M; Voigtmann, R; Voliotis, D | 1 |
| Strumberg, D | 1 |
| Rini, BI | 1 |
| Abou-Alfa, GK; Amadori, D; De Greve, J; Douillard, JY; Figer, A; Lathia, C; Moscovici, M; Ricci, S; Saltz, LB; Santoro, A; Schwartz, B; Schwartz, L; Taylor, I | 1 |
| Burton, A | 1 |
| Cao, Y; Carter, C; Chen, C; Liu, L; Lynch, M; McNabola, A; Wilhelm, S; Wilkie, D; Zhang, X | 1 |
| Alexandrescu, DT; Dasanu, CA; Dutcher, J | 1 |
| Flaherty, KT | 1 |
| Bargetzi, M; Puric, E; Schönenberger, A; Sendi, P | 1 |
| Hobday, TJ; McWilliams, RR; Morris, JC; Robinson, SI; Sathananthan, A | 1 |
| Hampton, T | 1 |
| Blum, HE; Mohr, L; Spangenberg, HC; Thimme, R | 1 |
| Furuse, J; Ishii, H; Nakachi, K; Nakajima, K; Shimizu, S; Suzuki, E | 1 |
| O'Neil, BH; Venook, AP | 1 |
| Keating, GM; Simpson, D | 1 |
| Di Fiore, F; Michel, P | 1 |
| Lang, L | 1 |
| Angelotti, U; Antonaci, S; Fransvea, E; Giannelli, G | 1 |
| Barbare, JC; Boige, V; Rosmorduc, O | 1 |
| Bajetta, E; Catena, L; Gevorgyan, A; Guadalupi, V; Mancin, M; Martinetti, A; Platania, M; Procopio, G; Pusceddu, S; Verzoni, E | 1 |
| Cui, YZ; Luo, RC; Wu, J; Zhang, H | 1 |
450 review(s) available for sorafenib and Cancer of Liver
| Article | Year |
|---|---|
Novel benzothiazole-based dual VEGFR-2/EGFR inhibitors targeting breast and liver cancers: Synthesis, cytotoxic activity, QSAR and molecular docking studies.
Topics: Antineoplastic Agents; Benzothiazoles; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; ErbB Receptors; Humans; Liver Neoplasms; Molecular Docking Simulation; Molecular Structure; Protein Kinase Inhibitors; Quantitative Structure-Activity Relationship; Vascular Endothelial Growth Factor Receptor-2 | 2022 |
Paradigm shift in the treatment options of hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Humans; Immunotherapy; Liver Neoplasms; Sorafenib | 2022 |
Comparative efficacy and safety for second-line treatment with ramucirumab, regorafenib, and cabozantinib in patients with advanced hepatocellular carcinoma progressed on sorafenib treatment: A network meta-analysis.
Topics: Anilides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Drug Administration Schedule; Humans; Liver Neoplasms; Neoplasm Metastasis; Phenylurea Compounds; Pyridines; Ramucirumab; Randomized Controlled Trials as Topic; Sorafenib | 2021 |
Efficacy and safety of sorafenib plus hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Randomized Controlled Trials as Topic; Sorafenib; Treatment Outcome | 2021 |
Advances in Pharmacotherapy of Hepatocellular Carcinoma: A State-of-the-Art Review.
Topics: Carcinoma, Hepatocellular; Humans; Immune Checkpoint Inhibitors; Immunotherapy; Liver Neoplasms; Sorafenib | 2022 |
Immunotherapies for hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Humans; Immune Checkpoint Inhibitors; Immunotherapy; Liver Neoplasms; Sorafenib; Tumor Microenvironment | 2022 |
Changes in therapeutic options for hepatocellular carcinoma in Asia.
Topics: Bevacizumab; Carcinoma, Hepatocellular; Clinical Trials, Phase III as Topic; Humans; Immunotherapy; Liver Neoplasms; Randomized Controlled Trials as Topic; Sorafenib | 2022 |
Efficacy and Safety Associated With Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma: A Meta-analysis.
Topics: Carcinoma, Hepatocellular; Drug-Related Side Effects and Adverse Reactions; Humans; Immune Checkpoint Inhibitors; Immunotherapy; Liver Neoplasms; Progression-Free Survival; Randomized Controlled Trials as Topic; Sorafenib; Treatment Outcome | 2021 |
Immunotherapies for hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Humans; Immunotherapy; Liver Neoplasms; Sorafenib | 2022 |
Management of hepatocellular carcinoma patients with portal vein tumor thrombosis: A narrative review.
Topics: Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neoplasms; Portal Vein; Retrospective Studies; Sorafenib; Treatment Outcome; Venous Thrombosis | 2022 |
Potential Therapeutic Strategies to Combat HCC.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Humans; Liver Neoplasms; Mammals; Sorafenib; Vascular Endothelial Growth Factor A | 2022 |
AGA Technical Review on Systemic Therapies for Hepatocellular Carcinoma.
Topics: Anilides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Chemotherapy, Adjuvant; Hepatectomy; Humans; Liver Neoplasms; Liver Transplantation; Phenylurea Compounds; Pyridines; Quinolines; Ramucirumab; Retreatment; Sorafenib | 2022 |
Early predictive value of circulating biomarkers for sorafenib in advanced hepatocellular carcinoma.
Topics: Antineoplastic Agents; Biomarkers; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib | 2022 |
The Treatment Landscape of Advanced Hepatocellular Carcinoma.
Topics: Carcinoma, Hepatocellular; Humans; Immune Checkpoint Inhibitors; Immunotherapy; Liver Neoplasms; Sorafenib | 2022 |
Safety, efficacy, and tolerability of immune checkpoint inhibitors in the treatment of hepatocellular carcinoma.
Topics: Antibodies, Monoclonal; Carcinoma, Hepatocellular; Humans; Immune Checkpoint Inhibitors; Liver Neoplasms; Sorafenib | 2022 |
Immune checkpoint inhibitors for hepatocellular carcinoma - A game changer in treatment landscape.
Topics: Carcinoma, Hepatocellular; Humans; Immune Checkpoint Inhibitors; Liver Neoplasms; Nivolumab; Sorafenib | 2022 |
Systemic Therapy in Metastatic Hepatocellular Carcinoma.
Topics: Carcinoma, Hepatocellular; Humans; Immunotherapy; Liver Neoplasms; Sorafenib | 2022 |
Effects of Atezolizumab and Bevacizumab on Adrenal Gland Metastasis of Hepatocellular Carcinoma: A Case Report and Review of Literature.
Topics: Adrenal Gland Neoplasms; Adrenal Glands; Bevacizumab; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Male; Middle Aged; Sorafenib | 2022 |
Decoding the Mechanism of Drugs of Heterocyclic Nature against Hepatocellular Carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Phenylurea Compounds; Pyridines; Pyrimidines; Quinolines; Sorafenib | 2023 |
Cost-Effectiveness Analysis of Five Systemic Treatments for Unresectable Hepatocellular Carcinoma in China: An Economic Evaluation Based on Network Meta-Analysis.
Topics: Bevacizumab; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Humans; Liver Neoplasms; Network Meta-Analysis; Sorafenib | 2022 |
New treatment paradigm with systemic therapy in intermediate-stage hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Protein Kinase Inhibitors; Sorafenib | 2022 |
Experimental drug treatments for hepatocellular carcinoma: clinical trial failures 2015 to 2021.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Clinical Trials as Topic; Drugs, Investigational; Humans; Liver Neoplasms; Sorafenib | 2022 |
Sorafenib in Metastatic Papillary Thyroid Carcinoma with
Topics: Aged; Carcinoma, Hepatocellular; Humans; Iodine Radioisotopes; Kidney Neoplasms; Liquid Biopsy; Liver Neoplasms; Male; Mutation; Proto-Oncogene Proteins B-raf; Quality of Life; Sorafenib; Thyroid Cancer, Papillary; Thyroid Neoplasms | 2022 |
Cost-Effectiveness of Donafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma in China.
Topics: Carcinoma, Hepatocellular; China; Cost-Benefit Analysis; Humans; Liver Neoplasms; Pyridines; Quality-Adjusted Life Years; Sorafenib | 2022 |
Hepatocellular Carcinoma: Pick the Winner-Tyrosine Kinase Inhibitor Versus Immuno-oncology Agent-Based Combinations.
Topics: Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Protein Kinase Inhibitors; Sorafenib; Vascular Endothelial Growth Factor A | 2022 |
Advances in Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma.
Topics: Carcinoma, Hepatocellular; Humans; Immune Checkpoint Inhibitors; Liver Neoplasms; Sorafenib | 2022 |
Economic evaluations of radioembolization with Itrium-90 microspheres in hepatocellular carcinoma: a systematic review.
Topics: Canada; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Cost-Benefit Analysis; Female; Humans; Liver Neoplasms; Microspheres; Pregnancy; Sorafenib | 2022 |
Ranking of transarterial and targeted therapies for advanced hepatocellular carcinoma in the era of immuno-oncology: A network meta-analysis of randomized sorafenib-controlled trials.
Topics: Antineoplastic Agents; Bevacizumab; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Humans; Liver Neoplasms; Network Meta-Analysis; Phenylurea Compounds; Quinolines; Randomized Controlled Trials as Topic; Sorafenib | 2022 |
Prognostic models for outcome prediction in patients with advanced hepatocellular carcinoma treated by systemic therapy: a systematic review and critical appraisal.
Topics: Bilirubin; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Prognosis; Sorafenib | 2022 |
Toxicity Profiles of Systemic Therapies for Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-analysis.
Topics: Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Child; Female; Humans; Immunotherapy; Liver Neoplasms; Male; Middle Aged; Sorafenib | 2022 |
Role of interventional oncology in hepatocellular carcinoma: Future best practice beyond current guidelines.
Topics: Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neoplasms; Neoplasm Staging; Sorafenib; Treatment Outcome | 2022 |
Comparative efficacy of novel combination strategies for unresectable hepatocellular carcinoma: A network metanalysis of phase III trials.
Topics: Antineoplastic Agents; Bevacizumab; Carcinoma, Hepatocellular; Clinical Trials, Phase III as Topic; Humans; Immune Checkpoint Inhibitors; Liver Neoplasms; Nivolumab; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolines; Sorafenib; Systematic Reviews as Topic; Vascular Endothelial Growth Factor A | 2022 |
Prognosis and treatment pattern of advanced hepatocellular carcinoma after failure of first-line atezolizumab and bevacizumab treatment.
Topics: Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Prognosis; Sorafenib | 2022 |
The liver cancer immune microenvironment: Therapeutic implications for hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Humans; Immunotherapy; Liver Neoplasms; Sorafenib; Tumor Microenvironment | 2023 |
Advances in novel systemic therapies for advanced hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Humans; Immune Checkpoint Inhibitors; Immunotherapy; Liver Neoplasms; Sorafenib | 2022 |
Drug Treatment for Advanced Hepatocellular Carcinoma: First-Line and Beyond.
Topics: B7-H1 Antigen; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Protein Kinase Inhibitors; Sorafenib; United States | 2022 |
Benefits of combination therapy with immune checkpoint inhibitors and predictive role of tumour mutation burden in hepatocellular carcinoma: A systematic review and meta-analysis.
Topics: Antineoplastic Agents, Immunological; B7-H1 Antigen; Biomarkers, Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Humans; Immune Checkpoint Inhibitors; Liver Neoplasms; Lung Neoplasms; Mutation; Prospective Studies; Sorafenib | 2022 |
A Review of Current and Emerging Therapies for Advanced Hepatocellular Carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Prospective Studies; Protein Kinase Inhibitors; Sorafenib; Vascular Endothelial Growth Factor A | 2022 |
Therapeutic strategies for post-transplant recurrence of hepatocellular carcinoma.
Topics: Calcineurin Inhibitors; Carcinoma, Hepatocellular; Humans; Immune Checkpoint Inhibitors; Liver Neoplasms; Neoplasm Recurrence, Local; Retrospective Studies; Sorafenib; TOR Serine-Threonine Kinases | 2022 |
Non-alcoholic fatty liver disease-related hepatocellular carcinoma: Is there a role for immunotherapy?
Topics: Bevacizumab; Carcinogenesis; Carcinoma, Hepatocellular; Humans; Immunotherapy; Liver Neoplasms; Non-alcoholic Fatty Liver Disease; Sorafenib | 2022 |
Resistance of Lenvatinib in Hepatocellular Carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Phenylurea Compounds; Quinolines; Sorafenib | 2022 |
Natural Products for Liver Cancer Treatment: From Traditional Medicine to Modern Drug Discovery.
Topics: Antineoplastic Agents; Biological Products; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Drug Discovery; Humans; Liver Neoplasms; Medicine, Traditional; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2022 |
Evolving therapeutic landscape of advanced hepatocellular carcinoma.
Topics: Bevacizumab; Carcinoma, Hepatocellular; Combined Modality Therapy; Humans; Liver Neoplasms; Sorafenib | 2023 |
Angiogenesis and immune checkpoint dual blockade: Opportunities and challenges for hepatocellular carcinoma therapy.
Topics: Carcinoma, Hepatocellular; Clinical Trials, Phase III as Topic; Humans; Immune Checkpoint Inhibitors; Immunotherapy; Liver Neoplasms; Sorafenib | 2022 |
Treatment-related adverse events of first-line immunotherapy versus sorafenib for advanced hepatocellular carcinoma: a meta-analysis.
Topics: Carcinoma, Hepatocellular; Drug-Related Side Effects and Adverse Reactions; Humans; Immunotherapy; Liver Neoplasms; Sorafenib | 2023 |
Second-line treatment options for hepatocellular carcinoma: current state and challenges for the future.
Topics: Administration, Cutaneous; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Quality of Life; Sorafenib | 2022 |
Impact of Post-progression Survival on Outcomes of Lenvatinib Treatment for Unresectable Hepatocellular Carcinoma: A Systematic Review and Retrospective Cohort Study.
Topics: Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Retrospective Studies; Sorafenib | 2022 |
Comparison of the effects of lenvatinib and sorafenib on survival in patients with advanced hepatocellular carcinoma: A systematic review and meta-analysis.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Phenylurea Compounds; Randomized Controlled Trials as Topic; Sorafenib | 2023 |
An overview: Management of patients with advanced hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatectomy; Humans; Liver Neoplasms; Sorafenib | 2022 |
External radiotherapy combined with sorafenib has better efficacy in unresectable hepatocellular carcinoma: a systematic review and meta-analysis.
Topics: Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neoplasms; Sorafenib; Treatment Outcome | 2023 |
Sorafenib plus hepatic arterial infusion chemotherapy versus sorafenib alone for advanced hepatocellular carcinoma: A systematic review and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Sorafenib; Thrombocytopenia; Treatment Outcome | 2023 |
Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Chinese perspective.
Topics: Bevacizumab; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Male; Sorafenib | 2023 |
Immune-Based Combinations versus Sorafenib as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Meta-Analysis.
Topics: Carcinoma, Hepatocellular; Combined Modality Therapy; Humans; Liver Neoplasms; Progression-Free Survival; Sorafenib | 2023 |
Efficacy of Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombus: A Systematic Review and Meta-Analysis.
Topics: Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neoplasms; Portal Vein; Sorafenib; Thrombosis; Treatment Outcome; Tyrosine Kinase Inhibitors | 2023 |
Epigenetic modification-related mechanisms of hepatocellular carcinoma resistance to immune checkpoint inhibition.
Topics: Carcinoma, Hepatocellular; Epigenesis, Genetic; Humans; Immune Checkpoint Inhibitors; Liver Neoplasms; Sorafenib; Tumor Microenvironment | 2022 |
Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Taiwan perspective.
Topics: Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neoplasms; Neoplasm Staging; Sorafenib; Taiwan | 2023 |
Immunotherapy or targeted therapy as the first-line strategies for unresectable hepatocellular carcinoma: A network meta-analysis and cost-effectiveness analysis.
Topics: Bevacizumab; Biosimilar Pharmaceuticals; Carcinoma, Hepatocellular; Cost-Effectiveness Analysis; Humans; Immunotherapy; Liver Neoplasms; Network Meta-Analysis; Sorafenib | 2022 |
Comparison of the efficacy and safety of selective internal radiotherapy and sorafenib alone or combined for hepatocellular carcinoma: a systematic review and Bayesian network meta-analysis.
Topics: Bayes Theorem; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Network Meta-Analysis; Sorafenib | 2023 |
TKIs in combination with immunotherapy for hepatocellular carcinoma.
Topics: Bevacizumab; Carcinoma, Hepatocellular; Humans; Immunotherapy; Liver Neoplasms; Sorafenib; Tumor Microenvironment | 2023 |
Donafenib in hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Multicenter Studies as Topic; Phenylurea Compounds; Sorafenib | 2023 |
Combination immunotherapy for hepatocellular carcinoma.
Topics: Bevacizumab; Carcinoma, Hepatocellular; Humans; Immunotherapy; Liver Neoplasms; Sorafenib | 2023 |
Immunotherapy for hepatocellular carcinoma: Recent advances and future targets.
Topics: Carcinoma, Hepatocellular; Cytokines; Humans; Immunotherapy; Liver Neoplasms; Sorafenib | 2023 |
Systemic treatment for unresectable hepatocellular carcinoma.
Topics: Bevacizumab; Carcinoma, Hepatocellular; Humans; Immune Checkpoint Inhibitors; Liver Neoplasms; Sorafenib | 2023 |
Sorafenib Plus Hepatic Arterial Infusion Chemotherapy in Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Sorafenib; Treatment Outcome | 2023 |
Target immune components to circumvent sorafenib resistance in hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Prospective Studies; Sorafenib; Tumor Microenvironment | 2023 |
Regorafenib compared to nivolumab after sorafenib failure in patients with hepatocellular carcinoma: A systematic review and meta-analysis.
Topics: Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Nivolumab; Sorafenib | 2023 |
Lenvatinib in the treatment of unresectable hepatocellular carcinoma: a systematic review of economic evaluations.
Topics: Carcinoma, Hepatocellular; Cost-Benefit Analysis; Humans; Liver Neoplasms; Sorafenib; Vascular Endothelial Growth Factor A | 2023 |
Current and novel approaches in the pharmacological treatment of hepatocellular carcinoma.
Topics: Antibodies, Monoclonal; Carcinoma, Hepatocellular; Humans; Immunotherapy; Liver Neoplasms; Molecular Targeted Therapy; Sorafenib | 2023 |
[Status Quo and Development of Immunotherapy for Hepatocellular Carcinoma].
Topics: Carcinoma, Hepatocellular; Humans; Immunotherapy; Liver Neoplasms; Oncolytic Viruses; Sorafenib | 2023 |
Comparison of different adjuvant therapy regimen efficacies in patients with high risk of recurrence after radical resection of hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatectomy; Humans; Liver Neoplasms; Sorafenib; Treatment Outcome | 2023 |
The multikinase inhibitor axitinib in the treatment of advanced hepatocellular carcinoma: the current clinical applications and the molecular mechanisms.
Topics: Axitinib; Carcinoma, Hepatocellular; Humans; Imidazoles; Indazoles; Liver Neoplasms; Programmed Cell Death 1 Receptor; Sorafenib; Vascular Endothelial Growth Factor A | 2023 |
The evolution of immune checkpoint inhibitor combinations in advanced hepatocellular carcinoma - A systematic review.
Topics: Bevacizumab; Carcinoma, Hepatocellular; Humans; Immune Checkpoint Inhibitors; Liver Neoplasms; Sorafenib | 2023 |
Angiogenesis and Hepatocellular Carcinoma: From Molecular Mechanisms to Systemic Therapies.
Topics: Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Sorafenib | 2023 |
Understanding sorafenib-induced ferroptosis and resistance mechanisms: Implications for cancer therapy.
Topics: Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Ferroptosis; Humans; Liver Neoplasms; Sorafenib | 2023 |
[Ramucirumab Treatment for Unresectable Advanced Hepatocellular Carcinoma-A Review of Clinical Trial Data and Real-World Evidence in Japan].
Topics: alpha-Fetoproteins; Carcinoma, Hepatocellular; Humans; Japan; Liver Neoplasms; Ramucirumab; Sorafenib | 2023 |
Molecular targeted therapy and immunotherapy in advanced hepatocellular carcinoma: a systematic review and Bayesian network meta-analysis based on randomized controlled trials.
Topics: Bayes Theorem; Carcinoma, Hepatocellular; Humans; Immunotherapy; Liver Neoplasms; Molecular Targeted Therapy; Network Meta-Analysis; Randomized Controlled Trials as Topic; Sorafenib | 2023 |
Perspective on the Role of Gut Microbiome in the Treatment of Hepatocellular Carcinoma with Immune Checkpoint Inhibitors.
Topics: Carcinoma, Hepatocellular; Gastrointestinal Microbiome; Humans; Immune Checkpoint Inhibitors; Liver Neoplasms; Sorafenib | 2023 |
Biomarkers for immunotherapy of hepatocellular carcinoma.
Topics: Biomarkers; Carcinoma, Hepatocellular; Humans; Immunotherapy; Liver Neoplasms; Sorafenib | 2023 |
Hepatic arterial infusion chemotherapy combined with sorafenib versus sorafenib alone for advanced hepatocellular carcinoma: a systematic review and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Sorafenib; Treatment Outcome | 2023 |
Surgery for Hepatocellular Carcinoma With Macroscopic Vascular Invasion in the Era of Modern Molecular Therapy.
Topics: Bevacizumab; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neoplasms; Neoplasm Invasiveness; Randomized Controlled Trials as Topic; Sorafenib; Treatment Outcome | 2023 |
Green synthesis of nano-based drug delivery systems developed for hepatocellular carcinoma treatment: a review.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Delivery Systems; Humans; Liver Neoplasms; Nanoparticle Drug Delivery System; Nanoparticles; Sorafenib | 2023 |
Sequencing Systemic Therapy in Hepatocellular Carcinoma.
Topics: Bevacizumab; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Sorafenib; Vascular Endothelial Growth Factor A | 2023 |
The New Era of Systemic Treatment for Hepatocellular Carcinoma: From the First Line to the Optimal Sequence.
Topics: Carcinoma, Hepatocellular; Humans; Immunotherapy; Liver Neoplasms; Quality of Life; Sorafenib; Tumor Microenvironment | 2023 |
Efficacy and safety comparison between Lenvatinib and Sorafenib in hepatocellular carcinoma treatment: a systematic review and meta-analysis of real-world study.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Sorafenib | 2024 |
Anti-tumoral activity of single and combined regorafenib treatments in preclinical models of liver and gastrointestinal cancers.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Gastrointestinal Neoplasms; Humans; Liver; Liver Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Tumor Microenvironment | 2019 |
Economic Implications of Hepatocellular Carcinoma Surveillance and Treatment: A Guide for Clinicians.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Early Detection of Cancer; Humans; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Models, Economic; Practice Guidelines as Topic; Quality-Adjusted Life Years; Sorafenib; Ultrasonography | 2020 |
Outcomes of hepatocellular carcinoma patients treated with sorafenib: a meta-analysis of Phase III trials.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Clinical Trials, Phase III as Topic; Humans; Liver Neoplasms; Sorafenib; Survival Rate; Treatment Outcome | 2019 |
Emerging role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma.
Topics: Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolines; Sorafenib | 2019 |
Predictive and Prognostic Factors in HCC Patients Treated with Sorafenib.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Quinolines; Sorafenib | 2019 |
The emerging role of microRNAs and long noncoding RNAs in drug resistance of hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; MicroRNAs; RNA Interference; RNA, Long Noncoding; Sorafenib | 2019 |
Psoriasiform drug eruption secondary to sorafenib: case series and review of the literature.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Eruptions; Hepatitis B, Chronic; Humans; Liver Neoplasms; Male; Psoriasis; Sorafenib | 2019 |
Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma.
Topics: Anilides; Antibodies, Monoclonal, Humanized; B7-H1 Antigen; Carcinoma, Hepatocellular; Clinical Trials as Topic; Drug Resistance, Neoplasm; Humans; Immunotherapy; Liver Neoplasms; Molecular Targeted Therapy; Phenylurea Compounds; Programmed Cell Death 1 Receptor; Pyridines; Quinolines; Ramucirumab; Sorafenib; Treatment Outcome | 2019 |
Review article: new therapeutic interventions for advanced hepatocellular carcinoma.
Topics: Anilides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Hepatocellular; Clinical Trials as Topic; Disease Progression; Humans; Immunotherapy; Liver Neoplasms; Neoplasm Staging; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinolines; Ramucirumab; Sorafenib; Therapies, Investigational | 2020 |
Resection might be a meaningful choice for hepatocellular carcinoma with portal vein thrombosis: A systematic review and meta-analysis.
Topics: Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Conservative Treatment; Female; Hepatectomy; Humans; Liver Neoplasms; Male; Portal Vein; Sorafenib; Survival Rate; Treatment Outcome; Venous Thrombosis | 2019 |
Tackling hepatocellular carcinoma with individual or combinatorial immunotherapy approaches.
Topics: Antigens, Neoplasm; Antineoplastic Agents, Immunological; Cancer Vaccines; Carcinoma, Hepatocellular; Clinical Trials as Topic; Combined Modality Therapy; DNA Modification Methylases; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Humans; Immunotherapy; Liver Neoplasms; Mutation; Oncolytic Virotherapy; Oncolytic Viruses; Programmed Cell Death 1 Receptor; Protein Kinase Inhibitors; Radiofrequency Ablation; Sorafenib; Survival Rate; Treatment Outcome; Tumor Microenvironment | 2020 |
The microenvironmental and metabolic aspects of sorafenib resistance in hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Epigenesis, Genetic; Humans; Liver Neoplasms; Sorafenib; Tumor Microenvironment | 2020 |
Switching to systemic therapy after locoregional treatment failure: Definition and best timing.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neoplasms; Neoplasm Metastasis; Sorafenib; Treatment Failure; Treatment Switching | 2020 |
Molecular therapies for HCC: Looking outside the box.
Topics: Algorithms; Anilides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Nivolumab; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinolines; Ramucirumab; Sorafenib; Treatment Outcome | 2020 |
The efficacy of sorafenib in preventing hepatocellular carcinoma recurrence after resection: a systematic review and meta-analysis.
Topics: Carcinoma, Hepatocellular; Hepatectomy; Humans; Liver Neoplasms; Neoplasm Recurrence, Local; Sorafenib; Treatment Outcome | 2020 |
Systematic review of hepatic arterial infusion chemotherapy versus sorafenib in patients with hepatocellular carcinoma with portal vein tumor thrombosis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Neoplasm Staging; Neoplastic Cells, Circulating; Portal Vein; Prognosis; Safety; Sorafenib; Survival Rate; Treatment Outcome; Venous Thrombosis | 2020 |
Sorafenib in pediatric hepatocellular carcinoma from a clinician perspective.
Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Child; Cisplatin; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Humans; Liver Neoplasms; Sorafenib | 2020 |
Systemic therapies in advanced hepatocellular carcinoma: How do older patients fare?
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Hepatocellular; Frail Elderly; Geriatric Assessment; Humans; Immune Checkpoint Inhibitors; Liver Neoplasms; Protein Kinase Inhibitors; Risk Factors; Sorafenib | 2021 |
Mouse Models of Oncoimmunology in Hepatocellular Carcinoma.
Topics: Animals; Antibodies, Monoclonal, Humanized; Carcinoma, Hepatocellular; Disease Models, Animal; Humans; Immunotherapy; Liver Neoplasms; Mice; Nivolumab; Protein Kinase Inhibitors; Sorafenib | 2020 |
NEMESIS: Noninferiority, Individual-Patient Metaanalysis of Selective Internal Radiation Therapy with
Topics: Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Microspheres; Sorafenib; Treatment Outcome; Yttrium Radioisotopes | 2020 |
New insights into the pharmacological, immunological, and CAR-T-cell approaches in the treatment of hepatocellular carcinoma.
Topics: Angiogenesis Inhibitors; Antigens, Neoplasm; Antineoplastic Agents; Carcinoma, Hepatocellular; Cytokines; Drug Resistance, Neoplasm; Humans; Immunotherapy, Adoptive; Liver Neoplasms; Neoplasm Staging; Pharmacogenetics; Protein Kinase Inhibitors; Radiotherapy, Adjuvant; Receptors, Chimeric Antigen; Sorafenib; T-Lymphocytes; Tumor Microenvironment; Vascular Endothelial Growth Factor A | 2020 |
Navigating the new landscape of second-line treatment in advanced hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Quality of Life; Sorafenib | 2020 |
[A new hope in the treatment of hepatocellular carcinoma].
Topics: Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Sorafenib | 2020 |
Pharyngeal metastasis following living-donor liver transplantation for hepatocellular carcinoma: a case report and literature review.
Topics: Allografts; Biopsy; Carcinoma, Hepatocellular; Catheter Ablation; Chemotherapy, Adjuvant; Drug Combinations; End Stage Liver Disease; Hepatectomy; Humans; Liver; Liver Neoplasms; Liver Transplantation; Living Donors; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Pharyngeal Neoplasms; Pharynx; Positron Emission Tomography Computed Tomography; Sorafenib; Tegafur; Treatment Outcome | 2020 |
New insights on sorafenib resistance in liver cancer with correlation of individualized therapy.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Disease Progression; Drug Resistance, Neoplasm; Humans; Liver; Liver Neoplasms; Metabolic Clearance Rate; Neoplasm Staging; Patient Selection; Precision Medicine; Prognosis; Randomized Controlled Trials as Topic; Sorafenib; Survival Analysis; Treatment Outcome; Tumor Microenvironment | 2020 |
The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects.
Topics: Apoptosis; Carcinoma, Hepatocellular; Cell Proliferation; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Sorafenib; Tumor Microenvironment | 2020 |
Sorafenib Plus Hepatic Arterial Infusion Chemotherapy in Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Sorafenib; Treatment Outcome | 2020 |
Hepatocellular carcinoma: recent advances and emerging medical therapies.
Topics: Carcinoma, Hepatocellular; Humans; Immunotherapy; Liver Neoplasms; Sorafenib | 2020 |
Emerging Opportunities for Combining Locoregional Therapy with Immune Checkpoint Inhibitors in Hepatocellular Carcinoma.
Topics: Animals; Brachytherapy; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Humans; Immune Checkpoint Inhibitors; Liver Neoplasms; Radiofrequency Ablation; Sorafenib | 2020 |
Adjuvant transarterial chemoembolization to sorafenib in unresectable hepatocellular carcinoma: A meta-analysis.
Topics: Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Chemotherapy, Adjuvant; Combined Modality Therapy; Humans; Liver Neoplasms; Safety; Sorafenib; Survival Rate; Treatment Outcome | 2021 |
Ferroptosis in Liver Diseases: An Overview.
Topics: alpha-Tocopherol; Animals; Autophagy; Chemical and Drug Induced Liver Injury; Cyclohexylamines; Cysteine; Ferroptosis; Glutathione; Heme; Humans; Iron; Kelch-Like ECH-Associated Protein 1; Lipid Peroxidation; Lipoxygenase; Liver Diseases; Liver Neoplasms; Oxidative Stress; Phenylenediamines; Phospholipid Hydroperoxide Glutathione Peroxidase; Piperazines; Quinoxalines; Reactive Oxygen Species; Reperfusion Injury; Signal Transduction; Sorafenib; Spiro Compounds; Sulfasalazine; Tumor Suppressor Protein p53 | 2020 |
Trans-catheter arterial chemoembolization plus Sorafenib, an unsuccessful therapy in the treatment of hepatocellular carcinoma?: A systematic review and meta-analysis.
Topics: Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Humans; Liver Neoplasms; Protein Kinase Inhibitors; Sorafenib | 2020 |
Is transcatheter arterial chemoembolization plus sorafenib better than chemoembolization plus placebo in the treatment of hepatocellular carcinoma?
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Humans; Liver Neoplasms; Sorafenib | 2021 |
Targeted therapy for hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Drug Delivery Systems; Drug Resistance, Neoplasm; Humans; Immune Checkpoint Inhibitors; Liver Neoplasms; Phenylurea Compounds; Pyridines; Sorafenib | 2020 |
Sorafenib in the treatment of patients with hepatocellular carcinoma (HCC) and microvascular infiltration: a systematic review and meta-analysis.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Neoplasm Recurrence, Local; Sorafenib | 2020 |
Is Macroscopic Portal Vein Tumor Thrombosis of HCC Really an Exclusion for Liver Transplantation?
Topics: Carcinoma, Hepatocellular; Disease-Free Survival; Embolization, Therapeutic; Humans; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Neoplasm Invasiveness; Neoplasm Staging; Patient Selection; Portal Vein; Preoperative Care; Radiosurgery; Sorafenib; Venous Thrombosis | 2020 |
Management of Recurrent HCC After Liver Transplantation.
Topics: Ablation Techniques; Allografts; Antineoplastic Agents; Carcinoma, Hepatocellular; Clinical Decision-Making; Graft Rejection; Hepatectomy; Humans; Immunosuppressive Agents; Liver; Liver Neoplasms; Liver Transplantation; Neoplasm Recurrence, Local; Patient Selection; Postoperative Period; Practice Guidelines as Topic; Protein Kinase Inhibitors; Sorafenib; Survival Rate; Treatment Outcome | 2020 |
Targeted Molecular Therapeutic Options for Hepatocellular Carcinoma.
Topics: Carcinoma, Hepatocellular; Clinical Trials as Topic; Humans; Liver Neoplasms; Molecular Targeted Therapy; Phenylurea Compounds; Quinolines; Signal Transduction; Sorafenib | 2020 |
Optimizing Survival and the Changing Landscape of Targeted Therapy for Intermediate and Advanced Hepatocellular Carcinoma: A Systematic Review.
Topics: Anilides; Antibodies, Monoclonal, Humanized; Carcinoma, Hepatocellular; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Humans; Immune Checkpoint Inhibitors; Liver Neoplasms; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinolines; Ramucirumab; Sorafenib; Survival Analysis; Vascular Endothelial Growth Factor A | 2021 |
The combination therapy of transarterial chemoembolisation and sorafenib is the preferred palliative treatment for advanced hepatocellular carcinoma patients: a meta-analysis.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Humans; Liver Neoplasms; Niacinamide; Palliative Care; Phenylurea Compounds; Prognosis; Sorafenib; Treatment Outcome | 2020 |
Tyrosine Kinase Inhibitors and Hepatocellular Carcinoma.
Topics: Anilides; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Molecular Targeted Therapy; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Quinolines; Sorafenib | 2020 |
A concise review of the changing landscape of hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Sorafenib | 2020 |
Herbal and Natural Dietary Products: Upcoming Therapeutic Approach for Prevention and Treatment of Hepatocellular Carcinoma.
Topics: Biological Products; Carcinoma, Hepatocellular; Diet; Humans; Liver Neoplasms; Sorafenib | 2021 |
The Current Landscape of Immune Checkpoint Blockade in Hepatocellular Carcinoma: A Review.
Topics: Carcinoma, Hepatocellular; Humans; Immune Checkpoint Inhibitors; Liver Neoplasms; Sorafenib; Vascular Endothelial Growth Factor A | 2021 |
Systemic targeted and immunotherapy for advanced hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Clinical Trials, Phase I as Topic; Humans; Immunotherapy; Liver Neoplasms; Nivolumab; Sorafenib | 2021 |
Milestones in the treatment of hepatocellular carcinoma: A systematic review.
Topics: Carcinoma, Hepatocellular; Humans; Immunotherapy; Liver Neoplasms; Sorafenib | 2021 |
Management of hepatocellular carcinoma after progression on first-line systemic treatment: defining the optimal sequencing strategy in second line and beyond.
Topics: Carcinoma, Hepatocellular; Humans; Immunotherapy; Liver Neoplasms; Protein Kinase Inhibitors; Sorafenib | 2020 |
Non-immunotherapy options for the first-line management of hepatocellular carcinoma: exploring the evolving role of sorafenib and lenvatinib in advanced disease.
Topics: Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Phenylurea Compounds; Quinolines; Sorafenib | 2020 |
Role of immunotherapy in the management of hepatocellular carcinoma: current standards and future directions.
Topics: Carcinoma, Hepatocellular; Clinical Trials as Topic; Humans; Immunotherapy; Liver Neoplasms; Nivolumab; Sorafenib; United States | 2020 |
A systematic review and network meta-analysis of second-line therapy in hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Network Meta-Analysis; Progression-Free Survival; Sorafenib | 2020 |
Hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Combined Modality Therapy; Humans; Immunotherapy; Liver Neoplasms; Sorafenib | 2021 |
Anti-VEGF Mediated Immunomodulatory Role of Phytochemicals: Scientific Exposition for Plausible HCC Treatment.
Topics: Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Phytochemicals; Sorafenib; Tumor Microenvironment; Vascular Endothelial Growth Factor A | 2021 |
Epidemiology, mutational landscape and staging of hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Hepatitis B; Humans; Liver Neoplasms; Neoplasm Staging; Non-alcoholic Fatty Liver Disease; Sorafenib | 2021 |
Systemic therapies for hepatocellular carcinoma: the present and the future.
Topics: Carcinoma, Hepatocellular; Humans; Immunotherapy; Liver Neoplasms; Nivolumab; Sorafenib | 2021 |
Targeting Key Transcription Factors in Hepatocellular Carcinoma.
Topics: Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Sorafenib; Transcription Factors | 2021 |
Nivolumab + Ipilimumab for patients with hepatocellular carcinoma previously treated with Sorafenib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Clinical Trials as Topic; Drug Synergism; Humans; Immune Checkpoint Inhibitors; Ipilimumab; Liver; Liver Neoplasms; Neoplasm Grading; Nivolumab; Protein Kinase Inhibitors; Sorafenib | 2021 |
Immune-Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: A Synopsis of Response Rates.
Topics: Carcinoma, Hepatocellular; Humans; Immune Checkpoint Inhibitors; Liver Neoplasms; Sorafenib | 2021 |
Role of ATP-binding Cassette Transporters in Sorafenib Therapy for Hepatocellular Carcinoma: An Overview.
Topics: ATP-Binding Cassette Transporters; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Neoplasm Proteins; Sorafenib | 2022 |
Current status of sorafenib nanoparticle delivery systems in the treatment of hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Delivery Systems; Humans; Liver Neoplasms; Nanoparticles; Sorafenib | 2021 |
Therapeutic Efficacy of Sorafenib in Patients with Hepatocellular Carcinoma Recurrence After Liver Transplantation: A Systematic Review and Meta-Analysis.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Liver Transplantation; Neoplasm Recurrence, Local; Prospective Studies; Sorafenib; Treatment Outcome | 2021 |
FDA Approval Summary: Nivolumab Plus Ipilimumab for the Treatment of Patients with Hepatocellular Carcinoma Previously Treated with Sorafenib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Humans; Ipilimumab; Liver Neoplasms; Nivolumab; Sorafenib; United States; United States Food and Drug Administration | 2021 |
A meta-analysis of the efficacy and safety of adjuvant sorafenib for hepatocellular carcinoma after resection.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib; Treatment Outcome | 2021 |
Second-line treatments for Advanced Hepatocellular Carcinoma: A Systematic Review and Bayesian Network Meta-analysis.
Topics: Bayes Theorem; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Network Meta-Analysis; Sorafenib | 2022 |
Efficacy of combined transarterial radioembolization and sorafenib in the treatment of hepatocarcinoma: A meta-analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Disease Progression; Female; Humans; Liver Neoplasms; Male; Middle Aged; Proportional Hazards Models; Sorafenib; Survival Analysis; Treatment Outcome | 2022 |
Trial eligibility in advanced hepatocellular carcinoma: Does it support clinical practice in underrepresented subgroups?
Topics: Bevacizumab; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Sorafenib | 2021 |
Evolving therapeutic strategies for advanced hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Humans; Immunotherapy; Liver Neoplasms; Sorafenib | 2021 |
Treatment for liver cancer: From sorafenib to natural products.
Topics: Antineoplastic Agents; Biological Products; Flavonoids; Ginsenosides; Humans; Immediate-Early Proteins; Liver Neoplasms; Neoplastic Stem Cells; Protein Serine-Threonine Kinases; Resveratrol; Sorafenib | 2021 |
Lenvatinib: established and promising drug for the treatment of advanced hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Humans; Immunotherapy; Liver Neoplasms; Molecular Targeted Therapy; Phenylurea Compounds; Progression-Free Survival; Protein Kinase Inhibitors; Quinolines; Sorafenib; Survival Rate | 2021 |
Recent advances in immunotherapy for hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Immunotherapy; Liver Neoplasms; Sorafenib | 2021 |
Hypoxia, Metabolic Reprogramming, and Drug Resistance in Liver Cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Hepatocellular; Cellular Reprogramming; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Immune Checkpoint Inhibitors; Liver Neoplasms; Metabolic Networks and Pathways; Nivolumab; Protein Kinase Inhibitors; Pyruvate Dehydrogenase Acetyl-Transferring Kinase; Sorafenib; Tumor Microenvironment | 2021 |
Upregulation of lncRNA NIFK-AS1 in hepatocellular carcinoma by m
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease Progression; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Intracellular Signaling Peptides and Proteins; Liver Neoplasms; Methylation; Methyltransferases; Molecular Targeted Therapy; Neoplasm Invasiveness; Nuclear Proteins; RNA, Long Noncoding; Sorafenib; Up-Regulation | 2021 |
An Overview of Hepatocellular Carcinoma with Emphasis on Dietary Products and Herbal Remedies.
Topics: Biological Products; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Sorafenib; Tumor Microenvironment | 2022 |
Transarterial chemoembolization plus sorafenib versus sorafenib for intermediate-advanced hepatocellular carcinoma: A meta-analysis comparing clinical outcomes.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Humans; Liver Neoplasms; Sorafenib | 2021 |
Current pharmacological treatment of hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Sorafenib | 2021 |
New knowledge of the mechanisms of sorafenib resistance in liver cancer.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib | 2017 |
Tivantinib for the treatment of hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrrolidinones; Quinolines; Sorafenib | 2017 |
Update on Embolization Therapies for Hepatocellular Carcinoma.
Topics: Carcinoma, Hepatocellular; Embolization, Therapeutic; Humans; Liver; Liver Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Sorafenib; Yttrium Radioisotopes | 2017 |
Epithelial-to-Mesenchymal Transition: A Mediator of Sorafenib Resistance in Advanced Hepatocellular Carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Humans; Liver Neoplasms; Neoplastic Stem Cells; Niacinamide; Phenylurea Compounds; Sorafenib | 2017 |
Hepatocellular carcinoma treatment: a comparative review of emerging growth factor receptor antagonists.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Drug Design; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Receptors, Growth Factor; Sorafenib; Survival Rate | 2017 |
Oncolytic Virus-Based Immunotherapies for Hepatocellular Carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Immunotherapy; Liver Neoplasms; Niacinamide; Oncolytic Virotherapy; Oncolytic Viruses; Phenylurea Compounds; Sorafenib | 2017 |
Regorafenib for the treatment of unresectable hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quality of Life; Randomized Controlled Trials as Topic; Sorafenib; Survival Rate | 2017 |
Current Standard and Future Perspectives in Non-Surgical Therapy for Hepatocellular Carcinoma.
Topics: Antineoplastic Agents, Immunological; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Clinical Trials as Topic; Combined Modality Therapy; Humans; Liver Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Practice Guidelines as Topic; Proton Therapy; Radiosurgery; Radiotherapy; Sorafenib; Survival Rate; Treatment Outcome; Tumor Burden; Yttrium Radioisotopes | 2017 |
Complete response of advanced hepatocellular carcinoma to sorafenib: another case and a comprehensive review.
Topics: alpha-Fetoproteins; Carcinoma, Hepatocellular; Hepatectomy; Humans; Liver Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Sorafenib; Tomography, X-Ray Computed; Venous Thrombosis | 2017 |
Postsorafenib systemic treatments for hepatocellular carcinoma: questions and opportunities after the regorafenib trial.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Clinical Trials as Topic; Combined Modality Therapy; Humans; Liver Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyridines; Retreatment; Sorafenib; Treatment Failure; Treatment Outcome | 2017 |
Bridging to liver transplantation in HCC patients.
Topics: Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Female; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Niacinamide; Patient Selection; Phenylurea Compounds; Preoperative Care; Risk Assessment; Sorafenib; Survival Rate; Time Factors; Treatment Outcome; Waiting Lists | 2017 |
Multimodal oncological approach in patients affected by recurrent hepatocellular carcinoma after liver transplantation.
Topics: Carcinoma, Hepatocellular; Humans; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Neoplasm Recurrence, Local; Niacinamide; Patient Selection; Phenylurea Compounds; Prognosis; Risk Factors; Sorafenib | 2017 |
Hand-foot skin reaction is a beneficial indicator of sorafenib therapy for patients with hepatocellular carcinoma: a systemic review and meta-analysis.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chi-Square Distribution; Disease Progression; Hand-Foot Syndrome; Humans; Liver Neoplasms; Niacinamide; Odds Ratio; Phenylurea Compounds; Quality of Life; Risk Factors; Sorafenib; Treatment Outcome | 2018 |
New insights into sorafenib resistance in hepatocellular carcinoma: Responsible mechanisms and promising strategies.
Topics: Antineoplastic Agents; Autophagy; Carcinoma, Hepatocellular; Clinical Trials as Topic; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Humans; Liver Neoplasms; MicroRNAs; Neoplastic Stem Cells; Niacinamide; Phenylurea Compounds; Programmed Cell Death 1 Receptor; Protein Kinase Inhibitors; Sorafenib | 2017 |
Transcatheter arterial chemoembolization plus sorafenib versus transcatheter arterial chemoembolization alone to treat advanced hepatocellular carcinoma: a meta-analysis.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Survival Analysis; Treatment Outcome | 2017 |
Treatment options after sorafenib failure in patients with hepatocellular carcinoma.
Topics: Antibodies, Monoclonal; Carcinoma, Hepatocellular; Humans; Immunotherapy; Liver Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Treatment Failure | 2017 |
Multiple Roles of Autophagy in the Sorafenib Resistance of Hepatocellular Carcinoma.
Topics: Antineoplastic Agents; Autophagy; Autophagy-Related Proteins; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Drug Therapy, Combination; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib | 2017 |
Transarterial Chemoembolization in Combination with a Molecular Targeted Agent: Lessons Learned from Negative Trials (Post-TACE, BRISK-TA, SPACE, ORIENTAL, and TACE-2).
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic; Sorafenib | 2017 |
Regorafenib for the treatment of hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Clinical Trials, Phase III as Topic; Humans; Liver Neoplasms; Phenylurea Compounds; Pyridines; Randomized Controlled Trials as Topic; Sorafenib | 2018 |
[Systemic treatment options of primary hepatocellular carcinoma].
Topics: Carcinoma, Hepatocellular; Humans; Immunotherapy; Liver Neoplasms; Molecular Targeted Therapy; Sorafenib | 2018 |
Systemic therapy for intermediate and advanced hepatocellular carcinoma: Sorafenib and beyond.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Clinical Trials as Topic; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic; Sorafenib | 2018 |
Exploring the role of oncolytic viruses in hepatobiliary cancers.
Topics: Animals; Carcinoma, Hepatocellular; Clinical Trials as Topic; Drug Evaluation, Preclinical; Hepatobiliary Elimination; Humans; Liver Neoplasms; Oncolytic Virotherapy; Oncolytic Viruses; Sorafenib; Treatment Outcome; Vaccinia virus | 2018 |
Regorafenib: A Review in Hepatocellular Carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Disease-Free Survival; Drug Approval; Humans; Liver Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2018 |
Which is the best combination of TACE and Sorafenib for advanced hepatocellular carcinoma treatment? A systematic review and network meta-analysis.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Humans; Liver Neoplasms; Protein Kinase Inhibitors; Sorafenib | 2018 |
Review article: systemic treatment of hepatocellular carcinoma.
Topics: Anilides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Immunotherapy; Liver Neoplasms; Nivolumab; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinolines; Ramucirumab; Sorafenib | 2018 |
Molecular therapies and precision medicine for hepatocellular carcinoma.
Topics: Anilides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma, Hepatocellular; Humans; Immunotherapy; Liver Neoplasms; Molecular Targeted Therapy; Phenylurea Compounds; Precision Medicine; Pyridines; Quinolines; Ramucirumab; Sorafenib | 2018 |
The Expanding Role of Systemic Therapy in the Management of Hepatocellular Carcinoma.
Topics: Carcinoma, Hepatocellular; Clinical Trials, Phase III as Topic; Female; Forecasting; Humans; Liver Neoplasms; Male; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Risk Assessment; Sorafenib; Survival Analysis; Treatment Outcome | 2018 |
Role of ferroptosis in hepatocellular carcinoma.
Topics: Animals; Carcinogenesis; Carcinoma, Hepatocellular; Cell Death; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Genetic Variation; Humans; Lipid Metabolism; Liver Neoplasms; Signal Transduction; Sorafenib | 2018 |
Transarterial chemoembolization plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review and meta-analysis.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Disease Progression; Humans; Liver Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Sorafenib; Survival Analysis; Time Factors | 2018 |
Lenvatinib as a therapy for unresectable hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolines; Sorafenib; Survival Rate | 2018 |
Comprehensive treatments for hepatocellular carcinoma with portal vein tumor thrombosis.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatectomy; Humans; Liver Neoplasms; Portal Vein; Radiotherapy; Sorafenib; Treatment Outcome; Venous Thrombosis | 2019 |
Optimal management of patients with hepatocellular carcinoma treated with lenvatinib.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolines; Sorafenib; Survival Rate | 2018 |
Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers?
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Clinical Trials, Phase III as Topic; Drug Resistance, Neoplasm; Humans; Leukocyte Count; Liver; Liver Neoplasms; Neoplasm Invasiveness; Prognosis; Sorafenib; Treatment Outcome | 2018 |
Fatal adverse events with molecular targeted agents in the treatment of advanced hepatocellular carcinoma: a meta-analysis of randomized controlled trials.
Topics: Aged; Alanine; Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Middle Aged; Molecular Targeted Therapy; Randomized Controlled Trials as Topic; Risk Factors; Sorafenib; Triazines | 2018 |
Combination of transarterial chemoembolization and sorafenib improves outcomes of unresectable hepatocellular carcinoma: an updated systematic review and meta-analysis.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Disease Progression; Female; Humans; Liver Neoplasms; Male; Middle Aged; Sorafenib; Treatment Outcome | 2018 |
The Role of Angiogenesis in Hepatocellular Carcinoma.
Topics: Angiogenesis Inhibitors; Angiostatins; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Neovascularization, Pathologic; Prognosis; Protein Kinase Inhibitors; Sorafenib; Vascular Endothelial Growth Factor A | 2019 |
Sorafenib resistance in hepatocarcinoma: role of hypoxia-inducible factors.
Topics: Animals; Antineoplastic Agents; Biomarkers; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Humans; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Liver Neoplasms; Molecular Targeted Therapy; Protein Kinase Inhibitors; Sorafenib; Tumor Microenvironment | 2018 |
Complete response of hepatocellular carcinoma with right atrium and pulmonary metastases treated by combined treatments (a possible treatment effect of natural killer cell): A case report and literature review.
Topics: Antineoplastic Agents; Antineoplastic Protocols; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Heart Atria; Heart Neoplasms; Humans; Killer Cells, Natural; Liver Neoplasms; Lung; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Radiotherapy, Adjuvant; Remission Induction; Response Evaluation Criteria in Solid Tumors; Sorafenib; Tumor Burden | 2018 |
Regorafenib: a promising treatment for hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Screening Assays, Antitumor; Humans; Liver Neoplasms; Phenylurea Compounds; Pyridines; Sorafenib | 2018 |
Combined hepatocellular-cholangiocarcinoma successfully treated with sorafenib: case report and review of the literature.
Topics: Antineoplastic Agents; Antiviral Agents; Carcinoma, Hepatocellular; Cholangiocarcinoma; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Neoplasms, Multiple Primary; Protein Kinase Inhibitors; Remission Induction; Sorafenib | 2019 |
Sorafenib as first-line therapy in patients with advanced Child-Pugh B hepatocellular carcinoma-a meta-analysis.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Hepatocellular; Clinical Trials as Topic; Disease Progression; Disease-Free Survival; Female; Humans; Liver; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Multicenter Studies as Topic; Protein Kinase Inhibitors; Retrospective Studies; Severity of Illness Index; Sorafenib | 2018 |
Systemic therapy for hepatocellular carcinoma: beyond sorafenib.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Humans; Immunotherapy; Liver Neoplasms; Protein Kinase Inhibitors; Sorafenib | 2018 |
An update of treatments of hepatocellular carcinoma in patients refractory to sorafenib.
Topics: Anilides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Hepatocellular; Clinical Trials, Phase III as Topic; Humans; Liver Neoplasms; Phenylurea Compounds; Pyridines; Ramucirumab; Randomized Controlled Trials as Topic; Sorafenib | 2018 |
Role of microRNAs in the development of hepatocellular carcinoma and acquired drug resistance.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; MicroRNAs; Signal Transduction; Sorafenib | 2019 |
Sorafenib: key lessons from over 10 years of experience.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Liver Neoplasms; Molecular Targeted Therapy; Sorafenib; Thyroid Neoplasms | 2019 |
Goals and targets for personalized therapy for HCC.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatectomy; Humans; Liver Neoplasms; Liver Transplantation; Molecular Targeted Therapy; Neoplasm Staging; Palliative Care; Patient Care Planning; Radiofrequency Ablation; Radiosurgery; Sorafenib | 2019 |
Systematic review with meta-analysis: the critical role of dermatological events in patients with hepatocellular carcinoma treated with sorafenib.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Retrospective Studies; Skin Diseases; Sorafenib; Survival Rate | 2019 |
Efficacy and safety of selective internal radiotherapy versus sorafenib for intermediate-locally advanced hepatocellular carcinoma: a systematic review and meta-analysis.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Clinical Decision-Making; Humans; Liver Neoplasms; Protein Kinase Inhibitors; Radiotherapy Dosage; Risk Factors; Sorafenib; Treatment Outcome | 2019 |
Comparison of Radioembolization and Sorafenib for the Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: A Systematic Review and Meta-Analysis of Safety and Efficacy.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Diarrhea; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Severity of Illness Index; Sorafenib; Venous Thrombosis | 2019 |
Identifying Clonal Origin of Multifocal Hepatocellular Carcinoma and Its Clinical Implications.
Topics: Biomarkers, Tumor; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Chemotherapy, Adjuvant; Chromosome Aberrations; Clone Cells; Diagnosis, Differential; Hepatectomy; Hepatitis B virus; High-Throughput Nucleotide Sequencing; Humans; Liver; Liver Neoplasms; Mutation; Neoplasms, Multiple Primary; Neoplasms, Second Primary; Patient Selection; Precision Medicine; Sorafenib; Treatment Outcome; Tumor Suppressor Protein p53 | 2019 |
Supplementary Sorafenib Therapies for Hepatocellular Carcinoma-A Systematic Review and Meta-Analysis: Supplementary Sorafenib for Liver Cancer.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Disease Progression; Humans; Liver Neoplasms; Randomized Controlled Trials as Topic; Sorafenib; Survival Rate; Treatment Outcome | 2019 |
Pharmacological treatment of hepatocellular carcinoma with cavoatrial tumor thrombus - case series and literature review.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Fatal Outcome; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplastic Cells, Circulating; Sorafenib; Thrombosis; Vena Cava, Inferior; Venous Thrombosis | 2019 |
Lenvatinib: A Review in Hepatocellular Carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Dose-Response Relationship, Drug; Humans; Liver Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolines; Sorafenib; Treatment Outcome; Tyrosine | 2019 |
Sorafenib versus hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: a systematic review and meta-analysis.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Female; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Middle Aged; Retrospective Studies; Sorafenib; Treatment Outcome | 2019 |
Clinical Pharmacokinetics and Pharmacodynamics of Transarterial Chemoembolization and Targeted Therapies in Hepatocellular Carcinoma.
Topics: Aged; Aged, 80 and over; Anilides; Animals; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Disease Progression; Female; Humans; Liver Neoplasms; Male; Models, Animal; Molecular Targeted Therapy; Pharmacokinetics; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinolines; Sorafenib; Treatment Outcome | 2019 |
Cabozantinib in patients with hepatocellular carcinoma failing previous treatment with sorafenib.
Topics: Anilides; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Clinical Trials as Topic; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Molecular Structure; Molecular Targeted Therapy; Neoplasm Staging; Neovascularization, Pathologic; Prognosis; Protein Kinase Inhibitors; Pyridines; Randomized Controlled Trials as Topic; Retreatment; Sorafenib; Treatment Outcome | 2019 |
[Clinical research progression of molecular-targeted drugs and PD-1 inhibitors for advanced hepatocellular carcinoma].
Topics: Carcinoma, Hepatocellular; Clinical Trials as Topic; Humans; Liver Neoplasms; Molecular Targeted Therapy; Neoplasm Staging; Programmed Cell Death 1 Receptor; Sorafenib | 2019 |
Capsaicin: Effects on the Pathogenesis of Hepatocellular Carcinoma.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Capsaicin; Carcinoma, Hepatocellular; Cell Differentiation; Cell Proliferation; Drug Synergism; Humans; Liver Neoplasms; Neovascularization, Pathologic; Oxidative Stress; Signal Transduction; Sorafenib; TRPV Cation Channels | 2019 |
Hepatocellular carcinoma: Current situation and challenge.
Topics: Anilides; Carcinoma, Hepatocellular; Clinical Trials, Phase III as Topic; Female; Humans; Liver Neoplasms; Male; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyridines; Quinolines; Risk Assessment; Sorafenib; Survival Analysis; Treatment Outcome | 2019 |
Evolution in medicinal chemistry of sorafenib derivatives for hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Proliferation; Chemistry, Pharmaceutical; ErbB Receptors; Humans; Liver Neoplasms; Molecular Structure; Protein Kinase Inhibitors; Sorafenib | 2019 |
Is the treatment outcome of hepatocellular carcinoma inferior in elderly patients?
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Comorbidity; Disease-Free Survival; Hepatectomy; Humans; Liver Neoplasms; Liver Transplantation; Middle Aged; Molecular Targeted Therapy; Patient Selection; Radiofrequency Ablation; Sorafenib; Survival Rate; Treatment Outcome | 2019 |
Management of patients with hepatocellular carcinoma and portal vein tumour thrombosis: comparing east and west.
Topics: Anilides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Endovascular Procedures; Hepatectomy; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Liver Transplantation; Nivolumab; Patient Care Team; Phenylurea Compounds; Portal Vein; Pyridines; Quinolines; Radiotherapy, Adjuvant; Ramucirumab; Sorafenib; Stents; Venous Thrombosis | 2019 |
Yttrium-90 radioembolization for hepatocellular carcinoma: what we know and what we need to know.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Catheterization; Chemoembolization, Therapeutic; Drug Carriers; Humans; Liver Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Sorafenib; Survival Rate; Yttrium Radioisotopes | 2013 |
Rethinking future development of molecular therapies in hepatocellular carcinoma: a bottom-up approach.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Clinical Trials, Phase III as Topic; Drug Discovery; Humans; Liver Neoplasms; Molecular Targeted Therapy; Niacinamide; Patient Selection; Phenylurea Compounds; Sorafenib; Treatment Failure | 2013 |
Treatment of hepatocellular carcinoma combining sorafenib and transarterial locoregional therapy: state of the science.
Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Signal Transduction; Sorafenib; Time Factors; Treatment Outcome | 2013 |
[Current status of molecular targeted therapies in hepatocellular carcinoma].
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Mitogen-Activated Protein Kinase Kinases; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Receptor, IGF Type 1; Signal Transduction; Sorafenib; TOR Serine-Threonine Kinases; Wnt Proteins | 2013 |
Antiangiogenic therapies for advanced hepatocellular carcinoma.
Topics: Angiogenesis Inhibitors; Carcinoma, Hepatocellular; Fibroblast Growth Factors; Humans; Liver Neoplasms; Molecular Targeted Therapy; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Platelet-Derived Growth Factor; Sorafenib; Vascular Endothelial Growth Factor A | 2013 |
Meta-analysis of the efficacy of sorafenib for hepatocellular carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Diarrhea; Disease Progression; Humans; Hypertension; Hypokinesia; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Receptors, Vascular Endothelial Growth Factor; Skin Diseases; Sorafenib; Survival | 2013 |
Advanced unresectable hepatocellular carcinoma: new biologics as fresh ammunition or clues to disease understanding?
Topics: Biological Products; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib | 2013 |
Intermediate hepatocellular carcinoma: current treatments and future perspectives.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neoplasms; Molecular Targeted Therapy; Neoplasm Staging; Niacinamide; Patient Selection; Phenylurea Compounds; Protein Kinase Inhibitors; Risk Factors; Sorafenib; Time Factors; Treatment Outcome | 2013 |
Sorafenib: from literature to clinical practice.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Evidence-Based Medicine; Humans; Liver Neoplasms; Molecular Targeted Therapy; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic; Risk Factors; Sorafenib; Time Factors; Translational Research, Biomedical; Treatment Outcome | 2013 |
A complete response induced by 21-day sorafenib therapy in a patient with advanced hepatocellular carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Administration Schedule; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Remission Induction; Sorafenib; Treatment Outcome | 2013 |
[Resection or interventional treatment of hepatocellular carcinoma: which method for which patient?].
Topics: Antineoplastic Agents; Brachytherapy; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Hepatectomy; Humans; Liver Neoplasms; Liver Transplantation; Living Donors; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Sorafenib; Therapy, Computer-Assisted | 2013 |
Targeted therapies in hepatocellular carcinoma.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Hepatocellular; ErbB Receptors; Humans; Liver; Liver Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2014 |
Met as a therapeutic target in HCC: facts and hopes.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Hepatocyte Growth Factor; Humans; Liver Neoplasms; Models, Biological; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Signal Transduction; Sorafenib | 2014 |
Combination trans arterial chemoembolization (TACE) plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review of the literature.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Clinical Trials as Topic; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib | 2013 |
Hepatocellular carcinoma: options for diagnosing and managing a deadly disease.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Hepatectomy; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Population Surveillance; Risk Factors; Sorafenib | 2013 |
Targeted therapy for advanced hepatocellular cancer in the elderly: focus on sorafenib.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Clinical Trials, Phase III as Topic; Humans; Liver Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Sorafenib | 2013 |
Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: a systematic review and meta-analysis of clinical trials.
Topics: Adverse Drug Reaction Reporting Systems; Carcinoma, Renal Cell; Clinical Trials as Topic; Diarrhea; Gastrointestinal Diseases; Gastrointestinal Tract; Humans; Incidence; Indazoles; Indoles; Liver Neoplasms; Neoplasms; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib; Vomiting | 2014 |
Is the efficacy of sorafenib treatment in patients with hepatocellular carcinoma affected by age?
Topics: Age Factors; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib | 2013 |
Rationale of personalized immunosuppressive medication for hepatocellular carcinoma patients after liver transplantation.
Topics: Antineoplastic Agents; Calcineurin Inhibitors; Carcinoma, Hepatocellular; Glucocorticoids; Graft Rejection; Humans; Immunosuppression Therapy; Immunosuppressive Agents; IMP Dehydrogenase; Liver Neoplasms; Liver Transplantation; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Sorafenib; TOR Serine-Threonine Kinases; Treatment Outcome | 2014 |
New biological perspectives for the improvement of the efficacy of sorafenib in hepatocellular carcinoma.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Clinical Trials as Topic; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Precision Medicine; Protein Kinase Inhibitors; Sorafenib | 2014 |
Sorafenib-based combination as a first line treatment for advanced hepatocellular carcinoma: a systematic review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib | 2014 |
Hepatocellular carcinoma: clinical frontiers and perspectives.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Catheter Ablation; Combined Modality Therapy; Decision Support Techniques; Embolization, Therapeutic; Genome-Wide Association Study; Humans; Liver Neoplasms; Liver Transplantation; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Prognosis; Risk Assessment; Sorafenib | 2014 |
Deregulation of signaling pathways involved in sorafenib resistance of hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Signal Transduction; Sorafenib | 2013 |
Newer treatments for advanced hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Embolization, Therapeutic; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Radiopharmaceuticals; Signal Transduction; Sorafenib; Treatment Outcome | 2014 |
Combination therapy of sorafenib and TACE for unresectable HCC: a systematic review and meta-analysis.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Disease Progression; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib; Survival Analysis; Time Factors | 2014 |
Systemic therapy of hepatocellular carcinoma: current status and future perspectives.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Hepatocellular; Clinical Trials as Topic; ErbB Receptors; Evidence-Based Medicine; Glypicans; Hormones; Humans; Liver Neoplasms; MAP Kinase Kinase Kinases; Medical Oncology; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; TOR Serine-Threonine Kinases; Treatment Outcome | 2014 |
Hepatocellular carcinoma review: current treatment, and evidence-based medicine.
Topics: Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Clinical Trials as Topic; Combined Modality Therapy; Evidence-Based Medicine; Humans; Liver Neoplasms; Liver Transplantation; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Signal Transduction; Sorafenib; Treatment Outcome | 2014 |
Chemotherapy for advanced hepatocellular carcinoma in the sorafenib age.
Topics: Algorithms; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; Clinical Trials as Topic; Disease Progression; Hepatic Artery; Humans; Liver Neoplasms; Medical Oncology; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2014 |
Sorafenib enhances effects of transarterial chemoembolization for hepatocellular carcinoma: a systematic review and meta-analysis.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Randomized Controlled Trials as Topic; Sorafenib; Survival Analysis; Treatment Outcome | 2014 |
Sorafenib use in the transplant setting.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Humans; Immunosuppressive Agents; Liver Neoplasms; Liver Transplantation; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Risk Factors; Sorafenib; Treatment Outcome | 2014 |
Advances in managing hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Hepatectomy; Humans; Liver Neoplasms; Liver Transplantation; Niacinamide; Phenylurea Compounds; Sorafenib | 2014 |
Focal gains of VEGFA: candidate predictors of sorafenib response in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Proliferation; Disease Progression; Drug Resistance, Neoplasm; Gene Amplification; Hepatocyte Growth Factor; Humans; Liver Neoplasms; Macrophages; Mice; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2014 |
Transarterial chemoembolization and sorafenib in hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Clinical Trials as Topic; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib | 2014 |
Combination of intra-arterial therapies and sorafenib: is there a clinical benefit?
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Embolization, Therapeutic; Hepatectomy; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Microspheres; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Radiography, Interventional; Sorafenib; Survival Rate | 2014 |
Treating advanced hepatocellular carcinoma: How to get out of first gear.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib | 2014 |
Transarterial chemoembolization (TACE) plus sorafenib versus TACE for intermediate or advanced stage hepatocellular carcinoma: a meta-analysis.
Topics: Aged; Arteries; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Sorafenib; Time Factors | 2014 |
Magnetic resonance imaging following treatment of advanced hepatocellular carcinoma with sorafenib.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Tomography, X-Ray Computed | 2014 |
Treatment of intermediate-stage hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Sorafenib; Yttrium Radioisotopes | 2014 |
Transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: a systematic review and meta-analysis.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Disease Progression; Humans; Liver Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Publication Bias; Sorafenib; Treatment Outcome | 2014 |
Management of hepatocellular carcinoma.
Topics: alpha-Fetoproteins; Antineoplastic Agents; Antiviral Agents; Carcinoma, Hepatocellular; Disease Management; Hepatitis B; Hepatitis C; Hepatitis, Viral, Human; Humans; Incidence; Liver Neoplasms; Mass Screening; Niacinamide; Palliative Care; Phenylurea Compounds; Population Surveillance; Quality of Life; Sorafenib; Viral Hepatitis Vaccines | 2015 |
Hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Hepatectomy; Humans; Liver; Liver Neoplasms; Liver Transplantation; Niacinamide; Phenylurea Compounds; Risk Factors; Sorafenib | 2014 |
Decade in review-hepatocellular carcinoma: HCC-subtypes, stratification and sorafenib.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib | 2014 |
A short update on cancer chemoresistance.
Topics: Carcinoma, Hepatocellular; Combined Modality Therapy; Drug Resistance, Neoplasm; Hepatectomy; Humans; Liver Neoplasms; Liver Transplantation; MicroRNAs; Molecular Targeted Therapy; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib | 2014 |
Systemic treatment.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Patient Selection; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2014 |
Refining sorafenib therapy: lessons from clinical practice.
Topics: Age Factors; Antineoplastic Agents; Carcinoma, Hepatocellular; Clinical Trials as Topic; Combined Modality Therapy; Disease Progression; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Retreatment; Sorafenib; Treatment Outcome | 2015 |
Adjuvant therapy for hepatocellular carcinoma after curative treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Female; Humans; Immunotherapy; Liver Neoplasms; Male; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Prognosis; Risk Assessment; Sorafenib; Survival Analysis; Treatment Outcome | 2014 |
Downregulation of signal transducer and activator of transcription 3 by sorafenib: a novel mechanism for hepatocellular carcinoma therapy.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Down-Regulation; Humans; Liver Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Signal Transduction; Sorafenib; STAT3 Transcription Factor; Treatment Outcome | 2014 |
Transarterial chemoembolization failure/refractoriness: JSH-LCSGJ criteria 2014 update.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Ethiodized Oil; Health Care Surveys; Hepatic Artery; Humans; Japan; Liver Function Tests; Liver Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Practice Patterns, Physicians'; Predictive Value of Tests; Sorafenib; Treatment Failure | 2014 |
Multimodality treatment involving radiotherapy for advanced liver-confined hepatocellular carcinoma.
Topics: alpha-Fetoproteins; Antineoplastic Agents; Biomarkers; Biomarkers, Tumor; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Chemoradiotherapy; Chemotherapy, Adjuvant; Combined Modality Therapy; Hepatectomy; Humans; Liver Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Practice Guidelines as Topic; Protein Precursors; Prothrombin; Radiotherapy, Adjuvant; Republic of Korea; Sorafenib; Treatment Outcome | 2014 |
An updated meta-analysis of randomized controlled trials assessing the effect of sorafenib in advanced hepatocellular carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Disease Progression; Humans; Liver Neoplasms; Niacinamide; Patient Safety; Phenylurea Compounds; Prognosis; Randomized Controlled Trials as Topic; Sorafenib; Treatment Outcome | 2014 |
Managing localized unresectable hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Combined Modality Therapy; Early Detection of Cancer; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Risk Factors; Sorafenib | 2015 |
New therapeutic strategy for hepatocellular carcinoma by molecular targeting agents via inhibition of cellular stress defense mechanisms.
Topics: Antineoplastic Agents; Autophagy; Carcinoma, Hepatocellular; Cytoprotection; Drug Therapy, Combination; Endoplasmic Reticulum Stress; Humans; Keratins; Liver Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Phosphorylation; Prognosis; Proteasome Inhibitors; Sorafenib; Unfolded Protein Response | 2014 |
Treatment of hepatocellular carcinoma: beyond international guidelines.
Topics: Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Guidelines as Topic; Humans; Internationality; Liver Neoplasms; Liver Transplantation; Neoplasm Staging; Niacinamide; Patient Selection; Phenylurea Compounds; Sorafenib | 2015 |
Systemic treatment of advanced hepatocellular carcinoma: from disillusions to new horizons.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Drugs, Investigational; Humans; Liver Neoplasms; Neoadjuvant Therapy; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Failure | 2015 |
Treatment efficacy differences of sorafenib for advanced hepatocellular carcinoma: a meta-analysis of randomized clinical trials.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Clinical Trials, Phase III as Topic; Hepatitis B; Hepatitis C; Humans; Liver Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Randomized Controlled Trials as Topic; Sorafenib; Survival Analysis; Treatment Outcome | 2015 |
Survival of patients treated with sorafenib for hepatocellular carcinoma recurrence after liver transplantation: a systematic review and meta-analysis.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Liver Transplantation; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Postoperative Period; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Survival Rate | 2015 |
Is Notch Signaling a Specific Target in Hepatocellular Carcinoma?
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Combined Modality Therapy; Doxorubicin; Gene Knockdown Techniques; Genetic Therapy; Humans; Liver Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Receptors, Notch; Signal Transduction; Sorafenib; Valproic Acid | 2015 |
Case analysis of complete remission of advanced hepatocellular carcinoma achieved with sorafenib.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Disease-Free Survival; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib | 2015 |
Peri-operative use of sorafenib in liver transplantation: a time-to-event meta-analysis.
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Chi-Square Distribution; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Liver Transplantation; Neoadjuvant Therapy; Niacinamide; Odds Ratio; Phenylurea Compounds; Protein Kinase Inhibitors; Risk Factors; Sorafenib; Time Factors; Treatment Outcome | 2015 |
Clinical observation of liver cancer patients treated with axitinib and cabozantinib after failed sorafenib treatment: a case report and literature review.
Topics: Anilides; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Carcinoma, Hepatocellular; Fatal Outcome; Humans; Imidazoles; Indazoles; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Retreatment; Sorafenib; Tomography, X-Ray Computed; Treatment Failure; Treatment Outcome | 2015 |
[Successful treatment of metastatic hepatocellular carcinoma with sorafenib combined with transcatheter arterial chemoembolization/hepatic arterial infusion chemotherapy].
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Embolization, Therapeutic; Hepatectomy; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Recurrence; Sorafenib; Treatment Outcome | 2014 |
The Ras/MAPK pathway and hepatocarcinoma: pathogenesis and therapeutic implications.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Apoptosis Regulatory Proteins; Carcinogenesis; Carcinoma, Hepatocellular; Humans; Intracellular Signaling Peptides and Proteins; Liver Neoplasms; MAP Kinase Signaling System; Membrane Proteins; Mice; Mitogen-Activated Protein Kinases; Monomeric GTP-Binding Proteins; Mutation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; raf Kinases; ras GTPase-Activating Proteins; ras Proteins; Rats; Sorafenib; Tumor Suppressor Proteins | 2015 |
Management of hepatocellular carcinoma with portal vein thrombosis.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Contraindications; Humans; Liver Neoplasms; Liver Transplantation; Niacinamide; Phenylurea Compounds; Portal Vein; Practice Guidelines as Topic; Protein Kinase Inhibitors; Radiopharmaceuticals; Sorafenib; Treatment Outcome; Venous Thrombosis | 2015 |
Long-term complete response of advanced hepatocellular carcinoma treated with multidisciplinary therapy including reduced dose of sorafenib: case report and review of the literature.
Topics: Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Combined Modality Therapy; Embolization, Therapeutic; Hepatectomy; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Prognosis; Remission Induction; Sorafenib | 2015 |
MEK 1/2 inhibitors in the treatment of hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzimidazoles; Carcinoma, Hepatocellular; Diphenylamine; Humans; Liver Neoplasms; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Sulfonamides | 2015 |
Systemic therapy of hepatocellular carcinoma: current and promising.
Topics: Alanine; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Hepatectomy; Humans; Indoles; Liver Neoplasms; Liver Transplantation; Niacinamide; Phenylurea Compounds; Preoperative Care; Proto-Oncogene Proteins c-met; Pyrroles; Signal Transduction; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Triazines | 2015 |
Liquid biopsy in liver cancer.
Topics: Alleles; Biomarkers, Tumor; Biopsy; Carcinoma, Hepatocellular; Clinical Trials as Topic; DNA, Neoplasm; Humans; Liver Neoplasms; Molecular Targeted Therapy; Neoplastic Cells, Circulating; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib | 2015 |
Systematic review of catheter-based intra-arterial therapies in hepatocellular carcinoma: state of the art and future directions.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Combined Modality Therapy; Diffusion of Innovation; Embolization, Therapeutic; Female; Forecasting; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Microspheres; Niacinamide; Patient Selection; Phenylurea Compounds; Radiopharmaceuticals; Sorafenib; Yttrium Radioisotopes | 2015 |
Novel drugs in clinical development for hepatocellular carcinoma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Design; Humans; Liver Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Sorafenib | 2015 |
[Advanced hepatocellular carcinoma: importance of clinical trials].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Disease Progression; Humans; Liver Neoplasms; Niacinamide; Patient Selection; Phenylurea Compounds; Sorafenib | 2015 |
New perspectives on the management of hepatocellular carcinoma with portal vein thrombosis.
Topics: Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Portal Vein; Protein Kinase Inhibitors; Sorafenib; Venous Thrombosis | 2015 |
Sorafenib: 10 years after the first pivotal trial.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Thyroid Neoplasms | 2015 |
Potential molecular, cellular and microenvironmental mechanism of sorafenib resistance in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Humans; Liver Neoplasms; Molecular Targeted Therapy; Neoplastic Stem Cells; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Signal Transduction; Sorafenib; Tumor Microenvironment | 2015 |
New molecular therapies for hepatocellular carcinoma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Hepatocellular; Clinical Trials, Phase II as Topic; Fibroblast Growth Factors; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-met; Proto-Oncogene Proteins p21(ras); Signal Transduction; Sorafenib; Transforming Growth Factor beta | 2015 |
Hepatocellular carcinoma treatment over sorafenib: epigenetics, microRNAs and microenvironment. Is there a light at the end of the tunnel?
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; DNA Methylation; Drug Design; Epigenesis, Genetic; Histone Deacetylase Inhibitors; Humans; Liver Neoplasms; MicroRNAs; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Sorafenib; Tumor Microenvironment | 2015 |
Sorafenib for Hepatocellular Carcinoma: From Randomized Controlled Trials to Clinical Practice.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Practice Patterns, Physicians'; Randomized Controlled Trials as Topic; Sorafenib | 2015 |
Predictive biomarkers of sorafenib efficacy in advanced hepatocellular carcinoma: Are we getting there?
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Diagnostic Imaging; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Protein Kinase Inhibitors; Risk Factors; Sorafenib; Treatment Outcome | 2015 |
Genetic and epigenetic aspects of initiation and progression of hepatocellular carcinoma.
Topics: Animals; Carcinoma, Hepatocellular; Cell Cycle Proteins; Disease Progression; DNA Methylation; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Humans; Interleukin-6; Liver Neoplasms; Membrane Glycoproteins; Microtubule-Associated Proteins; Neoplasm Recurrence, Local; Niacinamide; Nuclear Proteins; Oncogenes; Phenylurea Compounds; Prognosis; Receptors, Immunologic; Sirtuin 1; Sorafenib; Trans-Activators; Transcription Factors; Treatment Outcome; Triggering Receptor Expressed on Myeloid Cells-1 | 2015 |
Congenital extrahepatic portosystemic shunt complicated by the development of hepatocellular carcinoma.
Topics: Adult; Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Embolization, Therapeutic; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Portal Vein; Sorafenib; Vascular Malformations | 2015 |
Radiofrequency ablation-combined multimodel therapies for hepatocellular carcinoma: Current status.
Topics: Bevacizumab; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Combined Modality Therapy; Humans; Immunotherapy; Liver Neoplasms; Molecular Targeted Therapy; Nanoparticles; Niacinamide; Phenylurea Compounds; Sorafenib | 2016 |
Prognostic Value of VEGF in Hepatocellular Carcinoma Patients Treated with Sorafenib: A Meta-Analysis.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Disease-Free Survival; Female; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Male; Middle Aged; Mutation; Niacinamide; Observational Studies as Topic; Phenylurea Compounds; Polymorphism, Genetic; Prognosis; Sorafenib; Treatment Outcome; Vascular Endothelial Growth Factor A; Young Adult | 2015 |
Modulation of sensitivity and resistance to multikinase inhibitors by microenvironmental platelet factors in HCC.
Topics: Antineoplastic Agents; Blood Platelets; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Tumor Microenvironment | 2015 |
Molecular Mechanism and Prediction of Sorafenib Chemoresistance in Human Hepatocellular Carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib | 2015 |
Managements of recurrent hepatocellular carcinoma after liver transplantation: A systematic review.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Liver Transplantation; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Reoperation; Risk Factors; Sorafenib; Survival Analysis; Time Factors; Treatment Outcome | 2015 |
Sorafenib-based combined molecule targeting in treatment of hepatocellular carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Histone Deacetylase Inhibitors; Humans; Liver Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Signal Transduction; Sorafenib; Treatment Outcome | 2015 |
Biology, Epidemiology, Clinical Aspects of Hepatocellular Carcinoma and the Role of Sorafenib.
Topics: Animals; Autophagy; Carcinoma, Hepatocellular; Clinical Trials as Topic; Female; Genetic Predisposition to Disease; Humans; Liver Neoplasms; Male; Niacinamide; Non-alcoholic Fatty Liver Disease; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Survival Analysis; Treatment Outcome | 2016 |
Paradoxical exacerbation of chronic plaque psoriasis by sorafenib.
Topics: Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Psoriasis; Sorafenib | 2016 |
Treatment of hepatocellular carcinoma: beyond international guidelines.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neoplasms; Liver Transplantation; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Societies, Medical; Sorafenib; Survival Rate; Treatment Outcome | 2016 |
Treatment of hepatocellular carcinoma with portal venous tumor thrombosis: A comprehensive review.
Topics: ADAM17 Protein; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Embolization, Therapeutic; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Portal Vein; Radiotherapy, Conformal; Sorafenib; Venous Thrombosis | 2016 |
Sorafenib in combination with transarterial chemoembolization for hepatocellular carcinoma: a meta-analysis.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2016 |
Sorafenib combined with transarterial chemoembolization in patients with hepatocellular carcinoma: a meta-analysis and systematic review.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib | 2016 |
Rationally combining anti-VEGF therapy with checkpoint inhibitors in hepatocellular carcinoma.
Topics: Animals; Carcinoma, Hepatocellular; Cell Cycle; Cell Differentiation; Dendritic Cells; Humans; Immunosuppression Therapy; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Tumor Microenvironment | 2016 |
Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Embolization, Therapeutic; Humans; Liver Neoplasms; Microspheres; Niacinamide; Phenylurea Compounds; Randomized Controlled Trials as Topic; Sorafenib; Yttrium Radioisotopes | 2016 |
Sorafenib-induced Acute Pancreatitis: A Case Report and Review of the Literature.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Fatal Outcome; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Pancreatitis; Phenylurea Compounds; Sorafenib | 2016 |
The use of genetic alterations in the development of liver cancer drugs.
Topics: Animals; Carcinoma, Hepatocellular; Clinical Trials, Phase III as Topic; Disease-Free Survival; Humans; Liver Neoplasms; Mutation; Niacinamide; Phenylurea Compounds; Randomized Controlled Trials as Topic; Sorafenib; Survival Rate | 2015 |
Management of hepatocellular carcinoma: an overview of major findings from meta-analyses.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Disease-Free Survival; Hepatectomy; Humans; Liver Neoplasms; Liver Transplantation; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2016 |
Liver Transplantation After Neoadjuvant Sorafenib Therapy: Preliminary Experience and Literature Review.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Feasibility Studies; Female; France; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Preliminary Data; Protein Kinase Inhibitors; Retrospective Studies; Sorafenib; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2018 |
Efficacy and safety of transarterial chemoembolization plus sorafenib for early or intermediate stage hepatocellular carcinoma: A systematic review and meta-analysis of randomized controlled trials.
Topics: Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Disease Progression; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic; Sorafenib | 2016 |
Current status and future prospects of chemotherapy for advanced hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Hepatic Artery; Humans; Immunotherapy; Infusions, Intra-Arterial; Liver Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Sorafenib | 2016 |
Hepatocellular carcinoma: Will novel targeted drugs really impact the next future?
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Discovery; ErbB Receptors; Humans; Liver Neoplasms; Mitogen-Activated Protein Kinase Kinases; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Vascular Endothelial Growth Factors | 2016 |
Systemic treatment of hepatocellular carcinoma: why so many failures in the development of new drugs?
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Drug Design; Humans; Liver Neoplasms; Molecular Targeted Therapy; Niacinamide; Patient Selection; Phenylurea Compounds; Randomized Controlled Trials as Topic; Research Design; Sorafenib | 2016 |
Systemic treatment for advanced hepatocellular carcinoma: the search of new agents to join sorafenib in the effective therapeutic armamentarium.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2016 |
Targeted Therapy for Hepatocellular Carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Humans; Liver Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Sorafenib | 2016 |
Challenges of advanced hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; Clinical Trials as Topic; Humans; Liver; Liver Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Portal Vein; Sorafenib; Thrombosis | 2016 |
New chemical treatment options in second-line hepatocellular carcinoma: what to do when sorafenib fails?
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-met; Sorafenib | 2017 |
Development of sorafenib-related side effects in patients diagnosed with advanced hepatocellular carcinoma treated with sorafenib: a systematic-review and meta-analysis of the impact on survival.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chi-Square Distribution; Humans; Liver Neoplasms; Niacinamide; Odds Ratio; Phenylurea Compounds; Protein Kinase Inhibitors; Risk Factors; Sorafenib; Time Factors; Treatment Outcome | 2017 |
Short-term and long-term efficacy of 7 targeted therapies for the treatment of advanced hepatocellular carcinoma: a network meta-analysis: Efficacy of 7 targeted therapies for AHCC.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma, Hepatocellular; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Liver Neoplasms; Male; Molecular Targeted Therapy; Neoplasm Invasiveness; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Ramucirumab; Randomized Controlled Trials as Topic; Risk Assessment; Sorafenib; Survival Analysis; Treatment Outcome | 2016 |
Impact of Viral Status on Survival in Patients Receiving Sorafenib for Advanced Hepatocellular Cancer: A Meta-Analysis of Randomized Phase III Trials.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Clinical Trials, Phase III as Topic; Female; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic; Sorafenib | 2017 |
Immune Checkpoint Inhibition in Hepatocellular Carcinoma: Basics and Ongoing Clinical Trials.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; B7-H1 Antigen; Carcinoma, Hepatocellular; Clinical Trials as Topic; Humans; Liver Neoplasms; Membrane Transport Proteins; Niacinamide; Nivolumab; Phenylurea Compounds; Programmed Cell Death 1 Receptor; Sorafenib | 2017 |
Recent advances in hepatocellular carcinoma therapy.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Disease Progression; Drug Delivery Systems; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib | 2017 |
Transarterial chemoembolization (TACE) combined with sorafenib versus TACE for hepatocellular carcinoma with portal vein tumor thrombus: a systematic review and meta-analysis.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib | 2017 |
Exceptional serological and radiological response to sorafenib in 2 patients with advanced hepatocellular carcinoma and chronic hepatitis C viral infection: case report and review of the literature.
Topics: Aged; alpha-Fetoproteins; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Hepatitis C, Chronic; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Tomography, X-Ray Computed | 2017 |
Management of people with intermediate-stage hepatocellular carcinoma: an attempted network meta-analysis.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neoplasms; Network Meta-Analysis; Niacinamide; Phenylurea Compounds; Randomized Controlled Trials as Topic; Severity of Illness Index; Sorafenib | 2017 |
Sorafenib: A Review in Hepatocellular Carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Sorafenib | 2017 |
Contemporary management of hepatocellular carcinoma.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Hepatectomy; Humans; Iodine Radioisotopes; Iodized Oil; Liver Neoplasms; Liver Transplantation; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Receptors, Vascular Endothelial Growth Factor; Risk Factors; Sorafenib; Yttrium Radioisotopes | 2008 |
Review article: pharmacological therapy for hepatocellular carcinoma with sorafenib and other oral agents.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Extracellular Signal-Regulated MAP Kinases; Humans; Liver Neoplasms; Mitogen-Activated Protein Kinase Kinases; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; raf Kinases; Signal Transduction; Sorafenib; Survival Rate | 2008 |
Molecular targeted therapies in hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Drug Design; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Signal Transduction; Sorafenib | 2008 |
Systemic therapy of hepatocellular carcinoma: are we making progress?
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Estrogens; Humans; Injections, Intravenous; Interferons; Liver Neoplasms; Niacinamide; Palliative Care; Phenylurea Compounds; Pyridines; Risk Factors; Sorafenib; Tretinoin | 2008 |
Molecular therapy for the treatment of hepatocellular carcinoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Hepatocellular; Clinical Trials as Topic; Humans; Indoles; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2009 |
Evolution of systemic therapy of advanced hepatocellular carcinoma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Benzenesulfonates; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Humans; Immunologic Factors; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Somatostatin; Sorafenib; Thalidomide; Treatment Outcome | 2008 |
Sorafenib for the treatment of unresectable hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Drug Approval; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Randomized Controlled Trials as Topic; Sorafenib; United States; United States Food and Drug Administration | 2009 |
[Sorafenib for the treatment of HCC--the beginning of a new era in the treatment of HCC].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Controlled Clinical Trials as Topic; Drug Delivery Systems; Humans; Liver Neoplasms; Neoplasm Staging; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2009 |
Multimodal approaches to the treatment of hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Combined Modality Therapy; Embolization, Therapeutic; Ethanol; Humans; Injections; Liver Neoplasms; Liver Transplantation; Niacinamide; Phenylurea Compounds; Preoperative Care; Pyridines; Radiotherapy, Adjuvant; Salvage Therapy; Sorafenib; Waiting Lists | 2009 |
Sorafenib: a review of its use in advanced hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Drug Interactions; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2009 |
[Targeted therapies and their indications in solid neoplasias].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; ErbB Receptors; Erlotinib Hydrochloride; Everolimus; Gefitinib; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Receptor, ErbB-2; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2009 |
Epidemiology, screening, diagnosis and treatment of hepatocellular carcinoma.
Topics: Algorithms; alpha-Fetoproteins; Anti-Infective Agents, Local; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Hepatocellular; Catheter Ablation; Drug Therapy, Combination; Embolization, Therapeutic; Ethanol; Evidence-Based Medicine; Global Health; Hepatectomy; Humans; Incidence; Liver Neoplasms; Liver Transplantation; Mass Screening; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Population Surveillance; Practice Guidelines as Topic; Pyridines; Randomized Controlled Trials as Topic; Risk Factors; Sorafenib; Survival Rate; Texas; Treatment Outcome | 2009 |
Systemic treatment in hepatocellular carcinoma; 'A small step for man...'.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2009 |
PDGFRalpha: a new therapeutic target in the treatment of hepatocellular carcinoma?
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Drug Delivery Systems; Drug Design; Embryonic Development; Humans; Liver Neoplasms; Liver Neoplasms, Experimental; Mice; Mice, Transgenic; Neoplasm Proteins; Neovascularization, Pathologic; Neovascularization, Physiologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Receptor, Platelet-Derived Growth Factor alpha; Signal Transduction; Sorafenib | 2009 |
Pathogenesis of hepatocellular carcinoma and molecular therapies.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Receptors, Vascular Endothelial Growth Factor; Risk Factors; Signal Transduction; Sorafenib | 2009 |
Selection of patients with hepatocellular carcinoma for sorafenib.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Humans; Liver Neoplasms; Niacinamide; Patient Selection; Phenylurea Compounds; Pyridines; Receptors, Vascular Endothelial Growth Factor; Sorafenib | 2009 |
[The treatment of hepatocellular carcinoma. New developments].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Humans; Liver Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Sorafenib; Treatment Outcome | 2009 |
[Current advances in molecular targeted therapy of primary hepatocellular carcinoma].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Adhesion; Cell Proliferation; Humans; Liver Neoplasms; Neoplasm Metastasis; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Signal Transduction; Sorafenib | 2009 |
Current management of hepatocellular carcinoma.
Topics: Algorithms; Benzenesulfonates; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Disease Progression; Hepatectomy; Hepatitis B; Hepatitis C; Humans; Liver; Liver Neoplasms; Liver Transplantation; Magnetic Resonance Imaging; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Niacinamide; Patient Selection; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome; Ultrasonography | 2009 |
Molecular targeting for treatment of advanced hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-raf; Pyridines; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib | 2009 |
Medical treatments: in association or alone, their roles and their future perspectives: the Western experience.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Survival Rate; Treatment Outcome; United States | 2010 |
Review article: the management of hepatocellular carcinoma.
Topics: Ablation Techniques; Adult; Antineoplastic Agents; Asian People; Benzenesulfonates; Biopsy; Black People; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Contrast Media; Drug Eruptions; Female; Health Care Costs; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Incidence; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Staging; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Population Surveillance; Practice Guidelines as Topic; Pyridines; Quality of Life; Randomized Controlled Trials as Topic; Recurrence; Risk Factors; Sorafenib; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome; United States; Young Adult | 2010 |
Sorafenib improves the survival of patients with advanced hepatocellular carcinoma: a meta-analysis of randomized trials.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials, Phase III as Topic; Diarrhea; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Randomized Controlled Trials as Topic; Sorafenib; Syndrome; Treatment Outcome | 2010 |
Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Molecular Diagnostic Techniques; Niacinamide; Phenylurea Compounds; Precision Medicine; Prognosis; Pyridines; Sorafenib | 2010 |
Development of molecularly targeted therapies in hepatocellular carcinoma: where do we go now?
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Pharmacological; Biomarkers, Tumor; Carcinoma, Hepatocellular; Chemistry, Pharmaceutical; Drug Delivery Systems; Drug Design; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2010 |
Sorafenib.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Receptors, Vascular Endothelial Growth Factor; Sorafenib | 2010 |
Current strategy for staging and treatment: the BCLC update and future prospects.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials, Phase III as Topic; Drug Delivery Systems; Female; Forecasting; Hepatectomy; Humans; Liver Neoplasms; Liver Transplantation; Male; Neoplasm Invasiveness; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Randomized Controlled Trials as Topic; Risk Assessment; Sorafenib; Spain; Survival Analysis; Treatment Outcome | 2010 |
[Use of sorafenib in patients with hepatocellular or renal carcinoma].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Clinical Trials as Topic; Diarrhea; Fatigue; Foot Dermatoses; Hand Dermatoses; Humans; Hypertension; Kidney Neoplasms; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome | 2010 |
[Chemotherapy].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Randomized Controlled Trials as Topic; Sorafenib | 2010 |
Beyond sorafenib: novel targeted therapies for advanced hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials, Phase III as Topic; Drug Delivery Systems; Drug Design; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2010 |
Novel inhibitors in development for hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Drug Delivery Systems; Drug Design; Drugs, Investigational; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Signal Transduction; Sorafenib | 2010 |
Systemic treatment of hepatocellular carcinoma: dawn of a new era?
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Receptors, Vascular Endothelial Growth Factor; Sorafenib | 2010 |
Downstaging of hepatocellular carcinoma prior to liver transplant: is there a role for adjuvant sorafenib in locoregional therapy?
Topics: alpha-Fetoproteins; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoadjuvant Therapy; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2010 |
[Hepatocellular carcinoma: occurrence, risk factors, biomarkers].
Topics: Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Hepatocellular; Copper; Developed Countries; Developing Countries; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Incidence; Iron; Liver Cirrhosis, Alcoholic; Liver Cirrhosis, Biliary; Liver Neoplasms; Metabolic Diseases; Niacinamide; Phenylurea Compounds; Pyridines; Risk Factors; Smoking; Sorafenib | 2010 |
Sorafenib for the treatment of advanced hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Disease Progression; Humans; Liver Neoplasms; Models, Economic; Niacinamide; Phenylurea Compounds; Pyridines; Quality of Life; Sorafenib; Survival Analysis; Treatment Outcome; United Kingdom | 2010 |
[Current therapy for hepatocellular carcinoma].
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Catheter Ablation; Combined Modality Therapy; Embolization, Therapeutic; Hepatic Artery; Humans; Liver Neoplasms; Neoplasm Recurrence, Local; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2010 |
The present and the future landscape of treatment of advanced hepatocellular carcinoma.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Drug Design; Humans; Liver Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Survival Analysis | 2010 |
Molecular targeted therapy for advanced hepatocellular carcinoma: current status and future perspectives.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Drug Delivery Systems; Humans; Liver Neoplasms; Molecular Targeted Therapy; Neovascularization, Pathologic; Niacinamide; Patient Selection; Phenylurea Compounds; Pyridines; Sorafenib; Vascular Endothelial Growth Factor A | 2010 |
Sorafenib: where do we go from here?
Topics: Angiogenesis Inhibitors; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Intracellular Signaling Peptides and Proteins; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyridines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; TOR Serine-Threonine Kinases | 2010 |
Hepatocellular carcinoma--what's new?
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Hepatectomy; Humans; Liver Neoplasms; Liver Transplantation; Metabolic Syndrome; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Risk Factors; Sorafenib; Treatment Outcome | 2010 |
Positioning of a molecular-targeted agent, sorafenib, in the treatment algorithm for hepatocellular carcinoma and implication of many complete remission cases in Japan.
Topics: Algorithms; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Survival Rate; Treatment Outcome | 2010 |
Positioning and indication of sorafenib in the treatment algorithm and real practice setting: Western and eastern approach--Asian perspective.
Topics: Algorithms; Asia; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Receptors, Vascular Endothelial Growth Factor; Sorafenib | 2010 |
Molecular targeted therapy of advanced hepatocellular carcinoma beyond sorafenib.
Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Disease Progression; Female; Humans; Liver Neoplasms; Male; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Treatment Outcome | 2010 |
[Nonsurgical management of hepatocellular carcinoma].
Topics: Angiogenesis Inhibitors; Benzenesulfonates; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Drug Delivery Systems; Humans; Liver Neoplasms; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Portal Vein; Pyridines; Radiotherapy, Conformal; Sorafenib; Yttrium Radioisotopes | 2010 |
[Treatment of primary hepatocellular carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Internationality; Liver Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Population Surveillance; Pyridines; Randomized Controlled Trials as Topic; Risk Factors; Sorafenib | 2010 |
Evolving strategies for the treatment of hepatocellular carcinoma: from clinical-guided to molecularly-tailored therapeutic options.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Drug Delivery Systems; Humans; Indoles; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2011 |
Sorafenib in hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Treatment Outcome | 2010 |
Developing better treatments in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Disease Models, Animal; Humans; Liver Neoplasms; Mice; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Research Design; Sorafenib; Treatment Outcome | 2010 |
[Multimodality treatment for hepatocellular carcinoma].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Combined Modality Therapy; Cooperative Behavior; Ethanol; Hepatectomy; Humans; Injections, Intralesional; Interdisciplinary Communication; Liver Neoplasms; Liver Transplantation; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Risk Factors; Sorafenib; Survival Rate | 2010 |
[New possibilities of targeted therapy in the treatment of hepatocellular carcinoma with the help of molecular biology].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Biomarkers, Tumor; Carcinoma, Hepatocellular; Catheter Ablation; Cell Cycle; Chemoembolization, Therapeutic; Chemotherapy, Adjuvant; Epigenesis, Genetic; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Hepatectomy; Humans; Indoles; Intracellular Signaling Peptides and Proteins; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Proteasome Endopeptidase Complex; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Quinazolines; Signal Transduction; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A; Wnt Proteins | 2010 |
[Hepatocellular carcinoma].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2010 |
Inherited hepatocellular carcinoma.
Topics: Algorithms; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Genetic Predisposition to Disease; Hemochromatosis; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Liver Neoplasms; Liver Transplantation; Neoplasm Invasiveness; Neoplasm Staging; Neoplasms; Niacinamide; Patient Selection; Phenylurea Compounds; Population Surveillance; Prognosis; Pyridines; Risk Factors; Severity of Illness Index; Sorafenib; Treatment Outcome; United States | 2010 |
Economic evaluation of sorafenib in unresectable hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Humans; Liver Neoplasms; Markov Chains; Models, Economic; Niacinamide; Phenylurea Compounds; Pyridines; Randomized Controlled Trials as Topic; Sorafenib; Survival Analysis | 2010 |
Treatment of intermediate/advanced hepatocellular carcinoma in the clinic: how can outcomes be improved?
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neoplasms; Neoplasm Staging; Niacinamide; Palliative Care; Phenylurea Compounds; Pyridines; Randomized Controlled Trials as Topic; Sorafenib; Standard of Care; Treatment Outcome | 2010 |
Targeting EGFR in bilio-pancreatic and liver carcinoma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Benzenesulfonates; Biliary Tract Neoplasms; Carcinoma; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Liver Neoplasms; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Sorafenib | 2011 |
Novel molecular therapies in hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Receptor, IGF Type 1; Receptors, Platelet-Derived Growth Factor; Sorafenib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factors | 2011 |
Sorafenib: activity and clinical application in patients with hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Proliferation; Clinical Trials as Topic; Drug Evaluation, Preclinical; Drug Interactions; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2011 |
Emerging strategies in the treatment of advanced hepatocellular carcinoma: the role of targeted therapies.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Epidermal Growth Factor; Humans; Liver Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Vascular Endothelial Growth Factor A | 2011 |
[Sorafenib and radiotherapy association for hepatocellular carcinoma].
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Proliferation; Extracellular Signal-Regulated MAP Kinases; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Pyridines; Radiotherapy, Adjuvant; Signal Transduction; Sorafenib; Vascular Endothelial Growth Factor A | 2011 |
Assessment of the treatment response of HCC.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Contrast Media; Ethanol; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Tomography, X-Ray Computed; Yttrium Radioisotopes | 2011 |
Recent advances in cytogenetics and molecular biology of adult hepatocellular tumors: implications for imaging and management.
Topics: Adenoma, Liver Cell; Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cytogenetic Analysis; Focal Nodular Hyperplasia; Genetic Association Studies; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Mutation; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Tomography, X-Ray Computed | 2011 |
Sorafenib for advanced hepatocellular carcinoma: a systematic review.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2011 |
[Hepatocellular carcinoma].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2011 |
Classic biphasic pulmonary blastoma: a case report and review of the literature.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Bone Neoplasms; Fatal Outcome; Humans; Intestinal Perforation; Liver Neoplasms; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pulmonary Blastoma; Pyridines; Sorafenib | 2011 |
What is the indication for sorafenib in hepatocellular carcinoma? A clinical challenge.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2011 |
Candidacy for sorafenib in HCC patients: is there a slippery slope beyond a SHARP edge?
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2011 |
Sorafenib for HCC: a pragmatic perspective.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2011 |
Targeting receptor tyrosine kinase pathways in hepatocellular carcinoma.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Signal Transduction; Sorafenib | 2011 |
Strategies for assessing and managing the adverse events of sorafenib and other targeted therapies in the treatment of renal cell and hepatocellular carcinoma: recommendations from a European nursing task group.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Diarrhea; Drug Eruptions; Europe; Fatigue; Foot Dermatoses; Hand Dermatoses; Humans; Kidney Neoplasms; Liver Neoplasms; Molecular Targeted Therapy; Mucositis; Niacinamide; Nursing Assessment; Phenylurea Compounds; Practice Guidelines as Topic; Pyridines; Randomized Controlled Trials as Topic; Societies, Nursing; Sorafenib | 2012 |
[Sorafenib in the treatment of hepatocellular carcinoma].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2011 |
Signaling pathway and molecular-targeted therapy for hepatocellular carcinoma.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Humans; Liver Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyridines; Signal Transduction; Sorafenib | 2011 |
Molecularly targeted therapies for hepatocellular carcinoma: sorafenib as a stepping stone.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Humans; Liver Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2011 |
Hepatocellular carcinoma and liver transplantation: clinical perspective on molecular targeted strategies.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Transformation, Neoplastic; Humans; Immunosuppressive Agents; Liver Neoplasms; Liver Transplantation; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-raf; Pyridines; Randomized Controlled Trials as Topic; Signal Transduction; Sirolimus; Sorafenib; TOR Serine-Threonine Kinases | 2011 |
A single center experience of sorafenib in advanced hepatocellular carcinoma patients: evaluation of prognostic factors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials, Phase II as Topic; Epidemiologic Methods; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Sorafenib; Treatment Outcome; Young Adult | 2011 |
Are there opportunities for chemotherapy in the treatment of hepatocellular cancer?
Topics: Antibiotics, Antineoplastic; Benzenesulfonates; Carcinoma, Hepatocellular; Doxorubicin; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2012 |
Diagnostic and prognostic molecular markers in hepatocellular carcinoma.
Topics: alpha-Fetoproteins; Benzenesulfonates; beta Catenin; Biomarkers, Tumor; Carcinoma, Hepatocellular; DNA Methylation; Epigenesis, Genetic; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Liver; Liver Cirrhosis; Liver Neoplasms; MicroRNAs; Niacinamide; Phenylurea Compounds; Precision Medicine; Prognosis; Pyridines; Risk Factors; Severity of Illness Index; Sorafenib; Survival Rate; Tumor Microenvironment | 2011 |
Management of cirrhotic patients with hepatocellular carcinoma treated with sorafenib.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Management; Humans; Liver Cirrhosis; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2011 |
Management of hepatocellular carcinoma with transarterial chemoembolization in the era of systemic targeted therapy.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Drug Delivery Systems; Humans; Liver; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2012 |
Sorafenib: complexities of Raf-dependent and Raf-independent signaling are now unveiled.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Drug Synergism; Endoplasmic Reticulum Stress; Humans; Liver Neoplasms; MAP Kinase Signaling System; Myeloid Cell Leukemia Sequence 1 Protein; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-bcl-2; Pyridines; raf Kinases; Sorafenib | 2011 |
Signaling pathways in hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; ErbB Receptors; Humans; Intercellular Signaling Peptides and Proteins; Liver Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyridines; Signal Transduction; Sorafenib; Vascular Endothelial Growth Factors | 2011 |
Adjuvant therapy after curative treatment for hepatocellular carcinoma.
Topics: Antineoplastic Agents; Antiviral Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Clinical Trials as Topic; Hepatitis C; Humans; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Meta-Analysis as Topic; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Polyethylene Glycols; Pyridines; Recombinant Proteins; Ribavirin; Sorafenib | 2011 |
Radiotherapeutic strategies in the management of hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Humans; Liver; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Sorafenib; Survival Rate; Treatment Outcome | 2011 |
Sorafenib (BAY 43-9006) in hepatocellular carcinoma patients: from discovery to clinical development.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Drug Discovery; Humans; Inhibitory Concentration 50; Liver Neoplasms; Molecular Structure; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2012 |
[Hepatocellular carcinoma: what's new?].
Topics: alpha-Fetoproteins; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Diagnostic Imaging; Gene Expression Profiling; Humans; Immunosuppressive Agents; Liver Function Tests; Liver Neoplasms; Liver Transplantation; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Sirolimus; Sorafenib; Survival Rate; Treatment Outcome | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Disease Progression; Hepatectomy; Humans; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Molecular Targeted Therapy; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Randomized Controlled Trials as Topic; Sorafenib; Survival Rate; Ultrasonography | 2012 |
Advanced HCC: emerging molecular therapies.
Topics: Antibodies, Monoclonal; Benzenesulfonates; California; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Clinical Trials as Topic; Evidence-Based Medicine; Global Health; Hepatectomy; Humans; Incidence; Liver Neoplasms; Molecular Targeted Therapy; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prevalence; Protein Kinase Inhibitors; Pyridines; Randomized Controlled Trials as Topic; Sorafenib; Survival Rate; Treatment Outcome | 2012 |
Management of hepatocellular carcinoma: beyond sorafenib.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Drug Therapy, Combination; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Sorafenib; Vascular Endothelial Growth Factor A | 2012 |
Sorafenib for treatment of hepatocellular carcinoma: a systematic review.
Topics: Antineoplastic Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Proliferation; Chemoembolization, Therapeutic; Hand-Foot Syndrome; Hepatitis, Viral, Human; Humans; Liver; Liver Cirrhosis; Liver Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; raf Kinases; Randomized Controlled Trials as Topic; Receptor Protein-Tyrosine Kinases; Sorafenib; Treatment Outcome | 2012 |
Sorafenib in liver cancer.
Topics: Antineoplastic Agents; Benzenesulfonates; Clinical Trials as Topic; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2012 |
[Treatment of advanced hepatocellular carcinoma].
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Sorafenib | 2012 |
[Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil; Humans; Infusions, Intra-Arterial; Interferons; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib | 2012 |
[Current status and future perspective of sorafenib for advanced hepatocellular carcinoma].
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib | 2012 |
Current status of hepatocellular carcinoma treatment in Japan: transarterial chemoembolization.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Ethiodized Oil; Humans; Japan; Liver Neoplasms; Molecular Targeted Therapy; Neoplasm Staging; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Time Factors | 2012 |
Current status of hepatocellular carcinoma treatment in Japan: hepatic arterial infusion chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Hepatic Artery; Humans; Infusions, Intra-Arterial; Japan; Liver Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2012 |
Current status of hepatocellular carcinoma treatment in Japan: practical use of sorafenib (Nexavar®).
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Dose-Response Relationship, Drug; Humans; Japan; Liver Neoplasms; Medication Adherence; Niacinamide; Patient Education as Topic; Phenylurea Compounds; Pyridines; Sorafenib; Time Factors | 2012 |
Hypothyroidism during treatment with tyrosine kinase inhibitors.
Topics: Carcinoma, Renal Cell; Dose-Response Relationship, Drug; Gastrointestinal Neoplasms; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Neoplasm Metastasis; Neoplasms; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib; Thyroid Diseases; Thyroid Function Tests; Thyroid Gland; Thyroid Neoplasms | 2012 |
Targeted agents and systemic therapy in hepatocellular carcinoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Benzenesulfonates; Carcinoma, Hepatocellular; ErbB Receptors; Erlotinib Hydrochloride; Humans; Immunotherapy; Liver Neoplasms; Molecular Targeted Therapy; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinazolines; Sorafenib; Vascular Endothelial Growth Factor A | 2013 |
Treatment of hepatocellular carcinoma with sorafenib - focus on special populations and adverse event management.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Dose-Response Relationship, Drug; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome | 2012 |
Impact of restricting access to high-cost medications for hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Decision Making; Drug Costs; Health Services Accessibility; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; United Kingdom | 2012 |
Recurrent hepatocellular carcinoma after liver transplantation - an emerging clinical challenge.
Topics: Animals; Carcinoma, Hepatocellular; Humans; Immunosuppressive Agents; Liver Neoplasms; Liver Transplantation; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Risk Factors; Sorafenib; Time Factors; TOR Serine-Threonine Kinases; Treatment Outcome | 2013 |
[Nintedanib (BIBF 1120) in the treatment of solid cancers: an overview of biological and clinical aspects].
Topics: Animals; Antineoplastic Agents; Axitinib; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Colorectal Neoplasms; Digestive System; Enzyme Inhibitors; Female; Genital Neoplasms, Female; Humans; Imidazoles; Indazoles; Indoles; Liver Neoplasms; Lung Neoplasms; Male; Neoplasms; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phthalazines; Piperidines; Prostatic Neoplasms; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Quinazolines; Receptors, Fibroblast Growth Factor; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sulfonamides; Xenograft Model Antitumor Assays | 2012 |
Adverse events affect sorafenib efficacy in patients with recurrent hepatocellular carcinoma after liver transplantation: experience at a single center and review of the literature.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Drug Evaluation; Everolimus; Female; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Recurrence; Retrospective Studies; Sirolimus; Sorafenib; Survival Analysis; Treatment Outcome | 2013 |
Sorafenib in treatment of patients with advanced hepatocellular carcinoma: a systematic review.
Topics: Aged; alpha-Fetoproteins; Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib | 2012 |
Hemorrhagic events in hepatocellular carcinoma patients treated with antiangiogenic therapies.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Hepatocellular; Hemorrhage; Humans; Incidence; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Risk Factors; Sorafenib | 2013 |
Extrahepatic spread of hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Molecular Targeted Therapy; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Sorafenib | 2012 |
Medical therapies for hepatocellular carcinoma: a critical view of the evidence.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Evidence-Based Medicine; Hepatectomy; Humans; Liver Neoplasms; Liver Transplantation; Niacinamide; Phenylurea Compounds; Precision Medicine; Sorafenib | 2013 |
Pathways and targets in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Clinical Trials as Topic; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Randomized Controlled Trials as Topic; Signal Transduction; Sorafenib | 2012 |
Consensus recommendations and review by an International Expert Panel on Interventions in Hepatocellular Carcinoma (EPOIHCC).
Topics: Antineoplastic Agents; Asian People; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib | 2013 |
Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisions.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib | 2012 |
Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Clinical Trials as Topic; Drug Evaluation, Preclinical; Humans; Kidney Neoplasms; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Receptors, Vascular Endothelial Growth Factor; Sarcoma; Sorafenib | 2005 |
Sorafenib.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Drug Administration Schedule; Humans; Kidney Neoplasms; Liver Neoplasms; Melanoma; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; raf Kinases; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Treatment Outcome; Xenograft Model Antitumor Assays | 2006 |
Sorafenib: delivering a targeted drug to the right targets.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Clinical Trials as Topic; Disease-Free Survival; Humans; Kidney Neoplasms; Liver Neoplasms; Melanoma; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Receptors, Vascular Endothelial Growth Factor; Skin Neoplasms; Sorafenib | 2007 |
[The hepatocellular carcinoma: alternative therapeutical strategies].
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Follow-Up Studies; Genetic Therapy; Humans; Immunotherapy; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Randomized Controlled Trials as Topic; Sorafenib; Time Factors | 2007 |
Hepatocellular carcinoma: the role of the North American GI Steering Committee Hepatobiliary Task Force and the advent of effective drug therapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Erlotinib Hydrochloride; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinazolines; Sorafenib | 2007 |
Sorafenib: in hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Doxorubicin; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Treatment Outcome | 2008 |
Novel advancements in the management of hepatocellular carcinoma in 2008.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Catheter Ablation; Combined Modality Therapy; Ethanol; Humans; Liver Neoplasms; Liver Transplantation; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2008 |
271 trial(s) available for sorafenib and Cancer of Liver
| Article | Year |
|---|---|
Gadoxetic acid uptake as a molecular imaging biomarker for sorafenib resistance in patients with hepatocellular carcinoma: a post hoc analysis of the SORAMIC trial.
Topics: Biomarkers; Carcinoma, Hepatocellular; Catenins; Contrast Media; Gadolinium DTPA; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Molecular Imaging; Retrospective Studies; Sorafenib | 2022 |
Prognostic value of baseline imaging and clinical features in patients with advanced hepatocellular carcinoma.
Topics: Aged; Antineoplastic Agents; Bilirubin; Biomarkers, Tumor; Carcinoma, Hepatocellular; Female; Humans; Liver; Liver Neoplasms; Magnetic Resonance Imaging; Male; Prognosis; Sorafenib; Tumor Burden | 2022 |
A Leap from TACE to TACE Potentiated by Immune Response Modulation and Angiogenesis Inhibition for Patients with Intermediate-Stage Hepatocellular Carcinoma: LEAP-012 Phase 3 Randomized Control Trial Protocol.
Topics: Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Clinical Trials, Phase III as Topic; Humans; Immunity; Liver Neoplasms; Randomized Controlled Trials as Topic; Sorafenib; Treatment Outcome | 2022 |
Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Sorafenib | 2022 |
Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1).
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; China; Female; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Middle Aged; Mutation; Oxaliplatin; Progression-Free Survival; Sorafenib; Time Factors | 2022 |
Validation of the prophylactic efficacy of urea-based creams on sorafenib-induced hand-foot skin reaction in patients with advanced hepatocellular carcinoma: A randomised experiment study.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Hand-Foot Syndrome; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Quality of Life; Sorafenib; Urea | 2022 |
Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial.
Topics: Aged; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Nivolumab; Sorafenib | 2022 |
The transcatheter arterial chemoembolization combined with targeted nanoparticle delivering sorafenib system for the treatment of microvascular invasion of hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Catheterization; Chemoembolization, Therapeutic; Female; Humans; Liver; Liver Neoplasms; Male; Microvessels; Middle Aged; Nanoparticles; Neoplasm Invasiveness; Sorafenib | 2021 |
GALNT14 genotype-guided chemoembolization plus sorafenib therapy in hepatocellular carcinoma: a randomized trial.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Genotype; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2022 |
A clinical scoring tool validated with machine learning for predicting severe hand-foot syndrome from sorafenib in hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Female; Hand-Foot Syndrome; Humans; Liver Neoplasms; Machine Learning; Male; Risk Assessment; Sorafenib | 2022 |
Phase I Study Evaluating Dose De-escalation of Sorafenib with Metformin and Atorvastatin in Hepatocellular Carcinoma (SMASH).
Topics: Antineoplastic Agents; Atorvastatin; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Metformin; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2022 |
Comparison of the outcomes between sorafenib and lenvatinib as the first-line systemic treatment for HBV-associated hepatocellular carcinoma: a propensity score matching analysis.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Hepatitis B virus; Humans; Liver Neoplasms; Phenylurea Compounds; Propensity Score; Quinolines; Retrospective Studies; Sorafenib; Treatment Outcome | 2022 |
Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib.
Topics: Adult; Antibodies, Monoclonal, Humanized; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Sorafenib | 2022 |
Extracellular Vesicles May Predict Response to Radioembolization and Sorafenib Treatment in Advanced Hepatocellular Carcinoma: An Exploratory Analysis from the SORAMIC Trial.
Topics: Carcinoma, Hepatocellular; Extracellular Vesicles; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Proteomics; Sorafenib | 2022 |
Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial.
Topics: Anilides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Pyridines; Sorafenib | 2022 |
Overall survival and objective response in advanced unresectable hepatocellular carcinoma: A subanalysis of the REFLECT study.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Retrospective Studies; Sorafenib | 2023 |
Comparison of the effects of lenvatinib and sorafenib on survival in patients with advanced hepatocellular carcinoma: A systematic review and meta-analysis.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Phenylurea Compounds; Randomized Controlled Trials as Topic; Sorafenib | 2023 |
Nivolumab Plus Cabozantinib With or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results From Cohort 6 of the CheckMate 040 Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Humans; Ipilimumab; Liver Neoplasms; Nivolumab; Sorafenib | 2023 |
Irradiation stent with 125 I plus TACE versus sorafenib plus TACE for hepatocellular carcinoma with major portal vein tumor thrombosis: a multicenter randomized trial.
Topics: Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neoplasms; Portal Vein; Retrospective Studies; Sorafenib; Stents; Treatment Outcome; Venous Thrombosis | 2023 |
A Phase I Study to Investigate the Safety, Tolerability and Pharmacokinetics of Napabucasin Combined with Sorafenib in Japanese Patients with Unresectable Hepatocellular Carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzofurans; Carcinoma, Hepatocellular; East Asian People; Humans; Liver Neoplasms; Naphthoquinones; Sorafenib | 2023 |
Impact of body composition in advanced hepatocellular carcinoma: A subanalysis of the SORAMIC trial.
Topics: Body Composition; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Prospective Studies; Sorafenib | 2023 |
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Sorafenib | 2023 |
Augmentation of IFN-γ+ CD8+ T cell responses correlates with survival of HCC patients on sorafenib therapy.
Topics: Administration, Oral; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; CD8-Positive T-Lymphocytes; Female; Humans; Interferon-gamma; Liver Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib | 2019 |
Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma.
Topics: Ablation Techniques; Aged; Antineoplastic Agents; Brachytherapy; Carcinoma, Hepatocellular; Combined Modality Therapy; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Microspheres; Middle Aged; Neoplasm Staging; Palliative Care; Research Design; Sorafenib; Yttrium Radioisotopes | 2019 |
Efficacy and Safety of Bavituximab in Combination with Sorafenib in Advanced Hepatocellular Carcinoma: A Single-Arm, Open-Label, Phase II Clinical Trial.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Female; Follow-Up Studies; Humans; Immunomodulation; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Phosphatidylserines; Sorafenib; Survival Analysis; Treatment Outcome | 2019 |
Randomized, phase II trial of sequential hepatic arterial infusion chemotherapy and sorafenib versus sorafenib alone as initial therapy for advanced hepatocellular carcinoma: SCOOP-2 trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Female; Follow-Up Studies; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Middle Aged; Sorafenib; Survival Rate; Treatment Outcome | 2019 |
Cabozantinib exposure-response analyses of efficacy and safety in patients with advanced hepatocellular carcinoma.
Topics: Anilides; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease-Free Survival; Double-Blind Method; Female; Humans; Liver Neoplasms; Male; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2019 |
REFLECT-a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Intention to Treat Analysis; Japan; Liver Neoplasms; Male; Middle Aged; Phenylurea Compounds; Quinolines; Sorafenib; Survival Analysis; Treatment Outcome | 2020 |
Tumor burden and liver function in HCC patient selection for selective internal radiation therapy: SARAH post-hoc study.
Topics: Aged; Antineoplastic Agents; Brachytherapy; Carcinoma, Hepatocellular; Female; Follow-Up Studies; Humans; Liver Function Tests; Liver Neoplasms; Male; Microspheres; Patient Selection; Prognosis; Sorafenib; Survival Rate; Tumor Burden; Yttrium Radioisotopes | 2020 |
Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Disease Progression; Female; Humans; Liver Neoplasms; Male; Middle Aged; Progression-Free Survival; Prospective Studies; Sorafenib; Survival Rate | 2020 |
Sorafenib may enhance antitumour efficacy in hepatocellular carcinoma patients by modulating the proportions and functions of natural killer cells.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Immunologic Factors; Kaplan-Meier Estimate; Killer Cells, Natural; Liver Neoplasms; Male; Middle Aged; Proportional Hazards Models; Protein Kinase Inhibitors; Response Evaluation Criteria in Solid Tumors; Sorafenib; Young Adult | 2020 |
Efficacy and Safety of Liver-Directed Concurrent Chemoradiotherapy and Sequential Sorafenib for Advanced Hepatocellular Carcinoma: A Prospective Phase 2 Trial.
Topics: Aged; Carcinoma, Hepatocellular; Chemoradiotherapy; Female; Humans; Liver Neoplasms; Male; Middle Aged; Prospective Studies; Safety; Sorafenib; Survival Analysis; Time Factors; Treatment Outcome | 2020 |
Ramucirumab after prior sorafenib in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein: Japanese subgroup analysis of the REACH-2 trial.
Topics: Adult; Aged; Aged, 80 and over; alpha-Fetoproteins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Double-Blind Method; Female; Humans; Japan; Liver Neoplasms; Male; Middle Aged; Progression-Free Survival; Ramucirumab; Sorafenib; Survival Rate; Treatment Outcome | 2020 |
Metabolic Switch in Hepatocellular Carcinoma Patients Treated with Sorafenib: a Proof-of-Concept Trial.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Prognosis; Progression-Free Survival; Proof of Concept Study; Sorafenib | 2020 |
Prognostic Significance of VEGF and HIF-1 α in Hepatocellular Carcinoma Patients Receiving Sorafenib Versus Metformin Sorafenib Combination.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; Disease Progression; Egypt; Female; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Liver Neoplasms; Male; Metformin; Middle Aged; Prognosis; Progression-Free Survival; Prospective Studies; Response Evaluation Criteria in Solid Tumors; Sorafenib; Time Factors; Treatment Outcome; Vascular Endothelial Growth Factor A | 2021 |
Covariate-adjusted analysis of the Phase 3 REFLECT study of lenvatinib versus sorafenib in the treatment of unresectable hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Phenylurea Compounds; Prognosis; Quinolines; Risk Factors; Sorafenib | 2020 |
A Multicenter Phase II Study of Second-Line Axitinib for Patients with Advanced Hepatocellular Carcinoma Failing First-Line Sorafenib Monotherapy.
Topics: Antineoplastic Agents; Axitinib; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2020 |
Ramucirumab in elderly patients with hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib in REACH and REACH-2.
Topics: Aged; alpha-Fetoproteins; Antibodies, Monoclonal, Humanized; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Ramucirumab; Sorafenib; Treatment Outcome | 2020 |
Effect of early adverse events resulting in sorafenib dose adjustments on survival outcomes of advanced hepatocellular carcinoma patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Progression-Free Survival; Sorafenib; Young Adult | 2020 |
Cabozantinib in combination with atezolizumab versus sorafenib in treatment-naive advanced hepatocellular carcinoma: COSMIC-312 Phase III study design.
Topics: Anilides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Clinical Trials, Phase III as Topic; Drug Interactions; Humans; Liver Neoplasms; Pyridines; Sorafenib | 2020 |
Phase Ib Study of Enzalutamide with or Without Sorafenib in Patients with Advanced Hepatocellular Carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Nitriles; Phenylthiohydantoin; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2020 |
A Phase I Trial of Trametinib in Combination with Sorafenib in Patients with Advanced Hepatocellular Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Humans; Leukocytes, Mononuclear; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridones; Pyrimidinones; Sorafenib | 2020 |
Phase II trial of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma after disease progression on sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; Disease Management; Disease Progression; Doxorubicin; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Retreatment; Sorafenib; Survival Analysis; Treatment Outcome; Young Adult | 2020 |
Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial.
Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Male; Middle Aged; Pyridines; Sorafenib; Young Adult | 2020 |
Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Humans; Ipilimumab; Liver Neoplasms; Male; Nivolumab; Sorafenib | 2020 |
Effect of urea cream on sorafenib-associated hand-foot skin reaction in patients with hepatocellular carcinoma: A multicenter, randomised, double-blind controlled study.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Double-Blind Method; Female; Hand-Foot Syndrome; Humans; Liver Neoplasms; Male; Middle Aged; Quality of Life; Skin; Skin Cream; Skin Diseases; Sorafenib; Urea | 2020 |
Phase II Study of Avelumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; B7-H1 Antigen; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Progression-Free Survival; Response Evaluation Criteria in Solid Tumors; Sorafenib; Time Factors | 2021 |
Pattern of progression in advanced hepatocellular carcinoma treated with ramucirumab.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Male; Middle Aged; Ramucirumab; Sorafenib; Treatment Outcome | 2021 |
Phase 2 trial comparing sorafenib, pravastatin, their combination or supportive care in HCC with Child-Pugh B cirrhosis.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Combinations; Humans; Liver Cirrhosis; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pravastatin; Prospective Studies; Sorafenib; Treatment Outcome | 2021 |
Efficacy and safety of sorafenib plus vitamin K treatment for hepatocellular carcinoma: A phase II, randomized study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Neoplasm Recurrence, Local; Prognosis; Sorafenib; Survival Rate; Vitamin K | 2021 |
Atezolizumab and bevacizumab combination compared with sorafenib as the first-line systemic treatment for patients with unresectable hepatocellular carcinoma: A cost-effectiveness analysis in China and the United states.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Hepatocellular; China; Cost-Benefit Analysis; Humans; Liver Neoplasms; Sorafenib; United States | 2021 |
Potential of novel colchicine dosage schedule for the palliative treatment of advanced hepatocellular carcinoma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Cholestasis; Colchicine; Diarrhea; Drug Administration Schedule; Female; Humans; Liver Neoplasms; Male; Middle Aged; Palliative Care; Sorafenib; Treatment Outcome | 2021 |
Efficacy of Ramucirumab
Topics: Aged; Aged, 80 and over; alpha-Fetoproteins; Antibodies, Monoclonal, Humanized; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Cohort Studies; Disease Progression; Female; Humans; Japan; Liver Neoplasms; Male; Middle Aged; Progression-Free Survival; Ramucirumab; Sorafenib; Survival Rate; Treatment Outcome | 2021 |
Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Administration Schedule; Female; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Piperidines; Proto-Oncogene Proteins c-met; Pyridazines; Pyrimidines; Sorafenib; Survival Analysis; Treatment Outcome; Up-Regulation; Young Adult | 2021 |
Baseline Interleukin-6 and -8 predict response and survival in patients with advanced hepatocellular carcinoma treated with sorafenib monotherapy: an exploratory post hoc analysis of the SORAMIC trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Disease Progression; Europe; Female; Follow-Up Studies; Humans; Interleukin-6; Interleukin-8; Liver Neoplasms; Male; Middle Aged; Predictive Value of Tests; Prognosis; Sorafenib; Survival Analysis; Turkey; Young Adult | 2022 |
Randomised Phase 1b/2 trial of tepotinib vs sorafenib in Asian patients with advanced hepatocellular carcinoma with MET overexpression.
Topics: Administration, Oral; Adult; Aged; Asian People; Carcinoma, Hepatocellular; Drug Administration Schedule; Female; Humans; Liver Neoplasms; Male; Middle Aged; Piperidines; Proto-Oncogene Proteins c-met; Pyridazines; Pyrimidines; Sorafenib; Survival Analysis; Treatment Outcome; Up-Regulation | 2021 |
Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Patient Reported Outcome Measures; Progression-Free Survival; Protein Kinase Inhibitors; Quality of Life; Sorafenib; Time Factors | 2021 |
Cost-Utility Analysis of Transarterial Radioembolization With Yttrium-90 Resin Microspheres Compared With Sorafenib in Locally Advanced and Inoperable Hepatocellular Carcinoma.
Topics: Carcinoma, Hepatocellular; Cost-Benefit Analysis; Humans; Liver Neoplasms; Microspheres; Quality of Life; Sorafenib; Yttrium Radioisotopes | 2021 |
Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Neoplasm Staging; Patient Reported Outcome Measures; Phenylurea Compounds; Quinolines; Sorafenib; Treatment Outcome | 2021 |
Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biosimilar Pharmaceuticals; Carcinoma, Hepatocellular; China; Disease Progression; Female; Hepatitis B; Humans; Liver Neoplasms; Male; Middle Aged; Progression-Free Survival; Sorafenib; Time Factors; Young Adult | 2021 |
Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pyridines; Sorafenib | 2021 |
Characterization of response to atezolizumab + bevacizumab versus sorafenib for hepatocellular carcinoma: Results from the IMbrave150 trial.
Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Hepatocellular; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Progression-Free Survival; Response Evaluation Criteria in Solid Tumors; Sorafenib; Tomography, X-Ray Computed | 2021 |
The Impact of Sorafenib in Combination with Intermittent Hepatic Arterial Infusion Chemotherapy for Unresectable Hepatocellular Carcinoma with Major Vascular Invasion.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Prospective Studies; Sorafenib | 2022 |
Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A prospective randomized study.
Topics: Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neoplasms; Phenylurea Compounds; Portal Vein; Prospective Studies; Quinolines; Retrospective Studies; Sorafenib; Thrombosis; Treatment Outcome | 2021 |
Health-related quality of life in locally advanced hepatocellular carcinoma treated by either radioembolisation or sorafenib (SARAH trial).
Topics: Aged; Carcinoma, Hepatocellular; Embolization, Therapeutic; Female; Humans; Liver Neoplasms; Male; Middle Aged; Quality of Life; Sorafenib | 2021 |
Priming of Sorafenib Prior to Radiofrequency Ablation Does Not Increase Treatment Effect in Hepatocellular Carcinoma.
Topics: Carcinoma, Hepatocellular; Catheter Ablation; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Prospective Studies; Radiofrequency Ablation; Retrospective Studies; Sorafenib; Treatment Outcome | 2022 |
Efficacy and Safety Results from a Phase 2, Randomized, Double-Blind Study of Enzalutamide Versus Placebo in Advanced Hepatocellular Carcinoma.
Topics: Benzamides; Carcinoma, Hepatocellular; Double-Blind Method; Humans; Liver Neoplasms; Nitriles; Phenylthiohydantoin; Sorafenib | 2021 |
Upregulation of C/EBPα Inhibits Suppressive Activity of Myeloid Cells and Potentiates Antitumor Response in Mice and Patients with Cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; CCAAT-Enhancer-Binding Protein-alpha; Humans; Liver Neoplasms; Mice; Myeloid Cells; Sorafenib; Treatment Outcome; Tumor Cells, Cultured; Up-Regulation | 2021 |
Liver function after combined selective internal radiation therapy or sorafenib monotherapy in advanced hepatocellular carcinoma.
Topics: Aged; Carcinoma, Hepatocellular; Female; Humans; Liver Function Tests; Liver Neoplasms; Male; Middle Aged; Prospective Studies; Radiotherapy; Sorafenib; Spain; Treatment Outcome | 2021 |
Evaluation of sorafenib in Chinese unresectable hepatocellular carcinoma patients with prior surgery and portal vein tumor thrombosis: A subset analysis of GIDEON study data.
Topics: Adult; Aged; Aged, 80 and over; Asian People; Carcinoma, Hepatocellular; China; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Portal Vein; Sorafenib; Treatment Outcome; Venous Thrombosis | 2017 |
Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study.
Topics: Adult; Aged; Anilides; Carcinoma, Hepatocellular; Disease-Free Survival; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2017 |
Exposure-response relationship of regorafenib efficacy in patients with hepatocellular carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Treatment Outcome | 2017 |
Pro-angiogenic TIE-2-expressing monocytes/TEMs as a biomarker of the effect of sorafenib in patients with advanced hepatocellular carcinoma.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Area Under Curve; Biomarkers, Tumor; Carcinoma, Hepatocellular; Female; Flow Cytometry; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Monocytes; Niacinamide; Phenylurea Compounds; Pilot Projects; Proportional Hazards Models; Prospective Studies; Receptor, TIE-2; Response Evaluation Criteria in Solid Tumors; ROC Curve; Sorafenib | 2017 |
Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Disease-Free Survival; Double-Blind Method; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Quality of Life; Ramucirumab; Sorafenib | 2017 |
Phase II Study of First-Line Trebananib Plus Sorafenib in Patients with Advanced Hepatocellular Carcinoma.
Topics: Angiopoietin-2; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Disease-Free Survival; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Recombinant Fusion Proteins; Sorafenib; Treatment Outcome | 2017 |
Feasibility study of personalized peptide vaccination for hepatocellular carcinoma patients refractory to locoregional therapies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cancer Vaccines; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Drug Resistance, Neoplasm; Feasibility Studies; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Precision Medicine; Sorafenib; T-Lymphocytes, Cytotoxic; Treatment Outcome; Vaccination; Vaccines, Subunit | 2017 |
Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Disease-Free Survival; Double-Blind Method; Embolization, Therapeutic; Female; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Treatment Outcome | 2017 |
Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies.
Topics: alpha-Fetoproteins; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Leukocyte Count; Liver Neoplasms; Lymphocytes; Male; Middle Aged; Neoplasm Invasiveness; Neutrophils; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Prognosis; Sorafenib | 2017 |
Phase II Trial of Sorafenib in Combination with Capecitabine in Patients with Hepatocellular Carcinoma: INST 08-20.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Capecitabine; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib | 2017 |
Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy.
Topics: Adult; Aged; alpha-Fetoproteins; Angiogenesis Inhibitors; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Disease Progression; Disease-Free Survival; Female; Humans; Lenalidomide; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Thalidomide; Treatment Outcome | 2017 |
Combination of transcatheter arterial chemoembolization and interrupted dosing sorafenib improves patient survival in early-intermediate stage hepatocellular carcinoma: A post hoc analysis of the START trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Drug Administration Schedule; Female; Humans; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Regression Analysis; Sorafenib; Survival Analysis; Taiwan; Treatment Outcome | 2017 |
Sorafenib-Regorafenib Sequential Therapy in Advanced Hepatocellular Carcinoma: A Single-Institute Experience.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Serum Albumin; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome | 2017 |
Hepatic Function during Repeated TACE Procedures and Prognosis after Introducing Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: Multicenter Analysis.
Topics: Adult; Aged; Bilirubin; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Prognosis; Serum Albumin; Sorafenib | 2017 |
Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Brachytherapy; Carcinoma, Hepatocellular; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Microspheres; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Radiotherapy Dosage; Sorafenib; Survival Analysis; Treatment Outcome; Yttrium Radioisotopes | 2017 |
Combined endovascular brachytherapy, sorafenib, and transarterial chemobolization therapy for hepatocellular carcinoma patients with portal vein tumor thrombus.
Topics: Antineoplastic Agents; Brachytherapy; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Palliative Care; Phenylurea Compounds; Portal Vein; Propensity Score; Retrospective Studies; Sorafenib; Stents; Survival Rate; Treatment Outcome; Venous Thrombosis | 2017 |
Hand-Foot Syndrome and Post-Progression Treatment Are the Good Predictors of Better Survival in Advanced Hepatocellular Carcinoma Treated with Sorafenib: A Multicenter Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Hand-Foot Syndrome; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Sorafenib; Survival Rate; Treatment Outcome | 2017 |
Benefit-Risk Summary of Regorafenib for the Treatment of Patients with Advanced Hepatocellular Carcinoma That Has Progressed on Sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Disease Progression; Double-Blind Method; Female; Humans; Liver Neoplasms; Male; Middle Aged; Phenylurea Compounds; Pyridines; Response Evaluation Criteria in Solid Tumors; Safety; Sorafenib; Survival Analysis; Treatment Outcome; Young Adult | 2018 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Quinolines; Sorafenib; Survival Rate; Treatment Outcome | 2018 |
Impact of baseline characteristics on outcomes of advanced HCC patients treated with sorafenib: a secondary analysis of a phase III study.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Cohort Studies; Female; Humans; Indoles; Kaplan-Meier Estimate; Liver Neoplasms; Male; Multivariate Analysis; Niacinamide; Outcome Assessment, Health Care; Phenylurea Compounds; Proportional Hazards Models; Pyrroles; Sorafenib; Sunitinib | 2018 |
A multicenter Phase II study of sorafenib in Japanese patients with advanced hepatocellular carcinoma and Child Pugh A and B class.
Topics: Aged; Asian People; Carcinoma, Hepatocellular; Disease Progression; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Sorafenib; Survival Analysis; Time Factors; Treatment Outcome | 2018 |
SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma.
Topics: Antineoplastic Agents; Brachytherapy; Carcinoma, Hepatocellular; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Microspheres; Middle Aged; Prospective Studies; Sorafenib; Yttrium Radioisotopes | 2018 |
A phase I trial of escalating doses of cixutumumab (IMC-A12) and sorafenib in the treatment of advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Dose-Response Relationship, Drug; Feasibility Studies; Female; Humans; Liver Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Progression-Free Survival; Sorafenib | 2018 |
A multicentre, open-label, phase-I/randomised phase-II study to evaluate safety, pharmacokinetics, and efficacy of nintedanib vs. sorafenib in European patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Disease Progression; Disease-Free Survival; Europe; Female; Humans; Indoles; Liver Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Sorafenib; Treatment Outcome | 2018 |
Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Monitoring; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome | 2018 |
Antitumor effect of sorafenib and mammalian target of rapamycin inhibitor in liver transplantation recipients with hepatocellular carcinoma recurrence.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Survival; Female; Hep G2 Cells; Humans; Liver Neoplasms; Liver Transplantation; Male; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Middle Aged; Neoplasm Recurrence, Local; Postoperative Period; Progression-Free Survival; Retrospective Studies; Sorafenib; Survival Analysis; Time Factors; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2018 |
A Randomized Phase II Open-Label Multi-Institution Study of the Combination of Bevacizumab and Erlotinib Compared to Sorafenib in the First-Line Treatment of Patients with Advanced Hepatocellular Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Hepatocellular; Disease-Free Survival; Erlotinib Hydrochloride; Humans; Liver Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Treatment Outcome | 2018 |
Hepatic arterial infusion chemotherapy followed by sorafenib in patients with advanced hepatocellular carcinoma (HICS 55): an open label, non-comparative, phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Female; Fluorouracil; Humans; Infusions, Intra-Arterial; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Proportional Hazards Models; Sorafenib; Treatment Outcome | 2018 |
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.
Topics: Aged; Antibodies, Monoclonal, Humanized; Carcinoma, Hepatocellular; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Internationality; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Remission Induction; Sorafenib; Survival Rate | 2018 |
Multicenter Phase II Clinical Trial of Sorafenib Combined with Transarterial Chemoembolization for Advanced Stage Hepatocellular Carcinomas (Barcelona Clinic Liver Cancer Stage C): STAB Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Disease Progression; Disease-Free Survival; Female; Humans; Japan; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Risk Factors; Sorafenib; Time Factors; Treatment Outcome | 2018 |
Are we SHARP enough? The importance of adequate patient selection in sorafenib treatment for hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Patient Selection; Retrospective Studies; Sorafenib; Treatment Outcome | 2018 |
Survival and tolerance to sorafenib in Child-Pugh B patients with hepatocellular carcinoma: a prospective study.
Topics: Aged; alpha-Fetoproteins; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Sorafenib; Survival Analysis | 2018 |
Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; beta Catenin; Carcinoma, Hepatocellular; Circulating Tumor DNA; Diphenylamine; Disease-Free Survival; Female; Humans; Liver Neoplasms; Male; MAP Kinase Kinase Kinases; Middle Aged; Mutation; Protein Kinase Inhibitors; ras Proteins; Sorafenib; Sulfonamides; Telomerase; Tumor Suppressor Protein p53 | 2018 |
Randomized, prospective, comparative study on the effects and safety of sorafenib vs. hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Catheters, Indwelling; Cisplatin; Female; Fluorouracil; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Middle Aged; Portal Vein; Prospective Studies; Sorafenib; Survival Rate; Venous Thrombosis | 2018 |
A phase 1b study of transforming growth factor-beta receptor I inhibitor galunisertib in combination with sorafenib in Japanese patients with unresectable hepatocellular carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Prognosis; Pyrazoles; Quinolines; Receptor, Transforming Growth Factor-beta Type I; Sorafenib; Tissue Distribution | 2019 |
Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Biopsy, Needle; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Immunohistochemistry; Liver Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Predictive Value of Tests; Prognosis; Sorafenib; Survival Analysis; Tissue Embedding; Treatment Outcome | 2019 |
Drug effect analysis of sorafenib combined with transcatheter arterial chemoembolization in the treatment of advanced hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Female; Humans; Liver Neoplasms; Male; Middle Aged; Sorafenib; Treatment Outcome | 2018 |
Regorafenib treatment for patients with hepatocellular carcinoma who progressed on sorafenib-A cost-effectiveness analysis.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Computer Simulation; Cost-Benefit Analysis; Disease Progression; Drug Resistance, Neoplasm; Health Care Costs; Humans; Liver Neoplasms; Markov Chains; Middle Aged; Monte Carlo Method; Phenylurea Compounds; Pyridines; Quality-Adjusted Life Years; Sorafenib; Treatment Outcome | 2018 |
Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: The phase III STAH trial.
Topics: Aged; Alanine Transaminase; Antineoplastic Agents; Ascites; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Hyperbilirubinemia; Liver Neoplasms; Male; Middle Aged; Progression-Free Survival; Sorafenib; Thrombocytopenia | 2019 |
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Aged; alpha-Fetoproteins; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Hepatocellular; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Ramucirumab; Sorafenib; Treatment Outcome | 2019 |
RATIONALE 301 study: tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Agents, Immunological; B7-H1 Antigen; Carcinoma, Hepatocellular; Female; Humans; Induction Chemotherapy; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Protein Kinase Inhibitors; Sorafenib; Treatment Outcome | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Female; Fluorouracil; Humans; Infusions, Intra-Arterial; Leucovorin; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Portal Vein; Protein Kinase Inhibitors; Sorafenib; Treatment Outcome; Young Adult | 2019 |
Pravastatin combination with sorafenib does not improve survival in advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Diarrhea; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Pravastatin; Prognosis; Progression-Free Survival; Quality of Life; Sorafenib | 2019 |
Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Immunological; Asia; B7-H1 Antigen; Carcinoma, Hepatocellular; Disease Progression; Female; Follow-Up Studies; Hepacivirus; Hepatitis B; Hepatitis B virus; Hepatitis C; Humans; Liver Neoplasms; Male; Middle Aged; Nivolumab; Sorafenib; Treatment Outcome; Young Adult | 2019 |
A prospective clinical trial on sorafenib treatment of hepatocellular carcinoma before liver transplantation.
Topics: Adult; Aged; Antineoplastic Agents; Blood Flow Velocity; Carcinoma, Hepatocellular; Drug Tolerance; Female; Follow-Up Studies; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoadjuvant Therapy; Pilot Projects; Prospective Studies; Quality of Life; Response Evaluation Criteria in Solid Tumors; Sorafenib; Tomography, X-Ray Computed | 2019 |
Urine protein:creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Creatinine; Humans; Liver Neoplasms; Phenylurea Compounds; Proteinuria; Quinolines; Sorafenib | 2019 |
A Phase 2 Study of Galunisertib (TGF-β1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; alpha-Fetoproteins; Carcinoma, Hepatocellular; Case-Control Studies; Disease Progression; Drug Therapy, Combination; Female; Humans; Liver Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Pyrazoles; Quinolines; Receptors, Transforming Growth Factor beta; Safety; Sorafenib; Transforming Growth Factor beta1; Treatment Outcome | 2019 |
Phase I Study of Sorafenib and Vorinostat in Advanced Hepatocellular Carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemical and Drug Induced Liver Injury; Drug Eruptions; Female; Humans; Hypokalemia; Hypophosphatemia; Liver Neoplasms; Male; Middle Aged; Sorafenib; Thrombocytopenia; Vorinostat | 2019 |
Sorafenib in advanced hepatocellular carcinoma: a nationwide retrospective study of efficacy and tolerability.
Topics: Aged; alpha-Fetoproteins; Antineoplastic Agents; Biomarkers; Carcinoma, Hepatocellular; Female; Humans; Hypertension; Liver; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Retrospective Studies; Sorafenib; Treatment Outcome | 2013 |
Sorafenib in combination with transarterial chemoembolization in Chinese patients with hepatocellular carcinoma: a subgroup interim analysis of the START trial.
Topics: Adult; Aged; Antineoplastic Agents; Asian People; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Disease-Free Survival; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2013 |
Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates.
Topics: Aged; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Biomarkers, Tumor; Carcinoma, Hepatocellular; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Liver Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplastic Cells, Circulating; Niacinamide; Phenylurea Compounds; Protein Precursors; Prothrombin; Sirolimus; Sorafenib; Treatment Outcome | 2013 |
Sorafenib in combination with oxaliplatin, leucovorin, and fluorouracil (modified FOLFOX6) as first-line treatment of metastatic colorectal cancer: the RESPECT trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Survival; Double-Blind Method; Female; Fluorouracil; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neutropenia; Niacinamide; Organoplatinum Compounds; Oxaliplatin; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2013 |
A phase II randomized dose escalation trial of sorafenib in patients with advanced hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Disease-Free Survival; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Humans; Liver Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Sorafenib | 2013 |
Sorafenib in patients with progressive epithelioid hemangioendothelioma: a phase 2 study by the French Sarcoma Group (GSF/GETO).
Topics: Adult; Aged; Antineoplastic Agents; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; France; Head and Neck Neoplasms; Hemangioendothelioma, Epithelioid; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Rare Diseases; Sorafenib; Time Factors; Treatment Outcome | 2013 |
Lenalidomide for second-line treatment of advanced hepatocellular cancer: a Brown University oncology group phase II study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease-Free Survival; Female; Humans; Lenalidomide; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Neutropenia; Niacinamide; Phenylurea Compounds; Sorafenib; Thalidomide; Treatment Failure; Treatment Outcome; Young Adult | 2015 |
Radiological-pathological analysis of WHO, RECIST, EASL, mRECIST and DWI: Imaging analysis from a prospective randomized trial of Y90 ± sorafenib.
Topics: Aged; Carcinoma, Hepatocellular; Diffusion Magnetic Resonance Imaging; Female; Humans; Liver Neoplasms; Male; Microspheres; Middle Aged; Niacinamide; Phenylurea Compounds; Prospective Studies; Sorafenib; Technetium Tc 99m Aggregated Albumin; World Health Organization; Yttrium Radioisotopes | 2013 |
Phase I adjuvant trial of sorafenib in patients with hepatocellular carcinoma after orthotopic liver transplantation.
Topics: Adolescent; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2013 |
Sorafenib versus capecitabine in the management of advanced hepatocellular carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Capecitabine; Carcinoma, Hepatocellular; Deoxycytidine; Disease-Free Survival; Fluorouracil; Humans; Liver Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib | 2013 |
Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Everolimus; Female; Humans; Liver Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Niacinamide; Phenylurea Compounds; Sirolimus; Sorafenib | 2013 |
Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study.
Topics: Adult; Aged; Aged, 80 and over; Alanine; Carcinoma, Hepatocellular; Double-Blind Method; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Sorafenib; Survival Rate; Triazines; Young Adult | 2013 |
Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study.
Topics: Adult; Aged; Aged, 80 and over; Alanine; Carcinoma, Hepatocellular; Double-Blind Method; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Salvage Therapy; Sorafenib; Survival Rate; Triazines; Young Adult | 2013 |
Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease-Free Survival; Female; Humans; Indoles; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Pyrroles; Sorafenib; Sunitinib; Young Adult | 2013 |
Changes in plasma vascular endothelial growth factor at 8 weeks after sorafenib administration as predictors of survival for advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; alpha-Fetoproteins; Biomarkers, Tumor; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Prognosis; Protein Kinase Inhibitors; Sorafenib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2014 |
Metronomic capecitabine in advanced hepatocellular carcinoma patients: a phase II study.
Topics: Administration, Metronomic; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Hepatocellular; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2013 |
GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prospective Studies; Sorafenib; Young Adult | 2014 |
Practical effect of sorafenib monotherapy on advanced hepatocellular carcinoma and portal vein tumor thrombosis.
Topics: Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Agents; Carcinoma, Hepatocellular; Diarrhea; Disease-Free Survival; Fatigue; Female; Hand-Foot Syndrome; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Nausea; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Portal Vein; Proportional Hazards Models; Sorafenib; Tomography, Spiral Computed; Venous Thrombosis | 2013 |
Efficacy and safety of sorafenib-gemcitabine combination therapy in advanced hepatocellular carcinoma: an open-label Phase II feasibility study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Demography; Deoxycytidine; Feasibility Studies; Female; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2014 |
The feasibility of combined transcatheter arterial chemoembolization and radiotherapy for advanced hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Cohort Studies; Doxorubicin; Ethiodized Oil; Feasibility Studies; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Republic of Korea; Sorafenib | 2014 |
Phase I study of combination chemotherapy using sorafenib and transcatheter arterial infusion with cisplatin for advanced hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Disease-Free Survival; Humans; Infusions, Intra-Arterial; Kaplan-Meier Estimate; Liver Neoplasms; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2014 |
A phase I/II study of S-1 with sorafenib in patients with advanced hepatocellular carcinoma.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Drug Combinations; Female; Humans; Liver Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Niacinamide; Oxonic Acid; Phenylurea Compounds; Prospective Studies; Sorafenib; Tegafur | 2014 |
Multicenter phase II study of sequential radioembolization-sorafenib therapy for inoperable hepatocellular carcinoma.
Topics: Aged; Carcinoma, Hepatocellular; Disease Progression; Dose-Response Relationship, Drug; Embolization, Therapeutic; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Quality of Life; Sorafenib; Time Factors; Yttrium Radioisotopes | 2014 |
Phase 2 study of combined sorafenib and radiation therapy in patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Chemoradiotherapy; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Female; Fibrosis; Hand-Foot Syndrome; Humans; Liver; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Portal Vein; Radiation Dosage; Sorafenib; Time Factors; Treatment Outcome; Venous Thrombosis | 2014 |
Prospective randomized pilot study of Y90+/-sorafenib as bridge to transplantation in hepatocellular carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Embolization, Therapeutic; Female; Graft Rejection; Hepatitis C; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pilot Projects; Prospective Studies; Radiation Dosage; Sorafenib; Yttrium Radioisotopes | 2014 |
Sorafenib in liver function impaired advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Cross-Over Studies; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Liver Function Tests; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome; Young Adult | 2014 |
Hepatocellular carcinoma with portal vein tumor thrombus: treatment with transarterial chemoembolization combined with sorafenib--a retrospective controlled study.
Topics: Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Contrast Media; Female; Humans; Liver Function Tests; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Portal Vein; Retrospective Studies; Sorafenib; Survival Rate; Tomography, Spiral Computed; Treatment Outcome; Venous Thrombosis | 2014 |
A phase I/II trial of capecitabine combined with peginterferon α-2a in Patients with sorafenib-refractory advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Hepatocellular; Deoxycytidine; Female; Fluorouracil; Humans; Interferon-alpha; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Polyethylene Glycols; Recombinant Proteins; Sorafenib | 2014 |
Safety and efficacy of sorafenib in the treatment of advanced hepatocellular carcinoma: a single center experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Retrospective Studies; Safety; Sorafenib; Survival Rate | 2014 |
Neutrophil-lymphocyte ratio as a predictor of outcomes for patients with hepatocellular carcinoma undergoing TAE combined with Sorafenib.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Embolization, Therapeutic; Female; Humans; Liver Neoplasms; Lymphocyte Count; Male; Middle Aged; Neutrophils; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Prognosis; Sorafenib; Treatment Outcome | 2014 |
Efficacy and safety of sorafenib in combination with gemcitabine in patients with advanced hepatocellular carcinoma: a multicenter, open-label, single-arm phase II study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib | 2014 |
Analysis of survival factors in patients with intermediate-advanced hepatocellular carcinoma treated with transcatheter arterial chemoembolization combined with sorafenib.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Sorafenib | 2014 |
Safety and toxicity of radioembolization plus Sorafenib in advanced hepatocellular carcinoma: analysis of the European multicentre trial SORAMIC.
Topics: Carcinoma, Hepatocellular; Combined Modality Therapy; Embolization, Therapeutic; Europe; Follow-Up Studies; Liver Neoplasms; Microspheres; Niacinamide; Phenylurea Compounds; Portal Vein; Sorafenib; Treatment Outcome; Yttrium | 2015 |
Randomized Phase II Study of the X-linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 in Combination With Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC).
Topics: Administration, Oral; Adult; Aged; Carcinoma, Hepatocellular; Cohort Studies; Confidence Intervals; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Niacinamide; Oligonucleotides; Phenylurea Compounds; Proportional Hazards Models; Retrospective Studies; Risk Assessment; Sorafenib; Survival Analysis; Treatment Outcome | 2016 |
Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Double-Blind Method; Everolimus; Female; Humans; Liver; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sirolimus; Sorafenib; Survival Analysis; Young Adult | 2014 |
The combination of transcatheter arterial chemoembolization and sorafenib is well tolerated and effective in Asian patients with hepatocellular carcinoma: final results of the START trial.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prospective Studies; Sorafenib | 2015 |
TACE plus sorafenib for the treatment of hepatocellular carcinoma: results of the multicenter, phase II SOCRATES trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Doxorubicin; Ethiodized Oil; Fatigue; Hepatic Encephalopathy; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2014 |
Poor results for everolimus in patients with liver cancer.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Everolimus; Female; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Prognosis; Risk Assessment; Sirolimus; Sorafenib; Survival Analysis; Treatment Failure | 2014 |
Volumetric assessment of tumour response using functional MR imaging in patients with hepatocellular carcinoma treated with a combination of doxorubicin-eluting beads and sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Delayed-Action Preparations; Dose-Response Relationship, Drug; Doxorubicin; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Male; Maryland; Middle Aged; Niacinamide; Phenylurea Compounds; Prospective Studies; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Survival Rate; Time Factors; Tumor Burden | 2015 |
A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Biomarkers; Carcinoma, Hepatocellular; Diphenylamine; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Sorafenib; Sulfonamides; Treatment Outcome | 2014 |
Clinical efficacy and prognostic factors of tumor progression in Japanese patients with advanced renal cell carcinoma treated with sorafenib.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Treatment Outcome | 2015 |
Radioembolisation with yttrium‒90 microspheres versus sorafenib for treatment of advanced hepatocellular carcinoma (SARAH): study protocol for a randomised controlled trial.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Clinical Protocols; Cost-Benefit Analysis; Disease Progression; Disease-Free Survival; Drug Costs; Embolization, Therapeutic; France; Humans; Liver Neoplasms; Microspheres; Niacinamide; Phenylurea Compounds; Prospective Studies; Protein Kinase Inhibitors; Quality of Life; Research Design; Sorafenib; Time Factors; Treatment Outcome; Yttrium Radioisotopes | 2014 |
Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Administration Schedule; Female; Hand-Foot Syndrome; Humans; Hypertension; Indazoles; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Odds Ratio; Phenylurea Compounds; Protein Kinase Inhibitors; Receptor Protein-Tyrosine Kinases; Risk Factors; Sorafenib; Treatment Outcome | 2015 |
SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Double-Blind Method; Erlotinib Hydrochloride; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Placebos; Quinazolines; Sorafenib | 2015 |
[Therapeutic decisions in the treatment of hepatocellular carcinoma and patterns of sorafenib use. Results of the international observational GIDEON trial in Spain].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Diarrhea; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Fatigue; Female; Hand-Foot Syndrome; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prospective Studies; Protein Kinase Inhibitors; Salvage Therapy; Severity of Illness Index; Sorafenib; Spain; Treatment Outcome | 2015 |
Randomized controlled trial of the prophylactic effect of urea-based cream on sorafenib-associated hand-foot skin reactions in patients with advanced hepatocellular carcinoma.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; Emulsions; Female; Hand-Foot Syndrome; Humans; Incidence; Liver Neoplasms; Logistic Models; Male; Middle Aged; Multivariate Analysis; Niacinamide; Odds Ratio; Phenylurea Compounds; Quality of Life; Skin; Sorafenib; Surveys and Questionnaires; Treatment Outcome; Urea; Young Adult | 2015 |
Sorafenib combined with percutaneous radiofrequency ablation for the treatment of medium-sized hepatocellular carcinoma.
Topics: Adult; Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Combined Modality Therapy; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2015 |
Adjuvant sorafenib therapy in patients with resected hepatocellular carcinoma: evaluation of predictive factors.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Female; Follow-Up Studies; gamma-Glutamyltransferase; Humans; Liver Neoplasms; Lymphocytes; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neutrophils; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib; Survival Rate | 2015 |
Integrated Stable Isotope Labeling by Amino Acids in Cell Culture (SILAC) and Isobaric Tags for Relative and Absolute Quantitation (iTRAQ) Quantitative Proteomic Analysis Identifies Galectin-1 as a Potential Biomarker for Predicting Sorafenib Resistance i
Topics: Amino Acids; Animals; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Galectin 1; Gene Knockdown Techniques; Humans; Isotope Labeling; Liver Neoplasms; Mice, Inbred BALB C; Niacinamide; Phenylurea Compounds; Protein Interaction Maps; Proteomics; Sorafenib; Treatment Outcome | 2015 |
SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Lymph Nodes; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Pyrroles; Sorafenib; Sunitinib | 2015 |
Impact of neo-adjuvant Sorafenib treatment on liver transplantation in HCC patients - a prospective, randomized, double-blind, phase III trial.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Germany; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoadjuvant Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Treatment Outcome | 2015 |
SLC15A2 genomic variation is associated with the extraordinary response of sorafenib treatment: whole-genome analysis in patients with hepatocellular carcinoma.
Topics: Aged; Antineoplastic Agents; Base Sequence; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Line, Tumor; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Genome, Human; Genotype; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Polymorphism, Single Nucleotide; Sequence Analysis, DNA; Sorafenib; Symporters; Treatment Outcome | 2015 |
Open-Label Single-Arm Phase II Trial of Sorafenib Therapy with Drug-eluting Bead Transarterial Chemoembolization in Patients with Unresectable Hepatocellular Carcinoma: Clinical Results.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Contrast Media; Drug Therapy, Combination; Female; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Survival Rate; Tomography, X-Ray Computed | 2015 |
Safety and efficacy of tigatuzumab plus sorafenib as first-line therapy in subjects with advanced hepatocellular carcinoma: A phase 2 randomized study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Sorafenib; Time Factors; Treatment Outcome | 2015 |
Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma, Hepatocellular; Confidence Intervals; Disease-Free Survival; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Patient Selection; Phenylurea Compounds; Proportional Hazards Models; Ramucirumab; Remission Induction; Sorafenib; Survival Analysis; Time Factors; Treatment Outcome | 2015 |
Impact of sorafenib dosing on outcome from the European patient subset of the GIDEON study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Treatment Outcome; Young Adult | 2015 |
Prospective analysis of tiopronin in prevention of sorafenib and antiviral therapy inducing liver toxicity in advanced hepatitis B virus-related hepatocellular carcinoma.
Topics: Antineoplastic Agents; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Hepatitis B, Chronic; Humans; Liver; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Tiopronin | 2015 |
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; Catheter Ablation; Chemotherapy, Adjuvant; Disease Progression; Disease-Free Survival; Double-Blind Method; Europe; Female; Hepatectomy; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; New Zealand; Niacinamide; North America; Phenylurea Compounds; Protein Kinase Inhibitors; Risk Factors; Sorafenib; South America; Time Factors; Treatment Outcome; Young Adult | 2015 |
Early Clinical Response after 2 Weeks of Sorafenib Therapy Predicts Outcomes and Anti-Tumor Response in Patients with Advanced Hepatocellular Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Disease-Free Survival; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prospective Studies; Sorafenib; Survival Rate; Time Factors | 2015 |
Sorafenib With and Without Transarterial Chemoembolization for Advanced Hepatocellular Carcinoma With Main Portal Vein Tumor Thrombosis: A Retrospective Analysis.
Topics: Adult; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Portal Vein; Retrospective Studies; Sorafenib; Survival Analysis; Thrombosis; Treatment Outcome | 2015 |
Phase II study of temozolomide and veliparib combination therapy for sorafenib-refractory advanced hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carcinoma, Hepatocellular; Dacarbazine; Disease-Free Survival; DNA Methylation; DNA Repair; DNA, Neoplasm; Drug Resistance, Neoplasm; Fatigue; Female; Genes, BRCA1; Genes, BRCA2; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Poly(ADP-ribose) Polymerase Inhibitors; Salvage Therapy; Sorafenib; Temozolomide; Treatment Failure | 2015 |
Liver function assessment according to the Albumin-Bilirubin (ALBI) grade in sorafenib-treated patients with advanced hepatocellular carcinoma.
Topics: Antineoplastic Agents; Bilirubin; Carcinoma, Hepatocellular; Disease Progression; Exanthema; Fatigue; Female; Humans; Liver Function Tests; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Prospective Studies; Serum Albumin; Serum Albumin, Human; Sorafenib; Treatment Outcome | 2015 |
Safety and efficacy of sorafenib therapy in patients with hepatocellular carcinoma: final outcome from the Chinese patient subset of the GIDEON study.
Topics: Antineoplastic Agents; Asian People; Carcinoma, Hepatocellular; Drug Administration Schedule; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2016 |
Post-progression survival in patients with advanced hepatocellular carcinoma resistant to sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Sorafenib; Survival Analysis; Time Factors | 2016 |
A randomized, double-blind, placebo-controlled phase II study to assess the efficacy and safety of mapatumumab with sorafenib in patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Disease-Free Survival; Double-Blind Method; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Treatment Outcome | 2016 |
Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Double-Blind Method; Doxorubicin; Drug Carriers; Female; Follow-Up Studies; Humans; Injections, Intra-Arterial; Liver Neoplasms; Male; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Sorafenib; Time Factors; Treatment Outcome | 2016 |
The Prognostic Value of Alpha-Fetoprotein Response for Advanced-Stage Hepatocellular Carcinoma Treated with Sorafenib Combined with Transarterial Chemoembolization.
Topics: Adult; Aged; alpha-Fetoproteins; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Disease-Free Survival; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Survival Rate | 2016 |
Antibody-Mediated Blockade of Phosphatidylserine Enhances the Antitumor Effect of Sorafenib in Hepatocellular Carcinomas Xenografts.
Topics: Adult; Aged; Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; Endothelium; Female; Human Umbilical Vein Endothelial Cells; Humans; Liver Neoplasms; Male; Maximum Tolerated Dose; Mice; Middle Aged; Neoplasm Transplantation; Niacinamide; Phenotype; Phenylurea Compounds; Phosphatidylserines; Rituximab; Sorafenib; Xenograft Model Antitumor Assays | 2016 |
Phase 1 Trial of Sorafenib and Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Dose Fractionation, Radiation; Female; Humans; Intestines; Liver; Liver Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Niacinamide; Phenylurea Compounds; Radiosurgery; Radiotherapy Dosage; Sorafenib | 2016 |
Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma (HCC): a randomized multicenter, multinational phase II trial (SAKK 77/08 and SASL 29).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Everolimus; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Sorafenib | 2016 |
Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma - The SHELTER study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Humans; Hydroxamic Acids; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib; Sulfonamides | 2016 |
Changes in Liver Volume Observed Following Sorafenib and Liver Radiation Therapy.
Topics: Adult; Aged; Antineoplastic Agents; Breath Holding; Female; Humans; Liver; Liver Neoplasms; Male; Middle Aged; Niacinamide; Organ Size; Phenylurea Compounds; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Image-Guided; Sorafenib; Time Factors; Tomography, Spiral Computed; Tumor Burden; Young Adult | 2016 |
Concurrent sorafenib therapy extends the interval to subsequent TACE for patients with unresectable hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prospective Studies; Sorafenib; Survival Analysis; Time Factors; Treatment Outcome | 2016 |
Randomized, open-label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Asia, Eastern; Benzimidazoles; Biomarkers; Carcinoma, Hepatocellular; Cell Line, Tumor; Female; Humans; Liver Neoplasms; Male; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Nude; Middle Aged; Niacinamide; Phenylurea Compounds; Quinolones; Sorafenib; Treatment Outcome; Xenograft Model Antitumor Assays | 2016 |
Biomarker Analyses of Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib with or without Erlotinib in the SEARCH Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Intercellular Signaling Peptides and Proteins; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Sorafenib | 2016 |
Phase I Study of Lenalidomide and Sorafenib in Patients With Advanced Hepatocellular Carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Female; Humans; Lenalidomide; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Thalidomide | 2016 |
Angiogenic Response following Radioembolization: Results from a Randomized Pilot Study of Yttrium-90 with or without Sorafenib.
Topics: Aged; Angiogenesis Inhibitors; Biomarkers, Tumor; Carcinoma, Hepatocellular; Chicago; Down-Regulation; Embolization, Therapeutic; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pilot Projects; Platelet-Derived Growth Factor; Prospective Studies; Radiopharmaceuticals; Sorafenib; Time Factors; Treatment Outcome; Yttrium Radioisotopes | 2016 |
Adjuvant sorafenib after heptectomy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma patients.
Topics: Adolescent; Adult; Aged; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease-Free Survival; Female; Hepatectomy; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prospective Studies; Retrospective Studies; Risk Factors; Sorafenib; Spain; Survival Rate; Treatment Outcome; Young Adult | 2016 |
Pilot Study of Intrahepatic Artery Chemotherapy in Combination with Sorafenib in Hepatocellular Carcinoma.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Hepatocellular; Cisplatin; Female; Hepatic Artery; Hepatitis C; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pilot Projects; Sorafenib | 2016 |
Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: Japanese subgroup analysis of the REACH trial.
Topics: Adult; Aged; Aged, 80 and over; alpha-Fetoproteins; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Double-Blind Method; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Ramucirumab; Sorafenib; Treatment Outcome | 2017 |
Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma: randomized phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2016 |
A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carcinoma, Hepatocellular; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib | 2016 |
Real-life experience with sorafenib for the treatment of hepatocellular carcinoma in HIV-infected patients.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Spain; Survival Analysis; Treatment Outcome | 2017 |
Sorafenib Combined with Radio-frequency Ablation Compared with Sorafenib Alone in Treatment of Hepatocellular Carcinoma Invading Portal Vein: A Western Randomized Controlled Trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Combined Modality Therapy; Female; Humans; Liver Neoplasms; Male; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Portal Vein; Sorafenib | 2016 |
Single administration of Selective Internal Radiation Therapy versus continuous treatment with sorafeNIB in locally advanced hepatocellular carcinoma (SIRveNIB): study protocol for a phase iii randomized controlled trial.
Topics: Antineoplastic Agents; Brachytherapy; Carcinoma, Hepatocellular; Clinical Protocols; Combined Modality Therapy; Female; Humans; Liver Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Research Design; Sorafenib | 2016 |
HATT: a phase IV, single-arm, open-label study of sorafenib in Taiwanese patients with advanced hepatocellular carcinoma.
Topics: Administration, Topical; Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease-Free Survival; Female; Hand-Foot Syndrome; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Ointments; Phenylurea Compounds; Sorafenib; Taiwan | 2017 |
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Double-Blind Method; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome | 2017 |
Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: North Central Cancer Treatment Group Trial N0745 (Alliance).
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Bevacizumab; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Sorafenib; Young Adult | 2017 |
mRECIST to predict survival in advanced hepatocellular carcinoma: Analysis of two randomised phase II trials comparing nintedanib vs sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chi-Square Distribution; Female; Humans; Indoles; Kaplan-Meier Estimate; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Proportional Hazards Models; Prospective Studies; Protein Kinase Inhibitors; Response Evaluation Criteria in Solid Tumors; Risk Factors; Sorafenib; Time Factors; Tomography, X-Ray Computed | 2017 |
Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC).
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Female; Glypicans; Humans; Iodine Radioisotopes; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Positron-Emission Tomography; Sorafenib | 2017 |
Phase I trial of radiation therapy and sorafenib in unresectable liver metastases.
Topics: Adult; Aged; Antineoplastic Agents; Chemoradiotherapy; Female; Humans; Liver; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prospective Studies; Radiosurgery; Sorafenib | 2017 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Double-Blind Method; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Pyridines; raf Kinases; Sorafenib; Survival Analysis | 2008 |
Economic evaluation of sorafenib in the treatment of hepatocellular carcinoma in Canada.
Topics: Antineoplastic Agents; Benzenesulfonates; Canada; Carcinoma, Hepatocellular; Disease-Free Survival; Europe; Humans; Liver Neoplasms; Markov Chains; Models, Theoretical; Niacinamide; Phenylurea Compounds; Pyridines; Sensitivity and Specificity; Sorafenib; Survival Rate | 2008 |
Prospective, randomized, double-blind, multi-center, Phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation - HeiLivCa [ISRCTN
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Double-Blind Method; Female; Humans; Liver Neoplasms; Liver Transplantation; Male; Niacinamide; Phenylurea Compounds; Pyridines; Research Design; Sorafenib | 2008 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Double-Blind Method; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2009 |
Combination of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma: results from a phase I extension trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Doxorubicin; Drug Administration Schedule; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome | 2009 |
Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response.
Topics: Adult; Aged; Antineoplastic Agents; Asian People; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Hepatitis B; Humans; Liver Cirrhosis; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2009 |
[Palliative management of hepatocarcinoma with sorafenib (Nexavar). Results of the SHARP study (sorafenib hepatocarcinoma assessment randomized protocol trial)].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Palliative Care; Phenylurea Compounds; Pyridines; Sorafenib | 2009 |
[Clinical observation of sorafenib monotherapy in Chinese patients with advanced hepatocellular carcinoma].
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Diarrhea; Female; Foot Dermatoses; Hand Dermatoses; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Remission Induction; Sorafenib; Survival Rate; Syndrome; Young Adult | 2009 |
Incidence of brain metastases in renal cell carcinoma treated with sorafenib.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Benzenesulfonates; Brain Neoplasms; Carcinoma, Renal Cell; Female; Follow-Up Studies; Humans; Incidence; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pyridines; Retrospective Studies; Sorafenib; Survival Rate | 2010 |
New pharmacological developments in the treatment of hepatocellular cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Breast Neoplasms; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Drug Delivery Systems; Drug Design; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Liver Neoplasms; Meta-Analysis as Topic; Niacinamide; Patient Selection; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Risk Assessment; Severity of Illness Index; Signal Transduction; Sorafenib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2009 |
Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So.LAR. study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Diarrhea; Disease Progression; Female; Humans; Hypertension; Liver Neoplasms; Male; Middle Aged; Niacinamide; Octreotide; Phenylurea Compounds; Pyridines; Sorafenib; Survival; Treatment Outcome | 2010 |
Maintenance of Sorafenib following combined therapy of three-dimensional conformal radiation therapy/intensity-modulated radiation therapy and transcatheter arterial chemoembolization in patients with locally advanced hepatocellular carcinoma: a phase I/I
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Radiotherapy; Radiotherapy, Conformal; Radiotherapy, Intensity-Modulated; Research Design; Sorafenib | 2010 |
Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Diarrhea; Disease-Free Survival; Drug Eruptions; Fatigue; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Tegafur; Uracil | 2010 |
A single-institute experience with sorafenib in untreated and previously treated patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Progression; Female; Humans; Liver Neoplasms; Male; Medical Oncology; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Retrospective Studies; Sorafenib; Treatment Outcome | 2010 |
Design and rationale for the non-interventional Global Investigation of Therapeutic DEcisions in Hepatocellular Carcinoma and Of its Treatment with Sorafenib (GIDEON) study.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Clinical Trials, Phase IV as Topic; Humans; Liver Neoplasms; Niacinamide; Patient Selection; Phenylurea Compounds; Prospective Studies; Pyridines; Research Design; Sorafenib; Treatment Outcome | 2010 |
A phase I trial of sorafenib plus gemcitabine and capecitabine for patients with advanced renal cell carcinoma: New York Cancer Consortium Trial NCI 6981.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bone Neoplasms; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Survival Rate; Treatment Outcome | 2011 |
[Clinical analysis of the treatment:transcatheter arterial chemoembolization combined with sorafenib in advanced hepatocellular carcinoma].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Survival Rate; Young Adult | 2010 |
Continuous administration of sorafenib in combination with transarterial chemoembolization in patients with hepatocellular carcinoma: results of a phase I study.
Topics: Antineoplastic Agents; Antineoplastic Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Catheters, Indwelling; Chemoembolization, Therapeutic; Combined Modality Therapy; Doxorubicin; Humans; Liver Neoplasms; Mitomycin; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2010 |
Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Progression; Double-Blind Method; Doxorubicin; Female; Humans; Infusions, Intravenous; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome | 2010 |
[Clinical observation of transarterial chemoembolization combined with sorafenib for advanced hepatocellular carcinoma].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Diarrhea; Disease Progression; Doxorubicin; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Organoplatinum Compounds; Oxaliplatin; Phenylurea Compounds; Pyridines; Remission Induction; Sorafenib; Survival Rate; Thrombocytopenia; Young Adult | 2010 |
Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Biomarkers; Carcinoma, Hepatocellular; Contrast Media; Feasibility Studies; Female; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Pyridines; Sorafenib; Tegafur; Uracil; Young Adult | 2011 |
Reversible decrease of portal venous flow in cirrhotic patients: a positive side effect of sorafenib.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Progression; Female; Humans; Hypertension, Portal; Liver Cirrhosis; Liver Neoplasms; Magnetic Resonance Angiography; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Portal Vein; Protein Kinase Inhibitors; Pyridines; Regional Blood Flow; Sorafenib; Survival Analysis | 2011 |
PR-104 plus sorafenib in patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asian People; Benzenesulfonates; Carcinoma, Hepatocellular; Cohort Studies; Female; Half-Life; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Nitrogen Mustard Compounds; Phenylurea Compounds; Prodrugs; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2011 |
Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease Progression; Double-Blind Method; Female; Humans; Intention to Treat Analysis; Japan; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Republic of Korea; Sorafenib; Survival Analysis; Treatment Outcome | 2011 |
Phase 1 trial of S-1 in combination with sorafenib for patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Drug Combinations; Female; Fluorouracil; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Niacinamide; Oxonic Acid; Phenylurea Compounds; Pyridines; Sorafenib; Tegafur; Treatment Outcome | 2012 |
The significance of early alpha-fetoprotein level changes in predicting clinical and survival benefits in advanced hepatocellular carcinoma patients receiving sorafenib.
Topics: Adult; Aged; alpha-Fetoproteins; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Survival Analysis | 2011 |
Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Doxorubicin; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prospective Studies; Pyridines; Sorafenib | 2011 |
Sorafenib and cisplatin/doxorubicin (PLADO) in pediatric hepatocellular carcinoma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Child; Cisplatin; Disease-Free Survival; Doxorubicin; Female; Follow-Up Studies; Humans; Liver Neoplasms; Liver Transplantation; Male; Niacinamide; Phenylurea Compounds; Prospective Studies; Protein Kinase Inhibitors; Pyridines; Retrospective Studies; Sorafenib; Survival Rate; Transplantation, Homologous | 2012 |
Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cohort Studies; Diarrhea; Disease Progression; Drug Therapy, Combination; Everolimus; Female; Humans; Immunosuppressive Agents; Incidence; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pyridines; Retrospective Studies; Sirolimus; Sorafenib; Survival Rate; TOR Serine-Threonine Kinases; Treatment Outcome | 2012 |
A single center experience of sorafenib in advanced hepatocellular carcinoma patients: evaluation of prognostic factors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials, Phase II as Topic; Epidemiologic Methods; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Sorafenib; Treatment Outcome; Young Adult | 2011 |
[Safety and efficacy of Sorafenib in treatment of tumor recurrence in liver transplantation recipients].
Topics: Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Liver Transplantation; Male; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Postoperative Period; Sorafenib; Survival Rate; Treatment Outcome | 2011 |
Sorafenib in hepatocellular carcinoma - a post marketing evaluation.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Disease-Free Survival; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Product Surveillance, Postmarketing; Protein Kinase Inhibitors; Pyridines; Registries; Sorafenib; Survival Rate | 2012 |
High circulating endothelial progenitor levels associated with poor survival of advanced hepatocellular carcinoma patients receiving sorafenib combined with metronomic chemotherapy.
Topics: Administration, Metronomic; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Endothelial Cells; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Stem Cells | 2011 |
Phase II trial of sorafenib in combination with 5-fluorouracil infusion in advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2012 |
Conventional transarterial chemoembolisation in combination with sorafenib for patients with hepatocellular carcinoma: a pilot study.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Doxorubicin; Female; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pilot Projects; Pyridines; Radiography; Sorafenib; Treatment Outcome | 2012 |
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: subset analyses of the phase III Sorafenib Asia-Pacific trial.
Topics: Adult; Benzenesulfonates; Carcinoma, Hepatocellular; China; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Placebos; Prognosis; Pyridines; Republic of Korea; Sorafenib; Taiwan; Time Factors; Treatment Outcome | 2012 |
Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalyses.
Topics: Adult; Aged; Aged, 80 and over; Alanine Transaminase; alpha-Fetoproteins; Antineoplastic Agents; Aspartate Aminotransferases; Benzenesulfonates; Bilirubin; Biomarkers; Carcinoma, Hepatocellular; Female; Humans; Liver; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Sorafenib; Survival Rate; Treatment Outcome | 2012 |
Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prospective Studies; Pyridines; Sorafenib | 2012 |
Transarterial chemoembolization plus sorafenib: a sequential therapeutic scheme for HCV-related intermediate-stage hepatocellular carcinoma: a randomized clinical trial.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Disease Progression; Double-Blind Method; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Kaplan-Meier Estimate; Liver Cirrhosis; Liver Neoplasms; Male; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prospective Studies; Pyridines; Sorafenib | 2012 |
Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma.
Topics: Alkaline Phosphatase; alpha-Fetoproteins; Angiopoietin-2; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cohort Studies; Disease-Free Survival; Female; Hepatocyte Growth Factor; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-kit; Pyridines; Sorafenib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2012 |
Phase II study of bevacizumab and erlotinib in the treatment of advanced hepatocellular carcinoma patients with sorafenib-refractory disease.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Quinazolines; Sorafenib | 2012 |
Cryotherapy is associated with improved clinical outcomes of Sorafenib therapy for advanced hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Combined Modality Therapy; Cryotherapy; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Microvessels; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome | 2012 |
The efficacy of hepatic arterial infusion chemotherapy as an alternative to sorafenib in advanced hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Survival Analysis; Treatment Outcome | 2012 |
Intermediate and advanced hepatocellular carcinoma treated with the antiangiogenic agent sorafenib. Evaluation with unenhanced and contrast-enhanced ultrasonography.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Benzenesulfonates; Carcinoma, Hepatocellular; Contrast Media; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Reproducibility of Results; Sensitivity and Specificity; Sorafenib; Treatment Outcome; Ultrasonography | 2012 |
Selective internal radiation therapy of hepatocellular carcinoma: potential hepatopulmonary shunt reduction after sorafenib administration.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Hepatopulmonary Syndrome; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Radiography; Radiotherapy, Adjuvant; Sorafenib; Treatment Outcome | 2012 |
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial.
Topics: Aged; Alcoholism; Antineoplastic Agents; Carcinoma, Hepatocellular; Diarrhea; Disease Progression; Fatigue; Female; Hand-Foot Syndrome; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Severity of Illness Index; Sorafenib; Time Factors; Tumor Burden | 2012 |
Sorafenib-induced hepatocellular carcinoma cell death depends on reactive oxygen species production in vitro and in vivo.
Topics: Advanced Oxidation Protein Products; Aged; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Death; Cell Proliferation; Dose-Response Relationship, Drug; Female; Hep G2 Cells; Human Umbilical Vein Endothelial Cells; Humans; Kinetics; Liver Neoplasms; Male; Mice; Mice, Inbred C57BL; Middle Aged; Niacinamide; Nitrates; Phenylurea Compounds; Reactive Oxygen Species; Sorafenib | 2012 |
Could interferon still play a role in metastatic renal cell carcinoma? A randomized study of two schedules of sorafenib plus interferon-alpha 2a (RAPSODY).
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Renal Cell; Disease-Free Survival; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Interferon alpha-2; Interferon-alpha; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prospective Studies; Recombinant Proteins; Sorafenib; Treatment Outcome | 2013 |
Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease-Free Survival; Feasibility Studies; Female; Humans; Liver; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Prospective Studies; Protein Kinase Inhibitors; Severity of Illness Index; Sorafenib; Survival Rate; Treatment Outcome | 2013 |
Interim analysis of START: Study in Asia of the combination of TACE (transcatheter arterial chemoembolization) with sorafenib in patients with hepatocellular carcinoma trial.
Topics: Adult; Aged; Antineoplastic Agents; Asia; Asian People; Carcinoma, Hepatocellular; Catheterization; Chemoembolization, Therapeutic; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Hepatic Artery; Humans; Infusions, Intra-Arterial; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prospective Studies; Protein Kinase Inhibitors; Research Design; Sorafenib; Treatment Outcome | 2013 |
Phase II study of sorafenib in combination with cisplatin and 5-fluorouracil to treat recurrent or metastatic nasopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Metastasis; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Sorafenib; Ultrasonography | 2013 |
Quantitative therapy response assessment by volumetric iodine-uptake measurement: initial experience in patients with advanced hepatocellular carcinoma treated with sorafenib.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Contrast Media; Female; Humans; Imaging, Three-Dimensional; Iopamidol; Liver Neoplasms; Male; Middle Aged; Niacinamide; Outcome Assessment, Health Care; Phenylurea Compounds; Pilot Projects; Radiography, Dual-Energy Scanned Projection; Reproducibility of Results; Sensitivity and Specificity; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome | 2013 |
MRI assessment of early tumor response in metastatic renal cell carcinoma patients treated with sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Contrast Media; Female; Gadolinium; Humans; Kidney Neoplasms; Liver Neoplasms; Lymphatic Metastasis; Magnetic Resonance Imaging; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2013 |
Early response to anti-tumoral treatment in hepatocellular carcinoma--can quantitative contrast-enhanced ultrasound predict outcome?
Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Contrast Media; Dose-Response Relationship, Drug; Female; Humans; Image Enhancement; Image Interpretation, Computer-Assisted; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Prognosis; Regional Blood Flow; Sorafenib; Treatment Outcome; Ultrasonography | 2013 |
Sorafenib in hepatocellular carcinoma: prospective study on adverse events, quality of life, and related feasibility under daily conditions.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Quality of Life; Sorafenib; Surveys and Questionnaires | 2013 |
Advanced Hepatocellular Carcinoma: early evaluation of response to targeted therapy and prognostic value of Perfusion CT and Dynamic Contrast Enhanced-Ultrasound. Preliminary results.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Hepatocellular; Contrast Media; Early Detection of Cancer; Female; Humans; Indoles; Liver Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Perfusion Imaging; Phenylurea Compounds; Pilot Projects; Prognosis; Pyrroles; Reproducibility of Results; Sensitivity and Specificity; Sorafenib; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome; Ultrasonography | 2013 |
CF102 for the treatment of hepatocellular carcinoma: a phase I/II, open-label, dose-escalation study.
Topics: Adenosine; Adult; Aged; Apoptosis; Carcinoma, Hepatocellular; Child; Female; Humans; Leukocytes, Mononuclear; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Purinergic P1 Receptor Agonists; Receptor, Adenosine A3; Sorafenib; Wnt Signaling Pathway | 2013 |
Sorafenib in combination with transarterial chemoembolization improves the survival of patients with unresectable hepatocellular carcinoma: a propensity score matching study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Disease Progression; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Propensity Score; Prospective Studies; Sorafenib; Survival Analysis; Treatment Outcome | 2013 |
A phase I clinical and pharmacokinetic study of the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with doxorubicin in patients with solid tumors.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Aspartate Aminotransferases; Benzenesulfonates; Doxorubicin; Humans; Liver Neoplasms; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome | 2003 |
Results of a phase I trial of BAY 43-9006 in combination with doxorubicin in patients with primary hepatic cancer.
Topics: Adult; Aged; Anti-Bacterial Agents; Antibiotics, Antineoplastic; Area Under Curve; Benzenesulfonates; Cholangiocarcinoma; Doxorubicin; Drug Therapy, Combination; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2004 |
Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cohort Studies; Colonic Neoplasms; Diarrhea; Extracellular Signal-Regulated MAP Kinases; Fatigue; Female; Humans; Liver Neoplasms; Lymphocytes; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Phosphatidylethanolamine Binding Protein; Phosphorylation; Protein Kinase Inhibitors; Pyridines; Receptors, Vascular Endothelial Growth Factor; Rectal Neoplasms; Safety; Sorafenib | 2005 |
Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Hepatocellular; Disease-Free Survival; Drug Administration Schedule; Extracellular Signal-Regulated MAP Kinases; Female; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Protein Kinase Inhibitors; Pyridines; RNA, Neoplasm; Sorafenib; Survival Analysis; Treatment Outcome | 2006 |
Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Dose-Response Relationship, Drug; Female; Humans; Japan; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2008 |
2251 other study(ies) available for sorafenib and Cancer of Liver
| Article | Year |
|---|---|
Novel nitric oxide-releasing derivatives of farnesylthiosalicylic acid: synthesis and evaluation of antihepatocellular carcinoma activity.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Extracellular Signal-Regulated MAP Kinases; Farnesol; Humans; Liver Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Nitric Oxide Donors; Oxadiazoles; Phosphorylation; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-raf; Salicylates; Stereoisomerism; Structure-Activity Relationship; Toxicity Tests, Acute; Transplantation, Heterologous | 2011 |
Indoline ureas as potential anti-hepatocellular carcinoma agents targeting VEGFR-2: Synthesis, in vitro biological evaluation and molecular docking.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Hep G2 Cells; Humans; Indoles; Liver Neoplasms; Molecular Docking Simulation; Molecular Structure; Protein Kinase Inhibitors; Structure-Activity Relationship; Urea; Vascular Endothelial Growth Factor Receptor-2 | 2015 |
Discovery of benzenesulfonamide derivatives as potent PI3K/mTOR dual inhibitors with in vivo efficacies against hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Benzenesulfonamides; Carcinoma, Hepatocellular; Cell Line, Tumor; Humans; Liver; Liver Neoplasms; Male; Mice, Inbred BALB C; Mice, Nude; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Signal Transduction; Sulfonamides; TOR Serine-Threonine Kinases | 2016 |
Identification of a thalidomide derivative that selectively targets tumorigenic liver progenitor cells and comparing its effects with lenalidomide and sorafenib.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Humans; Lenalidomide; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib; Stem Cells; Thalidomide | 2016 |
Cytotoxic effect of levoglucosenone and related derivatives against human hepatocarcinoma cell lines.
Topics: Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Cell Survival; Glucose; Humans; Liver Neoplasms | 2016 |
Design and synthesis of novel tetrandrine derivatives as potential anti-tumor agents against human hepatocellular carcinoma.
Topics: Antineoplastic Agents; Apoptosis; Benzylisoquinolines; Carcinoma, Hepatocellular; Cell Line, Tumor; Chemistry Techniques, Synthetic; Drug Design; Endoplasmic Reticulum Stress; Enzyme Activation; Humans; JNK Mitogen-Activated Protein Kinases; Liver Neoplasms; Structure-Activity Relationship | 2017 |
Using gene expression database to uncover biology functions of 1,4-disubstituted 1,2,3-triazole analogues synthesized via a copper (I)-catalyzed reaction.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Carcinoma, Hepatocellular; Cell Line, Tumor; Copper; Curcumin; Databases, Genetic; Glycogen Synthase Kinase 3; Humans; Liver Neoplasms; Structure-Activity Relationship; Thiazoles; Triazoles; Urea | 2017 |
Design, synthesis and biological evaluation of new pyrrolidine carboxamide analogues as potential chemotherapeutic agents for hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Humans; Liver Neoplasms; Molecular Structure; Pyrrolidines; Structure-Activity Relationship | 2017 |
Design, Synthesis, and Preclinical Evaluation of Fused Pyrimidine-Based Hydroxamates for the Treatment of Hepatocellular Carcinoma.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Screening Assays, Antitumor; Heterografts; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Liver Neoplasms; Liver Neoplasms, Experimental; Mice; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Pyrimidines; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2018 |
Elephantopinolide A-P, germacrane-type sesquiterpene lactones from Elephantopus scaber induce apoptosis, autophagy and G2/M phase arrest in hepatocellular carcinoma cells.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Carcinoma, Hepatocellular; Cell Cycle Checkpoints; Cell Division; Cell Line, Tumor; Drug Screening Assays, Antitumor; G2 Phase; Humans; Lactones; Liver Neoplasms; Magnoliopsida; MAP Kinase Signaling System; Membrane Potential, Mitochondrial; Models, Molecular; Plant Extracts; Proto-Oncogene Proteins c-akt; Reactive Oxygen Species; Sesquiterpenes; Sesquiterpenes, Germacrane; Structure-Activity Relationship | 2020 |
Discovery of novel quinazolinone derivatives as potential anti-HBV and anti-HCC agents.
Topics: Antineoplastic Agents; Antiviral Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Design; Drug Resistance, Viral; Hepatitis B virus; Humans; Liver Neoplasms; Quinazolinones; Virus Replication | 2020 |
Design, synthesis, biological evaluation, and modeling studies of novel conformationally-restricted analogues of sorafenib as selective kinase-inhibitory antiproliferative agents against hepatocellular carcinoma cells.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Humans; Liver Neoplasms; Models, Molecular; Molecular Structure; Protein Kinase Inhibitors; Protein Kinases; Sorafenib; Structure-Activity Relationship; Tumor Cells, Cultured | 2021 |
In pursuit of a selective hepatocellular carcinoma therapeutic agent: Novel thalidomide derivatives with antiproliferative, antimigratory and STAT3 inhibitory properties.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Movement; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Liver Neoplasms; Molecular Structure; STAT3 Transcription Factor; Structure-Activity Relationship; Sulfides; Tumor Cells, Cultured | 2021 |
Synthesis and biological evaluation of novel isoxazole-piperazine hybrids as potential anti-cancer agents with inhibitory effect on liver cancer stem cells.
Topics: Antineoplastic Agents; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Isoxazoles; Liver Neoplasms; Molecular Structure; Piperazine; Structure-Activity Relationship; Tumor Cells, Cultured | 2021 |
Identification of a Novel TAR RNA-Binding Protein 2 Modulator with Potential Therapeutic Activity against Hepatocellular Carcinoma.
Topics: Animals; Carcinoma, Hepatocellular; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cell Proliferation; DEAD-box RNA Helicases; Enoxacin; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Mice; Mice, Nude; MicroRNAs; Polycyclic Compounds; Proteome; Ribonuclease III; RNA-Binding Proteins; Structure-Activity Relationship; Transcriptome; Transplantation, Heterologous | 2021 |
Synthesis and evaluation of FAK inhibitors with a 5-fluoro-7H-pyrrolo[2,3-d]pyrimidine scaffold as anti-hepatocellular carcinoma agents.
Topics: Animals; Binding Sites; Carcinoma, Hepatocellular; Catalytic Domain; Cell Line, Tumor; Cell Proliferation; Focal Adhesion Protein-Tyrosine Kinases; Half-Life; Humans; Liver Neoplasms; Male; Mice; Mice, Nude; Molecular Docking Simulation; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Small Molecule Libraries; Structure-Activity Relationship; Transplantation, Heterologous | 2021 |
Discovery of Novel Indazoles as Potent and Selective PI3Kδ Inhibitors with High Efficacy for Treatment of Hepatocellular Carcinoma.
Topics: Carcinoma, Hepatocellular; Class I Phosphatidylinositol 3-Kinases; Humans; Indazoles; Liver Neoplasms; Protein Kinase Inhibitors | 2022 |
Design, synthesis and biological evaluation of 3-arylisoquinoline derivatives as topoisomerase I and II dual inhibitors for the therapy of liver cancer.
Topics: Alkaloids; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; DNA; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Drug Design; Humans; Isoquinolines; Liver Neoplasms; Molecular Docking Simulation; Phosphatidylinositol 3-Kinases; Structure-Activity Relationship; Topoisomerase II Inhibitors | 2022 |
Benzobis(imidazole) derivatives as STAT3 signal inhibitors with antitumor activity.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Humans; Imidazoles; Liver Neoplasms; Mice; Mice, Nude; Phosphorylation; STAT3 Transcription Factor; Xenograft Model Antitumor Assays | 2022 |
Design, synthesis and antitumor evaluation of novel 1H-indole-2-carboxylic acid derivatives targeting 14-3-3η protein.
Topics: 14-3-3 Proteins; Antineoplastic Agents; Apoptosis; Carboxylic Acids; Cell Line, Tumor; Cell Proliferation; Drug Design; Drug Screening Assays, Antitumor; Humans; Indoles; Liver Neoplasms; Molecular Docking Simulation; Structure-Activity Relationship | 2022 |
Design, synthesis, and biological evaluation of a new series of pyrazole derivatives: Discovery of potent and selective JNK3 kinase inhibitors.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Design; Drug Screening Assays, Antitumor; Humans; Liver Neoplasms; Molecular Structure; Protein Kinase Inhibitors; Pyrazoles; Structure-Activity Relationship | 2022 |
meta-Ureidophenoxy-1,2,3-triazole hybrid as a novel scaffold for promising HepG2 hepatocellular carcinoma inhibitors: Synthesis, biological evaluation and molecular docking studies.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Proliferation; Drug Design; Drug Screening Assays, Antitumor; Humans; Liver Neoplasms; Molecular Docking Simulation; Molecular Structure; Sorafenib; Structure-Activity Relationship; Triazoles; Vascular Endothelial Growth Factor Receptor-2 | 2022 |
Overall Survival in Patients with Hepatocellular Carcinoma Treated with Sorafenib: A Polish Experience.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Poland; Retrospective Studies; Sorafenib; Survival Analysis; Young Adult | 2021 |
Nrf2 signaling promotes cancer stemness, migration, and expression of ABC transporter genes in sorafenib-resistant hepatocellular carcinoma cells.
Topics: Antineoplastic Agents; ATP-Binding Cassette Transporters; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Gene Expression; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Liver Neoplasms; NF-E2-Related Factor 2; Protein Kinase Inhibitors; Signal Transduction; Sorafenib; Transfection | 2021 |
Sulfarotene, a synthetic retinoid, overcomes stemness and sorafenib resistance of hepatocellular carcinoma via suppressing SOS2-RAS pathway.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Mice; Retinoids; Signal Transduction; Son of Sevenless Proteins; Sorafenib | 2021 |
Transarterial chemoembolization combined with sorafenib and iodine-125 seed brachytherapy for hepatocellular carcinoma with portal vein tumor thrombus: a retrospective controlled study.
Topics: Brachytherapy; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Humans; Iodine Radioisotopes; Liver Neoplasms; Portal Vein; Retrospective Studies; Sorafenib; Thrombosis; Treatment Outcome | 2022 |
Rutin attenuates Sorafenib-induced Chemoresistance and Autophagy in Hepatocellular Carcinoma by regulating BANCR/miRNA-590-5P/OLR1 Axis.
Topics: Animals; Antineoplastic Agents; Autophagy; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Hep G2 Cells; Humans; Liver Neoplasms; Male; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; RNA, Long Noncoding; Rutin; Scavenger Receptors, Class E; Sorafenib; Xenograft Model Antitumor Assays | 2021 |
Multimolecular-Targeted Agents for Intermediate-Stage Hepatocellular Carcinoma Influence Time to Stage Progression and Overall Survival.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Disease Progression; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Phenylurea Compounds; Propensity Score; Quinolines; Retrospective Studies; Sorafenib; Survival Rate; Treatment Outcome | 2021 |
Prolonged survival in patients with hand-foot skin reaction secondary to cooperative sorafenib treatment.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Prospective Studies; Retrospective Studies; Sorafenib; Treatment Outcome | 2021 |
Replication of Oncology Randomized Trial Results using Swedish Registry Real World-Data: A Feasibility Study.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Data Interpretation, Statistical; Feasibility Studies; Female; Humans; Liver Neoplasms; Male; Middle Aged; Multiple Myeloma; Randomized Controlled Trials as Topic; Registries; Sorafenib; Sweden | 2021 |
Hepatocellular Carcinoma (HCC) in North-Western India: A Retrospective Study Focusing on Epidemiology, Risk Factors, and Survival.
Topics: Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neoplasms; Male; Middle Aged; Retrospective Studies; Risk Factors; Sorafenib; Treatment Outcome | 2022 |
Induction of Anti-Proliferative and Apoptotic Effects of Sorafenib Using miR-27a Inhibitor in Hepatocellular Carcinoma Cell Lines.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Humans; Liver Neoplasms; MicroRNAs; Sorafenib | 2021 |
The role of daurisoline treatment in hepatocellular carcinoma: Inhibiting vasculogenic mimicry formation and enhancing sensitivity to sorafenib.
Topics: Animals; Benzylisoquinolines; Carcinoma, Hepatocellular; Cell Line, Tumor; Humans; Liver Neoplasms; Mice; Neovascularization, Pathologic; Sorafenib | 2021 |
Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Immunological; Bevacizumab; Carcinoma, Hepatocellular; Female; Germany; Humans; Immunotherapy; Italy; Liver Neoplasms; Male; Middle Aged; Prognosis; Proportional Hazards Models; Retrospective Studies; Sorafenib; Switzerland; Treatment Outcome | 2022 |
YAP/TAZ and ATF4 drive resistance to Sorafenib in hepatocellular carcinoma by preventing ferroptosis.
Topics: Activating Transcription Factor 4; Carcinoma, Hepatocellular; Cell Cycle Proteins; Ferroptosis; Humans; Liver Neoplasms; Sorafenib; Transcription Factors; Transcriptional Coactivator with PDZ-Binding Motif Proteins | 2021 |
Sintilimab plus sorafenib: a novel regimen for hepatocellular carcinoma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Budd-Chiari Syndrome; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Sorafenib | 2021 |
A Combinatorial CRISPR-Cas9 Screen Identifies Ifenprodil as an Adjunct to Sorafenib for Liver Cancer Treatment.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Proliferation; CRISPR-Cas Systems; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Piperidines; Sorafenib; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2021 |
Porphyrin Based 2D-MOF Structures as Dual-Kinetic Sorafenib Nanocarriers for Hepatoma Treatment.
Topics: Animals; Antineoplastic Agents; Biocompatible Materials; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Drug Delivery Systems; Drug Liberation; Humans; Liver Neoplasms; MAP Kinase Signaling System; Metal-Organic Frameworks; Nanomedicine; Phosphorylation; Porphyrins; Rats; Rats, Sprague-Dawley; Sorafenib | 2021 |
Induction of IL-6Rα by ATF3 enhances IL-6 mediated sorafenib and regorafenib resistance in hepatocellular carcinoma.
Topics: Activating Transcription Factor 3; Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Interleukin-6; Liver Neoplasms; Mice; Phenylurea Compounds; Pyridines; Receptors, Interleukin-6; Sorafenib; Xenograft Model Antitumor Assays | 2022 |
Role of radiotherapy in Barcelona Clinic Liver Cancer stage C hepatocellular carcinoma treated with sorafenib.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoradiotherapy; Humans; Liver Neoplasms; Neoplasm Staging; Retrospective Studies; Sorafenib; Treatment Outcome | 2022 |
First-line sorafenib sequential therapy and liver disease etiology for unresectable hepatocellular carcinoma using inverse probability weighting: A multicenter retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Japan; Liver Neoplasms; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Progression-Free Survival; Retrospective Studies; Sorafenib | 2021 |
Dipeptidyl peptidase-8 induces sorafenib resistance via binding with c-Rel to mediate NF-κB signaling in hepatocellular carcinoma.
Topics: Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Dipeptidyl-Peptidases and Tripeptidyl-Peptidases; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; NF-kappa B; Sorafenib | 2022 |
OATP1B1 Plays an Important Role in the Transport and Treatment Efficacy of Sorafenib in Hepatocellular Carcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Proliferation; Humans; Liver Neoplasms; Liver-Specific Organic Anion Transporter 1; Male; Mutation; Rats; Rats, Sprague-Dawley; Sorafenib; Tissue Distribution; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2021 |
EZH1/2 inhibition augments the anti-tumor effects of sorafenib in hepatocellular carcinoma.
Topics: Aged; Animals; Antineoplastic Agents; Benzamides; Carcinoma, Hepatocellular; Cell Line, Tumor; Down-Regulation; Enhancer of Zeste Homolog 2 Protein; Female; Genetic Therapy; Humans; Indazoles; Liver Neoplasms; Male; Mice, SCID; Middle Aged; Piperazines; Polycomb Repressive Complex 2; Pyridones; Sorafenib | 2021 |
Integrated Transcriptomic Analysis Revealed Hub Genes and Pathways Involved in Sorafenib Resistance in Hepatocellular Carcinoma.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Computational Biology; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Humans; Liver Neoplasms; Prognosis; Protein Interaction Maps; Software; Sorafenib; Survival Rate; Transcriptome | 2021 |
Sorafenib and triptolide loaded cancer cell-platelet hybrid membrane-camouflaged liquid crystalline lipid nanoparticles for the treatment of hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Biomimetic Materials; Blood Platelets; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Membrane; Diterpenes; Epoxy Compounds; Humans; Liposomes; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Nanomedicine; Nanoparticles; Phenanthrenes; RAW 264.7 Cells; Sorafenib | 2021 |
ABCC5 facilitates the acquired resistance of sorafenib through the inhibition of SLC7A11-induced ferroptosis in hepatocellular carcinoma.
Topics: Amino Acid Transport System y+; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Ferroptosis; Humans; Liver Neoplasms; Multidrug Resistance-Associated Proteins; Sorafenib | 2021 |
Autophagy-Related Chemoprotection against Sorafenib in Human Hepatocarcinoma: Role of FOXO3 Upregulation and Modulation by Regorafenib.
Topics: Antineoplastic Agents; Autophagy; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Forkhead Box Protein O3; Hep G2 Cells; Humans; Liver Neoplasms; Phenylurea Compounds; Pyridines; Sorafenib; Up-Regulation | 2021 |
Focal adhesion kinase inhibitor TAE226 combined with Sorafenib slows down hepatocellular carcinoma by multiple epigenetic effects.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Epigenesis, Genetic; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred NOD; Morpholines; Sorafenib | 2021 |
Regorafenib for Taiwanese patients with unresectable hepatocellular carcinoma after sorafenib failure: Impact of alpha-fetoprotein levels.
Topics: Adult; Aged; Aged, 80 and over; alpha-Fetoproteins; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Female; Humans; Liver Neoplasms; Male; Middle Aged; Phenylurea Compounds; Pyridines; Risk Factors; Salvage Therapy; Sorafenib; Survival Analysis; Taiwan | 2022 |
Cullin3 deficiency shapes tumor microenvironment and promotes cholangiocarcinoma in liver-specific Smad4/Pten mutant mice.
Topics: Animals; Antibodies; Antineoplastic Agents; CD8-Positive T-Lymphocytes; Cholangiocarcinoma; CRISPR-Cas Systems; Cullin Proteins; Gene Expression Regulation; Gene Knockdown Techniques; Liver; Liver Neoplasms; Mice; Mutation; Programmed Cell Death 1 Receptor; PTEN Phosphohydrolase; Smad4 Protein; Sorafenib; Tumor Microenvironment | 2021 |
How to choose second-line treatment for hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Phenylurea Compounds; Sorafenib | 2021 |
KAT6A is associated with sorafenib resistance and contributes to progression of hepatocellular carcinoma by targeting YAP.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Cycle Proteins; Cell Line, Tumor; Cell Survival; Disease Progression; Drug Resistance, Neoplasm; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Histone Acetyltransferases; Humans; Liver Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Sorafenib; Transcription Factors | 2021 |
Acquired Resistance to Antiangiogenic Therapies in Hepatocellular Carcinoma Is Mediated by Yes-Associated Protein 1 Activation and Transient Expansion of Stem-Like Cancer Cells.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Sorafenib; YAP-Signaling Proteins | 2022 |
Clusterin and Related Scoring Index as Potential Early Predictors of Response to Sorafenib in Hepatocellular Carcinoma.
Topics: Biomarkers; Carcinoma, Hepatocellular; Clusterin; Humans; Liver Neoplasms; Sorafenib; TOR Serine-Threonine Kinases | 2022 |
Design, synthesis, anticancer, and docking of some S- and/or N-heterocyclic derivatives as VEGFR-2 inhibitors.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Hepatocellular; Chlorocebus aethiops; Doxorubicin; Female; Hep G2 Cells; Heterocyclic Compounds; Humans; Inhibitory Concentration 50; Liver Neoplasms; MCF-7 Cells; Molecular Docking Simulation; Sorafenib; Structure-Activity Relationship; Vascular Endothelial Growth Factor Receptor-2; Vero Cells | 2022 |
CircRNA-001241 mediates sorafenib resistance of hepatocellular carcinoma cells by sponging miR-21-5p and regulating TIMP3 expression.
Topics: Carcinoma, Hepatocellular; Cell Proliferation; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; MicroRNAs; RNA, Circular; Sorafenib; Tissue Inhibitor of Metalloproteinase-3 | 2022 |
Evaluating the Effect of Lenvatinib on Sorafenib-Resistant Hepatocellular Carcinoma Cells.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Mice, Inbred BALB C; MicroRNAs; Neovascularization, Pathologic; Phenylurea Compounds; Quinolines; Sorafenib; Xenograft Model Antitumor Assays | 2021 |
Validation of a Lab-on-Chip Assay for Measuring Sorafenib Effectiveness on HCC Cell Proliferation.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Proliferation; Drug Evaluation, Preclinical; Fibroblasts; Humans; Lab-On-A-Chip Devices; Liver Neoplasms; Sorafenib | 2021 |
Nivolumab and sorafenib in hepatocellular carcinoma: lessons from the CheckMate 459 study.
Topics: Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Nivolumab; Sorafenib | 2022 |
Effects of direct-acting antiviral therapy for patients with advanced hepatocellular carcinoma and concomitant hepatitis C-A population-based cohort study.
Topics: Aged; Antineoplastic Agents; Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Female; Hepatitis C, Chronic; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Retrospective Studies; Sorafenib; Survival Rate; Treatment Outcome | 2021 |
A targetable LIFR-NF-κB-LCN2 axis controls liver tumorigenesis and vulnerability to ferroptosis.
Topics: Animals; Antibodies, Neutralizing; Carcinogenesis; Carcinoma, Hepatocellular; Cell Line, Tumor; Down-Regulation; Ferroptosis; Gene Expression Regulation, Neoplastic; HEK293 Cells; Humans; Leukemia Inhibitory Factor Receptor alpha Subunit; Lipocalin-2; Liver Neoplasms; Male; Mice, Inbred C57BL; NF-kappa B; Piperazines; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Signal Transduction; Sorafenib; Up-Regulation; Xenograft Model Antitumor Assays | 2021 |
Dihydroartemisinin enhances the inhibitory effect of sorafenib on HepG2 cells by inducing ferroptosis and inhibiting energy metabolism.
Topics: Animals; Antineoplastic Agents; Artemisinins; Depression, Chemical; Drug Synergism; Drug Therapy, Combination; Energy Metabolism; Female; Ferroptosis; Hep G2 Cells; Humans; Liver Neoplasms; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Sorafenib | 2022 |
Targeting FAM134B-mediated reticulophagy activates sorafenib-induced ferroptosis in hepatocellular carcinoma.
Topics: Animals; Autophagy; Carcinoma, Hepatocellular; Cell Line, Tumor; Down-Regulation; Endoplasmic Reticulum; Ferroptosis; Humans; Intracellular Signaling Peptides and Proteins; Liver Neoplasms; Male; Membrane Proteins; Mice, Inbred BALB C; Mice, Nude; Poly(A)-Binding Protein I; Protein Biosynthesis; Sorafenib | 2022 |
Treatment of hepatocellular carcinoma with autologous platelets encapsulating sorafenib or lenvatinib: A novel therapy exploiting tumor-platelet interactions.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Endothelial Cells; Humans; Liver Neoplasms; Phenylurea Compounds; Quinolines; Rats; Sorafenib | 2022 |
Single cell RNA-seq analysis identifies a noncoding RNA mediating resistance to sorafenib treatment in HCC.
Topics: Biomarkers, Tumor; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; RNA, Long Noncoding; Single-Cell Analysis; Sorafenib; Transcriptome | 2022 |
Epigenetic regulation of ferroptosis via ETS1/miR-23a-3p/ACSL4 axis mediates sorafenib resistance in human hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Coenzyme A Ligases; Drug Resistance, Neoplasm; Epigenesis, Genetic; Ferroptosis; Humans; Liver Neoplasms; Mice, Inbred NOD; Sorafenib | 2022 |
Early tumor shrinkage and response assessment according to mRECIST predict overall survival in hepatocellular carcinoma patients under sorafenib.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Male; Retrospective Studies; Sorafenib; Treatment Outcome | 2022 |
PDA-Based Glyconanomicelles for Hepatocellular Carcinoma Cells Active Targeting Via Mannose and Asialoglycoprotein Receptors.
Topics: Antineoplastic Agents; Apoptosis; Asialoglycoprotein Receptor; Carcinoma, Hepatocellular; Cell Proliferation; Endosomes; Galactose; Hep G2 Cells; Humans; Liver Neoplasms; Mannose; Mannose Receptor; Micelles; Nanoparticles; Polyacetylene Polymer; Sorafenib | 2021 |
MiRNA-124-3p.1 sensitizes hepatocellular carcinoma cells to sorafenib by regulating FOXO3a by targeting AKT2 and SIRT1.
Topics: Acetylation; Animals; Apoptosis; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Nucleus; Drug Resistance, Neoplasm; Forkhead Box Protein O3; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Mice; MicroRNAs; Proto-Oncogene Proteins c-akt; Sirtuin 1; Sorafenib; Xenograft Model Antitumor Assays | 2022 |
HAIC-FO improves outcomes in HCC.
Topics: Carcinoma, Hepatocellular; Fluorouracil; Humans; Liver Neoplasms; Oxaliplatin; Sorafenib | 2022 |
Maternal embryonic leucine zipper kinase serves as a potential prognostic marker and leads to sorafenib chemoresistance modified by miR-142-5p in hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Leucine Zippers; Liver Neoplasms; MicroRNAs; Prognosis; Protein Serine-Threonine Kinases; Sorafenib | 2022 |
Anti-PD-1 combined sorafenib versus anti-PD-1 alone in the treatment of advanced hepatocellular cell carcinoma: a propensity score-matching study.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Humans; Immune Checkpoint Inhibitors; Liver Neoplasms; Male; Middle Aged; Programmed Cell Death 1 Receptor; Propensity Score; Retrospective Studies; Sorafenib | 2022 |
Establishment of childhood hepatoblastoma xenografts and evaluation of the anti-tumour effects of anlotinib, oxaliplatin and sorafenib.
Topics: Animals; Hepatoblastoma; Heterografts; Humans; Indoles; Liver Neoplasms; Mice; Oxaliplatin; Quinolines; Sorafenib | 2022 |
The hsa_circRNA_102049 mediates the sorafenib sensitivity of hepatocellular carcinoma cells by regulating
Topics: Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; HEK293 Cells; Hep G2 Cells; Humans; Liver Neoplasms; Neoplasm Proteins; Reelin Protein; RNA, Circular; RNA, Neoplasm; Sorafenib | 2022 |
Long intergenic non-protein coding RNA 1273 confers sorafenib resistance in hepatocellular carcinoma via regulation of methyltransferase 3.
Topics: Adult; Aged; Aged, 80 and over; Animals; Carcinoma, Hepatocellular; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Male; Methyltransferases; Mice; Mice, Nude; Middle Aged; RNA, Long Noncoding; Sorafenib; Tumor Cells, Cultured | 2022 |
Solamargine inhibits the growth of hepatocellular carcinoma and enhances the anticancer effect of sorafenib by regulating HOTTIP-TUG1/miR-4726-5p/MUC1 pathway.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; MicroRNAs; Mucin-1; RNA, Long Noncoding; Solanaceous Alkaloids; Sorafenib | 2022 |
Effectiveness of Lenvatinib Versus Sorafenib for Unresectable Hepatocellular Carcinoma in Patients with Hepatic Decompensation.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Phenylurea Compounds; Quinolines; Retrospective Studies; Sorafenib | 2022 |
Novel FLT3/AURK multikinase inhibitor is efficacious against sorafenib-refractory and sorafenib-resistant hepatocellular carcinoma.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Endothelial Cells; fms-Like Tyrosine Kinase 3; Humans; Liver Neoplasms; Sorafenib; Xenograft Model Antitumor Assays | 2022 |
Galectin-1 confers resistance to doxorubicin in hepatocellular carcinoma cells through modulation of P-glycoprotein expression.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Hepatocellular; Cell Line, Tumor; Doxorubicin; Drug Resistance, Neoplasm; Galectin 1; Hep G2 Cells; Humans; Liver Neoplasms; Sorafenib; Tumor Microenvironment | 2022 |
Therapeutic efficacy of FASN inhibition in preclinical models of HCC.
Topics: Anilides; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Fatty Acid Synthase, Type I; Fatty Acid Synthases; Fatty Liver; Humans; Liver; Liver Neoplasms; Mammals; Mice; Phosphoric Monoester Hydrolases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-met; Pyridines; Sorafenib; Tensins; TOR Serine-Threonine Kinases | 2022 |
Hepatectomy Versus Sorafenib in Advanced Nonmetastatic Hepatocellular Carcinoma: A Real-life Multicentric Weighted Comparison.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Hepatectomy; Humans; Liver Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Treatment Outcome | 2022 |
The effects of Sorafenib and Natural killer cell co-injection in combinational treatment of hepatocellular carcinoma; an in vivo approach.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Humans; Killer Cells, Natural; Liver Neoplasms; Mice; Mice, Nude; Sorafenib | 2022 |
Impact of psoas muscle index assessed by a simple measurement method on tolerability and duration of continued treatment with sorafenib in hepatocellular carcinoma patients.
Topics: Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Psoas Muscles; Retrospective Studies; Sorafenib | 2022 |
Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma in the Era of New Systemic Agents.
Topics: Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Portal Vein; Sorafenib; Venous Thrombosis | 2022 |
Dual Immunotherapy Makes Strides against HCC.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Humans; Immunotherapy; Liver Neoplasms; Sorafenib | 2022 |
Advanced Hepatocellular Cancer Treated with Sorafenib and Novel Inflammatory Markers.
Topics: Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Lymphocytes; Neutrophils; Prognosis; Retrospective Studies; Sorafenib | 2023 |
Sorafenib is an antagonist of the aryl hydrocarbon receptor.
Topics: Animals; Carcinoma, Hepatocellular; Cytochrome P-450 CYP1A1; Ligands; Liver Neoplasms; Mice; Receptors, Aryl Hydrocarbon; Sorafenib | 2022 |
LncRNA LIMT (LINC01089) contributes to sorafenib chemoresistance via regulation of miR-665 and epithelial to mesenchymal transition in hepatocellular carcinoma cells.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; MicroRNAs; RNA, Long Noncoding; Sorafenib | 2022 |
Limited sorafenib anticancer effects on primary cultured hepatocellular carcinoma cells with high NANOG expression.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Nanog Homeobox Protein; Octamer Transcription Factor-3; Sorafenib; Treatment Outcome; Tumor Cells, Cultured | 2022 |
Combination therapy of sorafenib and drug-eluting bead transarterial chemoembolization for advanced hepatocellular carcinoma with and without hepatic arteriovenous shunt.
Topics: Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neoplasms; Retrospective Studies; Sorafenib; Treatment Outcome | 2022 |
MiR-25 enhances autophagy and promotes sorafenib resistance of hepatocellular carcinoma via targeting FBXW7.
Topics: Antineoplastic Agents; Autophagy; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; F-Box-WD Repeat-Containing Protein 7; Humans; Liver; Liver Neoplasms; MicroRNAs; Sorafenib | 2022 |
The Relationship between albumin-Bilirubin grade and survival in hepatocelluler carcinoma patients treated with sorefanib.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Bilirubin; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Prognosis; Retrospective Studies; Sorafenib; Young Adult | 2022 |
Piperlongumine synergistically enhances the antitumour activity of sorafenib by mediating ROS-AMPK activation and targeting CPSF7 in liver cancer.
Topics: AMP-Activated Protein Kinases; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cleavage And Polyadenylation Specificity Factor; Dioxolanes; Humans; Liver Neoplasms; Reactive Oxygen Species; Sorafenib | 2022 |
Upregulation of USP22 and ABCC1 during Sorafenib Treatment of Hepatocellular Carcinoma Contribute to Development of Resistance.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Multidrug Resistance-Associated Proteins; Sorafenib; Ubiquitin Thiolesterase; Up-Regulation | 2022 |
AGA Clinical Practice Guideline on Systemic Therapy for Hepatocellular Carcinoma.
Topics: Anilides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Chemotherapy, Adjuvant; Hepatectomy; Humans; Liver Neoplasms; Liver Transplantation; Phenylurea Compounds; Pyridines; Quinolines; Ramucirumab; Retreatment; Sorafenib | 2022 |
Low miR-10b-3p associated with sorafenib resistance in hepatocellular carcinoma.
Topics: Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; MicroRNAs; Sorafenib | 2022 |
DYRK1A suppression attenuates HIF‑1α accumulation and enhances the anti‑liver cancer effects of regorafenib and sorafenib under hypoxic conditions.
Topics: Dyrk Kinases; Humans; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Liver Neoplasms; Phenylurea Compounds; Protective Factors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Pyridines; Sorafenib | 2022 |
Antitumor effects of rhamnazinon sorafenib-treated human hepatocellular carcinoma cell lines via modulation of VEGF signaling and PI3K/NF-κB p38/caspase-3 axes cross talk.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Caspase 3; Cell Line; Cell Line, Tumor; Cell Proliferation; Humans; Liver Neoplasms; NF-kappa B; Niacinamide; p38 Mitogen-Activated Protein Kinases; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Sorafenib; Vascular Endothelial Growth Factor A | 2022 |
Transcriptional suppression of Dicer by HOXB-AS3/EZH2 complex dictates sorafenib resistance and cancer stemness.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; DEAD-box RNA Helicases; Drug Resistance, Neoplasm; Enhancer of Zeste Homolog 2 Protein; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Ribonuclease III; RNA, Long Noncoding; Sorafenib | 2022 |
Real-world Treatment Patterns and Reasons for Therapy Selection in Patients with Advanced Hepatocellular Carcinoma in US Oncology Practices.
Topics: Adult; Carcinoma, Hepatocellular; Cross-Sectional Studies; Female; Humans; Infant; Liver Neoplasms; Male; Retrospective Studies; Sorafenib | 2022 |
Treatment Patterns and Health Resource Utilization in Patients With Hepatocellular Carcinoma After Failure of Sorafenib in Real-World Setting in Taiwan.
Topics: Adult; Aged; Aged, 80 and over; alpha-Fetoproteins; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Patient Acceptance of Health Care; Sorafenib; Taiwan; Treatment Failure | 2022 |
Transarterial Radioembolization Versus Atezolizumab-Bevacizumab in Unresectable Hepatocellular Carcinoma: A Matching-Adjusted Indirect Comparison of Time to Deterioration in Quality of Life.
Topics: Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Quality of Life; Sorafenib; Yttrium Radioisotopes | 2022 |
Macropinocytosis is an alternative pathway of cysteine acquisition and mitigates sorafenib-induced ferroptosis in hepatocellular carcinoma.
Topics: Animals; Carcinoma, Hepatocellular; Cysteine; Female; Ferroptosis; Humans; Liver Neoplasms; Male; Mice; Pinocytosis; Protein Kinase Inhibitors; Sorafenib | 2022 |
Increased CD8+ T-cell Infiltration and Efficacy for Multikinase Inhibitors After PD-1 Blockade in Hepatocellular Carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Hepatocellular; CD8-Positive T-Lymphocytes; Humans; Liver Neoplasms; Mice; Programmed Cell Death 1 Receptor; Sorafenib; Vascular Endothelial Growth Factor A | 2022 |
Expanding the immunotherapy roadmap for hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Humans; Immunologic Factors; Immunotherapy; Liver Neoplasms; Nivolumab; Sorafenib | 2022 |
Economic Evaluation of Sintilimab Plus Bevacizumab Versus Sorafenib as a First-line Treatment for Unresectable Hepatocellular Carcinoma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Humans; Liver Neoplasms; Quality-Adjusted Life Years; Sorafenib | 2022 |
Clinical usefulness of geriatric assessment in elderly patients with unresectable hepatocellular carcinoma receiving sorafenib or lenvatinib therapy.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Geriatric Assessment; Humans; Liver Neoplasms; Sorafenib | 2022 |
Sperm associated antigen 4 promotes SREBP1-mediated de novo lipogenesis via interaction with lamin A/C and contributes to tumor progression in hepatocellular carcinoma.
Topics: Animals; Carcinogenesis; Carcinoma, Hepatocellular; Carrier Proteins; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Humans; Lamin Type A; Lipogenesis; Liver Neoplasms; Mice; Orlistat; Sorafenib; Sterol Regulatory Element Binding Protein 1 | 2022 |
Daidzein and Chicory Extract Arrest the Cell Cycle
Topics: Animals; Carcinoma, Hepatocellular; Cell Cycle; Cell Cycle Checkpoints; Cell Proliferation; Cichorium intybus; Cyclin A; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase 4; Gene Expression; Humans; Ki-67 Antigen; Liver Neoplasms; Proto-Oncogene Proteins c-bcl-2; Rats; Sorafenib | 2022 |
Breaking the Child-Pugh Dogma in Hepatocellular Carcinoma.
Topics: Carcinoma, Hepatocellular; Humans; Liver Cirrhosis; Liver Neoplasms; Phenylurea Compounds; Retrospective Studies; Sorafenib | 2022 |
Cholesterol sensor SCAP contributes to sorafenib resistance by regulating autophagy in hepatocellular carcinoma.
Topics: Animals; Autophagy; Carcinoma, Hepatocellular; Cholesterol; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Mice; Mice, Nude; Phenylurea Compounds; Sorafenib | 2022 |
Myeloid-derived suppressor cells promote tumor growth and sorafenib resistance by inducing FGF1 upregulation and fibrosis.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Fibroblast Growth Factor 1; Fibrosis; Humans; Liver Neoplasms; Mice; Myeloid-Derived Suppressor Cells; Sorafenib; Up-Regulation | 2022 |
CRISPR-Cas9-based genome-wide screening identified novel targets for treating sorafenib-resistant hepatocellular carcinoma: a cross-talk between FGF21 and the NRF2 pathway.
Topics: Carcinoma, Hepatocellular; CRISPR-Cas Systems; Fibroblast Growth Factors; Humans; Kelch-Like ECH-Associated Protein 1; Liver Neoplasms; NF-E2-Related Factor 2; Signal Transduction; Sorafenib | 2022 |
Development and External Validation of the Munich Sorafenib Evaluation Score for Hepatocellular Carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Neoplasm Staging; Phenylurea Compounds; Prognosis; Retrospective Studies; Sorafenib | 2023 |
EGFR/MET promotes hepatocellular carcinoma metastasis by stabilizing tumor cells and resisting to RTKs inhibitors in circulating tumor microemboli.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Liver Neoplasms; Neoplasm Metastasis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Receptor Protein-Tyrosine Kinases; Sorafenib | 2022 |
Sodium butyrate inhibits aerobic glycolysis of hepatocellular carcinoma cells via the c-myc/hexokinase 2 pathway.
Topics: Animals; Butyric Acid; Carcinoma, Hepatocellular; Cell Line; Cell Line, Tumor; Cell Proliferation; Glycolysis; Hexokinase; Humans; Lactates; Liver Neoplasms; Mice; Sorafenib | 2022 |
The Cost Effectiveness of Donafenib Compared With Sorafenib for the First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma in China.
Topics: Carcinoma, Hepatocellular; Cost-Benefit Analysis; Humans; Liver Neoplasms; Pyridines; Sorafenib | 2022 |
CT-707 overcomes hypoxia-mediated sorafenib resistance in Hepatocellular carcinoma by inhibiting YAP signaling.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Hypoxia; Liver Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides | 2022 |
Effectiveness and safety of sorafenib for renal cell, hepatocellular and thyroid carcinoma: pooled analysis in patients with renal impairment.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Humans; Kidney; Kidney Neoplasms; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Prospective Studies; Retrospective Studies; Sorafenib; Thyroid Neoplasms; Vascular Endothelial Growth Factor A | 2022 |
Fluorescence-Reporting-Guided Tumor Acidic Environment-Activated Triple Photodynamic, Chemodynamic, and Chemotherapeutic Reactions for Efficient Hepatocellular Carcinoma Cell Ablation.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Ferric Compounds; Fluorescence; Humans; Hydrogen Peroxide; Liver Neoplasms; Nanoparticles; Photochemotherapy; Photosensitizing Agents; Sorafenib | 2022 |
AZD4547 and the Alleviation of Hepatoma Cell Sorafenib Resistance via the Promotion of Autophagy.
Topics: Autophagy; Beclin-1; Benzamides; Carcinoma, Hepatocellular; Cell Line; Cell Line, Tumor; Cell Proliferation; Humans; Liver Neoplasms; Piperazines; Pyrazoles; Receptors, Fibroblast Growth Factor; Saline Solution; Sorafenib; Toll-Like Receptor 4 | 2022 |
Differences Between Sorafenib and Lenvatinib Treatment from Genetic and Clinical Perspectives for Patients with Hepatocellular Carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; MicroRNAs; Phenylurea Compounds; Quinolines; Sorafenib | 2022 |
Sorafenib-Loaded PLGA-TPGS Nanosystems Enhance Hepatocellular Carcinoma Therapy Through Reversing P-Glycoprotein-Mediated Multidrug Resistance.
Topics: alpha-Tocopherol; Animals; ATP Binding Cassette Transporter, Subfamily B; Carcinoma, Hepatocellular; Drug Resistance, Multiple; Glycolates; Humans; Lactic Acid; Liver Neoplasms; Mice; Mice, Nude; Polyesters; Polyethylene Glycols; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Sorafenib; Vitamin E | 2022 |
Circulating Tumor Cells Derived from Advanced Hepatocellular Carcinoma Rapidly Develop Resistance to Cytotoxic Chemotherapy.
Topics: Carcinoma, Hepatocellular; Cell Count; Humans; Liver Neoplasms; Neoplastic Cells, Circulating; Sorafenib | 2022 |
Hepatitis C virus eradication ameliorates the prognosis of advanced hepatocellular carcinoma treated with sorafenib.
Topics: Antineoplastic Agents; Bilirubin; Carcinoma, Hepatocellular; Hepacivirus; Hepatitis C; Humans; Liver Neoplasms; Prognosis; Retrospective Studies; Sorafenib | 2022 |
The Cost-Effectiveness of Selective Internal Radiation Therapies Compared With Sorafenib for Treating Advanced Unresectable Hepatocellular Carcinoma in the United Kingdom.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib; United Kingdom | 2022 |
Reducing Postoperative Recurrence of Early-Stage Hepatocellular Carcinoma by a Wound-Targeted Nanodrug.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Liver Neoplasms; Mice; Nanoparticles; Neoplasm Recurrence, Local; Sorafenib | 2022 |
[Pan-cancer analysis of the expression pattern of long non-coding RNA MIR22HG].
Topics: Biomarkers, Tumor; Carcinoma, Hepatocellular; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Lymphatic Metastasis; Microsatellite Instability; RNA, Long Noncoding; Sorafenib | 2022 |
Epigenetic regulation of the DNMT1/MT1G/KLF4/CA9 axis synergises the anticancer effects of sorafenib in hepatocellular carcinoma.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Carbonic Anhydrase IX; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; DNA (Cytosine-5-)-Methyltransferase 1; Drug Resistance, Neoplasm; Epigenesis, Genetic; Humans; Kruppel-Like Factor 4; Liver Neoplasms; Metallothionein; Signal Transduction; Sorafenib | 2022 |
Ivermectin synergizes sorafenib in hepatocellular carcinoma via targeting multiple oncogenic pathways.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Humans; Ivermectin; Liver Neoplasms; Mice; Sorafenib | 2022 |
Radiomics signature: A potential biomarker for β-arrestin1 phosphorylation prediction in hepatocellular carcinoma.
Topics: beta-Arrestin 1; Biomarkers; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Nomograms; Phosphorylation; Retrospective Studies; Sorafenib | 2022 |
Impact of lenvatinib on renal function compared to sorafenib for unresectable hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Kidney; Liver Neoplasms; Phenylurea Compounds; Proteinuria; Quinolines; Sorafenib | 2022 |
Implications of Withaferin A for the metastatic potential and drug resistance in hepatocellular carcinoma cells via Nrf2-mediated EMT and ferroptosis.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Ferroptosis; Humans; Kelch-Like ECH-Associated Protein 1; Liver Neoplasms; NF-E2-Related Factor 2; Sorafenib | 2023 |
Indonesian consensus on systemic therapies for hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Consensus; Humans; Indonesia; Liver Neoplasms; Sorafenib; Vascular Endothelial Growth Factor A | 2023 |
Hepatocellular carcinoma in Stockholm, Sweden 2003-2018: a population-based cohort study.
Topics: Carcinoma, Hepatocellular; Cohort Studies; Humans; Liver Neoplasms; Sorafenib; Sweden | 2022 |
UDP-glucose 6-dehydrogenase lessens sorafenib sensitivity via modulating unfolded protein response.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Glucuronic Acid; Humans; Liver Neoplasms; Sorafenib; Unfolded Protein Response; Uridine Diphosphate Glucose Dehydrogenase; Xenograft Model Antitumor Assays | 2022 |
Sorafenib and nitazoxanide disrupt mitochondrial function and inhibit regrowth capacity in three-dimensional models of hepatocellular and colorectal carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Colorectal Neoplasms; Humans; Liver Neoplasms; Mitochondria; Nitro Compounds; Sorafenib; Thiazoles | 2022 |
Efficacy of Lipid Nanoparticle-Loaded Sorafenib Combined with Hepatic Artery Chemoembolization in the Treatment of Primary Hepatocellular Carcinoma Complicated with Microvascular Invasion.
Topics: Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatic Artery; Humans; Liposomes; Liver Neoplasms; Nanoparticles; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Sorafenib; Treatment Outcome | 2022 |
EMT-Related Gene Signature: A New Method for Personalized Risk Assessment in Patients with Hepatocellular Carcinoma.
Topics: Biomarkers, Tumor; Carcinoma, Hepatocellular; Epithelial-Mesenchymal Transition; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Membrane Proteins; Prognosis; Risk Assessment; Sorafenib; SOXC Transcription Factors | 2023 |
CAF-derived exosomes transmitted Gremlin-1 promotes cancer progression and decreases the sensitivity of hepatoma cells to sorafenib.
Topics: beta Catenin; Cancer-Associated Fibroblasts; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Epithelial-Mesenchymal Transition; Exosomes; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; MicroRNAs; Sorafenib | 2022 |
Selenium nanoparticles overcomes sorafenib resistance in thioacetamide induced hepatocellular carcinoma in rats by modulation of mTOR, NF-κB pathways and LncRNA-AF085935/GPC3 axis.
Topics: Animals; Antineoplastic Agents; bcl-2-Associated X Protein; Carcinoma, Hepatocellular; Caspase 3; Cell Line, Tumor; Glypicans; Liver Neoplasms; Mammals; Nanoparticles; NF-kappa B; Proto-Oncogene Proteins c-akt; Rats; RNA, Long Noncoding; Selenium; Sorafenib; Thioacetamide; TOR Serine-Threonine Kinases | 2022 |
SREBF2-STARD4 axis confers sorafenib resistance in hepatocellular carcinoma by regulating mitochondrial cholesterol homeostasis.
Topics: Carcinoma, Hepatocellular; Carrier Proteins; Cell Line, Tumor; Cell Proliferation; Cholesterol; Cytochromes c; Drug Resistance, Neoplasm; Homeostasis; Humans; Liver Neoplasms; Membrane Transport Proteins; Sorafenib; Sterol Regulatory Element Binding Protein 2 | 2023 |
A Functional Screening Identifies a New Organic Selenium Compound Targeting Cancer Stem Cells: Role of c-Myc Transcription Activity Inhibition in Liver Cancer.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Early Detection of Cancer; Liver Neoplasms; Mice; Molecular Docking Simulation; Neoplastic Stem Cells; Selenium; Selenium Compounds; Sorafenib | 2022 |
Comparison of nivolumab and sorafenib for first systemic therapy in patients with hepatocellular carcinoma and Child-Pugh B cirrhosis.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Cirrhosis; Liver Neoplasms; Niacinamide; Nivolumab; Phenylurea Compounds; Retrospective Studies; Sorafenib; Treatment Outcome | 2023 |
Efficacy and safety of radiotherapy plus anti-PD1 versus transcatheter arterial chemoembolization plus sorafenib for advanced hepatocellular carcinoma: a real-world study.
Topics: Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib | 2022 |
Clinical Outcomes of Radiological Treatment Modalities of Hepatocellular Carcinoma: A Single-Center Experience from Saudi Arabia.
Topics: Aged; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Humans; Liver Neoplasms; Middle Aged; Retrospective Studies; Saudi Arabia; Sorafenib; Treatment Outcome | 2022 |
Bimodal Treatment of Hepatocellular Carcinoma by Targeted Minimally Interventional Photodynamic/Chemotherapy Using Glyco-Covalent-Organic Frameworks-Guided Porphyrin/Sorafenib.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Liver Neoplasms; Metal-Organic Frameworks; Mice; Photochemotherapy; Porphyrins; Sorafenib | 2022 |
Osthole Increases the Sensitivity of Liver Cancer to Sorafenib by Inhibiting Cholesterol Metabolism.
Topics: Animals; Cholesterol; Coumarins; Liver; Liver Neoplasms; Mice; Sorafenib; Sterol Regulatory Element Binding Protein 1; Sterol Regulatory Element Binding Protein 2 | 2022 |
Ginsenoside Rg3 and sorafenib combination therapy relieves the hepatocellular carcinomaprogression through regulating the HK2-mediated glycolysis and PI3K/Akt signaling pathway.
Topics: Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Ginsenosides; Glucose; Glycolysis; Humans; Lactates; Liver Neoplasms; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Signal Transduction; Sorafenib | 2022 |
ATF4 protects against sorafenib-induced cardiotoxicity by suppressing ferroptosis.
Topics: Activating Transcription Factor 4; Animals; Cardiotoxicity; Ferroptosis; Liver Neoplasms; Mice; Sorafenib | 2022 |
Percentage genome change and chromosome 7q amplification predict sorafenib response in advanced hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chromosomes; Humans; Liver Neoplasms; Sorafenib; Treatment Outcome | 2021 |
ORM 1 as a biomarker of increased vascular invasion and decreased sorafenib sensitivity in hepatocellular carcinoma.
Topics: Biomarkers; Carcinoma, Hepatocellular; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Orosomucoid; RNA, Messenger; Sorafenib | 2022 |
Caspase-3-Induced Activation of SREBP2 Drives Drug Resistance via Promotion of Cholesterol Biosynthesis in Hepatocellular Carcinoma.
Topics: Animals; Carcinoma, Hepatocellular; Caspase 3; Cell Line, Tumor; Cholesterol; Drug Resistance, Neoplasm; Hedgehog Proteins; Humans; Liver Neoplasms; Mice; Neoplastic Stem Cells; Protein Kinase Inhibitors; Sorafenib; Sterol Regulatory Element Binding Protein 2 | 2022 |
DJ-1/FGFR-1 Signaling Pathway Contributes to Sorafenib Resistance in Hepatocellular Carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Endothelial Cells; Humans; Liver Neoplasms; Signal Transduction; Sorafenib; Tumor Microenvironment | 2022 |
Long-term survival with sorafenib-based multidisciplinary treatment for Vp4 hepatocellular carcinoma: a case report.
Topics: Carcinoma, Hepatocellular; Cisplatin; Fluorouracil; Humans; Interferons; Liver Neoplasms; Male; Portal Vein; Sorafenib; Thrombosis; Venous Thrombosis | 2022 |
Sorafenib plus drug-eluting bead transarterial chemoembolization for early intrahepatic stage-progressed advanced hepatocellular carcinoma refractory to conventional transarterial chemoembolization.
Topics: Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neoplasms; Retrospective Studies; Sorafenib; Treatment Outcome | 2023 |
Ets1 mediates sorafenib resistance by regulating mitochondrial ROS pathway in hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Proto-Oncogene Protein c-ets-1; Reactive Oxygen Species; Sorafenib; Transcription Factors | 2022 |
Imaging Diagnosis of Primary Liver Cancer Using Magnetic Resonance Dilated Weighted Imaging and the Treatment Effect of Sorafenib.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Sorafenib; Treatment Outcome | 2022 |
The Efficacy of Combined Therapy of Regorafenib with Detoxicating and Stasis Softening Chinese Herbal Spleen Tonics in Mid-/Late-Stage Hepatocellular Carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; China; Humans; Liver Neoplasms; Mice; Niacinamide; Phenylurea Compounds; Pyridines; Retrospective Studies; Sorafenib; Spleen; Vascular Endothelial Growth Factor A | 2022 |
Sorafenib as adjuvant therapy following radiofrequency ablation for recurrent hepatocellular carcinoma within Milan criteria: a multicenter analysis.
Topics: Carcinoma, Hepatocellular; Catheter Ablation; Hepatectomy; Humans; Liver Neoplasms; Neoplasm Recurrence, Local; Propensity Score; Radiofrequency Ablation; Retrospective Studies; Sorafenib; Treatment Outcome | 2022 |
A case of hepatocellular carcinoma with long-term survival by multidisciplinary treatment for cranial and skeletal muscle metastases.
Topics: Carcinoma, Hepatocellular; Drugs, Investigational; Fluorodeoxyglucose F18; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Muscle, Skeletal; Skull; Sorafenib; Tegafur | 2022 |
Iron chelator deferasirox inhibits NF-κB activity in hepatoma cells and changes sorafenib-induced programmed cell deaths.
Topics: Apoptosis; Carcinoma, Hepatocellular; Caspase 3; Cell Line; Cell Line, Tumor; Deferasirox; Humans; Iron Chelating Agents; Liver Neoplasms; NF-kappa B; Sorafenib | 2022 |
Anti-inflammatory effect of mesenchymal stem cells on hepatocellular carcinoma in the xenograft mice model.
Topics: Alanine Transaminase; Animals; Anti-Inflammatory Agents; Aspartate Aminotransferases; Carcinoma, Hepatocellular; Disease Models, Animal; Heterografts; Humans; Interleukin-10; Liver Neoplasms; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells; Mice; Mice, Nude; Rodent Diseases; Sorafenib; Tumor Necrosis Factor-alpha | 2022 |
N4BP3 promotes angiogenesis in hepatocellular carcinoma by binding with KAT2B.
Topics: Angiogenesis Inducing Agents; Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Histones; Humans; Liver Neoplasms; Lysine Acetyltransferases; Mice; Mice, Nude; Neovascularization, Pathologic; Oxygen; Sorafenib; STAT3 Transcription Factor | 2022 |
Eupalinolide B inhibits hepatic carcinoma by inducing ferroptosis and ROS-ER-JNK pathway.
Topics: Carcinoma, Hepatocellular; Ferroptosis; Humans; Lactones; Liver Neoplasms; MAP Kinase Signaling System; Reactive Oxygen Species; Sesquiterpenes, Germacrane; Sorafenib | 2022 |
Synergistic antitumor activity of sorafenib and MG149 in hepatocellular carcinoma cells.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Humans; Liver Neoplasms; Sorafenib | 2022 |
Inhibition of lysyl oxidase-like 2 overcomes adhesion-dependent drug resistance in the collagen-enriched liver cancer microenvironment.
Topics: Amino Acid Oxidoreductases; Collagen; Collagen Type I; Drug Resistance; Ecosystem; Fluorouracil; Humans; Integrins; Liver Cirrhosis; Liver Neoplasms; Phosphatidylinositol 3-Kinase; Phosphatidylinositol 3-Kinases; Protein-Lysine 6-Oxidase; Receptor, Serotonin, 5-HT1A; rho-Associated Kinases; Sorafenib; Tumor Microenvironment | 2022 |
Metformin Enhances the Anti-Cancer Efficacy of Sorafenib via Suppressing MAPK/ERK/Stat3 Axis in Hepatocellular Carcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Liver Neoplasms; Metformin; Mice; Niacinamide; Phenylurea Compounds; Sorafenib; Xenograft Model Antitumor Assays | 2022 |
Nutritional status in patients with hepatocellular carcinoma: Potential relevance for clinical outcome.
Topics: alpha-Fetoproteins; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Neoplasm Staging; Nutritional Status; Prospective Studies; Retrospective Studies; Sorafenib; Treatment Outcome | 2022 |
Addition of Y-90 radioembolization increases tumor response and local disease control in hepatocellular carcinoma patients receiving sorafenib.
Topics: Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Phenylurea Compounds; Sorafenib; Yttrium Radioisotopes | 2022 |
Sorafenib suppresses the activation of type I interferon pathway induced by RLR-MAVS and cGAS-STING signaling.
Topics: Carcinoma, Hepatocellular; Humans; Immunity, Innate; Interferon Regulatory Factor-3; Interferon Type I; Liver Neoplasms; Nucleotidyltransferases; Protein Serine-Threonine Kinases; Sorafenib | 2022 |
[Hepatectomy vs. sorafenib in advanced hepatocellular cancer].
Topics: Carcinoma, Hepatocellular; Hepatectomy; Humans; Liver Neoplasms; Phenylurea Compounds; Sorafenib | 2022 |
Anti-tumor immunity and ferroptosis of hepatocellular carcinoma are enhanced by combined therapy of sorafenib and delivering modified GO-based PD-L1 siRNAs.
Topics: Animals; B7-H1 Antigen; Carcinoma, Hepatocellular; Ferroptosis; Graphite; Liver Neoplasms; Mice; Mice, Inbred C57BL; Programmed Cell Death 1 Receptor; RNA, Small Interfering; Sorafenib | 2022 |
Chromenopyrimidinone exhibit antitumor effects through inhibition of CAP1 (Adenylyl cyclase-associated protein 1) expression in hepatocellular carcinoma.
Topics: Adenylyl Cyclases; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Cycle Proteins; Cell Line, Tumor; Cytoskeletal Proteins; Humans; Liver Neoplasms; Neoplastic Stem Cells; Oligopeptides; Pyrimidinones; Sorafenib | 2022 |
ITGA5 and ITGB1 contribute to Sorafenib resistance by promoting vasculogenic mimicry formation in hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Hypoxia; Liver Neoplasms; Sorafenib | 2023 |
KDM5B regulates the PTEN/PI3K/Akt pathway to increase sorafenib-resistance in hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Hep G2 Cells; Humans; Jumonji Domain-Containing Histone Demethylases; Liver Neoplasms; Lysine; Nuclear Proteins; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Repressor Proteins; Sorafenib; Tensins | 2022 |
Iridium Complex-Loaded Sorafenib Nanocomposites for Synergistic Chemo-photodynamic Therapy of Hepatocellular Carcinoma.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Humans; Iridium; Liver Neoplasms; Nanocomposites; Photochemotherapy; Photosensitizing Agents; Sorafenib | 2022 |
Inhibition of LPAR6 overcomes sorafenib resistance by switching glycolysis into oxidative phosphorylation in hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Glycolysis; Humans; Lactic Acid; Liver Neoplasms; Oxidative Phosphorylation; Pyruvic Acid; Receptors, Lysophosphatidic Acid; Sorafenib | 2022 |
Response to PD-1 inhibitor after progression on PD-L1 inhibitor in advanced HCC.
Topics: Bevacizumab; Carcinoma, Hepatocellular; Humans; Immune Checkpoint Inhibitors; Liver Neoplasms; Sorafenib | 2022 |
Lysine demethylase KDM1A promotes cell growth via FKBP8-BCL2 axis in hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Histone Demethylases; Histones; Humans; Liver Neoplasms; Lysine; Proto-Oncogene Proteins c-bcl-2; Sorafenib; Tacrolimus Binding Proteins | 2022 |
Rational drug combination design in patient-derived avatars reveals effective inhibition of hepatocellular carcinoma with proteasome and CDK inhibitors.
Topics: Animals; Antineoplastic Agents; Bortezomib; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Combinations; Humans; Liver Neoplasms; Mice; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Kinase Inhibitors; Sorafenib; Xenograft Model Antitumor Assays | 2022 |
Alpha7 nicotinic acetylcholine receptor expression in Sorafenib-resistant Hepatocellular carcinoma cells.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; RNA, Small Interfering; Sorafenib | 2022 |
Regulation of the sensitivity of hepatocarcinoma cells by ORMDL3, to sorafenib by autophagy.
Topics: Animals; Apoptosis; Autophagy; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Membrane Proteins; Mice; Mice, Nude; Sorafenib; Tumor Microenvironment | 2022 |
S-palmitoylation of PCSK9 induces sorafenib resistance in liver cancer by activating the PI3K/AKT pathway.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Cysteine; Drug Resistance, Neoplasm; Hep G2 Cells; Humans; Lipoylation; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Proprotein Convertase 9; Proto-Oncogene Proteins c-akt; Sorafenib | 2022 |
FXYD5 promotes sorafenib resistance through the Akt/mTOR signaling pathway in hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Ion Channels; Liver Neoplasms; Microfilament Proteins; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-akt; Signal Transduction; Sorafenib; TOR Serine-Threonine Kinases | 2022 |
Sorafenib combined with STAT3 knockdown triggers ER stress-induced HCC apoptosis and cGAS-STING-mediated anti-tumor immunity.
Topics: Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Endoplasmic Reticulum Stress; Humans; Liver Neoplasms; Nucleotidyltransferases; Sorafenib; STAT3 Transcription Factor; Tumor Microenvironment | 2022 |
MYBL1 induces transcriptional activation of ANGPT2 to promote tumor angiogenesis and confer sorafenib resistance in human hepatocellular carcinoma.
Topics: Adaptor Proteins, Signal Transducing; Angiopoietin-2; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Intracellular Signaling Peptides and Proteins; Liver Neoplasms; Neovascularization, Pathologic; Protein-Arginine N-Methyltransferases; Proto-Oncogene Proteins; Sorafenib; Trans-Activators; Transcriptional Activation | 2022 |
Hepatic arterial infusion chemotherapy and sequential ablation treatment in large hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Sorafenib; Treatment Outcome | 2022 |
Outcomes of Sorafenib for Recurrent Hepatocellular Carcinoma After Liver Transplantation in the Era of Combined and Sequential Treatments.
Topics: Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Liver Transplantation; Neoplasm Recurrence, Local; Prospective Studies; Retrospective Studies; Sorafenib | 2023 |
High-glucose-induced hyperosmolar stress sensitizes HepG2 cell lines to sorafenib.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line; Cell Line, Tumor; Cell Proliferation; Glucose; Hep G2 Cells; Humans; Liver Neoplasms; Mannitol; RNA, Long Noncoding; Sorafenib | 2022 |
CRNDE acts as an epigenetic modulator of the p300/YY1 complex to promote HCC progression and therapeutic resistance.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Chromatin; Colorectal Neoplasms; DNA Methylation; Drug Resistance, Neoplasm; Epigenesis, Genetic; ErbB Receptors; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Mice; Mice, Nude; RNA, Long Noncoding; Sorafenib; YY1 Transcription Factor | 2022 |
N-acetyl-galactosamine modified metal-organic frameworks to inhibit the growth and pulmonary metastasis of liver cancer stem cells through targeted chemotherapy and starvation therapy.
Topics: Animals; Asialoglycoproteins; Carcinoma, Hepatocellular; Cell Line, Tumor; Galactosamine; Glucose; Glucose Oxidase; Liver Neoplasms; Lung Neoplasms; Metal-Organic Frameworks; Mice; Neoplastic Stem Cells; Sorafenib | 2022 |
miR-23b-3p Modulating Cytoprotective Autophagy and Glutamine Addiction in Sorafenib Resistant HepG2, a Hepatocellular Carcinoma Cell Line.
Topics: Autophagy; Carcinoma, Hepatocellular; Cell Line; Chloroquine; Gene Expression Regulation, Neoplastic; Glutamine; Humans; Liver Neoplasms; MicroRNAs; Sorafenib | 2022 |
DN200434, an orally available inverse agonist of estrogen-related receptor γ, induces ferroptosis in sorafenib-resistant hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Estrogens; Ferroptosis; Humans; Liver Neoplasms; Sorafenib | 2022 |
ABI2-mediated MEOX2/KLF4-NANOG axis promotes liver cancer stem cell and drives tumour recurrence.
Topics: Adaptor Proteins, Signal Transducing; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Transformation, Neoplastic; Homeodomain Proteins; Humans; Kruppel-Like Factor 4; Liver Neoplasms; Nanog Homeobox Protein; Neoplasm Recurrence, Local; Neoplastic Stem Cells; Sorafenib; Transcription Factors | 2022 |
Fucoidan inhibits EGFR redistribution and potentiates sorafenib to overcome sorafenib-resistant hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Liver Neoplasms; Mice; Mice, Nude; Phenylurea Compounds; Polysaccharides; Receptors, Growth Factor; Sorafenib; Xenograft Model Antitumor Assays | 2022 |
IGF2BP3-NRF2 axis regulates ferroptosis in hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Ferroptosis; Humans; Liver Neoplasms; NF-E2-Related Factor 2; RNA-Binding Proteins; RNA, Messenger; Sorafenib | 2022 |
Heterogeneity, inherent and acquired drug resistance in patient-derived organoid models of primary liver cancer.
Topics: alpha-Fetoproteins; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Resistance; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Organoids; Ribosomal Protein S6 Kinases; Sorafenib; TOR Serine-Threonine Kinases | 2022 |
Sorafenib suppresses radioresistance and synergizes radiotherapy-mediated CD8
Topics: B7-H1 Antigen; Carcinoma, Hepatocellular; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Cytokines; Granzymes; Humans; Interferon Type I; Interleukin-2; Interleukin-6; Liver Neoplasms; Myeloid Cell Leukemia Sequence 1 Protein; Perforin; Sorafenib | 2022 |
[Sorafenib regulates vascular endothelial growth factor by runt-related transcription factor-3 to inhibit angiogenesis in hepatocellular carcinoma].
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Core Binding Factor Alpha 3 Subunit; Humans; Liver Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Sorafenib; Vascular Endothelial Growth Factor A | 2022 |
Expanding Sorafenib Treatment for Hepatocellular Carcinoma Beyond Barcelona Clinic Liver Cancer Stage C Patients: A National Study.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Treatment Outcome | 2022 |
Small-molecule High-throughput Screening Identifies an MEK Inhibitor PD198306 that Enhances Sorafenib Efficacy via MCL-1 and BIM in Hepatocellular Carcinoma Cells.
Topics: Antineoplastic Agents; Apoptosis; Bcl-2-Like Protein 11; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; High-Throughput Screening Assays; Humans; Liver Neoplasms; Mitogen-Activated Protein Kinase Kinases; Myeloid Cell Leukemia Sequence 1 Protein; Protein Kinase Inhibitors; Sorafenib | 2023 |
Hepatectomy versus sorafenib for advanced hepatocellular carcinoma with macroscopic portal vein tumor thrombus: A bi-institutional propensity-matched cohort study.
Topics: Carcinoma, Hepatocellular; Cohort Studies; Hepatectomy; Humans; Liver Neoplasms; Portal Vein; Retrospective Studies; Sorafenib; Thrombosis; Treatment Outcome; Venous Thrombosis | 2023 |
Loss of GABARAPL1 confers ferroptosis resistance to cancer stem-like cells in hepatocellular carcinoma.
Topics: Adaptor Proteins, Signal Transducing; Carcinoma, Hepatocellular; Cell Death; Ferroptosis; Humans; Liver Neoplasms; Microtubule-Associated Proteins; Sorafenib | 2022 |
Overexpression of nucleotide metabolic enzyme DUT in hepatocellular carcinoma potentiates a therapeutic opportunity through targeting its dUTPase activity.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Humans; Liver Neoplasms; NF-kappa B; Nucleotides; Pyrophosphatases; Sorafenib; Uracil | 2022 |
Advantage of clinical colchicine concentration to promote sorafenib or regorafenib anti-cancer effects on hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Colchicine; Humans; Liver Neoplasms; Phenylurea Compounds; Pyridines; Sorafenib | 2022 |
miR-200c-3p, miR-222-5p, and miR-512-3p Constitute a Biomarker Signature of Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma.
Topics: Biomarkers; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; MicroRNAs; Sorafenib | 2022 |
Pharmacokinetic Interactions between Canagliflozin and Sorafenib or Lenvatinib in Rats.
Topics: Animals; Canagliflozin; Carcinoma, Hepatocellular; Diabetes Mellitus, Type 2; Drug Interactions; Liver Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolines; Rats; Sodium-Glucose Transporter 2 Inhibitors; Sorafenib | 2022 |
Treatment outcomes of advanced hepatocellular carcinoma in real-life practice: Chemotherapy versus multikinase inhibitors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Retrospective Studies; Sorafenib; Treatment Outcome | 2023 |
Therapeutic efficacy of nivolumab plus sorafenib therapy in patients with unresectable hepatocellular carcinoma.
Topics: alpha-Fetoproteins; Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Immune Checkpoint Inhibitors; Liver Neoplasms; Niacinamide; Nivolumab; Phenylurea Compounds; Sorafenib | 2022 |
LncRNA AC026401.3 interacts with OCT1 to intensify sorafenib and lenvatinib resistance by activating E2F2 signaling in hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; E2F2 Transcription Factor; Humans; Liver Neoplasms; Neoplasm Recurrence, Local; Octamer Transcription Factor-1; Phenylurea Compounds; Quinolines; RNA, Long Noncoding; Sorafenib; Transcription Factors | 2022 |
CPLX2 Regulates Ferroptosis and Apoptosis Through NRF2 Pathway in Human Hepatocellular Carcinoma Cells.
Topics: Adaptor Proteins, Vesicular Transport; Apoptosis; Carcinoma, Hepatocellular; Ferroptosis; Humans; Iron; Liver Neoplasms; NF-E2-Related Factor 2; Reactive Oxygen Species; Sorafenib | 2023 |
Sorafenib triggers ferroptosis via inhibition of HBXIP/SCD axis in hepatocellular carcinoma.
Topics: Adaptor Proteins, Signal Transducing; Carcinoma, Hepatocellular; Ferroptosis; Humans; Liver Neoplasms; Sorafenib; Stearoyl-CoA Desaturase | 2023 |
Case report: Primary hepatocellular carcinoma with portal vein tumor thrombus characterized by active tumor immune microenvironment achieving a complete response following treatment of combined immunotherapy.
Topics: Carcinoma, Hepatocellular; Humans; Immunotherapy; Liver Neoplasms; Middle Aged; Portal Vein; Sorafenib; Thrombosis; Tumor Microenvironment | 2022 |
A Photoactivated Sorafenib-Ruthenium(II) Prodrug for Resistant Hepatocellular Carcinoma Therapy through Ferroptosis and Purine Metabolism Disruption.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Ferroptosis; Hep G2 Cells; Humans; Lipid Peroxides; Liver Neoplasms; Prodrugs; Purines; Reactive Oxygen Species; Ruthenium; Sorafenib | 2022 |
PROZ Associated with Sorafenib Sensitivity May Serve as a Potential Target to Enhance the Efficacy of Combined Immunotherapy for Hepatocellular Carcinoma.
Topics: Carcinoma, Hepatocellular; Humans; Immunotherapy; Liver Neoplasms; Prognosis; Sorafenib | 2022 |
Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study.
Topics: Albumins; alpha-Fetoproteins; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Bilirubin; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Sorafenib; Venous Thrombosis | 2022 |
Targeting Tumor Microenvironment in Liver Cancers: Rationale, Current Progress, and Future Perspective.
Topics: Angiogenesis Inhibitors; B7-H1 Antigen; Carcinoma, Hepatocellular; Clinical Trials, Phase III as Topic; Humans; Liver Neoplasms; Randomized Controlled Trials as Topic; Sorafenib; Tumor Microenvironment | 2022 |
Reduction of Hepatopulmonary and Intrahepatic Shunts after Treatment with Sorafenib in Hepatocellular Carcinoma Patients.
Topics: Carcinoma, Hepatocellular; Embolization, Therapeutic; Humans; Liver Neoplasms; Retrospective Studies; Sorafenib; Treatment Outcome; Yttrium Radioisotopes | 2022 |
The natural medicinal fungus Huaier promotes the anti-hepatoma efficacy of sorafenib through the mammalian target of rapamycin-mediated autophagic cell death.
Topics: Animals; Autophagic Cell Death; Beclin-1; Carcinoma, Hepatocellular; Complex Mixtures; Fungi; Humans; Liver Neoplasms; Mammals; Mice; Ribosomal Protein S6 Kinases, 70-kDa; Sincalide; Sirolimus; Sorafenib; TOR Serine-Threonine Kinases; Trametes | 2022 |
Synergistic anticancer effect of flavonoids from Sophora alopecuroides with Sorafenib against hepatocellular carcinoma.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Flavonoids; Humans; Liver Neoplasms; Phenylurea Compounds; Sophora; Sorafenib | 2023 |
α-Fetoprotein fragment synergizes with sorafenib to inhibit hepatoma cell growth and migration and promote the apoptosis.
Topics: alpha-Fetoproteins; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Humans; Liver Neoplasms; Sorafenib | 2022 |
Ramucirumab for Patients with Advanced Hepatocellular Carcinoma and Elevated Alpha Fetoprotein Following Non-Sorafenib Systemic Therapy: An Expansion Cohort of REACH-2.
Topics: alpha-Fetoproteins; Carcinoma, Hepatocellular; Europe; Humans; Liver Neoplasms; Sorafenib | 2022 |
Role of Trans-Arterial Chemoembolization (TACE) in patients with hepatocellular carcinoma.
Topics: Adult; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neoplasms; Sorafenib; Thrombosis; Treatment Outcome | 2022 |
Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis.
Topics: Bevacizumab; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Non-alcoholic Fatty Liver Disease; Propensity Score; Retrospective Studies; Sorafenib | 2022 |
Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma progressing after molecular targeted therapy: A multicenter prospective observational study.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Molecular Targeted Therapy; Phenylurea Compounds; Quinolines; Sorafenib | 2022 |
Needle tract seeding following percutaneous irreversible electroporation for hepatocellular carcinoma.
Topics: Ablation Techniques; Carcinoma, Hepatocellular; Electroporation; Humans; Liver Neoplasms; Male; Sorafenib | 2022 |
SHP-1/STAT3-Signaling-Axis-Regulated Coupling between BECN1 and SLC7A11 Contributes to Sorafenib-Induced Ferroptosis in Hepatocellular Carcinoma.
Topics: Amino Acid Transport System y+; Antiporters; Apoptosis; Beclin-1; Carcinoma, Hepatocellular; Cell Line, Tumor; Cystine; Ferroptosis; Glutamates; Humans; Iron; Liver Neoplasms; Myeloid Cell Leukemia Sequence 1 Protein; Protein Tyrosine Phosphatase, Non-Receptor Type 6; RNA, Small Interfering; Sorafenib; STAT3 Transcription Factor | 2022 |
Multi-Omics Analysis Revealed a Significant Alteration of Critical Metabolic Pathways Due to Sorafenib-Resistance in Hep3B Cell Lines.
Topics: Alanine; Amino Acids; Antineoplastic Agents; Biomarkers; Calpain; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Folic Acid Antagonists; Glucose; Humans; L-Iditol 2-Dehydrogenase; Liver Neoplasms; Metabolic Networks and Pathways; Nucleotides; Phosphatidylcholines; Proline; Protein Kinase Inhibitors; Proteome; Proteomics; Sorafenib; Succinic Acid; Superoxide Dismutase; Tyrosine; Ubiquitin Thiolesterase; Uridine Diphosphate | 2022 |
Development of UPLC-MS/MS Method to Study the Pharmacokinetic Interaction between Sorafenib and Dapagliflozin in Rats.
Topics: Acetonitriles; Animals; Benzhydryl Compounds; Carcinoma, Hepatocellular; Chromatography, High Pressure Liquid; Chromatography, Liquid; Diabetes Mellitus, Type 2; Glucose; Glucosides; Glucuronosyltransferase; Liver Neoplasms; Rats; Reproducibility of Results; RNA, Messenger; Sodium; Sodium-Glucose Transporter 2 Inhibitors; Sorafenib; Tandem Mass Spectrometry; Uridine Diphosphate | 2022 |
HDLBP Promotes Hepatocellular Carcinoma Proliferation and Sorafenib Resistance by Suppressing Trim71-dependent RAF1 Degradation.
Topics: Biomarkers; Carcinoma, Hepatocellular; Cell Proliferation; Humans; Liver Neoplasms; Proto-Oncogene Proteins c-raf; RNA-Binding Proteins; Sorafenib; Tripartite Motif Proteins; Ubiquitin-Protein Ligases | 2023 |
Lenvatinib Synergistically Promotes Radiation Therapy in Hepatocellular Carcinoma by Inhibiting Src/STAT3/NF-κB-Mediated Epithelial-Mesenchymal Transition and Metastasis.
Topics: Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Epithelial-Mesenchymal Transition; Liver Neoplasms; Negotiating; NF-kappa B; Sorafenib; STAT3 Transcription Factor | 2023 |
Revisiting Antiangiogenic Multikinase Inhibitors in the Era of Immune Checkpoint Blockade: The Case of Sorafenib.
Topics: Angiogenesis Inhibitors; Endothelial Cells; Humans; Immune Checkpoint Inhibitors; Immunotherapy; Liver Neoplasms; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase Kinases; Neovascularization, Pathologic; Receptor Protein-Tyrosine Kinases; Sorafenib; Tyrosine | 2022 |
A history of variceal bleeding is associated with further bleeding under atezolizumab-bevacizumab in patients with HCC.
Topics: Bevacizumab; Carcinoma, Hepatocellular; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Prospective Studies; Retrospective Studies; Sorafenib | 2022 |
SNS-023 sensitizes hepatocellular carcinoma to sorafenib by inducing degradation of cancer drivers SIX1 and RPS16.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Gefitinib; Homeodomain Proteins; Humans; Liver Neoplasms; Proto-Oncogene Proteins c-akt; Ribosomal Proteins; Sorafenib | 2023 |
Ovatodiolide and antrocin synergistically inhibit the stemness and metastatic potential of hepatocellular carcinoma via impairing ribosome biogenesis and modulating ERK/Akt-mTOR signaling axis.
Topics: Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Diterpenes; Humans; Lactones; Liver Neoplasms; Mice; Neoplastic Stem Cells; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Ribosomes; Sesquiterpenes; Sorafenib; TOR Serine-Threonine Kinases | 2023 |
Serum hsa_circ_0000615 is a prognostic biomarker of sorafenib resistance in hepatocellular carcinoma.
Topics: Biomarkers, Tumor; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Prognosis; RNA, Circular; Sorafenib | 2022 |
Targeting DNA repair to enhance the efficacy of sorafenib in hepatocellular carcinoma.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; DNA Repair; Humans; Liver Neoplasms; Sorafenib | 2022 |
Identification of copper metabolism and cuproptosis-related subtypes for predicting prognosis tumor microenvironment and drug candidates in hepatocellular carcinoma.
Topics: Apoptosis; Carcinoma, Hepatocellular; Copper; CTLA-4 Antigen; DNA Copy Number Variations; Humans; Imatinib Mesylate; Liver Neoplasms; Methotrexate; Prognosis; Sorafenib; Tumor Microenvironment | 2022 |
Identification of an Oxidative Stress-Related LncRNA Signature for Predicting Prognosis and Chemotherapy in Patients With Hepatocellular Carcinoma.
Topics: Biomarkers, Tumor; Carcinoma, Hepatocellular; Dasatinib; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Liver Neoplasms; Oxidative Stress; Prognosis; RNA, Long Noncoding; Sorafenib | 2022 |
Ramucirumab combination with sorafenib enhances the inhibitory effect of sorafenib on HepG2 cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Bevacizumab; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Hep G2 Cells; Humans; Liver Neoplasms; Matrix Metalloproteinase 9; Niacinamide; Panitumumab; Phenylurea Compounds; Ramucirumab; Sorafenib | 2022 |
Study of siRNA Delivery via Polymeric Nanoparticles in Combination with Angiogenesis Inhibitor for The Treatment of
Topics: alpha-Fetoproteins; Angiogenesis Inhibitors; Carcinoma, Hepatocellular; Cell Line, Tumor; Humans; Liver Neoplasms; Nanoparticles; Polymers; RNA, Messenger; RNA, Small Interfering; Sorafenib; Sunitinib | 2022 |
[Advances in targeted and immune therapies for hepatocellular carcinoma].
Topics: Bevacizumab; Biosimilar Pharmaceuticals; Carcinoma, Hepatocellular; Humans; Immune Checkpoint Inhibitors; Liver Neoplasms; Sorafenib | 2022 |
LPCAT1 acts as an independent prognostic biomarker correlated with immune infiltration in hepatocellular carcinoma.
Topics: 1-Acylglycerophosphocholine O-Acyltransferase; Biomarkers; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Prognosis; Sorafenib; Tumor Microenvironment | 2022 |
DDX24 regulates the chemosensitivity of hepatocellular carcinoma to sorafenib via mediating the expression of SNORA18.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; DEAD-box RNA Helicases; Humans; Liver Neoplasms; Sorafenib | 2022 |
Factors Contributing to the Prognosis after Second-line Therapy with Ramucirumab in Advanced Hepatocellular Carcinoma.
Topics: alpha-Fetoproteins; Bilirubin; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Prognosis; Ramucirumab; Retrospective Studies; Sorafenib | 2022 |
Downregulation of MCF2L Promoted the Ferroptosis of Hepatocellular Carcinoma Cells through PI3K/mTOR Pathway in a RhoA/Rac1 Dependent Manner.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Down-Regulation; Ferroptosis; Iron; Liver Neoplasms; Phosphatidylinositol 3-Kinases; Reactive Oxygen Species; Sorafenib; TOR Serine-Threonine Kinases | 2022 |
Sorafenib-Entrapped, Self-Assembled Pullulan-Stearic Acid Biopolymer-Derived Drug Delivery System to PLC/PRF/5 Hepatocellular Carcinoma Model.
Topics: Animals; Antineoplastic Agents; Asialoglycoprotein Receptor; Carcinoma, Hepatocellular; Drug Carriers; Drug Delivery Systems; Glucans; Liver Neoplasms; Mice; Nanoparticles; Sorafenib; Tissue Distribution | 2022 |
Thioredoxin-interacting protein-activated intracellular potassium deprivation mediates the anti-tumour effect of a novel histone acetylation inhibitor HL23, a fangchinoline derivative, in human hepatocellular carcinoma.
Topics: Acetylation; Animals; Carcinoma, Hepatocellular; Histone Deacetylases; Histones; Humans; Liver Neoplasms; Mice; Sorafenib; Thioredoxins; Vorinostat | 2023 |
A radiomics-based model can predict recurrence-free survival of hepatocellular carcinoma after curative ablation.
Topics: Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Neoplasm Recurrence, Local; Retrospective Studies; Sorafenib | 2023 |
Application and Impact of Antiviral Therapy for Patients with HBV-Related Hepatocellular Carcinoma Receiving Sorafenib and Lenvatinib Treatment.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Hepatitis B virus; Humans; Liver Neoplasms; Retrospective Studies; Sorafenib | 2022 |
Transcriptional regulation of NDUFA4L2 by NFIB induces sorafenib resistance by decreasing reactive oxygen species in hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; NFI Transcription Factors; Reactive Oxygen Species; Sorafenib | 2023 |
Pentraxin 3 regulates tyrosine kinase inhibitor-associated cardiomyocyte contraction and mitochondrial dysfunction via ERK/JNK signalling pathways.
Topics: Animals; C-Reactive Protein; Carcinoma, Hepatocellular; Cardiotoxicity; Female; Humans; Liver Neoplasms; Male; Mitochondria; Protein Kinase Inhibitors; Sorafenib; Tyrosine Kinase Inhibitors | 2023 |
Simultaneous treatment with sorafenib and glucose restriction inhibits hepatocellular carcinoma in vitro and in vivo by impairing SIAH1-mediated mitophagy.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Glucose; Humans; Liver Neoplasms; Mitophagy; Niacinamide; Sorafenib | 2022 |
Differential in vitro effects of targeted therapeutics in primary human liver cancer: importance for combined liver cancer.
Topics: Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Carcinoma, Hepatocellular; Cholangiocarcinoma; Dasatinib; Hepatoblastoma; Humans; Liver Neoplasms; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Sirolimus; Sorafenib | 2022 |
ASO Author Reflections: The Barcelona Clinic Liver Cancer Criteria and Child-Pugh Classification Determine Short-Term Outcomes in Hepatocellular Carcinoma.
Topics: Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Prognosis; Sorafenib | 2023 |
Tumor-associated macrophages promote resistance of hepatocellular carcinoma cells against sorafenib by activating CXCR2 signaling.
Topics: Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Receptors, Interleukin-8B; Sorafenib; Tumor-Associated Macrophages | 2022 |
The effects of sorafenib in healthy and cisplatin-treated rats.
Topics: Animals; Antioxidants; Cisplatin; Kidney; Liver Neoplasms; Oxidative Stress; Rats; Sorafenib | 2023 |
KIAA1429 mediates epithelial mesenchymal transition in sorafenib-resistant hepatocellular carcinoma through m6A methylation modification.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Epithelial-Mesenchymal Transition; Humans; Liver Neoplasms; Methylation; Sorafenib | 2023 |
Deoxyelephantopin, a germacrane-type sesquiterpene lactone from Elephantopus scaber, induces mitochondrial apoptosis of hepatocarcinoma cells by targeting Hsp90α in vitro and in vivo.
Topics: Apoptosis; Asteraceae; Carcinoma, Hepatocellular; Cell Line, Tumor; Humans; Lactones; Liver Neoplasms; Mitochondria; Molecular Docking Simulation; Sesquiterpenes; Sesquiterpenes, Germacrane; Sorafenib | 2023 |
Extracellular vesicles derived from cancer-associated fibroblasts carry tumor-promotive microRNA-1228-3p to enhance the resistance of hepatocellular carcinoma cells to sorafenib.
Topics: Cancer-Associated Fibroblasts; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Extracellular Vesicles; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; MicroRNAs; Phosphatidylinositol 3-Kinases; Proteins; Proto-Oncogene Proteins c-akt; Sorafenib | 2023 |
HMGCS2 Mediation of Ketone Levels Affects Sorafenib Treatment Efficacy in Liver Cancer Cells.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Extracellular Signal-Regulated MAP Kinases; Humans; Hydroxymethylglutaryl-CoA Synthase; Ketone Bodies; Ketones; Liver Neoplasms; Male; Sorafenib; Treatment Outcome | 2022 |
Effects of Sorafenib and Quercetin Alone or in Combination in Treating Hepatocellular Carcinoma: In Vitro and In Vivo Approaches.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Humans; Liver Neoplasms; Quercetin; Sorafenib; Xenograft Model Antitumor Assays | 2022 |
Neo-Adjuvant Use of Sorafenib for Hepatocellular Carcinoma Awaiting Liver Transplantation.
Topics: Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Liver Transplantation; Neoadjuvant Therapy; Sorafenib | 2022 |
Treatment options for unresectable hepatocellular carcinoma with hepatitis virus infection following sorafenib failure.
Topics: Carcinoma, Hepatocellular; Female; Hepatitis Viruses; Humans; Immune Checkpoint Inhibitors; Liver Neoplasms; Male; Middle Aged; Sorafenib | 2023 |
Circular RNA ITCH increases sorafenib-sensitivity in hepatocellular carcinoma via sequestering miR-20b-5p and modulating the downstream PTEN-PI3K/Akt pathway.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; MicroRNAs; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; RNA, Circular; Sorafenib | 2023 |
Sorafenib inhibits interferon production by plasmacytoid dendritic cells in hepatocellular carcinoma.
Topics: Antibodies; Carcinoma, Hepatocellular; Dendritic Cells; Humans; Interferon-alpha; Liver Neoplasms; Sorafenib; Tumor Microenvironment | 2022 |
Prospective Observational Study of Sorafenib in Hepatocellular Carcinoma Patients With Very High Risk of Recurrence After Surgery.
Topics: Carcinoma, Hepatocellular; Disease Progression; Humans; Liver Neoplasms; Prospective Studies; Sorafenib | 2022 |
Aptamer-mediated hollow MnO
Topics: Animals; Carcinoma, Hepatocellular; Glypicans; Humans; Liver Neoplasms; Manganese Compounds; Mice; Oligonucleotides; Oxides; Sorafenib; Tumor Microenvironment | 2023 |
Construction and validation of an angiogenesis-related scoring model to predict prognosis, tumor immune microenvironment and therapeutic response in hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Prognosis; Sorafenib; Tumor Microenvironment | 2022 |
Copper transporter gene ATP7A: A predictive biomarker for immunotherapy and targeted therapy in hepatocellular carcinoma.
Topics: B7-H1 Antigen; Biomarkers, Tumor; Carcinoma, Hepatocellular; Copper Transport Proteins; Copper-Transporting ATPases; Humans; Immunotherapy; Liver Neoplasms; Peptide Fragments; Sorafenib | 2023 |
Cellular Genome-Scale Metabolic Modeling Identifies New Potential Drug Targets Against Hepatocellular Carcinoma.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Hep G2 Cells; Humans; Liver Neoplasms; Sorafenib; Sterols | 2022 |
Crithmum maritimum Improves Sorafenib Sensitivity by Decreasing Lactic Acid Fermentation and Inducing a Pro-Hepatocyte Marker Profile in Hepatocellular Carcinoma.
Topics: Apiaceae; Carcinoma, Hepatocellular; Fermentation; Hepatocytes; Liver Neoplasms; Sorafenib | 2023 |
Effect of Novel AKT Inhibitor Vevorisertib as Single Agent and in Combination with Sorafenib on Hepatocellular Carcinoma in a Cirrhotic Rat Model.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Liver Cirrhosis; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Rats; Sorafenib | 2022 |
Therapeutic targeting of hepatocellular carcinoma cells with antrocinol, a novel, dual-specificity, small-molecule inhibitor of the KRAS and ERK oncogenic signaling pathways.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Liver Neoplasms; MAP Kinase Signaling System; Mice; Niacinamide; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins p21(ras); Signal Transduction; Sorafenib | 2023 |
A bile acid-related prognostic signature in hepatocellular carcinoma.
Topics: Bile Acids and Salts; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Prognosis; Sorafenib | 2022 |
Sorafenib versus nivolumab after lenvatinib treatment failure in patients with advanced hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Middle Aged; Nivolumab; Phenylurea Compounds; Sorafenib; Treatment Failure | 2023 |
Machine Learning Predictive Model to Guide Treatment Allocation for Recurrent Hepatocellular Carcinoma After Surgery.
Topics: Aged; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Female; Hepatectomy; Humans; Liver Neoplasms; Male; Neoplasm Recurrence, Local; Retrospective Studies; Sorafenib | 2023 |
Bacterial metabolite butyrate in modulating sorafenib-targeted microRNAs to curtail its resistance in hepatocellular carcinoma.
Topics: Antineoplastic Agents; Bacteria; Butyric Acid; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; MicroRNAs; RNA, Ribosomal, 16S; Sorafenib | 2023 |
Hsa_circ_0006988 Promotes Sorafenib Resistance of Hepatocellular Carcinoma by Modulating IGF1 Using miR-15a-5p.
Topics: Carcinoma, Hepatocellular; Humans; Insulin-Like Growth Factor I; Liver Neoplasms; MicroRNAs; RNA, Circular; Sorafenib | 2022 |
Identification and functional characterization of potential oncofetal targets in human hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Cell Line; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Sorafenib | 2022 |
Risk Factors for Hepatic Encephalopathy in Hepatocellular Carcinoma After Sorafenib or Lenvatinib Treatment: A Real-World Study.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Hepatic Encephalopathy; Humans; Liver Cirrhosis; Liver Cirrhosis, Alcoholic; Liver Neoplasms; Phenylurea Compounds; Quinolines; Retrospective Studies; Risk Factors; Sorafenib | 2022 |
Targeting fatty acid synthase modulates sensitivity of hepatocellular carcinoma to sorafenib via ferroptosis.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Fatty Acid Synthases; Ferroptosis; Humans; Liver Neoplasms; Orlistat; Sorafenib | 2023 |
Cuproptosis regulatory genes greatly contribute to clinical assessments of hepatocellular carcinoma.
Topics: Apoptosis; Carcinoma, Hepatocellular; Copper; Genes, Regulator; Humans; Liver Neoplasms; Risk Factors; Sorafenib; Tumor Microenvironment | 2023 |
SMYD2 Promotes Hepatocellular Carcinoma Progression by Reprogramming Glutamine Metabolism via c-Myc/GLS1 Axis.
Topics: Carcinoma, Hepatocellular; Glutamine; Histone-Lysine N-Methyltransferase; Humans; Liver Neoplasms; Sorafenib | 2022 |
Synergistic effects of concurrent photodynamic therapy with indocyanine green and chemotherapy in hepatocellular carcinoma cell lines and mouse models.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Disease Models, Animal; Doxorubicin; Humans; Indocyanine Green; Liver Neoplasms; Mice; Photochemotherapy; Photosensitizing Agents; Sorafenib | 2023 |
A case of multiple hepatocellular carcinoma experiencing complete responses to sorafenib and atezolizumab-bevacizumab and developing severe, refractory venous congestive cutaneous ulcers on either regimen.
Topics: Angiogenesis Inhibitors; Bevacizumab; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Male; Sorafenib; Ulcer; Varicose Ulcer; Vascular Endothelial Growth Factor A | 2023 |
SLC27A5 promotes sorafenib-induced ferroptosis in hepatocellular carcinoma by downregulating glutathione reductase.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Fatty Acid Transport Proteins; Ferroptosis; Glutathione Reductase; Humans; Liver Neoplasms; NF-E2-Related Factor 2; Sorafenib | 2023 |
Inhibition of CEMIP potentiates the effect of sorafenib on metastatic hepatocellular carcinoma by reducing the stiffness of lung metastases.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Humans; Hyaluronoglucosaminidase; Liver Neoplasms; Lung Neoplasms; Signal Transduction; Sorafenib; Tumor Microenvironment | 2023 |
Cost-utility analysis of atezolizumab with bevacizumab in untreated unresectable or advanced hepatocellular carcinoma in France.
Topics: Adult; Bevacizumab; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Humans; Liver Neoplasms; Quality of Life; Quality-Adjusted Life Years; Retrospective Studies; Sorafenib | 2023 |
Amphiphilic Dendrimer Doping Enhanced pH-Sensitivity of Liposomal Vesicle for Effective Co-delivery toward Synergistic Ferroptosis-Apoptosis Therapy of Hepatocellular Carcinoma.
Topics: Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Dendrimers; Ferroptosis; Hemin; Humans; Hydrogen-Ion Concentration; Liposomes; Liver Neoplasms; Polymers; Sorafenib; Tumor Microenvironment | 2023 |
Tiliroside targets TBK1 to induce ferroptosis and sensitize hepatocellular carcinoma to sorafenib.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Ferroptosis; Flavonoids; Humans; Kelch-Like ECH-Associated Protein 1; Liver Neoplasms; Mice; Mice, Nude; Molecular Docking Simulation; NF-E2-Related Factor 2; Protein Serine-Threonine Kinases; Sorafenib | 2023 |
The PTBP1‑NCOA4 axis promotes ferroptosis in liver cancer cells.
Topics: Animals; Autophagy; Ferroptosis; Heterogeneous-Nuclear Ribonucleoproteins; Humans; Iron; Liver Neoplasms; Nuclear Receptor Coactivators; Polypyrimidine Tract-Binding Protein; RNA; RNA, Messenger; Sorafenib; Transcription Factors | 2023 |
Identification of Potential Predictors of Prognosis and Sorafenib-Associated Survival Benefits in Patients with Hepatocellular Carcinoma after Transcatheter Arterial Chemoembolization.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Retrospective Studies; Sorafenib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2022 |
A Single Nucleotide Polymorphism rs1010816 Predicts Sorafenib Therapeutic Outcomes in Advanced Hepatocellular Carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Genome-Wide Association Study; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Polymorphism, Single Nucleotide; Retrospective Studies; Sorafenib; Treatment Outcome | 2023 |
Difficulties for providing evidence in hepatocellular carcinoma with Child-Pugh B liver function.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Retrospective Studies; Sorafenib | 2023 |
TEA Domain Transcription Factor 1 Inhibits Ferroptosis and Sorafenib Sensitivity of Hepatocellular Carcinoma Cells.
Topics: 3,4-Methylenedioxyamphetamine; Carcinoma, Hepatocellular; Ferroptosis; Humans; Liver Neoplasms; Reactive Oxygen Species; Sorafenib; TEA Domain Transcription Factors | 2023 |
A novel polypeptide encoded by the circular RNA ZKSCAN1 suppresses HCC via degradation of mTOR.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Mammals; Mice; Mice, Nude; MicroRNAs; Peptides; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; RNA, Circular; Sirolimus; Sorafenib; TOR Serine-Threonine Kinases | 2023 |
EGFR and Lyn inhibition augments regorafenib induced cell death in sorafenib resistant 3D tumor spheroid model.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Death; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Liver Neoplasms; Sorafenib; Tumor Microenvironment | 2023 |
Lenvatinib
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Hepatocytes; Humans; Liver Neoplasms; Phenylurea Compounds; Retrospective Studies; Sorafenib; Treatment Outcome | 2023 |
IGF-1R down regulates the sensitivity of hepatocellular carcinoma to sorafenib through the PI3K / akt and RAS / raf / ERK signaling pathways.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Humans; Liver Neoplasms; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Receptor, IGF Type 1; Signal Transduction; Sorafenib | 2023 |
TPX2 enhances the transcription factor activation of PXR and enhances the resistance of hepatocellular carcinoma cells to antitumor drugs.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Cycle Proteins; Cytochrome P-450 CYP3A; Humans; Liver Neoplasms; Microtubule-Associated Proteins; Pregnane X Receptor; Sorafenib; Transcription Factors | 2023 |
Overweight/obesity-related transcriptomic signature as a correlate of clinical outcome, immune microenvironment, and treatment response in hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Cyclic Nucleotide Phosphodiesterases, Type 6; Eye Proteins; Humans; Liver Neoplasms; Obesity; Overweight; Retrospective Studies; Serine Endopeptidases; Sorafenib; Transcriptome; Tumor Microenvironment | 2022 |
Real-world systemic sequential therapy with regorafenib for recurrent hepatocellular carcinoma: analysis of 93 cases from a single center.
Topics: Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Phenylurea Compounds; Retrospective Studies; Sorafenib; Treatment Outcome | 2023 |
Anti-angiogenic effect of the combination of low-dose sorafenib and EGCG in HCC-induced Wistar rats.
Topics: Animals; Carcinoma, Hepatocellular; Liver Neoplasms; Male; Rats; Rats, Wistar; Sorafenib; Vascular Endothelial Growth Factor A | 2022 |
Pien Tze Huang regulates phosphorylation of metabolic enzymes in mice of hepatocellular carcinoma.
Topics: Animals; Apoptosis; Carcinoma, Hepatocellular; Drugs, Chinese Herbal; Liver Neoplasms; Mice; Phosphorylation; Proteomics; Sorafenib | 2023 |
[Long-Term Survival of a Patient with Hepatocellular Carcinoma after Surgical Resection of Metachronous Hilar Lymph Node Metastases].
Topics: Aged; Carcinoma, Hepatocellular; Female; Hepatectomy; Humans; Liver Neoplasms; Lung; Lymph Nodes; Lymphatic Metastasis; Sorafenib | 2022 |
Camptothecin improves sorafenib sensitivity by inhibiting Nrf2‑ARE pathway in hepatocellular carcinoma.
Topics: Animals; Camptothecin; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Liver Neoplasms; Mice; NAD; NF-E2-Related Factor 2; Oxidoreductases; Quinones; Rabbits; Sorafenib | 2023 |
Microfluidics-enabled Serial Assembly of Lipid-siRNA-sorafenib Nanoparticles for Synergetic Hepatocellular Carcinoma Therapy.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Humans; Lipids; Liver Neoplasms; Mice; Microfluidics; Nanoparticles; RNA, Small Interfering; Sorafenib | 2023 |
Clinical characteristics and outcome of patients with combined hepatocellular-cholangiocarcinoma-a European multicenter cohort.
Topics: Aged; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Carcinoma, Hepatocellular; Cholangiocarcinoma; Female; Humans; Liver Neoplasms; Male; Middle Aged; Retrospective Studies; Sorafenib | 2023 |
Comments on Comparison of Sorafenib versus Hepatic Arterial Infusion Chemotherapy-Based Treatment for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Portal Vein; Sorafenib; Treatment Outcome; Venous Thrombosis | 2023 |
Comments on Comparison of Sorafenib versus Hepatic Arterial Infusion Chemotherapy-Based Treatment for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: Reply.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Phenylurea Compounds; Portal Vein; Sorafenib; Treatment Outcome; Venous Thrombosis | 2023 |
XPO1 intensifies sorafenib resistance by stabilizing acetylation of NPM1 and enhancing epithelial-mesenchymal transition in hepatocellular carcinoma.
Topics: Acetylation; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Humans; Karyopherins; Liver Neoplasms; Nucleophosmin; Sorafenib | 2023 |
A comprehensive computational analysis to explore the importance of SIGLECs in HCC biology.
Topics: Biomarkers, Tumor; Carcinoma, Hepatocellular; Clinical Relevance; Computational Biology; Humans; Liver Neoplasms; Prognosis; Sorafenib | 2023 |
Proto-Oncogene FAM50A Can Regulate the Immune Microenvironment and Development of Hepatocellular Carcinoma In Vitro and In Vivo.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; DNA-Binding Proteins; Humans; Liver Neoplasms; RNA-Binding Proteins; Sorafenib; Tumor Microenvironment | 2023 |
An Angiogenic Gene Signature for Prediction of the Prognosis and Therapeutic Responses of Hepatocellular Carcinoma.
Topics: Angiogenesis Inhibitors; Biomarkers, Tumor; Carcinoma, Hepatocellular; Crizotinib; Humans; Liver Neoplasms; Sorafenib | 2023 |
Sorafenib Loaded Resealed Erythrocytes for the Treatment of Hepatocellular Carcinoma.
Topics: Animals; Carcinoma, Hepatocellular; Erythrocytes; Liver Neoplasms; Rats; Rats, Wistar; Renal Dialysis; Sorafenib | 2023 |
Liver SBRT dose accumulation to assess the impact of anatomic variations on normal tissue doses and toxicity in patients treated with concurrent sorafenib.
Topics: Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Radiosurgery; Radiotherapy Dosage; Sorafenib | 2023 |
Co-delivery of doxorubicin/sorafenib by DNA-decorated green ZIF-67-based nanocarriers for chemotherapy and hepatocellular carcinoma treatment.
Topics: Carcinoma, Hepatocellular; Doxorubicin; Escherichia coli; HEK293 Cells; Humans; Liver Neoplasms; Nanoparticles; Sorafenib; Spectroscopy, Fourier Transform Infrared | 2023 |
Thymoquinone, piperine, and sorafenib combinations attenuate liver and breast cancers progression: epigenetic and molecular docking approaches.
Topics: Epigenesis, Genetic; Humans; Liver Neoplasms; MicroRNAs; Molecular Docking Simulation; Sorafenib | 2023 |
Use of ramucirumab for various treatment lines in real-world practice of patients with advanced hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Ramucirumab; Retrospective Studies; Sorafenib | 2023 |
Pembrolizumab for second line treatment of advanced hepatocellular carcinoma-who would benefit?
Topics: Antibodies, Monoclonal, Humanized; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Sorafenib | 2023 |
Cancer-associated fibroblast-derived secreted phosphoprotein 1 contributes to resistance of hepatocellular carcinoma to sorafenib and lenvatinib.
Topics: Cancer-Associated Fibroblasts; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Osteopontin; Phosphatidylinositol 3-Kinases; Sorafenib | 2023 |
SLC27A4-mediated selective uptake of mono-unsaturated fatty acids promotes ferroptosis defense in hepatocellular carcinoma.
Topics: Breast Neoplasms; Carcinoma, Hepatocellular; Fatty Acid Transport Proteins; Fatty Acids; Fatty Acids, Unsaturated; Female; Ferroptosis; Humans; Liver Neoplasms; Neoplasm Recurrence, Local; Ovarian Neoplasms; Sorafenib; Tumor Microenvironment | 2023 |
Repolarization of macrophages to improve sorafenib sensitivity for combination cancer therapy.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Humans; Liver Neoplasms; Macrophages; Nanoparticles; Sorafenib; Tumor Microenvironment | 2023 |
Rs9679162 genotype predicts prognosis of real-world advanced hepatocellular carcinoma treated by sorafenib.
Topics: Carcinoma, Hepatocellular; Genotype; Humans; Liver Neoplasms; Prognosis; Sorafenib | 2023 |
FOXM1 augments sorafenib resistance and promotes progression of hepatocellular carcinoma by epigenetically activating KIF23 expression.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Forkhead Box Protein M1; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Microtubule-Associated Proteins; Sorafenib; Transcriptional Activation; Up-Regulation | 2023 |
Targeted downregulation of MYC mediated by a highly efficient lactobionic acid-based glycoplex to enhance chemosensitivity in human hepatocellular carcinoma cells.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; RNA, Small Interfering; Sorafenib | 2023 |
Gut microbial metabolite butyrate improves anticancer therapy by regulating intracellular calcium homeostasis.
Topics: Antineoplastic Agents; Butyrates; Calcium; Carcinoma, Hepatocellular; Gastrointestinal Microbiome; Homeostasis; Liver Neoplasms; Sorafenib | 2023 |
Survival Benefit of Experience of Liver Resection for Advanced Recurrent Hepatocellular Carcinoma Treated with Sorafenib: A Propensity Score Matching Analysis.
Topics: Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Propensity Score; Retrospective Studies; Sorafenib | 2023 |
Human menstrual blood-derived stem cells reverse sorafenib resistance in hepatocellular carcinoma cells through the hyperactivation of mitophagy.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Humans; Liver Neoplasms; Mice; Mitophagy; Proto-Oncogene Proteins c-bcl-2; Sorafenib; Stem Cells | 2023 |
An ATG4B inhibitor blocks autophagy and sensitizes Sorafenib inhibition activities in HCC tumor cells.
Topics: Autophagy; Autophagy-Related Proteins; Carcinoma, Hepatocellular; Cysteine Endopeptidases; Humans; Liver Neoplasms; Sorafenib | 2023 |
Dihydroergotamine mesylate enhances the anti-tumor effect of sorafenib in liver cancer cells.
Topics: Apoptosis; Cell Line, Tumor; Dihydroergotamine; Humans; Liver Neoplasms; Myeloid Cell Leukemia Sequence 1 Protein; Phenylurea Compounds; Sorafenib | 2023 |
Postprogression treatment of lenvatinib plus PD-1 inhibitor in advanced hepatocellular carcinoma refractory to hepatic arterial infusion chemotherapy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Humans; Immune Checkpoint Inhibitors; Infusions, Intra-Arterial; Liver Neoplasms; Sorafenib; Treatment Outcome | 2023 |
First-line systemic treatment strategies for unresectable hepatocellular carcinoma: A cost-effectiveness analysis.
Topics: Bevacizumab; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Cost-Effectiveness Analysis; Erlotinib Hydrochloride; Humans; Liver Neoplasms; Quality-Adjusted Life Years; Sorafenib; Sunitinib | 2023 |
A cuproptosis random forest cox score model-based evaluation of prognosis, mutation characterization, immune infiltration, and drug sensitivity in hepatocellular carcinoma.
Topics: Apoptosis; Carcinoma, Hepatocellular; Copper; Humans; Liver Neoplasms; Prognosis; Random Forest; Sorafenib; Tumor Microenvironment | 2023 |
MiR-375 attenuates sorafenib resistance of hepatocellular carcinoma cells by inhibiting cell autophagy.
Topics: Autophagy; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Liver Neoplasms; MicroRNAs; Sorafenib | 2023 |
Circ_RBM23 knockdown suppresses chemoresistance, proliferation, migration and invasion of sorafenib-resistant HCC cells through miR-338-3p/RAB1B axis.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; MicroRNAs; Neoplastic Processes; rab1 GTP-Binding Proteins; Sorafenib | 2023 |
Iron deficiency in hepatocellular carcinoma cells induced sorafenib resistance by upregulating HIF-1α to inhibit apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Iron; Iron Deficiencies; Liver Neoplasms; Proto-Oncogene Proteins c-bcl-2; Sorafenib | 2023 |
Carvacrol enhances anti-tumor activity and mitigates cardiotoxicity of sorafenib in thioacetamide-induced hepatocellular carcinoma model through inhibiting TRPM7.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cardiotoxicity; Cell Line, Tumor; Cell Proliferation; Liver Neoplasms; Rats; Sorafenib; Thioacetamide; TRPM Cation Channels | 2023 |
Diarylheptanoids/sorafenib as a potential anticancer combination against hepatocellular carcinoma: the p53/MMP9 axis of action.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Interleukin-6; Liver Neoplasms; Matrix Metalloproteinase 9; Mice; Molecular Docking Simulation; Sorafenib; Tumor Suppressor Protein p53; Vascular Endothelial Growth Factor A | 2023 |
Upregulation of CSNK1A1 induced by ITGB5 confers to hepatocellular carcinoma resistance to sorafenib in vivo by disrupting the EPS15/EGFR complex.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Liver Neoplasms; Proto-Oncogene Proteins c-akt; Sorafenib; TOR Serine-Threonine Kinases; Up-Regulation | 2023 |
RNF8 depletion attenuates hepatocellular carcinoma progression by inhibiting epithelial-mesenchymal transition and enhancing drug sensitivity.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; DNA-Binding Proteins; Epithelial-Mesenchymal Transition; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Sorafenib; Ubiquitin-Protein Ligases | 2023 |
Butyrate Modification Promotes Intestinal Absorption and Hepatic Cancer Cells Targeting of Ferroptosis Inducer Loaded Nanoparticle for Enhanced Hepatocellular Carcinoma Therapy.
Topics: Butyrates; Carcinoma, Hepatocellular; Cell Line, Tumor; Ferroptosis; Humans; Intestinal Absorption; Liver Neoplasms; Nanoparticles; Sorafenib | 2023 |
Camptothecin Sensitizes Hepatocellular Carcinoma Cells to Sorafenib- Induced Ferroptosis Via Suppression of Nrf2.
Topics: Camptothecin; Carcinoma, Hepatocellular; Cell Line, Tumor; Ferroptosis; Humans; Iron; Kelch-Like ECH-Associated Protein 1; Liver Neoplasms; NF-E2-Related Factor 2; Sorafenib | 2023 |
Glucosamine-Modified Reduction-Responsive Polymeric Micelles for Liver Cancer Therapy.
Topics: Animals; Carcinoma, Hepatocellular; Doxorubicin; Drug Carriers; Drug Delivery Systems; Hydrogen-Ion Concentration; Liver Neoplasms; Mice; Micelles; Polymers; Sorafenib; Tumor Microenvironment | 2023 |
RAD51 Inhibition Shows Antitumor Activity in Hepatocellular Carcinoma.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Humans; Liver Neoplasms; Rad51 Recombinase; Sorafenib; Xenograft Model Antitumor Assays | 2023 |
MiR-21-5p promotes sorafenib resistance and hepatocellular carcinoma progression by regulating SIRT7 ubiquitination through USP24.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Gene Expression Regulation, Neoplastic; Ki-67 Antigen; Liver Neoplasms; Mice; Mice, Nude; MicroRNAs; Sirtuins; Sorafenib; Ubiquitination | 2023 |
Low Pi stress enhances the sensitivity of hepatocellular carcinoma to sorafenib.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Liver Neoplasms; Mice; Mice, Inbred Strains; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-akt; Sorafenib | 2023 |
Remodeling Serine Synthesis and Metabolism via Nanoparticles (NPs)-Mediated CFL1 Silencing to Enhance the Sensitivity of Hepatocellular Carcinoma to Sorafenib.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cofilin 1; Humans; Liver Neoplasms; Nanoparticles; Sorafenib | 2023 |
BEX1 mediates sorafenib resistance in hepatocellular carcinoma by regulating AKT signaling.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Nerve Tissue Proteins; Proto-Oncogene Proteins c-akt; Sorafenib | 2023 |
Polyphyllin D punctures hypertrophic lysosomes to reverse drug resistance of hepatocellular carcinoma by targeting acid sphingomyelinase.
Topics: Autophagy; Carcinoma, Hepatocellular; Drug Resistance; Humans; Liver Neoplasms; Lysosomes; Punctures; Sorafenib; Sphingomyelin Phosphodiesterase | 2023 |
Transmembrane protein 147, as a potential Sorafenib target, could expedite cell cycle process and confer adverse prognosis in hepatocellular carcinoma.
Topics: Animals; Carcinoma, Hepatocellular; Cell Cycle; Cell Division; Cell Line, Tumor; Liver Neoplasms; Mice; Sorafenib | 2023 |
Ganetespib (STA-9090) augments sorafenib efficacy via necroptosis induction in hepatocellular carcinoma: Implications from preclinical data for a novel therapeutic approach.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Hypoxia; Liver Neoplasms; Mice; Necroptosis; Sorafenib | 2023 |
Glutamine synthetase-negative hepatocellular carcinoma has better prognosis and response to sorafenib treatment after hepatectomy.
Topics: Carcinoma, Hepatocellular; Glutamate-Ammonia Ligase; Hepatectomy; Humans; Liver Neoplasms; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Sorafenib | 2023 |
Comparing the effectiveness and safety of Sorafenib plus TACE with Apatinib plus TACE for treating patients with unresectable hepatocellular carcinoma: a multicentre propensity score matching study.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Humans; Liver Neoplasms; Propensity Score; Retrospective Studies; Sorafenib | 2023 |
Transarterial radioembolization versus tyrosine kinase inhibitor in hepatocellular carcinoma with portal vein thrombosis.
Topics: Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neoplasms; Portal Vein; Protein Kinase Inhibitors; Retrospective Studies; Sorafenib; Thrombosis; Treatment Outcome; Tyrosine Kinase Inhibitors | 2023 |
Norcantharidin potentiates sorafenib antitumor activity in hepatocellular carcinoma rat model through inhibiting IL-6/STAT3 pathway.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Interleukin-6; Liver Neoplasms; Male; Rats; Sorafenib | 2023 |
Ferroptosis inducers enhanced cuproptosis induced by copper ionophores in primary liver cancer.
Topics: Animals; Apoptosis; Copper; Disease Models, Animal; Ferroptosis; Humans; Ionophores; Liver Neoplasms; Mice; Sorafenib | 2023 |
Furanocoumarin Notopterol: Inhibition of Hepatocellular Carcinogenesis through Suppression of Cancer Stemness Signaling and Induction of Oxidative Stress-Associated Cell Death.
Topics: Animals; Apoptosis; Carcinogenesis; Carcinoma, Hepatocellular; Cell Death; Cell Line, Tumor; Endoplasmic Reticulum Stress; Furocoumarins; Humans; Liver Neoplasms; Mice; Oxidative Stress; Sorafenib | 2023 |
MiR-494 induces metabolic changes through G6pc targeting and modulates sorafenib response in hepatocellular carcinoma.
Topics: Animals; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Liver Neoplasms; MicroRNAs; Rats; Sorafenib | 2023 |
Identification of PANoptosis-Based Prognostic Signature for Predicting Efficacy of Immunotherapy and Chemotherapy in Hepatocellular Carcinoma.
Topics: Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Immunotherapy; Liver Neoplasms; Prognosis; Sorafenib | 2023 |
Sorafenib as first-line treatment for patients with primary hepatocellular carcinoma: an outcome evaluation.
Topics: Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Outcome Assessment, Health Care; Retrospective Studies; Sorafenib | 2023 |
Metformin promotes ferroptosis and sensitivity to sorafenib in hepatocellular carcinoma cells via ATF4/STAT3.
Topics: Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Ferroptosis; Liver Neoplasms; Metformin; Mice; Sorafenib | 2023 |
HBV precore G1896A mutation promotes growth of hepatocellular carcinoma cells by activating ERK/MAPK pathway.
Topics: Carcinoma, Hepatocellular; Genotype; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Mutation; Sorafenib | 2023 |
Loss of LncRNA DUXAP8 synergistically enhanced sorafenib induced ferroptosis in hepatocellular carcinoma via SLC7A11 de-palmitoylation.
Topics: Amino Acid Transport System y+; Carcinoma, Hepatocellular; Ferroptosis; Humans; Lipoylation; Liver Neoplasms; RNA, Long Noncoding; Sorafenib | 2023 |
Design and synthesis of guaianolide-germacranolide heterodimers as novel anticancer agents against hepatocellular carcinoma.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Proliferation; Drug Screening Assays, Antitumor; Hep G2 Cells; Humans; Liver Neoplasms; Molecular Structure; Sorafenib; Structure-Activity Relationship | 2023 |
Upregulation of lncRNA PTOV1-AS1 in hepatocellular carcinoma contributes to disease progression and sorafenib resistance through regulating miR-505.
Topics: Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease Progression; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; MicroRNAs; Neoplasm Proteins; RNA, Long Noncoding; Sorafenib; Up-Regulation | 2023 |
Cucurbitacin E shows synergistic effect with sorafenib by inducing apoptosis in hepatocellular carcinoma cells and regulates Jak/Stat3, ERK/MAPK, PI3K/Akt/mTOR signaling pathways.
Topics: Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Humans; Liver Neoplasms; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Signal Transduction; Sorafenib; TOR Serine-Threonine Kinases; Triterpenes | 2023 |
Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients.
Topics: Bevacizumab; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Retrospective Studies; Sorafenib | 2023 |
PANoptosis-based molecular subtyping and HPAN-index predicts therapeutic response and survival in hepatocellular carcinoma.
Topics: Apoptosis; Carcinoma, Hepatocellular; Cell Cycle; Humans; Liver Neoplasms; Sorafenib | 2023 |
MiR-3677-3p promotes development and sorafenib resistance of hepatitis B-related hepatocellular carcinoma by inhibiting FOXM1 ubiquitination.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Forkhead Box Protein M1; Gene Expression Regulation, Neoplastic; Hepatitis B; Humans; Liver Neoplasms; Mice; Mice, Nude; MicroRNAs; Sorafenib | 2023 |
Cost-effectiveness of nivolumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Clinical Trials as Topic; Cost-Benefit Analysis; Humans; Liver Neoplasms; Nivolumab; Sorafenib | 2023 |
Comprehensive bioinformatics analysis of a RBM family-based prognostic signature with experiment validation in hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Computational Biology; Humans; Liver Neoplasms; Nerve Tissue Proteins; Prognosis; RNA-Binding Proteins; Sorafenib; Tumor Microenvironment | 2023 |
Galectin-1-mediated MET/AXL signaling enhances sorafenib resistance in hepatocellular carcinoma by escaping ferroptosis.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Ferroptosis; Galectin 1; Humans; Liver Neoplasms; Receptor Protein-Tyrosine Kinases; Sorafenib | 2023 |
A novel prognostic signature for hepatocellular carcinoma based on SUMOylation-related genes.
Topics: Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Prognosis; Sorafenib; Sumoylation | 2023 |
Cuproptosis-related signature for clinical prognosis and immunotherapy sensitivity in hepatocellular carcinoma.
Topics: Apoptosis; Carcinoma, Hepatocellular; Humans; Immunotherapy; Liver Neoplasms; Prognosis; Sorafenib; Tumor Microenvironment | 2023 |
Cost-effectiveness analysis of sintilimab plus IBI305 versus sorafenib for unresectable hepatic cell carcinoma in China.
Topics: Aged; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Cost-Effectiveness Analysis; Hepatocytes; Humans; Liver Neoplasms; Medicare; Sorafenib; United States | 2023 |
Analysis and prediction of the efficacy and influencing factors of camrelizumab combined with TACE and sorafenib in the treatment of advanced hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Humans; Liver Neoplasms; Retrospective Studies; Sorafenib; Treatment Outcome | 2023 |
Immunogenic landscape and risk score prediction based on unfolded protein response (UPR)-related molecular subtypes in hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Humans; Immunotherapy; Liver Neoplasms; Qb-SNARE Proteins; Risk Factors; Sorafenib | 2023 |
Rab11-FIP4 interacts with ARF5 to promote cancer stemness in hepatocellular carcinoma.
Topics: ADP-Ribosylation Factors; Carcinoma, Hepatocellular; Carrier Proteins; Cell Line; Cell Line, Tumor; Humans; Liver Neoplasms; Neoplastic Stem Cells; Sorafenib | 2023 |
MEX3A determines in vivo hepatocellular carcinoma progression and induces resistance to sorafenib in a Hippo-dependent way.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Humans; Intracellular Signaling Peptides and Proteins; Liver Neoplasms; Phosphoproteins; Protein Serine-Threonine Kinases; RNA-Binding Proteins; Sorafenib | 2023 |
Fabrication and characterization of nanodelivery platform based on chitosan to improve the anticancer outcome of sorafenib in hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Chitosan; Drug Carriers; Humans; Liver Neoplasms; Nanoparticles; Sorafenib | 2023 |
HSP90β Impedes STUB1-Induced Ubiquitination of YTHDF2 to Drive Sorafenib Resistance in Hepatocellular Carcinoma.
Topics: Carcinoma, Hepatocellular; HSP90 Heat-Shock Proteins; Humans; Liver Neoplasms; RNA-Binding Proteins; Sorafenib; Ubiquitin-Protein Ligases; Ubiquitination; Up-Regulation | 2023 |
Comprehensive Analysis of the Sorafenib-Associated Druggable Targets on Differential Gene Expression and ceRNA Network in Hepatocellular Carcinoma.
Topics: Carcinoma, Hepatocellular; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Gene Expression; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Humans; Liver Neoplasms; MicroRNAs; RNA, Long Noncoding; Sorafenib | 2023 |
Sorafenib-Loaded PLGA Carriers for Enhanced Drug Delivery and Cellular Uptake in Liver Cancer Cells.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Carriers; Humans; Lactic Acid; Liver Neoplasms; Nanoparticles; Particle Size; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Sorafenib | 2023 |
ATRA sensitized the response of hepatocellular carcinoma to Sorafenib by downregulation of p21-activated kinase 1.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; p21-Activated Kinases; Sorafenib; Tretinoin | 2023 |
Modelling the Sorafenib-resistant Liver Cancer Microenvironment by Using 3-D Spheroids.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Sorafenib; Tumor Microenvironment | 2023 |
UBE2S promotes malignant properties via VHL/HIF-1α and VHL/JAK2/STAT3 signaling pathways and decreases sensitivity to sorafenib in hepatocellular carcinoma.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Janus Kinase 2; Liver Neoplasms; Signal Transduction; Sorafenib; STAT3 Transcription Factor; Von Hippel-Lindau Tumor Suppressor Protein | 2023 |
β-HB treatment reverses sorafenib resistance by shifting glycolysis-lactate metabolism in HCC.
Topics: 3-Hydroxybutyric Acid; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Glycolysis; Humans; Lactates; Liver Neoplasms; Sorafenib | 2023 |
Assessing the effectiveness of camrelizumab plus apatinib versus sorafenib for the treatment of primary liver cancer: a single-center retrospective study.
Topics: Body Weight; Humans; Liver Neoplasms; Retrospective Studies; Sorafenib | 2023 |
Novel VEGFR2 inhibitors with thiazoloquinoxaline scaffold targeting hepatocellular carcinoma with lower cardiotoxic impact.
Topics: Animals; Carcinoma, Hepatocellular; Cardiotoxicity; Drug-Related Side Effects and Adverse Reactions; Liver Neoplasms; Mice; Myocytes, Cardiac; Sorafenib; Sulfapyridine; Vascular Endothelial Growth Factor Receptor-2 | 2023 |
Changing treatment landscape associated with improved survival in advanced hepatocellular carcinoma: a nationwide, population-based study.
Topics: Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Phenylurea Compounds; Sorafenib | 2023 |
Sorafenib induces ferroptosis by promoting TRIM54-mediated FSP1 ubiquitination and degradation in hepatocellular carcinoma.
Topics: Animals; Carcinoma, Hepatocellular; Ferroptosis; Humans; Lipids; Liver Neoplasms; Sorafenib; Ubiquitination | 2023 |
Glycolysis maintains AMPK activation in sorafenib-induced Warburg effect.
Topics: AMP-Activated Protein Kinases; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Glycolysis; Humans; Liver Neoplasms; Sorafenib | 2023 |
Role of organic cation transporter 3 (OCT3) in the response of hepatocellular carcinoma to tyrosine kinase inhibitors.
Topics: Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Membrane Transport Proteins; Sorafenib; Tyrosine Kinase Inhibitors | 2023 |
Complete response with sorafenib after immune-induced hepatitis with atezolizumab/bevacizumab for advanced hepatocellular carcinoma, synergic effect?
Topics: Bevacizumab; Carcinoma, Hepatocellular; Hepatitis; Humans; Liver Neoplasms; Sorafenib | 2023 |
cDCBLD2 mediates sorafenib resistance in hepatocellular carcinoma by sponging miR-345-5p binding to the TOP2A coding sequence.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Mice; MicroRNAs; RNA, Circular; RNA, Small Interfering; Sorafenib | 2023 |
Unusual Presentation of an Uncommon Malignancy: A 74-Year-Old Woman with Aggressive Fibromatosis of the Large Intestine Presenting as a Liver Mass and the Therapeutic Management.
Topics: Aged; Female; Fibromatosis, Aggressive; Humans; Liver Neoplasms; Sorafenib; Tamoxifen | 2023 |
Explosomes: A new modality for DEB-TACE local delivery of sorafenib: In vivo proof of sustained release.
Topics: Animals; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Delayed-Action Preparations; Doxorubicin; Humans; Liver Neoplasms; Rabbits; Sorafenib; Treatment Outcome | 2023 |
Kiwi-derived extracellular vesicles for oral delivery of sorafenib.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Extracellular Vesicles; Humans; Liver Neoplasms; Sorafenib | 2023 |
FANCD2 as a novel prognostic biomarker correlated with immune and drug therapy in Hepatitis B-related hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Fanconi Anemia; Fanconi Anemia Complementation Group D2 Protein; Humans; Liver Neoplasms; Prognosis; Sorafenib | 2023 |
DLAT is a promising prognostic marker and therapeutic target for hepatocellular carcinoma: a comprehensive study based on public databases.
Topics: Carcinoma, Hepatocellular; Dihydrolipoyllysine-Residue Acetyltransferase; Humans; Liver Neoplasms; Prognosis; Sorafenib | 2023 |
Intratumoral injection of norcantharidin liposome emulsion hybrid delivery system amplifies the cancer-fighting effects of oral sorafenib against hepatocellular carcinoma.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Emulsions; Humans; Injections, Intralesional; Liposomes; Liver Neoplasms; Sorafenib | 2023 |
Efficacy and safety analysis of TACE + Donafenib + Toripalimab versus TACE + Sorafenib in the treatment of unresectable hepatocellular carcinoma: a retrospective study.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib | 2023 |
CRISPR/Cas9 screens unravel miR-3689a-3p regulating sorafenib resistance in hepatocellular carcinoma via suppressing CCS/SOD1-dependent mitochondrial oxidative stress.
Topics: Carcinoma, Hepatocellular; Copper; CRISPR-Cas Systems; Humans; Liver Neoplasms; MicroRNAs; Oxidative Stress; Proteomics; Sorafenib; Superoxide Dismutase; Superoxide Dismutase-1 | 2023 |
Africa Guidelines for Hepatocellular Carcinoma Buildup Process.
Topics: Africa; Carcinoma, Hepatocellular; Hepatitis B; Humans; Liver Neoplasms; Sorafenib | 2023 |
Combination treatment of transcatheter arterial chemoembolization, intensity-modulated radiotherapy, and sorafenib for hepatocellular carcinoma with macrovascular invasion.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neoplasms; Radiotherapy, Intensity-Modulated; Retrospective Studies; Sorafenib | 2023 |
Long Noncoding RNA URB1-Antisense RNA 1 (AS1) Suppresses Sorafenib-Induced Ferroptosis in Hepatocellular Carcinoma by Driving Ferritin Phase Separation.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Ferritins; Ferroptosis; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; MicroRNAs; Nuclear Proteins; RNA, Antisense; RNA, Long Noncoding; RNA, Small Interfering; Sorafenib | 2023 |
Inhibition of Dickkopf-1 enhances the anti-tumor efficacy of sorafenib via inhibition of the PI3K/Akt and Wnt/β-catenin pathways in hepatocellular carcinoma.
Topics: Animals; beta Catenin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Glycogen Synthase Kinase 3 beta; Humans; Liver Neoplasms; Mice; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Sorafenib | 2023 |
RNA helicase DDX5 modulates sorafenib sensitivity in hepatocellular carcinoma via the Wnt/β-catenin-ferroptosis axis.
Topics: beta Catenin; Carcinoma, Hepatocellular; Cell Line, Tumor; Ferroptosis; Humans; Liver Neoplasms; RNA Helicases; Sorafenib; Wnt Signaling Pathway | 2023 |
Cancer-associated fibroblasts induce sorafenib resistance of hepatocellular carcinoma cells through CXCL12/FOLR1.
Topics: Cancer-Associated Fibroblasts; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Chemokine CXCL12; Drug Resistance, Neoplasm; Fibroblasts; Folate Receptor 1; Humans; Liver Neoplasms; Sorafenib | 2023 |
HBx Modulates Drug Resistance of Sorafenib-Resistant Hepatocellular Carcinoma Cells.
Topics: Cadherins; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance; Gene Expression Regulation, Neoplastic; Hepatitis B virus; Humans; Liver Neoplasms; Sorafenib; Vimentin | 2023 |
Anti-GPC3 Antibody Tagged Cationic Switchable Lipid-Based Nanoparticles for the Co-Delivery of Anti-miRNA27a And Sorafenib in Liver Cancers.
Topics: Animals; Antagomirs; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferation; Cell Survival; Cholesterol; Drug Synergism; Forkhead Box Protein O1; Glypicans; Hep G2 Cells; Humans; Hydrogen-Ion Concentration; Lipids; Liver Neoplasms; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Nanoparticles; Phosphorylcholine; Polyethylene Glycols; PPAR gamma; Sorafenib | 2019 |
A Multifunctional Lipid-Based Nanodevice for the Highly Specific Codelivery of Sorafenib and Midkine siRNA to Hepatic Cancer Cells.
Topics: Carcinoma, Hepatocellular; Cell Survival; Combined Modality Therapy; Drug Delivery Systems; Drug Liberation; Drug Synergism; Fatty Acids, Monounsaturated; Gene Knockdown Techniques; Gene Silencing; Genetic Therapy; HeLa Cells; Hep G2 Cells; Humans; Inhibitory Concentration 50; Lipids; Liver Neoplasms; Midkine; Nanoparticles; Piperidines; Quaternary Ammonium Compounds; RNA, Small Interfering; Sorafenib | 2019 |
Bi-monthly hepatic arterial infusion chemotherapy as a novel strategy for advanced hepatocellular carcinoma in decompensated cirrhotic patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Drug Administration Schedule; Female; Humans; Infusions, Intra-Arterial; Kaplan-Meier Estimate; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Retrospective Studies; Sorafenib | 2019 |
The combination of lonafarnib and sorafenib induces cyclin D1 degradation via ATG3-mediated autophagic flux in hepatocellular carcinoma cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Autophagy-Related Proteins; Carcinoma, Hepatocellular; Cell Proliferation; Cyclin D1; Enzyme Inhibitors; Farnesyltranstransferase; Female; Gene Knockdown Techniques; Hep G2 Cells; Humans; Liver Neoplasms; Mice; Mice, Nude; Models, Biological; Piperidines; Protein Kinase Inhibitors; Proteolysis; Pyridines; Sorafenib; Ubiquitin-Conjugating Enzymes; Xenograft Model Antitumor Assays | 2019 |
Sorafenib-Induced Apoptosis in Hepatocellular Carcinoma Is Reversed by SIRT1.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Humans; Liver Neoplasms; Nicotinamide Mononucleotide; Sirtuin 1; Sorafenib | 2019 |
Histone chaperone FACT complex mediates oxidative stress response to promote liver cancer progression.
Topics: Animals; Antineoplastic Agents; Carbazoles; Carcinoma, Hepatocellular; Cell Cycle Proteins; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease Progression; DNA-Binding Proteins; Gene Expression Regulation, Neoplastic; Gene Knockout Techniques; High Mobility Group Proteins; Histone Chaperones; Humans; Liver Neoplasms; Liver Neoplasms, Experimental; Mice, Inbred BALB C; Mice, Nude; Oxidative Stress; Sorafenib; Transcription Factors; Transcriptional Elongation Factors; Up-Regulation; Xenograft Model Antitumor Assays | 2020 |
Targeting PI3K/Akt/mTOR Pathway Identifies Differential Expression and Functional Role of IL8 in Liver Cancer Stem Cell Enrichment.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Humans; Interleukin-8; Liver Neoplasms; Neoplastic Stem Cells; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Signal Transduction; Sirolimus; Sorafenib; Sulfonamides; TOR Serine-Threonine Kinases | 2019 |
Management of adverse events with tailored sorafenib dosing prolongs survival of hepatocellular carcinoma patients.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Duration of Therapy; Female; Humans; Italy; Learning Curve; Liver Neoplasms; Male; Medication Therapy Management; Middle Aged; No-Observed-Adverse-Effect Level; Off-Label Use; Practice Patterns, Physicians'; Sorafenib; Survival Analysis | 2019 |
Mechanistically detailed systems biology modeling of the HGF/Met pathway in hepatocellular carcinoma.
Topics: Anilides; Antibodies, Monoclonal, Humanized; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Computer Simulation; Drug Resistance, Neoplasm; Hep G2 Cells; Hepatocyte Growth Factor; Humans; Integrins; Liver Neoplasms; Proto-Oncogene Proteins c-met; Pyridines; Signal Transduction; Sorafenib; Systems Biology | 2019 |
Activation of EGFR-KLF4 positive feedback loop results in acquired resistance to sorafenib in hepatocellular carcinoma.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gene Expression Regulation, Neoplastic; Humans; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Liver Neoplasms; Mice; Signal Transduction; Sorafenib; Xenograft Model Antitumor Assays | 2019 |
Transarterial Chemoembolization (TACE) Combined with Sorafenib in Treatment of HBV Background Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Propensity Score Matching Study.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Disease-Free Survival; Female; Hepatitis B virus; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Portal Vein; Sorafenib; Treatment Outcome; Venous Thrombosis | 2019 |
Sorafenib attenuated the function of natural killer cells infiltrated in HCC through inhibiting ERK1/2.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Extracellular Signal-Regulated MAP Kinases; Killer Cells, Natural; Liver Neoplasms; Mice, Inbred C57BL; Protein Kinase Inhibitors; Sorafenib | 2019 |
Artesunate promotes sensitivity to sorafenib in hepatocellular carcinoma.
Topics: Animals; Apoptosis; Artesunate; Carcinogenesis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Liver Neoplasms; MAP Kinase Signaling System; Mice, Inbred BALB C; Mice, Nude; Proto-Oncogene Proteins c-akt; Sorafenib; TOR Serine-Threonine Kinases | 2019 |
Sigma-1 receptor protects against ferroptosis in hepatocellular carcinoma cells.
Topics: Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Death; Cell Line, Tumor; Ferroptosis; Hep G2 Cells; Humans; Lipid Peroxidation; Liver Neoplasms; Mice; Piperazines; Reactive Oxygen Species; Receptors, sigma; Sigma-1 Receptor; Sorafenib; Up-Regulation | 2019 |
Enhanced antitumour effect for hepatocellular carcinoma in the advanced stage using a cyclodextrin-sorafenib-chaperoned inclusion complex.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cyclodextrins; Hep G2 Cells; Humans; Liver Neoplasms; Liver Neoplasms, Experimental; Mice; Molecular Chaperones; Optical Imaging; Positron-Emission Tomography; Solubility; Sorafenib | 2019 |
[E26 transformation-specific variant 4 promotes sorafenib and cisplatin resistance in hepatocellular carcinoma cells
Topics: Apoptosis; Apoptosis Regulatory Proteins; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cisplatin; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Membrane Proteins; Niacinamide; Phenylurea Compounds; Sorafenib | 2019 |
SREBP-1 inhibitor Betulin enhances the antitumor effect of Sorafenib on hepatocellular carcinoma via restricting cellular glycolytic activity.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Movement; Cell Proliferation; Drug Synergism; Gene Expression Regulation, Neoplastic; Glycolysis; Hep G2 Cells; Humans; Lipid Metabolism; Liver Neoplasms; Mice; Mice, Nude; Prognosis; Sorafenib; Sterol Regulatory Element Binding Protein 1; Transplantation, Heterologous; Triterpenes | 2019 |
Experience With Early Sorafenib Treatment With mTOR Inhibitors in Hepatocellular Carcinoma Recurring After Liver Transplantation.
Topics: Adult; Aged; Allografts; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Disease Progression; Drug Administration Schedule; Everolimus; Female; Follow-Up Studies; Humans; Liver; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Postoperative Period; Retrospective Studies; Sorafenib; Survival Analysis; Time Factors; Time-to-Treatment; TOR Serine-Threonine Kinases; Treatment Outcome | 2020 |
CDK12 inhibition mediates DNA damage and is synergistic with sorafenib treatment in hepatocellular carcinoma.
Topics: Anilides; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Culture Techniques; Cell Line, Tumor; Cyclin-Dependent Kinases; Humans; Liver Neoplasms; Pyrimidines; Sorafenib | 2020 |
Melatonin Increases the Sensitivity of Hepatocellular Carcinoma to Sorafenib through the PERK-ATF4-Beclin1 Pathway.
Topics: Activating Transcription Factor 4; Autophagy; Beclin-1; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Endoplasmic Reticulum Stress; Flow Cytometry; Fluorescent Antibody Technique; Hep G2 Cells; Humans; In Situ Nick-End Labeling; In Vitro Techniques; Liver Neoplasms; Melatonin; Microscopy, Electron, Transmission; Signal Transduction; Sorafenib; Tissue Array Analysis | 2019 |
Sorafenib encapsulated in nanocarrier functionalized with glypican-3 specific peptide for targeted therapy of hepatocellular carcinoma.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Carriers; Drug Compounding; Female; Glypicans; Humans; Liver Neoplasms; Mice, Nude; Molecular Targeted Therapy; Nanoparticles; Peptides; Protein Kinase Inhibitors; Sorafenib; Tumor Burden; Xenograft Model Antitumor Assays | 2019 |
LncRNA NEAT1 promotes autophagy via regulating miR-204/ATG3 and enhanced cell resistance to sorafenib in hepatocellular carcinoma.
Topics: Autophagy; Autophagy-Related Proteins; Carcinogenesis; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Liver Neoplasms; MicroRNAs; RNA, Long Noncoding; Sorafenib; Ubiquitin-Conjugating Enzymes | 2020 |
Hand-foot skin reaction induced by sorafenib in a hepatocellular carcinoma patient.
Topics: Administration, Topical; Adrenal Cortex Hormones; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Clobetasol; Drug Tapering; Enzyme Inhibitors; Hand-Foot Syndrome; Humans; Liver Neoplasms; Male; Sorafenib; Treatment Outcome | 2020 |
Exosomal MiR-744 Inhibits Proliferation and Sorafenib Chemoresistance in Hepatocellular Carcinoma by Targeting PAX2.
Topics: Aged; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Exosome Multienzyme Ribonuclease Complex; Exosomes; Hep G2 Cells; Humans; Liver Neoplasms; Male; MicroRNAs; Middle Aged; PAX2 Transcription Factor; Prognosis; Sorafenib | 2019 |
Vimentin as a potential therapeutic target in sorafenib resistant HepG2, a HCC model cell line.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Carcinoma, Hepatocellular; Cell Survival; Chromatography, High Pressure Liquid; Down-Regulation; Drug Resistance, Neoplasm; Hep G2 Cells; Humans; Liver Neoplasms; Proteomics; Sorafenib; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Vimentin; Withanolides | 2020 |
Leukocytoclastic vasculitis associated with sorafenib treatment for hepatocellular carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Male; Sorafenib; Vasculitis, Leukocytoclastic, Cutaneous | 2020 |
Improved survival prediction and comparison of prognostic models for patients with hepatocellular carcinoma treated with sorafenib.
Topics: Aged; alpha-Fetoproteins; Antineoplastic Agents; Bilirubin; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Phenylurea Compounds; Predictive Value of Tests; Prognosis; Reproducibility of Results; Retrospective Studies; Risk Factors; Serum Albumin, Human; Sorafenib; Survival Analysis | 2020 |
Ibrutinib Potentiates Antihepatocarcinogenic Efficacy of Sorafenib by Targeting EGFR in Tumor Cells and BTK in Immune Cells in the Stroma.
Topics: Adenine; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Synergism; Female; Humans; Liver Neoplasms; Mice; Piperidines; Sorafenib | 2020 |
Verteporfin-induced lysosomal compartment dysregulation potentiates the effect of sorafenib in hepatocellular carcinoma.
Topics: Alkalies; Animals; Autophagy; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Drug Synergism; Hepatocytes; Humans; Hydrogen-Ion Concentration; Intracellular Membranes; Liver Neoplasms; Lysosomes; Male; Mice; Models, Biological; Neoplasm Proteins; Permeability; ras Proteins; Sorafenib; Verteporfin | 2019 |
Potential Areas of Interest in a Trial of Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin for Hepatocellular Carcinoma-In Reply.
Topics: Carcinoma, Hepatocellular; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Oxaliplatin; Portal Vein; Sorafenib | 2019 |
Potential Areas of Interest in a Trial of Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin for Hepatocellular Carcinoma.
Topics: Carcinoma, Hepatocellular; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Oxaliplatin; Portal Vein; Sorafenib | 2019 |
Hepatitis B-associated hepatocellular carcinoma in a young Haitian man: a review of screening guidelines.
Topics: Adult; Antineoplastic Agents; Carcinoma, Hepatocellular; Deoxycytidine; Diagnosis, Differential; Fatal Outcome; Gemcitabine; Haiti; Hepatitis B, Chronic; Humans; Liver Neoplasms; Male; Mass Screening; Oxaliplatin; Practice Guidelines as Topic; Sorafenib; Tomography, X-Ray Computed | 2019 |
Overriding Adaptive Resistance to Sorafenib Through Combination Therapy With Src Homology 2 Domain-Containing Phosphatase 2 Blockade in Hepatocellular Carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Combinations; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Piperidines; Pyrimidines; Receptor Protein-Tyrosine Kinases; SH2 Domain-Containing Protein Tyrosine Phosphatases; Sorafenib | 2020 |
MicroRNA-3163 targets ADAM-17 and enhances the sensitivity of hepatocellular carcinoma cells to molecular targeted agents.
Topics: ADAM17 Protein; Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Female; Humans; Liver Neoplasms; Male; MicroRNAs; Middle Aged; Molecular Targeted Therapy; Sorafenib; Young Adult | 2019 |
Genome-wide CRISPR/Cas9 library screening identified PHGDH as a critical driver for Sorafenib resistance in HCC.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; CRISPR-Cas Systems; Drug Resistance, Neoplasm; Gene Knock-In Techniques; Gene Knockout Techniques; Humans; Liver Neoplasms; Phenylurea Compounds; Phosphoglycerate Dehydrogenase; Pyridines; Quinolines; Reactive Oxygen Species; Sorafenib | 2019 |
Phloretin attenuates STAT-3 activity and overcomes sorafenib resistance targeting SHP-1-mediated inhibition of STAT3 and Akt/VEGFR2 pathway in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Mice; Molecular Docking Simulation; Phloretin; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Proto-Oncogene Proteins c-akt; Signal Transduction; Sorafenib; src Homology Domains; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2019 |
Galectin-1 promotes hepatocellular carcinoma and the combined therapeutic effect of OTX008 galectin-1 inhibitor and sorafenib in tumor cells.
Topics: Animals; Calixarenes; Carcinoma, Hepatocellular; Galectin 1; Humans; Liver Neoplasms; Male; Mice; Mice, Nude; Sorafenib; Transfection | 2019 |
Sorafenib for Patients with Hepatocellular Carcinoma and Child-Pugh B Liver Cirrhosis: Lessons Learned from a Terminated Study.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Cirrhosis; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2020 |
Sorafenib- Taurine Combination Model for Hepatocellular Carcinoma Cells: Immunological Aspects.
Topics: Carcinoma, Hepatocellular; Cell Proliferation; Cytokines; Drug Therapy, Combination; Forkhead Transcription Factors; Hep G2 Cells; Humans; L-Lactate Dehydrogenase; Leukocytes, Mononuclear; Liver Neoplasms; Protein Kinase Inhibitors; Sorafenib; Taurine; Transforming Growth Factor beta | 2019 |
Duodenum perforated after combination with sorafenib and radiotherapy for retroperitoneal lymph node metastasis of hepatocellular carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Duodenum; Humans; Intestinal Perforation; Liver Neoplasms; Lymph Nodes; Lymphatic Metastasis; Radiotherapy; Retroperitoneal Neoplasms; Retroperitoneal Space; Sorafenib; Tomography, X-Ray Computed | 2020 |
Low density lipoprotein receptor (LDLR)-targeted lipid nanoparticles for the delivery of sorafenib and Dihydroartemisinin in liver cancers.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Artemisinins; Cell Survival; Drug Delivery Systems; Hep G2 Cells; Humans; Lipids; Liver Neoplasms; Mice; Mice, Inbred BALB C; Nanoparticles; Neoplasm Transplantation; Reactive Oxygen Species; Receptors, LDL; Sorafenib | 2019 |
Dual GSH-exhausting sorafenib loaded manganese-silica nanodrugs for inducing the ferroptosis of hepatocellular carcinoma cells.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chlorides; Drug Carriers; Drug Compounding; Drug Liberation; Ferroptosis; Glutathione; Hep G2 Cells; Humans; Lipid Peroxidation; Liver Neoplasms; Manganese Compounds; Metal Nanoparticles; Phospholipid Hydroperoxide Glutathione Peroxidase; Porosity; Signal Transduction; Silicon Dioxide; Sorafenib | 2019 |
Sorafenib treatment on Chinese patients with advanced hepatocellular carcinoma: A study on prognostic factors of the viral and tumor status.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Female; Hepatitis B; Hepatitis C; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Retrospective Studies; Sorafenib; Survival Analysis | 2019 |
Bioinformatics analysis revealed hub genes and pathways involved in sorafenib resistance in hepatocellular carcinoma.
Topics: Base Sequence; Biomarkers; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Computational Biology; Disease Progression; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Neovascularization, Pathologic; Prognosis; Proto-Oncogene Proteins c-akt; Signal Transduction; Sorafenib | 2019 |
Enhancement of sorafenib-mediated death of Hepatocellular carcinoma cells by Carnosic acid and Vitamin D2 analog combination.
Topics: Abietanes; Antineoplastic Agents; Antioxidants; Apoptosis; Autophagy; Bone Density Conservation Agents; Carcinoma, Hepatocellular; Cell Proliferation; Drug Synergism; Drug Therapy, Combination; Ergocalciferols; Humans; Liver Neoplasms; Signal Transduction; Sorafenib; Tumor Cells, Cultured | 2020 |
Prognostication of HCC under sorafenib: Is it always possible?
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Prognosis; Sorafenib | 2020 |
Complete response of advanced hepatocellular carcinoma achieved by sorafenib dose re-escalation after failure of long-term low-dose-sorafenib treatment combined with transcatheter arterial chemoembolization: a case report.
Topics: Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Female; Humans; Liver Neoplasms; Sorafenib; Treatment Failure; Treatment Outcome | 2020 |
Early Fibrosis but Late Tumor Stage and Worse Outcomes in Hepatocellular Carcinoma Patients Without Hepatitis B or Hepatitis C.
Topics: Aged; Aged, 80 and over; Alanine Transaminase; Antineoplastic Agents; Aspartate Aminotransferases; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Comorbidity; Diabetes Mellitus; Female; Hepatectomy; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Hypertension; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Staging; Obesity; Platelet Count; Prevalence; Prognosis; Proportional Hazards Models; Radiotherapy; Serum Albumin; Severity of Illness Index; Sorafenib; Survival Rate | 2020 |
miR-541 potentiates the response of human hepatocellular carcinoma to sorafenib treatment by inhibiting autophagy.
Topics: Animals; Antineoplastic Agents; Autophagy; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Feasibility Studies; Humans; Liver Neoplasms; Mice; MicroRNAs; Neoplasm Recurrence, Local; Phenotype; Sorafenib | 2020 |
Co-delivery of plantamajoside and sorafenib by a multi-functional nanoparticle to combat the drug resistance of hepatocellular carcinoma through reprograming the tumor hypoxic microenvironment.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Catechols; Cell Line, Tumor; Cell-Penetrating Peptides; Drug Resistance, Neoplasm; Glucosides; Hep G2 Cells; Humans; Hypoxia; Liver Neoplasms; Mice; Nanoparticles; Sorafenib; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2019 |
Liver X Receptor Agonism Sensitizes a Subset of Hepatocellular Carcinoma to Sorafenib by Dual-Inhibiting MET and EGFR.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cholesterol; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Immunohistochemistry; Liver Neoplasms; Liver X Receptors; Male; Mice; Protein Binding; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Sorafenib; Xenograft Model Antitumor Assays | 2020 |
Treatment with a new benzimidazole derivative bearing a pyrrolidine side chain overcomes sorafenib resistance in hepatocellular carcinoma.
Topics: Animals; Benzimidazoles; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Mice; Mice, Inbred NOD; Pyrrolidines; Sorafenib; Xenograft Model Antitumor Assays | 2019 |
Design And Characterisation Of Novel Sorafenib-Loaded Carbon Nanotubes With Distinct Tumour-Suppressive Activity In Hepatocellular Carcinoma.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Body Weight; Carcinoma, Hepatocellular; Cell Proliferation; Drug Compounding; Drug Design; Hep G2 Cells; Humans; Hydrogen-Ion Concentration; Liver; Liver Neoplasms; Male; Nanotubes, Carbon; Niacinamide; Rats, Wistar; Sorafenib; Spectroscopy, Fourier Transform Infrared; Static Electricity | 2019 |
The Synergistic Cytotoxic Effect of Laser-Irradiated Gold Nanoparticles and Sorafenib Against the Growth of a Human Hepatocellular Carcinoma Cell Line.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Caspases; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Gold; Hep G2 Cells; Humans; Liver Neoplasms; Metal Nanoparticles; Sorafenib | 2019 |
JNK activation and translocation to mitochondria mediates mitochondrial dysfunction and cell death induced by VDAC opening and sorafenib in hepatocarcinoma cells.
Topics: Anthracenes; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Death; Cell Line, Tumor; Enzyme Activation; Hep G2 Cells; Humans; JNK Mitogen-Activated Protein Kinases; Liver Neoplasms; Membrane Potential, Mitochondrial; Mitochondria; Oxidative Stress; Protein Transport; Reactive Oxygen Species; Sorafenib; Voltage-Dependent Anion Channels | 2020 |
DNMT3b/OCT4 expression confers sorafenib resistance and poor prognosis of hepatocellular carcinoma through IL-6/STAT3 regulation.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Disease Models, Animal; DNA (Cytosine-5-)-Methyltransferases; DNA Methyltransferase 3B; Drug Resistance, Neoplasm; Female; Hep G2 Cells; Heterografts; Humans; Interleukin-6; Liver Neoplasms; Mice; Mice, Inbred BALB C; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Middle Aged; Octamer Transcription Factor-3; Prognosis; Sorafenib; STAT3 Transcription Factor | 2019 |
USP22 promotes hypoxia-induced hepatocellular carcinoma stemness by a HIF1α/USP22 positive feedback loop upon TP53 inactivation.
Topics: Animals; Carcinoma, Hepatocellular; Cell Hypoxia; Cell Line, Tumor; Drug Resistance, Neoplasm; Glycolysis; Hypoxia-Inducible Factor 1, alpha Subunit; Liver Neoplasms; Mice; Neoplastic Stem Cells; Sorafenib; Tumor Suppressor Protein p53; Ubiquitin Thiolesterase | 2020 |
An NIR-responsive mesoporous silica nanosystem for synergetic photothermal-immunoenhancement therapy of hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Female; Immunotherapy; Indocyanine Green; Liver Neoplasms; Mice; Mice, Inbred C57BL; Nanoparticles; Phototherapy; Silicon Dioxide; Sorafenib; Theranostic Nanomedicine | 2020 |
Targeting adenosinergic pathway enhances the anti-tumor efficacy of sorafenib in hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Disease Models, Animal; Female; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred C57BL; Middle Aged; Sorafenib; Survival Analysis; Tumor Microenvironment; Young Adult | 2020 |
Presentation and Outcomes of Hepatocellular Carcinoma in the Arabian Peninsula: A Review of a Single Institution Experience in the Sorafenib Era.
Topics: Aged; Carcinoma, Hepatocellular; Diabetes Mellitus; Disease Progression; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Kaplan-Meier Estimate; Kuwait; Liver; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Prognosis; Retrospective Studies; Risk Factors; Severity of Illness Index; Sex Factors; Sorafenib; Treatment Outcome | 2021 |
Apolipoprotein E Peptide-Guided Disulfide-Cross-Linked Micelles for Targeted Delivery of Sorafenib to Hepatocellular Carcinoma.
Topics: Animals; Antineoplastic Agents; Apolipoproteins E; Carcinoma, Hepatocellular; Cell Survival; Cross-Linking Reagents; Disulfides; Dose-Response Relationship, Drug; Drug Delivery Systems; Female; Hep G2 Cells; Humans; Liver Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Micelles; Sorafenib; Xenograft Model Antitumor Assays | 2020 |
Comprehensive characterization of tumor infiltrating natural killer cells and clinical significance in hepatocellular carcinoma based on gene expression profiles.
Topics: Carcinoma, Hepatocellular; Cohort Studies; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Killer Cells, Natural; Ligands; Liver Neoplasms; Lymphocytes, Tumor-Infiltrating; Prognosis; Receptors, Immunologic; Sorafenib | 2020 |
As Clinical Markers, Hand-Foot-Skin Reaction and Diarrhea Can Predict Better Outcomes for Hepatocellular Carcinoma Patients Receiving Transarterial Chemoembolization plus Sorafenib.
Topics: Adult; Antineoplastic Agents; Biomarkers; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Diarrhea; Female; Humans; Liver Neoplasms; Male; Middle Aged; Predictive Value of Tests; Retrospective Studies; Skin Diseases; Sorafenib; Survival Rate; Treatment Outcome | 2019 |
Bioactivity Evaluation of a Novel Formulated Curcumin.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Aurora Kinase A; Biological Availability; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Curcumin; Drug Delivery Systems; Humans; Liver Neoplasms; Male; Rats; Rats, Sprague-Dawley; Sorafenib | 2019 |
Upregulation of SNX5 predicts poor prognosis and promotes hepatocellular carcinoma progression by modulating the EGFR-ERK1/2 signaling pathway.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Male; MAP Kinase Signaling System; Middle Aged; Prognosis; Protein Kinase Inhibitors; Sorafenib; Sorting Nexins | 2020 |
Mebendazole augments sensitivity to sorafenib by targeting MAPK and BCL-2 signalling in n-nitrosodiethylamine-induced murine hepatocellular carcinoma.
Topics: Alanine Transaminase; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cyclin D1; Diethylnitrosamine; Hep G2 Cells; Humans; Kaplan-Meier Estimate; Ki-67 Antigen; Liver Neoplasms; Male; MAP Kinase Signaling System; Matrix Metalloproteinase 2; Mebendazole; Mice; Mitogen-Activated Protein Kinases; Molecular Targeted Therapy; Phosphorylation; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; Signal Transduction; Sorafenib; Tissue Inhibitor of Metalloproteinase-1; Tumor Burden; Vascular Endothelial Growth Factor A | 2019 |
LATS1 but not LATS2 represses autophagy by a kinase-independent scaffold function.
Topics: Animals; Autophagy; Beclin-1; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Datasets as Topic; Disease-Free Survival; Drug Resistance, Neoplasm; Hippo Signaling Pathway; Humans; Kaplan-Meier Estimate; Liver; Liver Neoplasms; Lysine; Mice; Mice, Knockout; Organoids; Protein Serine-Threonine Kinases; Protein Stability; Signal Transduction; Sorafenib; Tumor Suppressor Proteins; Ubiquitination; Xenograft Model Antitumor Assays | 2019 |
Letter: are sorafenib-related adverse events associated with prolonged survival?
Topics: Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib | 2020 |
Letter: are sorafenib-related adverse events associated with prolonged survival? Authors' reply.
Topics: Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib | 2020 |
Add-on sorafenib is beneficial for hepatocellular carcinoma patients with transarterial chemoembolization refractoriness: a real-world experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Humans; Liver Neoplasms; Male; Middle Aged; Retrospective Studies; Sorafenib; Treatment Outcome | 2020 |
microRNA-29a regulates liver tumor-initiating cells expansion via Bcl-2 pathway.
Topics: 3' Untranslated Regions; Animals; Carcinogenesis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Self Renewal; Down-Regulation; Hep G2 Cells; Heterografts; Humans; Liver; Liver Neoplasms; Mice; MicroRNAs; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Sorafenib | 2020 |
TMPRSS4 Drives Angiogenesis in Hepatocellular Carcinoma by Promoting HB-EGF Expression and Proteolytic Cleavage.
Topics: Angiogenesis Inhibitors; Bacterial Proteins; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Heparin-binding EGF-like Growth Factor; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Liver Neoplasms; Matrix Metalloproteinase 9; Membrane Proteins; Neovascularization, Pathologic; Phosphatidylinositol 3-Kinases; Prognosis; Serine Endopeptidases; Signal Transduction; Sorafenib | 2020 |
NOD1 inhibits proliferation and enhances response to chemotherapy via suppressing SRC-MAPK pathway in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Fluorouracil; Humans; Liver Neoplasms; Mice, Nude; Nod1 Signaling Adaptor Protein; Protein Kinase Inhibitors; Proto-Oncogene Mas; RNA, Small Interfering; Signal Transduction; Sorafenib; src-Family Kinases | 2020 |
Mitochondrial metabolic study guided by proteomics analysis in hepatocellular carcinoma cells surviving long-term incubation with the highest dose of sorafenib.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Dose-Response Relationship, Drug; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Humans; Liver Neoplasms; Mitochondria; Proteomics; Sorafenib; Transcriptome | 2019 |
Response to: Prognostication of HCC patients under sorafenib is not always possible.
Topics: Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib | 2020 |
OGDHL silencing promotes hepatocellular carcinoma by reprogramming glutamine metabolism.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cohort Studies; Drug Resistance, Neoplasm; Female; Gene Silencing; Glutamine; Humans; Ketoglutarate Dehydrogenase Complex; Lipid Metabolism; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Signal Transduction; Sorafenib; Tumor Burden; Xenograft Model Antitumor Assays | 2020 |
Positive feedback loop of FAM83A/PI3K/AKT/c-Jun induces migration, invasion and metastasis in hepatocellular carcinoma.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Feedback, Physiological; Female; Gene Silencing; Humans; Liver Neoplasms; Male; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Phosphatidylinositol 3-Kinases; Promoter Regions, Genetic; Protein Binding; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-jun; Signal Transduction; Sorafenib | 2020 |
Therapeutic Drug Monitoring of Sorafenib in Hepatocellular Carcinoma Patients.
Topics: Antineoplastic Agents; Asian People; Carcinoma, Hepatocellular; Drug Monitoring; Humans; India; Liver Neoplasms; Reference Values; Sorafenib | 2020 |
Are we ready for targeted therapy combinations in HCC?
Topics: Carcinoma, Hepatocellular; Cyclin-Dependent Kinases; DNA Damage; Humans; Liver Neoplasms; Molecular Targeted Therapy; Sorafenib | 2020 |
Sorafenib Inhibits Ribonucleotide Reductase Regulatory Subunit M2 (RRM2) in Hepatocellular Carcinoma Cells.
Topics: Antineoplastic Agents; Autophagy; Carcinoma, Hepatocellular; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Liver Neoplasms; Ribonucleoside Diphosphate Reductase; Sorafenib | 2020 |
Rhabdomyolysis in a patient under treatment with sorafenib.
Topics: Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Prognosis; Rhabdomyolysis; Sorafenib | 2020 |
Small interfering RNA targeting alpha7 nicotinic acetylcholine receptor sensitizes hepatocellular carcinoma cells to sorafenib.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Liver Neoplasms; Mice; RNA, Small Interfering; Sorafenib | 2020 |
The role of the key autophagy kinase ULK1 in hepatocellular carcinoma and its validation as a treatment target.
Topics: Animals; Apoptosis; Autophagy; Autophagy-Related Protein-1 Homolog; Carcinoma, Hepatocellular; Cell Proliferation; CHO Cells; Cricetinae; Cricetulus; Disease Progression; Drug Design; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Intracellular Signaling Peptides and Proteins; Liver Neoplasms; Mice; Mice, Inbred C57BL; Molecular Docking Simulation; Mutagenesis; Neoplasm Invasiveness; Neoplasm Transplantation; Rats; Rats, Sprague-Dawley; Sorafenib | 2020 |
Hedgehog signaling promotes sorafenib resistance in hepatocellular carcinoma patient-derived organoids.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Disease Models, Animal; Drug Resistance, Neoplasm; Hedgehog Proteins; Humans; Liver Neoplasms; Mice; Organoids; Signal Transduction; Sorafenib | 2020 |
Simvastatin re-sensitizes hepatocellular carcinoma cells to sorafenib by inhibiting HIF-1α/PPAR-γ/PKM2-mediated glycolysis.
Topics: Animals; Anticholesteremic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Carrier Proteins; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Glycolysis; Hep G2 Cells; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Liver Neoplasms; Membrane Proteins; Mice; Mice, Nude; PPAR gamma; Simvastatin; Sorafenib; Thyroid Hormone-Binding Proteins; Thyroid Hormones; Xenograft Model Antitumor Assays | 2020 |
Treatment patterns and survival in patients with hepatocellular carcinoma in the Swedish national registry SweLiv.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Databases, Factual; Female; Hepatectomy; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Registries; Sorafenib; Survival Analysis; Sweden; Treatment Outcome; Young Adult | 2020 |
Overcoming sorafenib treatment-resistance in hepatocellular carcinoma: A future perspective at a time of rapidly changing treatment paradigms.
Topics: Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib | 2020 |
Relationship Between Adverse Events and Microbiomes in Advanced Hepatocellular Carcinoma Patients Treated With Sorafenib.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Microbiota; Sorafenib | 2020 |
Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE-2 Study.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Female; Genotype; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Liver Neoplasms; Male; Middle Aged; Neovascularization, Pathologic; Polymorphism, Single Nucleotide; Prognosis; Retrospective Studies; Sorafenib; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1 | 2020 |
Patterns and Outcomes in Hepatocellular Carcinoma Patients with Portal Vein Invasion: A Multicenter Prospective Cohort Study.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Cohort Studies; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Portal Vein; Prospective Studies; Sorafenib; Survival Rate; Treatment Outcome; Vascular Neoplasms | 2021 |
Efficacy and Safety of Sorafenib After Liver Transplantation: Experience in Our Center.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Postoperative Period; Retrospective Studies; Sorafenib; Treatment Outcome | 2020 |
DNA methylation-driven EMT is a common mechanism of resistance to various therapeutic agents in cancer.
Topics: Azacitidine; Carcinoma, Hepatocellular; Cell Line, Tumor; Circulating Tumor DNA; DNA Methylation; Drug Resistance, Neoplasm; Enzyme Inhibitors; Epigenesis, Genetic; Epithelial-Mesenchymal Transition; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; MicroRNAs; Protein Kinase Inhibitors; Sorafenib | 2020 |
NRF2/SHH signaling cascade promotes tumor-initiating cell lineage and drug resistance in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Lineage; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Hedgehog Proteins; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred NOD; Mice, SCID; Middle Aged; Neoplasm Recurrence, Local; Neoplastic Stem Cells; NF-E2-Related Factor 2; Prognosis; Sorafenib; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2020 |
Inhibitors of the protein-protein interaction between phosphorylated p62 and Keap1 attenuate chemoresistance in a human hepatocellular carcinoma cell line.
Topics: 1-Naphthylamine; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Synergism; Humans; Kelch-Like ECH-Associated Protein 1; Liver Neoplasms; Naphthalenes; NF-E2-Related Factor 2; Phosphorylation; Protein Interaction Domains and Motifs; RNA-Binding Proteins; Sorafenib; Sulfonamides | 2020 |
Clinical significance of circulating soluble immune checkpoint proteins in sorafenib-treated patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; B7-H1 Antigen; Biomarkers, Tumor; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Proportional Hazards Models; Protein Kinase Inhibitors; Receptors, Immunologic; Sorafenib; Survival Rate; Tumor Necrosis Factor Receptor Superfamily, Member 7; Young Adult | 2020 |
Outcomes in hepatocellular carcinoma patients undergoing sorafenib treatment: toxicities, cellular oxidative stress, treatment adherence, and quality of life.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Humans; Leukocytes, Mononuclear; Liver Neoplasms; Longitudinal Studies; Male; Middle Aged; Oxidative Stress; Prospective Studies; Quality of Life; Sorafenib; Surveys and Questionnaires; Treatment Adherence and Compliance; Treatment Outcome | 2020 |
Targeted Therapy for Hepatocellular Carcinoma: Co-Delivery of Sorafenib and Curcumin Using Lactosylated pH-Responsive Nanoparticles.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line; Cell Proliferation; Curcumin; Drug Delivery Systems; Drug Screening Assays, Antitumor; Drug Tolerance; Hep G2 Cells; Humans; Injections, Intravenous; Liver Neoplasms; Liver Neoplasms, Experimental; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Targeted Therapy; Particle Size; Sorafenib; Surface Properties | 2020 |
TMT-based proteomics analysis of the anti-hepatocellular carcinoma effect of combined dihydroartemisinin and sorafenib.
Topics: Antimalarials; Antineoplastic Agents; Artemisinins; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Drug Therapy, Combination; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Sorafenib; Up-Regulation | 2020 |
Dysregulated lipid metabolism in hepatocellular carcinoma cancer stem cells.
Topics: Acetyl-CoA Carboxylase; AMP-Activated Protein Kinases; Carcinoma, Hepatocellular; Cell Line, Tumor; Gene Expression Regulation; Hep G2 Cells; Humans; Lipid Metabolism; Lipogenesis; Liver Neoplasms; Metformin; Neoplastic Stem Cells; Phosphorylation; Sorafenib | 2020 |
Diffuse advanced hepatocellular carcinoma after HCV eradication in an HIV-infected patient: A unique complete response to sorafenib.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Coinfection; Hepacivirus; Hepatitis C; HIV; HIV Infections; Humans; Induction Chemotherapy; Liver Neoplasms; Male; Sorafenib | 2020 |
NOD2 inhibits tumorigenesis and increases chemosensitivity of hepatocellular carcinoma by targeting AMPK pathway.
Topics: AMP-Activated Protein Kinases; Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Transformation, Neoplastic; Liver Neoplasms; Mice; Nod2 Signaling Adaptor Protein; Sorafenib | 2020 |
REACH-2: first biomarker-based anti-angiogenic therapy in patients with advanced hepatocellular carcinoma.
Topics: alpha-Fetoproteins; Antibodies, Monoclonal, Humanized; Carcinoma, Hepatocellular; Double-Blind Method; Humans; Liver Neoplasms; Ramucirumab; Sorafenib | 2020 |
Dose-dependent regulation of mitochondrial function and cell death pathway by sorafenib in liver cancer cells.
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Autophagy; Carcinoma, Hepatocellular; Caspase 9; Cell Death; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Hep G2 Cells; Humans; Liver Neoplasms; Male; Mitochondria, Liver; Nitric Oxide; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Rats, Wistar; Signal Transduction; Sorafenib | 2020 |
Sorafenib treatment has the potential to downstage advanced hepatocellular carcinoma before liver resection.
Topics: Carcinoma, Hepatocellular; Hepatectomy; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Portal Vein; Sorafenib; Treatment Outcome; Venous Thrombosis | 2020 |
Lenvatinib Versus Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma: A Cost-Utility Analysis.
Topics: Antineoplastic Agents; Canada; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Humans; Liver Neoplasms; Phenylurea Compounds; Quinolines; Sorafenib | 2020 |
Real world clinical practice in treating advanced hepatocellular carcinoma: When East meets West.
Topics: Aged; Aged, 80 and over; alpha-Fetoproteins; Antineoplastic Agents; Carcinoma, Hepatocellular; Embolization, Therapeutic; Female; Hepatitis B Surface Antigens; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Retrospective Studies; Risk Factors; Sorafenib; Survival Analysis; Vascular Neoplasms | 2020 |
microRNA-454 promotes liver tumor-initiating cell expansion by regulating SOCS6.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Proliferation; Drug Resistance, Neoplasm; Hep G2 Cells; Humans; Liver; Liver Neoplasms; Mice; Mice, Inbred NOD; Mice, SCID; MicroRNAs; Neoplastic Stem Cells; Sorafenib; Suppressor of Cytokine Signaling Proteins | 2020 |
Effectiveness of sorafenib dose modifications on treatment outcome of hepatocellular carcinoma: Analysis in real-life settings.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Dose-Response Relationship, Drug; Drug Tapering; Female; Humans; Liver Neoplasms; Male; Medication Adherence; Middle Aged; Sorafenib; Survival Analysis; Time Factors; Treatment Outcome | 2020 |
Inactivation of Transcriptional Repressor Capicua Confers Sorafenib Resistance in Human Hepatocellular Carcinoma.
Topics: Aged; Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Chemotherapy, Adjuvant; Disease-Free Survival; DNA Mutational Analysis; Drug Resistance, Neoplasm; Exome Sequencing; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Hepatectomy; Humans; Liver; Liver Neoplasms; Male; MAP Kinase Signaling System; Mice; Mutation; Neoplasm Recurrence, Local; Repressor Proteins; Sorafenib; Xenograft Model Antitumor Assays | 2020 |
Changing TACTICS in intermediate HCC: TACE plus sorafenib.
Topics: Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neoplasms; Phenylurea Compounds; Prospective Studies; Sorafenib | 2020 |
Differential expression of Tim-3, PD-1, and CCR5 on peripheral T and B lymphocytes in hepatitis C virus-related hepatocellular carcinoma and their impact on treatment outcomes.
Topics: Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Biomarkers, Tumor; Capecitabine; Carcinoma, Hepatocellular; Case-Control Studies; Female; Follow-Up Studies; Hepacivirus; Hepatitis A Virus Cellular Receptor 2; Hepatitis C; Humans; Liver Neoplasms; Male; Middle Aged; Prognosis; Programmed Cell Death 1 Receptor; Receptors, CCR5; Sorafenib; Survival Rate; T-Lymphocytes | 2020 |
International and multicenter real-world study of sorafenib-treated patients with hepatocellular carcinoma under dialysis.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Europe; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Renal Dialysis; Sorafenib; Treatment Outcome | 2020 |
Liver transplantation for hepatocellular carcinoma after down staging with sorafenib: a monocentric case-matched series.
Topics: alpha-Fetoproteins; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Case-Control Studies; Eligibility Determination; Female; Glypicans; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Staging; Outcome and Process Assessment, Health Care; Preoperative Care; Sorafenib; Tumor Burden | 2020 |
Compound kushen injection relieves tumor-associated macrophage-mediated immunosuppression through TNFR1 and sensitizes hepatocellular carcinoma to sorafenib.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Proliferation; Drug Synergism; Drugs, Chinese Herbal; Humans; Immunosuppression Therapy; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Nude; Neoplasm Recurrence, Local; Receptors, Tumor Necrosis Factor, Type I; Sorafenib; Tumor Cells, Cultured; Tumor Microenvironment; Tumor-Associated Macrophages; Xenograft Model Antitumor Assays | 2020 |
Assessment of the Effect of Sorafenib on Omega-6 and Omega-3 Epoxyeicosanoid Formation in Patients with Hepatocellular Carcinoma.
Topics: Aged; Antineoplastic Agents; Arachidonic Acid; Carcinoma, Hepatocellular; Docosahexaenoic Acids; Eicosanoids; Epoxide Hydrolases; Epoxy Compounds; Fatty Acids, Omega-3; Fatty Acids, Omega-6; Female; Humans; Liver Neoplasms; Male; Middle Aged; Pilot Projects; Sorafenib | 2020 |
Sorafenib-Loaded Nanoparticles Based on Biodegradable Dendritic Polymers for Enhanced Therapy of Hepatocellular Carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Dendrimers; Drug Delivery Systems; Hep G2 Cells; Humans; Liver Neoplasms; Mice; Nanoparticles; Polymers; Sorafenib; Vitamin E; Xenograft Model Antitumor Assays | 2020 |
A novel multitarget kinase inhibitor BZG with potent anticancer activity in vitro and vivo enhances efficacy of sorafenib through PI3K pathways in hepatocellular carcinoma cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Aziridines; Benzoquinones; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Phosphatidylinositol 3-Kinase; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Signal Transduction; Sorafenib; Xenograft Model Antitumor Assays | 2020 |
High throughput lipid profiling for subtype classification of hepatocellular carcinoma cell lines and tumor tissues.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Line, Tumor; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Humans; Lipids; Liver Neoplasms; Sorafenib; Tandem Mass Spectrometry | 2020 |
Quantitative phosphoproteomic analysis identifies the potential therapeutic target EphA2 for overcoming sorafenib resistance in hepatocellular carcinoma cells.
Topics: Animals; Carcinoma, Hepatocellular; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease Models, Animal; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Mice; Phosphoproteins; Proteomics; Receptor, EphA2; Signal Transduction; Sorafenib; Xenograft Model Antitumor Assays | 2020 |
Sorafenib-Conjugated Zinc Phthalocyanine Based Nanocapsule for Trimodal Therapy in an Orthotopic Hepatocellular Carcinoma Xenograft Mouse Model.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Humans; Indoles; Isoindoles; Light; Liver Neoplasms; Male; Mice; Mice, Nude; Nanocapsules; Organometallic Compounds; Photochemotherapy; Photosensitizing Agents; Phototherapy; Reactive Oxygen Species; Serum Albumin, Bovine; Sorafenib; Xenograft Model Antitumor Assays; Zinc Compounds | 2020 |
Enhancing Anti-Tumor Activity of Sorafenib Mesoporous Silica Nanomatrix in Metastatic Breast Tumor and Hepatocellular Carcinoma via the Co-Administration with Flufenamic Acid.
Topics: 20-Hydroxysteroid Dehydrogenases; Aldo-Keto Reductase Family 1 Member C3; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Dinoprostone; Female; Flufenamic Acid; Hep G2 Cells; Humans; Liver Neoplasms; Male; Mice, Inbred BALB C; Mice, Nude; Nanostructures; Silicon Dioxide; Sorafenib; Xenograft Model Antitumor Assays | 2020 |
Exploiting Plug-and-Play Electrochemical Biosensors to Determine the Role of FGF19 in Sorafenib-Mediated Superoxide and Nitric Oxide Production in Hepatocellular Carcinoma Cells.
Topics: Antineoplastic Agents; Biosensing Techniques; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Fibroblast Growth Factors; Humans; Liver Neoplasms; Nitric Oxide; Sorafenib; Superoxides | 2020 |
Comparison of stereotactic body radiation therapy with and without sorafenib as treatment for hepatocellular carcinoma with portal vein tumor thrombosis.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoradiotherapy; Female; Humans; Liver Neoplasms; Male; Middle Aged; Portal Vein; Progression-Free Survival; Radiation Dosage; Radiosurgery; Retrospective Studies; Sorafenib; Taiwan; Venous Thrombosis | 2020 |
Sorafenib
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Phenylurea Compounds; Portal Vein; Quinolines; Retrospective Studies; Sorafenib; Survival Analysis; Treatment Outcome; Venous Thrombosis | 2020 |
Sorafenib Treatment and Modulation of the Sphingolipid Pathway Affect Proliferation and Viability of Hepatocellular Carcinoma In Vitro.
Topics: Apoptosis; Basic Helix-Loop-Helix Transcription Factors; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Ceramides; Hep G2 Cells; Humans; Liver Neoplasms; Protein Kinase Inhibitors; Sorafenib; Sphingolipids | 2020 |
Microbiota-derived SSL6 enhances the sensitivity of hepatocellular carcinoma to sorafenib by down-regulating glycolysis.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; CD47 Antigen; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Exotoxins; Glycolysis; Hep G2 Cells; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Microbiota; Phosphatidylinositol 3-Kinases; Sensitivity and Specificity; Sorafenib; Xenograft Model Antitumor Assays | 2020 |
Synergistic interaction between thioredoxin inhibitor 1-methylpropyl 2-imidazolyl disulfide and sorafenib in liver cancer cells.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Disulfides; Drug Synergism; Humans; Imidazoles; Inhibitory Concentration 50; Liver Neoplasms; Sorafenib; Thioredoxins | 2020 |
Zinc finger protein 703 induces EMT and sorafenib resistance in hepatocellular carcinoma by transactivating CLDN4 expression.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Carrier Proteins; Cell Line, Tumor; Claudin-4; Disease Progression; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Hep G2 Cells; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Sorafenib; Transcriptional Activation; Transfection; Up-Regulation; Xenograft Model Antitumor Assays; Zinc Fingers | 2020 |
The potential chemotherapeutic effect of β-ionone and/or sorafenib against hepatocellular carcinoma via its antioxidant effect, PPAR-γ, FOXO-1, Ki-67, Bax, and Bcl-2 signaling pathways.
Topics: Animals; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Carcinoma, Hepatocellular; Cell Proliferation; Diethylnitrosamine; Ki-67 Antigen; Liver Neoplasms; Male; Nerve Tissue Proteins; Norisoprenoids; Oxidative Stress; PPAR gamma; Proto-Oncogene Proteins c-bcl-2; Rats, Wistar; Signal Transduction; Sorafenib | 2020 |
The efficacy and safety of sorafenib in older adults with advanced hepatocellular carcinoma: An analysis of a majority Hispanic cohort.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Hispanic or Latino; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2020 |
CCL22 signaling contributes to sorafenib resistance in hepatitis B virus-associated hepatocellular carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemokine CCL22; Drug Resistance, Neoplasm; Hep G2 Cells; Hepatitis B; Humans; Liver Neoplasms; Lymphocytes, Tumor-Infiltrating; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Nude; Protein Kinase Inhibitors; Quinazolines; Receptors, CCR4; Signal Transduction; Sorafenib; T-Lymphocytes; Tumor Burden | 2020 |
Activator of thyroid and retinoid receptor increases sorafenib resistance in hepatocellular carcinoma by facilitating the Warburg effect.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Glycolysis; Hep G2 Cells; Humans; Liver Neoplasms; Male; Mice; Mice, Nude; Nuclear Receptor Coactivator 3; Sorafenib; Xenograft Model Antitumor Assays | 2020 |
Silencing MYH9 blocks HBx-induced GSK3β ubiquitination and degradation to inhibit tumor stemness in hepatocellular carcinoma.
Topics: Animals; beta Catenin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Epithelial-Mesenchymal Transition; Gene Expression Regulation, Neoplastic; Gene Silencing; Glycogen Synthase Kinase 3 beta; Heterografts; Humans; JNK Mitogen-Activated Protein Kinases; Liver Neoplasms; Mice; Myosin Heavy Chains; Neoplastic Stem Cells; Sorafenib; Trans-Activators; Ubiquitination; Viral Regulatory and Accessory Proteins; Wnt Signaling Pathway | 2020 |
Synergistic antitumor activity of sorafenib and artesunate in hepatocellular carcinoma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Artesunate; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Female; Humans; Liver Neoplasms; MAP Kinase Signaling System; Mice, Inbred BALB C; Mice, Nude; Sorafenib; Xenograft Model Antitumor Assays | 2020 |
[Establishment and gene expression analysis of drug-resistant cell lines in hepatocellular carcinoma induced by sorafenib].
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Humans; Ligases; Liver Neoplasms; Polycomb-Group Proteins; Serine Endopeptidases; Sorafenib | 2020 |
Modulation of SIRT3 expression through CDK4/6 enhances the anti-cancer effect of sorafenib in hepatocellular carcinoma cells.
Topics: Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Movement; Cell Proliferation; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Prognosis; Sirtuin 3; Sorafenib; Tumor Cells, Cultured | 2020 |
Comparison of Sorafenib versus Hepatic Arterial Infusion Chemotherapy-Based Treatment for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Portal Vein; Sorafenib; Thrombosis; Treatment Outcome | 2021 |
Genome-scale CRISPR activation screening identifies a role of LRP8 in Sorafenib resistance in Hepatocellular carcinoma.
Topics: Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Clustered Regularly Interspaced Short Palindromic Repeats; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Genetic Testing; Genome, Human; Humans; LDL-Receptor Related Proteins; Liver Neoplasms; Prognosis; Sorafenib | 2020 |
The therapeutic benefits of combined sorafenib and transarterial chemoembolization for advanced hepatocellular carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Sorafenib; Treatment Outcome | 2020 |
Comparative cost-effectiveness of cabozantinib as second-line therapy for patients with advanced hepatocellular carcinoma in Germany and the United States.
Topics: Anilides; Antineoplastic Agents; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Drug Resistance, Neoplasm; Germany; Humans; Liver Neoplasms; Markov Chains; Pyridines; Quality-Adjusted Life Years; Sorafenib; Survival Analysis; United States | 2020 |
Letter to the Editor: Role of Sorafenib in Liver Transplantation Outcomes of Patients With Hepatocellular Carcinoma Presenting Beyond Milan Criteria?
Topics: Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Liver Transplantation; Neoplasm Recurrence, Local; Neoplasm Staging; Sorafenib | 2020 |
Microwave ablation versus sorafenib for intermediate-Stage Hepatocellular carcinoma with transcatheter arterial chemoembolization refractoriness: a propensity score matching analysis.
Topics: Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neoplasms; Male; Middle Aged; Propensity Score; Radiofrequency Ablation; Retrospective Studies; Sorafenib; Treatment Outcome | 2020 |
SNGH16 regulates cell autophagy to promote Sorafenib Resistance through suppressing miR-23b-3p via sponging EGR1 in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Proliferation; Early Growth Response Protein 1; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred NOD; Mice, SCID; MicroRNAs; Prognosis; RNA, Long Noncoding; Sorafenib; Survival Rate; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2020 |
High FLT3 Levels May Predict Sorafenib Benefit in Hepatocellular Carcinoma.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Line, Tumor; Female; fms-Like Tyrosine Kinase 3; Gene Expression Regulation, Neoplastic; Heterografts; Humans; Liver Neoplasms; Male; Mice; Middle Aged; Sorafenib | 2020 |
Establishment and Preclinical Therapy of Patient-derived Hepatocellular Carcinoma Xenograft Model.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Disease Models, Animal; Drug Evaluation, Preclinical; Heterografts; Humans; Immunotherapy; Killer Cells, Natural; Liver Neoplasms; Mice; Mice, SCID; Sorafenib; Xenograft Model Antitumor Assays | 2020 |
Time Course of Changes in Sorafenib-Treated Hepatocellular Carcinoma Cells Suggests Involvement of Phospho-Regulated Signaling in Ferroptosis Induction.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; DNA-Binding Proteins; Ferritins; Ferroptosis; Gene Expression Regulation, Neoplastic; Heme Oxygenase-1; Homeostasis; Humans; Iron; Lipid Peroxidation; Liver Neoplasms; Oxidoreductases; Phosphoproteins; Phosphorylation; Protein Kinase Inhibitors; RNA-Binding Proteins; Signal Transduction; Sorafenib | 2020 |
Preparation and characterization of parthenolide nanocrystals for enhancing therapeutic effects of sorafenib against advanced hepatocellular carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Movement; Cell Proliferation; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Compounding; Drug Liberation; Drug Stability; Drug Synergism; Female; Hep G2 Cells; Humans; Liver Neoplasms; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Sesquiterpenes; Solubility; Sorafenib; Tumor Burden; Xenograft Model Antitumor Assays | 2020 |
Incapacitated Capicua in Sorafenib-Resistant HCC.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Sorafenib | 2020 |
Liposomal clodronate combined with Cisplatin or Sorafenib inhibits hepatocellular carcinoma cell proliferation, migration and invasion by suppressing FOXQ1 expression.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Movement; Cell Proliferation; Cisplatin; Clodronic Acid; Forkhead Transcription Factors; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Liposomes; Liver Neoplasms; Neoplasm Invasiveness; RNA, Messenger; Sorafenib | 2020 |
Nutrition and metabolism status alteration in advanced hepatocellular carcinoma patients treated with anti-PD-1 immunotherapy.
Topics: Antineoplastic Agents, Immunological; Carcinoma, Hepatocellular; Female; Humans; Immunotherapy; Liver Neoplasms; Male; Middle Aged; Nutrition Assessment; Nutritional Status; Prognosis; Programmed Cell Death 1 Receptor; Retrospective Studies; Sorafenib; Survival Analysis | 2020 |
RNA m
Topics: Adenosine; Animals; Autophagy; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Forkhead Box Protein O3; HEK293 Cells; Hep G2 Cells; Human Umbilical Vein Endothelial Cells; Humans; Liver Neoplasms; Male; Methylation; Methyltransferases; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Proteins; RNA, Messenger; RNA, Neoplasm; Sorafenib | 2020 |
Low-Dose Sorafenib Acts as a Mitochondrial Uncoupler and Ameliorates Nonalcoholic Steatohepatitis.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line; Dose-Response Relationship, Drug; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred C57BL; Mitochondria; Non-alcoholic Fatty Liver Disease; Sorafenib | 2020 |
Second-line treatment of hepatocellular carcinoma after sorafenib: Characterizing treatments used over the past 10 years and real-world eligibility for cabozantinib, regorafenib, and ramucirumab.
Topics: Anilides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Canada; Carcinoma, Hepatocellular; Clinical Trials, Phase III as Topic; Databases, Factual; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Patient Selection; Phenylurea Compounds; Pyridines; Ramucirumab; Randomized Controlled Trials as Topic; Sorafenib; Time Factors | 2020 |
The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Cohort Studies; Female; Humans; Italy; Kaplan-Meier Estimate; Liver Neoplasms; Lymphocyte Count; Male; Middle Aged; Nutrition Assessment; Prognosis; Retrospective Studies; Serum Albumin; Sorafenib | 2020 |
Epithelial cell -derived microvesicles: A safe delivery platform of CRISPR/Cas9 conferring synergistic anti-tumor effect with sorafenib.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Proliferation; Cell-Derived Microparticles; Combined Modality Therapy; CRISPR-Cas Systems; Epithelial Cells; Female; Gene Editing; Humans; Liver Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; ras GTPase-Activating Proteins; Sorafenib; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2020 |
[A Case of Advanced Hepatocellular Carcinoma Successfully Treated with Liver Resection after Administration of Sorafenib].
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Hepatectomy; Humans; Liver Neoplasms; Male; Neoplasm Recurrence, Local; Sorafenib | 2020 |
Differential effectiveness of tyrosine kinase inhibitors in 2D/3D culture according to cell differentiation, p53 status and mitochondrial respiration in liver cancer cells.
Topics: Adult; Anilides; Apoptosis; Cell Culture Techniques; Cell Differentiation; Cell Proliferation; Cell Respiration; Female; Hep G2 Cells; Hepatocytes; Humans; Liver Neoplasms; Male; Mitochondria; Oxygen Consumption; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinolines; Sorafenib; Spheroids, Cellular; Tumor Suppressor Protein p53 | 2020 |
Downregulation of thioredoxin-1-dependent CD95 S-nitrosation by Sorafenib reduces liver cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Humans; Liver Neoplasms; Mice; Mice, Nude; Nitrosation; Phenylurea Compounds; Sorafenib; Thioredoxins | 2020 |
Expression of FOXM1 and Aurora-A predicts prognosis and sorafenib efficacy in patients with hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aurora Kinase A; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Datasets as Topic; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Forkhead Box Protein M1; Gene Expression Regulation, Neoplastic; Humans; Liver; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Sorafenib; Up-Regulation; Young Adult | 2020 |
Different Mechanisms of Action of Regorafenib and Lenvatinib on Toll-Like Receptor-Signaling Pathways in Human Hepatoma Cell Lines.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Hep G2 Cells; Humans; Immunity, Innate; Liver Neoplasms; Neoplasm Proteins; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Mas; Pyridines; Quinolines; Real-Time Polymerase Chain Reaction; Signal Transduction; Sorafenib; Toll-Like Receptors; Transcriptome | 2020 |
An EGFR signature predicts cell line and patient sensitivity to multiple tyrosine kinase inhibitors.
Topics: Adenocarcinoma of Lung; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chemotherapy, Adjuvant; Datasets as Topic; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Inhibitory Concentration 50; Liver Neoplasms; Logistic Models; Lung Neoplasms; Models, Genetic; Molecular Targeted Therapy; Mutation; Predictive Value of Tests; Prognosis; Progression-Free Survival; Protein Kinase Inhibitors; RNA-Seq; Signal Transduction; Sorafenib; Transcriptome | 2020 |
Can sorafenib use influence outcome when comparing stereotactic body radiation therapy with radiofrequency ablation in patients with hepatocellular carcinoma?
Topics: Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Radiofrequency Ablation; Radiosurgery; Sorafenib | 2020 |
Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma.
Topics: Angiogenesis Inhibitors; Anilides; Antineoplastic Agents; Carcinoma, Hepatocellular; Comparative Effectiveness Research; Disease Progression; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Outcome and Process Assessment, Health Care; Phenylurea Compounds; Progression-Free Survival; Pyridines; Randomized Controlled Trials as Topic; Sorafenib | 2020 |
A reduction and pH dual-sensitive nanodrug for targeted theranostics in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line; Cell Survival; Drug Liberation; Ferric Compounds; Humans; Hydrogen-Ion Concentration; Liver Neoplasms; Mice, Inbred BALB C; Mice, Nude; Micelles; Nanoparticles; Polymers; Protein Kinase Inhibitors; Sorafenib; Theranostic Nanomedicine | 2020 |
Sequential systemic treatment in patients with hepatocellular carcinoma.
Topics: Anilides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Nivolumab; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinolines; Ramucirumab; Sorafenib | 2020 |
Efficacy and Safety of Sorafenib in Unresectable Hepatocellular Carcinoma with Bile Duct Invasion.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bile Duct Neoplasms; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Progression-Free Survival; Retrospective Studies; Sorafenib; Survival Rate | 2020 |
Systemic therapy for advanced hepatocellular carcinoma: targeted therapies.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Immunotherapy; Liver Neoplasms; Sorafenib | 2021 |
The effect of proton pump inhibitors on survival outcomes in advanced hepatocellular carcinoma treated with sorafenib.
Topics: Carcinoma, Hepatocellular; Clinical Trials, Phase III as Topic; Cohort Studies; Drug Synergism; Gastrointestinal Absorption; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Progression-Free Survival; Proportional Hazards Models; Protein Kinase Inhibitors; Proton Pump Inhibitors; Sorafenib; Survival Rate | 2020 |
Lenvatinib suppresses cancer stem-like cells in HCC by inhibiting FGFR1-3 signaling, but not FGFR4 signaling.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Female; Fibroblast Growth Factor 2; Fibroblast Growth Factors; Fluorouracil; Humans; Liver Neoplasms; Mice; Molecular Targeted Therapy; Neoplastic Stem Cells; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolines; Receptor, Fibroblast Growth Factor, Type 1; Receptor, Fibroblast Growth Factor, Type 2; Receptor, Fibroblast Growth Factor, Type 3; Receptor, Fibroblast Growth Factor, Type 4; Signal Transduction; Sorafenib; Xenograft Model Antitumor Assays | 2021 |
Effectiveness of nivolumab versus regorafenib in hepatocellular carcinoma patients who failed sorafenib treatment.
Topics: Aged; Antineoplastic Agents, Immunological; Carcinoma, Hepatocellular; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Nivolumab; Phenylurea Compounds; Proportional Hazards Models; Pyridines; Retrospective Studies; Sorafenib; Treatment Outcome | 2020 |
TFAM depletion overcomes hepatocellular carcinoma resistance to doxorubicin and sorafenib through AMPK activation and mitochondrial dysfunction.
Topics: Adult; AMP-Activated Protein Kinases; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; DNA-Binding Proteins; DNA, Mitochondrial; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Liver Neoplasms; Male; Middle Aged; Mitochondria; Mitochondrial Proteins; Sorafenib; Transcription Factors; Up-Regulation | 2020 |
Sorafenib-Loaded Long-Circulating Nanoliposomes for Liver Cancer Therapy.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Humans; Liposomes; Liver; Liver Neoplasms; Male; Mice, Inbred BALB C; Nanocapsules; Polyethylene Glycols; Receptors, Vascular Endothelial Growth Factor; Sorafenib | 2020 |
LncRNA HOTAIR Contributes to Sorafenib Resistance through Suppressing miR-217 in Hepatic Carcinoma.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Knockdown Techniques; Humans; Liver Neoplasms; MicroRNAs; RNA, Long Noncoding; Sorafenib | 2020 |
Sorafenib for the treatment of hepatocellular carcinoma: a single-centre real-world study.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Cohort Studies; Female; Humans; Liver Neoplasms; Male; Middle Aged; Patient Selection; Protein Kinase Inhibitors; Sorafenib | 2020 |
Safety and efficacy of endovascular implantation of a portal vein stent combined with iodine-125 seed-strips followed by transcatheter arterial chemoembolization with sorafenib for the treatment of hepatocellular carcinoma with portal vein tumor thrombosi
Topics: Aged; Antineoplastic Agents; Blood Vessel Prosthesis; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Endovascular Procedures; Female; Humans; Iodine Radioisotopes; Liver Neoplasms; Male; Middle Aged; Portal Vein; Sorafenib; Stents; Survival Analysis; Thrombosis; Treatment Outcome | 2020 |
Reply to: "Can sorafenib use influence outcome when comparing stereotactic body radiation therapy with radiofrequency ablation in patients with hepatocellular carcinoma?"
Topics: Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Radiofrequency Ablation; Radiosurgery; Sorafenib | 2020 |
Exacerbation of psoriasis vulgaris by sorafenib treatment for hepatocellular carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Psoriasis; Sorafenib; Treatment Outcome | 2020 |
Therapeutic benefits of combined sorafenib for intermediate hepatocellular carcinoma unresponsive to transarterial chemoembolization in a Chinese population.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Disease Progression; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Retrospective Studies; Sorafenib; Survival Rate; Treatment Outcome | 2020 |
Inhibition of EPS8L3 suppresses liver cancer progression and enhances efficacy of sorafenib treatment.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Cycle Checkpoints; Cell Movement; Cell Proliferation; Down-Regulation; Female; Hep G2 Cells; Humans; Liver Neoplasms; Male; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Neoplasm Invasiveness; Protein Kinase Inhibitors; Signal Transduction; Sorafenib; Xenograft Model Antitumor Assays | 2020 |
Utility of neutrophil-to-lymphocyte ratio to identify long-term survivors among HCC patients treated with sorafenib.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Cohort Studies; Female; Humans; Italy; Liver Neoplasms; Lymphocyte Count; Male; Middle Aged; Progression-Free Survival; Sorafenib; Survivors | 2020 |
Anti-hepatoma effect of taccalonolide A through suppression of sonic hedgehog pathway.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Survival; Drug Interactions; Hedgehog Proteins; Hep G2 Cells; Humans; Liver Neoplasms; Signal Transduction; Sorafenib; Steroids | 2020 |
Myeloid signature reveals immune contexture and predicts the prognosis of hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Hepatocellular; Disease-Free Survival; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Male; Middle Aged; Myeloid Cells; Sorafenib; Survival Rate | 2020 |
Overall survival predictors in hepatocellular carcinoma patients treated with sorafenib.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Epidemiologic Methods; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Palliative Care; Sorafenib; Treatment Outcome | 2020 |
Association of Gastric Acid Suppression and Sorafenib Efficacy in Advanced Hepatocellular Carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Gastric Acid; Humans; Liver Neoplasms; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Treatment Outcome; United Kingdom | 2021 |
Hepatocellular carcinoma, novel therapies on the horizon.
Topics: Carcinoma, Hepatocellular; Humans; Immunotherapy; Liver Neoplasms; Neoplasm Recurrence, Local; Sorafenib | 2021 |
Effect of sorafenib starting dose and dose intensity on survival in patients with hepatocellular carcinoma: Results from a Canadian Multicenter Database.
Topics: Antineoplastic Agents; Canada; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Sorafenib; Treatment Outcome | 2020 |
Pancreatic Insufficiency in Patients Under Sorafenib Treatment for Hepatocellular Carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Exocrine Pancreatic Insufficiency; Female; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2021 |
Comparable effects of Jiedu Granule, a compound Chinese herbal medicine, and sorafenib for advanced hepatocellular carcinoma: A prospective multicenter cohort study.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Drugs, Chinese Herbal; Humans; Liver Neoplasms; Prospective Studies; Sorafenib | 2020 |
BARMR1-mediated sorafenib resistance is derived through stem-like property acquisition by activating integrin-FAK signaling pathways.
Topics: Animals; Carcinoma, Hepatocellular; Female; Hep G2 Cells; Heterografts; Humans; Liver Neoplasms; Male; Mice; Proteins; Sorafenib | 2020 |
Robust combination of liver stereotactic body radiotherapy modulates pharmacokinetics of sorafenib toward preferable parameters.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Carcinoma, Hepatocellular; Cell Line, Tumor; Combined Modality Therapy; Cyclosporine; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Dose-Response Relationship, Radiation; Enzyme Induction; Humans; Liver Neoplasms; Male; NF-kappa B; Portal Vein; Protein Kinase Inhibitors; Radiosurgery; Rats; Rats, Sprague-Dawley; Retrospective Studies; Sorafenib; Specific Pathogen-Free Organisms; Tissue Distribution; Venous Thrombosis | 2020 |
[Effect of sorafenib and prophylactic TACE for prevention of postoperative relapse in patients with liver cancer combined with microvascular invasion].
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatectomy; Humans; Liver Neoplasms; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Retrospective Studies; Sorafenib; Treatment Outcome | 2020 |
ACSL4 is a predictive biomarker of sorafenib sensitivity in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Line, Tumor; Coenzyme A Ligases; Ferroptosis; Gene Knockout Techniques; Humans; Liver Neoplasms; Male; Mice, Inbred BALB C; Prognosis; Sorafenib; Xenograft Model Antitumor Assays | 2021 |
SOX9 enhances sorafenib resistance through upregulating ABCG2 expression in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Liver Neoplasms; Male; Mice, Nude; Neoplasm Proteins; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Signal Transduction; Sorafenib; SOX9 Transcription Factor; Up-Regulation; Xenograft Model Antitumor Assays | 2020 |
Lower Serum Sodium Levels Are Associated with the Therapeutic Effect of Sorafenib on Hepatocellular Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; alpha-Fetoproteins; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Predictive Value of Tests; Protein Kinase Inhibitors; Retrospective Studies; Sodium; Sorafenib; Time Factors; Treatment Outcome | 2021 |
A case report: Long-term complete response of metastatic hepatocellular carcinoma obtained after discontinuation of 2-month sorafenib monotherapy.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Neoplasm Recurrence, Local; Sorafenib | 2020 |
Comprehensive network analysis of the molecular mechanisms associated with sorafenib resistance in hepatocellular carcinoma.
Topics: Animals; Carcinoma, Hepatocellular; Databases, Genetic; Drug Resistance; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Humans; Liver Neoplasms; Mice; Sorafenib; Survival Analysis; Transcription Factors; Xenograft Model Antitumor Assays | 2020 |
Programmed Death Ligand-1 (PD-L1) Regulated by NRF-2/MicroRNA-1 Regulatory Axis Enhances Drug Resistance and Promotes Tumorigenic Properties in Sorafenib-Resistant Hepatoma Cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; B7-H1 Antigen; Carcinogenesis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Hep G2 Cells; Humans; Liver Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; NF-E2-Related Factor 2; RNA, Small Interfering; Sorafenib | 2020 |
Treatment with a New Barbituric Acid Derivative Exerts Antiproliferative and Antimigratory Effects against Sorafenib Resistance in Hepatocellular Carcinoma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Barbiturates; Carcinoma, Hepatocellular; Caspase 7; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Gene Expression Profiling; Humans; Liver Neoplasms; MAP Kinase Signaling System; Mice; Phenylurea Compounds; Poly (ADP-Ribose) Polymerase-1; Pyridines; Sorafenib; Vimentin; Wound Healing; Xenograft Model Antitumor Assays | 2020 |
Nanolipid-loaded Preyssler polyoxometalate: Synthesis, characterization and invitro inhibitory effects on HepG2 tumor cells.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line; Humans; Lipids; Liposomes; Liver Neoplasms; Microscopy, Electron, Scanning; Microscopy, Electron, Transmission; Nanoparticles; Sorafenib; Tungsten Compounds | 2020 |
[Gallbladder Perforation after Transarterial Chemoembolization in a Patient with a Huge Hepatocellular Carcinoma].
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Cholecystitis; Gallbladder; Humans; Liver; Liver Neoplasms; Lung Neoplasms; Male; Sorafenib; Tomography, X-Ray Computed | 2020 |
Clinicopathological and molecular analysis of SIRT7 in hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Female; Gene Knockdown Techniques; Hepatocytes; Humans; Liver Neoplasms; Male; Middle Aged; Prognosis; Sirtuins; Sorafenib; Survival Rate; Young Adult | 2020 |
Sorafenib exposure and its correlation with response and safety in advanced hepatocellular carcinoma: results from an observational retrospective study.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Retrospective Studies; Sorafenib; Treatment Outcome | 2020 |
The Prognosis of Hepatocellular Carcinoma Treated with Sorafenib in Combination with TACE.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Prognosis; Propensity Score; Retrospective Studies; Sorafenib; Survival Rate | 2020 |
Curcumin-enhanced antitumor effects of sorafenib via regulating the metabolism and tumor microenvironment.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Curcumin; Disease Models, Animal; Drug Synergism; Functional Food; Liver Neoplasms; Mice; Mice, Inbred Strains; Sorafenib; Tumor Microenvironment | 2020 |
MicroRNA-375 represses tumor angiogenesis and reverses resistance to sorafenib in hepatocarcinoma.
Topics: Animals; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Male; Mice; MicroRNAs; Neovascularization, Pathologic; Rats, Sprague-Dawley; Sorafenib | 2021 |
Intrahepatic Tumor Burden as a Novel Factor Influencing the Introduction of Second-line Chemotherapy for Hepatocellular Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Grading; Retrospective Studies; Severity of Illness Index; Sorafenib; Treatment Outcome; Tumor Burden | 2020 |
Toxicity and dosimetry in SORAMIC study.
Topics: Brachytherapy; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Sorafenib | 2020 |
Bufalin inhibits hepatitis B virus-associated hepatocellular carcinoma development through androgen receptor dephosphorylation and cell cycle-related kinase degradation.
Topics: Animals; beta Catenin; Bufanolides; Carcinogenesis; Carcinoma, Hepatocellular; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase-Activating Kinase; Cyclin-Dependent Kinases; Glycogen Synthase Kinase 3 beta; Hepatitis B virus; Liver Neoplasms; Mice, Nude; Mice, Transgenic; Models, Biological; Phosphorylation; Proteolysis; Receptors, Androgen; Signal Transduction; Sorafenib; Trans-Activators; Viral Regulatory and Accessory Proteins | 2020 |
Long non‑coding RNA H19 is involved in sorafenib resistance in hepatocellular carcinoma by upregulating miR‑675.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; MicroRNAs; RNA, Long Noncoding; RNA, Small Interfering; Sorafenib; Up-Regulation | 2020 |
miR-124 regulates liver cancer stem cells expansion and sorafenib resistance.
Topics: Animals; Base Sequence; Caveolin 1; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Mice; MicroRNAs; Neoplastic Stem Cells; Prognosis; Sorafenib | 2020 |
Optimal sequence of systemic therapy after sorafenib failure in patients with hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Nivolumab; Phenylurea Compounds; Pyridines; Sorafenib | 2020 |
Metabolic implication of tigecycline as an efficacious second-line treatment for sorafenib-resistant hepatocellular carcinoma.
Topics: Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Female; Humans; Liver Neoplasms; Mice, SCID; Mitochondria; Neoplasm Recurrence, Local; Protein Synthesis Inhibitors; Sorafenib; Tigecycline; Xenograft Model Antitumor Assays | 2020 |
Reply to: "Toxicity and dosimetry in SORAMIC study".
Topics: Brachytherapy; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Sorafenib | 2020 |
Artesunate synergizes with sorafenib to induce ferroptosis in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Artesunate; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Synergism; Ferroptosis; Humans; Lipid Peroxidation; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Oxidative Stress; Sorafenib; Xenograft Model Antitumor Assays | 2021 |
Therapeutic effects of regorafenib after sorafenib monotherapy with advanced hepatocellular carcinoma including Child-Pugh classification B: A retrospective observational study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Phenylurea Compounds; Pyridines; Retrospective Studies; Sorafenib | 2020 |
Trends in Hepatic Functional Reserve of Patients with Hepatocellular Carcinoma Treated with Tyrosine Kinase Inhibitors.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Cohort Studies; Female; Humans; Liver; Liver Neoplasms; Male; Middle Aged; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolines; Retrospective Studies; Sorafenib; Young Adult | 2020 |
Sensitization of hepatocellular carcinoma cells towards doxorubicin and sorafenib is facilitated by glucosedependent alterations in reactive oxygen species, P-glycoprotein and DKK4.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Hepatocellular; Cell Line, Tumor; Doxorubicin; Drug Resistance, Neoplasm; Glucose; Humans; Intercellular Signaling Peptides and Proteins; Liver Neoplasms; Reactive Oxygen Species; Sorafenib; Wnt Proteins | 2020 |
The PPRD score stratifies patients with hepatocellular carcinoma and portal vein tumor thrombus treated with sorafenib plus transarterial chemoembolization.
Topics: Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neoplasms; Portal Vein; Retrospective Studies; Sorafenib; Thrombosis; Treatment Outcome | 2021 |
Single center analysis of therapy and outcomes of hepatocellular carcinoma in Sub-Saharan Africa.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Cisplatin; Doxorubicin; End Stage Liver Disease; Ethiodized Oil; Ethiopia; Female; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Liver Neoplasms; Male; Middle Aged; Palliative Care; Retrospective Studies; Severity of Illness Index; Sorafenib; Survival Rate; Tenofovir; Treatment Outcome | 2020 |
Sorafenib for Hepatocellular Carcinoma Recurrence After Liver Transplant.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Liver Transplantation; Neoplasm Recurrence, Local; Sorafenib; TOR Serine-Threonine Kinases; Treatment Outcome | 2020 |
The Authors' Reply.
Topics: Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Liver Transplantation; Neoplasm Recurrence, Local; Sorafenib; TOR Serine-Threonine Kinases | 2020 |
Demographic and Clinicopathologic Factors of Patients With Hepatocellular Carcinoma in a Safety Net Hospital.
Topics: Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Disease-Free Survival; Female; Follow-Up Studies; Health Services Accessibility; Health Services Needs and Demand; Humans; Liver; Liver Neoplasms; Liver Transplantation; Male; Mass Screening; Middle Aged; Minority Groups; Neoplasm Staging; Retrospective Studies; Safety-net Providers; Socioeconomic Factors; Sorafenib | 2020 |
Lymphocyte to monocyte ratio-based nomogram for predicting outcomes of hepatocellular carcinoma treated with sorafenib.
Topics: Carcinoma, Hepatocellular; Drug Monitoring; Female; Humans; Leukocyte Count; Liver Neoplasms; Lymphocytes; Male; Middle Aged; Monocytes; Neoplasm Staging; Nomograms; Predictive Value of Tests; Prognosis; Protein Kinase Inhibitors; Republic of Korea; Risk Assessment; Sorafenib; Survival Analysis; United States | 2020 |
Real-world systemic sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Korea.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Patient Acuity; Phenylurea Compounds; Progression-Free Survival; Pyridines; Republic of Korea; Retrospective Studies; Sex Factors; Sorafenib | 2021 |
Valproic acid overcomes sorafenib resistance by reducing the migration of Jagged2-mediated Notch1 signaling pathway in hepatocellular carcinoma cells.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Drug Resistance, Neoplasm; Humans; Jagged-2 Protein; Liver Neoplasms; Mice; Phenotype; Receptor, Notch1; Signal Transduction; Sorafenib; Valproic Acid; Xenograft Model Antitumor Assays | 2020 |
LXR activation potentiates sorafenib sensitivity in HCC by activating microRNA-378a transcription.
Topics: Animals; Benzoates; Benzylamines; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Karyopherins; Liver Neoplasms; Liver X Receptors; Male; Mice; MicroRNAs; Middle Aged; Neoplasm Transplantation; Receptor, IGF Type 1; Sorafenib; Survival Analysis | 2020 |
HNF4α regulates sulfur amino acid metabolism and confers sensitivity to methionine restriction in liver cancer.
Topics: Animals; Biomarkers, Tumor; Cell Line, Tumor; Cell Movement; Cysteine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Gene Expression Regulation, Neoplastic; Hepatocyte Nuclear Factor 4; Liver; Liver Neoplasms; Mesoderm; Metabolic Networks and Pathways; Metabolome; Methionine; Mice; Sorafenib; Transcription, Genetic | 2020 |
PI16 attenuates response to sorafenib and represents a predictive biomarker in hepatocellular carcinoma.
Topics: Adult; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Carrier Proteins; Caspase 3; Cell Movement; Cell Proliferation; Databases, Nucleic Acid; Female; Gene Expression Regulation, Neoplastic; Glycoproteins; HEK293 Cells; Hep G2 Cells; Humans; Liver Neoplasms; Male; Mice, Inbred BALB C; Mice, Nude; Middle Aged; p38 Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Retrospective Studies; Signal Transduction; Sorafenib; Tumor Burden; Xenograft Model Antitumor Assays | 2020 |
Outcomes of sorafenib therapy in advanced hepatocellular carcinoma in a single center in Ethiopia.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Ethiopia; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib | 2020 |
Targeted Manganese doped silica nano GSH-cleaner for treatment of Liver Cancer by destroying the intracellular redox homeostasis.
Topics: A549 Cells; Animals; Antineoplastic Agents; Apoptosis; Cell Line; Cell Line, Tumor; Cell Proliferation; Glutathione; Hep G2 Cells; Homeostasis; Human Umbilical Vein Endothelial Cells; Humans; Liver Neoplasms; Male; Manganese; Mice, Nude; Nanoparticles; Oxidation-Reduction; Oxidative Stress; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Silicon Dioxide; Sorafenib | 2020 |
Real-world efficacy and safety of immune checkpoint inhibitors in advanced hepatocellular carcinoma: Experience of a tertiary Asian Center.
Topics: Aged; Carcinoma, Hepatocellular; Humans; Immune Checkpoint Inhibitors; Liver Neoplasms; Male; Retrospective Studies; Sorafenib | 2021 |
Analysis of Post-Progression Survival in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Hepatocellular; Cohort Studies; Disease Progression; Female; Humans; Liver Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolines; Ramucirumab; Retrospective Studies; Sorafenib; Survival Rate | 2020 |
Transarterial Chemoembolization Combined with Sorafenib in Patients with BCLC Stage C Hepatocellular Carcinoma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Epirubicin; Female; Fluorouracil; Glycosides; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Oxaliplatin; Retrospective Studies; Sorafenib | 2020 |
Dynamic Contrast-Enhanced Magnetic Resonance Imaging as Imaging Biomarker for Vascular Normalization Effect of Infigratinib in High-FGFR-Expressing Hepatocellular Carcinoma Xenografts.
Topics: Animals; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Proliferation; Contrast Media; Humans; Kinetics; Liver Neoplasms; Magnetic Resonance Imaging; Mice, SCID; Neovascularization, Pathologic; Perfusion; Phenylurea Compounds; Pyrimidines; Receptors, Fibroblast Growth Factor; Sorafenib; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2021 |
Aggressive surgical approach in patients with adrenal-only metastases from hepatocellular carcinoma enables higher survival rates than standard systemic therapy.
Topics: Adrenal Gland Neoplasms; Adrenalectomy; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Follow-Up Studies; Hepatectomy; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Progression-Free Survival; Retrospective Studies; Romania; Sorafenib; Survival Rate; Treatment Outcome | 2021 |
RSK2-inactivating mutations potentiate MAPK signaling and support cholesterol metabolism in hepatocellular carcinoma.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinogenesis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cholesterol; Exome Sequencing; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Loss of Function Mutation; MAP Kinase Signaling System; Ribosomal Protein S6 Kinases, 90-kDa; Sorafenib | 2021 |
SETD1A augments sorafenib primary resistance via activating YAP in hepatocellular carcinoma.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Histone-Lysine N-Methyltransferase; Humans; Liver Neoplasms; Phosphorylation; Prognosis; Proto-Oncogene Proteins c-akt; Sorafenib; Survival Rate; Transcription Factors; YAP-Signaling Proteins | 2020 |
Shifting paradigms in the systemic management of hepatocellular carcinoma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Bevacizumab; Carcinoma, Hepatocellular; Cytotoxins; Drug Therapy, Combination; Humans; Immunotherapy; Liver Neoplasms; Precision Medicine; Protein Kinase Inhibitors; Sorafenib | 2020 |
lncRNA-POIR promotes epithelial-mesenchymal transition and suppresses sorafenib sensitivity simultaneously in hepatocellular carcinoma by sponging miR-182-5p.
Topics: Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Proliferation; Epithelial-Mesenchymal Transition; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; MicroRNAs; RNA, Long Noncoding; Sorafenib; Tumor Cells, Cultured | 2021 |
Prognosis Nomogram for Hepatocellular Carcinoma Patients with Portal Vein Invasion Undergoing Transarterial Chemoembolization Plus Sorafenib Treatment: A Retrospective Multicentre Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Female; Humans; Liver Neoplasms; Male; Middle Aged; Nomograms; Portal Vein; Prognosis; Retrospective Studies; Sorafenib; Treatment Outcome | 2021 |
Treatment patterns and direct medical costs among patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Costs and Cost Analysis; Female; Health Care Costs; Humans; Liver Neoplasms; Male; Middle Aged; Pregnancy; Sorafenib; United States | 2020 |
Acteoside as a potential therapeutic option for primary hepatocellular carcinoma: a preclinical study.
Topics: Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Gene Expression Regulation, Neoplastic; Glucosides; Hep G2 Cells; Humans; Kallikreins; Liver Neoplasms; Mice; Neovascularization, Pathologic; Phenols; Sorafenib; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2020 |
KCNQ1OT1 contributes to sorafenib resistance and programmed death‑ligand‑1‑mediated immune escape via sponging miR‑506 in hepatocellular carcinoma cells.
Topics: Apoptosis; B7-H1 Antigen; Base Sequence; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cytokines; Down-Regulation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Immune Evasion; Liver Neoplasms; MicroRNAs; Models, Biological; Neoplasm Invasiveness; Potassium Channels, Voltage-Gated; Sorafenib; T-Lymphocytes; Tumor Microenvironment; Up-Regulation | 2020 |
Bismuth-Based Mesoporous Nanoball Carrying Sorafenib for Computed Tomography Imaging and Synergetic Chemoradiotherapy of Hepatocellular Carcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bismuth; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Chemoradiotherapy; Liver Neoplasms; Mice; Niacinamide; Sorafenib | 2020 |
Magnetically responsive, sorafenib loaded alginate microspheres for hepatocellular carcinoma treatment.
Topics: Alginates; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line; Cell Survival; Drug Carriers; Drug Delivery Systems; Drug Liberation; Electron Spin Resonance Spectroscopy; Ferric Compounds; Hep G2 Cells; Humans; Hyperthermia; In Vitro Techniques; Light; Liver Neoplasms; Magnetics; Magnetite Nanoparticles; Metal Nanoparticles; Mice; Microspheres; Neoplasms; Particle Size; Powders; Scattering, Radiation; Sorafenib; Temperature; X-Ray Absorption Spectroscopy | 2020 |
Advances in Hepatocellular Carcinoma.
Topics: Ablation Techniques; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Early Detection of Cancer; Hepatectomy; Humans; Liver Neoplasms; Liver Transplantation; Sorafenib | 2020 |
Valproic acid reverses sorafenib resistance through inhibiting activated Notch/Akt signaling pathway in hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Therapy, Combination; Enzyme Inhibitors; Humans; Liver Neoplasms; Sorafenib; Valproic Acid | 2021 |
Pharmacokinetics and pharmacogenetics of sorafenib in patients with hepatocellular carcinoma: Implications for combination trials.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Pharmacogenetics; Phenylurea Compounds; Sorafenib | 2020 |
Eradication of hepatitis C virus preserve liver function and prolong survival in advanced hepatocellular carcinoma patients with limited life expectancy.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Disease-Free Survival; Female; Hepacivirus; Humans; Life Expectancy; Liver; Liver Neoplasms; Male; Middle Aged; RNA, Viral; Sorafenib; Survival Analysis; Viremia | 2021 |
Synergistic Effects of Ellagic Acid and Sorafenib on Hepatocytes and Mitochondria Isolated from a Hepatocellular Carcinoma Rat Model.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Ellagic Acid; Hepatocytes; Liver Neoplasms; Mitochondria; Rats; Sorafenib | 2021 |
Liver stiffness in magnetic resonance elastography is prognostic for sorafenib-treated advanced hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Elasticity Imaging Techniques; Humans; Liver Neoplasms; Prognosis; Retrospective Studies; Sorafenib | 2021 |
Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Eosinophils; Female; Humans; Liver Neoplasms; Male; Middle Aged; Prognosis; Sorafenib; Survival Analysis; Young Adult | 2020 |
Research Progresses of Targeted Therapy and Immunotherapy for Hepatocellular Carcinoma.
Topics: Carcinoma, Hepatocellular; Humans; Immunotherapy; Liver Neoplasms; Molecular Targeted Therapy; Sorafenib | 2021 |
Torin2 overcomes sorafenib resistance via suppressing mTORC2-AKT-BAD pathway in hepatocellular carcinoma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-Associated Death Protein; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Humans; Liver Neoplasms; Mechanistic Target of Rapamycin Complex 2; Naphthyridines; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Signal Transduction; Sorafenib | 2020 |
CKD-5, a novel pan-histone deacetylase inhibitor, synergistically enhances the efficacy of sorafenib for hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Differentiation; Cell Line, Tumor; Cytoprotection; Disease Models, Animal; Histone Deacetylase Inhibitors; Humans; Liver Neoplasms; Mice; Sorafenib; Transfection; Urea | 2020 |
Impact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort study.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Cohort Studies; Dose-Response Relationship, Drug; Female; Humans; Liver Neoplasms; Male; Middle Aged; Prognosis; Sorafenib; Treatment Outcome | 2021 |
The miR-30a-5p/CLCF1 axis regulates sorafenib resistance and aerobic glycolysis in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Mice; MicroRNAs; Signal Transduction; Sorafenib | 2020 |
Branched-chain amino acid aminotransferase 2 regulates ferroptotic cell death in cancer cells.
Topics: AMP-Activated Protein Kinases; Animals; Carcinoma, Hepatocellular; CRISPR-Cas Systems; Female; Ferroptosis; Hep G2 Cells; Humans; Iron; Lipid Peroxidation; Liver Neoplasms; Mice; Mice, Inbred C57BL; Minor Histocompatibility Antigens; Pregnancy Proteins; Signal Transduction; Sorafenib; Transaminases; Xenograft Model Antitumor Assays | 2021 |
Systemic treatment for hepatocellular carcinoma.
Topics: Anilides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Immunotherapy; Liver Neoplasms; Phenylurea Compounds; Pyridines; Ramucirumab; Sorafenib | 2020 |
Pre-sarcopenia determines post-progression outcomes in advanced hepatocellular carcinoma after sorafenib failure.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cohort Studies; Disease Progression; Disease-Free Survival; Female; Humans; Liver Neoplasms; Male; Middle Aged; Sarcopenia; Sorafenib | 2020 |
Effect of Combined Sorafenib/Cisplatinum Treatment on the Autophagy and Proliferation of Hepatocellular Carcinoma hepG2 Cells in Vitro.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Carcinoma, Hepatocellular; Cell Proliferation; Cisplatin; Hep G2 Cells; Humans; In Vitro Techniques; Liver Neoplasms; Proto-Oncogene Proteins c-akt; Signal Transduction; Sorafenib; TOR Serine-Threonine Kinases | 2020 |
Complete Remission of Advanced Hepatocellular Carcinoma Treated with Sorafenib and Concomitant Appearance of IgG4- related Diseases. A Case Report.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Immunoglobulin G; Liver Neoplasms; Male; Middle Aged; Paraproteinemias; Remission Induction; Sorafenib | 2020 |
Reliable prediction of survival in advanced-stage hepatocellular carcinoma treated with sorafenib: comparing 1D and 3D quantitative tumor response criteria on MRI.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Phenylurea Compounds; Retrospective Studies; Sorafenib; Treatment Outcome | 2021 |
Topics: Adult; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib | 2021 |
Methyl Palmitate-A suitable adjuvant for Sorafenib therapy to reduce in vivo toxicity and to enhance anti-cancer effects on hepatocellular carcinoma cells.
Topics: Abnormalities, Drug-Induced; Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; Cell Movement; Hep G2 Cells; Humans; Liver Neoplasms; Palmitates; Sorafenib; Zebrafish | 2021 |
[Immune Response on Outcomes in Hepatocellular Carcinoma].
Topics: Bevacizumab; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Lung Neoplasms; Sorafenib; Tumor Microenvironment | 2020 |
Cost-Effectiveness of Lenvatinib Compared with Sorafenib for the First-Line Treatment of Advanced Hepatocellular Carcinoma in Australia.
Topics: Antineoplastic Agents; Australia; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Female; Humans; Liver Neoplasms; Male; Phenylurea Compounds; Quality-Adjusted Life Years; Quinolines; Sorafenib | 2020 |
Atezolizumab plus bevacizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma: a cost-effectiveness analysis.
Topics: Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Humans; Liver Neoplasms; Sorafenib | 2020 |
Sorafenib induces mitochondrial dysfunction and exhibits synergistic effect with cysteine depletion by promoting HCC cells ferroptosis.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cysteine; Ferroptosis; Glutathione; Humans; Liver Neoplasms; Mitochondria; Reactive Oxygen Species; Sorafenib | 2021 |
Sorafenib and CuB exert synergistic antitumor effects against hepatocellular carcinoma cells via inhibition of STAT3 phosphorylation.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; Cell Survival; Drug Synergism; Female; Hep G2 Cells; Humans; Liver Neoplasms; Mice; Phosphorylation; Signal Transduction; Sorafenib; STAT3 Transcription Factor; Triterpenes; Xenograft Model Antitumor Assays | 2021 |
Predictive factors for long-term survival in patients with advanced hepatocellular carcinoma treated with sorafenib.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Treatment Outcome | 2021 |
Combining immune checkpoint inhibitor with lenvatinib prolongs survival than lenvatinib alone in sorafenib-experienced hepatocellular carcinoma patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Female; Humans; Immune Checkpoint Inhibitors; Liver Neoplasms; Male; Phenylurea Compounds; Quinolines; Sorafenib; Survival Analysis | 2022 |
Cytochrome P450 1A2 overcomes nuclear factor kappa B-mediated sorafenib resistance in hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Cytochrome P-450 CYP1A2; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Neoplasm Proteins; NF-kappa B; Sorafenib | 2021 |
PRMT6 deficiency induces autophagy in hostile microenvironments of hepatocellular carcinoma tumors by regulating BAG5-associated HSC70 stability.
Topics: Adaptor Proteins, Signal Transducing; Animals; Autophagy; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Hep G2 Cells; HSC70 Heat-Shock Proteins; Humans; Liver Neoplasms; Male; Methylation; Mice; Neoplasm Transplantation; Nuclear Proteins; Protein Stability; Protein-Arginine N-Methyltransferases; Reverse Genetics; Sorafenib | 2021 |
Impact of Aspirin on clinical outcome in advanced HCC patients receiving sorafenib and regorafenib.
Topics: Antineoplastic Agents; Aspirin; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Phenylurea Compounds; Pyridines; Retrospective Studies; Sorafenib; Treatment Outcome | 2021 |
ADAMTSL5 is an epigenetically activated gene underlying tumorigenesis and drug resistance in hepatocellular carcinoma.
Topics: ADAMTS Proteins; ADAMTS5 Protein; Animals; Antineoplastic Agents, Immunological; Benzocycloheptenes; Carcinogenesis; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Epigenomics; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Mice; Phenylurea Compounds; Quinolines; Signal Transduction; Sorafenib; Transcriptional Activation; Triazoles; Tumor Microenvironment | 2021 |
Proteoglycan-4 is correlated with longer survival in HCC patients and enhances sorafenib and regorafenib effectiveness via CD44 in vitro.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Phenylurea Compounds; Proteoglycans; Pyridines; Sorafenib; Tumor Microenvironment | 2020 |
Silencing
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Databases, Genetic; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Hep G2 Cells; Humans; Kinesins; Liver Neoplasms; Male; Mice, Inbred BALB C; Mice, Nude; Oncogene Proteins; Protein Interaction Maps; Protein Kinase Inhibitors; Proto-Oncogene Protein c-ets-1; Proto-Oncogene Proteins c-akt; RNA Interference; Signal Transduction; Sorafenib; Tumor Burden; Xenograft Model Antitumor Assays | 2020 |
Studying the Role and Molecular Mechanisms of
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Cycle; Cell Proliferation; Drug Resistance, Neoplasm; Hep G2 Cells; Humans; Liver Neoplasms; Protein Serine-Threonine Kinases; Real-Time Polymerase Chain Reaction; Reproducibility of Results; Sorafenib; Transcriptome | 2020 |
Lenvatinib is independently associated with the reduced risk of progressive disease when compared with sorafenib in patients with advanced hepatocellular carcinoma.
Topics: Aged; alpha-Fetoproteins; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Disease Progression; Female; Humans; Liver Neoplasms; Male; Middle Aged; Phenylurea Compounds; Quinolines; Retrospective Studies; Sorafenib; Survival Rate; Treatment Outcome | 2021 |
Sirtuin 1 and 2 inhibitors enhance the inhibitory effect of sorafenib in hepatocellular carcinoma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; ATP Binding Cassette Transporter, Subfamily G, Member 2; Carbazoles; Carcinoma, Hepatocellular; Cell Cycle Proteins; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Hep G2 Cells; Histone Deacetylase Inhibitors; Humans; Liver Neoplasms; Multidrug Resistance-Associated Proteins; Naphthalenes; Neoplasm Invasiveness; Neoplasm Proteins; Pyrimidinones; Signal Transduction; Sirtuin 1; Sirtuin 2; Sorafenib; Spheroids, Cellular | 2021 |
LncRNA MIAT correlates with immune infiltrates and drug reactions in hepatocellular carcinoma.
Topics: Antineoplastic Agents; Biomarkers; Carcinoma, Hepatocellular; Databases, Factual; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; RNA, Long Noncoding; Single-Cell Analysis; Sorafenib | 2020 |
Cost-utility analysis of selective internal radiation therapy with Y-90 resin microspheres in hepatocellular carcinoma.
Topics: Brachytherapy; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Health Care Costs; Humans; Liver; Liver Neoplasms; Microspheres; Patient Selection; Quality of Life; Quality-Adjusted Life Years; Sorafenib; Survival Analysis; Tumor Burden; United Kingdom; Yttrium Radioisotopes | 2021 |
N
Topics: Adenosine; Animals; Antineoplastic Agents; Apoptosis; beta Catenin; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; RNA, Circular; Sorafenib; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2020 |
Reactive perforating collagenosis: a rare side effect associated with sorafenib.
Topics: Carcinoma, Hepatocellular; Collagen Diseases; Humans; Liver Neoplasms; Skin Diseases; Sorafenib | 2020 |
Overriding sorafenib resistance via blocking lipid metabolism and Ras by sphingomyelin synthase 1 inhibition in hepatocellular carcinoma.
Topics: Adult; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Ceramides; Drug Resistance, Neoplasm; Humans; Lipid Metabolism; Liver Neoplasms; Membrane Proteins; Nerve Tissue Proteins; ras Proteins; Sorafenib; Sphingomyelins; Transferases (Other Substituted Phosphate Groups); Up-Regulation | 2021 |
Exploring the mechanism of resistance to sorafenib in two hepatocellular carcinoma cell lines.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Hep G2 Cells; Humans; Liver Neoplasms; Protein Interaction Maps; Protein Kinase Inhibitors; Signal Transduction; Sorafenib; Transcription, Genetic; Transcriptome | 2020 |
Re: Chen S, Shi M, Shen L, et al. Microwave ablation versus sorafenib for intermediate-stage hepatocellular carcinoma with transcatheter arterial chemoembolization refractoriness: a propensity score matching analysis. Int J hyperthermia 2020.
Topics: Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Hyperthermia; Liver Neoplasms; Microwaves; Propensity Score; Sorafenib | 2020 |
Baseline Sarcopenia is Associated with Lack of Response to Therapy, Liver Decompensation and High Mortality in Hepatocellular Carcinoma Patients.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Female; Follow-Up Studies; Hepatectomy; Humans; Liver; Liver Neoplasms; Male; Middle Aged; Prognosis; Radiofrequency Ablation; Sarcopenia; Sorafenib; Survival Rate | 2020 |
Hypoxia induces sorafenib resistance mediated by autophagy via activating FOXO3a in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Autophagy; Carcinoma, Hepatocellular; Cell Hypoxia; Forkhead Box Protein O3; Humans; Liver Neoplasms; Mice; Sorafenib; Transfection; Tumor Microenvironment | 2020 |
The PGC1α/NRF1-MPC1 axis suppresses tumor progression and enhances the sensitivity to sorafenib/doxorubicin treatment in hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Doxorubicin; Humans; Liver Neoplasms; Mitochondrial Membrane Transport Proteins; Monocarboxylic Acid Transporters; Nuclear Respiratory Factor 1; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Sorafenib | 2021 |
Mitophagy promotes sorafenib resistance through hypoxia-inducible ATAD3A dependent Axis.
Topics: Animals; Antineoplastic Agents; ATPases Associated with Diverse Cellular Activities; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; Liver Neoplasms; Membrane Proteins; Mice; Mice, Inbred BALB C; Mice, Nude; Mitochondrial Proteins; Mitophagy; Sorafenib; Tumor Hypoxia | 2020 |
Stereotactic body radiation therapy for hepatocellular carcinoma with Macrovascular invasion.
Topics: Carcinoma, Hepatocellular; Dose Fractionation, Radiation; Humans; Liver Neoplasms; Middle Aged; Radiosurgery; Retrospective Studies; Sorafenib; Treatment Outcome | 2021 |
ST6GAL1 Is a Novel Serum Biomarker for Lenvatinib-Susceptible FGF19-Driven Hepatocellular Carcinoma.
Topics: Aged; Aged, 80 and over; Animals; Antigens, CD; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Line, Tumor; Disease-Free Survival; Down-Regulation; Drug Resistance, Neoplasm; Female; Fibroblast Growth Factors; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Male; Mice; Middle Aged; Neoplasm Recurrence, Local; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolines; Sialyltransferases; Sorafenib | 2021 |
Regulatory Mechanisms of Coicis Semen on Bionetwork of Liver Cancer Based on Network Pharmacology.
Topics: Carcinoma, Hepatocellular; Caspase 3; Coix; Gene Ontology; Humans; Liver Neoplasms; Sitosterols; Small Molecule Libraries; Sorafenib | 2020 |
Release of a liver anticancer drug, sorafenib from its PVA/LDH- and PEG/LDH-coated iron oxide nanoparticles for drug delivery applications.
Topics: 3T3 Cells; Animals; Antineoplastic Agents; Drug Delivery Systems; Drug Liberation; Hep G2 Cells; Humans; Liver; Liver Neoplasms; Magnetic Iron Oxide Nanoparticles; Magnetics; Magnetite Nanoparticles; Mice; Polyethylene Glycols; Polyvinyl Alcohol; Sorafenib; Spectroscopy, Fourier Transform Infrared; X-Ray Diffraction | 2020 |
The m6A methylation landscape stratifies hepatocellular carcinoma into 3 subtypes with distinct metabolic characteristics.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Databases, Factual; DNA Methylation; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Internationality; Liver Neoplasms; Methyltransferases; Neoplasm Staging; Prognosis; Sorafenib; Time Factors | 2020 |
Co-delivery of Sorafenib and CRISPR/Cas9 Based on Targeted Core-Shell Hollow Mesoporous Organosilica Nanoparticles for Synergistic HCC Therapy.
Topics: Animals; Aptamers, Nucleotide; Carcinoma, Hepatocellular; Cell Line, Tumor; CRISPR-Associated Protein 9; CRISPR-Cas Systems; Drug Carriers; Drug Liberation; Epithelial Cell Adhesion Molecule; ErbB Receptors; Gene Editing; Genes, erbB-1; Humans; Liver Neoplasms; Mice; Nanoparticles; Polyamines; Porosity; Signal Transduction; Silicon Dioxide; Sorafenib | 2020 |
Combined treatment of sorafenib and doxorubicin-loaded microbubble-albumin nanoparticle complex for hepatocellular carcinoma: A feasibility study.
Topics: Albumins; Animals; Body Weight; Carcinoma, Hepatocellular; Cell Line, Tumor; Doxorubicin; Drug Carriers; Drug Interactions; Feasibility Studies; Humans; Liver Neoplasms; Microbubbles; Nanoparticles; Rats; Sorafenib; Tumor Burden; Xenograft Model Antitumor Assays | 2020 |
Predicting HCC Response to Multikinase Inhibitors With In Vivo Cirrhotic Mouse Model for Personalized Therapy.
Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; Cell Proliferation; Disease Models, Animal; Female; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Mice; Mice, Inbred NOD; Mice, SCID; Middle Aged; Neovascularization, Pathologic; Phenylurea Compounds; Precision Medicine; Prognosis; Protein Kinase Inhibitors; Quinolines; Sorafenib; Thioacetamide; Tumor Cells, Cultured; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2021 |
Comparison of prognostic models in advanced hepatocellular carcinoma patients undergoing Sorafenib: A multicenter study.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Italy; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Proportional Hazards Models; Prospective Studies; Retrospective Studies; Risk Assessment; Severity of Illness Index; Sorafenib; Treatment Outcome | 2021 |
CircRNA-SORE mediates sorafenib resistance in hepatocellular carcinoma by stabilizing YBX1.
Topics: Animals; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Hep G2 Cells; Humans; Liver Neoplasms; Mice; Mice, Inbred BALB C; Mice, Inbred NOD; Mice, SCID; Neoplasm Proteins; RNA, Circular; RNA, Neoplasm; Sorafenib; Y-Box-Binding Protein 1 | 2020 |
m6A RNA methylation-mediated HNF3γ reduction renders hepatocellular carcinoma dedifferentiation and sorafenib resistance.
Topics: Animals; Antibodies, Heterophile; Carcinoma, Hepatocellular; Cell Dedifferentiation; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Hepatocyte Nuclear Factor 3-gamma; Humans; Liver Neoplasms; Male; Mice; Neoplasm Proteins; Neoplasm Transplantation; RNA Processing, Post-Transcriptional; RNA, Messenger; RNA, Neoplasm; Sorafenib | 2020 |
Therapeutic response monitoring after targeted therapy in an orthotopic rat model of hepatocellular carcinoma using contrast-enhanced ultrasound: Focusing on inter-scanner, and inter-operator reproducibility.
Topics: Animals; Carcinoma, Hepatocellular; Contrast Media; Disease Models, Animal; Liver Neoplasms; Male; Perfusion; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Sorafenib; Ultrasonography | 2020 |
LncRNA TTN-AS1 intensifies sorafenib resistance in hepatocellular carcinoma by sponging miR-16-5p and upregulation of cyclin E1.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Proliferation; Cyclin E; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Liver Neoplasms; Male; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Oncogene Proteins; Protein Kinase Inhibitors; RNA, Long Noncoding; Signal Transduction; Sorafenib; Tumor Burden; Up-Regulation; Xenograft Model Antitumor Assays | 2021 |
Y-Box Binding Protein-1 Promotes Epithelial-Mesenchymal Transition in Sorafenib-Resistant Hepatocellular Carcinoma Cells.
Topics: Animals; Biomarkers, Tumor; Carcinoma, Hepatocellular; cdc42 GTP-Binding Protein; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Mice; Neoplasm Invasiveness; Phosphorylation; Phosphoserine; Prognosis; Pseudopodia; Reproducibility of Results; Signal Transduction; Sorafenib; Spheroids, Cellular; Y-Box-Binding Protein 1 | 2020 |
Prognostic roles of diabetes mellitus and hypertension in advanced hepatocellular carcinoma treated with sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Cohort Studies; Diabetes Complications; Diabetes Mellitus; Female; Humans; Hypertension; Liver Neoplasms; Male; Metformin; Middle Aged; Prognosis; Retrospective Studies; Sorafenib; Taiwan | 2020 |
A prognostic score model for predicting the survival benefits of patients undergoing sorafenib plus transarterial chemoembolization for hepatocellular carcinoma with portal vein invasion.
Topics: Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neoplasms; Portal Vein; Prognosis; Retrospective Studies; Sorafenib; Treatment Outcome | 2021 |
Cabozantinib in Japanese patients with advanced hepatocellular carcinoma: a phase 2 multicenter study.
Topics: Aged; Anilides; Carcinoma, Hepatocellular; Female; Humans; Japan; Liver Neoplasms; Male; Middle Aged; Pyridines; Sorafenib | 2021 |
3-Methyladenine-enhanced susceptibility to sorafenib in hepatocellular carcinoma cells by inhibiting autophagy.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Carcinoma, Hepatocellular; Drug Synergism; Hep G2 Cells; Humans; Liver Neoplasms; Protein Kinase Inhibitors; Sorafenib | 2021 |
Inflammatory microenvironment of fibrotic liver promotes hepatocellular carcinoma growth, metastasis and sorafenib resistance through STAT3 activation.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cellular Microenvironment; Cytokines; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Humans; Inflammation Mediators; Liver Cirrhosis; Liver Neoplasms; Mice; Protein Kinase Inhibitors; Sorafenib; STAT3 Transcription Factor; Xenograft Model Antitumor Assays | 2021 |
Cost-Effectiveness Analysis of Selective Internal Radiotherapy With Yttrium-90 Versus Sorafenib in Locally Advanced Hepatocellular Carcinoma.
Topics: Aged; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Humans; Liver Neoplasms; Medicare; Quality of Life; Sorafenib; United States; Yttrium Radioisotopes | 2021 |
Near-Infrared Light Laser-Triggered Release of Doxorubicin and Sorafenib from TemperatureSensitive Liposomes for Synergistic Therapy of Hepatocellular Carcinoma.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Doxorubicin; Drug Delivery Systems; Drug Liberation; Lasers; Liposomes; Liver Neoplasms; Phototherapy; Sorafenib | 2020 |
IL‑6 plays a crucial role in epithelial‑mesenchymal transition and pro‑metastasis induced by sorafenib in liver cancer.
Topics: Animals; Cell Line, Tumor; Cell Movement; Epithelial-Mesenchymal Transition; Humans; Interleukin-6; Janus Kinase 2; Liver; Liver Neoplasms; Male; Mice; Recombinant Proteins; Signal Transduction; Sorafenib; STAT3 Transcription Factor; Xenograft Model Antitumor Assays | 2021 |
Multiwalled carbon nanotubes co-delivering sorafenib and epidermal growth factor receptor siRNA enhanced tumor-suppressing effect on liver cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Proliferation; Drug Delivery Systems; ErbB Receptors; Hep G2 Cells; Humans; Liver; Liver Neoplasms; Mice; Mice, Nude; Nanotubes, Carbon; Neoplasm Transplantation; RNA, Small Interfering; Sorafenib | 2021 |
Application of self-assembly peptides targeting the mitochondria as a novel treatment for sorafenib-resistant hepatocellular carcinoma cells.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Delivery Systems; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Mitochondria; Organophosphorus Compounds; Peptides; Phenylalanine; Pyrenes; Reactive Oxygen Species; Sorafenib | 2021 |
Comparison of Prognostic Scores in Patients With Hepatocellular Carcinoma Treated With Sorafenib.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Prognosis; Prospective Studies; Protein-Tyrosine Kinases; Reproducibility of Results; Sorafenib; Survival Analysis | 2021 |
Stabilization of snail maintains the sorafenib resistance of hepatocellular carcinoma cells.
Topics: Ataxia Telangiectasia Mutated Proteins; Carcinoma, Hepatocellular; Cell Line, Tumor; COP9 Signalosome Complex; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gene Silencing; Humans; Liver Neoplasms; Protein Stability; RNA, Small Interfering; Snail Family Transcription Factors; Sorafenib; Up-Regulation | 2021 |
Effect of radiotherapy on survival in advanced hepatocellular carcinoma patients treated with sorafenib: a nationwide cancer-registry-based study.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Combined Modality Therapy; Databases, Factual; Humans; Liver Neoplasms; Male; Middle Aged; Proportional Hazards Models; Protein Kinase Inhibitors; Registries; Sorafenib; Survival Rate; Treatment Outcome | 2021 |
A polymeric nanoformulation improves the bioavailability and efficacy of sorafenib for hepatocellular carcinoma therapy.
Topics: Antineoplastic Agents; Biological Availability; Carcinoma, Hepatocellular; Cell Line, Tumor; Humans; Liver Neoplasms; Nanoparticles; Polymers; Sorafenib; Tumor Microenvironment | 2021 |
Inhibiting CBX4 efficiently protects hepatocellular carcinoma cells against sorafenib resistance.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Proliferation; Drug Resistance, Neoplasm; Female; Humans; Ligases; Liver Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Polycomb-Group Proteins; Sorafenib; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2021 |
Ultra-small lipid nanoparticles encapsulating sorafenib and midkine-siRNA selectively-eradicate sorafenib-resistant hepatocellular carcinoma in vivo.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Hep G2 Cells; Humans; Lipids; Liver Neoplasms; Mice; Midkine; Nanoparticles; RNA, Small Interfering; Sorafenib; Tumor Microenvironment | 2021 |
PARP inhibitor Olaparib overcomes Sorafenib resistance through reshaping the pluripotent transcriptome in hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Chromatin; DNA Damage; Drug Resistance, Neoplasm; Embryonic Stem Cells; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Sorafenib; Transcriptome | 2021 |
Transcriptomic characterization reveals prognostic molecular signatures of sorafenib resistance in hepatocellular carcinoma.
Topics: Antineoplastic Agents; Aryldialkylphosphatase; Carcinoma, Hepatocellular; Cell Line, Tumor; Chromosomes, Human, Pair 2; Complement Factor B; Databases, Genetic; Drug Resistance, Neoplasm; Gene Expression Profiling; Humans; Liver Neoplasms; Open Reading Frames; Protein Interaction Maps; Receptor, IGF Type 2; Regression Analysis; Sorafenib; Transcriptome | 2021 |
Sorafenib for advanced hepatocellular carcinoma provides better prognosis after liver transplantation than without liver transplantation.
Topics: Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Liver Transplantation; Phenylurea Compounds; Prognosis; Sorafenib | 2021 |
Efficacy and safety of sorafenib in elderly patients with advanced hepatocellular carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib | 2021 |
Urokinase-type Plasminogen Activator Is a Therapeutic Target for Overcoming Sorafenib Resistance in Hepatoma Cells.
Topics: Amiloride; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; Cell Proliferation; Drug Resistance, Neoplasm; Hep G2 Cells; Humans; Liver Neoplasms; Male; Membrane Proteins; Mice, Inbred BALB C; Mice, Nude; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; RNA Interference; RNA, Small Interfering; Sorafenib; Xenograft Model Antitumor Assays | 2021 |
Sorafenib Rechallenge and Sorafenib after Lenvatinib Failure in a Patient with Hepatocellular Carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Male; Phenylurea Compounds; Prospective Studies; Quinolines; Sorafenib | 2021 |
Targeting tumor lineage plasticity in hepatocellular carcinoma using an anti-CLDN6 antibody-drug conjugate.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Humans; Immunoconjugates; Liver Neoplasms; Neoplasm Recurrence, Local; Sorafenib | 2021 |
S100 family members: potential therapeutic target in patients with hepatocellular carcinoma: A STROBE study.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Molecular Targeted Therapy; S100 Proteins; Sorafenib | 2021 |
[New approval: Atezolizumab and bevacizumab for first line of unresecable hepatocellular carcinoma].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Bevacizumab; Carcinoma, Hepatocellular; Confidence Intervals; Humans; Immunotherapy; Liver Neoplasms; Proportional Hazards Models; Sorafenib | 2021 |
Lenvatinib versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: An inverse probability of treatment weighting analysis.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Phenylurea Compounds; Probability; Quinolines; Sorafenib | 2021 |
Microvesicles mediate sorafenib resistance in liver cancer cells through attenuating p53 and enhancing FOXM1 expression.
Topics: Animals; Antineoplastic Agents; Cell-Derived Microparticles; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Forkhead Box Protein M1; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Liver Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Sorafenib; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2021 |
Rhamnetin decelerates the elimination and enhances the antitumor effect of the molecular-targeting agent sorafenib in hepatocellular carcinoma cells via the miR-148a/PXR axis.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Interactions; Drug Resistance, Neoplasm; Liver; Liver Neoplasms; Mice; Mice, Nude; MicroRNAs; Pregnane X Receptor; Quercetin; Sorafenib | 2021 |
Dantrolene Potentiates the Antineoplastic Effect of Sorafenib in Hepatocellular Carcinoma via Targeting Ca
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Dantrolene; Liver Neoplasms; Phosphatidylinositol 3-Kinases; Rats; Signal Transduction; Sorafenib | 2021 |
Development and Validation of Sorafenib-eluting Microspheres to Enhance Therapeutic Efficacy of Transcatheter Arterial Chemoembolization in a Rat Model of Hepatocellular Carcinoma.
Topics: Animals; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Liver Neoplasms; Microspheres; Rats; Sorafenib | 2021 |
[A Case in Which Multiple Post-Operatively Recurring Hepatocellular Carcinomas Showed a Positive Response to Sorafenib-Hepatic Arterial Infusion Chemotherapy (HAIC)Sequential Therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Neoplasm Recurrence, Local; Sorafenib; Treatment Outcome | 2021 |
HDAC11 Regulates Glycolysis through the LKB1/AMPK Signaling Pathway to Maintain Hepatocellular Carcinoma Stemness.
Topics: Acetylation; AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Line, Tumor; Disease Models, Animal; Disease Progression; Drug Resistance, Neoplasm; Energy Metabolism; Gene Expression Profiling; Gene Silencing; Glycolysis; Hep G2 Cells; Histone Deacetylases; Histones; Humans; Liver Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplastic Stem Cells; Prognosis; Promoter Regions, Genetic; Protein Serine-Threonine Kinases; Signal Transduction; Sorafenib; Spheroids, Cellular; Tumor Stem Cell Assay | 2021 |
Co-Administration of iRGD with Sorafenib-Loaded Iron-Based Metal-Organic Framework as a Targeted Ferroptosis Agent for Liver Cancer Therapy.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Endocytosis; Ferroptosis; Hep G2 Cells; Humans; Iron; Lipid Peroxidation; Liver Neoplasms; Metal-Organic Frameworks; Mice; Nanoparticles; Oligopeptides; Peroxidase; Rabbits; Sorafenib; Toxicity Tests | 2021 |
Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Decision Trees; Disease Progression; Drug Costs; Female; Humans; Liver Neoplasms; Male; Middle Aged; Mortality; Progression-Free Survival; Proportional Hazards Models; Quality-Adjusted Life Years; Sorafenib; Treatment Outcome | 2021 |
Advances in pharmacotherapeutics for hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Protein Kinase Inhibitors; Sorafenib | 2021 |
Sorafenib blocks the activation of the HIF-2α/VEGFA/EphA2 pathway, and inhibits the rapid growth of residual liver cancer following high-intensity focused ultrasound therapy in vivo.
Topics: Angiogenesis Inhibitors; Animals; Basic Helix-Loop-Helix Transcription Factors; Carcinoma, Hepatocellular; Cell Proliferation; Chemotherapy, Adjuvant; Gene Expression Regulation, Neoplastic; Hep G2 Cells; High-Intensity Focused Ultrasound Ablation; Humans; Liver Neoplasms; Male; Mice, Inbred BALB C; Mice, Nude; Neoplasm, Residual; Protein Kinase Inhibitors; Receptor, EphA2; Signal Transduction; Sorafenib; Tumor Burden; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2021 |
Sequential Treatment of Sorafenib-Regorafenib Versus Sorafenib-Physician's Choice: A Propensity Score-Matched Analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Phenylurea Compounds; Propensity Score; Pyridines; Retrospective Studies; Sorafenib | 2021 |
YAP promotes sorafenib resistance in hepatocellular carcinoma by upregulating survivin.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Heterografts; Humans; Liver Neoplasms; Mice; Mice, Inbred BALB C; Sorafenib; Survivin; Up-Regulation; YAP-Signaling Proteins | 2021 |
The impact of FGF19/FGFR4 signaling inhibition in antitumor activity of multi-kinase inhibitors in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Fibroblast Growth Factors; Humans; Liver Neoplasms; Mice; Mice, Inbred NOD; Mice, SCID; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolines; Receptor, Fibroblast Growth Factor, Type 4; Sorafenib | 2021 |
The selective serotonin reuptake inhibitors enhance the cytotoxicity of sorafenib in hepatocellular carcinoma cells.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Combinations; Floxuridine; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Proto-Oncogene Proteins c-akt; Selective Serotonin Reuptake Inhibitors; Sertraline; Sorafenib; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2021 |
Comparison of the Clinical Outcome of Ramucirumab for Unresectable Hepatocellular Carcinoma with That of Prior Tyrosine Kinase Inhibitor Therapy.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Phenylurea Compounds; Prognosis; Pyridines; Quinolines; Ramucirumab; Retrospective Studies; Sorafenib; Survival Rate | 2021 |
Quantitative proteomics identifies FOLR1 to drive sorafenib resistance via activating autophagy in hepatocellular carcinoma cells.
Topics: Apoptosis; Autophagy; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Folate Receptor 1; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Liver Neoplasms; Proteomics; RNA, Small Interfering; Signal Transduction; Sorafenib | 2021 |
Regorafenib versus cabozantinb as second-line treatment after sorafenib for unresectable hepatocellular carcinoma: matching-adjusted indirect comparison analysis.
Topics: Adult; Aged; Anilides; Carcinoma, Hepatocellular; Clinical Trials, Phase III as Topic; Female; Humans; Liver Neoplasms; Male; Middle Aged; Phenylurea Compounds; Progression-Free Survival; Pyridines; Salvage Therapy; Sorafenib | 2021 |
A highly selective and potent CXCR4 antagonist for hepatocellular carcinoma treatment.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Line, Tumor; Diethylnitrosamine; Drug Synergism; Humans; Liver Neoplasms; Liver Neoplasms, Experimental; Lymphocytes, Tumor-Infiltrating; Male; Mice; Molecular Docking Simulation; Rats; Receptors, CXCR4; Signal Transduction; Sorafenib; T-Lymphocytes, Cytotoxic; Tumor Microenvironment; Tumor-Associated Macrophages; Xenograft Model Antitumor Assays | 2021 |
Pattern of macrovascular invasion in hepatocellular carcinoma.
Topics: Ablation Techniques; Aged; Antineoplastic Agents; Ascites; Carcinoma, Hepatocellular; End Stage Liver Disease; Female; Hepatectomy; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Italy; Liver Diseases, Alcoholic; Liver Neoplasms; Liver Transplantation; Male; Mesenteric Veins; Middle Aged; Neoplasm Invasiveness; Non-alcoholic Fatty Liver Disease; Patient Acuity; Portal Vein; Prognosis; Registries; Sorafenib; Survival Rate; Tumor Burden | 2021 |
Quiescin sulfhydryl oxidase 1 promotes sorafenib-induced ferroptosis in hepatocellular carcinoma by driving EGFR endosomal trafficking and inhibiting NRF2 activation.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; ErbB Receptors; Ferroptosis; Humans; Liver Neoplasms; NF-E2-Related Factor 2; Oxidoreductases; Oxidoreductases Acting on Sulfur Group Donors; Sorafenib | 2021 |
Adding Sorafenib-eluting Microspheres to TACE: The Next Step in Hepatocellular Carcinoma Treatment.
Topics: Animals; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Liver Neoplasms; Microspheres; Rats; Sorafenib | 2021 |
eIF4E-eIF4G complex inhibition synergistically enhances the effect of sorafenib in hepatocellular carcinoma.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Down-Regulation; Drug Combinations; Eukaryotic Initiation Factor-4E; Eukaryotic Initiation Factor-4F; Eukaryotic Initiation Factor-4G; Humans; Liver Neoplasms; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-bcl-2; Sorafenib; TOR Serine-Threonine Kinases | 2021 |
Comparative Efficacy of Cabozantinib and Ramucirumab After Sorafenib for Patients with Hepatocellular Carcinoma and Alpha-fetoprotein ≥ 400 ng/mL: A Matching-Adjusted Indirect Comparison.
Topics: Adult; alpha-Fetoproteins; Anilides; Antibodies, Monoclonal, Humanized; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Pyridines; Ramucirumab; Sorafenib | 2021 |
Herbal formula of Bushen Jianpi combined with sorafenib inhibits hepatocellular carcinoma growth by promoting cell apoptosis and blocking the cell cycle.
Topics: Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Therapy, Combination; Drugs, Chinese Herbal; Humans; Liver Neoplasms; Male; Mice, Inbred BALB C; Sorafenib | 2021 |
Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib for Patients With Unresectable or Metastatic Hepatocellular Carcinoma.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Female; Health Care Costs; Humans; Liver Neoplasms; Male; Quality-Adjusted Life Years; Sorafenib; United States | 2021 |
Comparison of Therapy in Advanced Hepatocellular Carcinoma Based on Clear Definition and Accurate Subgroup Data.
Topics: Carcinoma, Hepatocellular; Combined Modality Therapy; Humans; Liver Neoplasms; Sorafenib | 2021 |
Comparison of Therapy in Advanced Hepatocellular Carcinoma Based on Clear Definition and Accurate Subgroup Data-Reply.
Topics: Carcinoma, Hepatocellular; Combined Modality Therapy; Humans; Liver Neoplasms; Sorafenib | 2021 |
miR-93 regulates liver tumor initiating cells expansion and predicts chemotherapeutic response of patients.
Topics: 3' Untranslated Regions; Adult; Base Sequence; Carcinoma, Hepatocellular; Cell Line, Tumor; Down-Regulation; Female; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Male; MicroRNAs; Neoplastic Stem Cells; Protein Tyrosine Phosphatases, Non-Receptor; Sorafenib; Treatment Outcome | 2021 |
TRERNA1 upregulation mediated by HBx promotes sorafenib resistance and cell proliferation in HCC via targeting NRAS by sponging miR-22-3p.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; GTP Phosphohydrolases; Hep G2 Cells; Humans; Liver Neoplasms; Membrane Proteins; Mice; MicroRNAs; Prognosis; RNA, Long Noncoding; Sequence Analysis, RNA; Sorafenib; Trans-Activators; Up-Regulation; Viral Regulatory and Accessory Proteins | 2021 |
SPARC regulates ferroptosis induced by sorafenib in human hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Ferroptosis; Hep G2 Cells; Humans; Liver Neoplasms; Osteonectin; Reactive Oxygen Species; Sorafenib | 2021 |
Sorafenib combined with dasatinib therapy inhibits cell viability, migration, and angiogenesis synergistically in hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Cell Line; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Dasatinib; Hep G2 Cells; Human Umbilical Vein Endothelial Cells; Humans; Liver Neoplasms; Neovascularization, Pathologic; Signal Transduction; Sorafenib; Vascular Endothelial Growth Factor A | 2021 |
Sorafenib and Lenvatinib as first-line treatment of hepatocellular carcinoma: A still controversial comparison.
Topics: Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Phenylurea Compounds; Probability; Quinolines; Sorafenib | 2021 |
Bovine Serum Albumin Nanoparticle-Mediated Delivery of Sorafenib for Improving Hepatocellular Carcinoma Therapy.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Humans; Liver Neoplasms; Nanoparticles; Serum Albumin, Bovine; Sorafenib | 2021 |
Vaccinia-related kinase 2 blunts sorafenib's efficacy against hepatocellular carcinoma by disturbing the apoptosis-autophagy balance.
Topics: Animals; Apoptosis; Autophagy; bcl-2-Associated X Protein; Beclin-1; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Disease Progression; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Phosphorylation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-bcl-2; Sorafenib; Survival Rate; Xenograft Model Antitumor Assays | 2021 |
Novel small molecular inhibitor of Pit-Oct-Unc transcription factor 1 suppresses hepatocellular carcinoma cell proliferation.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; China; HEK293 Cells; Humans; Liver Neoplasms; Male; Mice; Mice, Nude; Molecular Docking Simulation; Octamer Transcription Factor-1; Prognosis; Sorafenib; Transcription Factor Pit-1 | 2021 |
Treatment efficacy by hepatic arterial infusion chemotherapy vs. sorafenib after liver-directed concurrent chemoradiotherapy for advanced hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoradiotherapy; Cisplatin; Female; Fluorouracil; Follow-Up Studies; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Prognosis; Retrospective Studies; Sorafenib; Survival Rate | 2021 |
Synergistic effects of α-Mangostin and sorafenib in hepatocellular carcinoma: New insights into α-mangostin cytotoxicity.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Gene Expression; Humans; Liver Neoplasms; Male; MAP Kinase Signaling System; Membrane Proteins; Mice; Mice, Inbred BALB C; Mice, Nude; Protein Kinase Inhibitors; RNA-Seq; Sorafenib; TOR Serine-Threonine Kinases; Ubiquitin-Protein Ligases; Xanthones; Xenograft Model Antitumor Assays | 2021 |
EPHB2 Activates β-Catenin to Enhance Cancer Stem Cell Properties and Drive Sorafenib Resistance in Hepatocellular Carcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; beta Catenin; Carcinoma, Hepatocellular; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred C57BL; Mice, SCID; Neoplastic Stem Cells; Receptor, EphB2; Sorafenib; Tumor Cells, Cultured; Wnt Signaling Pathway; Xenograft Model Antitumor Assays | 2021 |
The Impact of Sorafenib in Combination with Transarterial Chemoembolization on the Outcomes of Intermediate-Stage Hepatocellular Carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Retrospective Studies; Sorafenib; Survival Rate; Treatment Outcome | 2021 |
C1orf61 promotes hepatocellular carcinoma metastasis and increases the therapeutic response to sorafenib.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Proliferation; Cell Survival; Drug Screening Assays, Antitumor; Humans; Liver Neoplasms; Nerve Tissue Proteins; Proto-Oncogene Proteins c-fos; Sorafenib; Tumor Cells, Cultured | 2021 |
GSTZ1 sensitizes hepatocellular carcinoma cells to sorafenib-induced ferroptosis via inhibition of NRF2/GPX4 axis.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Ferroptosis; Glutathione Transferase; Humans; Liver Neoplasms; NF-E2-Related Factor 2; Phospholipid Hydroperoxide Glutathione Peroxidase; Sorafenib | 2021 |
High trough levels of everolimus combined to sorafenib improve patients survival after hepatocellular carcinoma recurrence in liver transplant recipients.
Topics: Carcinoma, Hepatocellular; Everolimus; Humans; Liver Neoplasms; Liver Transplantation; Neoplasm Recurrence, Local; Retrospective Studies; Sorafenib | 2021 |
C/EBPβ enhances efficacy of sorafenib in hepatoblastoma.
Topics: Animals; Antineoplastic Agents; CCAAT-Enhancer-Binding Protein-beta; Child; Female; Hep G2 Cells; Hepatoblastoma; Humans; Liver Neoplasms; Male; Mice; Mice, Nude; Sorafenib | 2021 |
Hemistepsin a Induces Apoptosis of Hepatocellular Carcinoma Cells by Downregulating STAT3.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Down-Regulation; Drug Screening Assays, Antitumor; Gene Expression Regulation, Neoplastic; Genes, Reporter; Humans; Lactones; Liver Neoplasms; Neoplasm Proteins; Oxidative Stress; Protein Kinase Inhibitors; Recombinant Proteins; Sesquiterpenes; Sorafenib; STAT3 Transcription Factor; Transcriptional Activation | 2021 |
Radiologic Response Combined with Dermatologic Toxicities is the Most Robust Predictor of Survival Benefits in Patients with Inoperable Hepatocellular Carcinoma After Transarterial Chemoembolization Plus Sorafenib Therapy.
Topics: Adult; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Female; Humans; Liver Neoplasms; Male; Middle Aged; Retrospective Studies; Sorafenib; Treatment Outcome | 2021 |
Safety and efficacy of lenvatinib by starting dose based on body weight in patients with unresectable hepatocellular carcinoma in REFLECT.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Body Weight; Carcinoma, Hepatocellular; Dose-Response Relationship, Drug; Female; Humans; Liver Neoplasms; Male; Middle Aged; Phenylurea Compounds; Quinolines; Sorafenib; Treatment Outcome | 2021 |
Pristimerin synergistically sensitizes conditionally reprogrammed patient derived-primary hepatocellular carcinoma cells to sorafenib through endoplasmic reticulum stress and ROS generation by modulating Akt/FoxO1/p27
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; Cell Survival; Cyclin-Dependent Kinase Inhibitor p27; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Forkhead Box Protein O1; Human Umbilical Vein Endothelial Cells; Humans; Liver Neoplasms; Middle Aged; Pentacyclic Triterpenes; Proto-Oncogene Proteins c-akt; Reactive Oxygen Species; Signal Transduction; Sorafenib; Tumor Cells, Cultured | 2021 |
Histone deacetylase inhibitor resminostat in combination with sorafenib counteracts platelet-mediated pro-tumoral effects in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Blood Platelets; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Drug Therapy, Combination; Epithelial-Mesenchymal Transition; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Liver Neoplasms; Mice; Signal Transduction; Sorafenib; Sulfonamides | 2021 |
TAK1 Is a Novel Target in Hepatocellular Carcinoma and Contributes to Sorafenib Resistance.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; F-Box Proteins; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Liver Neoplasms; Male; MAP Kinase Kinase Kinases; Membrane Proteins; Mice; Mutation; Proteolysis; RNA-Binding Proteins; Sorafenib; Ubiquitination; Up-Regulation; Xenograft Model Antitumor Assays | 2021 |
Evaluation of cardiovascular events in patients with hepatocellular carcinoma treated with sorafenib in the clinical practice. The CARDIO-SOR study.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cardiovascular Diseases; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Treatment Outcome | 2021 |
[Late line systemic therapy for advanced hepatocellular carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Sorafenib | 2021 |
Amplification of DDR2 mediates sorafenib resistance through NF-κB/c-Rel signaling in hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Discoidin Domain Receptor 2; Female; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Male; Middle Aged; Sorafenib | 2021 |
CircMEMO1 modulates the promoter methylation and expression of TCF21 to regulate hepatocellular carcinoma progression and sorafenib treatment sensitivity.
Topics: Antineoplastic Agents; Basic Helix-Loop-Helix Transcription Factors; Carcinoma, Hepatocellular; Disease Progression; DNA Methylation; Gene Expression Regulation, Neoplastic; Humans; Intracellular Signaling Peptides and Proteins; Liver Neoplasms; MicroRNAs; Promoter Regions, Genetic; RNA, Circular; Sorafenib | 2021 |
Drug-Drug Interaction between Metformin and Sorafenib Alters Antitumor Effect in Hepatocellular Carcinoma Cells.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Diabetes Mellitus; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Female; Hep G2 Cells; Humans; Liver Neoplasms; Metformin; Mice; Signal Transduction; Sorafenib; Treatment Outcome; Xenograft Model Antitumor Assays | 2021 |
Clinical Outcomes of 2nd- and 3rd-Line Regorafenib for Advanced Hepatocellular Carcinoma.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Cohort Studies; Female; Humans; Liver Neoplasms; Male; Middle Aged; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinolines; Retrospective Studies; Sorafenib; Survival Rate; Treatment Outcome | 2021 |
UBQLN1 mediates sorafenib resistance through regulating mitochondrial biogenesis and ROS homeostasis by targeting PGC1β in hepatocellular carcinoma.
Topics: Adaptor Proteins, Signal Transducing; Aged; Autophagy-Related Proteins; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Male; Middle Aged; Organelle Biogenesis; Reactive Oxygen Species; RNA-Binding Proteins; Sorafenib | 2021 |
Systemic immune-inflammation index predicts prognosis of sequential therapy with sorafenib and regorafenib in hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Disease Progression; Drug Administration Schedule; Female; Humans; Inflammation; Liver Neoplasms; Male; Middle Aged; Phenylurea Compounds; Prognosis; Progression-Free Survival; Pyridines; Retrospective Studies; Sorafenib | 2021 |
Resubclassification and clinical management for Barcelona Clinic Liver Cancer Stage C hepatocellular carcinoma.
Topics: Aged; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Neoplasm Staging; Prognosis; Retrospective Studies; Sorafenib | 2021 |
Treatment of liver cancer cells with ethyl acetate extract of Crithmum maritimum permits reducing sorafenib dose and toxicity maintaining its efficacy.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apiaceae; Apoptosis; Carcinoma, Hepatocellular; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Hep G2 Cells; Humans; Inhibitory Concentration 50; Liver; Liver Neoplasms; Phytotherapy; Plant Extracts; Sorafenib | 2021 |
Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
Topics: Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Sorafenib | 2021 |
Metastatic hepatocellular carcinoma cured by exclusive systemic antiangiogenic therapy: Two cases along with tumor molecular profiles.
Topics: Aged; Angiogenesis Inhibitors; Bevacizumab; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Male; Medical Illustration; Sorafenib; Transcriptome | 2021 |
Trilostane, a 3β-hydroxysteroid dehydrogenase inhibitor, suppresses growth of hepatocellular carcinoma and enhances anti-cancer effects of sorafenib.
Topics: Aged; Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Dihydrotestosterone; Drug Therapy, Combination; Estradiol; Female; Humans; Liver Neoplasms; Male; Mice; Mice, Nude; Middle Aged; Multienzyme Complexes; Progesterone Reductase; RNA, Small Interfering; Sorafenib; Steroid Isomerases; Testosterone; Xenograft Model Antitumor Assays | 2021 |
Successful management of the hepatocellular carcinoma with inferior vena cava tumor thrombus: A case report.
Topics: Carcinoma, Hepatocellular; Chemoradiotherapy, Adjuvant; Hepatectomy; Humans; Liver; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Radiosurgery; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome; Vena Cava, Inferior; Venous Thrombosis | 2021 |
The impact of recent chemotherapy on immunity in 2 COVID-19 cases with gastrointestinal tumors: A case report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; COVID-19; COVID-19 Drug Treatment; COVID-19 Nucleic Acid Testing; Cyclobutanes; Docetaxel; Drug Therapy, Combination; Humans; Liver Neoplasms; Lung; Male; Middle Aged; Organoplatinum Compounds; RNA, Viral; SARS-CoV-2; Sorafenib; Stomach Neoplasms; Tomography, X-Ray Computed; Treatment Outcome | 2021 |
Identification of hepatic fibrosis inhibitors through morphometry analysis of a hepatic multicellular spheroids model.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Colforsin; Drug Synergism; Epithelial-Mesenchymal Transition; Fibroblasts; Hep G2 Cells; Hepatic Stellate Cells; Human Umbilical Vein Endothelial Cells; Humans; Liver Cirrhosis; Liver Neoplasms; Small Molecule Libraries; Sorafenib; Spheroids, Cellular; Tretinoin; Tumor Microenvironment | 2021 |
A Combined Antitumor Strategy Mediated by a New Targeted Nanosystem to Hepatocellular Carcinoma.
Topics: Animals; Apoptosis; Carcinoma, Hepatocellular; Caspases; Cell Line, Tumor; Cell Survival; Humans; Liver Neoplasms; Membrane Potential, Mitochondrial; Molecular Targeted Therapy; Nanomedicine; Sorafenib | 2021 |
Time to move beyond the classical prognostic systems for patients with advanced hepatocellular carcinoma undergoing Sorafenib.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neoplasms; Prognosis; Sorafenib | 2021 |
Sorafenib is associated with a reduced rate of tumour growth and liver function deterioration in HCV-induced hepatocellular carcinoma.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Female; Growth and Development; Hepatitis C; Humans; Liver; Liver Function Tests; Liver Neoplasms; Male; Middle Aged; Sorafenib | 2021 |
Quantification of sorafenib, lenvatinib, and apatinib in human plasma for therapeutic drug monitoring by UPLC-MS/MS.
Topics: Chromatography, High Pressure Liquid; Chromatography, Liquid; Drug Monitoring; Humans; Liver Neoplasms; Pharmaceutical Preparations; Phenylurea Compounds; Pyridines; Quinolines; Reproducibility of Results; Sorafenib; Tandem Mass Spectrometry | 2021 |
Adoption of single agent anticancer therapy for advanced hepatocellular carcinoma and impact of facility type, insurance status, and income on survival: Analysis of the national cancer database 2004-2014.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Databases, Factual; Female; Health Facilities; Humans; Income; Insurance Coverage; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Proportional Hazards Models; Protein Kinase Inhibitors; Retrospective Studies; Sorafenib; Time Factors | 2021 |
The Outcomes of Systemic Treatment in Recurrent Hepatocellular Carcinomas Following Liver Transplants.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Liver Transplantation; Neoplasm Recurrence, Local; Phenylurea Compounds; Retrospective Studies; Sorafenib; Treatment Outcome | 2021 |
Fibrinogen-Like Protein 1 Modulates Sorafenib Resistance in Human Hepatocellular Carcinoma Cells.
Topics: Apoptosis; Autophagy; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Fibrinogen; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Liver Neoplasms; MAP Kinase Signaling System; Niacinamide; Phenylurea Compounds; Signal Transduction; Sorafenib | 2021 |
MicroRNA-92b augments sorafenib resistance in hepatocellular carcinoma via targeting PTEN to activate PI3K/AKT/mTOR signaling.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; MicroRNAs; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Signal Transduction; Sorafenib; TOR Serine-Threonine Kinases | 2021 |
Imatinib inhibits the malignancy of hepatocellular carcinoma by suppressing autophagy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Synergism; Humans; Imatinib Mesylate; Liver Neoplasms; Male; Mice; Neoplasm Invasiveness; Sorafenib; Xenograft Model Antitumor Assays | 2021 |
Significance of liver resection for intermediate stage hepatocellular carcinoma according to subclassification.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Cisplatin; Female; Follow-Up Studies; Hepatectomy; Humans; Iodized Oil; Kaplan-Meier Estimate; Liver; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Retrospective Studies; Risk Assessment; Sorafenib; Treatment Outcome | 2021 |
Sorafenib-Related Basal Cell Carcinoma.
Topics: Aged, 80 and over; Antineoplastic Agents; Carcinoma, Basal Cell; Facial Neoplasms; Humans; Liver Neoplasms; Male; Sorafenib | 2021 |
Hepatic arterial infusion chemotherapy in the treatment of advanced hepatocellular carcinoma with portal vein thrombosis: a case-control study.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Case-Control Studies; Cisplatin; Doxorubicin; Female; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Portal Vein; Sorafenib; Survival Rate; Treatment Outcome; Venous Thrombosis | 2021 |
Sorafenib plus partial splenic embolism for treatment of hepatocellular carcinoma Barcelona stage C combined with hypersplenism: a case series.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; China; Embolism; Humans; Hypersplenism; Liver Neoplasms; Neoplasm Staging; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2021 |
An update on atezolizumab for hepatocellular carcinoma.
Topics: Antibodies, Monoclonal, Humanized; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Sorafenib | 2021 |
Sorafenib and hepatocellular carcinoma: is alpha-fetoprotein a biomarker predictive of tumor biology and primary resistance?
Topics: alpha-Fetoproteins; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Drug Resistance; Humans; Liver Neoplasms; Prognosis; Sorafenib | 2021 |
Sorafenib use in hepatitis B virus- or hepatitis C virus-related hepatocellular carcinoma: A propensity score matching study.
Topics: Aged; Carcinoma, Hepatocellular; Female; Hepacivirus; Hepatitis B virus; Humans; Liver Neoplasms; Male; Middle Aged; Propensity Score; Sorafenib | 2021 |
Acetylation-induced PCK isoenzyme transition promotes metabolic adaption of liver cancer to systemic therapy.
Topics: Acetylation; Adaptation, Physiological; Cell Line; Cell Line, Tumor; Cytoplasm; HEK293 Cells; Hep G2 Cells; Histone Acetyltransferases; Humans; Isoenzymes; Liver; Liver Neoplasms; Neoplasm Recurrence, Local; Phenylurea Compounds; Phosphoenolpyruvate Carboxykinase (ATP); Progression-Free Survival; Quinolines; Sorafenib | 2021 |
A Novel atTAK Against Hepatocellular Carcinoma: Overcoming Resistance to Sorafenib.
Topics: Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Phenylurea Compounds; Sorafenib | 2021 |
Radioembolization vs sorafenib in locally advanced hepatocellular carcinoma with portal vein tumor thrombosis: A propensity score and Bayesian analysis.
Topics: Bayes Theorem; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neoplasms; Portal Vein; Propensity Score; Retrospective Studies; Sorafenib; Treatment Outcome; Venous Thrombosis | 2021 |
Complete Response for Advanced Hepatocellular Carcinoma by Conversion Surgery Therapy Following a Good Response of Regorafenib Despite Rapid Progressive Disease with Sorafenib.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Male; Phenylurea Compounds; Pyridines; Sorafenib | 2021 |
Dual Targeting of Sorafenib-Resistant HCC-Derived Cancer Stem Cells.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Humans; Liver Neoplasms; Neoplasm Recurrence, Local; Neoplastic Stem Cells; Sorafenib | 2021 |
Identification of an m6A-Related Signature as Biomarker for Hepatocellular Carcinoma Prognosis and Correlates with Sorafenib and Anti-PD-1 Immunotherapy Treatment Response.
Topics: Adenosine; Biomarkers, Tumor; Carcinoma, Hepatocellular; Databases, Genetic; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Immune Checkpoint Inhibitors; Liver Neoplasms; Male; Neoplasm Staging; Prognosis; Sorafenib; Treatment Outcome | 2021 |
Early diarrhoea under sorafenib as a marker to consider the early migration to second-line drugs.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Diarrhea; Drug Resistance, Neoplasm; Female; Humans; Liver Neoplasms; Male; Middle Aged; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Sorafenib; Survival Rate; Time Factors; Treatment Outcome | 2021 |
MYC-targeted WDR4 promotes proliferation, metastasis, and sorafenib resistance by inducing CCNB1 translation in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Movement; Cell Proliferation; Cyclin B1; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Eukaryotic Initiation Factor-2; Gene Expression Regulation, Neoplastic; GTP-Binding Proteins; Hep G2 Cells; Humans; Liver Neoplasms; Mice, Inbred BALB C; Mice, Nude; Phosphatidylinositol 3-Kinase; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Signal Transduction; Sorafenib; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2021 |
Systemic therapy for hepatocellular carcinoma: current status and future perspectives.
Topics: Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Progression-Free Survival; Sorafenib; Vascular Endothelial Growth Factor A | 2021 |
Phosphorylation of intestine-specific homeobox by ERK1 modulates oncogenic activity and sorafenib resistance.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Gene Expression Regulation, Neoplastic; Homeodomain Proteins; Humans; Intestines; Liver Neoplasms; Male; Mice; Mitogen-Activated Protein Kinase 3; Phosphorylation; Signal Transduction; Sorafenib; Transcription Factors | 2021 |
Anlotinib followed by transarterial chemoembolization and radiofrequency ablation is a safe and effective initial treatment for hepatocellular carcinoma patients with portal vein tumor thrombus: A retrospective case series study.
Topics: Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Indoles; Kaplan-Meier Estimate; Liver Neoplasms; Male; Neoplasm Invasiveness; Portal Vein; Postoperative Complications; Quinolines; Retrospective Studies; Sorafenib; Survival Rate; Venous Thrombosis | 2021 |
Sorafenib for hepatocellular carcinoma: potential molecular targets and resistance mechanisms.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Protein Kinase Inhibitors; Sorafenib | 2022 |
Increased effects of 2,5-dimethylcelecoxib on sensitivity of hepatocellular carcinoma cells to sorafenib via CYP3A5 expression and activation of AMPK.
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cytochrome P-450 CYP3A; Drug Interactions; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Sorafenib; Sulfonamides | 2021 |
Decision making in systemic therapy of hepatocellular carcinoma: Should we pay attention to disease aetiology?
Topics: Carcinoma, Hepatocellular; Cost-Benefit Analysis; Decision Making; Humans; Liver Neoplasms; Sorafenib | 2021 |
BH3-only protein expression determines hepatocellular carcinoma response to sorafenib-based treatment.
Topics: Apoptosis; Bcl-2-Like Protein 11; Biphenyl Compounds; Carcinoma, Hepatocellular; Caspases; Cell Death; Cell Line, Tumor; Cell Proliferation; Cell Survival; Enzyme Activation; Humans; Ki-67 Antigen; Liver Neoplasms; Mitochondrial Membrane Transport Proteins; Myeloid Cell Leukemia Sequence 1 Protein; Nitrophenols; Piperazines; Proto-Oncogene Proteins c-bcl-2; Sorafenib; Sulfonamides; TNF-Related Apoptosis-Inducing Ligand | 2021 |
The NUPR1/p73 axis contributes to sorafenib resistance in hepatocellular carcinoma.
Topics: Animals; Apoptosis; Autophagy; Basic Helix-Loop-Helix Transcription Factors; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Female; Hep G2 Cells; Humans; Liver Neoplasms; Mice; Mice, Nude; Neoplasm Proteins; Sorafenib; Tumor Protein p73 | 2021 |
Dichloroacetate enhances the anti-tumor effect of sorafenib via modulating the ROS-JNK-Mcl-1 pathway in liver cancer cells.
Topics: Acetylcysteine; Animals; Anthracenes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Dichloroacetic Acid; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Neoplastic; Hepatocytes; Humans; Liver Neoplasms; Male; MAP Kinase Kinase 4; Mice, Nude; Myeloid Cell Leukemia Sequence 1 Protein; Phosphorylation; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; Signal Transduction; Sorafenib; Tumor Burden; Xenograft Model Antitumor Assays | 2021 |
Coupling HDAC4 with transcriptional factor MEF2D abrogates SPRY4-mediated suppression of ERK activation and elicits hepatocellular carcinoma drug resistance.
Topics: Animals; Carcinoma, Hepatocellular; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Intracellular Signaling Peptides and Proteins; Liver Neoplasms; MAP Kinase Signaling System; MEF2 Transcription Factors; Mice; Nerve Tissue Proteins; Protein Kinase Inhibitors; Repressor Proteins; Signal Transduction; Sorafenib; Xenograft Model Antitumor Assays | 2021 |
Synthesis and anti-hepatocellular carcinoma activity of aminopyridinol-sorafenib hybrids.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line; Cell Line, Tumor; Cell Proliferation; Chick Embryo; Drug Screening Assays, Antitumor; Humans; Liver Neoplasms; Molecular Docking Simulation; Protein Kinase Inhibitors; Pyrimidines; Sorafenib; Xenograft Model Antitumor Assays | 2021 |
MicroRNA-138-1-3p sensitizes sorafenib to hepatocellular carcinoma by targeting PAK5 mediated β-catenin/ABCB1 signaling pathway.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Liver Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Protein Kinase Inhibitors; Signal Transduction; Sorafenib | 2021 |
Systems analysis identifies endothelin 1 axis blockade for enhancing the anti-tumor effect of multikinase inhibitor.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Endothelin-1; Humans; Liver Neoplasms; Mice; Sorafenib; Systems Analysis; Xenograft Model Antitumor Assays | 2022 |
Y-box binding protein 1 augments sorafenib resistance
Topics: Apoptosis; Carcinoma, Hepatocellular; Carrier Proteins; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Phosphatidylinositol 3-Kinase; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Signal Transduction; Sorafenib; Y-Box-Binding Protein 1 | 2021 |
Regorafenib Efficacy After Sorafenib in Patients With Recurrent Hepatocellular Carcinoma After Liver Transplantation: A Retrospective Study.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Liver Transplantation; Phenylurea Compounds; Pyridines; Retrospective Studies; Sorafenib | 2021 |
Transient deterioration of albumin-bilirubin scores in early post-dose period of molecular targeted therapies in advanced hepatocellular carcinoma with 50% or higher liver occupation: A STROBE-compliant retrospective observational study.
Topics: Aged; Antineoplastic Agents; Bilirubin; Biomarkers, Pharmacological; C-Reactive Protein; Carcinoma, Hepatocellular; Correlation of Data; Drug Monitoring; Drug Screening Assays, Antitumor; Female; Humans; Japan; Liver; Liver Neoplasms; Male; Molecular Targeted Therapy; Neoplasm Staging; Phenylurea Compounds; Quinolines; Serum Albumin; Sorafenib | 2021 |
Efficacy of apatinib in patients with sorafenib-transarterial chemoembolization refractory hepatocellular carcinoma: a retrospective study.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Humans; Liver Neoplasms; Pyridines; Retrospective Studies; Sorafenib; Treatment Outcome | 2021 |
Genome-scale CRISPRa screening identifies MTX1 as a contributor for sorafenib resistance in hepatocellular carcinoma by augmenting autophagy.
Topics: Animals; Antineoplastic Agents; Autophagy; Carcinoma, Hepatocellular; Cell Proliferation; Cells, Cultured; CRISPR-Cas Systems; Drug Resistance, Neoplasm; Flow Cytometry; Gain of Function Mutation; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Mice; Mice, Nude; Microscopy, Electron; Mitochondrial Membrane Transport Proteins; Real-Time Polymerase Chain Reaction; Sorafenib; Xenograft Model Antitumor Assays | 2021 |
The importance of the glucose-to-lymphocyte ratio in patients with hepatocellular carcinoma treated with sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Carcinoma, Hepatocellular; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Lymphocyte Count; Lymphocytes; Male; Middle Aged; Prognosis; Progression-Free Survival; Propensity Score; Retrospective Studies; Sorafenib; Young Adult | 2021 |
Secretory NPC2 Protein-Mediated Free Cholesterol Levels Were Correlated with the Sorafenib Response in Hepatocellular Carcinoma.
Topics: Animals; Carcinoma, Hepatocellular; Cholesterol; Female; Hep G2 Cells; Humans; Liver Neoplasms; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasm Proteins; Sorafenib; Vesicular Transport Proteins | 2021 |
Sorafenib use for recurrent hepatocellular cancer after resection or transplantation: Observations from a US regional analysis of the GIDEON registry.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Registries; Sorafenib | 2017 |
Vidatox 30 CH has tumor activating effect in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Cycle Proteins; Cell Line; Cell Line, Tumor; Cell Proliferation; Cytokines; Diethylnitrosamine; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Hepatocytes; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Rats, Wistar; Scorpions; Signal Transduction; Sorafenib; Spider Venoms; Tumor Suppressor Protein p53; Vascular Endothelial Growth Factor Receptor-2 | 2017 |
Overexpression of c-Jun contributes to sorafenib resistance in human hepatoma cell lines.
Topics: Anthracenes; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Caspase 3; Caspase 7; Cell Line, Tumor; Drug Resistance, Neoplasm; Hep G2 Cells; Humans; JNK Mitogen-Activated Protein Kinases; Liver Neoplasms; Niacinamide; Osteopontin; Phenylurea Compounds; Phosphorylation; Proto-Oncogene Mas; RNA Interference; RNA, Small Interfering; Sorafenib | 2017 |
Prognostic factors of sorafenib therapy in hepatocellular carcinoma patients with failure of transarterial chemoembolization.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Disease Progression; Disease-Free Survival; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Portal Vein; Prognosis; Protein Kinase Inhibitors; Retrospective Studies; Sorafenib; Treatment Failure; Treatment Outcome | 2017 |
Biomacromolecule/lipid hybrid nanoparticles for controlled delivery of sorafenib in targeting hepatocellular carcinoma therapy.
Topics: Animals; Carcinoma, Hepatocellular; Cell Survival; Drug Delivery Systems; Hep G2 Cells; Humans; Lipids; Liver Neoplasms; Mice; Nanoparticles; Niacinamide; Phenylurea Compounds; Sorafenib; Xenograft Model Antitumor Assays | 2017 |
TP53 and RET may serve as biomarkers of prognostic evaluation and targeted therapy in hepatocellular carcinoma.
Topics: Adult; Aged; Biomarkers, Tumor; Carcinoma, Hepatocellular; Exome; Female; High-Throughput Nucleotide Sequencing; Humans; Liver Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Niacinamide; Phenylurea Compounds; Prognosis; Proto-Oncogene Proteins c-ret; Sequence Analysis, DNA; Sorafenib; Survival Analysis; Tumor Suppressor Protein p53 | 2017 |
Upregulation of miR-137 reverses sorafenib resistance and cancer-initiating cell phenotypes by degrading ANT2 in hepatocellular carcinoma.
Topics: 3' Untranslated Regions; Adenine Nucleotide Translocator 2; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Hep G2 Cells; High-Intensity Focused Ultrasound Ablation; Humans; Liver Neoplasms; Male; MicroRNAs; Neoplastic Stem Cells; Niacinamide; Phenylurea Compounds; Sorafenib; Up-Regulation | 2017 |
3-bromopyruvate and buthionine sulfoximine effectively kill anoikis-resistant hepatocellular carcinoma cells.
Topics: Anoikis; Antineoplastic Agents; Buthionine Sulfoximine; Carcinoma, Hepatocellular; Epithelial-Mesenchymal Transition; Hep G2 Cells; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyruvates; Reactive Oxygen Species; Sorafenib | 2017 |
Sorafenib and 2,3,5-triiodobenzoic acid-loaded imageable microspheres for transarterial embolization of a liver tumor.
Topics: Animals; Antineoplastic Agents; Biocompatible Materials; Chemoembolization, Therapeutic; Disease Models, Animal; Drug Carriers; Drug Delivery Systems; Drug Liberation; Liver Neoplasms; Magnetic Resonance Imaging; Male; Materials Testing; Microspheres; Niacinamide; Phenylurea Compounds; Rats; Sorafenib; Tissue Distribution; Tomography, X-Ray Computed; Treatment Outcome; Triiodobenzoic Acids; Xenograft Model Antitumor Assays | 2017 |
Metastasis from Hepatocellular Carcinoma Masquerading as a Jugular Paraganglioma.
Topics: Aged; Antineoplastic Agents; Biopsy; Carcinoma, Hepatocellular; Diagnosis, Differential; Glomus Jugulare Tumor; Humans; Liver; Liver Neoplasms; Magnetic Resonance Imaging; Male; Palliative Care; Skull Neoplasms; Sorafenib; Temporal Bone | 2018 |
Targeting KDM1A attenuates Wnt/β-catenin signaling pathway to eliminate sorafenib-resistant stem-like cells in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzoates; Carcinoma, Hepatocellular; Cell Line, Tumor; Cyclopropanes; Drug Resistance, Neoplasm; Histone Demethylases; Humans; Liver Neoplasms; Male; Mice, Nude; Molecular Targeted Therapy; Neoplastic Stem Cells; Niacinamide; Pargyline; Phenotype; Phenylurea Compounds; Protein Kinase Inhibitors; RNA Interference; Sorafenib; Time Factors; Transfection; Tumor Burden; Wnt Signaling Pathway; Xenograft Model Antitumor Assays | 2017 |
Complete Response to the Combination of Pembrolizumab and Sorafenib for Metastatic Hepatocellular Carcinoma: A Case Report.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib | 2017 |
Evaluation of the Efficacy of Sorafenib on Overall Survival in Patients with Hepatocellular Carcinoma using FT Rate: A Devised Index.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Cohort Studies; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Sorafenib; Survival Rate; Treatment Outcome | 2017 |
Changes in serum α-fetoprotein level predicts treatment response and survival in hepatocellular carcinoma patients and literature review.
Topics: Adult; Aged; alpha-Fetoproteins; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Disease Progression; Female; Humans; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Niacinamide; Organoplatinum Compounds; Oxaliplatin; Phenylurea Compounds; Retrospective Studies; Severity of Illness Index; Sorafenib; Survival Analysis; Taiwan; Time Factors; Treatment Outcome | 2018 |
Inhibition of the prolyl isomerase Pin1 enhances the ability of sorafenib to induce cell death and inhibit tumor growth in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Death; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Drug Synergism; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Liver Neoplasms; Mice; Niacinamide; NIMA-Interacting Peptidylprolyl Isomerase; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Xenograft Model Antitumor Assays | 2017 |
Synergistic anti-tumor efficacy of sorafenib and fluvastatin in hepatocellular carcinoma.
Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Fatty Acids, Monounsaturated; Female; Fluvastatin; Hep G2 Cells; Humans; Indoles; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Rats; Rats, Wistar; Signal Transduction; Sorafenib | 2017 |
Secreted GRP78 activates EGFR-SRC-STAT3 signaling and confers the resistance to sorafeinib in HCC cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Proliferation; Drug Resistance, Neoplasm; Endoplasmic Reticulum Chaperone BiP; ErbB Receptors; Gene Expression Regulation, Neoplastic; Heat-Shock Proteins; Humans; Liver Neoplasms; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Phosphorylation; Proto-Oncogene Proteins pp60(c-src); Signal Transduction; Sorafenib; STAT3 Transcription Factor; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2017 |
Immune oncology in hepatocellular carcinoma-hype and hope.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2017 |
Protein disulfide isomerase inhibition synergistically enhances the efficacy of sorafenib for hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cohort Studies; Disease Models, Animal; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Mice; Mice, Inbred BALB C; Middle Aged; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Disulfide-Isomerases; Random Allocation; RNA, Messenger; Sorafenib; Statistics, Nonparametric; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2017 |
Barcelona clinic liver cancer-stage C hepatocellular carcinoma: A novel approach to subclassification and treatment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Retrospective Studies; Sorafenib; Tumor Burden | 2017 |
Management of hepatocellular carcinoma recurrence after liver transplant is far from perfect.
Topics: Adult; Carcinoma, Hepatocellular; Child; Humans; Liver Neoplasms; Liver Transplantation; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Registries; Sorafenib | 2018 |
Strategies for HCC target discovery.
Topics: Carcinoma, Hepatocellular; Clustered Regularly Interspaced Short Palindromic Repeats; Drug Discovery; Genetic Testing; Humans; Liver Neoplasms; Molecular Targeted Therapy; RNA, Small Interfering; Sorafenib | 2017 |
The outcome of sorafenib monotherapy on hepatocellular carcinoma with portal vein tumor thrombosis.
Topics: alpha-Fetoproteins; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Neoplasm Invasiveness; Neoplasm Staging; Portal Vein; Progression-Free Survival; Sorafenib; Treatment Outcome; Venous Thrombosis | 2018 |
Dysfunction of IKZF1/MYC/MDIG axis contributes to liver cancer progression through regulating H3K9me3/p21 activity.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Dioxygenases; Disease Progression; Histone Demethylases; Histones; Humans; Ikaros Transcription Factor; Liver Neoplasms; Methylation; Mice; Mice, Inbred BALB C; Mice, Nude; Niacinamide; Nuclear Proteins; Phenylurea Compounds; Promoter Regions, Genetic; Proto-Oncogene Proteins c-myc; Signal Transduction; Sorafenib; Transplantation, Heterologous | 2017 |
Fasting inhibits hepatic stellate cells activation and potentiates anti-cancer activity of Sorafenib in hepatocellular cancer cells.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Proliferation; Dose-Response Relationship, Drug; Fasting; Gene Expression Regulation, Neoplastic; Glucose; Hep G2 Cells; Hepatic Stellate Cells; Humans; Lipopolysaccharides; Liver Cirrhosis, Experimental; Liver Neoplasms; Mice, Inbred C57BL; Niacinamide; Non-alcoholic Fatty Liver Disease; Phenylurea Compounds; Sorafenib; Time Factors | 2018 |
Sorafenib in Hepatitis C Virus-Negative Patients With Hepatocellular Carcinoma: Don't Throw the Baby Out With the Bathwater!
Topics: Adult; Carcinoma, Hepatocellular; Hepacivirus; Humans; Liver Neoplasms; Sorafenib | 2017 |
Reply to N. Personeni et al.
Topics: Carcinoma, Hepatocellular; Hepacivirus; Humans; Liver Neoplasms; Prostatic Neoplasms; Sorafenib | 2017 |
Serum HMGB1 concentrations at 4 weeks is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; Disease Progression; Female; Hepatic Artery; HMGB1 Protein; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Prognosis; Sorafenib; Survival Rate; Young Adult | 2018 |
Upregulated expression of Nucleostemin/GNL3 is associated with poor prognosis and Sorafenib Resistance in Hepatocellular Carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; GTP-Binding Proteins; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Nuclear Proteins; Phenylurea Compounds; Prognosis; Proto-Oncogene Proteins c-bcl-2; Sorafenib; Survival Rate; Up-Regulation; Young Adult | 2017 |
Prescription Patterns of Sorafenib and Outcomes of Patients with Advanced Hepatocellular Carcinoma: A National Population Study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Practice Patterns, Physicians'; Protein Kinase Inhibitors; Sorafenib; Survival Analysis; Treatment Outcome; Young Adult | 2017 |
[Tumor-associated macrophages promote the proliferation and migration as well as invasion of sorafenib-resistant hepatocellular carcinoma cells].
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Hep G2 Cells; Humans; Liver Neoplasms; Macrophages; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Sorafenib | 2017 |
Immortal time bias or sorafenib effect in elderly patients with HCC?
Topics: Aged; Antineoplastic Agents; Bias; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib | 2017 |
Sub-classification of Advanced-Stage Hepatocellular Carcinoma: A Cohort Study Including 612 Patients Treated with Sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Cohort Studies; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib | 2018 |
Sorafenib and Regorafenib in HBV- or HCV-positive hepatocellular carcinoma patients: Analysis of RESORCE and SHARP trials.
Topics: Carcinoma, Hepatocellular; Double-Blind Method; Hepatitis B virus; Hepatitis C; Humans; Liver Neoplasms; Phenylurea Compounds; Pyridines; Sorafenib | 2017 |
Comparison of treatment outcome between living donor liver transplantation and sorafenib for patients with hepatocellular carcinoma beyond the Milan criteria.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Female; Humans; Liver Neoplasms; Liver Transplantation; Living Donors; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Sorafenib; Survival Analysis; Time Factors; Treatment Outcome | 2017 |
Prediction of Response to Sorafenib in Hepatocellular Carcinoma: A Putative Marker Panel by Multiple Reaction Monitoring-Mass Spectrometry (MRM-MS).
Topics: Adult; Aged; Aged, 80 and over; Antigens, Neoplasm; Antineoplastic Agents; Apoptosis Regulatory Proteins; Biomarkers, Tumor; Carcinoma, Hepatocellular; Carrier Proteins; Female; Glycoproteins; Humans; Immunoglobulin J-Chains; Liver Neoplasms; Male; Mass Spectrometry; Middle Aged; Niacinamide; Phenylurea Compounds; Precision Medicine; Proteomics; Receptors, Scavenger; Retrospective Studies; Scavenger Receptors, Class B; Sorafenib; Survival Analysis; Treatment Outcome | 2017 |
Sorafenib induces variations of the DNA methylome in HA22T/VGH human hepatocellular carcinoma-derived cells.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; DNA Methylation; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Promoter Regions, Genetic; Signal Transduction; Sorafenib; Tumor Cells, Cultured | 2017 |
Sorafenib-Induced Changes in Thyroid Hormone Levels in Patients Treated for Hepatocellular Carcinoma.
Topics: Aged; Amino Acid Transport Systems, Neutral; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Chlorocebus aethiops; Cohort Studies; COS Cells; Female; Humans; In Vitro Techniques; Liver Neoplasms; Male; Middle Aged; Monocarboxylic Acid Transporters; Niacinamide; Phenylurea Compounds; Prospective Studies; Sorafenib; Symporters; Thyrotropin; Thyroxine; Triiodothyronine | 2017 |
Diagnostic value of dynamic contrast-enhanced CT with perfusion imaging in the quantitative assessment of tumor response to sorafenib in patients with advanced hepatocellular carcinoma: A feasibility study.
Topics: Blood Volume; Carcinoma, Hepatocellular; Feasibility Studies; Humans; Liver Neoplasms; Niacinamide; Perfusion Imaging; Phenylurea Compounds; Sorafenib; Tomography, Spiral Computed | 2017 |
PPARδ Reprograms Glutamine Metabolism in Sorafenib-Resistant HCC.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Glutamine; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Niacinamide; Phenylurea Compounds; PPAR delta; Random Allocation; Sorafenib; Transfection; Xenograft Model Antitumor Assays | 2017 |
Anti-tumor Effects of Sorafenib Administered at Different Time Points in Combination with Transarterial Embolization in a Rabbit VX2 Liver Tumor Model.
Topics: Animals; Antineoplastic Agents; Combined Modality Therapy; Disease Models, Animal; Drug Administration Schedule; Embolization, Therapeutic; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Rabbits; Sorafenib | 2017 |
Sorafenib vs surgical resection for hepatocellular carcinoma with macrovascular invasion: A propensity score analysis.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; France; Humans; Liver; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Propensity Score; Retrospective Studies; Sorafenib | 2017 |
Targeting human liver cancer cells with lactobionic acid-G(4)-PAMAM-FITC sorafenib loaded dendrimers.
Topics: Asialoglycoprotein Receptor; Dendrimers; Disaccharides; Drug Carriers; Fluorescein-5-isothiocyanate; Hep G2 Cells; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib | 2017 |
Targeting the PD-L1/DNMT1 axis in acquired resistance to sorafenib in human hepatocellular carcinoma.
Topics: Apoptosis; B7-H1 Antigen; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; DNA (Cytosine-5-)-Methyltransferase 1; DNA Methylation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Liver Neoplasms; Molecular Targeted Therapy; NF-kappa B; Niacinamide; Phenylurea Compounds; Signal Transduction; Sorafenib; STAT3 Transcription Factor | 2017 |
Bruceine D inhibits hepatocellular carcinoma growth by targeting β-catenin/jagged1 pathways.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; beta Catenin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Down-Regulation; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Jagged-1 Protein; Liver Neoplasms; Male; Mice, Inbred BALB C; Mice, Nude; Niacinamide; Phenylurea Compounds; Proteasome Endopeptidase Complex; Protein Kinase Inhibitors; Proteolysis; Quassins; Sorafenib; Time Factors; Transcription, Genetic; Transfection; Tumor Burden; Wnt Signaling Pathway; Xenograft Model Antitumor Assays | 2017 |
Stearoyl-CoA desaturase regulates sorafenib resistance via modulation of ER stress-induced differentiation.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Endoplasmic Reticulum Stress; Hong Kong; Humans; Liver Neoplasms; Niacinamide; Pharmacogenomic Testing; Phenylurea Compounds; Sorafenib; Stearoyl-CoA Desaturase; Survival Analysis | 2017 |
Percutaneous Irreversible Electroporation for Portal Vein Tumor Thrombus: A Case Report.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Combined Modality Therapy; Electroporation; Humans; Liver Neoplasms; Male; Middle Aged; Portal Vein; Sorafenib; Ultrasonography; Venous Thrombosis | 2017 |
Survival Estimates after Stopping Sorafenib in Patients with Hepatocellular Carcinoma: NEXT Score Development and Validation.
Topics: Aged; Antineoplastic Agents; Area Under Curve; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Risk Factors; ROC Curve; Severity of Illness Index; Sorafenib; Survival Rate; Withholding Treatment | 2017 |
Impact of Individual Components of the Metabolic Syndrome on the Outcome of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Diabetes Mellitus, Type 2; Female; Humans; Liver Neoplasms; Male; Metabolic Syndrome; Middle Aged; Multivariate Analysis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Retrospective Studies; Sorafenib; Survival Analysis; Treatment Outcome; Young Adult | 2018 |
Natural History of T1N0M0 Hepatocellular Carcinoma: Large-Scale Study in the United States.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Disease-Free Survival; Female; Hepatectomy; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Retrospective Studies; Sorafenib; Treatment Outcome; United States | 2017 |
Aspirin disrupts the mTOR-Raptor complex and potentiates the anti-cancer activities of sorafenib via mTORC1 inhibition.
Topics: Adaptor Proteins, Signal Transducing; AMP-Activated Protein Kinases; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Apoptosis; Aspirin; Carcinoma, Hepatocellular; Cell Proliferation; Cells, Cultured; Drug Therapy, Combination; Embryo, Mammalian; Fibroblasts; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Mechanistic Target of Rapamycin Complex 1; Mice; Mice, Knockout; Multiprotein Complexes; Niacinamide; Phenylurea Compounds; Regulatory-Associated Protein of mTOR; Sorafenib; TOR Serine-Threonine Kinases; Tuberous Sclerosis Complex 2 Protein; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2017 |
Complete remission of refractory hepatoblastoma after liver transplantation in a child with sorafenib monotherapy: A new hope?
Topics: Antineoplastic Agents; Child; Female; Hepatoblastoma; Humans; Liver Neoplasms; Remission Induction; Sorafenib; Treatment Outcome | 2017 |
Sorafenib in Patients with Hepatocellular Carcinoma-Results of the Observational INSIGHT Study.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Disease Progression; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Sorafenib | 2017 |
Tolerance and outcomes of sorafenib in elderly patients treated for advanced hepatocellular carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Diarrhea; Female; France; Hand-Foot Syndrome; Humans; Liver Cirrhosis; Liver Neoplasms; Logistic Models; Male; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Treatment Outcome | 2017 |
Chronic inflammation-elicited liver progenitor cell conversion to liver cancer stem cell with clinical significance.
Topics: Animals; Antigens, Differentiation; Antineoplastic Agents; Cell Self Renewal; Cell Transformation, Neoplastic; Chromosomal Instability; Chronic Disease; Female; Humans; Inflammation; Interleukin-6; Keratin-19; Liver; Liver Neoplasms; Macrophages; Male; Mice; Middle Aged; Neoplastic Stem Cells; Niacinamide; Phenylurea Compounds; Rats, Wistar; Sorafenib; src-Family Kinases; STAT3 Transcription Factor; Tumor Necrosis Factor-alpha | 2017 |
Liver transplantation using the otherwise-discarded partial liver resection graft with hepatic benign tumor: Analysis of a preliminary experience on 15 consecutive cases.
Topics: Adult; Aged; Antineoplastic Agents; Blood Vessel Prosthesis; End Stage Liver Disease; Female; Hepatectomy; Hepatic Veins; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Postoperative Complications; Sorafenib; Treatment Outcome; Young Adult | 2017 |
Sorafenib-induced erythema annulare centrifugum with spontaneous resolution after skin biopsy.
Topics: Aged; Biopsy, Needle; Carcinoma, Hepatocellular; Erythema; Humans; Immunohistochemistry; Leg Dermatoses; Liver Neoplasms; Male; Remission, Spontaneous; Skin Diseases, Genetic; Sorafenib | 2018 |
Validation of the albumin-bilirubin grade-based integrated model as a predictor for sorafenib-failed hepatocellular carcinoma.
Topics: Aged; Antineoplastic Agents; Bilirubin; Biomarkers, Tumor; Carcinoma, Hepatocellular; Clinical Decision-Making; Disease Progression; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Predictive Value of Tests; Reproducibility of Results; Retreatment; Retrospective Studies; Risk Factors; Serum Albumin, Human; Sorafenib; Treatment Failure | 2018 |
A Natural CCR2 Antagonist Relieves Tumor-associated Macrophage-mediated Immunosuppression to Produce a Therapeutic Effect for Liver Cancer.
Topics: Abies; Animals; Binding Sites; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Hep G2 Cells; Humans; Immunosuppression Therapy; Liver Neoplasms; Macrophages; Mice; Niacinamide; Phenylurea Compounds; Plant Extracts; Receptors, CCR2; Sorafenib; THP-1 Cells; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2017 |
Simultaneous inhibition of growth and metastasis of hepatocellular carcinoma by co-delivery of ursolic acid and sorafenib using lactobionic acid modified and pH-sensitive chitosan-conjugated mesoporous silica nanocomplex.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Chitosan; Delayed-Action Preparations; Disaccharides; Drug Synergism; Humans; Hydrogen-Ion Concentration; Liver Neoplasms; Lung Neoplasms; Male; Mice; Nanoparticles; Niacinamide; Phenylurea Compounds; Porosity; Rats; Silicon Dioxide; Sorafenib; Triterpenes; Ursolic Acid | 2017 |
Haloperidol, a sigma receptor 1 antagonist, promotes ferroptosis in hepatocellular carcinoma cells.
Topics: Apoptosis; Carcinoma, Hepatocellular; Cell Survival; Dose-Response Relationship, Drug; Haloperidol; Humans; Iron; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Receptors, sigma; Sigma-1 Receptor; Sorafenib; Structure-Activity Relationship; Tumor Cells, Cultured | 2017 |
Validation of a Simple Scoring System to Predict Sorafenib Effectiveness in Patients with Hepatocellular Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Reproducibility of Results; Retrospective Studies; Sorafenib | 2017 |
Gankyrin induces STAT3 activation in tumor microenvironment and sorafenib resistance in hepatocellular carcinoma.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Interleukin-6; Liver; Liver Neoplasms; Male; Mice; Niacinamide; Phenylurea Compounds; Proteasome Endopeptidase Complex; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Proto-Oncogene Proteins; Sorafenib; STAT3 Transcription Factor; Survival Analysis; Up-Regulation; Vascular Endothelial Growth Factor A | 2017 |
Down-Regulation of TGF-β Expression Sensitizes the Resistance of Hepatocellular Carcinoma Cells to Sorafenib.
Topics: Adenoviridae; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Death; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Mice, Inbred BALB C; Mice, Nude; Niacinamide; p38 Mitogen-Activated Protein Kinases; Phenylurea Compounds; Phosphorylation; RNA, Small Interfering; Signal Transduction; Sorafenib; Transforming Growth Factor beta; Xenograft Model Antitumor Assays | 2017 |
Sorafenib Impedes Rift Valley Fever Virus Egress by Inhibiting Valosin-Containing Protein Function in the Cellular Secretory Pathway.
Topics: Adenosine Triphosphatases; Animals; Carcinoma, Hepatocellular; Cell Cycle Proteins; Chlorocebus aethiops; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Rift Valley Fever; Rift Valley fever virus; Secretory Pathway; Sorafenib; Tumor Cells, Cultured; Valosin Containing Protein; Vero Cells; Virion; Virus Release; Virus Replication | 2017 |
Survival benefit of transarterial chemoembolization in patients with metastatic hepatocellular carcinoma: a single center experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Regression Analysis; Retrospective Studies; Sorafenib; Survival Analysis; Treatment Outcome | 2017 |
An internally validated new clinical and inflammation-based prognostic score for patients with advanced hepatocellular carcinoma treated with sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Area Under Curve; Carcinoma, Hepatocellular; Diarrhea; Female; Humans; Inflammation; Liver Neoplasms; Lymphocyte Count; Male; Middle Aged; Neutrophils; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Retrospective Studies; ROC Curve; Severity of Illness Index; Sorafenib; Treatment Outcome | 2018 |
Use of Biocompatible Sorafenib-gold Nanoconjugates for Reversal of Drug Resistance in Human Hepatoblatoma Cells.
Topics: Animals; Antineoplastic Agents; Biocompatible Materials; Cell Survival; Drug Resistance, Neoplasm; Gold; Hep G2 Cells; Hepatoblastoma; Humans; Liver Neoplasms; Male; Metal Nanoparticles; Microscopy, Electron, Transmission; Nanoconjugates; Particle Size; Rats, Wistar; Sorafenib | 2017 |
6-Methoxyethylamino-numonafide inhibits hepatocellular carcinoma xenograft growth as a single agent and in combination with sorafenib.
Topics: Alanine Transaminase; Animals; Antineoplastic Agents; Apoptosis; Aspartate Aminotransferases; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Female; Hep G2 Cells; Humans; Liver Neoplasms; Male; Mice; Naphthalimides; Niacinamide; Phenylurea Compounds; Sorafenib; Xenograft Model Antitumor Assays | 2017 |
Association between Skeletal Muscle Depletion and Sorafenib Treatment in Male Patients with Hepatocellular Carcinoma: A Retrospective Cohort Study.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Cohort Studies; Female; Humans; Liver Neoplasms; Male; Middle Aged; Muscle, Skeletal; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sex Factors; Sorafenib | 2017 |
Nodular-cystic eruption in course of sorafenib administration for hepatocarcinoma: An unconventional skin reaction requiring unconventional treatment.
Topics: Aminolevulinic Acid; Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Eruptions; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Photochemotherapy; Photosensitizing Agents; Protein Kinase Inhibitors; Sorafenib | 2017 |
A typical presentation of a hepatocellular carcinoma in a middle-aged patient.
Topics: Antineoplastic Agents; Biopsy, Fine-Needle; Bone Neoplasms; Carcinoma, Hepatocellular; Clavicle; Fatal Outcome; Fractures, Bone; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib | 2017 |
A microRNA-7/growth arrest specific 6/TYRO3 axis regulates the growth and invasiveness of sorafenib-resistant cells in human hepatocellular carcinoma.
Topics: Analysis of Variance; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; MicroRNAs; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Real-Time Polymerase Chain Reaction; Receptor Protein-Tyrosine Kinases; RNA, Small Interfering; Signal Transduction; Sorafenib | 2018 |
By inhibiting PFKFB3, aspirin overcomes sorafenib resistance in hepatocellular carcinoma.
Topics: Animals; Aspirin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Neoplastic; Glycolysis; Humans; Liver Neoplasms; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Phosphofructokinase-2; Sorafenib; Xenograft Model Antitumor Assays | 2017 |
Might Sorafenib combined with radiotherapy be better option for treating hepatocellular carcinoma with portal vein tumour thrombosis?
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Portal Vein; Sorafenib; Venous Thrombosis | 2018 |
Starting Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma: A Retrospective, Multi-Institutional Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Cohort Studies; Dose-Response Relationship, Drug; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib | 2017 |
Characteristics of patients with sorafenib-treated advanced hepatocellular carcinoma eligible for second-line treatment.
Topics: Aged; Carcinoma, Hepatocellular; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome | 2018 |
Complete response under sorafenib in patients with hepatocellular carcinoma: Relationship with dermatologic adverse events.
Topics: Aged; alpha-Fetoproteins; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Retrospective Studies; Skin; Sorafenib | 2018 |
The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Hepatitis B Surface Antigens; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib; Treatment Outcome | 2017 |
The role of metronomic capecitabine for treatment of recurrent hepatocellular carcinoma after liver transplantation.
Topics: Administration, Metronomic; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Sorafenib; Survival Analysis; Treatment Outcome | 2017 |
MicroRNA pharmacogenomics based integrated model of miR-17-92 cluster in sorafenib resistant HCC cells reveals a strategy to forestall drug resistance.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Genes, erbB-1; Humans; Interleukin-6; Liver Neoplasms; MicroRNAs; Multigene Family; Pharmacogenetics; Signal Transduction; Sorafenib | 2017 |
Nanoparticles of a polyaspartamide-based brush copolymer for modified release of sorafenib: In vitro and in vivo evaluation.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Delayed-Action Preparations; Drug Delivery Systems; Drug Liberation; Humans; Liver Neoplasms; Male; Mice, Nude; Nanoparticles; Niacinamide; Peptides; Phenylurea Compounds; Polymethacrylic Acids; Protein Kinase Inhibitors; Sorafenib | 2017 |
Prognostic value of perfusion CT in hepatocellular carcinoma treatment with sorafenib: comparison with mRECIST in longitudinal follow-up.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Follow-Up Studies; Humans; Liver; Liver Neoplasms; Longitudinal Studies; Male; Niacinamide; Perfusion Imaging; Phenylurea Compounds; Prognosis; Prospective Studies; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome | 2018 |
Activation of phosphatidylinositol 3-kinase/AKT/snail signaling pathway contributes to epithelial-mesenchymal transition-induced multi-drug resistance to sorafenib in hepatocellular carcinoma cells.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Survival; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Heterocyclic Compounds, 3-Ring; Humans; Liver Neoplasms; Male; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Signal Transduction; Sorafenib | 2017 |
The in vivo antitumor effects of type I-interferon against hepatocellular carcinoma: the suppression of tumor cell growth and angiogenesis.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Human Umbilical Vein Endothelial Cells; Humans; Interferon Type I; Liver Neoplasms; Mice; Neovascularization, Pathologic; Sorafenib; Treatment Outcome; Xenograft Model Antitumor Assays | 2017 |
The SIRveNIB and SARAH trials and the role of SIR-Spheres® Y-90 resin microspheres in the management of hepatocellular carcinoma.
Topics: Brachytherapy; Carcinoma, Hepatocellular; Clinical Trials as Topic; Combined Modality Therapy; Disease Management; Humans; Liver Neoplasms; Microspheres; Multicenter Studies as Topic; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Treatment Outcome; Yttrium Radioisotopes | 2017 |
High plasma interleukin-6 levels associated with poor prognosis of patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Cohort Studies; Disease-Free Survival; Humans; Interleukin-6; Liver Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Sorafenib; Young Adult | 2017 |
Implications of FGF19 on sorafenib-mediated nitric oxide production in hepatocellular carcinoma cells - a short report.
Topics: Acrylamides; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Fibroblast Growth Factors; Hep G2 Cells; Humans; Liver Neoplasms; Niacinamide; Nitric Oxide; Phenylurea Compounds; Protein Kinase Inhibitors; Quinazolines; Receptor, Fibroblast Growth Factor, Type 4; Sorafenib | 2018 |
Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Databases, Factual; Diabetes Mellitus, Type 2; Disease-Free Survival; Drug Interactions; Drug Resistance, Neoplasm; Female; Humans; Hypoglycemic Agents; Immunohistochemistry; Insulin; Italy; Kaplan-Meier Estimate; Liver Neoplasms; Male; Metformin; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Retrospective Studies; Sirtuin 3; Sorafenib; Time Factors; Treatment Outcome | 2017 |
Prognostic scores for sorafenib-treated hepatocellular carcinoma patients: A new application for the hepatoma arterial embolisation prognostic score.
Topics: Adult; Aged; Aged, 80 and over; alpha-Fetoproteins; Antineoplastic Agents; Bilirubin; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Decision Support Techniques; Disease-Free Survival; Female; France; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Proportional Hazards Models; Protein Kinase Inhibitors; Reproducibility of Results; Retrospective Studies; Risk Assessment; Risk Factors; Serum Albumin, Human; Sorafenib; Time Factors; Treatment Outcome; Tumor Burden; United Kingdom | 2017 |
Cost-effectiveness analysis of transcatheter arterial chemoembolization with or without sorafenib for the treatment of unresectable hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Cost-Benefit Analysis; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Quality-Adjusted Life Years; Sorafenib | 2017 |
Cost-effectiveness analysis of treatment with non-curative or palliative intent for hepatocellular carcinoma in the real-world setting.
Topics: Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Cost-Benefit Analysis; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Palliative Care; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2017 |
Increasing AR by HIF-2α inhibitor (PT-2385) overcomes the side-effects of sorafenib by suppressing hepatocellular carcinoma invasion via alteration of pSTAT3, pAKT and pERK signals.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Basic Helix-Loop-Helix Transcription Factors; Carcinoma, Hepatocellular; Cell Hypoxia; Cell Line, Tumor; Extracellular Signal-Regulated MAP Kinases; Hep G2 Cells; Humans; Indans; Liver Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Niacinamide; Phenylurea Compounds; Promoter Regions, Genetic; Proto-Oncogene Proteins c-akt; Receptors, Androgen; Sorafenib; STAT3 Transcription Factor; Sulfones | 2017 |
Phosphorylated ERK is a potential prognostic biomarker for Sorafenib response in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Extracellular Signal-Regulated MAP Kinases; Female; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Histone-Lysine N-Methyltransferase; Humans; Liver Neoplasms; Mice, Nude; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Sorafenib; Time Factors; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |
High expression of HOXA13 correlates with poorly differentiated hepatocellular carcinomas and modulates sorafenib response in in vitro models.
Topics: Antineoplastic Agents; Binding Sites; Carcinoma, Hepatocellular; Cell Differentiation; Cell Line; Cell Proliferation; Cohort Studies; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Hepatocytes; Homeodomain Proteins; Humans; In Situ Hybridization; Liver; Liver Neoplasms; Neoplasm Proteins; Promoter Regions, Genetic; RNA, Long Noncoding; RNA, Neoplasm; Sorafenib; Survival Analysis; Tissue Array Analysis | 2018 |
The treatment path in hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Clinical Trials as Topic; Disease-Free Survival; Female; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Survival Rate | 2017 |
Predominance of regorafenib over sorafenib: Restoration of membrane-bound MICA in hepatocellular carcinoma cells.
Topics: ADAM Proteins; ADAM10 Protein; Amyloid Precursor Protein Secretases; Carcinoma, Hepatocellular; Depression, Chemical; Gene Expression; Hep G2 Cells; Hepatitis C, Chronic; Histocompatibility Antigens Class I; Humans; Liver Neoplasms; Membrane Proteins; Niacinamide; Phenylurea Compounds; Pyridines; RNA, Messenger; Solubility; Sorafenib | 2018 |
Phosphoprotein enriched in diabetes (PED/PEA15) promotes migration in hepatocellular carcinoma and confers resistance to sorafenib.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Apoptosis Regulatory Proteins; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Child; Drug Resistance, Neoplasm; Humans; Intracellular Signaling Peptides and Proteins; Liver Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Phosphoproteins; Sorafenib; Transfection; Young Adult | 2017 |
Reply to: "Predictors of sorafenib benefit in patients with hepatocellular carcinoma".
Topics: Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib | 2018 |
Predictors of sorafenib benefit in patients with hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib | 2018 |
Global Metabolic Profiling Identifies a Pivotal Role of Proline and Hydroxyproline Metabolism in Supporting Hypoxic Response in Hepatocellular Carcinoma.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Energy Metabolism; Humans; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Liver Neoplasms; Metabolome; Metabolomics; Phenotype; Proline; Sorafenib; Xenograft Model Antitumor Assays | 2018 |
Liver resection for hepatocellular carcinoma in patients with hematological malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Disease-Free Survival; Female; Hematologic Neoplasms; Hepacivirus; Hepatectomy; Hepatitis B; Hepatitis B virus; Hepatitis C; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Niacinamide; Patient Selection; Phenylurea Compounds; Postoperative Complications; Prognosis; Retrospective Studies; Serologic Tests; Sorafenib; Survival Rate; Young Adult | 2017 |
Use of Ultrasmall Superparamagnetic Iron Oxide Enhanced Susceptibility Weighted Imaging and Mean Vessel Density Imaging to Monitor Antiangiogenic Effects of Sorafenib on Experimental Hepatocellular Carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Hepatocellular; Ferric Compounds; Heterografts; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Mice; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Sorafenib | 2017 |
Codelivery of sorafenib and GPC3 siRNA with PEI-modified liposomes for hepatoma therapy.
Topics: Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Proliferation; Combined Modality Therapy; Drug Delivery Systems; Drug Resistance, Neoplasm; Gene Transfer Techniques; Glypicans; Hep G2 Cells; Humans; Liposomes; Liver Neoplasms; Mice; Niacinamide; Phenylurea Compounds; RNA, Small Interfering; Sorafenib | 2017 |
Co-delivery of sorafenib and siVEGF based on mesoporous silica nanoparticles for ASGPR mediated targeted HCC therapy.
Topics: Antineoplastic Agents; Apoptosis; Asialoglycoprotein Receptor; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Cell Survival; Drug Carriers; Drug Compounding; Drug Delivery Systems; Drug Liberation; Humans; Liver Neoplasms; Nanoparticles; Niacinamide; Phenylurea Compounds; RNA Interference; RNA, Small Interfering; Silicon Dioxide; Sorafenib; Vascular Endothelial Growth Factor A | 2018 |
Impact of surgical treatment after sorafenib therapy for advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Combined Modality Therapy; Female; Follow-Up Studies; Hepatectomy; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pneumonectomy; Sorafenib; Survival Rate; Time Factors; Treatment Outcome | 2018 |
Potential Visualization of Sorafenib-Induced Acidosis Using 11C-Acetate PET/CT in Patients With Hepatocellular Carcinoma.
Topics: Acetates; Acidosis; Aged, 80 and over; Carbon Radioisotopes; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Positron Emission Tomography Computed Tomography; Sorafenib | 2018 |
Arid1a regulates response to anti-angiogenic therapy in advanced hepatocellular carcinoma.
Topics: Angiogenesis Inhibitors; Angiopoietin-2; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Disease Progression; DNA-Binding Proteins; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Humans; Liver Neoplasms; Mice; Neoplasm Staging; Neovascularization, Pathologic; Nuclear Proteins; Sorafenib; Transcription Factors | 2018 |
Topics: Carcinoma, Hepatocellular; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Positron Emission Tomography Computed Tomography; Retrospective Studies; Sorafenib; Treatment Outcome | 2018 |
Outcomes of treatment with sorafenib in Egyptian patients with hepatocellular carcinoma: a retrospective cohort study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Clinical Decision-Making; Disease Progression; Disease-Free Survival; Egypt; Female; Hand-Foot Syndrome; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Patient Selection; Phenylurea Compounds; Protein Kinase Inhibitors; Retrospective Studies; Risk Factors; Sorafenib; Time Factors; Treatment Outcome; Young Adult | 2018 |
Synergistic anticancer activity of 20(S)-Ginsenoside Rg3 and Sorafenib in hepatocellular carcinoma by modulating PTEN/Akt signaling pathway.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Drug Synergism; Gene Expression Regulation, Neoplastic; Ginsenosides; Hep G2 Cells; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Signal Transduction; Sorafenib | 2018 |
Association of liver cirrhosis severity with type 2 diabetes mellitus in hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Diabetes Mellitus, Type 2; Female; Humans; Incidence; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Severity of Illness Index; Sorafenib | 2018 |
Sorafenib tosylate, Ribavirn and Sofosbuvir combination therapy for HCV virus infected patients with decompensated liver cancer.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Hepatitis C; Humans; Liver Neoplasms; Male; Middle Aged; Ribavirin; Sofosbuvir; Sorafenib; Sustained Virologic Response; Treatment Outcome | 2017 |
Transcatheter arterial chemoembolization after stopping sorafenib therapy for advanced hepatocellular carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Survival Analysis; Treatment Outcome | 2017 |
Prognostic Factors for Survival After Transarterial Chemoembolization Combined with Sorafenib in the Treatment of BCLC Stage B and C Hepatocellular Carcinomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Portal Vein; Prognosis; Proportional Hazards Models; Protective Factors; Retrospective Studies; Risk Factors; Sorafenib; Survival Rate; Treatment Outcome; Tumor Burden; Young Adult | 2018 |
Augmentation of Anticancer Drug Efficacy in Murine Hepatocellular Carcinoma Cells by a Peripherally Acting Competitive N-Methyl-d-aspartate (NMDA) Receptor Antagonist.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Discovery; Drug Resistance, Multiple; Humans; Liver Neoplasms; Mice; Niacinamide; Phenylurea Compounds; Receptors, N-Methyl-D-Aspartate; Sorafenib | 2017 |
Cost-effectiveness analysis of treatments involving radioembolization in intermediate-stage hepatocellular carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Cost-Benefit Analysis; Drug Costs; Health Resources; Hospitalization; Humans; Italy; Liver Neoplasms; Markov Chains; Quality of Life; Quality-Adjusted Life Years; Sorafenib; Treatment Outcome | 2018 |
High mobility group box 1 promotes sorafenib resistance in HepG2 cells and in vivo.
Topics: Animals; Carcinoma, Hepatocellular; Cytosol; Down-Regulation; Drug Resistance, Neoplasm; Gene Knockdown Techniques; Hep G2 Cells; HMGB1 Protein; Humans; Liver Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Mitochondria; Niacinamide; Phenylurea Compounds; Protein Transport; RNA, Small Interfering; Sorafenib; Treatment Outcome; Xenograft Model Antitumor Assays | 2017 |
Metronomic capecitabine as second-line treatment for hepatocellular carcinoma after sorafenib discontinuation.
Topics: Administration, Metronomic; Aged; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Retrospective Studies; Sorafenib; Survival Rate | 2018 |
Serum cytokine profiles predict survival benefits in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective cohort study.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cytokines; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2017 |
Wild type Kirsten rat sarcoma is a novel microRNA-622-regulated therapeutic target for hepatocellular carcinoma and contributes to sorafenib resistance.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Culture Techniques; Humans; Liver Neoplasms; MicroRNAs; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins p21(ras); Sorafenib | 2018 |
The Outcome of Sorafenib Therapy on Unresectable Hepatocellular Carcinoma: Experience of Conversion and Salvage Hepatectomy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Female; Fibroblast Growth Factor 4; Hepatectomy; Hepatitis B; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Salvage Therapy; Sorafenib; Survival Rate | 2018 |
The Safety and Efficacy of Combination Therapy of Sorafenib and Radiotherapy for Advanced Hepatocellular Carcinoma: A Retrospective Study.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Disease-Free Survival; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Radiation Dosage; Radiotherapy, Conformal; Retrospective Studies; Sorafenib; Survival Analysis | 2018 |
Hepatocellular carcinoma in 2017: Two large steps forward, one small step back.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Disease-Free Survival; Drug Approval; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Nivolumab; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome | 2018 |
Glutamine synthetase mediates sorafenib sensitivity in β-catenin-active hepatocellular carcinoma cells.
Topics: Antineoplastic Agents; Autophagy; beta Catenin; Carcinoma, Hepatocellular; Cell Line, Tumor; Glutamate-Ammonia Ligase; Humans; Liver Neoplasms; Sorafenib | 2018 |
The epigenetically regulated miR-494 associates with stem-cell phenotype and induces sorafenib resistance in hepatocellular carcinoma.
Topics: AC133 Antigen; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Disease Models, Animal; DNA (Cytosine-5-)-Methyltransferases; DNA Methyltransferase 3B; Drug Resistance, Neoplasm; Epigenesis, Genetic; Humans; Liver Neoplasms; Mice; MicroRNAs; Phenotype; PTEN Phosphohydrolase; Rats; Sorafenib; TOR Serine-Threonine Kinases | 2018 |
Image Gallery: Sorafenib-induced acne of the buttocks.
Topics: Acneiform Eruptions; Aged; Antineoplastic Agents; Buttocks; Carcinoma, Hepatocellular; Drug Eruptions; Humans; Liver Neoplasms; Male; Protein Kinase Inhibitors; Sorafenib | 2017 |
miR‑378a enhances the sensitivity of liver cancer to sorafenib by targeting VEGFR, PDGFRβ and c‑Raf.
Topics: Adult; Antagomirs; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Proliferation; Female; Hep G2 Cells; Humans; Liver Neoplasms; Male; Matrix Metalloproteinase 2; MicroRNAs; Middle Aged; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-raf; Receptor, Platelet-Derived Growth Factor beta; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib | 2018 |
Effect of histidine on sorafenib-induced vascular damage: Analysis using novel medaka fish model.
Topics: Animals; Antineoplastic Agents; Blood Flow Velocity; Blood Vessels; Carcinoma, Hepatocellular; Histidine; Humans; Liver Neoplasms; Niacinamide; Oryzias; Phenylurea Compounds; Sorafenib | 2018 |
Generation of matched patient-derived xenograft in vitro-in vivo models using 3D macroporous hydrogels for the study of liver cancer.
Topics: Carcinoma, Hepatocellular; Cell Survival; Elastic Modulus; Exome; Fluorescent Antibody Technique; Humans; Hydrogels; Liver Neoplasms; Niacinamide; Organoids; Phenylurea Compounds; Porosity; Sorafenib; Xenograft Model Antitumor Assays | 2018 |
Sorafenib prescribed by gastroenterologists and hepatologists for hepatocellular carcinoma: A retrospective, multi-institutional cohort study.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Costs; Drug Prescriptions; Female; Gastroenterologists; Humans; Liver Neoplasms; Male; Medical Oncology; Middle Aged; Niacinamide; Phenylurea Compounds; Practice Patterns, Physicians'; Retrospective Studies; Sorafenib; United States | 2018 |
Pregnane X receptor mediates sorafenib resistance in advanced hepatocellular carcinoma.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Mice, SCID; Niacinamide; Phenylurea Compounds; Pregnane X Receptor; Protein Kinase Inhibitors; Receptors, Steroid; RNA Interference; Sorafenib; Xenograft Model Antitumor Assays | 2018 |
Subacute Invasive Aspergillosis Associated With Sorafenib Therapy for Hepatocellular Carcinoma.
Topics: Adenine; Aspergillosis; Carcinoma, Hepatocellular; Humans; Invasive Fungal Infections; Liver Neoplasms; Piperidines; Pyrazoles; Pyrimidines; Signal Transduction; Sorafenib | 2018 |
Hexokinase-2 depletion inhibits glycolysis and induces oxidative phosphorylation in hepatocellular carcinoma and sensitizes to metformin.
Topics: Animals; Antineoplastic Agents; Carcinogenesis; Carcinoma, Hepatocellular; Glycolysis; Hep G2 Cells; Hexokinase; Humans; Hypoglycemic Agents; Liver Neoplasms; Male; Mechanistic Target of Rapamycin Complex 1; Metabolic Flux Analysis; Metformin; Mice, Nude; Molecular Targeted Therapy; Niacinamide; Oxidative Phosphorylation; Phenylurea Compounds; Sorafenib; Xenograft Model Antitumor Assays | 2018 |
Advanced Recurrent Hepatocellular Carcinoma: Treatment with Sorafenib Alone or in Combination with Transarterial Chemoembolization and Radiofrequency Ablation.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Combined Modality Therapy; Disease Progression; Female; Follow-Up Studies; Hepatectomy; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Survival Rate; Treatment Outcome; Young Adult | 2018 |
Early prediction of survival in hepatocellular carcinoma patients treated with transarterial chemoembolization plus sorafenib.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Patient Selection; Phenylurea Compounds; Portal Vein; Prognosis; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Sorafenib; Thrombosis; Young Adult | 2018 |
Negative phase 3 study of
Topics: Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Microspheres; Niacinamide; Phenylurea Compounds; Sorafenib; Yttrium Radioisotopes | 2018 |
Negative phase 3 study of
Topics: Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Microspheres; Niacinamide; Phenylurea Compounds; Sorafenib; Yttrium Radioisotopes | 2018 |
Negative phase 3 study of
Topics: Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Microspheres; Niacinamide; Phenylurea Compounds; Sorafenib; Yttrium Radioisotopes | 2018 |
Negative phase 3 study of
Topics: Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Microspheres; Niacinamide; Phenylurea Compounds; Sorafenib; Yttrium Radioisotopes | 2018 |
Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy Combined with Radiotherapy and Sorafenib for Advanced Hepatocellular Carcinoma Patients with Major Portal Vein Tumor Thrombosis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Female; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Interferons; Liver Neoplasms; Male; Middle Aged; Neoplastic Cells, Circulating; Niacinamide; Phenylurea Compounds; Portal Vein; Radiotherapy, Conformal; Retrospective Studies; Sorafenib; Survival Rate | 2018 |
Downregulation of secreted clusterin potentiates the lethality of sorafenib in hepatocellular carcinoma in association with the inhibition of ERK1/2 signals.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Clusterin; Gene Silencing; Humans; Liver Neoplasms; MAP Kinase Signaling System; Niacinamide; Phenylurea Compounds; RNA, Small Interfering; Sorafenib | 2018 |
Rage induces hepatocellular carcinoma proliferation and sorafenib resistance by modulating autophagy.
Topics: AMP-Activated Protein Kinases; Animals; Antigens, Neoplasm; Antineoplastic Agents; Autophagy; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; HMGB1 Protein; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Mitogen-Activated Protein Kinases; RNA, Small Interfering; S100 Calcium-Binding Protein A4; Signal Transduction; Sorafenib; TOR Serine-Threonine Kinases; Tumor Burden; Xenograft Model Antitumor Assays | 2018 |
Cripto-1 contributes to stemness in hepatocellular carcinoma by stabilizing Dishevelled-3 and activating Wnt/β-catenin pathway.
Topics: Animals; Apoptosis; Axin Protein; beta Catenin; Carcinoma, Hepatocellular; Cell Line, Tumor; Dishevelled Proteins; Drug Resistance, Neoplasm; Frizzled Receptors; GPI-Linked Proteins; Humans; Intercellular Signaling Peptides and Proteins; Liver Neoplasms; Low Density Lipoprotein Receptor-Related Protein-6; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasm Proteins; Protein Binding; RNA Interference; RNA, Small Interfering; Sorafenib; Wnt Signaling Pathway | 2018 |
EGFR-PI3K-PDK1 pathway regulates YAP signaling in hepatocellular carcinoma: the mechanism and its implications in targeted therapy.
Topics: 3-Phosphoinositide-Dependent Protein Kinases; Adaptor Proteins, Signal Transducing; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Proliferation; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Liver Neoplasms; Molecular Targeted Therapy; Phosphatidylinositol 3-Kinase; Protein Kinase Inhibitors; Pyridones; Pyrimidinones; Signal Transduction; Simvastatin; Sorafenib; Transcription Factors; YAP-Signaling Proteins | 2018 |
Genome-wide CRISPR screen reveals SGOL1 as a druggable target of sorafenib-treated hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Cycle Proteins; Cell Line, Tumor; Clustered Regularly Interspaced Short Palindromic Repeats; Drug Resistance, Neoplasm; Gene Knockdown Techniques; Genome-Wide Association Study; Humans; Liver Neoplasms; Mice; Mice, Inbred BALB C; Prognosis; Sorafenib | 2018 |
Strong enhancement by IGF1-R antagonists of hepatocellular carcinoma cell migration inhibition by Sorafenib and/or vitamin K1.
Topics: Actin Cytoskeleton; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Extracellular Signal-Regulated MAP Kinases; Humans; Imidazoles; Insulin-Like Growth Factor I; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Pyrazines; Pyrimidines; Pyrroles; Sorafenib; Vitamin K 1 | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Fluorouracil; Follow-Up Studies; Hepatic Artery; Humans; Immunosuppressive Agents; Infusions, Intra-Arterial; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Oxaliplatin; Retrospective Studies; Sorafenib; Survival Rate; Treatment Outcome; Vitamin B Complex; Young Adult | 2018 |
PU.1/microRNA-142-3p targets ATG5/ATG16L1 to inactivate autophagy and sensitize hepatocellular carcinoma cells to sorafenib.
Topics: Animals; Apoptosis; Autophagy; Autophagy-Related Protein 5; Autophagy-Related Proteins; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Mice; Mice, Inbred BALB C; MicroRNAs; Proto-Oncogene Proteins; Sorafenib; Trans-Activators | 2018 |
Transarterial Chemoembolization within First 3 Months of Sorafenib Initiation Improves Overall Survival in Hepatocellular Carcinoma: A Retrospective, Multi-Institutional Study with Propensity Matching.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Propensity Score; Retrospective Studies; Sorafenib; Survival Rate; Treatment Outcome | 2018 |
Liver cancer: Lenvatinib non-inferior to sorafenib for hepatocellular carcinoma.
Topics: Adult; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Phenylurea Compounds; Quinolines; Sorafenib | 2018 |
Reproducibility of European Association for the Study of the Liver criteria and modified Response Evaluation Criteria in Solid Tumors in patients treated with sorafenib.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver; Liver Neoplasms; Male; Middle Aged; Reproducibility of Results; Republic of Korea; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Sorafenib; Tomography, X-Ray Computed | 2018 |
Safety assessment of sorafenib in Chinese patients with unresectable hepatocellular carcinoma: subgroup analysis of the GIDEON study.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Retrospective Studies; Safety; Sorafenib; Treatment Outcome | 2018 |
Is Sorafenib an Optimal Treatment for Hepatocellular Carcinoma With Macrovascular Invasion or Metastatic Disease?
Topics: Adult; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib | 2018 |
Determinants of survival following hepatocellular carcinoma in Egyptian patients with untreated chronic HCV infection in the pre-DAA era.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Comorbidity; Egypt; Female; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Risk Factors; Sorafenib; Survival Analysis | 2018 |
Effectiveness and the strategy to treat the side effects of sorafenib administration after transarterial chemoembolization in advanced hepatocellular carcinoma patients.
Topics: Adult; Aftercare; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Liver Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Sorafenib; Survival Analysis; Treatment Outcome | 2018 |
Antitumor activity of the microtubule inhibitor MBRI-001 against human hepatocellular carcinoma as monotherapy or in combination with sorafenib.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Line, Tumor; Diketopiperazines; Drug Synergism; Humans; Liver Neoplasms; Mice, Nude; Microtubules; Sorafenib; Xenograft Model Antitumor Assays | 2018 |
Treatment of advanced hepatocellular carcinoma: beyond sorafenib.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Controlled Clinical Trials as Topic; Disease Progression; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib; Survival Analysis | 2018 |
Hepatocellular Carcinoma With Portal Venous Invasion: Radiating New Hope?
Topics: Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neoplasms; Portal Vein; Sorafenib | 2018 |
Enhancing anti-tumor efficiency in hepatocellular carcinoma through the autophagy inhibition by miR-375/sorafenib in lipid-coated calcium carbonate nanoparticles.
Topics: Animals; Calcium Carbonate; Carcinoma, Hepatocellular; Coated Materials, Biocompatible; Delayed-Action Preparations; Hep G2 Cells; Humans; Lipids; Liver Neoplasms; Mice; Mice, Nude; MicroRNAs; Nanoparticles; Sorafenib; Xenograft Model Antitumor Assays | 2018 |
Novel biomarker-based model for the prediction of sorafenib response and overall survival in advanced hepatocellular carcinoma: a prospective cohort study.
Topics: Antineoplastic Agents; Biomarkers; Carcinoma, Hepatocellular; Disease Progression; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Models, Statistical; Niacinamide; Phenylurea Compounds; Prognosis; Prospective Studies; Sorafenib; Survival Rate | 2018 |
Adverse reactions of sorafenib, sunitinib, and imatinib in treating digestive system tumors.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Diarrhea; Drug-Related Side Effects and Adverse Reactions; Female; Gastrointestinal Stromal Tumors; Humans; Hypertension; Imatinib Mesylate; Liver Neoplasms; Male; Middle Aged; Sorafenib; Sunitinib | 2018 |
No apparent benefit of preemptive sorafenib therapy in liver transplant recipients with advanced hepatocellular carcinoma on explant.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Follow-Up Studies; Graft Rejection; Graft Survival; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Preoperative Care; Prognosis; Retrospective Studies; Risk Factors; Sorafenib; Survival Rate | 2018 |
Treatment of hepatocellular carcinoma: a cost analysis of yttrium-90 transarterial radioembolization versus sorafenib.
Topics: Aged; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Cost-Benefit Analysis; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Yttrium Radioisotopes | 2018 |
Advanced Hepatocellular Carcinoma: Pretreatment Contrast-enhanced CT Texture Parameters as Predictive Biomarkers of Survival in Patients Treated with Sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers; Carcinoma, Hepatocellular; Contrast Media; Female; Humans; Liver; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Radiographic Image Enhancement; Retrospective Studies; Sorafenib; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome | 2018 |
Amentoflavone Enhances the Therapeutic Efficacy of Sorafenib by Inhibiting Anti-apoptotic Potential and Potentiating Apoptosis in Hepatocellular Carcinoma
Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Biflavonoids; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Synergism; Humans; Liver Neoplasms; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Sorafenib; Xenograft Model Antitumor Assays | 2018 |
CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma.
Topics: Aged; Aged, 80 and over; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Movement; Cell Proliferation; Doxorubicin; Drug Resistance, Neoplasm; Endoplasmic Reticulum Chaperone BiP; Epithelial-Mesenchymal Transition; Female; Gene Expression Regulation, Neoplastic; GPI-Linked Proteins; Hep G2 Cells; Humans; Intercellular Signaling Peptides and Proteins; Liver Neoplasms; Male; Mice, Inbred NOD; Middle Aged; Neoplasm Proteins; Neoplastic Stem Cells; Peptides; Phenotype; Protein Kinase Inhibitors; Signal Transduction; Sorafenib; Tissue Culture Techniques; Xenograft Model Antitumor Assays; Zebrafish | 2018 |
Evaluation of survival of patients with hepatocellular carcinoma: A comparative analysis of prognostic systems.
Topics: Aged; alpha-Fetoproteins; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Retrospective Studies; Sorafenib; Survival Rate; Tomography, X-Ray Computed | 2018 |
Synergistic anti-hepatoma effect of bufalin combined with sorafenib via mediating the tumor vascular microenvironment by targeting mTOR/VEGF signaling.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bufanolides; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Culture Media, Conditioned; Drug Synergism; Gene Expression Regulation, Neoplastic; Human Umbilical Vein Endothelial Cells; Humans; Liver Neoplasms; Mice; Niacinamide; Phenylurea Compounds; Signal Transduction; Sorafenib; TOR Serine-Threonine Kinases; Tumor Microenvironment; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2018 |
Sorafenib versus Transarterial chemoembolization for advanced-stage hepatocellular carcinoma: a cost-effectiveness analysis.
Topics: Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Cost-Benefit Analysis; Humans; Liver Neoplasms; Markov Chains; Monte Carlo Method; Neoplasm Metastasis; Neoplasm Staging; Protein Kinase Inhibitors; Quality-Adjusted Life Years; Sorafenib; Treatment Outcome | 2018 |
Comparative Effectiveness of Transarterial Embolization and Sorafenib for Hepatocellular Carcinoma: A Population-Based Study.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Comparative Effectiveness Research; Embolization, Therapeutic; Female; Humans; Liver Neoplasms; Male; Medicare; SEER Program; Sorafenib; Survival Rate; Treatment Outcome; United States | 2018 |
Sorafenib-loaded polymeric micelles as passive targeting therapeutic agents for hepatocellular carcinoma therapy.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Delivery Systems; Hep G2 Cells; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Micelles; Polyethylene Glycols; Polymers; Sorafenib | 2018 |
Sorafenib and hepatic arterial infusion chemotherapy: another failed combination.
Topics: Adult; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil; Humans; Liver Neoplasms; Sorafenib | 2018 |
Inter-operator variability and source of errors in tumour response assessment for hepatocellular carcinoma treated with sorafenib.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Clinical Competence; Diagnostic Errors; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Observer Variation; Phenylurea Compounds; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Sorafenib; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome | 2018 |
Multikinase inhibitor sorafenib induces skin toxicities in tumor-bearing mice.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Dose-Response Relationship, Drug; Drug Eruptions; Female; Humans; Liver Neoplasms; Mice; Mice, Nude; Protein Kinase Inhibitors; Signal Transduction; Skin; Smad Proteins; Sorafenib; Transforming Growth Factor beta1; Xenograft Model Antitumor Assays | 2018 |
Comparison of clinical outcome of hepatic arterial infusion chemotherapy and sorafenib for advanced hepatocellular carcinoma according to macrovascular invasion and transcatheter arterial chemoembolization refractory status.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Catheterization, Peripheral; Chemoembolization, Therapeutic; Female; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Microvessels; Neoplasm Invasiveness; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2018 |
Rupture of a Small Hepatocellular Carcinoma in a Stable Disease State in a Patient Receiving Sorafenib Treatment.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Rupture; Sorafenib; Treatment Outcome | 2018 |
Sorafenib suppresses TGF-β responses by inducing caveolae/lipid raft-mediated internalization/degradation of cell-surface type II TGF-β receptors: Implications in development of effective adjunctive therapy for hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Caveolae; Cell Line, Transformed; Cell Membrane; Dose-Response Relationship, Drug; Endocytosis; HEK293 Cells; Hep G2 Cells; Humans; Liver Neoplasms; Male; Membrane Microdomains; Mice; Mice, Inbred C57BL; Mink; Rats; Receptor, Transforming Growth Factor-beta Type II; Sorafenib; Transforming Growth Factor beta; Treatment Outcome | 2018 |
Sorafenib-induced tumor lysis syndrome in a patient with metastatic hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Fatal Outcome; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Sorafenib; Tumor Lysis Syndrome | 2020 |
Medium or Large Hepatocellular Carcinoma: Sorafenib Combined with Transarterial Chemoembolization and Radiofrequency Ablation.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Combined Modality Therapy; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Treatment Outcome | 2018 |
IL-17A promotes the invasion-metastasis cascade via the AKT pathway in hepatocellular carcinoma.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biomarkers, Tumor; Cadherins; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Enzyme Activation; Epithelial-Mesenchymal Transition; Hepatectomy; Humans; Interleukin-17; Interleukin-6; Liver Neoplasms; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Neoplasm Metastasis; Prognosis; Proto-Oncogene Proteins c-akt; Signal Transduction; Sorafenib; Treatment Outcome | 2018 |
Silencing activating transcription factor 2 promotes the anticancer activity of sorafenib in hepatocellular carcinoma cells.
Topics: Activating Transcription Factor 2; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Gene Silencing; Humans; Liver Neoplasms; Mitogen-Activated Protein Kinase 10; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; RNA, Small Interfering; Sorafenib; Tumor Necrosis Factor-alpha | 2018 |
Ovatodiolide suppresses yes-associated protein 1-modulated cancer stem cell phenotypes in highly malignant hepatocellular carcinoma and sensitizes cancer cells to chemotherapy in vitro.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Carcinoma, Hepatocellular; Diterpenes; Endoplasmic Reticulum Chaperone BiP; Humans; Liver Neoplasms; Neoplastic Stem Cells; Niacinamide; Phenotype; Phenylurea Compounds; Phosphoproteins; Sorafenib; Transcription Factors; YAP-Signaling Proteins | 2018 |
Comparison of clinical outcomes between sorafenib and hepatic artery infusion chemotherapy in advanced hepatocellular carcinoma: A STROBE-compliant article.
Topics: Adult; Antineoplastic Agents; Bilirubin; Carcinoma, Hepatocellular; Disease-Free Survival; Female; Hepatic Artery; Humans; Infusions, Intra-Arterial; International Normalized Ratio; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Retrospective Studies; Risk Factors; Sorafenib; Treatment Outcome | 2018 |
Cost-Effectiveness of Sorafenib Monotherapy and Selected Combination Therapy with Sorafenib in Patients with Advanced Hepatocellular Carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Cost-Benefit Analysis; Disease-Free Survival; Female; Humans; Liver Neoplasms; Male; Middle Aged; Models, Statistical; Niacinamide; Phenylurea Compounds; Quality-Adjusted Life Years; Sorafenib; Taiwan | 2018 |
The Rho GTPase Rnd1 inhibits epithelial-mesenchymal transition in hepatocellular carcinoma and is a favorable anti-metastasis target.
Topics: Animals; Carcinoma, Hepatocellular; Cell Movement; Cell Proliferation; Decitabine; Epigenesis, Genetic; Epithelial-Mesenchymal Transition; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Histone Deacetylase Inhibitors; Humans; Liver Neoplasms; Male; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Molecular Targeted Therapy; Neoplasm Invasiveness; Neoplasm Metastasis; Protein Kinase Inhibitors; raf Kinases; rho GTP-Binding Proteins; rhoA GTP-Binding Protein; Signal Transduction; Sorafenib; Vorinostat | 2018 |
Preparation of an efficient and safe polymeric-magnetic nanoparticle delivery system for sorafenib in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Biological Availability; Cell Survival; Drug Delivery Systems; Hep G2 Cells; Humans; Liver Neoplasms; Liver Neoplasms, Experimental; Magnetite Nanoparticles; Male; Neoplasm Proteins; Niacinamide; Particle Size; Phenylurea Compounds; Polyvinyl Alcohol; Rats; Rats, Wistar; Sorafenib | 2018 |
Radioembolization in Advanced Hepatocellular Carcinoma.
Topics: Aged; Asia; Brachytherapy; Carcinoma, Hepatocellular; Child; Humans; Liver Neoplasms; Male; Sorafenib | 2018 |
Recapitulation of pharmacogenomic data reveals that invalidation of SULF2 enhance sorafenib susceptibility in liver cancer.
Topics: Animals; Cell Line, Tumor; ErbB Receptors; Humans; Lipocalin-2; Liver Neoplasms; Mice; Mutation; Pharmacogenetics; Signal Transduction; Sorafenib; Sulfatases; Sulfotransferases | 2018 |
Prognostic Factors Associated with Postprogression Survival in Advanced Hepatocellular Carcinoma Patients Treated with Sorafenib Not Eligible for Second-Line Regorafenib Treatment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Treatment Outcome | 2018 |
Multicenter prospective study of angiogenesis polymorphism validation in HCC patients treated with sorafenib. An INNOVATE study protocol.
Topics: Adolescent; Angiopoietin-2; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease-Free Survival; Female; Humans; Hypoxia-Inducible Factor 1; Liver Neoplasms; Male; Neovascularization, Pathologic; Nitric Oxide Synthase Type III; Polymorphism, Single Nucleotide; Prospective Studies; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Vascular Endothelial Growth Factor A | 2018 |
Combined treatment with sorafenib and silibinin synergistically targets both HCC cells and cancer stem cells by enhanced inhibition of the phosphorylation of STAT3/ERK/AKT.
Topics: Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Self Renewal; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Humans; Kruppel-Like Factor 4; Liver Neoplasms; Neoplastic Stem Cells; Niacinamide; Phenylurea Compounds; Phosphorylation; Proto-Oncogene Proteins c-akt; Signal Transduction; Silybin; Silymarin; Sorafenib; STAT3 Transcription Factor | 2018 |
A novel thyroid function index associated with opposite therapeutic outcomes in advanced hepatocellular carcinoma patients receiving chemotherapy or sorafenib.
Topics: Antineoplastic Agents; Biomarkers; Carcinoma, Hepatocellular; Cohort Studies; Female; Humans; Liver Neoplasms; Male; Middle Aged; Sorafenib; Survival Rate; Thyroid Function Tests; Thyroid Gland; Thyroid Hormones; Treatment Outcome | 2018 |
[Insight and judgment on recurrence of hepatocellular carcinoma after liver transplantation].
Topics: Adult; Antineoplastic Agents; Carcinoma, Hepatocellular; China; Humans; Judgment; Liver Neoplasms; Liver Transplantation; Neoplasm Recurrence, Local; Sorafenib; Treatment Outcome | 2018 |
Chemical and genetic inhibition of STAT3 sensitizes hepatocellular carcinoma cells to sorafenib induced cell death.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Death; Cell Proliferation; Cell Survival; Hep G2 Cells; Humans; Liver Neoplasms; Phosphorylation; RNA Interference; Signal Transduction; Sorafenib; STAT3 Transcription Factor; Treatment Outcome | 2018 |
[Hepatocellular Carcinoma: New multimodal therapy concepts].
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Clinical Trials as Topic; Combined Modality Therapy; Humans; Liver Neoplasms; Liver Transplantation; Niacinamide; Phenylurea Compounds; Sorafenib | 2018 |
CD24 regulates sorafenib resistance via activating autophagy in hepatocellular carcinoma.
Topics: Animals; Autophagy; Carcinoma, Hepatocellular; CD24 Antigen; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Mice, Nude; Prognosis; Protein Phosphatase 2; Proto-Oncogene Proteins c-akt; RNA, Messenger; Signal Transduction; Sorafenib; TOR Serine-Threonine Kinases; Vacuoles | 2018 |
Locoregional versus systemic therapy - robust positive data remain elusive.
Topics: Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neoplasms; Neoplasm Recurrence, Local; Sorafenib | 2018 |
Downregulation of Raf-1 kinase inhibitory protein as a sorafenib resistance mechanism in hepatocellular carcinoma cell lines.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Hep G2 Cells; Humans; Liver Neoplasms; MAP Kinase Signaling System; Niacinamide; Phenylurea Compounds; Phosphatidylethanolamine Binding Protein; Protein Kinase Inhibitors; Sorafenib; Tumor Cells, Cultured | 2018 |
A dual-targeting reconstituted high density lipoprotein leveraging the synergy of sorafenib and antimiRNA21 for enhanced hepatocellular carcinoma therapy.
Topics: Animals; Carcinoma, Hepatocellular; Female; Hep G2 Cells; Human Umbilical Vein Endothelial Cells; Humans; Lipoproteins, HDL; Liver Neoplasms; Mice; Mice, Inbred BALB C; MicroRNAs; Oligopeptides; RNA, Neoplasm; Sorafenib | 2018 |
Rattle-Structured Rough Nanocapsules with in-Situ-Formed Gold Nanorod Cores for Complementary Gene/Chemo/Photothermal Therapy.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Proliferation; Combined Modality Therapy; DNA; Drug Delivery Systems; Drug Screening Assays, Antitumor; Genetic Therapy; Gold; HEK293 Cells; Hep G2 Cells; Humans; Liver Neoplasms; Molecular Structure; Nanocapsules; Nanotubes; Particle Size; Phototherapy; Plasmids; Porosity; Silicon Dioxide; Sorafenib; Surface Properties | 2018 |
Shaping the landscape of immune oncology in hepatocellular carcinoma.
Topics: Adult; Antibodies, Monoclonal, Humanized; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Sorafenib | 2018 |
Efficacy of annexin A3 blockade in sensitizing hepatocellular carcinoma to sorafenib and regorafenib.
Topics: Animals; Annexin A3; Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Hep G2 Cells; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; p38 Mitogen-Activated Protein Kinases; Phenylurea Compounds; Pyridines; Sorafenib; Xenograft Model Antitumor Assays | 2018 |
Sequence‑dependent effect of sorafenib in combination with natural phenolic compounds on hepatic cancer cells and the possible mechanism of action.
Topics: Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; DNA Fragmentation; Drug Therapy, Combination; Fibroblasts; Humans; Inhibitory Concentration 50; Liver Neoplasms; Membrane Potential, Mitochondrial; Niacinamide; Phenols; Phenylurea Compounds; Sorafenib | 2018 |
Impact of pre-sarcopenia in sorafenib treatment for advanced hepatocellular carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver; Liver Neoplasms; Male; Portal Vein; Prognosis; Proportional Hazards Models; Sarcopenia; Serum Albumin; Sorafenib; Treatment Outcome | 2018 |
Anti-GPC3 antibody-modified sorafenib-loaded nanoparticles significantly inhibited HepG2 hepatocellular carcinoma.
Topics: Animals; Antibodies; Antineoplastic Agents; Caproates; Carcinoma, Hepatocellular; Cell Line, Tumor; Glypicans; Hep G2 Cells; Humans; Lactones; Liver Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Niacinamide; Phenylurea Compounds; Polyethylene Glycols; Polymers; Sorafenib; Xenograft Model Antitumor Assays | 2018 |
The excellent antitumor effect of apatinib alone as second-line therapy in a patient with sorafenib-refractory hepatocellular carcinoma: A case report.
Topics: Adult; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Disease Progression; Fatal Outcome; Humans; Liver Neoplasms; Lung; Lung Neoplasms; Male; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Tomography, X-Ray Computed | 2018 |
Combinatorial treatment of Rhizoma Paridis saponins and sorafenib overcomes the intolerance of sorafenib.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Drug Therapy, Combination; Female; Humans; Liver Neoplasms; Metabolomics; Mice; Rhizome; Saponins; Signal Transduction; Sorafenib; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2018 |
Dual effects of the Nrf2 inhibitor for inhibition of hepatitis C virus and hepatic cancer cells.
Topics: Antineoplastic Agents; Antiviral Agents; Cell Line, Tumor; Hepatitis C; Humans; Liver Neoplasms; NF-E2-Related Factor 2; Quassins; RNA, Viral; Sorafenib; Transcriptome; Virus Replication | 2018 |
Sustained complete response of advanced hepatocellular carcinoma with metronomic capecitabine: a report of three cases.
Topics: Administration, Metronomic; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Hepatocellular; Humans; Liver; Liver Neoplasms; Male; Protein Kinase Inhibitors; Remission Induction; Sorafenib; Treatment Outcome | 2018 |
Sorafenib for Treatment of Hepatocellular Carcinoma: A Survival Analysis From the South American Liver Research Network.
Topics: Aged; Antineoplastic Agents; Blood Platelets; Carcinoma, Hepatocellular; Cohort Studies; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Retrospective Studies; Risk Factors; Sorafenib; South America; Survival Analysis; Survival Rate; Treatment Outcome | 2019 |
Concomitant use of sorafenib with ombitasvir/paritaprevir/ritonavir and dasabuvir: Effectiveness and safety in clinical practice.
Topics: 2-Naphthylamine; Aged; Anilides; Antineoplastic Agents; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Neoplasms; Macrocyclic Compounds; Male; Middle Aged; Proline; Prospective Studies; Ritonavir; Sorafenib; Sulfonamides; Treatment Outcome; Uracil; Valine | 2018 |
Efficacy and Safety of Sorafenib in a Racially Diverse Patient Population with Advanced Hepatocellular Carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Population Groups; Retrospective Studies; Sorafenib; Survival Analysis; Treatment Outcome | 2018 |
Refametinib in RAS-mutated hepatocellular cancer.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Clinical Trials, Phase II as Topic; Diphenylamine; Humans; Liver Neoplasms; Mutation; ras Proteins; Sorafenib; Sulfonamides | 2018 |
Sorafenib for Advanced Hepatocellular Carcinoma: A Real-Life Experience.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Probability; Pyridines; Retrospective Studies; Sorafenib; Treatment Outcome | 2018 |
Berberine, a natural plant alkaloid, synergistically sensitizes human liver cancer cells to sorafenib.
Topics: Antineoplastic Agents; Apoptosis; Berberine; Carcinoma, Hepatocellular; Cell Proliferation; Drug Synergism; Drug Therapy, Combination; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib; Tumor Cells, Cultured | 2018 |
Hand-foot-skin reaction of grade ≥ 2 within sixty days as the optimal clinical marker best help predict survival in sorafenib therapy for HCC.
Topics: Adult; Antineoplastic Agents; Biomarkers; Carcinoma, Hepatocellular; Female; Follow-Up Studies; Hand-Foot Syndrome; Humans; Liver Neoplasms; Male; Middle Aged; Prognosis; Retrospective Studies; Sorafenib; Survival Rate | 2019 |
Phospho-ERK is a biomarker of response to a synthetic lethal drug combination of sorafenib and MEK inhibition in liver cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Humans; Liver Neoplasms; Mitogen-Activated Protein Kinase Kinases; Phosphorylation; Sorafenib | 2018 |
Enhanced delivery of sorafenib with anti-GPC3 antibody-conjugated TPGS-b-PCL/Pluronic P123 polymeric nanoparticles for targeted therapy of hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents, Immunological; Carcinoma, Hepatocellular; Drug Delivery Systems; HeLa Cells; Hep G2 Cells; Humans; Liver Neoplasms; Mice; Mice, Nude; Nanoparticles; Poloxalene; Polyesters; Sorafenib; Xenograft Model Antitumor Assays | 2018 |
Inhibition of Cyclin-Dependent Kinase 5: A Strategy to Improve Sorafenib Response in Hepatocellular Carcinoma Therapy.
Topics: Animals; Carcinoma, Hepatocellular; Cyclin-Dependent Kinase 5; Female; Humans; Liver Neoplasms; Mice; Protein Kinase Inhibitors; Sorafenib; Treatment Outcome; Tumor Cells, Cultured | 2019 |
Targeted and synergistic therapy for hepatocellular carcinoma: monosaccharide modified lipid nanoparticles for the co-delivery of doxorubicin and sorafenib.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Doxorubicin; Drug Carriers; Drug Delivery Systems; Drug Screening Assays, Antitumor; Hep G2 Cells; Humans; Lipids; Liver Neoplasms; Liver Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Monosaccharides; Nanoparticles; Sorafenib; Structure-Activity Relationship | 2018 |
Tex10 is upregulated and promotes cancer stem cell properties and chemoresistance in hepatocellular carcinoma.
Topics: Animals; Carcinoma, Hepatocellular; Cell Cycle; Cell Differentiation; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Humans; Hyaluronan Receptors; Liver Neoplasms; Mice; Neoplasm Metastasis; Neoplastic Stem Cells; Nuclear Proteins; Phenotype; Signal Transduction; Sorafenib; STAT3 Transcription Factor; Up-Regulation | 2018 |
Lipid profiling of pre-treatment plasma reveals biomarker candidates associated with response rates and hand-foot skin reactions in sorafenib-treated patients.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Hand-Foot Syndrome; Humans; Lipids; Liver Neoplasms; Male; Middle Aged; Predictive Value of Tests; Prognosis; Reproducibility of Results; Sorafenib; Treatment Outcome | 2018 |
Increased cumulative doses and appearance of hand-foot skin reaction prolonged progression free survival in sorafenib-treated advanced hepatocellular carcinoma patients.
Topics: Aged; Carcinoma, Hepatocellular; Disease-Free Survival; Female; Foot; Hand; Humans; Liver Neoplasms; Male; Middle Aged; Progression-Free Survival; Protein Kinase Inhibitors; Skin; Sorafenib | 2018 |
Multikinase inhibitor-associated hand-foot skin reaction as a predictor of outcomes in patients with hepatocellular carcinoma treated with sorafenib.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Eruptions; Female; Foot; Hand; Humans; Incidence; Liver Neoplasms; Male; Medication Adherence; Middle Aged; Niacinamide; Pharmacists; Phenylurea Compounds; Protein Kinase Inhibitors; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Skin; Sorafenib; Survival Analysis; Treatment Failure | 2018 |
Inhibition of cFLIP overcomes acquired resistance to sorafenib via reducing ER stress‑related autophagy in hepatocellular carcinoma.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Biomarkers, Tumor; Carcinoma, Hepatocellular; CASP8 and FADD-Like Apoptosis Regulating Protein; Cell Proliferation; Drug Resistance, Neoplasm; Endoplasmic Reticulum Stress; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-akt; Signal Transduction; Sorafenib; Tumor Cells, Cultured | 2018 |
Activation of ferritinophagy is required for the RNA-binding protein ELAVL1/HuR to regulate ferroptosis in hepatic stellate cells.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Carcinoma, Hepatocellular; Cell Death; Cells, Cultured; Chemical and Drug Induced Liver Injury; Collagen Type I, alpha 1 Chain; ELAV-Like Protein 1; Female; Hepatic Stellate Cells; Humans; Iron; Lipid Peroxidation; Liver Cirrhosis; Liver Neoplasms; Male; Mice; Mice, Inbred C57BL; Middle Aged; Retrospective Studies; Sorafenib | 2018 |
Clinical outcomes with long-term sorafenib treatment of patients with hepatocellular carcinoma: a multicenter real-life study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Italy; Kaplan-Meier Estimate; Liver Neoplasms; Long-Term Care; Male; Middle Aged; Retrospective Studies; Severity of Illness Index; Sorafenib; Time Factors; Treatment Outcome; Young Adult | 2018 |
Hepatocellular Carcinoma with Orbital Metastasis: a Unique Multidisciplinary Case Report.
Topics: Biopsy; Carcinoma, Hepatocellular; Chemoradiotherapy, Adjuvant; Dose Fractionation, Radiation; Embolization, Therapeutic; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Orbit; Orbital Neoplasms; Sorafenib; Stereotaxic Techniques; Tomography, X-Ray Computed; Treatment Outcome | 2019 |
Synergistic effect of ursodeoxycholic acid on the antitumor activity of sorafenib in hepatocellular carcinoma cells via modulation of STAT3 and ERK.
Topics: Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Cell Survival; Extracellular Signal-Regulated MAP Kinases; Hep G2 Cells; Humans; Liver Neoplasms; Phosphorylation; Reactive Oxygen Species; Signal Transduction; Sorafenib; STAT3 Transcription Factor; Ursodeoxycholic Acid | 2018 |
Metformin reverses stem cell‑like HepG2 sphere formation and resistance to sorafenib by attenuating epithelial‑mesenchymal transformation.
Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Hep G2 Cells; Humans; Hypoglycemic Agents; Liver Neoplasms; Metformin; Neoplastic Stem Cells; Sorafenib | 2018 |
ETS-1 induces Sorafenib-resistance in hepatocellular carcinoma cells via regulating transcription factor activity of PXR.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Mice, Nude; Pregnane X Receptor; Protein Kinase Inhibitors; Proto-Oncogene Protein c-ets-1; Sorafenib | 2018 |
Disparities in Access to Sorafenib in Communities with Low Socioeconomic Status.
Topics: Carcinoma, Hepatocellular; Healthcare Disparities; Humans; Liver Neoplasms; Neoplasm Staging; Residence Characteristics; Social Class; Sorafenib; United States | 2018 |
Combined Treatment for Lung Metastasis from Hepatocellular Carcinoma: A Case Report.
Topics: Acupuncture; Carcinoma, Hepatocellular; Combined Modality Therapy; Female; Humans; Liver Neoplasms; Lung Neoplasms; Medicine, Korean Traditional; Middle Aged; Phytotherapy; Quality of Life; Sorafenib | 2018 |
LncRNA SNHG3 induces EMT and sorafenib resistance by modulating the miR-128/CD151 pathway in hepatocellular carcinoma.
Topics: Carcinogenesis; Carcinoma, Hepatocellular; Cell Movement; Cell Proliferation; Disease-Free Survival; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Liver Neoplasms; Male; MicroRNAs; Middle Aged; Neoplasm Invasiveness; RNA, Long Noncoding; Sorafenib; Tetraspanin 24 | 2019 |
Identification of a co-target for enhancing efficacy of sorafenib in HCC through a quantitative modeling approach.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Drug Synergism; Glutathione; Glutathione Transferase; Humans; Hydrogen Peroxide; Liver Neoplasms; Models, Biological; Sorafenib; Tumor Cells, Cultured | 2018 |
Cirrhotic stiffness affects the migration of hepatocellular carcinoma cells and induces sorafenib resistance through YAP.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Liver; Liver Cirrhosis; Liver Neoplasms; Proto-Oncogene Proteins c-yes; Sorafenib; Tumor Microenvironment | 2019 |
Dynamic contrast enhanced perfusion CT imaging: A diagnostic biomarker tool for survival prediction of tumour response to antiangiogenetic treatment in patients with advanced HCC lesions.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers; Carcinoma, Hepatocellular; Female; Humans; Liver; Liver Neoplasms; Male; Middle Aged; Prognosis; Radiographic Image Enhancement; Sorafenib; Survival Rate; Tomography, X-Ray Computed | 2018 |
Antrodia cinnamomea boosts the anti-tumor activity of sorafenib in xenograft models of human hepatocellular carcinoma.
Topics: Animals; Annexin A5; Antrodia; Apoptosis; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Cell Survival; Chromatography, Liquid; Hep G2 Cells; Humans; Immunoblotting; Liver Neoplasms; Mice; Mice, Inbred BALB C; Plant Extracts; Propidium; Sorafenib; Wound Healing | 2018 |
TIP60-dependent acetylation of the SPZ1-TWIST complex promotes epithelial-mesenchymal transition and metastasis in liver cancer.
Topics: Acetylation; Animals; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Bevacizumab; Carcinogenesis; Cell Cycle Proteins; Cell Line, Tumor; Epithelial-Mesenchymal Transition; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Liver Neoplasms, Experimental; Lysine Acetyltransferase 5; Mice; Mice, Nude; Mice, Transgenic; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neovascularization, Pathologic; Nuclear Proteins; Protein Interaction Mapping; Protein Processing, Post-Translational; Proto-Oncogene Mas; Signal Transduction; Sorafenib; Transcription Factors; Twist-Related Protein 1; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2019 |
ID1-induced p16/IL6 axis activation contributes to the resistant of hepatocellular carcinoma cells to sorafenib.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p16; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Inhibitor of Differentiation Protein 1; Interleukin-6; Liver Neoplasms; Male; Mice; Mice, Nude; Phosphorylation; Proto-Oncogene Proteins c-akt; Signal Transduction; Sorafenib; Up-Regulation | 2018 |
TACE with degradable starch microspheres (DSM-TACE) as second-line treatment in HCC patients dismissing or ineligible for sorafenib.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Female; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Male; Microspheres; Sorafenib; Starch; Tomography, X-Ray Computed; Treatment Outcome | 2019 |
Changes in plasma interleukin-8 and tumor necrosis factor-α levels during the early treatment period as a predictor of the response to sorafenib in patients with unresectable hepatocellular carcinoma.
Topics: Aged; Antineoplastic Agents; Biomarkers; Carcinoma, Hepatocellular; Cohort Studies; Dose-Response Relationship, Drug; Female; Humans; Interleukin-8; Liver Neoplasms; Male; Predictive Value of Tests; Retrospective Studies; Sorafenib; Survival Analysis; Tumor Necrosis Factor-alpha | 2018 |
Synergistic antimetastatic effect of cotreatment with licochalcone A and sorafenib on human hepatocellular carcinoma cells through the inactivation of MKK4/JNK and uPA expression.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Chalcones; Down-Regulation; Drug Synergism; Drug Therapy, Combination; Humans; Liver Neoplasms; MAP Kinase Kinase 4; MAP Kinase Signaling System; Mice; Mice, Inbred C57BL; Mice, Nude; Sorafenib; Urokinase-Type Plasminogen Activator; Xenograft Model Antitumor Assays | 2018 |
Molecularly targeted anti-cancer drugs inhibit the invasion and metastasis of hepatocellular carcinoma by regulating the expression of MMP and TIMP gene families.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Matrix Metalloproteinases; Molecular Targeted Therapy; Multigene Family; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinolines; Sorafenib; Tissue Inhibitor of Metalloproteinases | 2018 |
Sorafenib and Carfilzomib Synergistically Inhibit the Proliferation, Survival, and Metastasis of Hepatocellular Carcinoma.
Topics: Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Drug Synergism; Endoplasmic Reticulum Stress; Epithelial-Mesenchymal Transition; Female; Humans; Liver Neoplasms; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Neoplasm Metastasis; Oligopeptides; Signal Transduction; Sorafenib; Xenograft Model Antitumor Assays | 2018 |
Extracellular matrix collagen I promotes the tumor progression of residual hepatocellular carcinoma after heat treatment.
Topics: Animals; Carcinoma, Hepatocellular; Catheter Ablation; Cell Line, Tumor; Cell Movement; Cell Proliferation; Collagen Type I; Disease Progression; Epithelial-Mesenchymal Transition; Extracellular Matrix; Humans; Hyperthermia, Induced; Liver Neoplasms; Mice; Niacinamide; Phenylurea Compounds; Sorafenib; Xenograft Model Antitumor Assays | 2018 |
Specific CYP450 Genotypes in the Chinese Population Affect Sorafenib Toxicity in HBV/HCV-associated Hepatocellular Carcinoma Patients.
Topics: Adolescent; Adult; Animals; Antineoplastic Agents; Asian People; Carcinoma, Hepatocellular; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Genotype; Hepatitis B; Hepatitis C; Humans; Liver Neoplasms; Male; Middle Aged; Polymorphism, Genetic; Rats, Sprague-Dawley; Sorafenib; Young Adult | 2018 |
Primary peritoneal hepatoid adenocarcinoma: a diagnostic and therapeutic conundrum in patients with gastrointestinal bleeding.
Topics: Adenocarcinoma; Anemia, Iron-Deficiency; Antineoplastic Agents; Carcinoma, Hepatocellular; Docetaxel; Fatty Liver; Gastrointestinal Hemorrhage; Humans; Liver Neoplasms; Male; Middle Aged; Palliative Care; Peritoneal Neoplasms; Sorafenib | 2018 |
Effectiveness of Sorafenib in Hepatic Hemangioma.
Topics: Aged; Antineoplastic Agents; Female; Hemangioma; Humans; Liver Neoplasms; Sorafenib | 2018 |
Capsaicin and sorafenib combination treatment exerts synergistic anti‑hepatocellular carcinoma activity by suppressing EGFR and PI3K/Akt/mTOR signaling.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Capsaicin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; ErbB Receptors; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Mice; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Signal Transduction; Sorafenib; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2018 |
Sestrin 2 confers primary resistance to sorafenib by simultaneously activating AKT and AMPK in hepatocellular carcinoma.
Topics: AMP-Activated Protein Kinases; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Nuclear Proteins; Phosphorylation; Proto-Oncogene Proteins c-akt; Signal Transduction; Sorafenib; Up-Regulation | 2018 |
Emodin Sensitizes Hepatocellular Carcinoma Cells to the Anti-Cancer Effect of Sorafenib through Suppression of Cholesterol Metabolism.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cholesterol; Drug Synergism; Emodin; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Liver Neoplasms; Mice; Proto-Oncogene Proteins c-akt; Signal Transduction; Sorafenib; Sterol Regulatory Element Binding Protein 2; Xenograft Model Antitumor Assays | 2018 |
Combination therapy of sorafenib with mesenchymal stem cells as a novel cancer treatment regimen in xenograft models of hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Proliferation; Combined Modality Therapy; Gene Expression Regulation; Hep G2 Cells; Humans; Inflammation Mediators; Liver Neoplasms; Male; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells; Mice, Inbred BALB C; Mice, Nude; Sorafenib; Treatment Outcome; Xenograft Model Antitumor Assays | 2019 |
Drug response prediction model using a hierarchical structural component modeling method.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Agents; Biomarkers, Tumor; Cohort Studies; Female; Humans; Liver Neoplasms; Male; Mass Spectrometry; Middle Aged; Models, Statistical; Proteomics; Sorafenib | 2018 |
Using ALBI score at the start of sorafenib treatment to predict regorafenib treatment candidates in patients with hepatocellular carcinoma.
Topics: Aged; Carcinoma, Hepatocellular; Cohort Studies; Female; Humans; Liver Neoplasms; Male; Phenylurea Compounds; Prognosis; Pyridines; Retrospective Studies; Sorafenib | 2019 |
Sorafenib Reduced Significantly Heptopulmonary Shunt in a Large Hepatocelullar Carcinoma.
Topics: Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoradiotherapy; Humans; Liver Neoplasms; Male; Radiopharmaceuticals; Sorafenib; Technetium Tc 99m Aggregated Albumin; Yttrium Radioisotopes | 2019 |
Efficacy of Sorafenib for the Treatment of Post-Transplant Hepatocellular Carcinoma Recurrence.
Topics: alpha-Fetoproteins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Sorafenib; Tacrolimus; TOR Serine-Threonine Kinases | 2018 |
Sorafenib for Recurrent Hepatocellular Carcinoma after Liver Transplantation.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Liver Transplantation; Neoplasm Recurrence, Local; Sorafenib; Treatment Outcome | 2018 |
MiR-128-3p overexpression sensitizes hepatocellular carcinoma cells to sorafenib induced apoptosis through regulating DJ-1.
Topics: 3' Untranslated Regions; Antineoplastic Agents; Apoptosis; Binding Sites; Carcinoma, Hepatocellular; Dose-Response Relationship, Drug; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Liver Neoplasms; MicroRNAs; Phosphatidylinositol 3-Kinase; Protein Deglycase DJ-1; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Signal Transduction; Sorafenib; Up-Regulation | 2018 |
Monitoring serum proangiogenic cytokines from hepatocellular carcinoma patients treated with sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Angiopoietin-2; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cytokines; Female; Humans; Liver Neoplasms; Male; Middle Aged; Monitoring, Physiologic; Predictive Value of Tests; Prognosis; Sorafenib; Survival Rate; Treatment Outcome | 2019 |
Non-measurable infiltrative HCC: is post-contrast attenuation on CT a sign of tumor response?
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Cohort Studies; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Portal Vein; Prognosis; Retrospective Studies; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome | 2019 |
Clinicopathologic charcterization of sorafenib-induced endoplasmic reticulum stress in human liver cancer cells.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Humans; Liver Neoplasms; Protein Kinase Inhibitors; Sorafenib | 2018 |
Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Immunological; Carcinoma, Hepatocellular; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Cell Proliferation; Cell Survival; Immunocompetence; Immunomodulation; Liver Neoplasms; Mice; Phenylurea Compounds; Programmed Cell Death 1 Receptor; Quinolines; Sequence Analysis, RNA; Single-Cell Analysis; Sorafenib; Xenograft Model Antitumor Assays | 2018 |
Comparison of dynamic contrast-enhanced magnetic resonance imaging and contrast-enhanced ultrasound for evaluation of the effects of sorafenib in a rat model of hepatocellular carcinoma.
Topics: Animals; Biomarkers, Tumor; Capillary Permeability; Carcinoma, Hepatocellular; Cell Line, Tumor; Contrast Media; Disease Models, Animal; Hypoxia; Image Processing, Computer-Assisted; Liver Neoplasms; Magnetic Resonance Imaging; Male; Necrosis; Neovascularization, Pathologic; Permeability; Rats; Sorafenib | 2019 |
Perforating dermatosis associated with multikinase inhibitors: report of two cases, including one associated with lenvatinib.
Topics: Abdomen; Aged; Carcinoma; Carcinoma, Hepatocellular; Folliculitis; Hand-Foot Syndrome; Humans; Liver Neoplasms; Male; Middle Aged; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolines; Skin Diseases; Sorafenib; Thigh; Thyroid Neoplasms | 2018 |
Cytokine augments the sorafenib-induced apoptosis in Huh7 liver cancer cell by inducing mitochondrial fragmentation and activating MAPK-JNK signalling pathway.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Cytokines; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Humans; Interleukin-2; Liver Neoplasms; MAP Kinase Signaling System; Mitochondria; Sorafenib | 2019 |
Cost-effectiveness of sorafenib versus best supportive care in advanced hepatocellular carcinoma in Egypt.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Disease Progression; Disease-Free Survival; Egypt; Female; Health Expenditures; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Markov Chains; Middle Aged; Models, Econometric; Palliative Care; Quality-Adjusted Life Years; Sorafenib | 2019 |
Multicenter retrospective analysis of the safety and efficacy of regorafenib after progression on sorafenib in Korean patients with hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Female; Follow-Up Studies; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Peritoneal Neoplasms; Phenylurea Compounds; Pyridines; Republic of Korea; Retrospective Studies; Sorafenib; Survival Rate; Treatment Outcome | 2019 |
Impact of physician experience and multidisciplinary team on clinical outcome in patients receiving sorafenib.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Clinical Competence; Humans; Liver Neoplasms; Patient Care Team; Retrospective Studies; Sorafenib; Treatment Outcome | 2019 |
ASPP2 enhances chemotherapeutic sensitivity through the down-regulation of XIAP expression in a p53 independent manner in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Carcinoma, Hepatocellular; Down-Regulation; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Liver; Liver Neoplasms; Mice, Inbred BALB C; Sorafenib; Tumor Suppressor Protein p53; X-Linked Inhibitor of Apoptosis Protein | 2019 |
MicroRNA‑223 promotes hepatocellular carcinoma cell resistance to sorafenib by targeting FBW7.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; F-Box-WD Repeat-Containing Protein 7; Humans; Liver Neoplasms; MicroRNAs; Sorafenib | 2019 |
The effect of apatinib in the treatment of sorafenib resistant metastatic hepatocellular carcinoma: A case report.
Topics: Adult; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Drug Resistance, Neoplasm; Hepatitis B, Chronic; Humans; Liver Neoplasms; Male; Pyridines; Sorafenib | 2018 |
Safety and efficacy of cytotoxic chemotherapy in hepatocellular carcinoma after first-line treatment with sorafenib.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Cytotoxins; Databases, Factual; Female; Humans; Liver Neoplasms; Male; Middle Aged; Sorafenib; Survival Rate; Treatment Outcome; Young Adult | 2018 |
Prediction of sorafenib treatment-related gene expression for hepatocellular carcinoma: preoperative MRI and histopathological correlation.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Contrast Media; Feasibility Studies; Female; Gadolinium DTPA; Humans; Image Enhancement; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Preoperative Period; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-raf; Retrospective Studies; Risk Factors; Sorafenib; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factor Receptor-3 | 2019 |
Impact of albumin-bilirubin grade on survival in patients with hepatocellular carcinoma who received sorafenib: An analysis using time-dependent receiver operating characteristic.
Topics: Aged; Antineoplastic Agents; Bilirubin; Biomarkers, Tumor; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Predictive Value of Tests; ROC Curve; Serum Albumin, Human; Sorafenib; Survival Rate; Time Factors | 2019 |
Induction of Oxidative Stress Through Inhibition of Thioredoxin Reductase 1 Is an Effective Therapeutic Approach for Hepatocellular Carcinoma.
Topics: Animals; Antineoplastic Agents; Auranofin; Carcinoma, Hepatocellular; Drug Screening Assays, Antitumor; Hep G2 Cells; Humans; Kelch-Like ECH-Associated Protein 1; Liver Neoplasms; Mice; NF-E2-Related Factor 2; Oxidative Stress; Sorafenib; Thioredoxin Reductase 1 | 2019 |
Early decrease in serum amphiregulin or vascular endothelial growth factor levels predicts sorafenib efficacy in hepatocellular carcinoma.
Topics: Amphiregulin; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Line, Tumor; Enzyme-Linked Immunosorbent Assay; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Prognosis; Progression-Free Survival; Sorafenib; Time Factors; Treatment Outcome; Vascular Endothelial Growth Factor A | 2019 |
Development of Focal Segmental Glomerulosclerosis and Thrombotic Microangiopathy in a Liver Transplant Patient on Sorafenib for Hepatocellular Carcinoma: A Case Report.
Topics: Acute Kidney Injury; Calcineurin Inhibitors; Carcinoma, Hepatocellular; Glomerulosclerosis, Focal Segmental; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Protein Kinase Inhibitors; Sorafenib; Thrombotic Microangiopathies; Transplantation, Homologous | 2018 |
Liver computed tomographic perfusion for monitoring the early therapeutic response to sorafenib in advanced hepatocellular carcinoma patients.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Image Processing, Computer-Assisted; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Retrospective Studies; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome | 2018 |
Epigenetic events involved in organic cation transporter 1-dependent impaired response of hepatocellular carcinoma to sorafenib.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Proliferation; CHO Cells; Cricetulus; Drug Screening Assays, Antitumor; Epigenesis, Genetic; Gene Expression Profiling; Gene Silencing; HEK293 Cells; Hep G2 Cells; Humans; Liver Neoplasms; Liver Neoplasms, Experimental; Male; Octamer Transcription Factor-1; Rats; Rats, Wistar; RNA, Messenger; Sorafenib | 2019 |
TNF-α is a potential therapeutic target to overcome sorafenib resistance in hepatocellular carcinoma.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Disease Models, Animal; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Gene Expression Regulation, Neoplastic; Glycoproteins; Humans; Liver Neoplasms; Mice; Models, Biological; Protein Kinase Inhibitors; Sorafenib; Tumor Necrosis Factor-alpha; Xenograft Model Antitumor Assays | 2019 |
Stem Cell Markers Predict the Response to Sorafenib in Patients with Hepatocellular Carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplastic Stem Cells; Pharmacogenomic Testing; RNA, Messenger; Sorafenib; Treatment Outcome | 2019 |
Cotreatment with sorafenib and oleanolic acid induces reactive oxygen species-dependent and mitochondrial-mediated apoptotic cell death in hepatocellular carcinoma cells.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Proliferation; Drug Therapy, Combination; Humans; Liver Neoplasms; Membrane Potential, Mitochondrial; Mitochondria; Oleanolic Acid; Reactive Oxygen Species; Sorafenib; Tumor Cells, Cultured | 2019 |
The synergistic effect of sorafenib and TNF-α inhibitor on hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Synergism; Epithelial-Mesenchymal Transition; Humans; Liver Neoplasms; Protein Kinase Inhibitors; Signal Transduction; Sorafenib; Tumor Necrosis Factor-alpha | 2019 |
TARBP2-mediated destabilization of Nanog overcomes sorafenib resistance in hepatocellular carcinoma.
Topics: Animals; Autophagy; Carcinoma, Hepatocellular; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Lysosomes; Male; Mice, Inbred BALB C; MicroRNAs; Models, Biological; Nanog Homeobox Protein; Protein Stability; RNA-Binding Proteins; Sorafenib; Treatment Outcome | 2019 |
Chemosensitization of hepatocellular carcinoma cells to sorafenib by β-caryophyllene oxide-induced inhibition of ABC export pumps.
Topics: Animals; Antineoplastic Agents; ATP-Binding Cassette Transporters; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Mice; Neoplasm Proteins; Polycyclic Sesquiterpenes; Sorafenib | 2019 |
Treatment with metformin is associated with a prolonged survival in patients with hepatocellular carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Diabetes Mellitus, Type 2; Female; Germany; Humans; Hypoglycemic Agents; Liver Neoplasms; Male; Metformin; Middle Aged; Multivariate Analysis; Prognosis; Propensity Score; Retrospective Studies; Risk Factors; Sorafenib; Survival Analysis | 2019 |
Activation of MET promotes resistance to sorafenib in hepatocellular carcinoma cells via the AKT/ERK1/2-EGR1 pathway.
Topics: Apoptosis; Carcinoma, Hepatocellular; Cell Proliferation; Down-Regulation; Drug Interactions; Drug Resistance, Neoplasm; Early Growth Response Protein 1; Enzyme Activation; Enzyme Inhibitors; Hep G2 Cells; Hepatocyte Growth Factor; Humans; Liver Neoplasms; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-met; RNA, Small Interfering; Sorafenib | 2019 |
PDCD2 sensitizes HepG2 cells to sorafenib by suppressing epithelial‑mesenchymal transition.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Cadherins; Cell Movement; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Liver Neoplasms; Signal Transduction; Sorafenib; Vimentin | 2019 |
Ramucirumab and the controversial role of α-fetoprotein in hepatocellular carcinoma.
Topics: alpha-Fetoproteins; Antibodies, Monoclonal, Humanized; Carcinoma, Hepatocellular; Double-Blind Method; Humans; Liver Neoplasms; Ramucirumab; Sorafenib | 2019 |
PEGylated trimethylchitosan emulsomes conjugated to octreotide for targeted delivery of sorafenib to hepatocellular carcinoma cells of HepG2.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Membrane Permeability; Cell Survival; Chitosan; Delayed-Action Preparations; Drug Compounding; Drug Liberation; Emulsions; Hep G2 Cells; Humans; Liver Neoplasms; Nanocapsules; Octreotide; Polyethylene Glycols; Sorafenib; Surface Properties | 2019 |
Unusual eruption in association with sorafenib: a case of acquired perforating dermatosis, reactive perforating collagenosis type.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Collagen Diseases; HIV Infections; Humans; Liver Neoplasms; Male; Skin Diseases; Sorafenib | 2018 |
Novel Combination of Mesenchymal Stem Cell-Conditioned Medium with Sorafenib Have Synergistic Antitumor Effect of Hepatocellular Carcinoma Cells
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Hep G2 Cells; Humans; Liver Neoplasms; Mesenchymal Stem Cells; Sorafenib | 2019 |
Medical Treatment of Advanced Hepatocellular Carcinoma Patients: The Issue Is Not the Right Drug, but the Right Patient.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Sorafenib | 2019 |
Chrysin-induced ERK1/2 Phosphorylation Enhances the Sensitivity of Human Hepatocellular Carcinoma Cells to Sorafenib.
Topics: Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily G, Member 2; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Flavonoids; Hep G2 Cells; Humans; Liver Neoplasms; Neoplasm Proteins; Phosphorylation; Sorafenib | 2019 |
Sorafenib/MEK inhibitor combination inhibits tumor growth and the Wnt/β‑catenin pathway in xenograft models of hepatocellular carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carcinoma, Hepatocellular; Diphenylamine; Humans; Liver Neoplasms; Male; Mice; Mice, SCID; Mitogen-Activated Protein Kinase Kinases; Sorafenib; Sulfonamides; Wnt Signaling Pathway; Xenograft Model Antitumor Assays | 2019 |
Regorafenib reverses HGF-induced sorafenib resistance by inhibiting epithelial-mesenchymal transition in hepatocellular carcinoma.
Topics: Apoptosis; Carcinoma, Hepatocellular; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Extracellular Signal-Regulated MAP Kinases; Hepatocyte Growth Factor; Humans; Liver Neoplasms; Phenylurea Compounds; Pyridines; Sorafenib; STAT3 Transcription Factor; Tumor Cells, Cultured; Wound Healing | 2019 |
Integrated analysis of multiple receptor tyrosine kinases identifies Axl as a therapeutic target and mediator of resistance to sorafenib in hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Axl Receptor Tyrosine Kinase; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Humans; Liver Neoplasms; Male; Middle Aged; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; RNA, Messenger; Sorafenib | 2019 |
EGFR signaling confers resistance to BET inhibition in hepatocellular carcinoma through stabilizing oncogenic MYC.
Topics: Animals; Antineoplastic Agents; Azepines; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Humans; Liver Neoplasms; Mice; Proteins; Proto-Oncogene Proteins c-myc; Signal Transduction; Sorafenib; Triazoles; Xenograft Model Antitumor Assays | 2019 |
A real-life experience of sorafenib treatment for patients with advanced hepatocellular carcinoma: a retrospective analysis at Cathay General Hospital, 2007-2015.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Hospitals, General; Humans; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Retrospective Studies; Sorafenib; Survival Analysis; Taiwan; Treatment Outcome | 2019 |
Cost-effectiveness analysis of lenvatinib treatment for patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib in Japan.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Humans; Japan; Liver Neoplasms; Models, Economic; Phenylurea Compounds; Quality-Adjusted Life Years; Quinolines; Randomized Controlled Trials as Topic; Sorafenib; Survival Analysis | 2019 |
Autophagic flux modulation by Wnt/β-catenin pathway inhibition in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Autophagy; beta Catenin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Female; Gene Knockdown Techniques; Humans; Liver Neoplasms; Liver Neoplasms, Experimental; Mice; Mice, Nude; Sorafenib; Sulfonamides; Wnt Signaling Pathway; Xenograft Model Antitumor Assays | 2019 |
Low-density lipoprotein decorated silica nanoparticles co-delivering sorafenib and doxorubicin for effective treatment of hepatocellular carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; Doxorubicin; Hep G2 Cells; Humans; Lipoproteins, LDL; Liver Neoplasms; Mice; Mice, Nude; Nanoparticles; Rabbits; Receptors, LDL; Silicon Dioxide; Sorafenib; Tumor Burden; Xenograft Model Antitumor Assays | 2018 |
Hepatocellular carcinoma with extrahepatic metastasis: Are there still candidates for transarterial chemoembolization as an initial treatment?
Topics: Aged; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Disease-Free Survival; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Registries; Retrospective Studies; Sorafenib; Survival Rate | 2019 |
Treatment with Brivanib alaninate as a second-line monotherapy after Sorafenib failure in hepatocellular carcinoma: A case report.
Topics: Alanine; Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Male; Middle Aged; Retreatment; Sorafenib; Treatment Failure; Triazines | 2019 |
Hexokinase-II Inhibition Synergistically Augments the Anti-tumor Efficacy of Sorafenib in Hepatocellular Carcinoma.
Topics: Animals; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Endoplasmic Reticulum Stress; Gene Expression Regulation, Neoplastic; Hexokinase; Humans; Liver Neoplasms; Male; Mice, Inbred BALB C; Prognosis; Pyruvates; Sorafenib; Survival Analysis; Treatment Outcome; Up-Regulation; Xenograft Model Antitumor Assays | 2019 |
Long Noncoding RNA (lncRNA) Small Nucleolar RNA Host Gene 16 (SNHG16) Predicts Poor Prognosis and Sorafenib Resistance in Hepatocellular Carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; Female; Humans; In Situ Hybridization; Liver Neoplasms; Male; Middle Aged; Prognosis; RNA Interference; RNA, Long Noncoding; RNA, Small Nucleolar; Sorafenib; Transcriptome | 2019 |
Epigenetic regulation of UDP-Glucuronosyltransferase by microRNA-200a/-183: implications for responses to sorafenib treatment in patients with hepatocellular carcinoma.
Topics: 3' Untranslated Regions; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Epigenesis, Genetic; Glucuronosyltransferase; HEK293 Cells; Humans; Liver Neoplasms; Male; Mice; Mice, Nude; MicroRNAs; RNA, Messenger; Sorafenib; UDP-Glucuronosyltransferase 1A9; Xenograft Model Antitumor Assays | 2019 |
UBE2C functions as a potential oncogene by enhancing cell proliferation, migration, invasion, and drug resistance in hepatocellular carcinoma cells.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Disease Progression; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Neoplasm Invasiveness; Sorafenib; Ubiquitin-Conjugating Enzymes | 2019 |
[Sustained Complete Response of Hepatocellular Carcinoma with Multiple Intrahepatic Metastases following the Discontinuation of Sorafenib].
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Male; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2019 |
Impact of the Prognostic Nutritional Index on the Survival of Japanese Patients with Hepatocellular Carcinoma Treated with Sorafenib: A Multicenter Retrospective Study.
Topics: Aged; Carcinoma, Hepatocellular; Female; Humans; Japan; Liver Neoplasms; Lymphocyte Count; Male; Middle Aged; Multivariate Analysis; Nutrition Assessment; Nutritional Status; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Retrospective Studies; Serum Albumin; Sorafenib | 2019 |
Changes in the neutrophil-to-lymphocyte ratio predict the prognosis of patients with advanced hepatocellular carcinoma treated with sorafenib.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers; Carcinoma, Hepatocellular; Female; Follow-Up Studies; Humans; Leukocyte Count; Liver Neoplasms; Lymphocytes; Male; Middle Aged; Neutrophils; Prognosis; Retrospective Studies; Sorafenib; Survival Analysis | 2019 |
Preclinical comparison of regorafenib and sorafenib efficacy for hepatocellular carcinoma using multimodality molecular imaging.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Human Umbilical Vein Endothelial Cells; Humans; Immunohistochemistry; Liver Neoplasms; Mice; Molecular Imaging; Neovascularization, Pathologic; Phenylurea Compounds; Pyridines; Sorafenib; Xenograft Model Antitumor Assays | 2019 |
Polymyalgia rheumatica occurrence under multikinase inhibitors (sorafenib and erlotinib) treatment.
Topics: Aged; Carcinoma, Hepatocellular; Erlotinib Hydrochloride; Glucocorticoids; Humans; Liver Neoplasms; Male; Polymyalgia Rheumatica; Positron Emission Tomography Computed Tomography; Prednisone; Protein Kinase Inhibitors; Sorafenib | 2019 |
Genome-wide copy number alteration and VEGFA amplification of circulating cell-free DNA as a biomarker in advanced hepatocellular carcinoma patients treated with Sorafenib.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell-Free Nucleic Acids; DNA Copy Number Variations; Female; Gene Amplification; Humans; Liver Neoplasms; Male; Middle Aged; Sequence Analysis, DNA; Sorafenib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2019 |
Hepatocellular Carcinoma and Nuclear Paraspeckles: Induction in Chemoresistance and Prediction for Poor Survival.
Topics: Antineoplastic Agents; Area Under Curve; Carcinoma, Hepatocellular; Cell Line, Tumor; DNA-Binding Proteins; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Liver; Liver Neoplasms; Male; Middle Aged; Nuclear Matrix-Associated Proteins; Nuclear Proteins; Octamer Transcription Factors; Prognosis; Proportional Hazards Models; RNA-Binding Proteins; RNA, Long Noncoding; ROC Curve; Sorafenib | 2019 |
Influence of Sorafenib on Host Immunity in Patients with Liver Cirrhosis With Advanced Hepatocellular Carcinoma Stratified by Etiology.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Hepatitis B; Hepatitis C; Humans; Interferon-gamma; Interleukin-4; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Sorafenib; Th2 Cells | 2019 |
Systemic doxorubicin and hepatocellular carcinoma: the end of an era never risen up.
Topics: Carcinoma, Hepatocellular; Doxorubicin; Humans; Liver Neoplasms; Nanoparticles; Sorafenib; Treatment Failure | 2019 |
Targeting AMP-activated kinase impacts hepatocellular cancer stem cells induced by long-term treatment with sorafenib.
Topics: AMP-Activated Protein Kinases; Animals; Biomarkers, Tumor; Biphenyl Compounds; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Liver Neoplasms; Mice; Mice, Nude; Neoplasm Proteins; Neoplastic Stem Cells; Pyrones; Sorafenib; Thiophenes; Time Factors; Xenograft Model Antitumor Assays | 2019 |
Co-delivery of sorafenib and VEGF-siRNA via pH-sensitive liposomes for the synergistic treatment of hepatocellular carcinoma.
Topics: Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Female; Gene Silencing; Humans; Hydrogen-Ion Concentration; Liposomes; Liver Neoplasms; Mice; RNA, Small Interfering; Sorafenib; Vascular Endothelial Growth Factor A | 2019 |
KIAA1199 promotes sorafenib tolerance and the metastasis of hepatocellular carcinoma by activating the EGF/EGFR-dependent epithelial-mesenchymal transition program.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Epidermal Growth Factor; Epithelial-Mesenchymal Transition; ErbB Receptors; Female; Hep G2 Cells; Heterografts; Humans; Hyaluronoglucosaminidase; Liver Neoplasms; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasm Metastasis; Phosphorylation; Sorafenib | 2019 |
Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.
Topics: Animals; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease Progression; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Organic Cation Transport Proteins; Sorafenib; Transcription Factors | 2019 |
PFKFB3/HIF-1α feedback loop modulates sorafenib resistance in hepatocellular carcinoma cells.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Liver Neoplasms; Phosphofructokinase-2; Sorafenib | 2019 |
Inhibition of neddylation modification by MLN4924 sensitizes hepatocellular carcinoma cells to sorafenib.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; Cell Movement; Cell Proliferation; Cyclopentanes; Female; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Male; Mice; Middle Aged; NEDD8 Protein; Neoplasm Proteins; NF-KappaB Inhibitor alpha; Pyrimidines; Sorafenib; Ubiquitin-Activating Enzymes; Ubiquitins; Xenograft Model Antitumor Assays | 2019 |
Sorafenib Induces Pyroptosis in Macrophages and Triggers Natural Killer Cell-Mediated Cytotoxicity Against Hepatocellular Carcinoma.
Topics: Analysis of Variance; Animals; Carcinoma, Hepatocellular; Cytokines; Disease Models, Animal; Female; Flow Cytometry; Humans; Injections, Intravenous; Killer Cells, Natural; Liver Neoplasms; Macrophages; Mice; Mice, Transgenic; Protein Kinase Inhibitors; Pyroptosis; Random Allocation; Sorafenib; Tumor Burden; Tumor Cells, Cultured; X-Ray Microtomography; Xenograft Model Antitumor Assays | 2019 |
Treatment Patterns and Economic Burden by Lines of Therapy Among Patients with Advanced Hepatocellular Carcinoma Treated with Systemic Cancer Therapy.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cost of Illness; Female; Humans; Liver Neoplasms; Male; Middle Aged; Retrospective Studies; Sorafenib; Treatment Outcome | 2020 |
Investigation of new treatment option for hepatocellular carcinoma: a combination of sorafenib with usnic acid.
Topics: Annexin A5; Antineoplastic Agents; Apoptosis; Benzofurans; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Drug Therapy, Combination; Hep G2 Cells; Humans; Liver Neoplasms; Protein-Tyrosine Kinases; Sorafenib | 2019 |
Tumor Hypervascularity and hand-foot-skin reaction predict better outcomes in combination treatment of TACE and Sorafenib for intermediate hepatocellular carcinoma.
Topics: Adult; Angiography, Digital Subtraction; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Disease Progression; Female; Hand-Foot Syndrome; Humans; Liver Neoplasms; Male; Middle Aged; Retrospective Studies; Sorafenib; Survival Analysis; Treatment Outcome | 2019 |
LncRNA SNHG1 contributes to sorafenib resistance by activating the Akt pathway and is positively regulated by miR-21 in hepatocellular carcinoma cells.
Topics: Animals; Apoptosis; Autophagy; Carcinoma, Hepatocellular; Cell Proliferation; Drug Resistance, Neoplasm; Fusion Regulatory Protein 1, Heavy Chain; Gene Expression Regulation, Neoplastic; Gene Silencing; Hep G2 Cells; Humans; Liver Neoplasms; Mice; MicroRNAs; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; RNA, Long Noncoding; RNA, Small Interfering; Sorafenib; Xenograft Model Antitumor Assays | 2019 |
Liver Transplantation After Downstagings of Ruptured Advanced Hepatocellular Carcinoma in Cirrhotic Liver: Is It Advisable? A Case Report.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Follow-Up Studies; Humans; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Patient Selection; San Francisco; Sorafenib; Treatment Outcome | 2019 |
Another Treatment Option for Advanced Hepatocellular Carcinoma With Portal Vein Thrombosis in China.
Topics: Carcinoma, Hepatocellular; China; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Oxaliplatin; Portal Vein; Sorafenib | 2019 |
miR-613 inhibits liver cancer stem cell expansion by regulating SOX9 pathway.
Topics: 3' Untranslated Regions; Carcinoma, Hepatocellular; Cell Dedifferentiation; Cell Line, Tumor; Cell Self Renewal; Cisplatin; Down-Regulation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; MicroRNAs; Neoplastic Stem Cells; RNA, Small Interfering; Signal Transduction; Sorafenib; SOX9 Transcription Factor | 2019 |
Combined Antitumor Effects of Sorafenib and GPC3-CAR T Cells in Mouse Models of Hepatocellular Carcinoma.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Combined Modality Therapy; Cytokines; Disease Models, Animal; Drug Resistance, Neoplasm; Glypicans; Humans; Immunotherapy, Adoptive; Liver Neoplasms; Macrophages; Mice; Receptors, Antigen, T-Cell; Receptors, Chimeric Antigen; Sorafenib; T-Lymphocytes; Xenograft Model Antitumor Assays | 2019 |
pH-responsive hyaluronic acid nanoparticles coloaded with sorafenib and cisplatin for treatment of hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Membrane Permeability; Cell Survival; Cisplatin; Delayed-Action Preparations; Drug Liberation; Drug Therapy, Combination; Hep G2 Cells; Humans; Hyaluronic Acid; Hydrogen-Ion Concentration; Liver Neoplasms; Liver Neoplasms, Experimental; Mice, Nude; Nanocapsules; Sorafenib | 2019 |
Efficacy of anti-PD-1 antibody SHR-1210 as second-line treatment in hepatocellular carcinoma patient with sorafenib resistance: A case report.
Topics: alpha-Fetoproteins; Antineoplastic Agents, Immunological; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Programmed Cell Death 1 Receptor; Sorafenib; Treatment Outcome | 2019 |
Co-administration of combretastatin A4 nanoparticles and sorafenib for systemic therapy of hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Death; Cell Survival; Human Umbilical Vein Endothelial Cells; Humans; Ki-67 Antigen; Liver Neoplasms; Male; Mice, Inbred BALB C; Nanoparticles; Platelet Endothelial Cell Adhesion Molecule-1; Sorafenib; Stilbenes; Treatment Outcome; Vascular Endothelial Growth Factor A | 2019 |
PKM2 is the target of proanthocyanidin B2 during the inhibition of hepatocellular carcinoma.
Topics: Active Transport, Cell Nucleus; Animals; Apoptosis; Carcinoma, Hepatocellular; Carrier Proteins; Cell Cycle Checkpoints; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glycolysis; Heterografts; HSP90 Heat-Shock Proteins; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Liver Neoplasms; Membrane Proteins; Mice; Proanthocyanidins; Sorafenib; Thyroid Hormone-Binding Proteins; Thyroid Hormones | 2019 |
A survey on transarterial chemoembolization refractoriness and a real-world treatment pattern for hepatocellular carcinoma in Korea.
Topics: Adult; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Female; Humans; Internet; Liver Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Republic of Korea; Sorafenib; Surveys and Questionnaires | 2020 |
Hepatic arterial chemotherapy for hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Oxaliplatin; Portal Vein; Sorafenib | 2019 |
Oncofetal HLF transactivates c-Jun to promote hepatocellular carcinoma development and sorafenib resistance.
Topics: Adult; Antineoplastic Agents; Apoptosis; Basic-Leucine Zipper Transcription Factors; Carcinoma, Hepatocellular; Cell Line, Tumor; Disease Progression; DNA, Neoplasm; Drug Resistance, Neoplasm; Female; Genes, jun; Humans; Immunoprecipitation; Leucine Zippers; Liver Neoplasms; Male; Prognosis; Sorafenib | 2019 |
Inhibition of glycogen catabolism induces intrinsic apoptosis and augments multikinase inhibitors in hepatocellular carcinoma cells.
Topics: Amides; Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Energy Metabolism; Glycogen; Glycogen Phosphorylase; Hep G2 Cells; Humans; Indoles; Liver Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Rats; Sorafenib | 2019 |
Risk factors of mortality in the patients with hepatocellular carcinoma: A multicenter study in Indonesia.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Female; Follow-Up Studies; Hepatectomy; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Indonesia; Kaplan-Meier Estimate; Liver; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Palliative Care; Radiofrequency Ablation; Registries; Retrospective Studies; Risk Assessment; Risk Factors; Severity of Illness Index; Sorafenib; Treatment Outcome | 2020 |
M2 macrophages mediate sorafenib resistance by secreting HGF in a feed-forward manner in hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Hepatocyte Growth Factor; Humans; Liver Neoplasms; Macrophages; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Sorafenib | 2019 |
Microvascular Invasion as a Predictor of Response to Treatment with Sorafenib and Transarterial Chemoembolization for Recurrent Intermediate-Stage Hepatocellular Carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Female; Humans; Liver; Liver Neoplasms; Male; Microvessels; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Retrospective Studies; Sorafenib; Treatment Outcome | 2019 |
Combination Therapy in Intermediate-Stage Hepatocellular Carcinoma: Do We Need to Know about Microvascular Invasion?
Topics: Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatectomy; Humans; Liver Neoplasms; Sorafenib | 2019 |
Co-delivery of sorafenib and metapristone encapsulated by CXCR4-targeted PLGA-PEG nanoparticles overcomes hepatocellular carcinoma resistance to sorafenib.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Chemical Phenomena; Drug Compounding; Drug Resistance, Neoplasm; Female; Humans; Inhibitory Concentration 50; Liver Neoplasms; Mice; Mifepristone; Nanoparticles; Polyesters; Polyethylene Glycols; Protein Kinase Inhibitors; Receptors, CXCR4; Sorafenib; Xenograft Model Antitumor Assays | 2019 |
Celastrol Enhances the Anti-Liver Cancer Activity of Sorafenib.
Topics: Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Inhibitory Concentration 50; Liver Neoplasms; Mice; Mice, Inbred C57BL; Pentacyclic Triterpenes; Signal Transduction; Sorafenib; Triterpenes; Xenograft Model Antitumor Assays | 2019 |
Postoperative adjuvant sorafenib improves survival outcomes in hepatocellular carcinoma patients with microvascular invasion after R0 liver resection: a propensity score matching analysis.
Topics: Adult; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Female; Hepatectomy; Humans; Liver Neoplasms; Male; Matched-Pair Analysis; Middle Aged; Neoplasm Invasiveness; Propensity Score; Retrospective Studies; Sorafenib | 2019 |
Sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Japan.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Phenylurea Compounds; Prognosis; Pyridines; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Sorafenib; Survival Rate | 2020 |
Combined chemo/photothermal therapy based on mesoporous silica-Au core-shell nanoparticles for hepatocellular carcinoma treatment.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Combined Modality Therapy; Drug Carriers; Drug Compounding; Drug Liberation; Gold; Humans; Hyperthermia, Induced; Lasers; Liver Neoplasms; Low-Level Light Therapy; Metal Nanoparticles; Porosity; Silicon Dioxide; Sorafenib | 2019 |
Using prognostic and predictive clinical features to make personalised survival prediction in advanced hepatocellular carcinoma patients undergoing sorafenib treatment.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Prognosis; Sorafenib | 2019 |
Effect of body composition on survival benefit of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: A comparison with sorafenib therapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Body Composition; Carcinoma, Hepatocellular; Female; Hepatic Artery; Humans; Infusions, Intra-Arterial; Japan; Liver Neoplasms; Male; Retrospective Studies; Sorafenib; Treatment Outcome | 2019 |
Sorafenib kills liver cancer cells by disrupting SCD1-mediated synthesis of monounsaturated fatty acids
Topics: Adenosine Triphosphate; Adenylate Kinase; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Enzyme Activation; Fatty Acids, Monounsaturated; Humans; Lipidomics; Liver Neoplasms; Male; Mice, Inbred BALB C; Mice, Nude; Mitochondria; Neoplasm Proteins; Oleic Acid; Phosphorylation; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Recombinant Proteins; RNA Interference; RNA, Small Interfering; Signal Transduction; Sorafenib; Stearoyl-CoA Desaturase; Sterol Regulatory Element Binding Protein 1; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2019 |
Thermosensitive hydrogels for sustained-release of sorafenib and selenium nanoparticles for localized synergistic chemoradiotherapy.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoradiotherapy; Delayed-Action Preparations; Female; Humans; Hydrogels; Liver Neoplasms; Mice, Inbred BALB C; Mice, Inbred ICR; Mice, Nude; Nanoparticles; Selenium; Sorafenib | 2019 |
Cost-Effectiveness of Cabozantinib in the Second-Line Treatment of Advanced Hepatocellular Carcinoma.
Topics: Anilides; Antineoplastic Agents; Carcinoma, Hepatocellular; Clinical Decision-Making; Clinical Trials, Phase III as Topic; Computer Simulation; Cost-Benefit Analysis; Disease-Free Survival; Drug Costs; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Markov Chains; Models, Economic; Neoplasm Staging; Palliative Care; Patient Selection; Placebos; Progression-Free Survival; Protein Kinase Inhibitors; Pyridines; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Sorafenib | 2019 |
LncRNA FOXD2-AS1 as a competitive endogenous RNA against miR-150-5p reverses resistance to sorafenib in hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Liver Neoplasms; Male; Membrane Proteins; MicroRNAs; NF-E2-Related Factor 2; RNA, Long Noncoding; Signal Transduction; Sorafenib | 2019 |
Efficacy and toxicity of sorafenib in patients with adenoid cystic carcinoma of the head and neck: a case series of five patients.
Topics: Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Adenoid Cystic; Fatigue; Female; Hand-Foot Syndrome; Humans; Liver Neoplasms; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Mucositis; Neoplasm Recurrence, Local; Pericardium; Pleural Neoplasms; Progression-Free Survival; Retrospective Studies; Salivary Gland Neoplasms; Sorafenib | 2020 |
Sorafenib with concurrent multiple-line therapies improves overall survival in advanced stage hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; alpha-Fetoproteins; Chemoembolization, Therapeutic; Drug Therapy, Combination; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Prognosis; Proportional Hazards Models; Sorafenib; Survival Analysis; Taiwan | 2019 |
Activation of AKT/AP1/FoxM1 signaling confers sorafenib resistance to liver cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Proliferation; Drug Resistance, Neoplasm; Forkhead Box Protein M1; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Promoter Regions, Genetic; Proto-Oncogene Proteins c-akt; Sorafenib; Transcription Factor AP-1; Transcriptional Activation; Tumor Cells, Cultured | 2019 |
Synergistic antitumor effect of BRMS1 and sorafenib via inhibition of the PI3K/AKT/mTOR/ERK signaling pathway.
Topics: Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Proliferation; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Repressor Proteins; Signal Transduction; Sorafenib; TOR Serine-Threonine Kinases; Tumor Cells, Cultured | 2019 |
Outcomes of Liver Transplantation for Hepatocellular Carcinoma Beyond the University of California San Francisco Criteria: A Single-center Experience.
Topics: Ablation Techniques; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Disease-Free Survival; Female; Follow-Up Studies; Humans; Liver; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Patient Selection; Retrospective Studies; Risk Factors; Sorafenib; Time Factors; Tumor Burden | 2020 |
Differential expression profiling of long non-coding RNA GAS5 and miR-126-3p in human cancer cells in response to sorafenib.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Gene Expression Profiling; Humans; Liver Neoplasms; MicroRNAs; RNA, Long Noncoding; Sorafenib | 2019 |
Successful Treatment of Hepatocellular Carcinoma with Regorafenib after Sorafenib-induced Hypersensitivity.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Hypersensitivity; Humans; Liver Neoplasms; Male; Middle Aged; Phenylurea Compounds; Pyridines; Sorafenib | 2019 |
HIF-1α-induced RIT1 promotes liver cancer growth and metastasis and its deficiency increases sensitivity to sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Liver Neoplasms; Male; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Neoplasm Invasiveness; ras Proteins; Signal Transduction; Sorafenib; Xenograft Model Antitumor Assays; Young Adult | 2019 |
CCN2-MAPK-Id-1 loop feedback amplification is involved in maintaining stemness in oxaliplatin-resistant hepatocellular carcinoma.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Biomarkers, Tumor; Butadienes; Carcinoma, Hepatocellular; Cell Line, Tumor; Connective Tissue Growth Factor; Down-Regulation; Drug Resistance, Neoplasm; Feedback; Female; Gene Expression Regulation, Neoplastic; Heterografts; Humans; Liver Neoplasms; Male; MAP Kinase Signaling System; Mice, Nude; Middle Aged; Mitogen-Activated Protein Kinase 1; Neoplasm Recurrence, Local; Neoplasm Transplantation; Neoplastic Stem Cells; Nitriles; Oxaliplatin; Protein Kinase Inhibitors; RNA, Messenger; Sorafenib; Up-Regulation | 2019 |
Predictors of ribociclib-mediated antitumour effects in native and sorafenib-resistant human hepatocellular carcinoma cells.
Topics: Aminopyridines; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Cyclin-Dependent Kinase Inhibitor p16; Drug Resistance, Neoplasm; G1 Phase Cell Cycle Checkpoints; Hepatocytes; Humans; Liver Neoplasms; Purines; Retinoblastoma Protein; RNA, Small Interfering; Sorafenib | 2019 |
The prognostic factors between different viral etiologies among advanced hepatocellular carcinoma patients receiving sorafenib treatment.
Topics: Antineoplastic Agents; Bilirubin; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Prognosis; Sorafenib | 2019 |
Modulating the site-specific oral delivery of sorafenib using sugar-grafted nanoparticles for hepatocellular carcinoma treatment.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Proliferation; Drug Liberation; Galactose; Hep G2 Cells; Humans; Lipids; Liver Neoplasms; Membrane Potential, Mitochondrial; Mice, Inbred BALB C; Nanoparticles; Polyethylene Glycols; Sorafenib; Tissue Distribution | 2019 |
Hepatocellular carcinomas: evolution to sorafenib resistance through hepatic leukaemia factor.
Topics: Carcinoma, Hepatocellular; Humans; Leukemia; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib | 2019 |
Response to: Assessing the risk of bias and publication bias should be integral parts of the systematic review.
Topics: Bias; Carcinoma, Hepatocellular; Child; Humans; Liver Neoplasms; Publication Bias; Sorafenib | 2019 |
Assessing the risk of bias and publication bias should be integral parts of the systematic review.
Topics: Bias; Carcinoma, Hepatocellular; Child; Humans; Liver Neoplasms; Publication Bias; Sorafenib | 2019 |
Antitumorigenic and antiangiogenic efficacy of apatinib in liver cancer evaluated by multimodality molecular imaging.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Disease Models, Animal; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Imaging; Molecular Targeted Therapy; Multimorbidity; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2019 |
Comparison of lipiodol infusion and drug-eluting beads transarterial chemoembolization of hepatocellular carcinoma in a real-life setting.
Topics: Aged; Antibiotics, Antineoplastic; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Drug Delivery Systems; Ethiodized Oil; Female; Humans; Liver Neoplasms; Male; Microspheres; Middle Aged; Multivariate Analysis; Retrospective Studies; Sorafenib; Survival Analysis; Treatment Outcome; Venous Thrombosis | 2019 |
Immunologic Features of Patients With Advanced Hepatocellular Carcinoma Before and During Sorafenib or Anti-programmed Death-1/Programmed Death-L1 Treatment.
Topics: Aged; Antigens, CD; Carcinoma, Hepatocellular; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Disease Progression; Female; Hepatitis A Virus Cellular Receptor 2; Humans; Immunotherapy; Liver Neoplasms; Lymphocyte Activation Gene 3 Protein; Male; Neoplasm Staging; Predictive Value of Tests; Prognosis; Programmed Cell Death 1 Receptor; Protein Kinase Inhibitors; Sorafenib; Up-Regulation | 2019 |
Enhancer of zeste 2 polycomb repressive complex 2 subunit promotes sorafenib resistance of hepatocellular carcinoma though insulin-like growth factor 1 receptor.
Topics: Animals; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Proliferation; Drug Resistance, Neoplasm; Enhancer of Zeste Homolog 2 Protein; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Mice; MicroRNAs; Prognosis; Receptor, IGF Type 1; Sorafenib; Survival Rate; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2019 |
Selective targeting of tumor cells and tumor associated macrophages separately by twin-like core-shell nanoparticles for enhanced tumor-localized chemoimmunotherapy.
Topics: Animals; Benzamides; Carcinoma, Hepatocellular; Cell Survival; Chitosan; Drug Carriers; Humans; Immunotherapy; Liver Neoplasms; Macrophages; Mannose; Mice; Microscopy, Confocal; Nanoparticles; Protein Kinase Inhibitors; RAW 264.7 Cells; Sorafenib; Tissue Distribution | 2019 |
Establishment of a hepatocellular carcinoma patient-derived xenograft platform and its application in biomarker identification.
Topics: Animals; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Line, Tumor; Chemoradiotherapy, Adjuvant; Down-Regulation; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gene Expression Profiling; Genomics; Hepatectomy; Humans; Liver Neoplasms; Male; MAP Kinase Kinase Kinase 1; Middle Aged; Proof of Concept Study; Prospective Studies; Protein Kinase Inhibitors; Sorafenib; Treatment Outcome; Xenograft Model Antitumor Assays | 2020 |
Nek2 augments sorafenib resistance by regulating the ubiquitination and localization of β-catenin in hepatocellular carcinoma.
Topics: Animals; beta Catenin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Liver Neoplasms; Male; Mice; Neoplasm Transplantation; NIMA-Related Kinases; Signal Transduction; Sorafenib; Ubiquitination; Up-Regulation | 2019 |
Alliance of the Titans: An Effective Combination of a TKI with CAR T Cells.
Topics: Animals; Automobiles; Carcinoma, Hepatocellular; Liver Neoplasms; Mice; Sorafenib; T-Lymphocytes | 2019 |
PMPCB Silencing Sensitizes HCC Tumor Cells to Sorafenib Therapy.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Metalloendopeptidases; Mice; Mitochondrial Processing Peptidase; Mitochondrial Proteins; Myeloid Cell Leukemia Sequence 1 Protein; RNA, Small Interfering; Signal Transduction; Sorafenib; Survival Analysis; Xenograft Model Antitumor Assays | 2019 |
Inhibition of cyclin E1 sensitizes hepatocellular carcinoma cells to regorafenib by mcl-1 suppression.
Topics: Animals; Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Carcinoma, Hepatocellular; Cell Line, Tumor; Cyclic N-Oxides; Cyclin E; Drug Synergism; Flavonoids; Gene Expression Regulation, Neoplastic; Humans; Indolizines; Liver Neoplasms; Male; Mice; Myeloid Cell Leukemia Sequence 1 Protein; Oncogene Proteins; Phenylurea Compounds; Piperidines; Prognosis; Pyridines; Pyridinium Compounds; Sorafenib; STAT3 Transcription Factor; Xenograft Model Antitumor Assays | 2019 |
Sorafenib Activity and Disposition in Liver Cancer Does Not Depend on Organic Cation Transporter 1.
Topics: Animals; Antineoplastic Agents; Biological Transport; Carcinoma, Hepatocellular; Cell Line, Tumor; Female; Genotype; HEK293 Cells; Hep G2 Cells; Humans; Liver Neoplasms; Mice; Mice, Knockout; Octamer Transcription Factor-1; Oocytes; Sorafenib; Xenopus laevis | 2020 |
Therapeutic Effect of Sorafenib-Loaded TPGS-
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Liver Neoplasms; Mice; Nanoparticles; Polyethylene Glycols; Sorafenib; Vitamin E | 2018 |
[Nodulocystic eruption induced by sorafenib].
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Eruptions; Female; Humans; Liver Neoplasms; Male; Middle Aged; Sorafenib | 2019 |
Short-Term Oral Sorafenib for Therapy of Intratumoral Shunts of Hepatocellular Carcinoma to Enable Intraarterial Treatment.
Topics: Aged; Aged, 80 and over; Angiography, Digital Subtraction; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Female; Humans; Infusions, Intra-Arterial; Liver; Liver Neoplasms; Male; Neovascularization, Pathologic; Retrospective Studies; Sorafenib; Time; Tomography, X-Ray Computed; Treatment Outcome | 2019 |
Preliminary experience on safety of regorafenib after sorafenib failure in recurrent hepatocellular carcinoma after liver transplantation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Phenylurea Compounds; Prognosis; Pyridines; Retrospective Studies; Sorafenib; Young Adult | 2019 |
SLC27A5 deficiency activates NRF2/TXNRD1 pathway by increased lipid peroxidation in HCC.
Topics: Aldehydes; Amino Acid Sequence; Animals; Antioxidants; Apoptosis; Base Sequence; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Fatty Acid Transport Proteins; Fatty Acids, Unsaturated; Female; Gene Expression Regulation, Neoplastic; Humans; Kelch-Like ECH-Associated Protein 1; Lipid Peroxidation; Liver Neoplasms; Male; Mice, Inbred BALB C; Mice, Nude; Middle Aged; NF-E2-Related Factor 2; Oxidative Stress; Reactive Oxygen Species; Signal Transduction; Sorafenib; Thioredoxin Reductase 1 | 2020 |
Intermediate-advanced hepatocellular carcinoma in Argentina: Treatment and survival analysis.
Topics: Aged; Argentina; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Disease Progression; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Longitudinal Studies; Male; Middle Aged; Neoplasm Staging; Phenylurea Compounds; Prospective Studies; Quinolines; Retrospective Studies; Sorafenib; Treatment Outcome | 2019 |
Synthesis of pectin-deoxycholic acid conjugate for targeted delivery of anticancer drugs in hepatocellular carcinoma.
Topics: Antineoplastic Agents; Asialoglycoprotein Receptor; Carcinoma, Hepatocellular; Cell Cycle; Cell Movement; Cell Proliferation; Deoxycholic Acid; Drug Delivery Systems; Hep G2 Cells; Human Umbilical Vein Endothelial Cells; Humans; Liver Neoplasms; Magnetic Resonance Spectroscopy; Micelles; Particle Size; Pectins; Sorafenib; Spectroscopy, Fourier Transform Infrared; Tablets; Temperature; Time Factors | 2019 |
A Pharmacogenomic Landscape in Human Liver Cancers.
Topics: Animals; Antineoplastic Agents; Asian People; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Line, Tumor; Clinical Decision-Making; Databases, Genetic; Drug Resistance, Neoplasm; Female; Genetic Heterogeneity; Genetic Predisposition to Disease; High-Throughput Nucleotide Sequencing; Humans; Liver Neoplasms; Male; Mice, Inbred BALB C; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Patient Selection; Pharmacogenomic Testing; Pharmacogenomic Variants; Phenotype; Precision Medicine; Protein Kinase Inhibitors; Sorafenib; Xenograft Model Antitumor Assays | 2019 |
Preclinical efficacy of a novel dual PI3K/mTOR inhibitor, CMG002, alone and in combination with sorafenib in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; Drug Synergism; Hep G2 Cells; Humans; Liver Neoplasms; Mice; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Piperidines; Pyridines; Pyrimidines; Signal Transduction; Sorafenib; TOR Serine-Threonine Kinases | 2019 |
Ultrasound-Triggered Nanodroplets for Targeted Co-Delivery of Sorafenib/Doxorubicin for Hepatocellular Carcinoma Therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Doxorubicin; Drug Delivery Systems; Humans; Liver Neoplasms; Sorafenib | 2019 |
Decreased IL-6 induces sensitivity of hepatocellular carcinoma cells to sorafenib.
Topics: Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Humans; Interleukin-6; Liver Neoplasms; RNA, Small Interfering; Signal Transduction; Sorafenib | 2019 |
Can the tyrosine kinase inhibitors trigger metabolic encephalopathy in cirrhotic patients?
Topics: Aged; Brain Diseases, Metabolic; Carcinoma, Hepatocellular; Cognition Disorders; Electroencephalography; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Mood Disorders; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Retrospective Studies; Sorafenib; Treatment Outcome | 2013 |
Suppression of natural killer cells by sorafenib contributes to prometastatic effects in hepatocellular carcinoma.
Topics: Animals; Antigens, CD; Antigens, Differentiation, T-Lymphocyte; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Humans; Immunocompromised Host; Immunosuppressive Agents; K562 Cells; Killer Cells, Natural; Lectins, C-Type; Liver Neoplasms; Lung Neoplasms; Male; MAP Kinase Signaling System; Mice; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-raf; Signal Transduction; Sorafenib; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
Label-retaining liver cancer cells are relatively resistant to sorafenib.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Gene Expression Profiling; Humans; Liver Neoplasms; Niacinamide; Oncogene Protein v-akt; Phenylurea Compounds; Real-Time Polymerase Chain Reaction; Sorafenib; Stem Cells | 2013 |
Sorafenib suppresses growth and survival of hepatoma cells by accelerating degradation of enhancer of zeste homolog 2.
Topics: Antineoplastic Agents; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chromatin Immunoprecipitation; Enhancer of Zeste Homolog 2 Protein; Humans; In Situ Nick-End Labeling; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Polycomb Repressive Complex 2; Reverse Transcriptase Polymerase Chain Reaction; Sorafenib; Transfection | 2013 |
Sorafenib perpetuates cellular anticancer effector functions by modulating the crosstalk between macrophages and natural killer cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cytokines; Drug Evaluation, Preclinical; Humans; Killer Cells, Natural; Liver Neoplasms; Macrophage Activation; Macrophages; Mice; Mice, Inbred C57BL; NF-kappa B; Niacinamide; Phenylurea Compounds; Sorafenib | 2013 |
Sorafenib in elderly patients with advanced hepatocellular carcinoma: a case series.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Comorbidity; Disease Progression; Female; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Quality of Life; Retrospective Studies; Sorafenib; Survival Rate; Time Factors; Treatment Outcome | 2013 |
Is it time to adopt external beam radiotherapy in the NCCN guidelines as a therapeutic strategy for intermediate/advanced hepatocellular carcinoma?.
Topics: Adrenal Gland Neoplasms; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Disease-Free Survival; Ethiodized Oil; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Niacinamide; Phenylurea Compounds; Practice Guidelines as Topic; Retrospective Studies; Sorafenib; Survival Rate | 2013 |
Sorafenib enhances the chemotherapeutic efficacy of S-1 against hepatocellular carcinoma through downregulation of transcription factor E2F-1.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Dose-Response Relationship, Drug; Down-Regulation; Drug Combinations; Drug Synergism; E2F1 Transcription Factor; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Liver Neoplasms; Male; Mice; Mice, Inbred NOD; Mice, SCID; Niacinamide; Oxonic Acid; Phenylurea Compounds; Real-Time Polymerase Chain Reaction; Sorafenib; Tegafur; Thymidylate Synthase | 2013 |
Liver tumors and loco-regional therapy.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Evidence-Based Medicine; Hepatectomy; Humans; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Neoplasm Staging; Niacinamide; Palliative Care; Phenylurea Compounds; Sorafenib | 2013 |
Optimal timing of combining sorafenib with locoregional treatments in patients with advanced hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Administration Schedule; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Radiotherapy, Adjuvant; Sorafenib; Yttrium Radioisotopes | 2013 |
α-Fetoprotein promoter-driven Cre/LoxP-switched RNA interference for hepatocellular carcinoma tissue-specific target therapy.
Topics: alpha-Fetoproteins; Animals; Autophagy-Related Protein 5; Carcinoma, Hepatocellular; Cell Line, Tumor; Disease Models, Animal; Gene Expression Regulation, Neoplastic; Gene Order; Gene Silencing; Genetic Vectors; Homologous Recombination; Humans; Liver Neoplasms; Male; Mice; Microtubule-Associated Proteins; Niacinamide; Organ Specificity; Phenylurea Compounds; Promoter Regions, Genetic; RNA Interference; Sorafenib; Tumor Burden | 2013 |
MicroRNA-216a/217-induced epithelial-mesenchymal transition targets PTEN and SMAD7 to promote drug resistance and recurrence of liver cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Humans; In Vitro Techniques; Liver Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Signal Transduction; Smad7 Protein; Sorafenib; Transforming Growth Factor beta; Up-Regulation | 2013 |
Sorafenib enhances radiation-induced apoptosis in hepatocellular carcinoma by inhibiting STAT3.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Chemoradiotherapy; Cyclin D1; Humans; Inhibitor of Apoptosis Proteins; Liver Neoplasms; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-bcl-2; Radiation Tolerance; RNA Interference; Sorafenib; STAT3 Transcription Factor; Survivin | 2013 |
Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib.
Topics: Aminopyridines; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Everolimus; Humans; Imidazoles; Indoles; Kidney Neoplasms; Liver Neoplasms; Mechanistic Target of Rapamycin Complex 1; Morpholines; Multiprotein Complexes; Niacinamide; Phenylurea Compounds; Phosphoinositide-3 Kinase Inhibitors; Pyrimidines; Pyrroles; Quinolines; Signal Transduction; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases | 2013 |
Hepatocellular carcinoma and sorafenib: too many resistance mechanisms?
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib | 2013 |
Comparative efficacy of sorafenib versus best supportive care in recurrent hepatocellular carcinoma after liver transplantation: a case-control study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Case-Control Studies; Cohort Studies; Disease Progression; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome; Young Adult | 2013 |
Iron-dependent cell death of hepatocellular carcinoma cells exposed to sorafenib.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Death; Cell Line, Tumor; Cell Survival; Cyclohexylamines; Deferoxamine; Extracellular Signal-Regulated MAP Kinases; Humans; Iron; Iron Regulatory Protein 2; Liver Neoplasms; MAP Kinase Kinase Kinases; MAP Kinase Signaling System; Niacinamide; Oxidative Stress; Phenylenediamines; Phenylurea Compounds; Protein Kinase Inhibitors; raf Kinases; RNA Interference; Siderophores; Sorafenib | 2013 |
Sorafenib combined with transarterial chemoembolization for the treatment of advanced hepatocellular carcinoma: a large-scale multicenter study of 222 patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Diarrhea; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Retrospective Studies; ROC Curve; Sorafenib; Treatment Outcome; Young Adult | 2013 |
[Molecular targeted agent for hepatocellular carcinoma].
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Sorafenib | 2012 |
Expression of SLC22A1 variants may affect the response of hepatocellular carcinoma and cholangiocarcinoma to sorafenib.
Topics: Amino Acid Sequence; Animals; Antineoplastic Agents; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biopsy; Carcinoma, Hepatocellular; Cell Line, Tumor; Cells, Cultured; Cholangiocarcinoma; Female; Humans; In Vitro Techniques; Liver Neoplasms; Molecular Sequence Data; Niacinamide; Oocytes; Organic Cation Transporter 1; Pharmacogenetics; Phenylurea Compounds; Polymorphism, Single Nucleotide; Sorafenib; Treatment Outcome; Xenopus laevis | 2013 |
Sorafenib enhances proteasome inhibitor-induced cell death via inactivation of Akt and stress-activated protein kinases.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Death; Cell Line, Tumor; Down-Regulation; Drug Synergism; Humans; Leupeptins; Liver Neoplasms; Molecular Targeted Therapy; Niacinamide; Oligopeptides; Phenylurea Compounds; Proteasome Inhibitors; Protein Kinase Inhibitors; Protein Kinases; Proto-Oncogene Proteins c-akt; Signal Transduction; Sorafenib | 2014 |
Selection and management of hepatocellular carcinoma patients with sorafenib: recommendations and opinions from an Italian liver unit.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Diarrhea; Dose-Response Relationship, Drug; Fibrosis; Hepatitis B; Hepatitis C; Humans; Hypertension; Italy; Liver Cirrhosis; Liver Neoplasms; Middle Aged; Niacinamide; Patient Selection; Phenylurea Compounds; Sorafenib; Weight Loss | 2013 |
Field practice studies on sorafenib: lessons in systemic treatment of hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Sorafenib | 2013 |
Combining celecoxib with sorafenib synergistically inhibits hepatocellular carcinoma cells in vitro.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Celecoxib; Cell Proliferation; Dinoprostone; Drug Synergism; Fluorescent Antibody Technique; Humans; In Vitro Techniques; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyrazoles; Sorafenib; Sulfonamides; Tumor Cells, Cultured | 2013 |
Heterogeneous sensitivity of hepatocellular carcinoma to sorafenib revealed by the short-term culture of tumor fragments.
Topics: Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Female; Humans; Immunoblotting; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Niacinamide; Phenylurea Compounds; Phosphorylation; Sorafenib; Tumor Cells, Cultured | 2013 |
Education and imaging: Hepatobiliary and pancreatic: Volume-perfusion CT for monitoring therapy for hepatocellular carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Monitoring; Female; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib; Tomography, X-Ray Computed | 2013 |
Integrating sorafenib into an algorithm for the management of post-transplant hepatocellular carcinoma recurrence.
Topics: Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Liver Transplantation; Male; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Sorafenib | 2013 |
Molecular determinants of outcome in sorafenib-treated patients with hepatocellular carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Disease-Free Survival; Extracellular Signal-Regulated MAP Kinases; Female; Gene Dosage; Genes, myc; Humans; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-met; Retrospective Studies; Sorafenib; Treatment Outcome | 2013 |
Assessment of response to sorafenib in advanced hepatocellular carcinoma using perfusion computed tomography: results of a pilot study.
Topics: Aged; Aged, 80 and over; alpha-Fetoproteins; Antineoplastic Agents; Carcinoma, Hepatocellular; Cohort Studies; Feasibility Studies; Female; Humans; Liver; Liver Neoplasms; Male; Middle Aged; Multidetector Computed Tomography; Neovascularization, Pathologic; Niacinamide; Perfusion Imaging; Phenylurea Compounds; Pilot Projects; Prospective Studies; Regional Blood Flow; Sorafenib; Treatment Outcome | 2013 |
Antiproliferative effects of sorafenib and pegylated IFN‑α2b on human liver cancer cells in vitro and in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Caspase 3; Cell Line, Tumor; Cell Proliferation; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Microvessels; Niacinamide; Phenylurea Compounds; Polyethylene Glycols; Recombinant Proteins; Sorafenib | 2013 |
The evolving landscape of therapeutic drug development for hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Epigenesis, Genetic; ErbB Receptors; Fibroblast Growth Factors; Humans; Liver Neoplasms; Neovascularization, Pathologic; Niacinamide; Oncogene Protein v-akt; Phenylurea Compounds; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-met; Signal Transduction; Sorafenib; TOR Serine-Threonine Kinases | 2013 |
Sorafenib and entecavir: the dioscuri of treatment for advanced hepatocellular carcinoma?
Topics: Aged; Antineoplastic Agents; Antiviral Agents; Carcinoma, Hepatocellular; Female; Guanine; Hepatitis B; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Time Factors; Treatment Outcome | 2013 |
Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Diarrhea; Disease Progression; Female; Hand-Foot Syndrome; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Multivariate Analysis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Retrospective Studies; Sorafenib; Time Factors; Treatment Outcome | 2013 |
Targeted therapy for human hepatic carcinoma cells using folate-functionalized polymeric micelles loaded with superparamagnetic iron oxide and sorafenib in vitro.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Survival; Drug Carriers; Drug Delivery Systems; Ferrocyanides; Folic Acid; Hep G2 Cells; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Magnetite Nanoparticles; Micelles; Microscopy, Electron, Transmission; Niacinamide; Phenylurea Compounds; Sorafenib | 2013 |
Efficacy of using cancer stem cell markers in isolating and characterizing liver cancer stem cells.
Topics: AC133 Antigen; alpha-Fetoproteins; Antigens, CD; Antigens, Neoplasm; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Adhesion Molecules; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Epithelial Cell Adhesion Molecule; Gene Expression Profiling; Glycoproteins; Humans; Hyaluronan Receptors; Liver Neoplasms; Neoplastic Stem Cells; Niacinamide; Peptides; Phenylurea Compounds; Real-Time Polymerase Chain Reaction; Sorafenib; Thy-1 Antigens | 2013 |
Pharmacokinetic interaction between sorafenib and prednisolone in a patient with hepatocellular carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biotransformation; Carcinoma, Hepatocellular; Drug Eruptions; Drug Interactions; Drug Monitoring; Female; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Prednisolone; Sorafenib; Stomatitis; Treatment Outcome | 2013 |
Sorafenib and HDAC inhibitors synergize with TRAIL to kill tumor cells.
Topics: Animals; bcl-2-Associated X Protein; bcl-Associated Death Protein; Carcinoma, Hepatocellular; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspase 3; Caspase 9; Cell Line, Tumor; Drug Synergism; fas Receptor; Female; Hep G2 Cells; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Liver Neoplasms; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Ribosomal Protein S6 Kinases, 70-kDa; Sorafenib; TNF-Related Apoptosis-Inducing Ligand; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2013 |
Radiosensitivity enhancement of human hepatocellular carcinoma cell line SMMC-7721 by sorafenib through the MEK/ERK signal pathway.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; DNA Repair; Extracellular Signal-Regulated MAP Kinases; Humans; Liver Neoplasms; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase Kinases; Niacinamide; Phenylurea Compounds; Phosphorylation; Proto-Oncogene Proteins c-akt; Radiation-Sensitizing Agents; Sorafenib | 2013 |
Pre-transplant utilization of sorafenib is not associated with increased complications after liver transplantation.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Graft Survival; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib | 2013 |
Hepatocellular carcinoma treated by sorafenib with complete radiological response according to mRECIST criteria: could we stop the treatment? About four cases.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Dose-Response Relationship, Drug; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Radiography; Sorafenib; Treatment Outcome | 2014 |
[Suppression of the growth of subcutaneous transplanted human liver cancer and lung metastasis in nude mice treated by sorafenib combined with fluorouracil].
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; DNA Topoisomerases, Type II; Drug Synergism; Drug Therapy, Combination; Extracellular Signal-Regulated MAP Kinases; Fluorouracil; Humans; Liver Neoplasms; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Sorafenib; Tumor Burden | 2013 |
Safety of liver resection for hepatocellular carcinoma after sorafenib therapy: a multicenter case-matched study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Blood Transfusion; Carcinoma, Hepatocellular; Case-Control Studies; Combined Modality Therapy; Female; Follow-Up Studies; Hepatectomy; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Postoperative Complications; Prognosis; Sorafenib; Survival Rate; Young Adult | 2013 |
Antiangiogenic therapy promoted metastasis of hepatocellular carcinoma by suppressing host-derived interleukin-12b in mouse models.
Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Dendritic Cells; Diphosphonates; Heterografts; Humans; Imidazoles; Immunosuppression Therapy; Indoles; Interleukin-12 Subunit p40; Killer Cells, Natural; Liver Neoplasms; Lung Neoplasms; Macrophages; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Knockout; Mice, Nude; Neoplasm Transplantation; Neoplastic Cells, Circulating; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Zoledronic Acid | 2013 |
Recombinant human acid sphingomyelinase as an adjuvant to sorafenib treatment of experimental liver cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Death; Cell Line, Tumor; Cell Proliferation; Chemotherapy, Adjuvant; Female; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Mice; Mice, Inbred BALB C; Mice, SCID; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Recombinant Proteins; Signal Transduction; Sorafenib; Sphingolipids; Sphingomyelin Phosphodiesterase; Subcutaneous Tissue; Survival Analysis; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
Sorafenib enhances proteasome inhibitor-mediated cytotoxicity via inhibition of unfolded protein response and keratin phosphorylation.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Death; Cell Line, Tumor; Drug Synergism; Endoplasmic Reticulum Stress; Humans; Keratins; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Phosphorylation; Proteasome Inhibitors; Sorafenib; Ubiquitination; Unfolded Protein Response | 2013 |
Aspirin minimized the pro-metastasis effect of sorafenib and improved survival by up-regulating HTATIP2 in hepatocellular carcinoma.
Topics: Acetyltransferases; Animals; Aspirin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 2; Disease Models, Animal; Epithelial-Mesenchymal Transition; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Hep G2 Cells; Humans; Liver Neoplasms; Male; Mice; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Sorafenib; Transcription Factors; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
[Clinical observation of transcatheter arterial chemoembolization plus sorafenib in the treatment of advanced hepatocellular carcinoma with different types of portal vein tumor thrombosis].
Topics: Adult; Antineoplastic Agents; Carcinoma, Hepatocellular; Embolization, Therapeutic; Female; Hepatic Artery; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Portal Vein; Retrospective Studies; Sorafenib; Thrombosis | 2013 |
Hepatocellular carcinoma: perspective of an oncologist.
Topics: Antineoplastic Agents; Attitude of Health Personnel; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Medical Oncology; Niacinamide; Phenylurea Compounds; Sorafenib | 2013 |
Sorafenib sensitizes hepatocellular carcinoma cell to cisplatin via suppression of Wnt/β-catenin signaling.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Female; Humans; Liver Neoplasms; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Sorafenib; Wnt Signaling Pathway; Xenograft Model Antitumor Assays | 2013 |
Concurrent versus sequential sorafenib therapy in combination with radiation for hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Clinical Trials as Topic; Combined Modality Therapy; DNA Breaks, Double-Stranded; Gamma Rays; Gene Expression; Hindlimb; Histones; Humans; Liver Neoplasms; Mice; Mice, Nude; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Radiation Tolerance; Sorafenib; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
PKI-587 and sorafenib alone and in combination on inhibition of liver cancer stem cell proliferation.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Therapy, Combination; Humans; Liver Neoplasms; MAP Kinase Signaling System; Morpholines; Neoplastic Stem Cells; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins p21(ras); raf Kinases; Signal Transduction; Sorafenib; TOR Serine-Threonine Kinases; Triazines | 2013 |
Long-term treatment of hepatocellular carcinoma with sorafenib.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib; Time Factors | 2013 |
Novel combination of sorafenib and celecoxib provides synergistic anti-proliferative and pro-apoptotic effects in human liver cancer cells.
Topics: Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Celecoxib; Cell Line, Tumor; Cell Proliferation; DNA Primers; Drug Synergism; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; In Situ Nick-End Labeling; Liver Neoplasms; Microarray Analysis; Niacinamide; Phenylurea Compounds; Pyrazoles; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Sorafenib; Sulfonamides | 2013 |
Actionable gene expression-based patient stratification for molecular targeted therapy in hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cluster Analysis; Female; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; RNA, Messenger; Sorafenib; Transcriptome | 2013 |
Postprogression survival of patients with advanced hepatocellular carcinoma: rationale for second-line trial design.
Topics: Aged; Carcinoma, Hepatocellular; Disease Progression; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prospective Studies; Radiography; Randomized Controlled Trials as Topic; Sorafenib; Survival Analysis; Treatment Outcome | 2013 |
Efficacy of sorafenib in patients with hepatocellular carcinoma refractory to transcatheter arterial chemoembolization.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Cisplatin; Disease Progression; Female; Humans; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Survival Rate; Time Factors; Treatment Outcome | 2014 |
Regulation of accumulation and function of myeloid derived suppressor cells in different murine models of hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Movement; Cell Proliferation; Diethylnitrosamine; Disease Models, Animal; Granulocyte-Macrophage Colony-Stimulating Factor; Heterografts; Humans; Liver Neoplasms; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Myeloid Cells; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-myc; Sorafenib | 2013 |
Worse outcome of sorafenib therapy associated with ascites and Child-Pugh score in advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Ascites; Carcinoma, Hepatocellular; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Retrospective Studies; Sorafenib; Time Factors; Young Adult | 2013 |
Small-intestinal hemorrhage caused by treatment with sorafenib for hepatocellular carcinoma and diagnosed by capsule endoscopy.
Topics: Aged, 80 and over; Antineoplastic Agents; Capsule Endoscopy; Carcinoma, Hepatocellular; Female; Gastrointestinal Hemorrhage; Humans; Intestine, Small; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib | 2013 |
Cyclin G1 expands liver tumor-initiating cells by Sox2 induction via Akt/mTOR signaling.
Topics: Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cisplatin; Cyclin G1; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Heterografts; Humans; Liver Neoplasms; Male; Mice; Mice, SCID; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Transplantation; Neoplastic Stem Cells; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-akt; Signal Transduction; Sorafenib; SOXB1 Transcription Factors; TOR Serine-Threonine Kinases | 2013 |
Synergistic antitumour activity of sorafenib in combination with tetrandrine is mediated by reactive oxygen species (ROS)/Akt signaling.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzylisoquinolines; Carcinoma, Hepatocellular; Drug Synergism; HCT116 Cells; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Niacinamide; Oncogene Protein v-akt; Phenylurea Compounds; Reactive Oxygen Species; Signal Transduction; Sorafenib; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2013 |
Clinical outcome of sorafenib treatment in patients with advanced hepatocellular carcinoma refractory to hepatic arterial infusion chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Drug Evaluation; Female; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Retrospective Studies; Sorafenib; Survival Analysis; Treatment Failure; Treatment Outcome | 2013 |
Early prediction of response to sorafenib in patients with advanced hepatocellular carcinoma: the role of dynamic contrast enhanced ultrasound.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Disease-Free Survival; Endpoint Determination; Feasibility Studies; Female; Humans; Liver; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Prospective Studies; Retrospective Studies; Sorafenib; Survival Rate; Treatment Outcome; Ultrasonography | 2013 |
Ventricular thrombosis during sorafenib therapy for advanced hepatocellular carcinoma.
Topics: Aged; Anticoagulants; Antineoplastic Agents; Carcinoma, Hepatocellular; Enoxaparin; Heart Diseases; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Protein Kinase Inhibitors; Risk Factors; Sorafenib; Thrombosis; Treatment Outcome; Ultrasonography; Ventricular Dysfunction | 2013 |
Potentiating the efficacy of molecular targeted therapy for hepatocellular carcinoma by inhibiting the insulin-like growth factor pathway.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Cells, Cultured; Checkpoint Kinase 2; Drug Resistance, Neoplasm; Drug Synergism; Humans; Indoles; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Receptor, IGF Type 1; RNA Interference; Signal Transduction; Sorafenib; Sunitinib; Xenograft Model Antitumor Assays | 2013 |
Severe hypoglycemia due to possible interaction between glibenclamide and sorafenib in a patient with hepatocellular carcinoma.
Topics: Aged; Antineoplastic Agents; Blood Glucose; Carcinoma, Hepatocellular; Diabetes Mellitus, Type 2; Drug Interactions; Glyburide; Humans; Hypoglycemia; Hypoglycemic Agents; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Severity of Illness Index; Sorafenib | 2013 |
Prognostic impact of pERK in advanced hepatocellular carcinoma patients treated with sorafenib.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Immunohistochemistry; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Phosphorylation; Prognosis; PTEN Phosphohydrolase; Ribosomal Protein S6 Kinases, 70-kDa; Sorafenib; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-2; Young Adult | 2013 |
[Analysis of factors affecting the duration of treatment with sorafenib in patients with hepatocellular carcinoma].
Topics: Adult; Aged; alpha-Fetoproteins; Antineoplastic Agents; Biomarkers; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Precursors; Prothrombin; Sorafenib; Time Factors | 2013 |
In a 'real-world', clinic-based community setting, sorafenib dose of 400 mg/day is as effective as standard dose of 800 mg/day in patients with advanced hepatocellular carcimona, with better tolerance and similar survival.
Topics: Aged; alpha-Fetoproteins; Antineoplastic Agents; British Columbia; Carcinoma, Hepatocellular; Disease Progression; Dose-Response Relationship, Drug; Female; Humans; Insurance Coverage; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Retrospective Studies; Sorafenib; Survival Rate; Treatment Outcome | 2013 |
MicroRNA-34a targets Bcl-2 and sensitizes human hepatocellular carcinoma cells to sorafenib treatment.
Topics: Adult; Aged; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Female; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Male; MicroRNAs; Middle Aged; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-bcl-2; Sorafenib | 2014 |
[Complete response after sorafenib therapy plus zoledronic acid for advanced hepatocellular carcinoma with bone metastasis - a case report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Hepatocellular; Diphosphonates; Humans; Imidazoles; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Remission Induction; Sorafenib; Zoledronic Acid | 2013 |
Sorafenib alone versus sorafenib combined with transarterial chemoembolization for advanced-stage hepatocellular carcinoma: results of propensity score analyses.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Disease Progression; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Propensity Score; Retrospective Studies; Sorafenib; Survival Rate; Treatment Outcome | 2013 |
Histone deacetylase 3 participates in self-renewal of liver cancer stem cells through histone modification.
Topics: Antineoplastic Agents; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Gene Expression; Gene Knockdown Techniques; Histone Deacetylase Inhibitors; Histone Deacetylases; Histones; Humans; Liver Neoplasms; Neoplastic Stem Cells; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib | 2013 |
Sorafenib for advanced hepatocellular carcinoma (HCC): impact of rationing in the United Kingdom.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Cohort Studies; Female; Health Care Rationing; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasms, Multiple Primary; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; United Kingdom; Young Adult | 2013 |
Extending survival with the use of targeted therapy in the treatment of hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver; Liver Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Survival Rate | 2013 |
[The analysis of the efficacy and safety of combined transarterial chemoembolization with sorafenib in patients with large hepatocellular carcinoma].
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Treatment Outcome | 2013 |
Schedule-dependent antitumor effects of 5-fluorouracil combined with sorafenib in hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Flow Cytometry; Fluorouracil; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Signal Transduction; Sorafenib | 2013 |
Complete regression following sorafenib in unresectable, locally advanced hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Italy; Liver Neoplasms; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2013 |
Discovery of novel Src homology region 2 domain-containing phosphatase 1 agonists from sorafenib for the treatment of hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Catalytic Domain; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Mice; Models, Molecular; Niacinamide; Phenylurea Compounds; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Random Allocation; Sorafenib; STAT3 Transcription Factor; Xenograft Model Antitumor Assays | 2014 |
Complete pathological regression of hepatocellular carcinoma with portal vein thrombosis treated with sorafenib.
Topics: Aged; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Portal Vein; Protein Kinase Inhibitors; Remission Induction; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome; Venous Thrombosis | 2013 |
Feasibility of sorafenib combined with local radiotherapy in advanced hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Feasibility Studies; Female; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Radiation Dosage; Radiotherapy; Sorafenib | 2013 |
Reciprocal regulation by TLR4 and TGF-β in tumor-initiating stem-like cells.
Topics: AC133 Antigen; Adaptor Proteins, Signal Transducing; Animals; Antigens, CD; Antineoplastic Agents; Base Sequence; Carcinoma, Hepatocellular; Cell Separation; Drug Resistance, Neoplasm; Flow Cytometry; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Glycoproteins; Homeodomain Proteins; Humans; Inhibitory Concentration 50; Liver Neoplasms; Mice; Mice, Inbred NOD; Mice, SCID; Mice, Transgenic; Nanog Homeobox Protein; Neoplastic Stem Cells; Niacinamide; Oncogenes; Peptides; Phenylurea Compounds; Phosphoproteins; RNA-Binding Proteins; RNA, Small Interfering; Signal Transduction; Sirolimus; Smad Proteins; Sorafenib; Spheroids, Cellular; Toll-Like Receptor 4; Transcription Factors; Transcriptional Activation; Transforming Growth Factor beta; Tumor Burden; Tumor Cells, Cultured; Xenograft Model Antitumor Assays; YAP-Signaling Proteins | 2013 |
Towards new tools for refined management of patients with advanced hepatocellular carcinoma under systemic therapy: some enthusiasm with a word of caution.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Sorafenib; Ultrasonography | 2013 |
Brivanib and FOLFOX in hepatocellular carcinoma: finding the common themes among negative trials.
Topics: Alanine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Female; Humans; Liver Neoplasms; Male; Niacinamide; Palliative Care; Phenylurea Compounds; Protein Kinase Inhibitors; Salvage Therapy; Sorafenib; Triazines | 2013 |
Discovery of potent, orally active compounds of tyrosine kinase and serine/threonine-protein kinase inhibitor with anti-tumor activity in preclinical assays.
Topics: Antineoplastic Agents; Biological Products; Liver Neoplasms; Medicine, Traditional; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Sorafenib | 2012 |
Improving immunotherapy of hepatocellular carcinoma (HCC) using dendritic cells (DC) engineered to express IL-12 in vivo.
Topics: Adenoviridae; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Cytokines; Cytotoxicity, Immunologic; Dendritic Cells; Humans; Immunotherapy; Interleukin-12; Liver Neoplasms; Mice; Mice, Inbred C3H; Niacinamide; Phenylurea Compounds; Sorafenib | 2014 |
Predictors of non-adherence to systemic oral therapy for advanced hepatocellular carcinoma.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Databases, Factual; Female; Humans; Insurance Claim Review; Liver Neoplasms; Male; Medication Adherence; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sex Factors; Sorafenib | 2013 |
In vitro demonstration of synergy/additivity between (188)rhenium and sorafenib on hepatoma lines: preliminary results.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line; Cell Line, Tumor; Combined Modality Therapy; Humans; In Vitro Techniques; Liver Neoplasms; Mice; Niacinamide; Phenylurea Compounds; Radioisotopes; Rhenium; Sorafenib | 2013 |
Complete radiographic remission with 5-fluorouracil and leucovorin after sorafenib failure in hepatocellular carcinoma: is there a role for chemotherapy after targeted agents?
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Hepatocellular; Fatal Outcome; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoplasms, Multiple Primary; Niacinamide; Phenylurea Compounds; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome; Vitamin B Complex | 2013 |
Systemic cytotoxic chemotherapy of patients with advanced hepatocellular carcinoma in the era of sorafenib nonavailability.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Hepatocellular; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Doxorubicin; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Retrospective Studies; Risk Factors; Signal Transduction; Sorafenib; Time Factors; Treatment Outcome | 2014 |
Pro-angiogenic cytokines for prediction of outcomes in patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Angiopoietin-2; Antineoplastic Agents; Carcinoma, Hepatocellular; Cohort Studies; Cytokines; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib | 2013 |
Sorafenib in combination with transarterial chemoembolization and radiofrequency ablation in the treatment for unresectable hepatocellular carcinoma.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Disease Progression; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib | 2013 |
Correlation of skin toxicity and hypertension with clinical benefit in advanced hepatocellular carcinoma patients treated with sorafenib.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Hypertension; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Receptors, Vascular Endothelial Growth Factor; Skin; Sorafenib | 2013 |
Therapeutic potential of the translation inhibitor silvestrol in hepatocellular cancer.
Topics: Analysis of Variance; Animals; Apoptosis; Blotting, Western; Caspase 3; Caspase 7; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Synergism; Eukaryotic Initiation Factor-4A; Humans; Inhibitory Concentration 50; Liver Neoplasms; Membrane Potential, Mitochondrial; Mice; Mice, Nude; Niacinamide; Peptide Chain Initiation, Translational; Phenylurea Compounds; Sirolimus; Sorafenib; Survival Analysis; Triterpenes; Xenograft Model Antitumor Assays | 2013 |
Sorafenib treatment is save and may affect survival of recurrent hepatocellular carcinoma after liver transplantation.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Female; Humans; Immunosuppressive Agents; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Postoperative Complications; Retrospective Studies; Sirolimus; Sorafenib; Survival Rate; Treatment Outcome | 2013 |
Notch3 inhibition enhances sorafenib cytotoxic efficacy by promoting GSK3b phosphorylation and p21 down-regulation in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Down-Regulation; Drug Synergism; Female; Gene Knockdown Techniques; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Hep G2 Cells; Humans; Liver Neoplasms; Mice; Mice, Inbred NOD; Mice, SCID; Niacinamide; Phenylurea Compounds; Phosphorylation; Receptor, Notch3; Receptors, Notch; Signal Transduction; Sorafenib; Xenograft Model Antitumor Assays | 2013 |
Exposure-toxicity relationship of sorafenib in Japanese patients with renal cell carcinoma and hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Exanthema; Female; Hand-Foot Syndrome; Humans; Hypertension; Kidney Neoplasms; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Young Adult | 2014 |
Efficacy of sorafenib monotherapy versus sorafenib-based loco-regional treatments in advanced hepatocellular carcinoma.
Topics: alpha-Fetoproteins; Carcinoma, Hepatocellular; Cohort Studies; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2013 |
Serum response factor induces epithelial to mesenchymal transition with resistance to sorafenib in hepatocellular carcinoma.
Topics: Aged; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Serum Response Factor; Sorafenib; Vimentin | 2014 |
The blood neutrophil-to-lymphocyte ratio predicts survival in patients with advanced hepatocellular carcinoma receiving sorafenib.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Follow-Up Studies; Humans; Liver Neoplasms; Lymphocytes; Male; Middle Aged; Neoplasm Staging; Neutrophils; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib; Survival Rate | 2013 |
A synthetic dsRNA, as a TLR3 pathwaysynergist, combined with sorafenib suppresses HCC in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Caspase 8; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Gene Expression; Humans; Interferon-gamma; Liver Neoplasms; Male; NF-kappa B; Niacinamide; Phenylurea Compounds; Rats; RNA, Double-Stranded; Sorafenib; Toll-Like Receptor 3; Transcriptional Activation; Tumor Burden | 2013 |
Allosteric MEK1/2 inhibitor refametinib (BAY 86-9766) in combination with sorafenib exhibits antitumor activity in preclinical murine and rat models of hepatocellular carcinoma.
Topics: Allografts; Allosteric Regulation; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Diphenylamine; Drug Synergism; Female; Heterografts; Humans; Liver Neoplasms; Mice, Nude; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Niacinamide; Phenylurea Compounds; Rats; Sorafenib; Sulfonamides | 2013 |
Letter: Sorafenib hepatotoxicity may be enhanced during treatment of advanced hepatocellular carcinoma in HIV-infected patients.
Topics: Adult; Antineoplastic Agents; Antiretroviral Therapy, Highly Active; Carcinoma, Hepatocellular; Chemical and Drug Induced Liver Injury; Drug Interactions; HIV Infections; Humans; Liver Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib | 2013 |
Stimulatory effects of sorafenib on human non‑small cell lung cancer cells in vitro by regulating MAPK/ERK activation.
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Butadienes; Carcinoma, Non-Small-Cell Lung; Cell Cycle Checkpoints; Cell Line, Tumor; Cyclin D1; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Humans; Liver Neoplasms; MAP Kinase Kinase Kinases; Niacinamide; Nitriles; Phenylurea Compounds; Phosphorylation; Signal Transduction; Sorafenib | 2014 |
The germline BIM deletion polymorphism is not associated with the treatment efficacy of sorafenib in patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Carcinoma, Hepatocellular; Disease-Free Survival; Female; Gene Deletion; Genotype; Germ-Line Mutation; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Membrane Proteins; Middle Aged; Niacinamide; Phenylurea Compounds; Polymorphism, Single Nucleotide; Predictive Value of Tests; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Sorafenib; Treatment Outcome | 2013 |
Changes of cytokines in patients with liver cirrhosis and advanced hepatocellular carcinoma treated by sorafenib.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cytokines; Female; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib | 2014 |
A retrospective analysis of two different sequences of therapy lines for advanced kidney cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Everolimus; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib; Survival Rate; TOR Serine-Threonine Kinases | 2013 |
Effects of sorafenib combined with chemoembolization and radiofrequency ablation for large, unresectable hepatocellular carcinomas.
Topics: Adult; Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Treatment Outcome | 2013 |
Differential effects of sorafenib on liver versus tumor fibrosis mediated by stromal-derived factor 1 alpha/C-X-C receptor type 4 axis and myeloid differentiation antigen-positive myeloid cell infiltration in mice.
Topics: Animals; Carbon Tetrachloride; Carcinoma, Hepatocellular; CD11b Antigen; Cell Line, Tumor; Cell Movement; Chemokine CXCL12; Disease Models, Animal; Hepatocyte Growth Factor; Liver; Liver Cirrhosis; Liver Neoplasms; Male; Mice; Mice, Inbred C3H; Mice, Knockout; Myeloid Cells; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins; Receptors, Chemokine; Receptors, CXCR4; Receptors, Platelet-Derived Growth Factor; Signal Transduction; Sorafenib | 2014 |
The Enhanced metastatic potential of hepatocellular carcinoma (HCC) cells with sorafenib resistance.
Topics: Animals; Antineoplastic Agents; ATP-Binding Cassette Transporters; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Heterografts; Humans; Liver Neoplasms; Mice; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Sorafenib | 2013 |
High risk of lung metastasis after resection of hepatocellular carcinoma more than 7 cm in diameter.
Topics: Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Female; Hepatectomy; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Prognosis; Retrospective Studies; Risk; Sorafenib; Survival Rate | 2014 |
SC-60, a dimer-based sorafenib derivative, shows a better anti-hepatocellular carcinoma effect than sorafenib in a preclinical hepatocellular carcinoma model.
Topics: Apoptosis; Carcinoma, Hepatocellular; Catalytic Domain; Cell Line, Tumor; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Point Mutation; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Signal Transduction; Sorafenib; STAT3 Transcription Factor; Xenograft Model Antitumor Assays | 2014 |
Hepatocellular carcinoma enhancement on contrast-enhanced CT and MR imaging: response assessment after treatment with sorafenib: preliminary results.
Topics: Aged; Carcinoma, Hepatocellular; Contrast Media; Female; Humans; Iopamidol; Liver Neoplasms; Magnetic Resonance Imaging; Male; Meglumine; Middle Aged; Niacinamide; Organometallic Compounds; Phenylurea Compounds; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
[A case of tuberculosis that occurred during treatment of hepatocellular carcinoma with sorafenib].
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Sorafenib; Tuberculosis, Pulmonary | 2013 |
Connexin-dependent gap junction enhancement is involved in the synergistic effect of sorafenib and all-trans retinoic acid on HCC growth inhibition.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Communication; Cell Line, Tumor; Cell Proliferation; Connexins; Drug Synergism; Gap Junctions; Glycyrrhetinic Acid; Hep G2 Cells; Humans; Liver Neoplasms; Niacinamide; Oleic Acids; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Tretinoin | 2014 |
Long-term survival of patients with hepatocellular carcinoma with inferior vena cava tumor thrombus treated with sorafenib combined with transarterial chemoembolization: report of two cases and literature review.
Topics: Carcinoma, Hepatocellular; Catheterization, Peripheral; Chemoembolization, Therapeutic; Combined Modality Therapy; Hepatic Artery; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib; Thrombosis; Vena Cava, Inferior | 2014 |
Effects of miR-193a and sorafenib on hepatocellular carcinoma cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; MicroRNAs; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-met; Sorafenib; Urokinase-Type Plasminogen Activator | 2013 |
BCRP/ABCG2 inhibition sensitizes hepatocellular carcinoma cells to sorafenib.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport, Active; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Gefitinib; Hep G2 Cells; Humans; Liver Neoplasms; MAP Kinase Signaling System; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Quinazolines; RNA, Small Interfering; Sorafenib | 2013 |
[Three cases of recurrent hepatocellular carcinoma treated with laparoscopic hepatectomy after oral administration of sorafenib].
Topics: Administration, Oral; Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Female; Hepatectomy; Humans; Laparoscopy; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Recurrence; Sorafenib | 2013 |
[A case of a patient with hepatocellular carcinoma who achieved long-term survival after repeated transcatheter arterial chemoembolization and sorafenib therapy].
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Embolization, Therapeutic; Hepatectomy; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Recurrence; Sorafenib; Time Factors; Treatment Outcome | 2013 |
Epirubicin, cisplatin, 5-FU combination chemotherapy in sorafenib-refractory metastatic hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Disease Progression; Drug Resistance, Neoplasm; Epirubicin; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Retrospective Studies; Sorafenib; Time Factors; Treatment Outcome | 2014 |
YC-1 enhances the anti-tumor activity of sorafenib through inhibition of signal transducer and activator of transcription 3 (STAT3) in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Humans; Immunohistochemistry; Indazoles; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Niacinamide; Phenylurea Compounds; Sorafenib; STAT3 Transcription Factor; Xenograft Model Antitumor Assays | 2014 |
Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network.
Topics: Adenocarcinoma; Adenocarcinoma, Follicular; Adenoma, Oxyphilic; Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Carcinoma; Carcinoma, Neuroendocrine; Carcinoma, Papillary; Disease-Free Survival; Female; Humans; Indoles; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Piperidines; Pleural Neoplasms; Protein-Tyrosine Kinases; Pyrroles; Quinazolines; Retrospective Studies; Sorafenib; Sunitinib; Thyroid Cancer, Papillary; Thyroid Neoplasms; Treatment Outcome | 2014 |
Efficiency and side effects of sorafenib therapy for advanced hepatocellular carcinoma: a retrospective study by the anatolian society of medical oncology.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Maximum Tolerated Dose; Medical Oncology; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Retrospective Studies; Sorafenib; Survival Rate; Turkey | 2013 |
Liver abscess in advanced hepatocellular carcinoma after sorafenib treatment.
Topics: Anti-Bacterial Agents; Antineoplastic Agents; Carcinoma, Hepatocellular; Clostridium; Clostridium Infections; Humans; Liver Abscess; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Tomography, X-Ray Computed | 2014 |
Pro-apoptotic Sorafenib signaling in murine hepatocytes depends on malignancy and is associated with PUMA expression in vitro and in vivo.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Carcinoma, Hepatocellular; Caspase 3; Cell Cycle; Cells, Cultured; Gene Expression Regulation, Neoplastic; Hepatocytes; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred C57BL; Niacinamide; Phenylurea Compounds; Sorafenib; Tumor Suppressor Proteins | 2014 |
Upregulation of HIF-2α induced by sorafenib contributes to the resistance by activating the TGF-α/EGFR pathway in hepatocellular carcinoma cells.
Topics: Animals; Antineoplastic Agents; Basic Helix-Loop-Helix Transcription Factors; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Niacinamide; Phenylurea Compounds; Quinazolines; Signal Transduction; Sorafenib; Transforming Growth Factor alpha; Up-Regulation | 2014 |
Simultaneous inhibition of tumor growth and angiogenesis for resistant hepatocellular carcinoma by co-delivery of sorafenib and survivin small hairpin RNA.
Topics: Animals; Carcinoma, Hepatocellular; Cell Cycle; Drug Resistance, Neoplasm; Humans; Inhibitor of Apoptosis Proteins; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Repressor Proteins; RNA, Small Interfering; Sorafenib; Survivin | 2014 |
Comparison of systems for assessment of post-therapeutic response to sorafenib for hepatocellular carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Prognosis; Retrospective Studies; Sorafenib; Survival Rate; Treatment Outcome | 2014 |
Multimodality therapy and liver transplantation for hepatocellular carcinoma: a 14-year prospective analysis of outcomes.
Topics: Aged; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Hepatectomy; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Prospective Studies; Protein Kinase Inhibitors; Radiopharmaceuticals; Radiotherapy, Adjuvant; Risk Factors; Sorafenib; Time Factors; Treatment Outcome; Yttrium Radioisotopes | 2014 |
VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: the ALICE-1 study.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Proliferation; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Genotype; Humans; Liver Neoplasms; Lymphangiogenesis; Male; Middle Aged; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Retrospective Studies; Sorafenib; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor C; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factor Receptor-3 | 2014 |
Is intra-patient sorafenib dose re-escalation safe and tolerable in patients with advanced hepatocellular carcinoma?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib | 2014 |
Synergistic interaction between the HDAC inhibitor, MPT0E028, and sorafenib in liver cancer cells in vitro and in vivo.
Topics: Animals; Carcinoma, Hepatocellular; Caspases; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Models, Animal; Drug Synergism; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Signal Transduction; Sorafenib; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
The role of LDH serum levels in predicting global outcome in HCC patients treated with sorafenib: implications for clinical management.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Disease Management; Female; Humans; L-Lactate Dehydrogenase; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Retrospective Studies; Sorafenib; Treatment Outcome | 2014 |
NORE1A sensitises cancer cells to sorafenib-induced apoptosis and indicates hepatocellular carcinoma prognosis.
Topics: Adaptor Proteins, Signal Transducing; Adolescent; Adult; Aged; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Biomarkers, Tumor; Blotting, Western; Carcinoma, Hepatocellular; Female; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Monomeric GTP-Binding Proteins; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Real-Time Polymerase Chain Reaction; Sorafenib; Young Adult | 2014 |
Sorafenib for Egyptian patients with advanced hepatocellular carcinoma; single center experience.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Disease-Free Survival; Drug Administration Schedule; Egypt; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Multivariate Analysis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Retrospective Studies; Sorafenib; Treatment Outcome | 2014 |
Predictive role of the neutrophil-to-lymphocyte ratio in patients with advanced hepatocellular carcinoma receiving sorafenib.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Lymphocytes; Neutrophils; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib | 2014 |
Predictors of survival in patients with established cirrhosis and hepatocellular carcinoma treated with sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chi-Square Distribution; Female; Humans; Kaplan-Meier Estimate; Liver Cirrhosis; Liver Neoplasms; Logistic Models; Magnetic Resonance Imaging; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Risk Factors; Sorafenib; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
Management of sorafenib-related adverse events: a clinician's perspective.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Disease Management; Fatigue; Gastrointestinal Diseases; Hand-Foot Syndrome; Humans; Hypertension; Kidney Neoplasms; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Physicians; Sorafenib | 2014 |
Management of common adverse events in patients treated with sorafenib: nurse and pharmacist perspective.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Disease Management; Fatigue; Gastrointestinal Diseases; Hand-Foot Syndrome; Humans; Hypertension; Kidney Neoplasms; Liver Neoplasms; Niacinamide; Nurses; Patient Education as Topic; Pharmacists; Phenylurea Compounds; Randomized Controlled Trials as Topic; Sorafenib | 2014 |
[Efficacy and safety of combination of sorafenib and transarterial chemoembolization in treating primary hepatocellular carcinoma].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Treatment Outcome | 2014 |
[Diagnostics and treatment of hepatocellular carcinoma: trends in the Netherlands in the period 2003-2011].
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Combined Modality Therapy; Embolization, Therapeutic; Female; Hospitalization; Humans; Liver Neoplasms; Male; Middle Aged; Netherlands; Niacinamide; Palliative Care; Phenylurea Compounds; Retrospective Studies; Sorafenib | 2014 |
[Liver cancer: progress in diagnosis and treatments. Topics: VI. Progress in treatments of liver cancer; 4. Molecularly targeted agent].
Topics: Antineoplastic Agents; Humans; Liver Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Sorafenib | 2014 |
Sorafenib blocks the HIF-1α/VEGFA pathway, inhibits tumor invasion, and induces apoptosis in hepatoma cells.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cobalt; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Liver Neoplasms; Niacinamide; Phenylurea Compounds; RNA, Messenger; Sorafenib; Vascular Endothelial Growth Factor A | 2014 |
Rhodotorula mucilaginosa skin infection in a patient treated with sorafenib.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Dermatomycoses; Humans; Liver Neoplasms; Male; Niacinamide; Opportunistic Infections; Phenylurea Compounds; Rhodotorula; Sorafenib | 2015 |
Effect of BZG-4000, a novel multi-targeted kinase inhibitor with potent anticancer activity, on a hepatocellular carcinoma xenograft model.
Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Administration Schedule; Gene Expression; Hepatocytes; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Platelet Endothelial Cell Adhesion Molecule-1; Protein Kinase Inhibitors; Sorafenib; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2014 |
Sorafenib inhibition of hepatic stellate cell proliferation in tumor microenvironment of hepatocellular carcinoma: a study of the sorafenib mechanisms.
Topics: Actins; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Proliferation; Cell Survival; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Hepatic Stellate Cells; Humans; Liver Neoplasms; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Sorafenib; Tumor Microenvironment | 2014 |
Alternative mammalian target of rapamycin (mTOR) signal activation in sorafenib-resistant hepatocellular carcinoma cells revealed by array-based pathway profiling.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Phosphorylation; Proteomics; Signal Transduction; Sorafenib; TOR Serine-Threonine Kinases | 2014 |
Alternative Response Criteria (Choi, European association for the study of the liver, and modified Response Evaluation Criteria in Solid Tumors [RECIST]) Versus RECIST 1.1 in patients with advanced hepatocellular carcinoma treated with sorafenib.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Cohort Studies; Female; Humans; Liver; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Sorafenib; Survival Rate; Tomography, X-Ray Computed | 2014 |
Human and mouse VEGFA-amplified hepatocellular carcinomas are highly sensitive to sorafenib treatment.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP-Binding Cassette Sub-Family B Member 4; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Female; Hepatocytes; Humans; Liver Neoplasms; Macrophages; Male; Mice, Knockout; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Tumor Burden; Vascular Endothelial Growth Factor A | 2014 |
Hepatocellular carcinoma: concomitant sorafenib promotes necrosis after radiofrequency ablation--propensity score matching analysis.
Topics: Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Catheter Ablation; Combined Modality Therapy; Contrast Media; Female; Humans; Liver Neoplasms; Male; Middle Aged; Necrosis; Niacinamide; Phenylurea Compounds; Propensity Score; Retrospective Studies; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
Synergistic inhibition of HCC and liver cancer stem cell proliferation by targeting RAS/RAF/MAPK and WNT/β-catenin pathways.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Disease Models, Animal; Drug Synergism; Female; Humans; Immunophenotyping; Inhibitor of Apoptosis Proteins; Liver Neoplasms; Mice; Mitogen-Activated Protein Kinases; Neoplastic Stem Cells; Niacinamide; Phenotype; Phenylurea Compounds; Poly(ADP-ribose) Polymerases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins p21(ras); raf Kinases; Signal Transduction; Sorafenib; Sulfonamides; Survivin; Wnt Signaling Pathway | 2014 |
Sorafenib for the treatment of recurrent hepatocellular carcinoma after liver transplantation: does mTOR inhibitors association augment toxicity?
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Interactions; Everolimus; Humans; Immunosuppressive Agents; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sirolimus; Sorafenib; TOR Serine-Threonine Kinases; Treatment Outcome | 2014 |
RNAi screening with shRNAs against histone methylation-related genes reveals determinants of sorafenib sensitivity in hepatocellular carcinoma cells.
Topics: Antineoplastic Agents; Blotting, Western; Carcinoma, Hepatocellular; DNA Methylation; Drug Resistance, Neoplasm; Hep G2 Cells; High-Throughput Screening Assays; Histones; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; RNA, Small Interfering; Sorafenib | 2014 |
Cabozantinib suppresses tumor growth and metastasis in hepatocellular carcinoma by a dual blockade of VEGFR2 and MET.
Topics: Anilides; Animals; Antineoplastic Agents; Blotting, Western; Carcinoma, Hepatocellular; Cell Proliferation; Drug Resistance, Neoplasm; Female; Humans; Immunohistochemistry; Liver Neoplasms; Mice; Mice, Inbred BALB C; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-met; Pyridines; Sorafenib; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2014 |
Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prospective Studies; Skin; Sorafenib | 2014 |
Inhibition of Akt reverses the acquired resistance to sorafenib by switching protective autophagy to autophagic cell death in hepatocellular carcinoma.
Topics: Autophagy; Carcinoma, Hepatocellular; Cell Proliferation; Drug Resistance, Neoplasm; Hep G2 Cells; Humans; Liver Neoplasms; Molecular Targeted Therapy; Niacinamide; Oncogene Protein v-akt; Phenylurea Compounds; RNA, Small Interfering; Sorafenib | 2014 |
Identification of Zinc Finger, MYM-type 2 (ZMYM2) as a regulator of sorafenib resistance in hepatocellular carcinoma cell lines.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; DNA-Binding Proteins; Drug Resistance, Neoplasm; Gene Library; Hep G2 Cells; Humans; Liver Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; RNA, Small Interfering; Sorafenib; Transcription Factors | 2014 |
Poly(lactide-co-glycolide) microspheres for MRI-monitored transcatheter delivery of sorafenib to liver tumors.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Catheterization; Cell Line, Tumor; Cell Proliferation; Drug Carriers; Liver; Liver Neoplasms; Magnetic Resonance Imaging; Male; Microspheres; Niacinamide; Phenylurea Compounds; Polyglactin 910; Protein Kinase Inhibitors; Rats; Rats, Sprague-Dawley; Sorafenib | 2014 |
Development of hypertension within 2 weeks of initiation of sorafenib for advanced hepatocellular carcinoma is a predictor of efficacy.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Female; Humans; Hypertension; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib | 2015 |
Yttrium-90 radioembolization vs sorafenib for intermediate-locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Case-Control Studies; Cause of Death; Embolization, Therapeutic; Female; Humans; Italy; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Propensity Score; Retrospective Studies; Sorafenib; Yttrium Radioisotopes | 2015 |
Response of patients with metastatic uveal melanoma to combined treatment with fotemustine and sorafenib.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Liver Neoplasms; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Neoplasm Staging; Niacinamide; Nitrosourea Compounds; Organophosphorus Compounds; Phenylurea Compounds; Retrospective Studies; Sorafenib; Survival Rate; Uveal Neoplasms | 2014 |
A preclinical evaluation of a novel multikinase inhibitor, SKLB-329, as a therapeutic agent against hepatocellular carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Drug Evaluation, Preclinical; Endothelial Cells; Female; Human Umbilical Vein Endothelial Cells; Humans; Inhibitory Concentration 50; Liver; Liver Neoplasms; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrazoles; Signal Transduction; Sorafenib; Zebrafish | 2014 |
Sorafenib metabolism is significantly altered in the liver tumor tissue of hepatocellular carcinoma patient.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Cytochrome P-450 CYP3A; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Glucuronosyltransferase; Humans; Liver; Liver Neoplasms; Male; Microsomes, Liver; Middle Aged; Niacinamide; Phenylurea Compounds; Reproducibility of Results; Sorafenib; UDP-Glucuronosyltransferase 1A9 | 2014 |
Identification of responders to sorafenib in hepatocellular carcinoma: is tumor volume measurement the way forward?
Topics: Aged; Biomarkers, Tumor; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Prospective Studies; Retrospective Studies; Sorafenib; Survival Rate; Tomography, X-Ray Computed | 2014 |
Pretreatment MicroRNA Level and Outcome in Sorafenib-treated Hepatocellular Carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Biopsy, Fine-Needle; Carcinoma, Hepatocellular; Female; Gene Expression; Humans; Liver; Liver Neoplasms; Male; MicroRNAs; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Survival Analysis | 2014 |
Sorafenib increases efficacy of vorinostat against human hepatocellular carcinoma through transduction inhibition of vorinostat-induced ERK/NF-κB signaling.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Synergism; Humans; Hydroxamic Acids; Liver Neoplasms; Liver Neoplasms, Experimental; Male; MAP Kinase Signaling System; Mice; Mice, Nude; NF-kappaB-Inducing Kinase; Niacinamide; Phenylurea Compounds; Protein Serine-Threonine Kinases; Sorafenib; Vorinostat; Xenograft Model Antitumor Assays | 2014 |
Sorafenib continuation after first disease progression could reduce disease flares and provide survival benefits in patients with hepatocellular carcinoma: a pilot retrospective study.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Disease-Free Survival; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pilot Projects; Protein Kinase Inhibitors; Retrospective Studies; Sorafenib; Survival Analysis; Withholding Treatment | 2014 |
Sorafenib combined with transarterial chemoembolization versus transarterial chemoembolization alone for advanced-stage hepatocellular carcinoma: a propensity score matching study.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Diarrhea; Female; Gastrointestinal Hemorrhage; Hepatic Encephalopathy; Humans; Hypertension; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Niacinamide; Outcome Assessment, Health Care; Phenylurea Compounds; Propensity Score; Proportional Hazards Models; Retrospective Studies; Skin Diseases; Sorafenib | 2014 |
Valproic acid overcomes transforming growth factor-β-mediated sorafenib resistance in hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Liver Neoplasms; MAP Kinase Signaling System; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-akt; Signal Transduction; Sorafenib; Transforming Growth Factor beta; Treatment Failure; Treatment Outcome; Valproic Acid | 2014 |
Important role of CYP2J2 in protein kinase inhibitor degradation: a possible role in intratumor drug disposition and resistance.
Topics: Benzamides; Carcinoma, Hepatocellular; Cell Line, Tumor; Cytochrome P-450 CYP1A1; Cytochrome P-450 CYP1B1; Cytochrome P-450 CYP2J2; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dasatinib; Hep G2 Cells; Humans; Imatinib Mesylate; Indoles; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; Sorafenib; Sunitinib; Thiazoles | 2014 |
Inhibition of autophagy significantly enhances combination therapy with sorafenib and HDAC inhibitors for human hepatoma cells.
Topics: Acetylation; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Carcinoma, Hepatocellular; Cell Cycle Checkpoints; Cell Proliferation; Dose-Response Relationship, Drug; Drug Synergism; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Liver Neoplasms; Membrane Proteins; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; RNA Interference; Sorafenib; Transfection; Tumor Suppressor Protein p53; Vorinostat | 2014 |
Clinical features associated with radiological response to sorafenib in unresectable hepatocellular carcinoma: a large multicenter study in Japan.
Topics: Adult; Aged; Aged, 80 and over; alpha-Fetoproteins; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease-Free Survival; Female; Humans; Japan; Liver Neoplasms; Logistic Models; Male; Middle Aged; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Prognosis; Retrospective Studies; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
Hand, foot and scrotal blisters in a patient with cancer receiving oral chemotherapy.
Topics: Administration, Oral; Administration, Topical; Adrenal Cortex Hormones; Aged; Blister; Carcinoma, Hepatocellular; Drug Eruptions; Foot Dermatoses; Hand Dermatoses; Humans; Liver Neoplasms; Lung Neoplasms; Male; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Scrotum; Severity of Illness Index; Sorafenib; Syndrome; Treatment Outcome | 2014 |
The emerging questionable benefit of sorafenib as a neo-adjuvant in HCC patients treated with Y-90 radioembolization pending liver transplantation.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Embolization, Therapeutic; Female; Humans; Liver Neoplasms; Liver Transplantation; Male; Niacinamide; Phenylurea Compounds; Sorafenib; Yttrium Radioisotopes | 2014 |
Autocrine vascular endothelial growth factor signaling promotes cell proliferation and modulates sorafenib treatment efficacy in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Autocrine Communication; Carcinoma, Hepatocellular; Cell Proliferation; Disease Models, Animal; Female; Heterografts; Humans; Kaplan-Meier Estimate; Liver; Liver Neoplasms; MAP Kinase Signaling System; Mice; Mice, Inbred NOD; Mice, SCID; Niacinamide; Phenylurea Compounds; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Survival Rate; Treatment Outcome; Vascular Endothelial Growth Factor A | 2014 |
Enhanced therapeutic efficacy of combined use of sorafenib and transcatheter arterial chemoembolization for treatment of advanced hepatocellular carcinoma.
Topics: Adult; Alopecia; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Retrospective Studies; Severity of Illness Index; Sorafenib; Venous Thromboembolism | 2014 |
A quantitative HPLC-UV method for determination of serum sorafenib and sorafenib N-oxide and its application in hepatocarcinoma patients.
Topics: Acetonitriles; Carcinoma, Hepatocellular; Chromatography, High Pressure Liquid; Drug Stability; Humans; Ions; Liver Neoplasms; Mass Spectrometry; Niacinamide; Oxides; Phenylurea Compounds; Reference Standards; Solubility; Solutions; Sorafenib; Ultraviolet Rays | 2014 |
Antagonism of sorafenib and regorafenib actions by platelet factors in hepatocellular carcinoma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Blood Platelets; Carcinoma, Hepatocellular; Cell Movement; Cell Proliferation; Enzyme Activation; Epidermal Growth Factor; Extracellular Signal-Regulated MAP Kinases; Hep G2 Cells; Humans; Insulin-Like Growth Factor I; Liver Neoplasms; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Pyridines; Signal Transduction; Sorafenib; Time Factors | 2014 |
Overall survival in response to sorafenib versus radiotherapy in unresectable hepatocellular carcinoma with major portal vein tumor thrombosis: propensity score analysis.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Cohort Studies; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Middle Aged; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Portal Vein; Prognosis; Propensity Score; Proportional Hazards Models; Radiotherapy; Retrospective Studies; Sorafenib; Survival Rate; Treatment Outcome; Venous Thrombosis | 2014 |
VEGFA genomic amplification tailors treatment of HCCs with sorafenib.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Sorafenib; Vascular Endothelial Growth Factor A | 2014 |
Multidisciplinary management of hepatocellular carcinoma in clinical practice.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease-Free Survival; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Severity of Illness Index; Sorafenib | 2014 |
Evaluation of the impact of transient interruption of antiangiogenic treatment using ultrasound-based techniques in a murine model of hepatocellular carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Disease Models, Animal; Humans; Liver Neoplasms; Mice; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Sorafenib; Ultrasonography; Vascular Endothelial Growth Factor Receptor-2 | 2014 |
Transferrin targeted core-shell nanomedicine for combinatorial delivery of doxorubicin and sorafenib against hepatocellular carcinoma.
Topics: Apoptosis; Carcinoma, Hepatocellular; Doxorubicin; Drug Carriers; Drug Delivery Systems; Hep G2 Cells; Humans; Liver Neoplasms; Nanomedicine; Niacinamide; Phenylurea Compounds; Sorafenib; Transferrin | 2014 |
Expression and function analysis of mitotic checkpoint genes identifies TTK as a potential therapeutic target for human hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Cell Cycle Proteins; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Genes, cdc; Hep G2 Cells; Hepatocytes; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Sorafenib | 2014 |
Sorafenib and triptolide as combination therapy for hepatocellular carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; Caspase 3; Caspase 7; Cell Line, Tumor; Cell Proliferation; Cell Survival; Diterpenes; Drug Synergism; Epoxy Compounds; Humans; Liver Neoplasms; Liver Neoplasms, Experimental; Mice; Mice, Nude; Models, Biological; NF-kappa B p50 Subunit; Niacinamide; Organophosphates; Phenanthrenes; Phenylurea Compounds; Prodrugs; Signal Transduction; Sincalide; Sorafenib; Translational Research, Biomedical; Xenograft Model Antitumor Assays | 2014 |
Synergistic inhibitory effect of hyperbaric oxygen combined with sorafenib on hepatoma cells.
Topics: Apoptosis; Carcinoma, Hepatocellular; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cisplatin; Drug Synergism; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Hyperbaric Oxygenation; Liver Neoplasms; MicroRNAs; Niacinamide; Oligonucleotide Array Sequence Analysis; Phenylurea Compounds; Real-Time Polymerase Chain Reaction; Sorafenib; Tumor Stem Cell Assay | 2014 |
Oncolytic immunotherapy using recombinant vaccinia virus GLV-1h68 kills sorafenib-resistant hepatocellular carcinoma efficiently.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Death; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Genetic Engineering; Humans; Liver Neoplasms; Niacinamide; Oncolytic Virotherapy; Phenylurea Compounds; Sorafenib; Vaccinia virus; Viral Plaque Assay; Virus Replication | 2014 |
Feasibility of global miRNA analysis from fine-needle biopsy FFPE material in patients with hepatocellular carcinoma treated with sorafenib.
Topics: Antineoplastic Agents; Biopsy, Fine-Needle; Carcinoma, Hepatocellular; Feasibility Studies; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genetic Markers; Humans; Liver Neoplasms; Male; MicroRNAs; Middle Aged; Niacinamide; Oligonucleotide Array Sequence Analysis; Phenylurea Compounds; Real-Time Polymerase Chain Reaction; Retrognathia; Sorafenib; Treatment Outcome | 2015 |
Therapeutic effects of artesunate in hepatocellular carcinoma: repurposing an ancient antimalarial agent.
Topics: Animals; Antineoplastic Agents; Artemisinins; Artesunate; Carcinoma, Hepatocellular; Cell Death; Dose-Response Relationship, Drug; Drug Repositioning; Drug Resistance, Neoplasm; Drug Therapy, Combination; Humans; Liver Neoplasms; Liver Neoplasms, Experimental; Male; Mice; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome; Tumor Cells, Cultured; Unfolded Protein Response | 2014 |
Can sorafenib increase survival for recurrent hepatocellular carcinoma after liver transplantation? A pilot study.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Palliative Care; Phenylurea Compounds; Pilot Projects; Proportional Hazards Models; Retrospective Studies; Sorafenib; Survival Rate; Treatment Outcome | 2014 |
Invasive hepatocellular carcinoma with recurrent pulmonary embolism: use of AngioVac cannula thrombectomy device for mechanical aspiration.
Topics: Adult; Angiography; Anticoagulants; Antineoplastic Agents; Carcinoma, Hepatocellular; Enoxaparin; Fatal Outcome; Heart Atria; Humans; Liver Neoplasms; Male; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Pulmonary Embolism; Sorafenib; Suction; Thrombectomy; Vena Cava, Inferior | 2014 |
Earlier presentation and application of curative treatments in hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Child; Child, Preschool; Comorbidity; Early Diagnosis; Female; Humans; Incidence; Infant; Liver; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; SEER Program; Sorafenib; United States; Young Adult | 2014 |
[Two cases of successful sorafenib retreatment with the addition of steroid therapy following sorafenib-induced erythema multiforme in two patients with hepatocellular carcinoma].
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Erythema Multiforme; Female; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Prednisolone; Sorafenib | 2014 |
The combination of HTATIP2 expression and microvessel density predicts converse survival of hepatocellular carcinoma with or without sorafenib.
Topics: Acetyltransferases; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Microvessels; Middle Aged; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib; Transcription Factors; Young Adult | 2014 |
Genetic screen identifies suppressor of morphogenesis in genitalia-1 (SMG-1) as a modulator of sorafenib resistance in hepatocellular carcinoma cell lines.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Genome, Human; Hep G2 Cells; Hepatocytes; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Protein Serine-Threonine Kinases; RNA, Small Interfering; Signal Transduction; Sorafenib | 2014 |
A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Disease Progression; Epirubicin; Female; Fluorouracil; Humans; Infusions, Intra-Arterial; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Portal Vein; Retrospective Studies; Sorafenib; Treatment Outcome; Venous Thrombosis | 2015 |
Restoration of miR-193b sensitizes Hepatitis B virus-associated hepatocellular carcinoma to sorafenib.
Topics: 3' Untranslated Regions; Apoptosis; Carcinoma, Hepatocellular; Caspase 3; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Genes, Reporter; Hep G2 Cells; Hepatitis B virus; Humans; Liver Neoplasms; MicroRNAs; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Time Factors; Transfection | 2014 |
MicroRNA-425-3p predicts response to sorafenib therapy in patients with hepatocellular carcinoma.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Case-Control Studies; Hep G2 Cells; Humans; Liver Neoplasms; MicroRNAs; Niacinamide; Phenylurea Compounds; Sorafenib | 2015 |
SC-2001 overcomes STAT3-mediated sorafenib resistance through RFX-1/SHP-1 activation in hepatocellular carcinoma.
Topics: Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Models, Animal; DNA-Binding Proteins; Drug Resistance, Neoplasm; Drug Synergism; Humans; Liver Neoplasms; Male; Mice; Niacinamide; Phenylurea Compounds; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Pyrroles; Regulatory Factor X Transcription Factors; Regulatory Factor X1; Sorafenib; STAT3 Transcription Factor; Transcription Factors; Tumor Stem Cell Assay; Xenograft Model Antitumor Assays | 2014 |
Hepatic stellate cell coculture enables sorafenib resistance in Huh7 cells through HGF/c-Met/Akt and Jak2/Stat3 pathways.
Topics: Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Coculture Techniques; Culture Media; Drug Resistance, Neoplasm; Enzyme-Linked Immunosorbent Assay; Hepatic Stellate Cells; Humans; Janus Kinase 2; Ligands; Liver Neoplasms; Microscopy, Fluorescence; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-met; Signal Transduction; Sorafenib; STAT3 Transcription Factor | 2014 |
Network features suggest new hepatocellular carcinoma treatment strategies.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Prognosis; Signal Transduction; Sorafenib; Systems Biology; Transcriptome | 2014 |
Use of VEGFR-2 targeted ultrasound contrast agent for the early evaluation of response to sorafenib in a mouse model of hepatocellular carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Contrast Media; Humans; Liver Neoplasms; Mice; Microbubbles; Neoplasm Transplantation; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Random Allocation; Software; Sorafenib; Treatment Outcome; Ultrasonography; Vascular Endothelial Growth Factor Receptor-2 | 2015 |
Early changes in apparent diffusion coefficient as an indicator of response to sorafenib in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Diffusion Magnetic Resonance Imaging; Hep G2 Cells; Humans; Liver Neoplasms; Liver Neoplasms, Experimental; Male; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Time Factors; Xenograft Model Antitumor Assays | 2014 |
miR‑222 regulates sorafenib resistance and enhance tumorigenicity in hepatocellular carcinoma.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Liver Neoplasms; Male; MAP Kinase Signaling System; MicroRNAs; Middle Aged; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Sorafenib | 2014 |
Sorafenib-associated psoriasiform eruption in a patient with hepatocellular carcinoma.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Eruptions; Humans; Liver Neoplasms; Lung Neoplasms; Male; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Sorafenib | 2014 |
Potential synergistic anti-tumor activity between lenalidomide and sorafenib in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; CD8-Positive T-Lymphocytes; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Humans; Immunologic Factors; Interferon-gamma; Lenalidomide; Liver Neoplasms; Mice; Niacinamide; Phenylurea Compounds; Sorafenib; T-Lymphocyte Subsets; Thalidomide | 2014 |
Knockout of ADAM10 enhances sorafenib antitumor activity of hepatocellular carcinoma in vitro and in vivo.
Topics: ADAM Proteins; ADAM10 Protein; Amyloid Precursor Protein Secretases; Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gene Knockout Techniques; Genetic Vectors; Hep G2 Cells; Humans; In Vitro Techniques; Liver Neoplasms; Membrane Proteins; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Plasmids; RNA, Small Interfering; Sorafenib | 2014 |
Reproducible complete remission of advanced hepatocellular carcinoma with sorafenib in combination with clopidogrel.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Clopidogrel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Platelet Aggregation Inhibitors; Receptors, Vascular Endothelial Growth Factor; Remission Induction; Sorafenib; Ticlopidine; Time Factors; Tomography, X-Ray Computed | 2014 |
The relationship of kinase insert domain receptor gene polymorphisms and clinical outcome in advanced hepatocellular carcinoma patients treated with sorafenib.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Enzyme-Linked Immunosorbent Assay; Female; Genotype; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Polymorphism, Single Nucleotide; Retrospective Studies; Sorafenib; Survival Rate; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-2 | 2014 |
Tolerability of single-agent sorafenib in the treatment of elderly patients with hepatocellular carcinoma (HCC).
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib | 2014 |
BIRC6 promotes hepatocellular carcinogenesis: interaction of BIRC6 with p53 facilitating p53 degradation.
Topics: Animals; Apoptosis; Carcinogenesis; Carcinoma, Hepatocellular; Cell Cycle; Cell Proliferation; Humans; Inhibitor of Apoptosis Proteins; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib; Tumor Suppressor Protein p53; Ubiquitination | 2015 |
Synergistic effects of β-catenin inhibitors and sorafenib in hepatoma cells.
Topics: Animals; Antineoplastic Agents; beta Catenin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dose-Response Relationship, Drug; Drug Synergism; Liver Neoplasms; Mice; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Signal Transduction; Sorafenib | 2014 |
In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer.
Topics: Activating Transcription Factor 2; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Female; Humans; Liver Neoplasms; Liver Neoplasms, Experimental; Male; MAP Kinase Signaling System; Mice; Mice, Inbred C57BL; Mitogen-Activated Protein Kinase 14; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; RNA Interference; RNA, Small Interfering; Signal Transduction; Sorafenib; Xenograft Model Antitumor Assays | 2014 |
Sorafenib overcomes the chemoresistance in HBx-expressing hepatocellular carcinoma cells through down-regulation of HBx protein stability and suppresses HBV gene expression.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Carcinoma, Hepatocellular; Cisplatin; Dose-Response Relationship, Drug; Down-Regulation; Drug Resistance, Neoplasm; Etoposide; Gene Expression Regulation, Viral; Hep G2 Cells; Hepatitis B virus; Humans; Interferon-alpha; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Promoter Regions, Genetic; Proteasome Endopeptidase Complex; Protein Stability; Sorafenib; Trans-Activators; Transfection; Viral Regulatory and Accessory Proteins | 2014 |
2-Methoxyestradiol synergizes with sorafenib to suppress hepatocellular carcinoma by simultaneously dysregulating hypoxia-inducible factor-1 and -2.
Topics: 2-Methoxyestradiol; Active Transport, Cell Nucleus; Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Basic Helix-Loop-Helix Transcription Factors; Carcinoma, Hepatocellular; Cell Proliferation; Cyclin D1; Dose-Response Relationship, Drug; Drug Synergism; Estradiol; Hep G2 Cells; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Isoenzymes; L-Lactate Dehydrogenase; Lactate Dehydrogenase 5; Liver Neoplasms; Male; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; RNA Interference; Signal Transduction; Sorafenib; Time Factors; Transfection; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2014 |
Combination of macrophage inflammatory protein 1 alpha with existing therapies to enhance the antitumor effects on murine hepatoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Chemokine CCL3; Chemoradiotherapy; Liver Neoplasms; Male; Mice; Mice, Inbred C3H; Niacinamide; Phenylurea Compounds; Radiation Tolerance; Radiation-Sensitizing Agents; Sorafenib; Treatment Outcome | 2015 |
Efficacy of sorafenib in intermediate-stage hepatocellular carcinoma patients refractory to transarterial chemoembolization.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Disease Progression; Drug Resistance, Neoplasm; Female; Hepatic Artery; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Retrospective Studies; Sorafenib; Treatment Outcome | 2014 |
Comparison of standard-dose and half‑dose sorafenib therapy on clinical outcome in patients with unresectable hepatocellular carcinoma in field practice: A propensity score matching analysis.
Topics: Aged; Carcinoma, Hepatocellular; Disease-Free Survival; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Propensity Score; Sorafenib; Treatment Outcome | 2014 |
Metformin inhibits the invasion of human hepatocellular carcinoma cells and enhances the chemosensitivity to sorafenib through a downregulation of the ERK/JNK-mediated NF-κB-dependent pathway that reduces uPA and MMP-9 expression.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; MAP Kinase Kinase 4; Matrix Metalloproteinase 9; Metformin; Neoplasm Invasiveness; NF-kappa B; Niacinamide; Phenylurea Compounds; Signal Transduction; Sorafenib; Urokinase-Type Plasminogen Activator | 2014 |
Indicators of sorafenib efficacy in patients with advanced hepatocellular carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Disease-Free Survival; Female; Hand-Foot Syndrome; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Retrospective Studies; Risk Factors; Sorafenib; Time Factors; Treatment Outcome; Tumor Burden | 2014 |
Flavonoid-enriched apple fraction AF4 induces cell cycle arrest, DNA topoisomerase II inhibition, and apoptosis in human liver cancer HepG2 cells.
Topics: Antineoplastic Agents; Apoptosis; Caspase 3; Cell Cycle Checkpoints; Cell Proliferation; Cell Survival; DNA Fragmentation; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Flavonoids; Hep G2 Cells; Humans; Liver Neoplasms; Malus; Niacinamide; Phenylurea Compounds; Sorafenib; Topoisomerase II Inhibitors | 2014 |
The isothiocyanate erucin abrogates telomerase in hepatocellular carcinoma cells in vitro and in an orthotopic xenograft tumour model of HCC.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; DNA Damage; Gene Expression; Hep G2 Cells; Humans; Immunoblotting; Isothiocyanates; Kidney; Liver; Liver Neoplasms; Mice, Nude; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-bcl-2; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Sorafenib; Telomerase; Tumor Burden; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2014 |
Hepatocellular Carcinoma Management in Nonalcoholic Fatty Liver Disease Patients: Applicability of the BCLC Staging System.
Topics: Ablation Techniques; Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Hepatectomy; Humans; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Niacinamide; Non-alcoholic Fatty Liver Disease; Phenylurea Compounds; Prognosis; Retrospective Studies; Sorafenib; Survival Rate; Tumor Burden | 2016 |
Prognostic Scoring Models for Patients Undergoing Sorafenib Treatment for Advanced Stage Hepatocellular Carcinoma in Real-Life Practice.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Female; Humans; Liver Neoplasms; Male; Middle Aged; Models, Statistical; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Risk Assessment; Sorafenib; Survival Rate | 2017 |
Clinical outcomes and prognostic factors of patients with advanced hepatocellular carcinoma treated with sorafenib as first-line therapy: a Korean multicenter study.
Topics: Adult; Aged; alpha-Fetoproteins; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Prognosis; Republic of Korea; Retrospective Studies; Sorafenib; Treatment Outcome | 2014 |
Pre-treatment neutrophil-to-lymphocyte ratio affects survival in patients with advanced hepatocellular carcinoma treated with sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Lymphocytes; Male; Middle Aged; Neutrophils; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Survival Rate; Treatment Outcome; Young Adult | 2014 |
Combination of individualized local control and target-specific agent to improve unresectable liver cancer managements: a matched case-control study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Retrospective Studies; Risk Factors; Sorafenib; Time Factors; Treatment Outcome | 2015 |
Anti-proliferative but not anti-angiogenic tyrosine kinase inhibitors enrich for cancer stem cells in soft tissue sarcoma.
Topics: Aldehyde Dehydrogenase 1 Family; Angiogenesis Inhibitors; Animals; Antigens, CD; Cell Line, Tumor; Cell Proliferation; Cell Survival; Female; Humans; Indazoles; Isoenzymes; Liver Neoplasms; Lung Neoplasms; Mice, Inbred NOD; Neoadjuvant Therapy; Neoplastic Stem Cells; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Retinal Dehydrogenase; Sarcoma; Sorafenib; Sulfonamides; Tissue Array Analysis; Xenograft Model Antitumor Assays | 2014 |
Safety and efficacy of transarterial chemoembolization plus sorafenib for hepatocellular carcinoma with portal venous tumour thrombus.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Dermatitis; Diarrhea; Fatigue; Female; Fever; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Portal Vein; Retrospective Studies; Sorafenib; Survival Analysis; Treatment Outcome; Venous Thrombosis | 2014 |
Occurrence of hepatocellular carcinoma upon advanced liver fibrosis thirteen years after achieving sustained virological response to hepatitis C: how long surveillance should be maintained?
Topics: Antineoplastic Agents; Antiviral Agents; Biomarkers; Biopsy; Carcinoma, Hepatocellular; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; RNA, Viral; Severity of Illness Index; Sorafenib; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Viral Load | 2015 |
RFX-1-dependent activation of SHP-1 inhibits STAT3 signaling in hepatocellular carcinoma cells.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Carcinoma, Hepatocellular; Chromatin Immunoprecipitation; DNA-Binding Proteins; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; Immunoenzyme Techniques; Liver Neoplasms; Luciferases; Male; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Promoter Regions, Genetic; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Pyrroles; Real-Time Polymerase Chain Reaction; Regulatory Factor X Transcription Factors; Regulatory Factor X1; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Signal Transduction; Sorafenib; STAT3 Transcription Factor; Transcription Factors; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2014 |
Complete response to sorafenib in a patient with recurrent hepatocellular carcinoma.
Topics: Antineoplastic Agents; Biopsy; Carcinoma, Hepatocellular; Hepatectomy; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Remission Induction; Sorafenib; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
Coupled variable selection for regression modeling of complex treatment patterns in a clinical cancer registry.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Confounding Factors, Epidemiologic; Data Interpretation, Statistical; Decision Support Techniques; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Registries; Regression Analysis; Sorafenib | 2014 |
Combinatorial immunotherapy of sorafenib and blockade of programmed death-ligand 1 induces effective natural killer cell responses against hepatocellular carcinoma.
Topics: Animals; Antibodies, Monoclonal; B7-H1 Antigen; Carcinoma, Hepatocellular; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Disease Models, Animal; Humans; Immunotherapy; Killer Cells, Natural; Liver Neoplasms; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib | 2015 |
Duration of stable disease is associated with overall survival in patients with advanced hepatocellular carcinoma treated with sorafenib.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Cohort Studies; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hospitals, University; Humans; Japan; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Retrospective Studies; Risk Assessment; Sorafenib; Statistics, Nonparametric; Survival Analysis; Survival Rate; Treatment Outcome | 2014 |
Decreased blood flow after sorafenib administration is an imaging biomarker to predict overall survival in patients with advanced hepatocellular carcinoma.
Topics: Aged; Analysis of Variance; Antineoplastic Agents; Biomarkers; Carcinoma, Hepatocellular; Cohort Studies; Disease-Free Survival; Female; Humans; Japan; Kaplan-Meier Estimate; Liver Circulation; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Prognosis; Retrospective Studies; Sorafenib; Survival Analysis; Treatment Outcome | 2014 |
Combination therapy with sorafenib and radiofrequency ablation for BCLC Stage 0-B1 hepatocellular carcinoma: a multicenter retrospective cohort study.
Topics: Adult; Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Cohort Studies; Combined Modality Therapy; Disease-Free Survival; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Treatment Outcome | 2014 |
Safety of sorafenib therapy in elderly adults with advanced hepatocellular carcinoma.
Topics: Activities of Daily Living; Adverse Drug Reaction Reporting Systems; Age Factors; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Cohort Studies; Dose-Response Relationship, Drug; Female; Humans; Liver Neoplasms; Male; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Sorafenib | 2014 |
Arsenic trioxide potentiates the anti-cancer activities of sorafenib against hepatocellular carcinoma by inhibiting Akt activation.
Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Cell Proliferation; Drug Synergism; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Liver Neoplasms; Mice; Neoplasm Proteins; Niacinamide; Oxides; Phenylurea Compounds; Proto-Oncogene Proteins c-akt; Signal Transduction; Sorafenib | 2015 |
Generation of a murine hepatic angiosarcoma cell line and reproducible mouse tumor model.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Disease Models, Animal; Gene Expression Regulation, Neoplastic; Hemangiosarcoma; Immunohistochemistry; Liver; Liver Neoplasms; Mice, Inbred C57BL; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Microscopy, Electron; Niacinamide; Oligonucleotide Array Sequence Analysis; Phenylurea Compounds; Receptor, Notch1; Reverse Transcriptase Polymerase Chain Reaction; Sorafenib; Tumor Burden | 2015 |
Validation of the criteria of transcatheter arterial chemoembolization failure or refractoriness in patients with advanced hepatocellular carcinoma proposed by the LCSGJ.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Female; Hepatic Artery; Hepatitis C; Humans; Japan; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Reproducibility of Results; Retrospective Studies; Risk Factors; Sorafenib; Treatment Failure | 2014 |
Characteristics of long-term survivors following sorafenib treatment for advanced hepatocellular carcinoma: report of a workshop at the 50th Annual Meeting of the Liver Cancer Study Group of Japan.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Drug Administration Schedule; Hepatectomy; Humans; Japan; Liver Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Salvage Therapy; Sorafenib; Survivors; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
Measurement of sorafenib plasma concentration by high-performance liquid chromatography in patients with advanced hepatocellular carcinoma: is it useful the application in clinical practice? A pilot study.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chromatography, High Pressure Liquid; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pilot Projects; Sorafenib | 2015 |
The retinoblastoma (Rb) protein regulates ferroptosis induced by sorafenib in human hepatocellular carcinoma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Cell Proliferation; Female; Humans; Liver Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Mitochondria; Necrosis; Niacinamide; Oxidative Stress; Phenylurea Compounds; Reactive Oxygen Species; Retinoblastoma Protein; Sorafenib; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2015 |
Anti-tumor activity of sorafenib in a model of a pediatric hepatocellular carcinoma.
Topics: Adult; Animals; beta Catenin; Blotting, Western; Carcinoma, Hepatocellular; Cell Proliferation; Child; Epithelial-Mesenchymal Transition; Female; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred NOD; Mice, SCID; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2015 |
Early treatment response to sorafenib for rabbit VX2 orthotic liver tumors: evaluation by quantitative contrast-enhanced ultrasound.
Topics: Animals; Contrast Media; Humans; Liver; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Rabbits; Sorafenib; Tumor Burden; Ultrasonography | 2015 |
A rare primary liver tumor that responded to sorafenib.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cholangiocarcinoma; Eukaryotic Initiation Factor-3; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-kit; Sorafenib | 2014 |
Correlation between LDH levels and response to sorafenib in HCC patients: an analysis of the ITA.LI.CA database.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; L-Lactate Dehydrogenase; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; ROC Curve; Sorafenib; Treatment Outcome | 2015 |
Oncogenic c-Myc and prothymosin-alpha protect hepatocellular carcinoma cells against sorafenib-induced apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; DNA-Binding Proteins; Dose-Response Relationship, Drug; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Precursors; Sorafenib; Thymosin; Transcription Factors | 2015 |
Sorafenib inhibits macrophage-induced growth of hepatoma cells by interference with insulin-like growth factor-1 secretion.
Topics: Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Insulin-Like Growth Factor I; Liver Neoplasms; Macrophage Activation; Macrophage Colony-Stimulating Factor; Macrophages; Niacinamide; Phenylurea Compounds; raf Kinases; Receptors, Cell Surface; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib | 2015 |
Feasibility and safety of sorafenib treatment in hepatocellular carcinoma patients with spontaneous rupture.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Chemotherapy, Adjuvant; China; Embolization, Therapeutic; Feasibility Studies; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Rupture, Spontaneous; Sorafenib; Survival Rate; Time Factors; Treatment Outcome | 2014 |
Sorafenib use in elderly patients with hepatocellular carcinoma: caution about use of platelet aggregation inhibitors.
Topics: Aged; Aged, 80 and over; Aging; Antineoplastic Agents; Asthenia; Carcinoma, Hepatocellular; Comorbidity; Drug Interactions; Drug Monitoring; Female; Follow-Up Studies; France; Hemorrhage; Humans; Incidence; Liver; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Platelet Aggregation Inhibitors; Portal Vein; Retrospective Studies; Sorafenib; Survival Analysis; Tumor Burden; Venous Thrombosis | 2015 |
Incidental tumor necrosis caused by the interventional alteration of hepatic arterial flow in patients with advanced hepatocellular carcinoma.
Topics: Adult; Antineoplastic Agents; Carcinoma, Hepatocellular; Catheterization; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Middle Aged; Necrosis; Neoplastic Cells, Circulating; Niacinamide; Phenylurea Compounds; Portal Vein; Regional Blood Flow; Sorafenib; Vascular Access Devices | 2015 |
Hepatic arterial infusion chemotherapy with cisplatin and sorafenib in hepatocellular carcinoma patients unresponsive to transarterial chemoembolization: a propensity score-based weighting.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Cisplatin; Drug Evaluation; Female; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Propensity Score; Retrospective Studies; Sorafenib; Survival Analysis; Treatment Failure | 2015 |
[Percutaneous ablation of hepatocellular carcinoma in older patients in clinical practice].
Topics: Aged; Aged, 80 and over; Alcoholism; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Diabetes Complications; Ethanol; Female; Humans; Kaplan-Meier Estimate; Liver Cirrhosis; Liver Neoplasms; Male; Neoplasms, Second Primary; Niacinamide; Phenylurea Compounds; Prospective Studies; Remission Induction; Sorafenib | 2015 |
Addition of local hepatic therapy to sorafenib in patients with advanced hepatocellular carcinoma (stage BCLC C).
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Case-Control Studies; Chemoembolization, Therapeutic; Combined Modality Therapy; Embolization, Therapeutic; Epirubicin; Ethiodized Oil; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Tumor Burden | 2014 |
Prognostic factors in patients with hepatocellular carcinoma refractory or intolerant to sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Cohort Studies; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib; Survival Rate | 2015 |
[Clinical observation of transcatheter arterial chemoembolization plus sorafenib in the treatment of hepatocellular carcinoma with portal vein tumor thrombosis].
Topics: Antineoplastic Agents; Arteries; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Portal Vein; Retrospective Studies; Sorafenib; Venous Thrombosis | 2014 |
Sorafenib therapy for hepatocellular carcinoma with extrahepatic spread: treatment outcome and prognostic factors.
Topics: Aged; Antineoplastic Agents; Antiviral Agents; Carcinoma, Hepatocellular; Disease Progression; Female; Hepatitis B, Chronic; Humans; Liver; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Radiography; Republic of Korea; Retrospective Studies; Risk Factors; Sorafenib; Treatment Outcome | 2015 |
CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Immunotherapy; Liver Neoplasms; Mice; Niacinamide; Phenylurea Compounds; Programmed Cell Death 1 Receptor; Protein Kinase Inhibitors; Receptors, CXCR4; Sorafenib; Tumor Microenvironment | 2015 |
MiR-338-3p inhibits hepatocarcinoma cells and sensitizes these cells to sorafenib by targeting hypoxia-induced factor 1α.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Cell Proliferation; Drug Resistance, Neoplasm; Fluorescent Antibody Technique; Gene Expression Regulation, Neoplastic; Humans; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Immunoenzyme Techniques; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Niacinamide; Phenylurea Compounds; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Sorafenib; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2014 |
Hepatic arterial administration of sorafenib and iodized oil effectively attenuates tumor growth and intrahepatic metastasis in rabbit VX2 hepatocellular carcinoma model.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Models, Animal; Injections, Intra-Arterial; Iodized Oil; Liver; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Rabbits; Sorafenib; Treatment Outcome | 2014 |
Sorafenib inhibits proliferation and invasion of human hepatocellular carcinoma cells via up-regulation of p53 and suppressing FoxM1.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Forkhead Box Protein M1; Forkhead Transcription Factors; Hep G2 Cells; Humans; Liver Neoplasms; Mice; Mice, Knockout; Mice, Nude; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Sorafenib; Tumor Suppressor Protein p53; Up-Regulation | 2015 |
Expression of pERK and VEGFR-2 in advanced hepatocellular carcinoma and resistance to sorafenib treatment.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Disease-Free Survival; Drug Resistance, Neoplasm; eIF-2 Kinase; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Proportional Hazards Models; Prospective Studies; Randomized Controlled Trials as Topic; Risk Assessment; Sorafenib; Survival Analysis; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-2 | 2015 |
Sorafenib-induced severe urticaria in a patient with hepatocellular cancer.
Topics: Aged; Antineoplastic Agents; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Severity of Illness Index; Sorafenib; Urticaria | 2016 |
Cutaneous metastasis from hepatocellular carcinoma after a percutaneous interventional procedure.
Topics: Adult; Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Diathermy; Ethanol; Fatal Outcome; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Needles; Neoplasm Seeding; Niacinamide; Phenylurea Compounds; Radiofrequency Therapy; Sclerosing Solutions; Skin Neoplasms; Sorafenib | 2015 |
Hepatitis B viral load predicts survival in hepatocellular carcinoma patients treated with sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antiviral Agents; Biomarkers; Carcinoma, Hepatocellular; Disease Progression; DNA, Viral; Drug Therapy, Combination; Female; Forecasting; Hepatitis B virus; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Risk Factors; Sorafenib; Survival Rate; Viral Load; Virus Activation | 2015 |
Comparison of chemoembolization with and without radiation therapy and sorafenib for advanced hepatocellular carcinoma with portal vein tumor thrombosis: a propensity score analysis.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Chemoradiotherapy; Comorbidity; Female; Humans; Incidence; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Portal Vein; Radiography; Republic of Korea; Risk Assessment; Severity of Illness Index; Sorafenib; Survival Rate; Treatment Outcome; Venous Thrombosis | 2015 |
Paracrine factors of human fetal MSCs inhibit liver cancer growth through reduced activation of IGF-1R/PI3K/Akt signaling.
Topics: Carcinoma, Hepatocellular; Cell Proliferation; Culture Media, Conditioned; Fetus; Gene Knockdown Techniques; Humans; Indoles; Liver Neoplasms; Mesenchymal Stem Cells; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Pyrroles; Receptor, IGF Type 1; Signal Transduction; Sorafenib; Sunitinib | 2015 |
MicroRNA-93 activates c-Met/PI3K/Akt pathway activity in hepatocellular carcinoma by directly inhibiting PTEN and CDKN1A.
Topics: 3' Untranslated Regions; Adult; Aged; Aged, 80 and over; Apoptosis; Binding Sites; Carcinoma, Hepatocellular; Cell Movement; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Hep G2 Cells; Humans; Liver Neoplasms; Male; MicroRNAs; Middle Aged; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinase; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-met; PTEN Phosphohydrolase; Pyrrolidinones; Quinolines; Sorafenib; Time Factors; Transfection; Up-Regulation | 2015 |
Antiviral therapy in the improvement of survival of patients with hepatitis B virus-related hepatocellular carcinoma treated with sorafenib.
Topics: Antineoplastic Agents; Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Drug Therapy, Combination; Female; Hepatitis B; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Nucleosides; Phenylurea Compounds; Prognosis; Retrospective Studies; Risk Reduction Behavior; Sorafenib; Survival Rate | 2015 |
Adjuvant sorafenib reduced mortality and prolonged overall survival and post-recurrence survival in hepatocellular carcinoma patients after curative resection: a single-center experience.
Topics: Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Combined Modality Therapy; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Postoperative Care; Retrospective Studies; Sorafenib; Survival Analysis | 2014 |
Surgical resection versus transarterial chemoembolization for BCLC stage C hepatocellular carcinoma.
Topics: Aged; alpha-Fetoproteins; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Propensity Score; Proportional Hazards Models; Serum Albumin; Sorafenib; Taiwan | 2015 |
Predictors of survival in patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib.
Topics: Aged; Analysis of Variance; Antineoplastic Agents; Carcinoma, Hepatocellular; Cohort Studies; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Italy; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Invasiveness; Neoplasm Staging; Niacinamide; Patient Selection; Phenylurea Compounds; Predictive Value of Tests; Prospective Studies; Reproducibility of Results; Risk Assessment; Sorafenib; Survival Analysis; Withholding Treatment | 2015 |
Cyproheptadine significantly improves the overall and progression-free survival of sorafenib-treated advanced HCC patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Case-Control Studies; Cyproheptadine; Disease Progression; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib | 2015 |
Survival Outcome Between Hepatic Resection and Transarterial Embolization for Hepatocellular Carcinoma More Than 10 cm: A Propensity Score Model.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Female; Hepatectomy; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Propensity Score; Retrospective Studies; Sorafenib; Survival Rate; Tumor Burden | 2015 |
A high baseline HBV load and antiviral therapy affect the survival of patients with advanced HBV-related HCC treated with sorafenib.
Topics: Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; Female; Hepatectomy; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Prognosis; Retrospective Studies; Risk Factors; Sorafenib; Survival Analysis; Viral Load | 2015 |
Personalized dosimetry with intensification using 90Y-loaded glass microsphere radioembolization induces prolonged overall survival in hepatocellular carcinoma patients with portal vein thrombosis.
Topics: Aged; Carcinoma, Hepatocellular; Embolization, Therapeutic; Europe; False Positive Reactions; Female; Glass; Humans; Kaplan-Meier Estimate; Liver; Liver Neoplasms; Male; Microspheres; Middle Aged; Niacinamide; Phenylurea Compounds; Portal Vein; Radiometry; Retrospective Studies; Sorafenib; Thrombosis; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; Treatment Outcome; Yttrium Radioisotopes | 2015 |
Antiproliferative activity of long chain acylated esters of quercetin-3-O-glucoside in hepatocellular carcinoma HepG2 cells.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Caspase 3; Cell Cycle; Cell Proliferation; Cisplatin; DNA Fragmentation; DNA Topoisomerases, Type II; Drug Screening Assays, Antitumor; Esters; Fatty Acids; Flavonoids; Glucosides; Hep G2 Cells; Humans; Liver Neoplasms; Microscopy, Fluorescence; Niacinamide; Phenylurea Compounds; Quercetin; Sorafenib | 2015 |
Long-lasting tumour response to sorafenib therapy in advanced hepatocellular carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2014 |
Activation of AMP-activated protein kinase by retinoic acid sensitizes hepatocellular carcinoma cells to apoptosis induced by sorafenib.
Topics: Adenosine Triphosphate; AMP-Activated Protein Kinases; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; Benzoates; Carcinoma, Hepatocellular; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Glucose Transporter Type 1; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Retinoids; Sorafenib; Tetrahydronaphthalenes; Tretinoin | 2015 |
PROX1 promotes hepatocellular carcinoma proliferation and sorafenib resistance by enhancing β-catenin expression and nuclear translocation.
Topics: Animals; beta Catenin; Carcinoma, Hepatocellular; Cell Line; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Drug Resistance, Neoplasm; HEK293 Cells; Homeodomain Proteins; Humans; Liver; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Niacinamide; Phenylurea Compounds; Promoter Regions, Genetic; Sorafenib; Transcription, Genetic; Tumor Suppressor Proteins; Up-Regulation; Wnt Proteins | 2015 |
Predictive value of serum insulin-like growth factor-1 in hepatocellular carcinoma.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Humans; Insulin-Like Growth Factor I; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib; Survival Rate | 2015 |
Comparison of treatment safety and patient survival in elderly versus nonelderly patients with advanced hepatocellular carcinoma receiving sorafenib combined with transarterial chemoembolization: a propensity score matching study.
Topics: Age Factors; Aged; Antineoplastic Agents; Arteries; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Propensity Score; Retrospective Studies; Safety; Sorafenib; Survival Analysis; Treatment Outcome | 2015 |
miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cytochrome P-450 CYP1B1; Drug Resistance, Neoplasm; Hep G2 Cells; Humans; Inactivation, Metabolic; Kidney Neoplasms; Liver Neoplasms; Mice; MicroRNAs; Niacinamide; Phenylurea Compounds; RNA, Messenger; Sorafenib; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2015 |
Fulminant hepatitis in a patient with hepatocellular carcinoma related to nonalcoholic steatohepatitis treated with sorafenib.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Fatal Outcome; Humans; Jaundice; Liver Failure, Acute; Liver Neoplasms; Male; Muscle Weakness; Niacinamide; Non-alcoholic Fatty Liver Disease; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Tomography, X-Ray Computed; Tremor | 2015 |
First-line gemcitabine and oxaliplatin (GEMOX) plus sorafenib, followed by sorafenib as maintenance therapy, for patients with advanced hepatocellular carcinoma: a preliminary study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Deoxycytidine; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Organoplatinum Compounds; Phenylurea Compounds; Prospective Studies; Sorafenib | 2015 |
MiRNA153 Reduces Effects of Chemotherapeutic Agents or Small Molecular Kinase Inhibitor in HCC Cells.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Etoposide; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Liver Neoplasms; MicroRNAs; Molecular Targeted Therapy; Niacinamide; Paclitaxel; Phenylurea Compounds; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Sorafenib | 2015 |
Combination of Matrine and Sorafenib Decreases the Aggressive Phenotypes of Hepatocellular Carcinoma Cells.
Topics: Alkaloids; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; Cell Proliferation; Dose-Response Relationship, Drug; Hep G2 Cells; Humans; Liver Neoplasms; Matrines; Niacinamide; Phenotype; Phenylurea Compounds; Quinolizines; Sorafenib | 2014 |
[A case of advanced hepatocellular carcinoma successfully treated by liver resection after complete response induced by sorafenib administration].
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Hepatectomy; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2014 |
Complete remission of advanced hepatocellular carcinoma by radiofrequency ablation after sorafenib therapy.
Topics: Antineoplastic Agents; Biopsy; Carcinoma, Hepatocellular; Catheter Ablation; Humans; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Remission Induction; Sorafenib; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Ultrasonography, Interventional | 2015 |
Biomarkers of apoptosis and necrosis in patients with hepatocellular carcinoma treated with sorafenib.
Topics: Aged; Antineoplastic Agents; Apoptosis; Biomarkers; Carcinoma, Hepatocellular; Female; Humans; Keratin-18; Liver Neoplasms; Male; Necrosis; Niacinamide; Phenylurea Compounds; Receptors, Vascular Endothelial Growth Factor; Sorafenib | 2015 |
Complete disappearance of liver metastases in a patient with iodine-refractory differentiated thyroid cancer subjected to sorafenib re-challenge.
Topics: Antineoplastic Agents; Female; Humans; Iodine Radioisotopes; Liver; Liver Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Sorafenib; Thyroid Neoplasms | 2015 |
Sorafenib off-target effects predict outcomes in patients treated for hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Cohort Studies; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Risk Factors; Sorafenib; Treatment Outcome | 2015 |
Regulation of multidrug resistance proteins by genistein in a hepatocarcinoma cell line: impact on sorafenib cytotoxicity.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Genistein; Humans; Liver Neoplasms; Membrane Transport Proteins; MicroRNAs; Niacinamide; Phenylurea Compounds; Phytoestrogens; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sorafenib; Tumor Cells, Cultured | 2015 |
Sneddon-Wilkinson disease induced by sorafenib in a patient with advanced hepatocellular carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Skin Diseases, Vesiculobullous; Sorafenib | 2015 |
PHY906(KD018), an adjuvant based on a 1800-year-old Chinese medicine, enhanced the anti-tumor activity of Sorafenib by changing the tumor microenvironment.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Drugs, Chinese Herbal; Humans; Liver Neoplasms; Medicine, Chinese Traditional; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Plant Extracts; Scutellaria baicalensis; Sorafenib; Tumor Microenvironment | 2015 |
Decreased miR122 in hepatocellular carcinoma leads to chemoresistance with increased arginine.
Topics: Animals; Apoptosis; Arginine; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Mice; Mice, Inbred C57BL; Mice, Transgenic; MicroRNAs; Niacinamide; Phenylurea Compounds; Sorafenib | 2015 |
Radiation-induced hemorrhagic duodenitis associated with sorafenib treatment.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Duodenitis; Gastrointestinal Hemorrhage; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Radiation Injuries; Radiotherapy; Receptor Protein-Tyrosine Kinases; Sorafenib | 2015 |
Combined treatment with silibinin and either sorafenib or gefitinib enhances their growth-inhibiting effects in hepatocellular carcinoma cells.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Down-Regulation; Drug Screening Assays, Antitumor; Drug Synergism; ErbB Receptors; Gefitinib; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Silybin; Silymarin; Sorafenib | 2015 |
Low-dose steroid-induced tumor lysis syndrome in a hepatocellular carcinoma patient.
Topics: Acute Kidney Injury; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Creatinine; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Sorafenib; Steroids; Tomography, X-Ray Computed; Tumor Lysis Syndrome | 2015 |
Survival in relation to hospital type after resection or sorafenib treatment for hepatocellular carcinoma in The Netherlands.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Cohort Studies; Female; Hepatectomy; Hospitals; Humans; Liver Neoplasms; Male; Middle Aged; Netherlands; Niacinamide; Phenylurea Compounds; Sorafenib; Survival Rate | 2015 |
Determinants of survival after sorafenib failure in patients with BCLC-C hepatocellular carcinoma in real-world practice.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease-Free Survival; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Taiwan; Treatment Failure | 2015 |
Sorafenib treatment in Child-Pugh A and B patients with advanced hepatocellular carcinoma: safety, efficacy and prognostic factors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Dose-Response Relationship, Drug; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib; Treatment Outcome | 2015 |
Metronomic capecitabine as second-line treatment in hepatocellular carcinoma after sorafenib failure.
Topics: Administration, Metronomic; Aged; Antineoplastic Agents; Capecitabine; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Survival Analysis; Treatment Failure | 2015 |
Sorafenib inhibits migration and invasion of hepatocellular carcinoma cells through suppression of matrix metalloproteinase expression.
Topics: Carcinoma, Hepatocellular; Cell Movement; Epithelial-Mesenchymal Transition; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Liver Neoplasms; MAP Kinase Signaling System; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-met; Sorafenib | 2015 |
Synergistic effect of sorafenib and vitamin K on suppression of hepatocellular carcinoma cell migration and metastasis.
Topics: Carcinoma, Hepatocellular; Cell Movement; Cell Proliferation; Drug Synergism; Hep G2 Cells; Hepatocyte Growth Factor; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib; Vitamin K | 2015 |
Sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombus.
Topics: Aged; Carcinoma, Hepatocellular; Female; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Portal Vein; Prognosis; Retrospective Studies; Sorafenib; Thrombosis; Treatment Outcome | 2015 |
PTPN11/Shp2 overexpression enhances liver cancer progression and predicts poor prognosis of patients.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Disease Progression; Humans; Liver Neoplasms; MAP Kinase Signaling System; Mice; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Prognosis; Protein Tyrosine Phosphatase, Non-Receptor Type 11; raf Kinases; Sorafenib | 2015 |
Pre-clinical activity of PR-104 as monotherapy and in combination with sorafenib in hepatocellular carcinoma.
Topics: Animals; Carcinoma, Hepatocellular; Cell Hypoxia; Cell Line, Tumor; Female; Hep G2 Cells; Humans; Liver Neoplasms; Mice; Mice, Inbred NOD; Mice, SCID; Niacinamide; Nitrogen Mustard Compounds; Phenylurea Compounds; Prodrugs; Sorafenib; Xenograft Model Antitumor Assays | 2015 |
Pancreatic Atrophy in Hepatocellular Carcinoma Patients Receiving Long-Term Treatment with Sorafenib.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Atrophy; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Pancreas; Phenylurea Compounds; Retrospective Studies; Sorafenib; Survival Analysis; Treatment Outcome | 2015 |
Identification of a unique hepatocellular carcinoma line, Li-7, with CD13(+) cancer stem cells hierarchy and population change upon its differentiation during culture and effects of sorafenib.
Topics: Animals; Carcinoma, Hepatocellular; CD13 Antigens; Cell Differentiation; Cell Line, Tumor; Cell Lineage; Gene Expression Regulation, Neoplastic; Genetic Heterogeneity; Humans; Liver Neoplasms; Mice; Neoplastic Stem Cells; Niacinamide; Phenylurea Compounds; Sorafenib | 2015 |
Clinical outcomes of patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective study of routine clinical practice in multi-institutions.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Retrospective Studies; Risk Factors; Sorafenib; Treatment Outcome | 2015 |
Folate-decorated anticancer drug and magnetic nanoparticles encapsulated polymeric carrier for liver cancer therapeutics.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Drug Carriers; Drug Liberation; Folic Acid; Humans; Iron; Liver Neoplasms; Magnetic Phenomena; Nanoparticles; Niacinamide; Phenylurea Compounds; Polyesters; Polyethylene Glycols; Sorafenib | 2015 |
Complete Response to Full-Dose Sorafenib Treatment in an Elderly HCC Patient: a Case Report.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Male; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Remission Induction; Sorafenib | 2015 |
Sorafenib and DE605, a novel c-Met inhibitor, synergistically suppress hepatocellular carcinoma.
Topics: Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzoxazoles; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Liver Neoplasms; Mice; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Real-Time Polymerase Chain Reaction; Sorafenib; Transfection; Xenograft Model Antitumor Assays | 2015 |
Sorafenib in the treatment of recurrent hepatocellular carcinoma after liver transplantation: a report of four cases.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Positron-Emission Tomography; Sorafenib; Tomography, X-Ray Computed | 2015 |
RACK1 modulates apoptosis induced by sorafenib in HCC cells by interfering with the IRE1/XBP1 axis.
Topics: Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; DNA-Binding Proteins; Endoribonucleases; Gene Expression Regulation, Neoplastic; GTP-Binding Proteins; Humans; Liver Neoplasms; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Serine-Threonine Kinases; Receptors for Activated C Kinase; Receptors, Cell Surface; Regulatory Factor X Transcription Factors; Signal Transduction; Sorafenib; Transcription Factors; Unfolded Protein Response; X-Box Binding Protein 1 | 2015 |
Nuclear factor kappa B-mediated CD47 up-regulation promotes sorafenib resistance and its blockade synergizes the effect of sorafenib in hepatocellular carcinoma in mice.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; CD47 Antigen; Disease Models, Animal; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Mice; Mice, SCID; Molecular Targeted Therapy; NF-kappa B; Niacinamide; Phenylurea Compounds; Random Allocation; Signal Transduction; Sorafenib; Treatment Outcome; Tumor Cells, Cultured; Up-Regulation; Xenograft Model Antitumor Assays | 2015 |
Modulation of Regorafenib effects on HCC cell lines by epidermal growth factor.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Epidermal Growth Factor; Erlotinib Hydrochloride; Hep G2 Cells; Humans; Liver Neoplasms; MAP Kinase Signaling System; Niacinamide; Phenylurea Compounds; Phosphorylation; Pyridines; Quinazolines; Sorafenib | 2015 |
Effects of Sorafenib Dose on Acquired Reversible Resistance and Toxicity in Hepatocellular Carcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Male; Mice; Mice, Nude; Mice, SCID; Niacinamide; Phenylurea Compounds; Random Allocation; Sorafenib; Xenograft Model Antitumor Assays | 2015 |
Cost-effectiveness of sorafenib as a first-line treatment for advanced hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; China; Cost-Benefit Analysis; Disease Progression; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Treatment Outcome | 2015 |
Different survival of Barcelona clinic liver cancer stage C hepatocellular carcinoma patients by the extent of portal vein invasion and the type of extrahepatic spread.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Hepatitis B; Humans; Liver Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Portal Vein; Prognosis; Prospective Studies; Risk Factors; Sorafenib; Survival Analysis; Terminology as Topic | 2015 |
Skeletal muscle depletion predicts the prognosis of patients with hepatocellular carcinoma treated with sorafenib.
Topics: Aged; Aging; Carcinoma, Hepatocellular; Demography; Dose-Response Relationship, Drug; Female; Humans; Kaplan-Meier Estimate; Linear Models; Liver Neoplasms; Male; Multivariate Analysis; Muscle, Skeletal; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Risk Factors; Sorafenib; Withholding Treatment | 2015 |
High Serum Transforming Growth Factor-β1 Levels Predict Outcome in Hepatocellular Carcinoma Patients Treated with Sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Hepatocellular; Disease-Free Survival; Female; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; RNA, Messenger; Sorafenib; Transforming Growth Factor beta1; Treatment Outcome | 2015 |
Corosolic Acid Inhibits Hepatocellular Carcinoma Cell Migration by Targeting the VEGFR2/Src/FAK Pathway.
Topics: Actins; Adenosine Triphosphate; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Down-Regulation; Drug Synergism; Focal Adhesion Kinase 1; Hep G2 Cells; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Signal Transduction; Sorafenib; src-Family Kinases; Triterpenes; Vascular Endothelial Growth Factor Receptor-2 | 2015 |
Combination of oxaliplatin and S-1 versus sorafenib alone in patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Disease-Free Survival; Drug Combinations; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Phenylurea Compounds; Sorafenib; Tegafur; Treatment Outcome | 2014 |
[Therapeutic decisions and treatment with sorafenib in hepatocellular carcinoma: final analysis of GIDEON study in Italy].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Italy; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prospective Studies; Sorafenib | 2015 |
Model Matters: Differences in Orthotopic Rat Hepatocellular Carcinoma Physiology Determine Therapy Response to Sorafenib.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Biomarkers; Biopsy; Carcinoma, Hepatocellular; Cell Transformation, Neoplastic; Comparative Genomic Hybridization; Disease Models, Animal; Immunohistochemistry; Liver Neoplasms; Liver Neoplasms, Experimental; Magnetic Resonance Imaging; Male; Neoplasm Grading; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Rats; Sorafenib | 2015 |
Recurrence-free survival of a hepatocellular carcinoma patient with tumor thrombosis of the inferior vena cava after treatment with sorafenib and hepatic resection.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Blood Loss, Surgical; Carcinoma, Hepatocellular; Combined Modality Therapy; Diagnostic Imaging; Disease-Free Survival; Hepatectomy; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Operative Time; Phenylurea Compounds; Sorafenib; Thrombosis; Vena Cava, Inferior | 2015 |
Poly(lactide-co-glycolide) microspheres for MRI-monitored delivery of sorafenib in a rabbit VX2 model.
Topics: Animals; Antineoplastic Agents; Capsules; Cell Line, Tumor; Contrast Media; Diffusion; Drug Monitoring; Ferric Compounds; Liver Neoplasms; Magnetic Resonance Imaging; Niacinamide; Particle Size; Phenylurea Compounds; Polyglactin 910; Rabbits; Sorafenib | 2015 |
Effects of sorafenib on lung metastasis in rats with hepatocellular carcinoma: the role of microRNAs.
Topics: Animals; Biomarkers, Tumor; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Lung Neoplasms; MicroRNAs; Niacinamide; Phenylurea Compounds; Rats; Sorafenib | 2015 |
CSN5 silencing reverses sorafenib resistance of human hepatocellular carcinoma HepG2 cells.
Topics: Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Carcinoma, Hepatocellular; COP9 Signalosome Complex; Cyclin D1; Cyclin-Dependent Kinase 6; Drug Resistance, Neoplasm; Gene Expression; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Hep G2 Cells; Humans; Integrin beta1; Intracellular Signaling Peptides and Proteins; Liver Neoplasms; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; NF-kappa B; Niacinamide; Peptide Hydrolases; Phenylurea Compounds; RNA, Small Interfering; Signal Transduction; Sorafenib; Transforming Growth Factor beta1 | 2015 |
Active Targeting of Sorafenib: Preparation, Characterization, and In Vitro Testing of Drug-Loaded Magnetic Solid Lipid Nanoparticles.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Proliferation; Dextrans; Drug Carriers; Hep G2 Cells; Humans; Lipids; Liver Neoplasms; Magnetic Resonance Imaging; Magnetite Nanoparticles; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Niacinamide; Phenylurea Compounds; Sorafenib | 2015 |
Evaluation of sorafenib treatment and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: a comparative study using the propensity score matching method.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Female; Hepatic Artery; Humans; Infusions, Intra-Arterial; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Propensity Score; Protein Kinase Inhibitors; Sorafenib; Treatment Outcome | 2015 |
miR-494 promotes cell proliferation, migration and invasion, and increased sorafenib resistance in hepatocellular carcinoma by targeting PTEN.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Liver Neoplasms; MicroRNAs; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Promoter Regions, Genetic; PTEN Phosphohydrolase; Sorafenib | 2015 |
Interaction of key pathways in sorafenib-treated hepatocellular carcinoma based on a PCR-array.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Niacinamide; Oligonucleotide Array Sequence Analysis; Phenylurea Compounds; Polymerase Chain Reaction; Signal Transduction; Sorafenib | 2015 |
Targeted DNA and RNA sequencing of fine-needle biopsy FFPE specimens in patients with unresectable hepatocellular carcinoma treated with sorafenib.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; beta Catenin; Biomarkers; Biomarkers, Tumor; Biopsy, Fine-Needle; Carcinoma, Hepatocellular; Female; Formaldehyde; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; High-Throughput Nucleotide Sequencing; Humans; Liver Neoplasms; Male; Middle Aged; Mutation; Neuregulin-1; Niacinamide; Paraffin Embedding; Phenylurea Compounds; Platelet Endothelial Cell Adhesion Molecule-1; Sequence Analysis, DNA; Sequence Analysis, RNA; Sorafenib; Transforming Growth Factor alpha; Treatment Outcome; Tumor Suppressor Protein p53 | 2015 |
Effects of TGF-beta signalling inhibition with galunisertib (LY2157299) in hepatocellular carcinoma models and in ex vivo whole tumor tissue samples from patients.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Caspase 3; Cell Line, Tumor; Cell Proliferation; Female; Hep G2 Cells; Humans; Immunohistochemistry; Indoles; Ki-67 Antigen; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Pyrazoles; Pyrroles; Quinolines; Signal Transduction; Sorafenib; Sunitinib; Transforming Growth Factor beta1 | 2015 |
1118-20, an indazole diarylurea compound, inhibits hepatocellular carcinoma HepG2 proliferation and tumour angiogenesis involving Wnt/β-catenin pathway and receptor tyrosine kinases.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Movement; Cell Proliferation; Hep G2 Cells; Human Umbilical Vein Endothelial Cells; Humans; Indazoles; Liver Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Receptor Protein-Tyrosine Kinases; Sorafenib; Wnt Signaling Pathway | 2015 |
Comparative Metabolomic Profiling of Hepatocellular Carcinoma Cells Treated with Sorafenib Monotherapy vs. Sorafenib-Everolimus Combination Therapy.
Topics: Annexin A5; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Drug Synergism; Everolimus; Fluorescein-5-isothiocyanate; Hep G2 Cells; Humans; Liver Neoplasms; Magnetic Resonance Spectroscopy; Metabolic Networks and Pathways; Metabolomics; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Sorafenib; Tetrazolium Salts; Thiazoles | 2015 |
Sorafenib continuation or discontinuation in patients with unresectable hepatocellular carcinoma after a complete response.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Quality of Life; Retrospective Studies; Sorafenib; Treatment Outcome | 2015 |
Long-term therapy with sorafenib is associated with pancreatic atrophy.
Topics: Aged; Antineoplastic Agents; Atrophy; Carcinoma, Hepatocellular; China; Cohort Studies; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Pancreas; Pancreatic Diseases; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2015 |
Comparison of hepatic arterial infusion chemotherapy versus sorafenib monotherapy in patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blood Vessels; Carcinoma, Hepatocellular; Cisplatin; Female; Fluorouracil; Humans; Infusions, Intra-Arterial; Interferons; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Survival Rate; Treatment Outcome | 2015 |
Abdominal Distension in a Patient With Hepatocellular Carcinoma. Benign Pneumatosis Intestinalis and Pneumoperitoneum Associated With Sorafenib Therapy.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Jejunum; Liver Neoplasms; Male; Niacinamide; Peritoneal Cavity; Phenylurea Compounds; Pneumatosis Cystoides Intestinalis; Pneumoperitoneum; Sorafenib; Tomography, X-Ray Computed | 2015 |
Sustained complete remission of advanced hepatocellular carcinoma with sorafenib therapy.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Remission Induction; Sorafenib | 2015 |
Comparison of Sorafenib and Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Study.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chi-Square Distribution; Female; Hepatic Artery; Humans; Infusions, Intra-Arterial; Japan; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Propensity Score; Protein Kinase Inhibitors; Retrospective Studies; Sorafenib; Survival Rate; Time Factors; Treatment Outcome | 2014 |
Efficacy of Sorafenib for Advanced Hepatocellular Carcinoma and Prognostic Factors.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Niacinamide; Patient Selection; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Risk Assessment; Risk Factors; Sorafenib; Time Factors; Treatment Outcome; Young Adult | 2014 |
MiR-101 targets DUSP1 to regulate the TGF-β secretion in sorafenib inhibits macrophage-induced growth of hepatocarcinoma.
Topics: Adult; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Dual Specificity Phosphatase 1; Enzyme Activation; Female; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Immunohistochemistry; Lipopolysaccharides; Liver Neoplasms; Macrophages; Male; MicroRNAs; Mitogen-Activated Protein Kinases; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Sorafenib; Transforming Growth Factor beta1 | 2015 |
Systemic Treatment: Expecting Further Success.
Topics: alpha-Fetoproteins; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Polymorphism, Genetic; Sorafenib; Treatment Failure; Vascular Endothelial Growth Factor A | 2015 |
Next Generation of Preclinical Liver Cancer Models.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Comparative Genomic Hybridization; Disease Models, Animal; Genetic Heterogeneity; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Positron-Emission Tomography; Protein Kinase Inhibitors; Sorafenib | 2015 |
Growth arrest DNA damage-inducible gene 45 gamma expression as a prognostic and predictive biomarker in hepatocellular carcinoma.
Topics: Aged; Animals; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Blotting, Western; Carcinoma, Hepatocellular; CCAAT-Enhancer-Binding Proteins; Cell Cycle Proteins; Cell Line, Tumor; Chromatin Immunoprecipitation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Middle Aged; Niacinamide; Nuclear Proteins; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Reverse Transcriptase Polymerase Chain Reaction; RNA, Small Interfering; Sorafenib; Transfection; Xenograft Model Antitumor Assays | 2015 |
The Impact of Combined Transarterial Chemoembolization on the Overall Survival of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; China; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Retrospective Studies; Risk Factors; Sorafenib; Time Factors; Treatment Outcome | 2014 |
[Hepatocellular Carcinoma: therapeutic options 2015].
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Chemoradiotherapy; Combined Modality Therapy; Evidence-Based Medicine; Humans; Internationality; Liver Neoplasms; Liver Transplantation; Niacinamide; Phenylurea Compounds; Sorafenib | 2015 |
Sorafenib-Sunitinib Sequence: The Jury Is Out.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib | 2015 |
Hepatocellular Carcinoma with Cervical Spine and Pelvic Bone Metastases Presenting as Unknown Primary Neoplasm.
Topics: Antineoplastic Agents; Bone Neoplasms; Carcinoma, Hepatocellular; Cervical Cord; Chemoembolization, Therapeutic; Gamma Rays; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasms, Unknown Primary; Niacinamide; Pelvic Bones; Phenylurea Compounds; Sorafenib; Tomography, X-Ray Computed | 2015 |
[Two Patients with Recurrence of Hepatocellular Carcinoma after Liver Resection Who Achieved Long-Term Stable Disease with Small Doses of Sorafenib Therapy].
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Embolization, Therapeutic; Hepatectomy; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2015 |
Sorafenib Action in Hepatitis B Virus X-Activated Oncogenic Androgen Pathway in Liver through SHP-1.
Topics: Age Factors; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Enzyme Activation; Gene Expression Regulation, Neoplastic; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Hepatitis B; Hepatitis B virus; Incidence; Liver Neoplasms; Male; Mice; Mice, Transgenic; Niacinamide; Orchiectomy; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Proto-Oncogene Proteins c-akt; Receptors, Androgen; Signal Transduction; Sorafenib; Trans-Activators; Viral Regulatory and Accessory Proteins | 2015 |
Visceral fat area predicts survival in patients with advanced hepatocellular carcinoma treated with tyrosine kinase inhibitors.
Topics: Aged; Alanine; alpha-Fetoproteins; Carcinoma, Hepatocellular; Female; France; Hand-Foot Syndrome; Humans; Intra-Abdominal Fat; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Retrospective Studies; Sarcopenia; Sorafenib; Survival Rate; Tomography, X-Ray Computed; Triazines | 2015 |
CXCR4-targeted lipid-coated PLGA nanoparticles deliver sorafenib and overcome acquired drug resistance in liver cancer.
Topics: Animals; Carcinoma, Hepatocellular; Cell Death; Cell Line, Tumor; Cell Proliferation; Drug Delivery Systems; Drug Resistance, Neoplasm; Endocytosis; Human Umbilical Vein Endothelial Cells; Humans; Lactic Acid; Lipids; Liver Neoplasms; Male; Mice; Nanoparticles; Neoplasm Metastasis; Niacinamide; Phenotype; Phenylurea Compounds; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Receptors, CXCR4; Sorafenib; Survival Analysis; Tumor Microenvironment | 2015 |
Sorafenib combined with percutaneous radiofrequency ablation for the treatment of medium-sized hepatocellular carcinoma.
Topics: Antineoplastic Agents; Catheter Ablation; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib | 2015 |
Improving Drug Penetrability with iRGD Leverages the Therapeutic Response to Sorafenib and Doxorubicin in Hepatocellular Carcinoma.
Topics: Administration, Intravenous; Amino Acid Motifs; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Doxorubicin; Drug Delivery Systems; Evans Blue; Gadolinium DTPA; Hep G2 Cells; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Male; Mice, Nude; Mice, Transgenic; Niacinamide; Oligopeptides; Phenylurea Compounds; Sorafenib; Tissue Distribution | 2015 |
Complete pathological response induced by sorafenib for advanced hepatocellular carcinoma with multiple lung metastases and venous tumor thrombosis allowing for curative resection.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Hepatectomy; Hepatic Veins; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Portal Vein; Sorafenib; Venous Thrombosis | 2015 |
Meloxicam combined with sorafenib synergistically inhibits tumor growth of human hepatocellular carcinoma cells via ER stress-related apoptosis.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Meloxicam; Mice; Niacinamide; Phenylurea Compounds; Sorafenib; Thiazines; Thiazoles; Xenograft Model Antitumor Assays | 2015 |
High-Dose Vitamin C Promotes Regression of Multiple Pulmonary Metastases Originating from Hepatocellular Carcinoma.
Topics: Aged; Antineoplastic Agents; Ascorbic Acid; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Female; Humans; Liver Neoplasms; Lung Neoplasms; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2015 |
Sorafenib enriches epithelial cell adhesion molecule-positive tumor initiating cells and exacerbates a subtype of hepatocellular carcinoma through TSC2-AKT cascade.
Topics: Animals; Antigens, Neoplasm; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Adhesion Molecules; Disease Progression; Epithelial Cell Adhesion Molecule; Humans; Liver Neoplasms; Mice; Neoplastic Stem Cells; Niacinamide; Oncogene Protein v-akt; Phenylurea Compounds; Sorafenib; Tuberous Sclerosis Complex 2 Protein; Tumor Suppressor Proteins | 2015 |
Sorafenib: the gold standard therapy in advanced hepatocellular carcinoma and beyond.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Clinical Trials, Phase III as Topic; Humans; Liver Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Treatment Outcome | 2015 |
Transarterial chemoembolization and sorafenib in patients with intermediate-stage hepatocellular carcinoma: time to enter routine clinical practice?
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib | 2015 |
Delivery of siRNA Using CXCR4-targeted Nanoparticles Modulates Tumor Microenvironment and Achieves a Potent Antitumor Response in Liver Cancer.
Topics: Angiogenesis Inhibitors; Animals; Benzylamines; Carcinoma, Hepatocellular; Cell Line, Tumor; Chemokine CXCL12; Cyclams; Disease Progression; Genetic Therapy; Heterocyclic Compounds; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred C3H; Nanoparticles; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Receptors, CXCR4; RNA, Small Interfering; Signal Transduction; Sorafenib; Tumor Microenvironment; Vascular Endothelial Growth Factor A | 2015 |
TLR3 agonist and Sorafenib combinatorial therapy promotes immune activation and controls hepatocellular carcinoma progression.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carboxymethylcellulose Sodium; Carcinoma, Hepatocellular; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Progression; Extracellular Signal-Regulated MAP Kinases; Humans; Immune System; Immunosuppressive Agents; Liver Neoplasms; Male; MAP Kinase Kinase Kinases; Mice; Mice, Inbred C57BL; Mice, Inbred NOD; Mice, SCID; Niacinamide; Phenylurea Compounds; Phosphorylation; Poly I-C; Polylysine; Proto-Oncogene Proteins c-akt; Signal Transduction; Sorafenib; Toll-Like Receptor 3 | 2015 |
LincRNA-p21 activates endoplasmic reticulum stress and inhibits hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Endoplasmic Reticulum Stress; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Hep G2 Cells; Humans; Liver Neoplasms; Male; Mice, Inbred BALB C; Mice, Nude; Niacinamide; Phenylurea Compounds; Reverse Transcriptase Polymerase Chain Reaction; RNA, Long Noncoding; Sorafenib; Transplantation, Heterologous; Tumor Burden | 2015 |
MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.
Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Carcinoma, Hepatocellular; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Enzyme Activation; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Liver Neoplasms; Male; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Niacinamide; Oligonucleotides; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Signal Transduction; Sorafenib; Time Factors; Transfection; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
Multilayer-Coated Liquid Crystalline Nanoparticles for Effective Sorafenib Delivery to Hepatocellular Carcinoma.
Topics: Animals; Apoptosis; Calorimetry, Differential Scanning; Carcinoma, Hepatocellular; Cell Survival; Drug Carriers; Drug Liberation; Erythrocytes; Hemolysis; Hep G2 Cells; Humans; Hydrogen-Ion Concentration; Liquid Crystals; Liver Neoplasms; Male; Microscopy, Atomic Force; Microscopy, Electron, Transmission; Nanoparticles; Niacinamide; Phenylurea Compounds; Polymers; Rats; Rats, Sprague-Dawley; Sorafenib; Spectroscopy, Fourier Transform Infrared | 2015 |
[Efficacy of Sorafenib versus Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization].
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Female; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2015 |
An isocorydine derivative (d-ICD) inhibits drug resistance by downregulating IGF2BP3 expression in hepatocellular carcinoma.
Topics: AC133 Antigen; Antibiotics, Antineoplastic; Antigens, CD; Antineoplastic Agents; Aporphines; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drug Resistance, Neoplasm; Female; Glycoproteins; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Proteins; Neoplastic Stem Cells; Niacinamide; Peptides; Phenylurea Compounds; Protein Kinase Inhibitors; RNA Interference; RNA-Binding Proteins; Sorafenib; Survival Analysis; Time Factors; Transfection | 2015 |
Treatment of intermediate-stage hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib | 2015 |
Hepatocellular carcinoma: current questions and future directions.
Topics: Antineoplastic Agents; Biomarkers; Biopsy; Carcinoma, Hepatocellular; Clinical Trials as Topic; Combined Modality Therapy; Diagnostic Imaging; Drug Discovery; Humans; Image Interpretation, Computer-Assisted; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Treatment Outcome | 2015 |
The role of sorafenib in hepatocellular carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Clinical Trials as Topic; Humans; Hypophosphatemia; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Research; Sorafenib; Treatment Failure; Treatment Outcome | 2015 |
Promotion of Cancer Stem-Like Cell Properties in Hepatitis C Virus-Infected Hepatocytes.
Topics: Animals; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cyclic S-Oxides; Dasatinib; Epithelial-Mesenchymal Transition; Female; Hepacivirus; Hepatitis C; Hepatocytes; Humans; Imatinib Mesylate; Liver Neoplasms; Mice; Neoplasm Transplantation; Neoplastic Stem Cells; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-kit; RNA, Messenger; Sorafenib; Spheroids, Cellular; STAT3 Transcription Factor; Transplantation, Heterologous; Tumor Cells, Cultured | 2015 |
NDRG1 promotes growth of hepatocellular carcinoma cells by directly interacting with GSK-3β and Nur77 to prevent β-catenin degradation.
Topics: Animals; Antineoplastic Agents; beta Catenin; Carcinoma, Hepatocellular; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Doxycycline; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Hep G2 Cells; Humans; Immunoblotting; Intracellular Signaling Peptides and Proteins; Liver Neoplasms; Mice, Nude; Microscopy, Fluorescence; Niacinamide; Nuclear Receptor Subfamily 4, Group A, Member 1; Phenylurea Compounds; Protein Binding; Proteolysis; RNA Interference; Sorafenib; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
Feasibility of Using Volumetric Contrast-Enhanced Ultrasound with a 3-D Transducer to Evaluate Therapeutic Response after Targeted Therapy in Rabbit Hepatic VX2 Carcinoma.
Topics: Animals; Antineoplastic Agents; Contrast Media; Disease Models, Animal; Feasibility Studies; Image Enhancement; Imaging, Three-Dimensional; Liver; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Rabbits; Reproducibility of Results; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome; Ultrasonography | 2015 |
Bufalin Reverses Resistance to Sorafenib by Inhibiting Akt Activation in Hepatocellular Carcinoma: The Role of Endoplasmic Reticulum Stress.
Topics: Apoptosis; Bufanolides; Carcinoma, Hepatocellular; Cell Proliferation; Drug Resistance, Neoplasm; Endoplasmic Reticulum Stress; Hep G2 Cells; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Phosphorylation; Proto-Oncogene Proteins c-akt; Signal Transduction; Sorafenib | 2015 |
The Eltrombopag antitumor effect on hepatocellular carcinoma.
Topics: Apoptosis; Benzoates; Carcinoma, Hepatocellular; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Drug Synergism; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Hydrazines; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyrazoles; Receptors, Thrombopoietin; Sorafenib | 2015 |
Efficacy of transcatheter arterial chemoembolization followed by sorafenib for intermediate/advanced hepatocellular carcinoma in patients in Japan: a retrospective analysis.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Disease-Free Survival; Female; Humans; Japan; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Treatment Outcome | 2015 |
Selective internal radiation therapy compared with sorafenib for hepatocellular carcinoma with portal vein thrombosis.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Embolization, Therapeutic; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Portal Vein; Radiopharmaceuticals; Sorafenib; Venous Thrombosis; Yttrium Radioisotopes | 2016 |
Prognosis after recurrence of hepatocellular carcinoma in liver transplantation: predictors for successful treatment and survival.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Combined Modality Therapy; Follow-Up Studies; Graft Survival; Humans; Liver Neoplasms; Liver Transplantation; Lymphocytes; Multivariate Analysis; Neoplasm Recurrence, Local; Neutrophils; Niacinamide; Phenylurea Compounds; Postoperative Complications; Prognosis; Retrospective Studies; Risk Factors; Sirolimus; Sorafenib; Survival Rate | 2015 |
[A Case of Wilson's Disease with Psoriasis Vulgaris, Complicated with Hepatocellular Carcinoma and Successfully Treated with Sorafenib].
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Hepatectomy; Hepatolenticular Degeneration; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Portal Vein; Psoriasis; Recurrence; Sorafenib | 2015 |
[Successful Multimodal Treatment for Aggressive Extrahepatic Metastatic Hepatocellular Carcinoma - A Case Report].
Topics: Adult; Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Hepatectomy; Humans; Liver Neoplasms; Lung Neoplasms; Male; Niacinamide; Phenylurea Compounds; Recurrence; Remission Induction; Sorafenib | 2015 |
Sorafenib for the treatment of advanced hepatocellular carcinoma with extrahepatic metastasis: a prospective multicenter cohort study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Patient Compliance; Phenylurea Compounds; Proportional Hazards Models; Prospective Studies; Protein Kinase Inhibitors; Sorafenib; Treatment Outcome | 2015 |
Monitoring Serum Levels of Sorafenib and Its N-Oxide Is Essential for Long-Term Sorafenib Treatment of Patients with Hepatocellular Carcinoma.
Topics: Aged; Aged, 80 and over; Area Under Curve; Carcinoma, Hepatocellular; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Monitoring; Female; Half-Life; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Oxides; Phenylurea Compounds; Proportional Hazards Models; ROC Curve; Sorafenib; Time Factors; Withholding Treatment | 2015 |
A polymeric nanoparticle formulation of curcumin in combination with sorafenib synergistically inhibits tumor growth and metastasis in an orthotopic model of human hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Curcumin; Diffusion; Drug Synergism; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Nanocapsules; Niacinamide; Phenylurea Compounds; Polymers; Sorafenib; Treatment Outcome | 2015 |
Real-Life Clinical Practice with Sorafenib in Advanced Hepatocellular Carcinoma: A Single-Center Experience Second Analysis.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib | 2015 |
The STORM trial and beyond: narrowing the horizon of adjuvant sorafenib for postoperative hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Clinical Trials as Topic; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib | 2015 |
Modified response evaluation criteria in solid tumors is superior to response evaluation criteria in solid tumors for assessment of responses to sorafenib in patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Survival Analysis | 2015 |
Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Diabetes Mellitus, Type 2; Drug Resistance, Neoplasm; Humans; Hypoglycemic Agents; Liver Neoplasms; Metformin; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Retrospective Studies; Sorafenib; Survival Analysis; Treatment Outcome | 2015 |
Exosomes derived from miR-122-modified adipose tissue-derived MSCs increase chemosensitivity of hepatocellular carcinoma.
Topics: Adipose Tissue; Adult; Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Cell Survival; Exosomes; Female; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Liver Neoplasms; Male; Mesenchymal Stem Cells; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Microscopy, Confocal; Niacinamide; Phenylurea Compounds; Reverse Transcriptase Polymerase Chain Reaction; Sorafenib; Xenograft Model Antitumor Assays | 2015 |
Real Life Treatment of Hepatocellular Carcinoma: Impact of Deviation from Guidelines for Recommended Therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Egypt; Female; Guideline Adherence; Hepatectomy; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Practice Guidelines as Topic; Prospective Studies; Sorafenib; Survival Rate; Treatment Outcome | 2015 |
Identification of the β-catenin/JNK/prothymosin-alpha axis as a novel target of sorafenib in hepatocellular carcinoma cells.
Topics: Antineoplastic Agents; Apoptosis; beta Catenin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Humans; Liver Neoplasms; MAP Kinase Signaling System; Niacinamide; Phenylurea Compounds; Protein Precursors; Sorafenib; Thymosin; Transfection | 2015 |
Long-term outcomes of patients with advanced hepatocellular carcinoma who achieved complete remission after sorafenib therapy.
Topics: Adult; Aged; alpha-Fetoproteins; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Disease-Free Survival; Female; Hepatitis B, Chronic; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Remission Induction; Republic of Korea; Retrospective Studies; Sorafenib | 2015 |
pERK/pAkt phenotyping in circulating tumor cells as a biomarker for sorafenib efficacy in patients with advanced hepatocellular carcinoma.
Topics: Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Blotting, Western; Carcinoma, Hepatocellular; Cell Proliferation; Extracellular Signal-Regulated MAP Kinases; Female; Fluorescent Antibody Technique; Follow-Up Studies; Humans; Immunoenzyme Techniques; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Neoplastic Cells, Circulating; Niacinamide; Phenylurea Compounds; Phosphorylation; Prognosis; Proto-Oncogene Proteins c-akt; Sorafenib; Survival Rate; Tumor Cells, Cultured | 2016 |
Alpha-fetoprotein is a biomarker of unfolded protein response and altered proteostasis in hepatocellular carcinoma cells exposed to sorafenib.
Topics: alpha-Fetoproteins; Antineoplastic Agents; Biomarkers; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; DNA-Binding Proteins; Homeostasis; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Proteins; Regulatory Factor X Transcription Factors; Sorafenib; Transcription Factors; Unfolded Protein Response | 2016 |
Sorafenib, a multikinase inhibitor, induces formation of stress granules in hepatocarcinoma cells.
Topics: Activating Transcription Factor 4; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cytoplasmic Granules; Drug Resistance, Neoplasm; Eukaryotic Initiation Factor-2; Fluorescent Antibody Technique; Humans; In Situ Hybridization, Fluorescence; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Biosynthesis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Small Interfering; Signal Transduction; Sorafenib; Stress, Physiological; Transfection | 2015 |
Oct4 is a reliable marker of liver tumor propagating cells in hepatocellular carcinoma.
Topics: Animals; Biomarkers, Tumor; Carcinogenesis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Separation; Drug Resistance, Neoplasm; Flow Cytometry; Green Fluorescent Proteins; Humans; Liver Neoplasms; Mice, Inbred BALB C; Neoplastic Stem Cells; Niacinamide; Octamer Transcription Factor-3; Phenylurea Compounds; Sorafenib; Spheroids, Cellular | 2015 |
Derivate isocorydine inhibits cell proliferation in hepatocellular carcinoma cell lines by inducing G2/M cell cycle arrest and apoptosis.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Aporphines; Carcinoma, Hepatocellular; CCAAT-Enhancer-Binding Protein-beta; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Disease Models, Animal; Female; G2 Phase Cell Cycle Checkpoints; Humans; Liver Neoplasms; Niacinamide; Nuclear Proteins; Phenylurea Compounds; Signal Transduction; Sorafenib; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
Cyclin E1 Inhibition can Overcome Sorafenib Resistance in Hepatocellular Carcinoma Cells Through Mcl-1 Suppression.
Topics: Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin E; Drug Resistance, Neoplasm; Hep G2 Cells; Humans; Liver Neoplasms; Male; Mice, Inbred BALB C; Mice, Nude; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Oncogene Proteins; Phenylurea Compounds; Protein Kinase Inhibitors; RNA, Messenger; Signal Transduction; Sorafenib; Xenograft Model Antitumor Assays | 2016 |
Down-regulation of SDF1-α expression in tumor microenvironment is associated with aspirin-mediated suppression of the pro-metastasis effect of sorafenib in hepatocellular carcinoma.
Topics: Animals; Aspirin; Benzylamines; Carcinoma, Hepatocellular; Cell Proliferation; Chemokine CXCL12; Cyclams; Down-Regulation; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Heterocyclic Compounds; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Metastasis; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Receptors, CXCR4; Sorafenib; Tumor Microenvironment | 2015 |
Sorafenib suppresses the epithelial-mesenchymal transition of hepatocellular carcinoma cells after insufficient radiofrequency ablation.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Cell Line, Tumor; Cell Movement; Cell Survival; Epithelial-Mesenchymal Transition; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Liver Neoplasms; Mice; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Sorafenib; Xenograft Model Antitumor Assays | 2015 |
Complete radiological response after sorafenib treatment for advanced hepato-cellular carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Radiography; Remission Induction; Sorafenib; Treatment Outcome | 2015 |
MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS/RAF/ERK signaling pathways.
Topics: 3' Untranslated Regions; Animals; Antineoplastic Agents; Apoptosis; Binding Sites; Carcinoma, Hepatocellular; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Male; Mice, Inbred NOD; Mice, SCID; MicroRNAs; Neoplastic Stem Cells; Niacinamide; Oligonucleotide Array Sequence Analysis; Phenylurea Compounds; Protein Kinase Inhibitors; raf Kinases; ras Proteins; Receptor, IGF Type 1; Receptors, Somatomedin; Signal Transduction; Sorafenib; Time Factors; Transfection; Xenograft Model Antitumor Assays | 2016 |
Tumour initiating cells and IGF/FGF signalling contribute to sorafenib resistance in hepatocellular carcinoma.
Topics: Aged; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Disease Progression; Drug Resistance, Neoplasm; Female; Fibroblast Growth Factors; Gene Expression; Gene Expression Profiling; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Niacinamide; Phenylurea Compounds; Receptor, Fibroblast Growth Factor, Type 1; Receptor, IGF Type 1; Receptors, Somatomedin; Signal Transduction; Somatomedins; Sorafenib; Spheroids, Cellular; Survival Rate; Xenograft Model Antitumor Assays | 2017 |
Comprehensive multiplatform biomarker analysis of 350 hepatocellular carcinomas identifies potential novel therapeutic options.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; beta Catenin; Biomarkers, Tumor; Carcinoma, Hepatocellular; Erlotinib Hydrochloride; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Niacinamide; Phenylurea Compounds; Phosphoinositide-3 Kinase Inhibitors; Poly(ADP-ribose) Polymerase Inhibitors; Protein-Tyrosine Kinases; Retrospective Studies; Sorafenib; Tumor Suppressor Protein p53 | 2016 |
LB-100 sensitizes hepatocellular carcinoma cells to the effects of sorafenib during hypoxia by activation of Smad3 phosphorylation.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Carcinoma, Hepatocellular; Cell Hypoxia; Cell Line, Tumor; Drug Synergism; Gene Expression Regulation, Neoplastic; Genes, bcl-2; Humans; Liver Neoplasms; Male; Mice, Inbred BALB C; Mice, Nude; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-bcl-2; Random Allocation; Smad3 Protein; Sorafenib; Xenograft Model Antitumor Assays | 2016 |
A combination of sorafenib and SC-43 is a synergistic SHP-1 agonist duo to advance hepatocellular carcinoma therapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Activation; Enzyme Activators; Humans; Liver Neoplasms; Mice, Nude; Niacinamide; Phenyl Ethers; Phenylurea Compounds; Phosphorylation; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Signal Transduction; Sorafenib; STAT3 Transcription Factor; Time Factors; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
Prognosis of advanced hepatocellular carcinoma: a new stratification of Barcelona Clinic Liver Cancer stage C: results from a French multicenter study.
Topics: Aged; Algorithms; Angiogenesis Inhibitors; Area Under Curve; Carcinoma, Hepatocellular; Chi-Square Distribution; Decision Support Techniques; Female; France; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Proportional Hazards Models; Reproducibility of Results; Retrospective Studies; Risk Assessment; Risk Factors; ROC Curve; Sorafenib; Treatment Outcome | 2016 |
Sorafenib treatment during partial hepatectomy reduces tumorgenesis in an inflammation-associated liver cancer model.
Topics: Animals; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; ATP-Binding Cassette Sub-Family B Member 4; Carcinoma, Hepatocellular; Cell Proliferation; Cell Transformation, Neoplastic; Disease Models, Animal; Hepatectomy; Hepatitis; Immunoenzyme Techniques; Inflammation; Liver Neoplasms; Liver Regeneration; Mice; Mice, Knockout; Niacinamide; Phenylurea Compounds; Protein Array Analysis; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sorafenib | 2016 |
Effects of sorafenib combined with low-dose interferon therapy for advanced hepatocellular carcinoma: a pilot study.
Topics: Aged; Aged, 80 and over; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Biomarkers, Tumor; Carcinoma, Hepatocellular; Disease Progression; Female; Hepatitis C, Chronic; Hepatocyte Growth Factor; Humans; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pilot Projects; Polyethylene Glycols; Protein Precursors; Prothrombin; Recombinant Proteins; Sorafenib; Survival Rate; Vascular Endothelial Growth Factor A | 2016 |
Inducing tolerability of adverse events increases sorafenib exposure and optimizes patient's outcome in advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Dose-Response Relationship, Drug; Female; Humans; Italy; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Prospective Studies; Sorafenib; Time Factors; Withholding Treatment; Young Adult | 2016 |
MK2206 overcomes the resistance of human liver cancer stem cells to sorafenib by inhibition of pAkt and upregulation of pERK.
Topics: Animals; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Blotting, Western; Carcinoma, Hepatocellular; Cell Proliferation; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation, Neoplastic; Heterocyclic Compounds, 3-Ring; Humans; Immunoenzyme Techniques; Liver Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplastic Stem Cells; Niacinamide; Phenylurea Compounds; Phosphorylation; Proto-Oncogene Proteins c-akt; Signal Transduction; Sorafenib; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2016 |
[Anticancer effect of SN-38 combined with sorafenib on hepatocellular carcinoma in vitro and its mechanism].
Topics: Apoptosis; Camptothecin; Carcinoma, Hepatocellular; Caspase 3; Caspase 8; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Histones; Humans; Irinotecan; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Poly(ADP-ribose) Polymerases; Sorafenib; Tumor Suppressor Protein p53 | 2015 |
CT imaging findings in patients with advanced hepatocellular carcinoma treated with sorafenib: Alternative response criteria (Choi, European Association for the Study of the Liver, and modified Response Evaluation Criteria in Solid Tumor (mRECIST)) versus
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Sorafenib; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome | 2016 |
TACE Treatment in Patients with Sorafenib-treated Unresectable Hepatocellular Carcinoma in Clinical Practice: Final Analysis of GIDEON.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Disease Progression; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Survival Rate; Treatment Outcome | 2016 |
The Efficacy of Continued Sorafenib Treatment after Radiologic Confirmation of Progressive Disease in Patients with Advanced Hepatocellular Carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Prospective Studies; Radiography; Sorafenib; Treatment Outcome | 2016 |
JAMA PATIENT PAGE. Treatment of Liver Cancer.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Embolization, Therapeutic; Hepatectomy; Humans; Liver Neoplasms; Liver Transplantation; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Sorafenib; Survival Rate | 2016 |
Metformin inhibits the prometastatic effect of sorafenib in hepatocellular carcinoma by upregulating the expression of TIP30.
Topics: Acetyltransferases; Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Lung Neoplasms; Metformin; Mice; Neoplasm Invasiveness; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Signal Transduction; Sorafenib; Thioredoxins; Transcription Factors; Xenograft Model Antitumor Assays | 2016 |
Early Radiation Toxicity from Yttrium-90 Radioembolization for Advanced Hepatocellular Carcinoma.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Carcinoma, Hepatocellular; Comorbidity; Dyspnea; Embolization, Therapeutic; Hepatitis B virus; Humans; Liver Cirrhosis; Liver Neoplasms; Lung Injury; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prednisone; Radiation Exposure; Sorafenib; Ytterbium | 2016 |
MRP3 as a novel resistance factor for sorafenib in hepatocellular carcinoma.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Cell Proliferation; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Multidrug Resistance-Associated Proteins; Niacinamide; Phenylurea Compounds; Signal Transduction; Sorafenib; Tumor Cells, Cultured | 2016 |
Quantitative proteomics and phosphoproteomics on serial tumor biopsies from a sorafenib-treated HCC patient.
Topics: Antineoplastic Agents; Biopsy; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Phosphoproteins; Phosphorylation; Proteomics; Sorafenib | 2016 |
Elevated hepatocyte growth factor expression as an autocrine c-Met activation mechanism in acquired resistance to sorafenib in hepatocellular carcinoma cells.
Topics: Antibodies, Neutralizing; Apoptosis; Autocrine Communication; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Hepatocyte Growth Factor; Humans; Indoles; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Proto-Oncogene Proteins c-met; Signal Transduction; Sorafenib; Sulfonamides | 2016 |
[Efficacy of Sorafenib for Extrahepatic Recurrence of Hepatocellular Carcinoma after Liver Resection].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Hepatectomy; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Recurrence; Sorafenib; Treatment Outcome | 2015 |
[Survival after Sorafenib Treatment for Advanced Recurrent Hepatocellular Carcinoma with Tumor Thrombus in the Inferior Vena Cava].
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Hepatectomy; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Recurrence; Sorafenib; Thrombosis; Treatment Outcome; Vena Cava, Inferior | 2015 |
[Complete Surgical Resection of a Huge Hepatocellular Carcinoma Invading the Diaphragm and Lung after Transcatheter Arterial Chemoembolization (TACE) and Sorafenib--A Case Report].
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Diaphragm; Hepatectomy; Humans; Liver Neoplasms; Lung; Male; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Sorafenib | 2015 |
[A Case of Multiple HCC with Vp2 and Vv3 Invasion Controlled by Multidisciplinary Treatment Including Surgery].
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Cisplatin; Combined Modality Therapy; Hepatectomy; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Portal Vein; Prognosis; Sorafenib | 2015 |
[Combination Chemotherapy Using Sorafenib and Hepatic Arterial Infusion with a Fine-Powder Formulation of Cisplatin for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis--A Case Report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Embolization, Therapeutic; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Portal Vein; Powders; Sorafenib; Venous Thrombosis | 2015 |
Transketolase counteracts oxidative stress to drive cancer development.
Topics: Animals; Base Sequence; Carcinoma, Hepatocellular; Cell Cycle Checkpoints; Cell Death; Cell Line, Tumor; Cell Proliferation; Female; Gene Knockdown Techniques; Glucose; Glutathione; Glycolysis; Humans; Liver Neoplasms; Male; Metabolome; Mice, Nude; Molecular Sequence Data; Niacinamide; Oxidative Stress; Pentose Phosphate Pathway; Peroxides; Phenylurea Compounds; Reactive Oxygen Species; RNA, Messenger; Sorafenib; Transketolase; Up-Regulation | 2016 |
Intravoxel incoherent motion MRI as a biomarker of sorafenib treatment for advanced hepatocellular carcinoma: a pilot study.
Topics: Aged; Algorithms; Antineoplastic Agents; Biomarkers; Carcinoma, Hepatocellular; Contrast Media; Diffusion Magnetic Resonance Imaging; Disease Progression; Female; Follow-Up Studies; Humans; Image Processing, Computer-Assisted; Liver Neoplasms; Male; Middle Aged; Multidetector Computed Tomography; Niacinamide; Phenylurea Compounds; Pilot Projects; Prospective Studies; Protein Kinase Inhibitors; raf Kinases; Remission Induction; Sensitivity and Specificity; Sorafenib; Treatment Outcome | 2016 |
Protein tyrosine phosphatase 1B dephosphorylates PITX1 and regulates p120RasGAP in hepatocellular carcinoma.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Humans; Liver Neoplasms; Male; Mice; Models, Molecular; Niacinamide; p120 GTPase Activating Protein; Paired Box Transcription Factors; Phenylurea Compounds; Phosphorylation; Protein Tyrosine Phosphatase, Non-Receptor Type 1; Sorafenib | 2016 |
Organic Cation Transporter 1 (OCT1) mRNA expression in hepatocellular carcinoma as a biomarker for sorafenib treatment.
Topics: Aged; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cation Transport Proteins; Female; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Organic Cation Transporter 1; Phenylurea Compounds; RNA, Messenger; Sorafenib | 2016 |
Upregulation of the oncoprotein SET determines poor clinical outcomes in hepatocellular carcinoma and shows therapeutic potential.
Topics: Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; DNA-Binding Proteins; Female; Gene Expression Regulation, Neoplastic; Histone Chaperones; Humans; Liver Neoplasms; Male; Mice; Niacinamide; Phenylurea Compounds; Prognosis; Quinazolines; Sorafenib; Transcription Factors; Xenograft Model Antitumor Assays | 2016 |
[Treatment of refractory pulmonary metastases from hepatocellular carcinoma by transcatheter arterial chemoembolization using arsenic trioxide in combination with sorafinib].
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neoplasms; Lung Neoplasms; Niacinamide; Oxides; Phenylurea Compounds; Sorafenib | 2015 |
Early onset of hypertension and serum electrolyte changes as potential predictive factors of activity in advanced HCC patients treated with sorafenib: results from a retrospective analysis of the HCC-AVR group.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Electrolytes; Female; Follow-Up Studies; Humans; Hypertension; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Retrospective Studies; Sorafenib; Survival Rate | 2016 |
Regional differences in sorafenib-treated patients with hepatocellular carcinoma: GIDEON observational study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Disease Management; Drug-Related Side Effects and Adverse Reactions; Early Detection of Cancer; Europe; Female; Humans; Japan; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Pacific Islands; Phenylurea Compounds; Registries; Sorafenib; Young Adult | 2016 |
Multidisciplinary Approach in Hepatocellular Carcinoma in a Level II Hospital: The First Decade of Hospital Universitario Fundacion Alcorcon.
Topics: Ablation Techniques; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Cohort Studies; Embolization, Therapeutic; Female; Hepatectomy; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Liver Diseases, Alcoholic; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Staging; Niacinamide; Patient Care Team; Phenylurea Compounds; Prospective Studies; Secondary Care Centers; Sorafenib; Treatment Outcome; Tumor Burden | 2015 |
Real-Life Experience of Sorafenib Treatment for Hepatocellular Carcinoma in Korea: From GIDEON Data.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Republic of Korea; Sorafenib; Treatment Outcome | 2016 |
A comparison of survival in patients with hepatocellular carcinoma and portal vein invasion treated by radioembolization or sorafenib.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Female; Humans; Liver Neoplasms; Logistic Models; Male; Microspheres; Middle Aged; Niacinamide; Phenylurea Compounds; Portal Vein; Propensity Score; Radiopharmaceuticals; Retrospective Studies; Sorafenib; Spain; Survival Analysis; Yttrium Radioisotopes | 2016 |
AMPK-mediated up-regulation of mTORC2 and MCL-1 compromises the anti-cancer effects of aspirin.
Topics: AMP-Activated Protein Kinases; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Apoptosis; Aspirin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Humans; Liver Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasms, Experimental; Niacinamide; Phenylurea Compounds; Sorafenib; TOR Serine-Threonine Kinases; Up-Regulation; Xenograft Model Antitumor Assays | 2016 |
Tumor-Associated Neutrophils Recruit Macrophages and T-Regulatory Cells to Promote Progression of Hepatocellular Carcinoma and Resistance to Sorafenib.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Disease Progression; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Macrophages; Mice; Neutrophil Infiltration; Neutrophils; Niacinamide; Phenylurea Compounds; Sorafenib; T-Lymphocytes, Regulatory | 2016 |
Safety and effectiveness of sorafenib in Japanese patients with hepatocellular carcinoma in daily medical practice: interim analysis of a prospective postmarketing all-patient surveillance study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemical and Drug Induced Liver Injury; Child; Diarrhea; Disease Progression; Female; Follow-Up Studies; Hand-Foot Syndrome; Humans; Hypertension; Japan; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Patient Acuity; Phenylurea Compounds; Product Surveillance, Postmarketing; Prospective Studies; Sex Factors; Sorafenib; Survival Rate; Withholding Treatment; Young Adult | 2016 |
Targeting Androgen Receptor (AR)→IL12A Signal Enhances Efficacy of Sorafenib plus NK Cells Immunotherapy to Better Suppress HCC Progression.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Cytotoxicity, Immunologic; Disease Models, Animal; Disease Progression; Gene Expression Regulation, Neoplastic; Humans; Immunotherapy, Adoptive; Interleukin-12 Subunit p35; Killer Cells, Natural; Liver Neoplasms; Male; Mice; Niacinamide; Phenylurea Compounds; Receptors, Androgen; Signal Transduction; Sorafenib; Transcription, Genetic; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
New Approach for Treatment of Primary Liver Tumors: The Role of Quercetin.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; bcl-2-Associated X Protein; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Cell Survival; DNA Damage; Fluorodeoxyglucose F18; Glucose Transporter Type 1; Hep G2 Cells; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-bcl-2; Quercetin; Sorafenib; Tumor Suppressor Protein p53 | 2016 |
Trends and Patterns of Hepatocellular Carcinoma Treatment in Korea.
Topics: Aged; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Cross-Sectional Studies; Databases, Factual; Female; Humans; Insurance Claim Review; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prevalence; Protein Kinase Inhibitors; Republic of Korea; Sorafenib | 2016 |
Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models.
Topics: Acetyltransferases; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Basic Helix-Loop-Helix Transcription Factors; Blotting, Western; Carcinoma, Hepatocellular; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Epithelial-Mesenchymal Transition; Humans; Hypoglycemic Agents; Liver Neoplasms; Male; Metformin; Mice, Inbred BALB C; Mice, Nude; Neoplasm Metastasis; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Sorafenib; Transcription Factors; Xenograft Model Antitumor Assays | 2016 |
SH2 domain-containing phosphatase 1 regulates pyruvate kinase M2 in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Carrier Proteins; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Membrane Proteins; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Sorafenib; Thyroid Hormone-Binding Proteins; Thyroid Hormones; Xenograft Model Antitumor Assays | 2016 |
iRGD decorated lipid-polymer hybrid nanoparticles for targeted co-delivery of doxorubicin and sorafenib to enhance anti-hepatocellular carcinoma efficacy.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Carcinoma, Hepatocellular; Doxorubicin; Humans; Lipids; Liver Neoplasms; Mice; Nanoparticles; Niacinamide; Phenylurea Compounds; Polymers; Sorafenib | 2016 |
Activation of c-Jun predicts a poor response to sorafenib in hepatocellular carcinoma: Preliminary Clinical Evidence.
Topics: Adult; Aged; Apoptosis; Biomarkers, Tumor; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; JNK Mitogen-Activated Protein Kinases; Liver Neoplasms; Male; Middle Aged; Mitogen-Activated Protein Kinase Kinases; Niacinamide; Phenylurea Compounds; RNA, Messenger; Signal Transduction; Sorafenib | 2016 |
Hepatocellular carcinoma cases with high levels of c-Raf-1 expression may benefit from postoperative adjuvant sorafenib after hepatic resection even with high risk of recurrence.
Topics: Adult; Biomarkers, Tumor; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Gene Expression Regulation, Neoplastic; Hepatitis B; Humans; Liver; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Postoperative Period; Proto-Oncogene Proteins c-raf; Recurrence; Retrospective Studies; Sorafenib | 2016 |
Multimodality Treatment for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Large-Scale, Multicenter, Propensity Mathching Score Analysis.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; China; Combined Modality Therapy; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Portal Vein; Propensity Score; Radiotherapy; Retrospective Studies; Sorafenib; Venous Thrombosis | 2016 |
Epigastric Distress Caused by Esophageal Candidiasis in 2 Patients Who Received Sorafenib Plus Radiotherapy for Hepatocellular Carcinoma: Case Report.
Topics: Aged; Aged, 80 and over; Antifungal Agents; Antineoplastic Agents; Candidiasis; Carcinoma, Hepatocellular; Dose Fractionation, Radiation; Esophagitis; Fluconazole; Heartburn; Hiccup; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Proton Pump Inhibitors; Sorafenib; Stomach Ulcer | 2016 |
Complete Remission of Unresectable Hepatocellular Carcinoma After Combined Sorafenib and Adjuvant Yttrium-90 Radioembolization.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoradiotherapy; Embolization, Therapeutic; Female; Humans; Liver Neoplasms; Lymphatic Metastasis; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Portal Vein; Radiopharmaceuticals; Radiotherapy, Adjuvant; Remission Induction; Sorafenib; Thrombosis; Treatment Outcome; Yttrium Radioisotopes | 2016 |
Learning from 7 Years of Experience with Sorafenib in Advanced HCC: Sorafenib Better than Sorafenib?
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Clinical Trials, Phase III as Topic; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic; Sorafenib | 2016 |
Metallothionein-1G facilitates sorafenib resistance through inhibition of ferroptosis.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Death; Drug Resistance, Neoplasm; Hep G2 Cells; Humans; Liver Neoplasms; Metallothionein; Mice, Nude; NF-E2-Related Factor 2; Niacinamide; Phenylurea Compounds; Sorafenib | 2016 |
Synergistic effects of ascorbate and sorafenib in hepatocellular carcinoma: New insights into ascorbate cytotoxicity.
Topics: Apoptosis; Ascorbic Acid; Carcinoma, Hepatocellular; Cell Proliferation; Drug Synergism; Hep G2 Cells; Humans; Hydrogen Peroxide; Liver Neoplasms; Mitochondria; Niacinamide; Phenylurea Compounds; Sorafenib | 2016 |
Early sorafenib-related adverse events predict therapy response of TACE plus sorafenib: A multicenter clinical study of 606 HCC patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Disease Progression; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Retrospective Studies; Sorafenib; Treatment Outcome; Young Adult | 2016 |
Survival outcomes of hepatic resection compared with transarterial chemoembolization or sorafenib for hepatocellular carcinoma with portal vein tumor thrombosis.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Portal Vein; Proportional Hazards Models; Retrospective Studies; Severity of Illness Index; Sorafenib; Survival Rate; Treatment Outcome; Venous Thrombosis | 2016 |
Comprehensive treatments for hepatocellular carcinoma with tumor thrombus in major portal vein.
Topics: Adult; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Chemotherapy, Adjuvant; Chi-Square Distribution; Female; Hepatectomy; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplastic Cells, Circulating; Niacinamide; Odds Ratio; Phenylurea Compounds; Portal Vein; Proportional Hazards Models; Retrospective Studies; Risk Factors; Sorafenib; Time Factors; Treatment Outcome; Venous Thrombosis | 2016 |
eNOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: final results of the ePHAS study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Case-Control Studies; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Genotype; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Nitric Oxide Synthase Type III; Phenylurea Compounds; Polymorphism, Single Nucleotide; Retrospective Studies; Sorafenib | 2016 |
Co-option of Liver Vessels and Not Sprouting Angiogenesis Drives Acquired Sorafenib Resistance in Hepatocellular Carcinoma.
Topics: Actins; Animals; Antigens, CD34; Antineoplastic Agents; Blood Vessels; Carcinoma, Hepatocellular; Contrast Media; Disease Models, Animal; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Homeodomain Proteins; Humans; Liver; Liver Neoplasms; Male; Mice; Mice, SCID; MicroRNAs; Neoplasm Invasiveness; Neoplasm Transplantation; Neovascularization, Pathologic; Niacinamide; Osteopontin; Phenylurea Compounds; Repressor Proteins; Sequence Analysis, RNA; Signal Transduction; Sorafenib; Ultrasonography; Up-Regulation; Vascular Endothelial Growth Factor A; Vimentin; Zinc Finger E-box Binding Homeobox 2; Zinc Finger E-box-Binding Homeobox 1 | 2016 |
[Evaluation of Sorafenib for Hepatocellular Carcinoma with Low α-Fetoprotein by Arrival Time Parametric Imaging Using Contrast-Enhanced Ultrasonography with Sonazoid].
Topics: Aged; Aged, 80 and over; alpha-Fetoproteins; Antineoplastic Agents; Carcinoma, Hepatocellular; Contrast Media; Female; Ferric Compounds; Humans; Iron; Liver Neoplasms; Male; Middle Aged; Niacinamide; Oxides; Phenylurea Compounds; Sorafenib; Time Factors; Ultrasonography | 2016 |
Osteonecrosis of the jaw during sorafenib therapy for hepatocellular carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Combined Modality Therapy; Disease Progression; Fatal Outcome; Humans; Jaw; Liver Neoplasms; Male; Niacinamide; Osteonecrosis; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Tomography, X-Ray Computed | 2016 |
Sorafenib effect on liver neoplastic changes in rats: more than a kinase inhibitor.
Topics: Administration, Oral; Animals; Antineoplastic Agents; beta Catenin; Cell Proliferation; Cyclin D1; Disease Models, Animal; Glutathione; Histocytochemistry; Liver; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Rats; Sorafenib; Treatment Outcome | 2017 |
Iron depletion enhances the effect of sorafenib in hepatocarcinoma.
Topics: Animals; Carcinoma, Hepatocellular; Cell Proliferation; Disease Models, Animal; Female; Humans; Iron; Liver Neoplasms; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Prognosis; Retrospective Studies; Sorafenib; Survival Analysis | 2016 |
Rhamnetin induces sensitization of hepatocellular carcinoma cells to a small molecular kinase inhibitor or chemotherapeutic agents.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Etoposide; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Inhibitory Concentration 50; Liver Neoplasms; Male; Mice, SCID; MicroRNAs; Niacinamide; Paclitaxel; Phenylurea Compounds; Protein Kinase Inhibitors; Quercetin; Receptor, Notch1; Signal Transduction; Sorafenib; Transfection; Xenograft Model Antitumor Assays | 2016 |
Cytochrome P450 1A2 Metabolizes 17β-Estradiol to Suppress Hepatocellular Carcinoma.
Topics: 2-Methoxyestradiol; Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cytochrome P-450 CYP1A2; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogens; Humans; Liver; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Niacinamide; Phenylurea Compounds; Receptors, Estrogen; Sorafenib; Tumor Suppressor Protein p53 | 2016 |
Sorafenib after resection improves the outcome of BCLC stage C hepatocellular carcinoma.
Topics: Administration, Oral; Adult; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Drug Administration Schedule; Hepatectomy; Humans; Kaplan-Meier Estimate; Liver Function Tests; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Retrospective Studies; Risk Factors; Sorafenib; Time Factors; Treatment Outcome | 2016 |
CHD1L promotes lineage reversion of hepatocellular carcinoma through opening chromatin for key developmental transcription factors.
Topics: Animals; Carcinoma, Hepatocellular; Cell Differentiation; Cell Lineage; Chromatin; DNA Helicases; DNA-Binding Proteins; High-Throughput Nucleotide Sequencing; Liver Neoplasms; Mice; Mice, Inbred C57BL; Niacinamide; Phenylurea Compounds; Receptors, Estrogen; Sorafenib; Transcription Factors | 2016 |
Galectin-1 induces hepatocellular carcinoma EMT and sorafenib resistance by activating FAK/PI3K/AKT signaling.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Chromones; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Focal Adhesion Kinase 1; Galectin 1; Humans; Integrin alphaVbeta3; Liver Neoplasms; Male; Mice; Mice, Inbred C57BL; Mice, Nude; Morpholines; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; RNA Interference; Signal Transduction; Sorafenib; Survival Rate | 2016 |
Downregulation of amplified in breast cancer 1 contributes to the anti-tumor effects of sorafenib on human hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Down-Regulation; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Niacinamide; Nuclear Receptor Coactivator 3; Phenylurea Compounds; Signal Transduction; Sorafenib | 2016 |
Safety and efficacy of sorafenib in Japanese patients with hepatocellular carcinoma in clinical practice: a subgroup analysis of GIDEON.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Dose-Response Relationship, Drug; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Product Surveillance, Postmarketing; Prospective Studies; Sorafenib; Treatment Outcome; Young Adult | 2016 |
Evaluation of dose-efficacy of sorafenib and effect of transarterial chemoembolization in hepatocellular carcinoma patients: a retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Dose-Response Relationship, Drug; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Retrospective Studies; Sorafenib; Treatment Outcome | 2016 |
Cost-effectiveness analysis of antiviral therapy in patients with advanced hepatitis B virus-related hepatocellular carcinoma treated with sorafenib.
Topics: Adult; Aged; Antineoplastic Agents; Antiviral Agents; Carcinoma, Hepatocellular; China; Cost-Benefit Analysis; Disease Progression; Disease-Free Survival; Drug Costs; Female; Hepatitis B; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Markov Chains; Middle Aged; Models, Economic; Niacinamide; Phenylurea Compounds; Quality of Life; Quality-Adjusted Life Years; Retrospective Studies; Sorafenib; Time Factors; Treatment Outcome | 2016 |
A CD13 inhibitor, ubenimex, synergistically enhances the effects of anticancer drugs in hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; CD13 Antigens; Cell Cycle; Cell Line, Tumor; Cisplatin; Drug Synergism; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Leucine; Liver Neoplasms; Neoplastic Stem Cells; Niacinamide; Phenylurea Compounds; Reactive Oxygen Species; Sorafenib | 2016 |
Sorafenib-resistant hepatocellular carcinoma stratified by phosphorylated ERK activates PD-1 immune checkpoint.
Topics: Animals; Carcinoma, Hepatocellular; Cell Cycle Checkpoints; Cell Line, Tumor; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Female; Hep G2 Cells; Humans; K562 Cells; Liver Neoplasms; Mice; Mice, Nude; Mice, Transgenic; Niacinamide; Phenylurea Compounds; Phosphorylation; Programmed Cell Death 1 Receptor; Signal Transduction; Sorafenib | 2016 |
Radioembolization Is a Safe and Effective Treatment for Hepatocellular Carcinoma with Portal Vein Thrombosis: A Propensity Score Analysis.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Embolization, Therapeutic; Female; Humans; Liver Neoplasms; Male; Microspheres; Middle Aged; Niacinamide; Phenylurea Compounds; Portal Vein; Propensity Score; Radiopharmaceuticals; Republic of Korea; Retrospective Studies; Sorafenib; Treatment Outcome; Venous Thrombosis; Yttrium Radioisotopes | 2016 |
ADRB2 signaling promotes HCC progression and sorafenib resistance by inhibiting autophagic degradation of HIF1α.
Topics: Animals; Autophagy; Carcinoma, Hepatocellular; Disease Progression; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Receptors, Adrenergic, beta-2; Signal Transduction; Sorafenib | 2016 |
The effect of locoregional therapies in patients with advanced hepatocellular carcinoma treated with sorafenib.
Topics: Ablation Techniques; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Chemoradiotherapy, Adjuvant; Chi-Square Distribution; Female; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Liver Neoplasms; Logistic Models; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Propensity Score; Proportional Hazards Models; Retrospective Studies; Risk Factors; Sorafenib; Time Factors; Treatment Outcome | 2016 |
Acidic pH-Triggered Drug-Eluting Nanocomposites for Magnetic Resonance Imaging-Monitored Intra-arterial Drug Delivery to Hepatocellular Carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Delivery Systems; Hydrogen-Ion Concentration; Liver Neoplasms; Magnetic Resonance Imaging; Nanocomposites; Niacinamide; Phenylurea Compounds; Rats; Sorafenib | 2016 |
Sorafenib in the treatment of hepatocellular carcinoma: a multi-centre real-world study.
Topics: Aged; alpha-Fetoproteins; Antineoplastic Agents; Carcinoma, Hepatocellular; Cohort Studies; Female; Humans; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Retrospective Studies; Sorafenib; Treatment Outcome | 2016 |
Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways.
Topics: Animals; Antineoplastic Agents; Apoptosis; Biomarkers; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Antagonism; Hep G2 Cells; Humans; Liver Neoplasms; Mice, Nude; Mitogen-Activated Protein Kinases; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Phosphotransferases; Protein Precursors; Prothrombin; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-raf; Signal Transduction; Sorafenib; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2016 |
Metastatic renal cell carcinoma: the first report of unilateral fundus hemorrhage induced by sorafenib.
Topics: Adult; Antineoplastic Agents; Carcinoma, Renal Cell; Eye Hemorrhage; Fundus Oculi; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Sorafenib | 2016 |
Metallothionein-1 as a biomarker of altered redox metabolism in hepatocellular carcinoma cells exposed to sorafenib.
Topics: Antineoplastic Agents; Biomarkers; Carcinoma, Hepatocellular; Cell Line, Tumor; Cysteine; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Metallothionein; NF-E2-Related Factor 2; Niacinamide; Oxidation-Reduction; Oxidative Stress; Phenylurea Compounds; Prognosis; Promoter Regions, Genetic; Protein Kinase Inhibitors; Sorafenib; Transcription, Genetic | 2016 |
Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Clinical Trials, Phase III as Topic; Disease-Free Survival; Drug Costs; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Kaplan-Meier Estimate; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2016 |
Simultaneous multitarget radiotherapy using helical tomotherapy and its combination with sorafenib for pulmonary metastases from hepatocellular carcinoma.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cohort Studies; Combined Modality Therapy; Disease-Free Survival; Feasibility Studies; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Radiotherapy, Intensity-Modulated; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome | 2016 |
Cost-effectiveness of sorafenib versus SBRT for unresectable advanced hepatocellular carcinoma.
Topics: Aged; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Decision Making; Disease Progression; Disease-Free Survival; Female; Humans; Liver Neoplasms; Male; Markov Chains; Monte Carlo Method; Niacinamide; Phenylurea Compounds; Probability; Quality-Adjusted Life Years; Radiosurgery; Randomized Controlled Trials as Topic; Sorafenib; Taiwan | 2016 |
Expanded and Activated Natural Killer Cells for Immunotherapy of Hepatocellular Carcinoma.
Topics: Animals; Antineoplastic Agents; Biomarkers; Carcinoma, Hepatocellular; Cell Line, Tumor; Combined Modality Therapy; Cytotoxicity, Immunologic; Disease Models, Animal; Humans; Immunophenotyping; Immunotherapy; Immunotherapy, Adoptive; Killer Cells, Natural; Liver Neoplasms; Lymphocyte Activation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Xenograft Model Antitumor Assays | 2016 |
Sorafenib inhibits macrophage-mediated epithelial-mesenchymal transition in hepatocellular carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Epithelial-Mesenchymal Transition; Humans; Liver Neoplasms; Macrophages; Male; Niacinamide; Phenylurea Compounds; Signal Transduction; Sorafenib | 2016 |
A multicentre comparison between Child Pugh and Albumin-Bilirubin scores in patients treated with sorafenib for Hepatocellular Carcinoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Bilirubin; Carcinoma, Hepatocellular; Female; France; Humans; Liver Neoplasms; Lung; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Retrospective Studies; Serum Albumin; Severity of Illness Index; Sorafenib; Survival Analysis; United Kingdom; Young Adult | 2016 |
[Effective Prevention of Hand-Foot Syndrome by the Consumption of Dried Bonito Broth].
Topics: Aged; Antineoplastic Agents; Female; Fish Products; Hand-Foot Syndrome; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Bone Neoplasms; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease-Free Survival; Humans; Imidazoles; Indazoles; Indoles; Interferon-alpha; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Pyrroles; Remission Induction; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib; Survival Rate; Treatment Outcome; Tumor Burden | 2016 |
Potential efficacy of therapies targeting intrahepatic lesions after sorafenib treatment of patients with hepatocellular carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Prognosis; Retrospective Studies; Salvage Therapy; Sorafenib; Treatment Outcome | 2016 |
Aggressive Treatment of Performance Status 1 and 2 HCC Patients Significantly Improves Survival - an Egyptian Retrospective Cohort Study of 524 Cases.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Retrospective Studies; Sorafenib; Survival Rate | 2016 |
Advanced-stage hepatocellular carcinoma with portal vein thrombosis: conventional versus drug-eluting beads transcatheter arterial chemoembolization.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Portal Vein; Retrospective Studies; Sorafenib; Survival Analysis; Survival Rate; Treatment Outcome; Venous Thrombosis | 2017 |
Evaluation of antiangiogenic and antiproliferative effects of sorafenib by sequential histology and intravoxel incoherent motion diffusion-weighted imaging in an orthotopic hepatocellular carcinoma xenograft model.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Diffusion Magnetic Resonance Imaging; Image Enhancement; Image Interpretation, Computer-Assisted; Liver Neoplasms; Magnetic Resonance Angiography; Male; Mice; Mice, Inbred BALB C; Motion; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Reproducibility of Results; Sensitivity and Specificity; Sorafenib; Treatment Outcome | 2017 |
Clinical Trial Simulations From a Model-Based Meta-Analysis of Studies in Patients With Advanced Hepatocellular Carcinoma Receiving Antiangiogenic Therapy.
Topics: Aged; Angiogenesis Inhibitors; Carcinoma, Hepatocellular; Clinical Trials, Phase II as Topic; Computer Simulation; Female; Humans; Liver Neoplasms; Male; Middle Aged; Network Meta-Analysis; Niacinamide; Phenylurea Compounds; Sorafenib | 2016 |
Overexpression of DLX2 is associated with poor prognosis and sorafenib resistance in hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Female; Homeodomain Proteins; Humans; Immunohistochemistry; Ki-67 Antigen; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib; Survival Analysis; Transcription Factors | 2016 |
In vivo biodistribution, biocompatibility, and efficacy of sorafenib-loaded lipid-based nanosuspensions evaluated experimentally in cancer.
Topics: Administration, Intravenous; Animals; Antineoplastic Agents; Biocompatible Materials; Carcinoma, Hepatocellular; Cell Death; Cell Line, Tumor; Cell Survival; Drug Liberation; Female; Hemolysis; Humans; Inhibitory Concentration 50; Lipids; Liver Neoplasms; Mice; Nanoparticles; Niacinamide; Phenylurea Compounds; Rabbits; Sorafenib; Suspensions; Tissue Distribution; Treatment Outcome; Veins | 2016 |
Complete and Sustained Off-Therapy Response to Sorafenib in Advanced Hepatocellular Carcinoma.
Topics: Aged; alpha-Fetoproteins; Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Administration Schedule; Female; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Remission Induction; Sorafenib; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden | 2016 |
Decrease in tumor enhancement on contrast-enhanced CT is associated with improved survival in patients with hepatocellular carcinoma treated with Sorafenib.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Retrospective Studies; Sorafenib; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome | 2016 |
NUPR1, a new target in liver cancer: implication in controlling cell growth, migration, invasion and sorafenib resistance.
Topics: Aged; Aged, 80 and over; Apoptosis Regulatory Proteins; Basic Helix-Loop-Helix Transcription Factors; Carcinoma, Hepatocellular; Cell Movement; Cell Proliferation; Cell Survival; Computational Biology; Core Binding Factor Alpha 1 Subunit; Down-Regulation; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Gene Silencing; Humans; Liver Neoplasms; Male; Membrane Proteins; Middle Aged; Molecular Targeted Therapy; Neoplasm Invasiveness; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; RNA, Small Interfering; Sorafenib; Transcription Factor RelB; Transcriptome; Young Adult | 2016 |
Successful liver transplantation for hepatocellular carcinoma following down-staging using sorafenib single therapy.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Liver Transplantation; Niacinamide; Phenylurea Compounds; Sorafenib | 2016 |
Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy and Sorafenib in Patients with Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Drug Resistance, Neoplasm; Female; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Interferons; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Retrospective Studies; Sorafenib; Treatment Outcome | 2016 |
[Endovascular implantation of iodine-125 seeds strand and portal vein stenting followed by transcatheter arterial chemoembolization combined therapy with sorafenib for hepatocellular carcinoma with main portal vein tumor thrombus].
Topics: Arteries; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Endovascular Procedures; Humans; Iodine Radioisotopes; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Portal Vein; Sorafenib; Stents; Thrombosis; Treatment Outcome | 2016 |
Sirtuin 3 enhanced drug sensitivity of human hepatoma cells through glutathione S-transferase pi 1/JNK signaling pathway.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Separation; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Glutathione; Glutathione S-Transferase pi; Glycogen Synthase Kinase 3; Humans; Liver Neoplasms; MAP Kinase Kinase 4; MAP Kinase Signaling System; Niacinamide; Phenylurea Compounds; RNA, Messenger; Signal Transduction; Sirtuin 3; Sorafenib | 2016 |
Severe adverse skin reaction and desensitization to sorafenib.
Topics: Adult; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Growth Processes; Desensitization, Immunologic; Drug Hypersensitivity; Female; Humans; Immune Tolerance; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib; Urticaria; Young Adult | 2016 |
Increased FGF19 copy number is frequently detected in hepatocellular carcinoma with a complete response after sorafenib treatment.
Topics: Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Case-Control Studies; Disease Progression; Female; Fibroblast Growth Factors; Gene Dosage; High-Throughput Nucleotide Sequencing; Humans; Liver Neoplasms; Male; Middle Aged; Mutation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Receptors, Fibroblast Growth Factor; Remission Induction; Retrospective Studies; Sequence Analysis, DNA; Sorafenib; Treatment Outcome | 2016 |
miR-181a induces sorafenib resistance of hepatocellular carcinoma cells through downregulation of RASSF1 expression.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Caspase 3; Cell Cycle; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Liver Neoplasms; MicroRNAs; Niacinamide; Phenylurea Compounds; RNA Interference; Sorafenib; Tumor Suppressor Proteins | 2016 |
Efficacy of sorafenib in BRAF-mutated non-small-cell lung cancer (NSCLC) and no response in synchronous BRAF wild type-hepatocellular carcinoma: a case report.
Topics: Aged; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Humans; Liver Neoplasms; Lung Neoplasms; Male; Mutation; Neoplasms, Multiple Primary; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Sorafenib; Treatment Outcome | 2016 |
Inhibition of the Wnt/β-catenin signaling pathway improves the anti-tumor effects of sorafenib against hepatocellular carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; beta Catenin; Bridged Bicyclo Compounds, Heterocyclic; Carcinoma, Hepatocellular; Cell Proliferation; Dose-Response Relationship, Drug; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Liver Neoplasms; Male; Mice, Inbred BALB C; Mice, Nude; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidinones; RNA Interference; RNAi Therapeutics; Sorafenib; Transfection; Wnt Signaling Pathway; Xenograft Model Antitumor Assays | 2016 |
[Plasma Biomarkers as Predictive Factors for Advanced Hepatocellular Carcinoma with Sorafenib].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib | 2016 |
Clinical analysis of patients with hepatocellular carcinoma recurrence after living-donor liver transplantation.
Topics: Adult; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Liver Transplantation; Living Donors; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sirolimus; Sorafenib | 2016 |
Small-molecule inhibitor sorafenib regulates immunoreactions by inducing survival and differentiation of bone marrow cells.
Topics: Animals; Bone Marrow Cells; Cell Differentiation; Cytokines; Dendritic Cells; Female; Humans; Immunomodulation; Liver Neoplasms; Liver Transplantation; Lymphocyte Culture Test, Mixed; Mice; Mice, Inbred BALB C; Niacinamide; Phenylurea Compounds; Sorafenib; T-Lymphocytes | 2016 |
Is radioembolization or sorafenib the best option for patients with hepatocellular carcinoma and portal vein invasion?
Topics: Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Portal Vein; Sorafenib | 2016 |
Synergistic inhibition of characteristics of liver cancer stem-like cells with a combination of sorafenib and 8-bromo-7-methoxychrysin in SMMC-7721 cell line.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Drug Synergism; Flavonoids; Flow Cytometry; Humans; Liver Neoplasms; Neoplastic Stem Cells; Niacinamide; Phenylurea Compounds; Sorafenib | 2016 |
Alternative treatments in advanced hepatocellular carcinoma patients with progressive disease after sorafenib treatment: a prospective multicenter cohort study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Drug Substitution; Female; Humans; Japan; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Prospective Studies; Protein Kinase Inhibitors; Retreatment; Sorafenib; Time Factors; Treatment Outcome | 2016 |
A case report: delayed high fever and maculopapules during Sorafenib treatment of ectopic hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Drug Eruptions; Fever; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prednisone; Sorafenib; Treatment Outcome | 2016 |
Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Child; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Prospective Studies; Registries; Sorafenib | 2016 |
[Prediction and preventive strategies for recurrence after surgery for hepatocellular carcinoma].
Topics: Biopsy; Carcinoma, Hepatocellular; Embolization, Therapeutic; Humans; Immunotherapy; Interferons; Liver Neoplasms; MicroRNAs; Neoplasm Recurrence, Local; Niacinamide; Osteopontin; Phenylurea Compounds; Sorafenib; Tumor Microenvironment | 2016 |
Inactivation of hypoxia-induced YAP by statins overcomes hypoxic resistance tosorafenib in hepatocellular carcinoma cells.
Topics: Adaptor Proteins, Signal Transducing; Animals; Apoptosis; Atorvastatin; Carcinoma, Hepatocellular; Cell Hypoxia; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver Neoplasms; Mice, Nude; Niacinamide; Phenylurea Compounds; Phosphoproteins; Prognosis; Protein Transport; Sorafenib; Transcription Factors; Xenograft Model Antitumor Assays; YAP-Signaling Proteins | 2016 |
Capecitabine in advanced hepatocellular carcinoma.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Survival Analysis | 2016 |
Krüppel-like factor 8 promotes cancer stem cell-like traits in hepatocellular carcinoma through Wnt/β-catenin signaling.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Kruppel-Like Transcription Factors; Liver; Liver Neoplasms; Neoplastic Stem Cells; Niacinamide; Phenylurea Compounds; Prognosis; Repressor Proteins; Sorafenib; Wnt Proteins; Wnt Signaling Pathway | 2017 |
Melatonin-induced increase in sensitivity of human hepatocellular carcinoma cells to sorafenib is associated with reactive oxygen species production and mitophagy.
Topics: Apoptosis; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Liver Neoplasms; Melatonin; Mitophagy; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Reactive Oxygen Species; Sorafenib | 2016 |
FOLFOX4 or sorafenib as the first-line treatments for advanced hepatocellular carcinoma: A cost-effectiveness analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; China; Cohort Studies; Cost-Benefit Analysis; Female; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Monte Carlo Method; Niacinamide; Organoplatinum Compounds; Phenylurea Compounds; Quality-Adjusted Life Years; Sorafenib | 2016 |
The effect of radiotherapy in liver-confined but non-resectable Barcelona Clinic Liver Cancer stage C large hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Child; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Liver; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Propensity Score; Registries; Regression Analysis; Republic of Korea; Retrospective Studies; Sorafenib; Time Factors; Treatment Outcome; Young Adult | 2016 |
Sorafenib in combination with transarterial chemoembolization for the treatment of hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Clinical Decision-Making; Clinical Trials as Topic; Combined Modality Therapy; Disease Management; Humans; Liver Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Treatment Outcome | 2016 |
Role of transarterial chemoembolization in relation with sorafenib for patients with advanced hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Survival Analysis; Treatment Outcome | 2016 |
Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chromones; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Genes, myc; Humans; Liver Neoplasms; Mice; Niacinamide; Nuclear Proteins; Oligopeptides; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Binding; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; raf Kinases; ras Proteins; Signal Transduction; Sorafenib; TOR Serine-Threonine Kinases; Transcription Factors; Transcription Initiation Site; Xenograft Model Antitumor Assays | 2016 |
Impact of Diabetes on Outcomes of Sorafenib Therapy for Hepatocellular Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Diabetes Complications; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Survival Rate; Treatment Outcome | 2017 |
Response to Successful liver transplantation for hepatocellular carcinoma following down-staging using sorafenib single therapy by Borentain et al.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Liver Transplantation; Niacinamide; Phenylurea Compounds; Sorafenib | 2016 |
The Limonoids TS3 and Rubescin E Induce Apoptosis in Human Hepatoma Cell Lines and Interfere with NF-κB Signaling.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Humans; Limonins; Liver Neoplasms; NF-kappa B; Niacinamide; Phenylurea Compounds; Signal Transduction; Sorafenib | 2016 |
Angiopoietin-like protein 1 antagonizes MET receptor activity to repress sorafenib resistance and cancer stemness in hepatocellular carcinoma.
Topics: Angiopoietin-Like Protein 1; Angiopoietin-like Proteins; Angiopoietins; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Female; Humans; Liver Neoplasms; Male; Mice; Middle Aged; Neoplastic Stem Cells; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-met; Sorafenib | 2016 |
Polymorphisms in SLCO1B1 and UGT1A1 are associated with sorafenib-induced toxicity.
Topics: Adult; Aged; Antineoplastic Agents; Female; Genotype; Glucuronosyltransferase; Humans; Liver Neoplasms; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Multidrug Resistance-Associated Protein 2; Niacinamide; Phenylurea Compounds; Polymorphism, Single Nucleotide; Retrospective Studies; Sorafenib | 2016 |
Analysis of Sorafenib Outcome: Focusing on the Clinical Course in Patients with Hepatocellular Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Treatment Outcome | 2016 |
Identification of clinical biomarkers for patients with advanced hepatocellular carcinoma receiving sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Retrospective Studies; Sorafenib; Survival Rate | 2017 |
Identification of a novel oxidative stress induced cell death by Sorafenib and oleanolic acid in human hepatocellular carcinoma cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers; Carcinoma, Hepatocellular; Caspase 3; Caspase 7; Caspase Inhibitors; Cell Death; Cell Line, Tumor; Cell Survival; DNA Fragmentation; Drug Synergism; Enzyme Activation; Free Radical Scavengers; Humans; Liver Neoplasms; Niacinamide; Oleanolic Acid; Oxidative Stress; Phenylurea Compounds; Proteolysis; Reactive Oxygen Species; Sorafenib | 2016 |
Role of Sorafenib in Patients With Recurrent Hepatocellular Carcinoma After Liver Transplantation.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Liver Transplantation; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Treatment Outcome | 2016 |
Retrospective analysis of transarterial chemoembolization and sorafenib in Chinese patients with unresectable and recurrent hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Chi-Square Distribution; China; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Retrospective Studies; Risk Factors; Sorafenib; Time Factors; Treatment Outcome | 2016 |
Curative therapies are superior to standard of care (transarterial chemoembolization) for intermediate stage hepatocellular carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Female; Humans; Italy; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Niacinamide; Patient Selection; Phenylurea Compounds; Propensity Score; Retrospective Studies; Sorafenib; Standard of Care; Survival Analysis; Treatment Outcome | 2017 |
Indole-3- carbinol enhances sorafenib cytotoxicity in hepatocellular carcinoma cells: A mechanistic study.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Cycle; Cell Proliferation; Cell Survival; Drug Synergism; Epithelial-Mesenchymal Transition; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Indoles; Liver Neoplasms; NADPH Oxidase 1; Niacinamide; Phenylurea Compounds; Sorafenib | 2016 |
Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Disease-Free Survival; Female; Humans; Inflammation; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Retrospective Studies; Sorafenib | 2016 |
IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antibodies, Neutralizing; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Case-Control Studies; Cell Line, Tumor; Cell Movement; Cell Proliferation; DNA Methylation; Epigenesis, Genetic; Female; Gene Expression; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Insulin-Like Growth Factor II; Liver Neoplasms; Male; Mice, Inbred C57BL; MicroRNAs; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phosphorylation; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Receptor, IGF Type 1; Receptors, Somatomedin; RNA, Messenger; RNA, Small Interfering; Signal Transduction; Sorafenib; Tumor Stem Cell Assay; Up-Regulation | 2016 |
Sorafenib plus cisplatin for hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Clinical Trials, Phase II as Topic; Disease Progression; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Randomized Controlled Trials as Topic; Sorafenib; Treatment Outcome | 2016 |
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: age is not a problem.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chi-Square Distribution; Disease Progression; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Logistic Models; London; Male; Middle Aged; Multivariate Analysis; Niacinamide; Odds Ratio; Patient Selection; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Retrospective Studies; Risk Factors; Sorafenib; Time Factors; Treatment Outcome | 2017 |
Hepatic stellate cells induce hepatocellular carcinoma cell resistance to sorafenib through the laminin-332/α3 integrin axis recovery of focal adhesion kinase ubiquitination.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Focal Adhesion Protein-Tyrosine Kinases; Hepatic Stellate Cells; Humans; Integrin alpha3; Laminin; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib; Tumor Cells, Cultured; Ubiquitination | 2016 |
mRECIST response combined with sorafenib-related adverse events is superior to either criterion alone in predicting survival in HCC patients treated with TACE plus sorafenib.
Topics: Adult; Aged; Aged, 80 and over; alpha-Fetoproteins; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Retrospective Studies; Sorafenib; Treatment Outcome | 2017 |
The miR-367-3p Increases Sorafenib Chemotherapy Efficacy to Suppress Hepatocellular Carcinoma Metastasis through Altering the Androgen Receptor Signals.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease Models, Animal; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Male; Mice; MicroRNAs; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Receptors, Androgen; Signal Transduction; Sorafenib; Xenograft Model Antitumor Assays | 2016 |
An artificial lncRNA targeting multiple miRNAs overcomes sorafenib resistance in hepatocellular carcinoma cells.
Topics: Adenoviridae; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Disease Models, Animal; Drug Resistance, Neoplasm; Genetic Vectors; Humans; Liver Neoplasms; Male; Mice; MicroRNAs; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; RNA Interference; RNA, Long Noncoding; Signal Transduction; Sorafenib; Xenograft Model Antitumor Assays | 2016 |
Exosomes derived from HCC cells induce sorafenib resistance in hepatocellular carcinoma both in vivo and in vitro.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Exosomes; Gene Expression Regulation, Neoplastic; Hepatocyte Growth Factor; Humans; Liver Neoplasms; Mice; Mice, Nude; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-met; Signal Transduction; Sorafenib; Tumor Microenvironment | 2016 |
Overexpression of PCBP2 contributes to poor prognosis and enhanced cell growth in human hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gene Expression; Humans; Inhibitory Concentration 50; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; RNA-Binding Proteins; Sorafenib; Young Adult | 2016 |
Ginkgo biloba extract in combination with sorafenib is clinically safe and tolerable in advanced hepatocellular carcinoma patients.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Hepatocellular; Cohort Studies; Disease Progression; Drug Therapy, Combination; Female; Ginkgo biloba; Humans; Liver Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Niacinamide; Phenylurea Compounds; Plant Extracts; Prospective Studies; Sorafenib; Survival Analysis; Treatment Outcome | 2016 |
Survival and cost-effectiveness of sorafenib therapy in advanced hepatocellular carcinoma: An analysis of the SEER-Medicare database.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Databases, Factual; Female; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Medicare; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; SEER Program; Sorafenib; Survival Rate; United States | 2017 |
Multiparametric MR diffusion-weighted imaging for monitoring the ultra-early treatment effect of sorafenib in human hepatocellular carcinoma xenografts.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Diffusion Magnetic Resonance Imaging; Drug Monitoring; Early Detection of Cancer; Female; Humans; Image Interpretation, Computer-Assisted; Liver Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Multimodal Imaging; Niacinamide; Phenylurea Compounds; Reproducibility of Results; Sensitivity and Specificity; Sorafenib; Treatment Outcome | 2017 |
[Implementation of a nurse-driven educational program improves management of sorafenib's toxicities in hepatocellular carcinoma].
Topics: Administration, Oral; Aged; Antineoplastic Agents; Asthenia; Carcinoma, Hepatocellular; Diarrhea; Female; Hand-Foot Syndrome; Humans; Liver Neoplasms; Male; Niacinamide; Patient Education as Topic; Phenylurea Compounds; Practice Patterns, Nurses'; Protein Kinase Inhibitors; Retrospective Studies; Sorafenib | 2016 |
Painful Rashes on the Palms and Soles.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Hand-Foot Syndrome; Humans; Liver Neoplasms; Male; Neoplasms, Multiple Primary; Niacinamide; Phenylurea Compounds; Sorafenib | 2016 |
Longitudinal alterations in health-related quality of life and its impact on the clinical course of patients with advanced hepatocellular carcinoma receiving sorafenib treatment.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Longitudinal Studies; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prospective Studies; Quality of Life; Social Behavior; Sorafenib; Treatment Outcome | 2016 |
Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Death; Cell Line, Tumor; Cell Proliferation; Cellular Senescence; Drug Evaluation, Preclinical; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyridines; Retinoblastoma Binding Proteins; Sorafenib; Ubiquitin-Protein Ligases | 2017 |
TGFβ signaling confers sorafenib resistance via induction of multiple RTKs in hepatocellular carcinoma cells.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Liver; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyrazoles; Quinolines; Receptor Protein-Tyrosine Kinases; Signal Transduction; Sorafenib; Transforming Growth Factor beta | 2017 |
Sorafenib pretreatment enhances radiotherapy through targeting MEK/ERK/NF-κB pathway in human hepatocellular carcinoma-bearing mouse model.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Survival; Chemoradiotherapy; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Liver Neoplasms; Male; MAP Kinase Kinase Kinases; Mice, Inbred BALB C; Mice, Nude; NF-kappa B; Niacinamide; Phenylurea Compounds; Phosphorylation; Promoter Regions, Genetic; Signal Transduction; Sorafenib; Time Factors; Transfection; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
Long non-coding RNA TUC338 is functionally involved in sorafenib-sensitized hepatocarcinoma cells by targeting RASAL1.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; GTPase-Activating Proteins; Humans; Liver Neoplasms; Male; Mice, Nude; Niacinamide; Phenylurea Compounds; RNA, Long Noncoding; Sorafenib; Xenograft Model Antitumor Assays | 2017 |
Lactate dehydrogenase is a prognostic indicator in patients with hepatocellular carcinoma treated by sorafenib: results from the real life practice in HBV endemic area.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease-Free Survival; Female; Hepatitis B; Humans; L-Lactate Dehydrogenase; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib | 2016 |
Inhibition of acquired-resistance hepatocellular carcinoma cell growth by combining sorafenib with phosphoinositide 3-kinase and rat sarcoma inhibitor.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Diphenylamine; Drug Resistance, Neoplasm; Heterocyclic Compounds, 3-Ring; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib | 2016 |
Implications of vessel co-option in sorafenib-resistant hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Mice; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Sorafenib | 2016 |
Adjuvant therapies in advanced hepatocellular carcinoma: moving forward from the STORM.
Topics: Angiogenesis Inhibitors; Carcinoma, Hepatocellular; Catheter Ablation; Chemotherapy, Adjuvant; Disease Progression; Disease-Free Survival; Hepatectomy; Humans; Liver Neoplasms; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Randomized Controlled Trials as Topic; Sorafenib; Time Factors; Treatment Outcome | 2016 |
Blocking preferential glucose uptake sensitizes liver tumor-initiating cells to glucose restriction and sorafenib treatment.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Glucose; Humans; Liver Neoplasms; Neoplastic Stem Cells; Niacinamide; Phenylurea Compounds; Sorafenib | 2017 |
Complete response with sorafenib and transcatheter arterial chemoembolization in unresectable hepatocellular carcinoma.
Topics: Aged; Angiography, Digital Subtraction; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatectomy; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Phlebography; Portal Vein; Protein Kinase Inhibitors; Sorafenib; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Venous Thrombosis | 2016 |
Texture analysis of intermediate-advanced hepatocellular carcinoma: prognosis and patients' selection of transcatheter arterial chemoembolization and sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Disease Progression; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib; Young Adult | 2017 |
CXCL12 expression and PD-L1 expression serve as prognostic biomarkers in HCC and are induced by hypoxia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Biomarkers, Tumor; Carcinoma, Hepatocellular; Chemokine CXCL12; Chemotherapy, Adjuvant; Female; Hepatectomy; Humans; Hypoxia; Immunohistochemistry; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Radiotherapy, Adjuvant; Retrospective Studies; Sorafenib; Survival Analysis; Tissue Array Analysis; Young Adult | 2017 |
Neurotensin regulation induces overexpression and activation of EGFR in HCC and restores response to erlotinib and sorafenib.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Humans; Liver Neoplasms; Neurotensin; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib; Transfection | 2017 |
Contrary influence of clinically applied sorafenib concentrations among hepatocellular carcinoma patients.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib; Tumor Cells, Cultured | 2017 |
Sorafenib and 2-Deoxyglucose Synergistically Inhibit Proliferation of Both Sorafenib-Sensitive and -Resistant HCC Cells by Inhibiting ATP Production.
Topics: Adenosine Triphosphate; AMP-Activated Protein Kinases; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Deoxyglucose; Drug Synergism; G1 Phase; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Resting Phase, Cell Cycle; Sorafenib | 2017 |
Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.
Topics: Animals; Benzimidazoles; Blotting, Western; Butadienes; Carcinoma, Hepatocellular; Cell Line, Tumor; CRISPR-Cas Systems; Cytoskeletal Proteins; DNA, Neoplasm; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Genes, Neurofibromatosis 1; Genome-Wide Association Study; Hepatocytes; High-Throughput Nucleotide Sequencing; HMGA Proteins; HMGA2 Protein; Humans; Immunohistochemistry; Liver Neoplasms; Liver Neoplasms, Experimental; Membrane Glycoproteins; Mice; Mice, Knockout; Mice, Nude; Mitogen-Activated Protein Kinases; Nerve Tissue Proteins; Niacinamide; Nitriles; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-myc; Pyridones; Pyrimidinones; ras Proteins; Real-Time Polymerase Chain Reaction; Receptors, Cell Surface; Sequence Analysis, DNA; Sorafenib; Survival Analysis; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2017 |
Combination of metformin and sorafenib suppresses proliferation and induces autophagy of hepatocellular carcinoma via targeting the mTOR pathway.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Carcinoma, Hepatocellular; Cell Proliferation; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Metformin; Multiprotein Complexes; Niacinamide; Phenylurea Compounds; Signal Transduction; Sorafenib; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2017 |
Sorafenib for the Treatment of Advanced Hepatocellular Cancer - a UK Audit.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Clinical Audit; Databases, Factual; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Survival Analysis; Treatment Outcome; United Kingdom; Young Adult | 2017 |
Activated p53 with Histone Deacetylase Inhibitor Enhances L-Fucose-Mediated Drug Delivery through Induction of Fucosyltransferase 8 Expression in Hepatocellular Carcinoma Cells.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Delivery Systems; Drug Synergism; Fucose; Fucosyltransferases; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Histone Deacetylase Inhibitors; Humans; Liposomes; Liver Neoplasms; Mice; Niacinamide; Phenylurea Compounds; Sorafenib; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2016 |
Patterns of sorafenib and TACE treatment of unresectable hepatocellular carcinoma in a Chinese population: subgroup analysis of the GIDEON study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; China; Combined Modality Therapy; Female; Humans; Liver Function Tests; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib; Survival Analysis; Treatment Outcome; Young Adult | 2017 |
MicroRNA-125a-5p Is a Downstream Effector of Sorafenib in Its Antiproliferative Activity Toward Human Hepatocellular Carcinoma Cells.
Topics: Base Sequence; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; MicroRNAs; Niacinamide; Phenylurea Compounds; Proto-Oncogene Mas; Reproducibility of Results; Sorafenib; Up-Regulation | 2017 |
Ilexgenin A exerts anti-inflammation and anti-angiogenesis effects through inhibition of STAT3 and PI3K pathways and exhibits synergistic effects with Sorafenib on hepatoma growth.
Topics: Angiogenesis Inhibitors; Animals; Anti-Inflammatory Agents; Carcinoma, Hepatocellular; Cell Proliferation; Drug Synergism; Hep G2 Cells; Humans; Liver Neoplasms; Mice; Mice, Inbred BALB C; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Phosphorylation; Sorafenib; STAT3 Transcription Factor; Triterpenes | 2017 |
Synergistic Combination for Chemoprevention of Hepatocellular Carcinoma: An In Silico and In Vitro Approach.
Topics: Alanine Transaminase; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotransferases; Carcinoma, Hepatocellular; Chalcone; Chemoprevention; Drug Synergism; Hep G2 Cells; Humans; Liver Neoplasms; Molecular Docking Simulation; Niacinamide; Oxidative Stress; Phenylurea Compounds; Protein Interaction Maps; Sorafenib; Vitamin K 1 | 2017 |
Moving beyond sorafenib alone in advanced hepatocellular carcinoma: is hepatic arterial infusion chemotherapy the best option?
Topics: Carcinoma, Hepatocellular; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib | 2017 |
Validation of VX2 as a Hepatocellular Carcinoma Model: Comparison of the Molecular Reaction of VX2 and HepG2 Tumor Cells to Sorafenib In Vitro.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Hep G2 Cells; Hepatocyte Growth Factor; Humans; Insulin; Interleukin-1beta; Liver Neoplasms; Niacinamide; Phenotype; Phenylurea Compounds; Phosphorylation; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Rabbits; Signal Transduction; Sorafenib; Time Factors; Vascular Endothelial Growth Factor A | 2017 |
Digitoxin synergizes with sorafenib to inhibit hepatocelluar carcinoma cell growth without inhibiting cell migration.
Topics: Antineoplastic Agents; Basic Helix-Loop-Helix Transcription Factors; Carcinoma, Hepatocellular; Cardiotonic Agents; Cell Line, Tumor; Cell Movement; Cell Proliferation; Digitoxin; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Hep G2 Cells; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Liver; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib; Vascular Endothelial Growth Factor A | 2017 |
Liver cancer drug is rejected for routine NHS use but will remain in Cancer Drugs Fund.
Topics: Advisory Committees; Antineoplastic Agents; Cost-Benefit Analysis; Humans; Liver; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Quality-Adjusted Life Years; Sorafenib; United Kingdom | 2017 |
An Explorative Analysis for the Role of Serum miR-10b-3p Levels in Predicting Response to Sorafenib in Patients with Advanced Hepatocellular Carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Down-Regulation; Female; Humans; Liver Neoplasms; Male; MicroRNAs; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Sorafenib; Survival Rate; Up-Regulation | 2017 |
CDK4/6 inhibition and sorafenib: a ménage à deux in HCC therapy?
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib | 2017 |
Advantage of sorafenib combined with radiofrequency ablation for treatment of hepatocellular carcinoma.
Topics: Animals; Carcinoma, Hepatocellular; Catheter Ablation; Combined Modality Therapy; Disease Models, Animal; Dose-Response Relationship, Drug; Humans; Liver Neoplasms; Male; Mice; Necrosis; Niacinamide; Phenylurea Compounds; Sorafenib | 2017 |
FGF19/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Fibroblast Growth Factors; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Hep G2 Cells; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Reactive Oxygen Species; Receptor, Fibroblast Growth Factor, Type 4; Signal Transduction; Sorafenib; Up-Regulation | 2017 |
In Hepatocellular Carcinoma miR-221 Modulates Sorafenib Resistance through Inhibition of Caspase-3-Mediated Apoptosis.
Topics: Aged; Aged, 80 and over; Animals; Apoptosis; Biomarkers, Tumor; Carcinoma, Hepatocellular; Caspase 3; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Liver Neoplasms; Male; Mice; MicroRNAs; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Xenograft Model Antitumor Assays | 2017 |
MiR-199a-5p and let-7c cooperatively inhibit migration and invasion by targeting MAP4K3 in hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Female; Hep G2 Cells; Humans; Liver Neoplasms; Male; MicroRNAs; Middle Aged; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Protein Serine-Threonine Kinases; Sorafenib | 2017 |
The albumin-bilirubin grade improves hepatic reserve estimation post-sorafenib failure: implications for drug development.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Agents; Bilirubin; Carcinoma, Hepatocellular; Databases, Factual; Disease Progression; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Patient Selection; Phenylurea Compounds; Prospective Studies; Sorafenib | 2017 |
Synergy with interferon-lambda 3 and sorafenib suppresses hepatocellular carcinoma proliferation.
Topics: Animals; Apoptosis; Carcinogenesis; Carcinoma, Hepatocellular; Caspase 3; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p21; Drug Synergism; Female; Humans; Interferons; Interleukins; Liver Neoplasms; Membrane Potential, Mitochondrial; Mice, Nude; Niacinamide; Phenylurea Compounds; Reactive Oxygen Species; Sorafenib | 2017 |
[Treatment Experience with Sorafenib for Lung Metastases of Hepatocellular Carcinoma Complicated with Interstitial Pneumonia].
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Lung Diseases, Interstitial; Lung Neoplasms; Male; Niacinamide; Phenylurea Compounds; Sorafenib; Tomography, X-Ray Computed | 2016 |
[A Case of Advanced Hepatocellular Carcinoma, Its Disease Progression Could Be Controlled by Multimodal Treatment].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Combined Modality Therapy; Disease Progression; Hepatectomy; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2016 |
Reply to the Letter to the editor 'Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus Sorafenib for advanced hepatocellular carcinoma: randomized phase II trial' by Fornaro et al.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib | 2017 |
Overall survival in response to sorafenib with transarterial chemoembolization for BCLC stage B hepatocellular carcinoma: propensity score analysis
.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Propensity Score; Sorafenib | 2017 |
Mathematical modelling unveils the essential role of cellular phosphatases in the inhibition of RAF-MEK-ERK signalling by sorafenib in hepatocellular carcinoma cells.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Dual Specificity Phosphatase 1; Dual Specificity Phosphatase 6; Extracellular Signal-Regulated MAP Kinases; Humans; Liver Neoplasms; MAP Kinase Kinase Kinases; Models, Biological; Niacinamide; Phenylurea Compounds; Phosphoric Monoester Hydrolases; Phosphorylation; Protein Kinase Inhibitors; Protein Phosphatase 2; raf Kinases; Signal Transduction; Sorafenib; Time Factors | 2017 |
Abdominal aortic dissection during sorafenib therapy for hepatocellular carcinoma.
Topics: Antineoplastic Agents; Aortic Aneurysm, Abdominal; Aortic Dissection; Carcinoma, Hepatocellular; Endovascular Procedures; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Stents; Treatment Outcome | 2017 |
Dual inhibition of Akt and c-Met as a second-line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Hep G2 Cells; Humans; Liver; Liver Neoplasms; Male; Mice, Inbred BALB C; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-met; PTEN Phosphohydrolase; Signal Transduction; Sorafenib | 2017 |
Melatonin promotes sorafenib-induced apoptosis through synergistic activation of JNK/c-jun pathway in human hepatocellular carcinoma.
Topics: Anthracenes; Carcinoma, Hepatocellular; Caspase 3; Cell Line, Tumor; Dose-Response Relationship, Drug; Humans; JNK Mitogen-Activated Protein Kinases; Liver Neoplasms; MAP Kinase Kinase 4; Melatonin; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Signal Transduction; Sorafenib | 2017 |
The lack of the organic cation transporter OCT1 at the plasma membrane of tumor cells precludes a positive response to sorafenib in patients with hepatocellular carcinoma.
Topics: Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Cell Membrane; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Octamer Transcription Factor-1; Phenylurea Compounds; Protein Kinase Inhibitors; Retrospective Studies; Sorafenib | 2017 |
Sorafenib and FH535 in combination act synergistically on hepatocellular carcinoma by targeting cell bioenergetics and mitochondrial function.
Topics: Apoptosis; beta Catenin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Energy Metabolism; Humans; Liver Neoplasms; Mitochondria; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Signal Transduction; Sorafenib; Sulfonamides | 2017 |
Surgical Resection for Lymph Node Metastasis After Liver Transplantation for Hepatocellular Carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoradiotherapy; Feasibility Studies; Female; Humans; Liver; Liver Neoplasms; Liver Transplantation; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Sorafenib; Survival Analysis; Time Factors; Treatment Outcome | 2017 |
Integration of the cancer-related inflammatory response as a stratifying biomarker of survival in hepatocellular carcinoma treated with sorafenib.
Topics: Aged; Antineoplastic Agents; Biomarkers; Carcinoma, Hepatocellular; Female; Follow-Up Studies; Humans; Inflammation; Liver Neoplasms; Lymphocytes; Male; Middle Aged; Neoplasm Staging; Neutrophils; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Prognosis; Retrospective Studies; Risk; Sorafenib; Survival Analysis | 2017 |
Vascular CXCR4 Expression Promotes Vessel Sprouting and Sensitivity to Sorafenib Treatment in Hepatocellular Carcinoma.
Topics: Adult; Aged; Animals; Biomarkers, Tumor; Blood Vessels; Carcinoma, Hepatocellular; Cell Line, Tumor; Disease-Free Survival; Female; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Liver; Liver Neoplasms; Male; Mice; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Receptors, CXCR4; Signal Transduction; Sorafenib; Xenograft Model Antitumor Assays | 2017 |
Impact of Hepatitis C Virus Eradication on the Clinical Outcome of Patients with Hepatitis C Virus-Related Advanced Hepatocellular Carcinoma Treated with Sorafenib.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antiviral Agents; Carcinoma, Hepatocellular; Disease Progression; Disease-Free Survival; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Japan; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Time-to-Treatment; Treatment Outcome | 2017 |
Acquired Resistance with Epigenetic Alterations Under Long-Term Antiangiogenic Therapy for Hepatocellular Carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Disease Models, Animal; DNA Methylation; Drug Resistance, Neoplasm; Epigenesis, Genetic; Gene Expression Profiling; Gene Expression Regulation; Histones; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Mice; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Promoter Regions, Genetic; Sorafenib; Treatment Outcome; Xenograft Model Antitumor Assays | 2017 |
On-target sorafenib toxicity predicts improved survival in hepatocellular carcinoma: a multi-centre, prospective study.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Diarrhea; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Survival Analysis | 2017 |
Increased expression of HOXB9 in hepatocellular carcinoma predicts poor overall survival but a beneficial response to sorafenib.
Topics: Angiogenesis Inducing Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Disease-Free Survival; Female; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Homeodomain Proteins; Humans; Liver Neoplasms; Male; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Sorafenib; Survival Analysis; Treatment Outcome; Up-Regulation | 2017 |
Higher serum interleukin-17A levels as a potential biomarker for predicting early disease progression in patients with hepatitis B virus-associated advanced hepatocellular carcinoma treated with sorafenib.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers; Carcinoma, Hepatocellular; Cohort Studies; Cytokines; Disease Progression; Disease-Free Survival; Female; Hepatitis B; Humans; Interleukin-17; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Risk Factors; Sorafenib | 2017 |
Early Sorafenib-related Biomarkers for Combination Treatment with Transarterial Chemoembolization and Sorafenib in Patients with Hepatocellular Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; China; Combined Modality Therapy; Contrast Media; Female; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome | 2017 |
Inhibition of MMP-2 Expression Enhances the Antitumor Effect of Sorafenib in Hepatocellular Carcinoma by Suppressing the PI3K/AKT/mTOR Pathway.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Synergism; Female; Humans; Liver Neoplasms; Matrix Metalloproteinase 2; Matrix Metalloproteinase Inhibitors; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Sorafenib; TOR Serine-Threonine Kinases | 2017 |
Overcoming sorafenib evasion in hepatocellular carcinoma using CXCR4-targeted nanoparticles to co-deliver MEK-inhibitors.
Topics: Animals; Benzimidazoles; Carcinoma, Hepatocellular; Cell Line; Drug Delivery Systems; Humans; Liver Neoplasms; Mice; Nanoparticles; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Receptors, CXCR4; Sorafenib | 2017 |
Plectin deficiency in liver cancer cells promotes cell migration and sensitivity to sorafenib treatment.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Hep G2 Cells; Humans; Liver Neoplasms; Plectin; Protein Kinase Inhibitors; Signal Transduction; Sorafenib | 2018 |
Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Cycle Proteins; Cell Proliferation; Chaperonins; Computational Biology; Computer Simulation; Databases, Genetic; Dose-Response Relationship, Drug; Drug Discovery; Drug Repositioning; Ethanolamine; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Hep G2 Cells; HSP90 Heat-Shock Proteins; Humans; Liver Neoplasms; Male; Molecular Chaperones; Niacinamide; Niclosamide; Phenylurea Compounds; Signal Transduction; Sorafenib; Time Factors; Transcriptome; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |
Correlation between clinical response to sorafenib in hepatocellular carcinoma treatment and polymorphisms of P-glycoprotein (ABCB1) and of breast cancer resistance protein (ABCG2): monocentric study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Carcinoma, Hepatocellular; DNA; Drug Monitoring; Female; Genotype; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Sorafenib; Treatment Outcome | 2017 |
Real-World Data for the Evaluation of Transarterial Radioembolization versus Sorafenib in Hepatocellular Carcinoma: A Cost-Effectiveness Analysis.
Topics: Aged; Antineoplastic Agents; Cancer Care Facilities; Carcinoma, Hepatocellular; Cohort Studies; Cost-Benefit Analysis; Embolization, Therapeutic; Female; Humans; Italy; Kaplan-Meier Estimate; Liver Neoplasms; Male; Markov Chains; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Quality-Adjusted Life Years; Sorafenib; Survival | 2017 |
Albumin-Bilirubin grade predicts prognosis of HCC patients with sorafenib use.
Topics: Aged; Albuminuria; Antineoplastic Agents; Bilirubin; Biomarkers; Carcinoma, Hepatocellular; Female; Humans; Liver Function Tests; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Retrospective Studies; Sorafenib; Survival Rate; Treatment Failure | 2017 |
Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib.
Topics: Administration, Topical; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Female; Fluorouracil; Foot Dermatoses; Hand Dermatoses; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Male; Middle Aged; Niacinamide; Nicotinic Acids; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Urea | 2008 |
Oesophageal variceal bleeding in hepatocellular carcinoma with portal vein thrombosis: improved outcome in response to molecular target therapy.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Portal Vein; Pyridines; Sorafenib; Venous Thrombosis | 2008 |
18F-Fluorodeoxyglucose positron emission tomography for monitoring response to sorafenib treatment in patients with hepatocellular carcinoma.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Fluorodeoxyglucose F18; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Positron-Emission Tomography; Protein Kinase Inhibitors; Pyridines; Radiopharmaceuticals; Receptors, Vascular Endothelial Growth Factor; Sorafenib | 2008 |
[The 43rd Annual Meeting of the European Association for the Study of the Liver (EASL), Milan, Italy, April 23-27, 2008].
Topics: Antineoplastic Agents; Antiviral Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Delayed-Action Preparations; Europe; Hepatitis B; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Diseases; Liver Neoplasms; Niacinamide; Oligopeptides; Patient Compliance; Phenylurea Compounds; Polyethylene Glycols; Proline; Pyridines; Recombinant Proteins; Ribavirin; Societies, Medical; Sorafenib | 2008 |
Sorafenib in liver cancer--just the beginning.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Drug Costs; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyridines; raf Kinases; Sorafenib | 2008 |
Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesulfonates; Blotting, Western; Carcinoma, Hepatocellular; Cell Proliferation; Enzyme-Linked Immunosorbent Assay; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Liver Neoplasms; Male; Mice; Mice, Nude; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Platelet Endothelial Cell Adhesion Molecule-1; Pyridines; Sirolimus; Sorafenib; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2008 |
Secondary erythrocytosis produced by the tyrosine kinase inhibitors sunitinib and sorafenib.
Topics: Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Melanoma; Middle Aged; Niacinamide; Phenylurea Compounds; Polycythemia; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2008 |
[Coadministration of sorafenib and cisplatin inhibits proliferation of hepatocellular carcinoma HepG2 cells in vitro].
Topics: Antineoplastic Agents; Apoptosis; Benzenesulfonates; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cisplatin; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Flow Cytometry; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2008 |
Practical efficacy of sorafenib monotherapy for advanced hepatocellular carcinoma patients in a Hepatitis B virus-endemic area.
Topics: Adult; Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Progression; Female; Hepatitis B; Hepatitis C; Humans; Korea; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Sorafenib; Time Factors; Treatment Outcome | 2009 |
Response to sorafenib in cisplatin-resistant thymic carcinoma: a case report.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma; Cisplatin; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Thymus Neoplasms; Tomography, X-Ray Computed | 2009 |
Sorafenib in hepatocellular carcinoma: separating the hype from the hope.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Randomized Controlled Trials as Topic; Sorafenib; Survival Rate | 2008 |
Anti-glypican 3 antibody as a potential antitumor agent for human liver cancer.
Topics: Animals; Antibodies, Monoclonal; Antibody-Dependent Cell Cytotoxicity; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Cell Growth Processes; Cell Line, Tumor; Combined Modality Therapy; Doxorubicin; Glypicans; Humans; Killer Cells, Natural; Liver Neoplasms; Male; Mice; Mice, SCID; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Xenograft Model Antitumor Assays | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Hypertension; Incidence; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quality of Life; Sorafenib | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: alpha-Fetoproteins; Benzenesulfonates; Biomarkers; Carcinoma, Hepatocellular; Disease Progression; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Survival Rate | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2008 |
Combination of sorafenib and intensity modulated radiotherapy for unresectable hepatocellular carcinoma.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Radiotherapy, Intensity-Modulated; Salvage Therapy; Sorafenib; Treatment Outcome | 2009 |
Acute hepatitis in a patient with cirrhosis and hepatocellular carcinoma treated with sorafenib.
Topics: Acute Disease; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemical and Drug Induced Liver Injury; Hepatitis C; Humans; Liver; Liver Cirrhosis; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2009 |
Sorafenib for liver cancer: the horizon broadens.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Research Design; Sorafenib | 2009 |
Testing molecular therapies in hepatocellular carcinoma: the need for randomized phase II trials.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Randomized Controlled Trials as Topic; Sorafenib | 2009 |
Commentary: Sorafenib -- the end of a long journey in search of systemic therapy for hepatocellular carcinoma, or the beginning?
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Drug Approval; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; United States; United States Food and Drug Administration | 2009 |
Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2009 |
Commentary: Sorafenib use in patients with advanced hepatocellular carcinoma and underlying Child-Pugh B cirrhosis: evidence and controversy.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Cirrhosis; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2009 |
Treating hepatocellular carcinoma without liver transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Combined Modality Therapy; Humans; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Niacinamide; Phenylurea Compounds; Practice Guidelines as Topic; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2009 |
Remission of paraneoplastic dermatomyositis associated with hepatocellular carcinoma under prednisolone and azathiopin, and concommittant sorafenib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azathioprine; Benzenesulfonates; Carcinoma, Hepatocellular; Dermatomyositis; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Paraneoplastic Syndromes; Phenylurea Compounds; Prednisolone; Pyridines; Remission Induction; Sorafenib; Treatment Outcome | 2009 |
Major achievements in hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Female; Humans; Liver Neoplasms; Liver Transplantation; Male; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Survival Rate; Ultrasonography | 2009 |
[Diagnosis and treatment of hepatocellular carcinoma].
Topics: Algorithms; Benzenesulfonates; Carcinoma, Hepatocellular; Early Detection of Cancer; Hepatectomy; Humans; Liver Neoplasms; Liver Transplantation; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Sorafenib | 2009 |
[Hand-foot syndrome and sorafenib].
Topics: Benzenesulfonates; Dermatology; Drug Eruptions; Foot Dermatoses; Hand Dermatoses; Humans; Kidney Neoplasms; Liver Neoplasms; Medical Oncology; Niacinamide; Pharmacy; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Skin; Sorafenib; Syndrome | 2009 |
Hyperkeratosis of nipple skin during sorafenib treatment.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Breast Diseases; Carcinoma, Hepatocellular; Humans; Keratosis; Liver Neoplasms; Male; Niacinamide; Nipples; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2009 |
NF-kappaB inhibition in human hepatocellular carcinoma and its potential as adjunct to sorafenib based therapy.
Topics: Antineoplastic Agents; Apoptosis; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Humans; I-kappa B Proteins; Liver Neoplasms; MAP Kinase Signaling System; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Invasiveness; NF-kappa B; NF-KappaB Inhibitor alpha; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-bcl-2; Pyridines; Signal Transduction; Sorafenib; Transcription Factor RelA | 2009 |
[Hepatocellular carcinoma management in the era of sorafenib].
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2009 |
Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Bone Neoplasms; Brain Neoplasms; Carcinoma, Renal Cell; Disease Progression; Female; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Prospective Studies; Pyridines; Pyrroles; Salvage Therapy; Sorafenib; Sunitinib; Survival Rate; Treatment Outcome | 2009 |
[Reversion of drug-resistant hepatocellular carcinoma cell line BEL-7402/FU by sorafenib].
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzenesulfonates; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Membrane; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Exocytosis; Flow Cytometry; Humans; Immunohistochemistry; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Reverse Transcriptase Polymerase Chain Reaction; Rhodamine 123; Sorafenib | 2009 |
Targeting ELF in therapy of liver cancer.
Topics: Antineoplastic Agents; Benzenesulfonates; Carrier Proteins; Humans; Liver Neoplasms; Microfilament Proteins; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2007 |
A cross-over response to sequential use of sunitinib after sorafenib in a patient with metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome | 2009 |
[Prospect of hepatocellular carcinoma in 2008].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Diagnosis, Differential; Humans; Liver Neoplasms; Liver Transplantation; Neoplasm Recurrence, Local; Neoplasm Staging; Niacinamide; Oligonucleotide Array Sequence Analysis; Phenylurea Compounds; Polymerase Chain Reaction; Pyridines; Retrospective Studies; Sorafenib; Survival Rate | 2009 |
[Sorafenib reverses multidrug resistance of hepatoma cells in vitro].
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzenesulfonates; Cell Line, Tumor; Down-Regulation; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2009 |
Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trial.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials, Phase III as Topic; Disease Progression; Double-Blind Method; Humans; Liver Function Tests; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Randomized Controlled Trials as Topic; Severity of Illness Index; Sorafenib; Survival Rate | 2009 |
Localized dyskeratotic plaque with milia associated with sorafenib.
Topics: Acantholysis; Benzenesulfonates; Carcinoma, Hepatocellular; Diabetes Mellitus; Drug Eruptions; Hepatitis B; Humans; Keratosis; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2009 |
Early MRI response monitoring of patients with advanced hepatocellular carcinoma under treatment with the multikinase inhibitor sorafenib.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Humans; Liver; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Necrosis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Treatment Outcome | 2009 |
Portal vein tumor thrombosis revascularization during sorafenib treatment for hepatocellular carcinoma.
Topics: Angiography; Benzenesulfonates; Carcinoma, Hepatocellular; Dose-Response Relationship, Drug; Drug Administration Schedule; Follow-Up Studies; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Invasiveness; Neoplastic Cells, Circulating; Niacinamide; Phenylurea Compounds; Portal Vein; Pyridines; Risk Assessment; Sorafenib; Treatment Outcome | 2009 |
Tumor endothelial cells join the resistance.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Hepatocellular; Cells, Cultured; Drug Resistance, Neoplasm; Endothelium, Vascular; Humans; Liver Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Ranibizumab; Sorafenib | 2009 |
Human hepatocellular carcinoma tumor-derived endothelial cells manifest increased angiogenesis capability and drug resistance compared with normal endothelial cells.
Topics: Antigens, CD; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Cadherins; Carcinoma, Hepatocellular; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Survival; Doxorubicin; Drug Resistance, Neoplasm; Endoglin; Endothelium, Vascular; Fluorouracil; Humans; Liver Neoplasms; Mitogen-Activated Protein Kinase Kinases; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Platelet Endothelial Cell Adhesion Molecule-1; Proto-Oncogene Proteins c-akt; Pyridines; Receptors, Cell Surface; Signal Transduction; Sorafenib; STAT3 Transcription Factor; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2; von Willebrand Factor | 2009 |
[Schedule-dependent effects of sorafenib in combination with paclitaxel on human hepatocellular carcinoma cell line BEL-7402].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Drug Administration Schedule; Drug Interactions; Humans; Liver Neoplasms; Niacinamide; Paclitaxel; Phenylurea Compounds; Proto-Oncogene Proteins c-bcl-2; Pyridines; Sorafenib | 2009 |
Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; DNA Methylation; Drug Synergism; Female; Gene Dosage; Genes, ras; Humans; Liver Neoplasms; Liver Neoplasms, Experimental; Mice; Mice, Nude; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Promoter Regions, Genetic; Protein Kinases; Pyridines; ras Proteins; RNA, Messenger; RNA, Neoplasm; Signal Transduction; Sirolimus; Sorafenib; TOR Serine-Threonine Kinases; Transplantation, Heterologous | 2009 |
UGT1A1 polymorphism and hyperbilirubinemia in a patient who received sorafenib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials, Phase I as Topic; Cyclophosphamide; Doxorubicin; Glucuronosyltransferase; Humans; Hyperbilirubinemia; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Polymorphism, Genetic; Pyridines; Sorafenib | 2009 |
Hepatocellular carcinoma: The beginning of a long journey.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Humans; Liver Neoplasms; Matrix Metalloproteinases; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2009 |
Predicting the response to sorafenib in hepatocellular carcinoma: where is the evidence for phosphorylated extracellular signaling-regulated kinase (pERK)?
Topics: Antineoplastic Agents; Benzenesulfonates; Biomarkers; Carcinoma, Hepatocellular; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Extracellular Signal-Regulated MAP Kinases; Hepatocytes; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Randomized Controlled Trials as Topic; Sorafenib | 2009 |
Targeted therapies: Role of sorafenib in HCC patients with compromised liver function.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials, Phase III as Topic; Fibrosis; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Practice Guidelines as Topic; Pyridines; Randomized Controlled Trials as Topic; Sorafenib; Survival Analysis; Time Factors | 2009 |
Aurora kinase inhibitor PHA-739358 suppresses growth of hepatocellular carcinoma in vitro and in a xenograft mouse model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Aurora Kinase A; Aurora Kinase B; Aurora Kinases; Benzamides; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; G2 Phase; Humans; Immunoenzyme Techniques; In Vitro Techniques; Liver Neoplasms; Mice; Mice, Inbred NOD; Mice, SCID; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrazoles; Pyridines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Tissue Array Analysis; Xenograft Model Antitumor Assays | 2009 |
MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Blotting, Western; Carcinoma, Hepatocellular; Cell Proliferation; Humans; In Situ Hybridization; Liver Neoplasms; Luciferases; Mice; Mice, Nude; MicroRNAs; Niacinamide; Phenylurea Compounds; Pyridines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sorafenib; Transfection | 2009 |
Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Benzamides; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Survival; Drug Screening Assays, Antitumor; Drug Synergism; Endothelial Cells; Extracellular Signal-Regulated MAP Kinases; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Membrane Proteins; Mitogen-Activated Protein Kinase Kinases; Niacinamide; Phenylurea Compounds; Phosphorylation; Proto-Oncogene Proteins; Pyridines; raf Kinases; Reverse Transcriptase Polymerase Chain Reaction; RNA, Small Interfering; Sorafenib; Tumor Cells, Cultured | 2009 |
Sorafenib induced tumor lysis syndrome in an advanced hepatocellular carcinoma patient.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Fatal Outcome; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Tumor Lysis Syndrome | 2009 |
Diffusion-weighted MRI of advanced hepatocellular carcinoma during sorafenib treatment: initial results.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Diffusion Magnetic Resonance Imaging; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pilot Projects; Prognosis; Pyridines; Sensitivity and Specificity; Sorafenib; Treatment Outcome | 2009 |
Sorafenib induces preferential apoptotic killing of a drug- and radio-resistant Hep G2 cells through a mitochondria-dependent oxidative stress mechanism.
Topics: Antineoplastic Agents; Apoptosis; Benzenesulfonates; Calcium; Carcinoma, Hepatocellular; Caspase 3; Caspase 7; Cell Line, Tumor; Cell Survival; Cytochromes c; Dose-Response Relationship, Drug; Enzyme Activation; Glutathione; Humans; In Situ Nick-End Labeling; Inhibitory Concentration 50; Intracellular Space; Liver Neoplasms; Microscopy, Confocal; Mitochondria; Niacinamide; Oxidative Stress; Phenylurea Compounds; Pyridines; Reactive Oxygen Species; Sorafenib | 2009 |
Sorafenib as a feasible therapeutic option in haemophiliacs with hepatocellular carcinoma.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chronic Disease; Factor VIII; Hemophilia A; Hepatitis B; Hepatitis C; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
Clinical trials of note. Sorafenib as adjuvant treatment in the prevention of disease recurrence in patients with hepatocellular carcinoma (HCC) (STORM).
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Clinical Protocols; Humans; Liver Neoplasms; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pyridines; Randomized Controlled Trials as Topic; Sorafenib | 2009 |
Glucose-regulated protein 78 is a novel contributor to acquisition of resistance to sorafenib in hepatocellular carcinoma.
Topics: Antineoplastic Agents; Apoptosis; Benzenesulfonates; Blotting, Western; Carcinoma, Hepatocellular; Caspases; Cell Cycle; Cell Proliferation; Cytochromes c; Drug Resistance, Neoplasm; Endoplasmic Reticulum Chaperone BiP; Flow Cytometry; Heat-Shock Proteins; Humans; Liver Neoplasms; Membrane Potential, Mitochondrial; Niacinamide; Phenylurea Compounds; Pyridines; RNA, Small Interfering; Sorafenib; Tumor Cells, Cultured | 2010 |
Sorafenib-induced hepatic encephalopathy.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Dose-Response Relationship, Drug; Hepatic Encephalopathy; Humans; Liver Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Time Factors | 2009 |
Sorafenib-induced bilateral osteonecrosis of femoral heads.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Femur Head Necrosis; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2010 |
AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC).
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Benzimidazoles; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Humans; Liver Neoplasms; Male; Mice; Mice, SCID; Mitogen-Activated Protein Kinases; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; raf Kinases; Signal Transduction; Sorafenib; Xenograft Model Antitumor Assays | 2010 |
Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Cell Line, Tumor; Disease Models, Animal; Drug Synergism; Humans; Liver Neoplasms; Male; Mice; Mice, Nude; Niacinamide; Okadaic Acid; Phenylurea Compounds; Protein Phosphatase 2; Proto-Oncogene Proteins c-akt; Pyrazines; Pyridines; Sorafenib; Treatment Outcome; Xenograft Model Antitumor Assays | 2010 |
Elevated International Normalized Ratio associated with concurrent use of sorafenib and warfarin.
Topics: Aged; Anticoagulants; Benzenesulfonates; Carcinoma, Hepatocellular; Drug Interactions; Hemorrhage; Humans; International Normalized Ratio; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Warfarin | 2009 |
NICE rules that drug used in advanced liver cancer is not cost effective for the NHS.
Topics: Antineoplastic Agents; Benzenesulfonates; Cost-Benefit Analysis; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Quality-Adjusted Life Years; Sorafenib; United Kingdom | 2009 |
Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Disease Progression; Humans; Kaplan-Meier Estimate; Liver Cirrhosis; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Randomized Controlled Trials as Topic; Secondary Prevention; Sorafenib | 2010 |
Hepatitis C virus infection reduces hepatocellular polarity in a vascular endothelial growth factor-dependent manner.
Topics: Autocrine Communication; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Polarity; Hep G2 Cells; Hepacivirus; Humans; Liver Neoplasms; Membrane Proteins; Niacinamide; Occludin; Permeability; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Tight Junctions; Up-Regulation; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Virus Internalization | 2010 |
Baying for a flexible drug price.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Drug Industry; Fees, Pharmaceutical; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2009 |
Radiation recall dermatitis triggered by multi-targeted tyrosine kinase inhibitors: sunitinib and sorafenib.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyridines; Pyrroles; Radiodermatitis; Sorafenib; Sunitinib; Treatment Outcome | 2010 |
Platelet count less than SHARP: what does a case series reveal?
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Models, Biological; Niacinamide; Phenylurea Compounds; Platelet Count; Pyridines; Randomized Controlled Trials as Topic; Sorafenib; Thrombocytopenia | 2010 |
Probable sorafenib-induced reversible encephalopathy in a patient with hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Posterior Leukoencephalopathy Syndrome; Prognosis; Pyridines; Sorafenib | 2010 |
Apparent remission of a solitary metastatic pulmonary lesion in a liver transplant recipient treated with sorafenib.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Combined Modality Therapy; Hepatitis B, Chronic; Humans; Liver Neoplasms; Liver Transplantation; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2009 |
[Clinical observation of 21 cases of metastatic renal cell carcinoma treated with sorafenib].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Diarrhea; Female; Follow-Up Studies; Humans; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Remission Induction; Sorafenib | 2009 |
[Clinical observation of the treatment with combination of transcatheter arterial chemoembolization and sorafenib for hepatocellular carcinoma with lung metastasis].
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Diarrhea; Fatigue; Female; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2009 |
Evaluation of response in malignant tumors treated with the multitargeted tyrosine kinase inhibitor sorafenib: a multitechnique imaging assessment.
Topics: Adrenal Gland Neoplasms; Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Contrast Media; Female; Humans; Kidney Neoplasms; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pheochromocytoma; Protein Kinase Inhibitors; Pyridines; Sensitivity and Specificity; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome; Ultrasonography | 2010 |
Multifaceted perspective of the waiting list for liver transplantation: the value of pharmacokinetic models.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Humans; Liver Neoplasms; Liver Transplantation; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Tissue Donors; Waiting Lists | 2010 |
[Treatment approach of hepatocellular carcinoma in Spain. Analysis of 705 patients from 62 centers].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Comorbidity; Early Diagnosis; Embolization, Therapeutic; Female; Hemochromatosis; Hepatectomy; Hepatitis, Viral, Human; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Mass Screening; Niacinamide; Obesity; Phenylurea Compounds; Prospective Studies; Pyridines; Registries; Retrospective Studies; Sorafenib; Spain; Treatment Outcome; Young Adult; Yttrium Radioisotopes | 2010 |
Hepatocellular carcinoma: sorafenib before liver transplantation?
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Humans; Liver Neoplasms; Liver Transplantation; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2010 |
Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Progression; Drug Eruptions; Exanthema; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Pyridines; Retrospective Studies; Sorafenib; Survival Analysis | 2010 |
Complete response of hepatocellular carcinoma with systemic combination chemotherapy: not to get out the chemotherapy?
Topics: Adult; alpha-Fetoproteins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Deoxycytidine; Gemcitabine; Humans; Liver Neoplasms; Male; Niacinamide; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Phenylurea Compounds; Pyridines; Remission Induction; Sorafenib | 2010 |
Sorafenib inhibits the shedding of major histocompatibility complex class I-related chain A on hepatocellular carcinoma cells by down-regulating a disintegrin and metalloproteinase 9.
Topics: ADAM Proteins; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Dipeptides; Down-Regulation; Histocompatibility Antigens Class I; Humans; Hydroxamic Acids; Killer Cells, Natural; Liver Neoplasms; Membrane Proteins; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2010 |
Hepatitis C virus proteins modulate microRNA expression and chemosensitivity in malignant hepatocytes.
Topics: Apoptosis; Benzenesulfonates; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Hepacivirus; Hepatocytes; Humans; Liver Neoplasms; MicroRNAs; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-bcl-2; Pyridines; Sorafenib; Transfection; Viral Proteins | 2010 |
A retroperitoneal mass with elevated alpha-1-fetoprotein: not always a testicular carcinoma.
Topics: alpha-Fetoproteins; Antineoplastic Agents; Benzenesulfonates; Biopsy; Carcinoma, Hepatocellular; Choristoma; Diagnosis, Differential; Humans; Liver Diseases; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Retroperitoneal Neoplasms; Retroperitoneal Space; Sorafenib; Testicular Neoplasms; Ultrasonography | 2010 |
Safety of transarterial chemoembolization plus sorafenib combination treatment in unresectable hepatocellular carcinoma.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Cohort Studies; Combined Modality Therapy; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Survival Rate; Tomography, X-Ray Computed | 2010 |
Hepatocellular carcinoma: the search for innovative adjuvant therapies.
Topics: Antineoplastic Agents; Benzenesulfonates; Cancer Vaccines; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease-Free Survival; Humans; Immunotherapy, Adoptive; Liver Neoplasms; Liver Transplantation; Neoplasm Recurrence, Local; Neoplasm Seeding; Neoplasm Staging; Niacinamide; Patient Selection; Phenylurea Compounds; Pyridines; Risk Factors; Sorafenib | 2009 |
Sorafenib therapy for hepatocellular carcinoma in an HIV-HCV coinfected patient: a case report.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Comorbidity; Hepatitis C; HIV Infections; HIV Protease Inhibitors; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Risk Factors; Sorafenib | 2010 |
Tolerance and outcome of patients with unresectable hepatocellular carcinoma treated with sorafenib.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Humans; Liver Cirrhosis; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Retrospective Studies; Severity of Illness Index; Sorafenib; Survival Analysis; Tomography, X-Ray Computed | 2010 |
Clinical outcomes of sorafenib treatment in patients with metastatic hepatocellular carcinoma who had been previously treated with fluoropyrimidine plus platinum-based chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Capecitabine; Carcinoma, Hepatocellular; Cisplatin; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Pyridines; Republic of Korea; Retrospective Studies; Risk Factors; Sorafenib; Survival Analysis; Treatment Failure | 2011 |
Complete remission of unresectable hepatocellular carcinoma treated with reduced dose of sorafenib: a case report.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Drug Dosage Calculations; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Remission Induction; Sorafenib | 2010 |
Fatal hemobilia in advanced hepatocellular carcinoma invading biliary tract after treatment with sorafenib and biliary stenting.
Topics: Antineoplastic Agents; Benzenesulfonates; Biliary Tract Neoplasms; Biliary Tract Surgical Procedures; Carcinoma, Hepatocellular; Disease Progression; Fatal Outcome; Hemobilia; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Stents | 2010 |
The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma.
Topics: Antineoplastic Agents; Apoptosis; Base Sequence; bcl-X Protein; Benzenesulfonates; Carcinoma, Hepatocellular; Cyclin G1; Down-Regulation; Drug Synergism; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; MicroRNAs; Niacinamide; Oligonucleotide Array Sequence Analysis; Phenylurea Compounds; Pyridines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Sorafenib; Staurosporine; Up-Regulation | 2010 |
Personalized molecular targeted therapy in advanced, recurrent hepatocellular carcinoma after liver transplantation: a proof of principle.
Topics: alpha-Fetoproteins; Antineoplastic Agents; Antiviral Agents; Benzenesulfonates; beta Catenin; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; DNA Mutational Analysis; Everolimus; Hepatitis C; Humans; Immunosuppressive Agents; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Point Mutation; Precision Medicine; Pyridines; Ribavirin; Sirolimus; Sorafenib | 2010 |
The 2008 Okuda lecture: Management of hepatocellular carcinoma: from surveillance to molecular targeted therapy.
Topics: Algorithms; alpha-Fetoproteins; Antineoplastic Agents; Benzenesulfonates; Biomarkers; Biomarkers, Tumor; Carcinoma, Hepatocellular; Contrast Media; Early Detection of Cancer; Gadolinium DTPA; Humans; Infusion Pumps; Japan; Liver Neoplasms; Magnetic Resonance Imaging; Mass Screening; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Population Surveillance; Protein Precursors; Prothrombin; Pyridines; Sensitivity and Specificity; Sorafenib; Survival Rate | 2010 |
Sequential therapy of transarterial chemoembolisation and sorafenib in intermediate stage hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Disease-Free Survival; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2010 |
Drug therapy: sorafenib.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Hepatitis B; Hepatitis C; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Risk Factors; Sorafenib | 2010 |
Involvement of receptor tyrosine phosphatase DEP-1 mediated PI3K-cofilin signaling pathway in sorafenib-induced cytoskeletal rearrangement in hepatoma cells.
Topics: Actins; Benzenesulfonates; Carcinoma, Hepatocellular; Cofilin 1; Cytoskeleton; Enzyme Activation; Humans; Liver Neoplasms; Models, Biological; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Phosphoprotein Phosphatases; Phosphorylation; Phosphotyrosine; Proto-Oncogene Proteins c-met; Pyridines; Receptor-Like Protein Tyrosine Phosphatases, Class 3; Signal Transduction; Sorafenib | 2010 |
Sorafenib-induced acute pancreatitis.
Topics: Acute Disease; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Pancreatitis; Phenylurea Compounds; Pyridines; Sorafenib | 2010 |
A case of variant angina in a patient under chronic treatment with sorafenib.
Topics: Angina Pectoris, Variant; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cardiac Catheterization; Chronic Disease; Coronary Angiography; Electrocardiography; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Time Factors | 2010 |
Sorafenib for recurrent hepatocellular carcinoma after liver transplantation.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Progression; Drug Eruptions; Female; Hematologic Diseases; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Retrospective Studies; Sorafenib; Survival Rate | 2010 |
A patient with advanced hepatocellular carcinoma treated with sorafenib tosylate showed massive tumor lysis with avoidance of tumor lysis syndrome.
Topics: Adult; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Tumor Lysis Syndrome | 2010 |
Efficacy and safety of sorafenib in advanced hepatocellular carcinoma under daily practice conditions.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Sorafenib; Survival Rate; Treatment Outcome | 2010 |
Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus conference.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Consensus Development Conferences as Topic; Hepatectomy; Humans; Liver Neoplasms; Liver Transplantation; Neoplasm Staging; Niacinamide; Patient Selection; Phenylurea Compounds; Practice Guidelines as Topic; Protein Kinase Inhibitors; Pyridines; Radiopharmaceuticals; Radiotherapy; Sorafenib; Treatment Outcome; Yttrium | 2010 |
Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus statement.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatectomy; Humans; Liver Neoplasms; Liver Transplantation; Neoplasm Staging; Niacinamide; Patient Selection; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Radiopharmaceuticals; Radiotherapy; Sorafenib; Treatment Outcome; Yttrium | 2010 |
Long-term stable disease in metastatic renal cell carcinoma: sorafenib sequenced to sunitinib and everolimus: a case study.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Everolimus; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Sirolimus; Sorafenib; Sunitinib | 2011 |
Sorafenib-induced severe acute hepatitis in a stable liver transplant recipient.
Topics: Acute Disease; Antineoplastic Agents; Benzenesulfonates; Bilirubin; Carcinoma, Hepatocellular; Chemical and Drug Induced Liver Injury; Hepatitis C; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome | 2010 |
Management of hepatocellular carcinoma: from prevention to molecular targeted therapy.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Hepacivirus; Hepatitis B virus; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2010 |
Sorafenib and thyrotoxicosis.
Topics: Benzenesulfonates; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prednisone; Pyridines; Sorafenib; Thyrotoxicosis | 2010 |
Safe use of sorafenib in a patient undergoing salvage liver transplantation for recurrent hepatocellular carcinoma after hepatic resection.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pyridines; Salvage Therapy; Sorafenib | 2011 |
BAD, a proapoptotic member of the BCL2 family, is a potential therapeutic target in hepatocellular carcinoma.
Topics: Antineoplastic Agents; Apoptosis; Benzenesulfonates; Biomarkers, Tumor; Biphenyl Compounds; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Humans; Liver; Liver Neoplasms; Niacinamide; Nitrophenols; Phenylurea Compounds; Piperazines; Proto-Oncogene Proteins c-bcl-2; Pyridines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sorafenib; Sulfonamides | 2010 |
Sustained treatment response of metastatic hepatocellular carcinoma with bevacizumab and sorafenib.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Hepatocellular; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome | 2010 |
Health-related quality of life and sorafenib.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Quality of Life; Sorafenib | 2010 |
Managing patients receiving sorafenib for advanced hepatocellular carcinoma: a case study.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Continuity of Patient Care; Diarrhea; Drug Eruptions; Drug Monitoring; Female; Humans; Hypertension; Liver Neoplasms; Niacinamide; Nurse's Role; Oncology Nursing; Patient Care Team; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Safety; Sorafenib | 2010 |
The diffusion-weighted imaging perfusion fraction f is a potential marker of sorafenib treatment in advanced hepatocellular carcinoma: a pilot study.
Topics: Aged; Algorithms; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Diffusion Magnetic Resonance Imaging; Female; Humans; Image Enhancement; Image Interpretation, Computer-Assisted; Liver Neoplasms; Magnetic Resonance Angiography; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pilot Projects; Prognosis; Pyridines; Reproducibility of Results; Sensitivity and Specificity; Sorafenib; Treatment Outcome | 2011 |
Sorafenib and radiation therapy for the treatment of advanced hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoradiotherapy; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2012 |
From a cancer drug fund to value based pricing of drugs.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cost-Benefit Analysis; England; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Quality-Adjusted Life Years; Sorafenib; Wales | 2010 |
Pharmacokinetic interaction involving sorafenib and the calcium-channel blocker felodipine in a patient with hepatocellular carcinoma.
Topics: Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Calcium Channel Blockers; Carcinoma, Hepatocellular; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Felodipine; Humans; Hypertension; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2011 |
Radiologic complete response with sirolimus and sorafenib in a hepatocellular carcinoma patient who relapsed after orthotopic liver transplantation.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Diagnostic Imaging; Humans; Immunosuppressive Agents; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sirolimus; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome | 2011 |
The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib.
Topics: Animals; Antineoplastic Agents; Apoptosis; bcl-X Protein; Benzenesulfonates; Biphenyl Compounds; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Humans; Liver Neoplasms; Mice; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Transplantation; Niacinamide; Nitrophenols; Phenylurea Compounds; Piperazines; Proto-Oncogene Proteins c-bcl-2; Pyridines; RNA, Small Interfering; Sorafenib; Sulfonamides | 2010 |
Complete response after sorafenib therapy for hepatocellular carcinoma in an HIV-HBV co infected patient: Possible synergy with HAART ? A case report.
Topics: Aged; Antiretroviral Therapy, Highly Active; Benzenesulfonates; Carcinoma, Hepatocellular; Coinfection; Drug Synergism; Drug Therapy, Combination; Hepatitis B; HIV Infections; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome | 2011 |
Sorafenib therapy in patients with hepatocellular carcinoma before liver transplantation.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Progression; Humans; Liver Neoplasms; Liver Transplantation; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome | 2010 |
[Therapeutic efficacy of Nexavar on liver cancer and its relation to the expression of Ki-67 and CD34].
Topics: Adult; Aged; Antigens, CD34; Antineoplastic Agents; Female; Humans; Ki-67 Antigen; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib | 2010 |
Sorafenib-induced destructive thyroiditis.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chronic Disease; Hepatitis B, Chronic; Humans; Iodine Radioisotopes; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prednisone; Propranolol; Protein Kinase Inhibitors; Pyridines; Sorafenib; Technetium; Thyroiditis | 2010 |
[Recommendations for the management of Sorafenib in patients with hepatocellular carcinoma].
Topics: Administration, Oral; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cardiovascular Diseases; Clinical Trials as Topic; Drug Eruptions; Drug Interactions; Drug Monitoring; Gastrointestinal Diseases; Humans; Liver Cirrhosis; Liver Neoplasms; Molecular Targeted Therapy; Neoplasm Proteins; Niacinamide; Patient Selection; Phenylurea Compounds; Practice Guidelines as Topic; Protein Kinase Inhibitors; Pyridines; Radiography; raf Kinases; Sorafenib; Spain | 2010 |
Feasibility of (125)I brachytherapy combined with sorafenib treatment in patients with multiple lung metastases after liver transplantation for hepatocellular carcinoma.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Brachytherapy; Carcinoma, Hepatocellular; Cause of Death; Combined Modality Therapy; Follow-Up Studies; Humans; Iodine Radioisotopes; Liver Neoplasms; Liver Transplantation; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Patient Care Planning; Phenylurea Compounds; Pyridines; Sorafenib; Survival Rate; Time Factors | 2010 |
Sorafenib overcomes TRAIL resistance of hepatocellular carcinoma cells through the inhibition of STAT3.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Liver Neoplasms; Male; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Pyridines; Signal Transduction; Sorafenib; STAT3 Transcription Factor; TNF-Related Apoptosis-Inducing Ligand; Xenograft Model Antitumor Assays | 2010 |
Comparison of different tumor response criteria in patients with hepatocellular carcinoma after systemic therapy with the multikinase inhibitor sorafenib.
Topics: Adult; Aged; alpha-Fetoproteins; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Contrast Media; Female; Follow-Up Studies; Gadolinium DTPA; Humans; Image Enhancement; Liver; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Necrosis; Niacinamide; Phenylurea Compounds; Pyridines; Retrospective Studies; Sorafenib; Treatment Outcome; Tumor Burden | 2011 |
High-performance liquid chromatographic method for the determination of sorafenib in human serum and peritoneal fluid.
Topics: Antineoplastic Agents; Ascitic Fluid; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Chromatography, High Pressure Liquid; Drug Monitoring; Humans; Kidney Neoplasms; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sensitivity and Specificity; Sorafenib | 2011 |
Clinical management and case reports for the treatment of hepatocellular carcinoma with sorafenib.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Fatal Outcome; Female; Humans; Liver Neoplasms; Liver Transplantation; Male; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Practice Guidelines as Topic; Protein Kinase Inhibitors; Pyridines; Sorafenib; Time Factors; Treatment Outcome | 2011 |
Impressive efficacy of sorafenib in a patient with an hepatocellular carcinoma and a portal vein thrombosis associated with a metastatic ENT cancer.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Head and Neck Neoplasms; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Portal Vein; Pyridines; Sorafenib; Treatment Outcome; Venous Thrombosis | 2011 |
Efficacy of sorafenib, molecular targeting drug, for advanced hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials, Phase III as Topic; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Receptors, Vascular Endothelial Growth Factor; Sorafenib | 2010 |
Safety and feasibility of using sorafenib in recurrent hepatocellular carcinoma after orthotopic liver transplantation.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Drug Administration Schedule; Feasibility Studies; Humans; Immunosuppressive Agents; Liver Neoplasms; Liver Transplantation; Male; Medical Records; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Retrospective Studies; Sorafenib; Survival Analysis; Treatment Outcome | 2010 |
Sunitinib in patients with advanced hepatocellular carcinoma after progression under sorafenib treatment.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Indoles; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Radiography; Retrospective Studies; Severity of Illness Index; Sorafenib; Sunitinib; Treatment Failure; Treatment Outcome | 2010 |
Sirolimus plus sorafenib in treating HCC recurrence after liver transplantation: a case report.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Drug Therapy, Combination; Humans; Immunosuppressive Agents; Liver Neoplasms; Liver Transplantation; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sirolimus; Sorafenib; Treatment Outcome | 2010 |
Differential inhibition of transmembrane 4 L six family member 5 (TM4SF5)-mediated tumorigenesis by TSAHC and sorafenib.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chalcone; Drug Discovery; Humans; Liver Neoplasms; Membrane Proteins; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Pyridines; Signal Transduction; Sorafenib; Sulfonamides; Xenograft Model Antitumor Assays | 2011 |
Sorafenib extends the survival time of patients with multiple recurrences of hepatocellular carcinoma after liver transplantation.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Disease-Free Survival; Humans; Liver Neoplasms; Liver Transplantation; Male; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pyridines; Retrospective Studies; Sorafenib | 2010 |
mTOR inhibitors and sorafenib for recurrent heptocellular carcinoma after orthotopic liver transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Combined Modality Therapy; Everolimus; Humans; Liver Neoplasms; Liver Transplantation; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pyridines; Sirolimus; Sorafenib; TOR Serine-Threonine Kinases | 2011 |
Sorafenib modulates the gene expression of multi-drug resistance mediating ATP-binding cassette proteins in experimental hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Proliferation; Deoxycytidine; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Multidrug Resistance-Associated Proteins; Niacinamide; Phenylurea Compounds; Pyridines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sorafenib; Survival Rate; Tumor Cells, Cultured | 2010 |
[Therapeutic efficacy and prognostic factors of sorafenib treatment in patients with unresectable primary hepatocellular carcinoma].
Topics: Adult; Aged; Alopecia; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Diarrhea; Disease Progression; Follow-Up Studies; Humans; Hypertension; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Skin Diseases; Sorafenib; Survival Rate | 2010 |
Sorafenib as adjuvant therapy for high-risk hepatocellular carcinoma in liver transplant recipients: feasibility and efficacy.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease-Free Survival; Feasibility Studies; Female; Humans; Liver Neoplasms; Liver Transplantation; Los Angeles; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Recurrence; Retrospective Studies; Risk Assessment; Risk Factors; Sorafenib; Survival Rate; Time Factors; Treatment Outcome | 2010 |
Inhibition of lactic dehydrogenase as a way to increase the anti-proliferative effect of multi-targeted kinase inhibitors.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Drug Synergism; Glycolysis; Humans; L-Lactate Dehydrogenase; Liver Neoplasms; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Niacinamide; Oxamic Acid; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Thymidine | 2011 |
Treating hepatocellular carcinoma with sorafenib in liver transplant patients: an initial experience.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Combined Modality Therapy; Female; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2010 |
Clinical outcome of 251 patients with extrahepatic metastasis at initial diagnosis of hepatocellular carcinoma: does transarterial chemoembolization improve survival in these patients?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Cause of Death; Chemoembolization, Therapeutic; Chi-Square Distribution; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Pyridines; Republic of Korea; Retrospective Studies; Risk Assessment; Risk Factors; Sorafenib; Survival Rate; Time Factors; Treatment Outcome; Young Adult | 2011 |
PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Growth Processes; Cell Line, Tumor; Dose-Response Relationship, Drug; Epidermal Growth Factor; Furans; Humans; Liver Neoplasms; MAP Kinase Signaling System; Mitogen-Activated Protein Kinases; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyridines; Pyrimidines; raf Kinases; ras Proteins; Signal Transduction; Sorafenib; TOR Serine-Threonine Kinases | 2010 |
How I manage my patients with hepatocellular carcinoma.
Topics: Ablation Techniques; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Disease Management; Evidence-Based Medicine; Humans; Liver Neoplasms; Liver Transplantation; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Survival Rate | 2011 |
Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Enzyme Activation; Hep G2 Cells; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinase; Proto-Oncogene Proteins c-akt; Pyridines; Signal Transduction; Sorafenib | 2011 |
Myositis due to Sorafenib intake in a patient with hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Male; Middle Aged; Myositis; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2011 |
Sorafenib inhibits the hepatocyte growth factor-mediated epithelial mesenchymal transition in hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Down-Regulation; Epithelial-Mesenchymal Transition; Hepatocyte Growth Factor; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Signal Transduction; Sorafenib; Transfection | 2011 |
[The outcome of chemotherapy by sorafenib in advanced hepatocellular carcinoma].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome | 2010 |
[The effect of sorafenib and intermittent hepatic arterial infusion chemotherapy using cisplatin for advanced hepatocellular carcinoma with portal vein tumor thrombus--a pilot study].
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Cisplatin; Female; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Middle Aged; Neoplastic Cells, Circulating; Niacinamide; Phenylurea Compounds; Pilot Projects; Portal Vein; Pyridines; Sorafenib; Venous Thrombosis | 2010 |
Sorafenib in unresectable intrahepatic cholangiocellular carcinoma: a case report.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Cholangiocarcinoma; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome | 2011 |
Complete response for advanced liver cancer during sorafenib therapy: case report.
Topics: Aged, 80 and over; alpha-Fetoproteins; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Remission Induction; Sorafenib; Treatment Outcome | 2011 |
Invasive squamous cell carcinoma and sorafenib in a black patient.
Topics: Antineoplastic Agents; Benzenesulfonates; Black People; Carcinoma, Hepatocellular; Carcinoma, Squamous Cell; Drug Eruptions; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Skin Neoplasms; Sorafenib | 2011 |
Splenic infarction associated with sorafenib use in a hepatocellular carcinoma patient.
Topics: Aged; Antineoplastic Agents; Aspirin; Benzenesulfonates; Carcinoma, Hepatocellular; Contrast Media; Female; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Spleen; Splenic Infarction; Tomography, X-Ray Computed; Treatment Outcome | 2011 |
Sorafenib versus cytotoxic chemotherapy for patients with advanced hepatocellular carcinoma: a retrospective, single-institution study.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials, Phase II as Topic; Cytotoxins; Disease-Free Survival; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Retrospective Studies; Sorafenib; Treatment Outcome | 2012 |
Antitumor activity of sphingosine kinase 2 inhibitor ABC294640 and sorafenib in hepatocellular carcinoma xenografts.
Topics: Adamantane; Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Blotting, Western; Carcinoma, Hepatocellular; Flow Cytometry; Hep G2 Cells; Humans; Liver Neoplasms; Lysophospholipids; Mice; Mitogen-Activated Protein Kinases; Niacinamide; Phenylurea Compounds; Phosphotransferases (Alcohol Group Acceptor); Pyridines; Sorafenib; Sphingosine; Xenograft Model Antitumor Assays | 2011 |
Complete histologic response induced by sorafenib in advanced hepatocellular carcinoma: a case report.
Topics: alpha-Fetoproteins; Angiogenesis Inhibitors; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Diffusion Magnetic Resonance Imaging; Hepatectomy; Humans; Liver Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; raf Kinases; Sorafenib; Time Factors; Treatment Outcome | 2011 |
Sorafenib suppresses postsurgical recurrence and metastasis of hepatocellular carcinoma in an orthotopic mouse model.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease Models, Animal; Extracellular Signal-Regulated MAP Kinases; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Metastasis; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Transplantation, Heterologous; Treatment Outcome | 2011 |
Sorafenib induced thyroiditis in two patients with hepatocellular carcinoma.
Topics: Aged; Antineoplastic Agents; Atrophy; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Thyroid Gland; Thyroiditis; Ultrasonography | 2011 |
Sorafenib therapy in patients with advanced hepatocellular carcinoma in advanced liver cirrhosis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cohort Studies; Female; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome; Young Adult | 2011 |
Kinase inhibitor Sorafenib modulates immunosuppressive cell populations in a murine liver cancer model.
Topics: Animals; Benzenesulfonates; Bone Marrow Cells; Carcinoma, Hepatocellular; Cell Division; Cell Line, Tumor; Disease Progression; Immunity, Cellular; Liver Neoplasms; Mice; Mice, Inbred BALB C; Myeloid Cells; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Spleen; T-Lymphocytes, Regulatory | 2011 |
Doxorubicin plus sorafenib in treatment of advanced hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Progression; Doxorubicin; Endpoint Determination; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Randomized Controlled Trials as Topic; Reproducibility of Results; Sorafenib; Treatment Outcome | 2011 |
Liver transplantation in a patient treated by sorafenib for hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Combined Modality Therapy; Fatal Outcome; Humans; Liver Neoplasms; Liver Transplantation; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2011 |
Vitamin K enhancement of sorafenib-mediated HCC cell growth inhibition in vitro and in vivo.
Topics: Animals; Antifibrinolytic Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesulfonates; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Flow Cytometry; Humans; In Vitro Techniques; Liver Neoplasms; Mitogen-Activated Protein Kinase Kinases; Niacinamide; Phenylurea Compounds; Phosphorylation; Proto-Oncogene Proteins c-bcl-2; Pyridines; raf Kinases; Rats; Sorafenib; Vitamin K | 2010 |
Functional analysis of microRNAs in human hepatocellular cancer stem cells.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Survival; Cluster Analysis; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Male; Mice; Mice, SCID; MicroRNAs; Neoplasm Transplantation; Neoplastic Stem Cells; Niacinamide; Nuclear Proteins; Phenylurea Compounds; Pluripotent Stem Cells; Pyridines; Sorafenib; Twist-Related Protein 1 | 2012 |
Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma.
Topics: Animals; Apoptosis; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Down-Regulation; Humans; Liver Neoplasms; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Proto-Oncogene Proteins c-raf; Pyridines; Signal Transduction; Sorafenib; STAT3 Transcription Factor | 2011 |
Eruptive squamous cell carcinomas with keratoacanthoma-like features in a patient treated with sorafenib.
Topics: Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Squamous Cell; Humans; Keratoacanthoma; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Skin Neoplasms; Sorafenib | 2011 |
Computed tomography findings of sorafenib-treated hepatic tumors in patients with advanced hepatocellular carcinoma.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Progression; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Receptors, Vascular Endothelial Growth Factor; Republic of Korea; Retrospective Studies; Sorafenib; Survival Rate; Tomography, X-Ray Computed | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis C; Hepatitis, Autoimmune; Humans; Liver Neoplasms; Mass Screening; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Ultrasonography | 2011 |
[Contribution of microCT structural imaging to preclinical evaluation of hepatocellular carcinoma chemotherapeutics on orthotopic graft in ACI rats].
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Contrast Media; Deoxycytidine; Disease Models, Animal; Disease Progression; Doxorubicin; Drug Monitoring; Gemcitabine; Liver Neoplasms; Male; Niacinamide; Organoplatinum Compounds; Oxaliplatin; Phenylurea Compounds; Pyridines; Rats; Rats, Inbred ACI; Sorafenib; Survival Analysis; Tumor Burden; X-Ray Microtomography; Xenograft Model Antitumor Assays | 2011 |
Population pharmacokinetic analysis of sorafenib in patients with solid tumours.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Cytochrome P-450 CYP3A; Female; Glucuronosyltransferase; Humans; Liver Neoplasms; Male; Middle Aged; Models, Theoretical; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyridines; Sorafenib; Statistics as Topic; UDP-Glucuronosyltransferase 1A9 | 2011 |
Which treatment modality should we choose for advanced hepatocellular carcinoma?
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Cisplatin; Fluorouracil; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Survival Rate | 2010 |
Sequential therapy with JX-594, a targeted oncolytic poxvirus, followed by sorafenib in hepatocellular carcinoma: preclinical and clinical demonstration of combination efficacy.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Female; Hep G2 Cells; Humans; Liver Neoplasms; Melanoma; Mice; Mice, SCID; Niacinamide; Oncolytic Virotherapy; Phenylurea Compounds; Pyridines; Sorafenib; Vaccinia virus; Xenograft Model Antitumor Assays | 2011 |
Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver function.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome | 2011 |
Complete regression of locally advanced hepatocellular carcinoma induced by sorafenib allowing curative resection.
Topics: alpha-Fetoproteins; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Hepatectomy; Humans; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Portal Vein; Protein Kinase Inhibitors; Pyridines; Sorafenib; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Venous Thrombosis | 2011 |
All that glitters: sorafenib.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Fatal Outcome; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Tumor Lysis Syndrome | 2011 |
Sorafenib-induced acute localized exanthematous pustulosis in a patient with hepatocellular carcinoma.
Topics: Acute Generalized Exanthematous Pustulosis; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Drug Eruptions; Female; Humans; Liver Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2011 |
Survival of patients with advanced hepatocellular carcinoma: sorafenib versus other treatments.
Topics: alpha-Fetoproteins; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chi-Square Distribution; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Logistic Models; Male; Middle Aged; Neoplasm Invasiveness; Niacinamide; Patient Selection; Phenylurea Compounds; Propensity Score; Proportional Hazards Models; Protein Kinase Inhibitors; Pyridines; Republic of Korea; Retrospective Studies; Risk Assessment; Risk Factors; Sorafenib; Survival Rate; Time Factors; Treatment Outcome | 2011 |
Oxidative stress and ERK1/2 phosphorylation as predictors of outcome in hepatocellular carcinoma patients treated with sorafenib plus octreotide LAR.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Hepatocellular; Delayed-Action Preparations; Drug Resistance, Neoplasm; Female; Humans; Leukocytes, Mononuclear; Liver Neoplasms; Male; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Niacinamide; Nitric Oxide; Octreotide; Oxidative Stress; Phenylurea Compounds; Phosphorylation; Pyridines; Reactive Oxygen Species; Sorafenib; Superoxide Dismutase; Treatment Outcome | 2011 |
Laryngeal metastasis as first presentation of hepatocellular carcinoma.
Topics: Adenoma, Oxyphilic; Antineoplastic Agents; Biopsy, Fine-Needle; Carcinoma, Hepatocellular; Combined Modality Therapy; Diagnosis, Differential; Diagnostic Imaging; Embolization, Therapeutic; Humans; Laryngeal Neoplasms; Laryngectomy; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Thyroid Neoplasms; Thyroidectomy | 2011 |
microRNA-1274a, a modulator of sorafenib induced a disintegrin and metalloproteinase 9 (ADAM9) down-regulation in hepatocellular carcinoma.
Topics: ADAM Proteins; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Down-Regulation; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Liver Neoplasms; Membrane Proteins; MicroRNAs; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2011 |
The tyrosine kinase inhibitor sorafenib sensitizes hepatocellular carcinoma cells to taxol by suppressing the HURP protein.
Topics: Apoptosis; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Eukaryotic Initiation Factor-4E; Humans; Leupeptins; Liver Neoplasms; Neoplasm Proteins; NF-kappa B; Niacinamide; Paclitaxel; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-rel; Pyridines; Sorafenib | 2011 |
Inhibition of experimental HCC growth in mice by use of the kinase inhibitor DMAT.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Benzimidazoles; Carcinoma, Hepatocellular; Casein Kinase II; Cell Line, Tumor; Cell Proliferation; Cell Survival; Enzyme Activation; Gene Knockdown Techniques; Hep G2 Cells; Humans; Liver Neoplasms; Male; Mice; NF-kappaB-Inducing Kinase; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pyridines; Signal Transduction; Sorafenib; Wnt Proteins; Xenograft Model Antitumor Assays | 2011 |
Design and rationale of the HCC BRIDGE study in China: a longitudinal, multicenter cohort trial in hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; China; Disease Progression; Humans; Liver Neoplasms; Longitudinal Studies; Niacinamide; Phenylurea Compounds; Pyridines; Research Design; Sorafenib | 2011 |
Erythema marginatum hemorrhagicum: a unique cutaneous side effect of sorafenib.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Erythema; Hemorrhage; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Terminology as Topic | 2011 |
Clinical roundtable monograph. Integrating recent data in managing adverse events in the treatment of hepatocellular carcinoma.
Topics: Ablation Techniques; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver; Liver Neoplasms; Liver Transplantation; Niacinamide; Phenylurea Compounds; Postoperative Complications; Pyridines; Risk Factors; Sorafenib | 2010 |
Sorafenib sensitizes hepatocellular carcinoma cells to physiological apoptotic stimuli.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Autocrine Communication; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Gene Knockdown Techniques; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins; Pyridines; Signal Transduction; Sorafenib; Transforming Growth Factor beta; Tumor Necrosis Factor-alpha | 2012 |
The combination of sorafenib with transarterial chemoembolisation for hepatocellular carcinoma.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome | 2011 |
Bufalin enhances the anti-proliferative effect of sorafenib on human hepatocellular carcinoma cells through downregulation of ERK.
Topics: Antineoplastic Agents; Benzenesulfonates; Blotting, Western; Bufanolides; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Chromones; Drug Synergism; Gene Expression Regulation, Enzymologic; Humans; Liver Neoplasms; Microscopy, Electron, Transmission; Morpholines; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2012 |
Neoadjuvant sorafenib combined with gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Deoxycytidine; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Niacinamide; Organoplatinum Compounds; Oxaliplatin; Phenylurea Compounds; Pyridines; Sorafenib | 2011 |
Optimized management of advanced hepatocellular carcinoma: four long-lasting responses to sorafenib.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome | 2011 |
Severe sorafenib-induced hand-foot skin reaction.
Topics: Antineoplastic Agents; Benzenesulfonates; Bone Neoplasms; Carcinoma, Hepatocellular; Clobetasol; Disease Progression; Drug Eruptions; Fatal Outcome; Foot Dermatoses; Hand Dermatoses; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2011 |
Fatal gastric bleeding during sorafenib treatment for hepatocellular carcinoma recurrence after liver transplantation.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Fatal Outcome; Gastrointestinal Hemorrhage; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Stomach Diseases | 2011 |
[In vitro cytotox icity effects of cocultured DC-C IK cells combined with sorafenib against hepa to cellular carcinoma].
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Coculture Techniques; Cytokine-Induced Killer Cells; Cytotoxicity, Immunologic; Dendritic Cells; Humans; Immunotherapy, Adoptive; Liver Neoplasms; Mice; Mice, Nude; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2011 |
An investigation of the effect of sorafenib on tumour growth and recurrence after liver cancer resection in nude mice independent of phosphorylated extracellular signal-regulated kinase levels.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Cell Growth Processes; Cell Line, Tumor; Chemotherapy, Adjuvant; Extracellular Signal-Regulated MAP Kinases; Hep G2 Cells; Humans; Liver Neoplasms; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Pyridines; Sorafenib; Xenograft Model Antitumor Assays | 2011 |
Targeting autophagy enhances sorafenib lethality for hepatocellular carcinoma via ER stress-related apoptosis.
Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Endoplasmic Reticulum; Extracellular Signal-Regulated MAP Kinases; Humans; Liver Neoplasms; Male; MAP Kinase Kinase Kinases; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Pyridines; RNA, Small Interfering; Sorafenib; Time Factors; Treatment Outcome | 2011 |
Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective comparison with previously known prognostic models.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Disease-Free Survival; Female; Hepatitis B, Chronic; Humans; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Retrospective Studies; Severity of Illness Index; Sorafenib; Survival Rate; Young Adult | 2011 |
Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyridines; Retrospective Studies; Sorafenib; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Targeting STAT3 in hepatocellular carcinoma: sorafenib again….
Topics: Animals; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; STAT3 Transcription Factor | 2011 |
Sequential therapy with sunitinib and sorafenib in metastatic hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Progression; Female; Humans; Indoles; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Time Factors; Treatment Outcome | 2012 |
Quinacrine sensitizes hepatocellular carcinoma cells to TRAIL and chemotherapeutic agents.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Camptothecin; Carcinoma, Hepatocellular; Cell Death; Cell Nucleus; Cytoplasm; Deoxycytidine; Doxorubicin; Drug Synergism; Etoposide; Female; Fluorouracil; Gemcitabine; Genes, p53; Humans; Irinotecan; Liver Neoplasms; Mice; Microtubule-Associated Proteins; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-bcl-2; Pyridines; Quinacrine; Receptors, TNF-Related Apoptosis-Inducing Ligand; RNA, Small Interfering; Sorafenib; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2011 |
Proteome analysis of the effects of sorafenib on human hepatocellular carcinoma cell line HepG2.
Topics: Antineoplastic Agents; Blotting, Western; Carcinoma, Hepatocellular; Chromatography, High Pressure Liquid; Electrophoresis, Gel, Two-Dimensional; Gene Expression; Hep G2 Cells; Humans; Immunohistochemistry; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Proteome; Sorafenib; Tandem Mass Spectrometry | 2012 |
Pancreatic endocrine tumors: a report on a patient treated with sorafenib.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Humans; Liver Neoplasms; Male; Neuroendocrine Tumors; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Pyridines; Salvage Therapy; Skin Diseases; Sorafenib; Tomography, X-Ray Computed | 2011 |
Prognostic value of 18F-FDG PET for hepatocellular carcinoma patients treated with sorafenib.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Positron-Emission Tomography; Predictive Value of Tests; Proportional Hazards Models; Protein Kinase Inhibitors; Pyridines; Radiopharmaceuticals; Republic of Korea; Retrospective Studies; Risk Assessment; Risk Factors; Sorafenib; Survival Rate; Time Factors; Treatment Outcome; Young Adult | 2011 |
Coil extrusion from a gastric varice during sorafenib treatment for hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Esophageal and Gastric Varices; Female; Gastrointestinal Hemorrhage; Humans; Liver Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Portasystemic Shunt, Transjugular Intrahepatic; Prosthesis Failure; Pyridines; Sorafenib | 2011 |
Sorafenib therapy for hepatocellular carcinoma prior to liver transplant is associated with increased complications after transplant.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Progression; Female; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pilot Projects; Pyridines; Sorafenib; Time Factors; Treatment Outcome; Waiting Lists | 2011 |
Inhibition of doxorubicin-induced autophagy in hepatocellular carcinoma Hep3B cells by sorafenib--the role of extracellular signal-regulated kinase counteraction.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Autophagy; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin D1; Doxorubicin; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Humans; Liver Neoplasms; MAP Kinase Signaling System; Mitochondria, Liver; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Pyridines; Sorafenib | 2011 |
[Adverse effects of new oncologic therapies].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Cetuximab; Colonic Neoplasms; Diagnosis, Differential; Dose-Response Relationship, Drug; Drug Delivery Systems; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Everolimus; Facial Dermatoses; Humans; Indoles; Liver Neoplasms; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sunitinib; Trastuzumab | 2011 |
Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells.
Topics: Animals; Antineoplastic Agents; Autophagy; Benzenesulfonates; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Synergism; Gene Expression Regulation, Neoplastic; Glutamates; Guanine; Humans; Liver Neoplasms; Mice; Neoplasm Transplantation; Neoplasms; Neovascularization, Pathologic; Niacinamide; Pemetrexed; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2011 |
Synergistic effects of the combination of β-ionone and sorafenib on metastasis of human hepatoma SK-Hep-1 cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Survival; Drug Synergism; Focal Adhesion Protein-Tyrosine Kinases; Humans; Liver Neoplasms; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Neoplasm Invasiveness; Neoplasm Metastasis; Niacinamide; Norisoprenoids; Phenylurea Compounds; Phosphorylation; Pyridines; rac1 GTP-Binding Protein; rho GTP-Binding Proteins; Sorafenib; Tissue Inhibitor of Metalloproteinase-1; Tissue Inhibitor of Metalloproteinase-2 | 2012 |
Des-γ-carboxyprothrombin may be a promising biomarker to determine the therapeutic efficacy of sorafenib for hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Biomarkers; Biomarkers, Tumor; Carcinoma, Hepatocellular; Disease Progression; Female; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein Precursors; Prothrombin; Pyridines; Radiography; Sorafenib; Survival Analysis | 2011 |
Comparing the efficacy of sunitinib with sorafenib in xenograft models of human hepatocellular carcinoma: mechanistic explanation.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Humans; Indoles; Liver Neoplasms; Male; MAP Kinase Signaling System; Mice; Mice, SCID; Neoplasm Proteins; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Random Allocation; Sorafenib; Sunitinib; Xenograft Model Antitumor Assays | 2011 |
Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Apoptosis; Autophagy; Autophagy-Related Protein 7; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chloroquine; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Lysosomes; Mechanistic Target of Rapamycin Complex 1; Mice; Mice, Nude; Microtubule-Associated Proteins; Multiprotein Complexes; Niacinamide; Phenylurea Compounds; Proteins; Pyridines; RNA Interference; RNA, Small Interfering; Sequestosome-1 Protein; Sorafenib; TOR Serine-Threonine Kinases; Ubiquitin-Activating Enzymes; Xenograft Model Antitumor Assays | 2012 |
Polymeric nanoparticle-encapsulated hedgehog pathway inhibitor HPI-1 (NanoHHI) inhibits systemic metastases in an orthotopic model of human hepatocellular carcinoma.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Female; Hedgehog Proteins; Humans; Immunophenotyping; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Nanocapsules; Neoplasm Invasiveness; Neoplasm Metastasis; Niacinamide; Patched Receptors; Patched-1 Receptor; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyridines; Receptors, Cell Surface; Recurrence; Signal Transduction; Sorafenib; Transcription Factors; Zinc Finger Protein GLI1 | 2012 |
Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Retrospective Studies; Severity of Illness Index; Sorafenib; Statistics as Topic; Survival Rate; Tomography, X-Ray Computed | 2011 |
Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Progression; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Italy; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prospective Studies; Pyridines; Sorafenib; Survival Analysis | 2011 |
Using sorafenib for recurrent hepatocellular carcinoma after liver transplantation--interactions between calcineurin inhibitor: two case reports.
Topics: Antineoplastic Agents; Benzenesulfonates; Calcineurin Inhibitors; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Recurrence; Sorafenib | 2011 |
Effect of sorafenib on the energy metabolism of hepatocellular carcinoma cells.
Topics: Adenosine Triphosphate; Aerobiosis; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Respiration; Cell Survival; Energy Metabolism; Glycosylation; Humans; Liver Neoplasms; Niacinamide; Oxidative Phosphorylation; Phenylurea Compounds; Pyridines; Sorafenib | 2011 |
[Clinical characteristics, staging and treatment of patients with hepatocellular carcinoma in clinical practice. Prospective study of 136 patients].
Topics: Aged; Alcoholism; Benzenesulfonates; Carcinoma, Hepatocellular; Comorbidity; Diabetes Mellitus; Early Detection of Cancer; Ethanol; Female; Hepatitis, Viral, Human; HIV Infections; Humans; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasms, Second Primary; Niacinamide; Phenylurea Compounds; Prospective Studies; Pyridines; Sclerotherapy; Sorafenib; Spain | 2011 |
Safety and efficacy of sorafenib in hepatocellular carcinoma: the impact of the Child-Pugh score.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Case-Control Studies; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prospective Studies; Pyridines; Severity of Illness Index; Sorafenib; Survival Rate; Treatment Outcome | 2011 |
Hepatocellular carcinoma presenting with multiple bone and soft tissue metastases and atypical cytomorphological features--a rare case report.
Topics: Aged; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Radiography, Abdominal; Rare Diseases; Soft Tissue Neoplasms; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome | 2013 |
Partial Response and Cardiovascular Recovery after Sorafenib Dose Reduction in a Multinodular HCC Patient.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cardiovascular Diseases; Dose-Response Relationship, Drug; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib | 2012 |
AFP measurement in monitoring treatment response of advanced hepatocellular carcinoma to sorafenib: case report and review of the literature.
Topics: alpha-Fetoproteins; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Hepatocellular; Disease Progression; Dose-Response Relationship, Drug; Humans; Image Processing, Computer-Assisted; Liver; Liver Neoplasms; Male; Middle Aged; Multidetector Computed Tomography; Neoplasm Invasiveness; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Retrospective Studies; Sorafenib; Treatment Outcome | 2011 |
[Gastrointestinal hemorrhage associated with concurrent use of sorafenib and warfarin for hepatocellular carcinoma].
Topics: Anticoagulants; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Drug Therapy, Combination; Gastrointestinal Hemorrhage; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Tomography, X-Ray Computed; Warfarin | 2011 |
Sorafenib, doesn't it have any competitor in advanced hepatocellular carcinoma?
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2011 |
Predicting the treatment effect of sorafenib using serum angiogenesis markers in patients with hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenic Proteins; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cytokines; Disease-Free Survival; Female; Humans; Japan; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Proportional Hazards Models; Protein Kinase Inhibitors; Pyridines; Risk Assessment; Risk Factors; Sorafenib; Survival Rate; Time Factors; Treatment Outcome; Up-Regulation | 2011 |
Sorafenib inhibits growth and metastasis of hepatocellular carcinoma by blocking STAT3.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Enzyme Inhibitors; Extracellular Signal-Regulated MAP Kinases; Humans; Janus Kinase 2; Liver Neoplasms; Male; Mitogen-Activated Protein Kinase Kinases; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Pyridines; Rats; Signal Transduction; Sorafenib; STAT3 Transcription Factor | 2011 |
The effects of sorafenib on the portal hypertensive syndrome in patients with liver cirrhosis and hepatocellular carcinoma--a pilot study.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Humans; Hypertension, Portal; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pilot Projects; Portal Pressure; Protein Kinase Inhibitors; Pyridines; Real-Time Polymerase Chain Reaction; Sorafenib; Syndrome; Treatment Outcome | 2012 |
Patterns of care, prognosis, and survival in patients with metastatic gastrointestinal stromal tumors (GIST) refractory to first-line imatinib and second-line sunitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzenesulfonates; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation; Niacinamide; Phenylurea Compounds; Piperazines; Prognosis; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Retrospective Studies; Risk Factors; Serum Albumin; Sorafenib; Sunitinib; Survival Rate; Young Adult | 2012 |
A new rapid and sensitive LC-MS assay for the determination of sorafenib in plasma: application to a patient undergoing hemodialysis.
Topics: Antineoplastic Agents; Benzenesulfonates; Calibration; Carcinoma, Hepatocellular; Chromatography, High Pressure Liquid; Drug Stability; Fatal Outcome; Humans; Kidney Failure, Chronic; Limit of Detection; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Renal Dialysis; Reproducibility of Results; Solid Phase Extraction; Sorafenib; Spectrometry, Mass, Electrospray Ionization | 2011 |
Hepatic intra-arterial cetuximab in combination with 5-fluorouracil and cisplatin as salvage treatment for sorafenib-refractory hepatocellular carcinoma.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Cetuximab; Cisplatin; Drug Resistance, Neoplasm; Female; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Salvage Therapy; Sorafenib; Treatment Outcome | 2011 |
Early decrease in α-fetoprotein, but not des-γ-carboxy prothrombin, predicts sorafenib efficacy in patients with advanced hepatocellular carcinoma.
Topics: Aged; alpha-Fetoproteins; Antineoplastic Agents; Benzenesulfonates; Biomarkers; Biomarkers, Tumor; Carcinoma, Hepatocellular; Disease Progression; Female; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein Precursors; Prothrombin; Pyridines; Sorafenib | 2011 |
The outcomes and safety of single-agent sorafenib in the treatment of elderly patients with advanced hepatocellular carcinoma (HCC).
Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cohort Studies; Disease-Free Survival; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Retrospective Studies; Sorafenib; Treatment Outcome | 2011 |
SIRT1 promotes tumorigenesis and resistance to chemotherapy in hepatocellular carcinoma and its expression predicts poor prognosis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; alpha-Fetoproteins; Antibiotics, Antineoplastic; Antineoplastic Agents; Benzenesulfonates; beta Catenin; Biomarkers, Tumor; Blotting, Western; Carcinoma, Hepatocellular; Cell Proliferation; Cells, Cultured; Doxorubicin; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Half-Life; Humans; Immunoenzyme Techniques; Immunoprecipitation; Liver Neoplasms; Male; Middle Aged; Mutation; Neoplasm Grading; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Proteolysis; Pyridines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sirtuin 1; Sorafenib; Survival Rate; Young Adult | 2012 |
Novel EGFR-TK inhibitor EKB-569 inhibits hepatocellular carcinoma cell proliferation by AKT and MAPK pathways.
Topics: Aminoquinolines; Aniline Compounds; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Humans; Liver Neoplasms; Mitogen-Activated Protein Kinases; Niacinamide; Phenylurea Compounds; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyridines; Sorafenib | 2011 |
Dovitinib induces apoptosis and overcomes sorafenib resistance in hepatocellular carcinoma through SHP-1-mediated inhibition of STAT3.
Topics: Animals; Apoptosis; Benzenesulfonates; Benzimidazoles; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Male; Mice; Mice, Nude; Molecular Structure; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Pyridines; Quinolones; RNA Interference; Sorafenib; STAT3 Transcription Factor; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
Early evaluation of transcatheter arterial chemoembolization-refractory hepatocellular carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Cohort Studies; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Time Factors; Treatment Failure; Treatment Outcome | 2012 |
[Our experience of the treatment with sorafenib for unresectable hepatocellular carcinoma].
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Tomography, X-Ray Computed | 2011 |
[Three cases of hepatocellular carcinoma without distant metastasis effectively treated by sorafenib].
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Tomography, X-Ray Computed | 2011 |
[The possible role of sorafenib as a part of the multimodal treatment for hepatocellular carcinoma].
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Combined Modality Therapy; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Recurrence; Sorafenib; Tomography, X-Ray Computed | 2011 |
Multidisciplinary management of nonresectable hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Hepatitis B; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome | 2011 |
Treatment algorithm for intermediate and advanced stage hepatocellular carcinoma: Korea.
Topics: Algorithms; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Humans; Liver Neoplasms; Liver Transplantation; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Practice Guidelines as Topic; Pyridines; Republic of Korea; Sorafenib | 2011 |
Complete response of advanced hepatocellular carcinoma with multiple lung metastases treated with sorafenib: a case report.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Remission Induction; Sorafenib; Treatment Outcome | 2011 |
PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Division; Cell Line, Tumor; Drug Synergism; Feedback, Physiological; Furans; Humans; Liver Neoplasms; MAP Kinase Signaling System; Mechanistic Target of Rapamycin Complex 1; Morpholines; Multiprotein Complexes; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proteins; Proto-Oncogene Proteins c-akt; Pyridines; Pyrimidines; Sirolimus; Sorafenib; TOR Serine-Threonine Kinases; Transcription Factors; Triazines | 2012 |
Sorafenib for recurrence of hepatocellular carcinoma after liver transplantation.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Humans; Immunosuppressive Agents; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pyridines; Retrospective Studies; Sirolimus; Sorafenib; Tacrolimus | 2012 |
Blockade of ataxia telangiectasia mutated sensitizes hepatoma cell lines to sorafenib by interfering with Akt signaling.
Topics: Antineoplastic Agents; Ataxia Telangiectasia Mutated Proteins; Benzenesulfonates; Caffeine; Carcinoma, Hepatocellular; Cell Cycle Proteins; Cell Line, Tumor; DNA-Binding Proteins; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-akt; Pyridines; RNA, Small Interfering; Signal Transduction; Sorafenib; Tumor Suppressor Proteins | 2012 |
Sorafenib, risk of bleeding and spontaneous rupture of hepatocellular carcinoma. A clinical case.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Hemorrhage; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Rupture, Spontaneous; Sorafenib | 2011 |
Sorafenib down-regulates c-IAP expression post-transcriptionally in hepatic carcinoma cells to suppress apoptosis.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Down-Regulation; Genes, Reporter; Humans; Inhibitor of Apoptosis Proteins; Liver Neoplasms; Luciferases; Mice; Mice, Inbred C57BL; Niacinamide; Phenylurea Compounds; Protein Biosynthesis; Pyridines; RNA, Messenger; Sorafenib; Transcription, Genetic | 2012 |
Inflammation-based prognostic score for hepatocellular carcinoma patients on sorafenib treatment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Humans; Inflammation; Liver Neoplasms; Male; Middle Aged; Neoplasm Grading; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Severity of Illness Index; Sorafenib | 2012 |
A case of reversible cardiomyopathy associated with sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Cardiomyopathies; Coronary Angiography; Female; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib | 2012 |
Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design.
Topics: Adult; Aged; Aged, 80 and over; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Female; Hepatic Artery; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Research Design; Sorafenib | 2012 |
Hepatic androgen receptor suppresses hepatocellular carcinoma metastasis through modulation of cell migration and anoikis.
Topics: Animals; Anoikis; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Movement; Cell Proliferation; Disease Models, Animal; Disease Progression; Female; Humans; Immunohistochemistry; Liver; Liver Neoplasms; Liver Neoplasms, Experimental; Lung Neoplasms; Male; Mice; Mice, Knockout; Mice, Nude; NF-kappa B; Niacinamide; Phenylurea Compounds; Phosphorylation; Pyridines; Random Allocation; Receptors, Androgen; Sorafenib; Tumor Cells, Cultured | 2012 |
Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib.
Topics: Animals; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Benzenesulfonates; Cadherins; Carcinoma, Hepatocellular; Drug Synergism; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Inhibitor of Apoptosis Proteins; Liver Neoplasms; Niacinamide; Panobinostat; Phenylurea Compounds; Polymorphism, Single Nucleotide; Pyridines; RNA, Messenger; Sorafenib; Survivin; Xenograft Model Antitumor Assays | 2012 |
Sorafenib for hepatocellular carcinoma patients beyond Milan criteria after orthotopic liver transplantation: a case control study.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Case-Control Studies; Chemotherapy, Adjuvant; China; Female; Health Status Indicators; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Retrospective Studies; Sorafenib; Statistics as Topic; Time Factors | 2012 |
Sorafenib dose escalation in the treatment of advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2012 |
Intracranial metastasis from pediatric GI stromal tumor.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzenesulfonates; Brain Neoplasms; Drug Administration Schedule; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Piperazines; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Stomach Neoplasms; Sunitinib; Treatment Outcome | 2012 |
A maxillary mass in a HBV-cirrhotic patient.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Biopsy; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Hepatectomy; Hepatitis B, Chronic; Humans; Immunohistochemistry; Liver Cirrhosis; Liver Neoplasms; Male; Maxillary Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Tomography, X-Ray Computed | 2012 |
TACE with or without systemic therapy?
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Female; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2012 |
Portal hemodynamic effects of sorafenib in patients with advanced hepatocellular carcinoma: a prospective cohort study.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cohort Studies; Female; Hemodynamics; Humans; Liver; Liver Function Tests; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Portal Vein; Prospective Studies; Pyridines; Sorafenib; Treatment Outcome; Ultrasonography, Doppler, Duplex | 2012 |
Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; alpha-Fetoproteins; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Hepatocellular; Drug Monitoring; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Pyridines; Retrospective Studies; Sorafenib; Treatment Outcome | 2012 |
Potential impact of sorafenib on the survival benefit of liver transplantation for hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Liver Transplantation; Male; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2012 |
[Metastatic adrenal necrosis under sorafenib treatment for hepatocellular carcinoma].
Topics: Adrenal Gland Diseases; Adrenal Gland Neoplasms; Adrenal Glands; Antineoplastic Agents; Carcinoma, Hepatocellular; Hemorrhage; Humans; Liver Neoplasms; Male; Middle Aged; Necrosis; Niacinamide; Phenylurea Compounds; Sorafenib | 2013 |
Gemcitabine and oxaliplatin as second-line treatment in patients with hepatocellular carcinoma pre-treated with sorafenib.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Organoplatinum Compounds; Oxaliplatin; Phenylurea Compounds; Sorafenib | 2012 |
Advanced-stage hepatocellular carcinoma: transarterial chemoembolization versus sorafenib.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Chi-Square Distribution; Contrast Media; Disease Progression; Doxorubicin; Ethiodized Oil; Female; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Pyridines; Retrospective Studies; Sorafenib; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
The effects of sorafenib on liver regeneration in a model of partial hepatectomy.
Topics: Animals; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Proliferation; Dose-Response Relationship, Drug; Hepatectomy; Hepatocytes; Liver Cirrhosis; Liver Neoplasms; Liver Regeneration; Male; Mice; Mice, Inbred C57BL; Models, Animal; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2012 |
Sorafenib and bevacizumab for recurrent metastatic hepatoblastoma: stable radiographic disease with decreased AFP.
Topics: alpha-Fetoproteins; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Child, Preschool; Hepatoblastoma; Humans; Liver Neoplasms; Male; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pyridines; Radiography; Sorafenib | 2012 |
EGFR activation is a potential determinant of primary resistance of hepatocellular carcinoma cells to sorafenib.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; RNA Interference; Sorafenib | 2012 |
The use of single-agent sorafenib in the treatment of advanced hepatocellular carcinoma patients with underlying Child-Pugh B liver cirrhosis: a retrospective analysis of efficacy, safety, and survival benefits.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Retrospective Studies; Sorafenib; Young Adult | 2012 |
Intra-arterial infusion of chemotherapy for advanced hepatocellular carcinoma: an Asian perspective.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Female; Humans; Liver Neoplasms; Lung Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2012 |
Sorafenib in combination with transarterial chemoembolization and bronchial arterial chemoinfusion in the treatment of hepatocellular carcinoma with pulmonary metastasis.
Topics: Antineoplastic Agents; Benzenesulfonates; Bronchial Arteries; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Disease-Free Survival; Female; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Retrospective Studies; Sorafenib; Survival Analysis; Treatment Outcome | 2012 |
Applicability of BCLC stage for prognostic stratification in comparison with other staging systems: single centre experience from long-term clinical outcomes of 1717 treatment-naïve patients with hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Child; Female; Hepatitis B; Hepatitis C; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Republic of Korea; ROC Curve; Sorafenib; Treatment Outcome; Young Adult | 2012 |
Sorafenib in advanced hepatocellular carcinoma: hypertension as a potential surrogate marker for efficacy.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Carcinoma, Hepatocellular; Cohort Studies; Databases, Factual; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Hypertension; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Invasiveness; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Retrospective Studies; Risk Assessment; Sorafenib; Statistics, Nonparametric; Survival Analysis; Treatment Outcome | 2013 |
Clinical course of sorafenib treatment in patients with hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Diarrhea; Disease Progression; Fatigue; Female; Hand-Foot Syndrome; Humans; Kaplan-Meier Estimate; Liver Failure; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Pyridines; Retrospective Studies; Sorafenib; Time Factors | 2012 |
Painful leg mass.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Hospice Care; Humans; Kidney Neoplasms; Leg; Liver Neoplasms; Lung Neoplasms; Male; Medication Adherence; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Niacinamide; Pain; Palliative Care; Phenylurea Compounds; Prognosis; Pyridines; Skin Neoplasms; Sorafenib; Tomography, X-Ray Computed | 2012 |
Safety and effectiveness of sorafenib in patients with hepatocellular carcinoma in clinical practice.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Progression; Disease-Free Survival; Female; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Liver Neoplasms; Longitudinal Studies; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Prospective Studies; Pyridines; Radiography; Sorafenib | 2012 |
Activation of JNK and high expression level of CD133 predict a poor response to sorafenib in hepatocellular carcinoma.
Topics: AC133 Antigen; Adult; Aged; Animals; Antigens, CD; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Female; Glycoproteins; Humans; JNK Mitogen-Activated Protein Kinases; Liver Neoplasms; Male; Mice; Mice, Nude; Middle Aged; Neoplasm Transplantation; Niacinamide; Peptides; Phenylurea Compounds; Prognosis; Pyridines; Sorafenib; Transcriptional Activation; Treatment Outcome | 2012 |
Serum insulin-like growth factor-1 levels predict outcomes of patients with advanced hepatocellular carcinoma receiving antiangiogenic therapy.
Topics: Administration, Metronomic; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Carcinoma, Hepatocellular; Clinical Trials as Topic; Deoxycytidine; Fluorouracil; Humans; Insulin-Like Growth Factor I; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Serum; Sorafenib; Tegafur; Treatment Outcome | 2012 |
Combined anti-tumor effects of IFN-α and sorafenib on hepatocellular carcinoma in vitro and in vivo.
Topics: Animals; Antineoplastic Protocols; bcl-X Protein; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Survival; Cyclin A; Cyclin B; Extracellular Signal-Regulated MAP Kinases; Humans; Interferon-alpha; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Pyridines; Sorafenib; STAT1 Transcription Factor; STAT3 Transcription Factor | 2012 |
Erlotinib and sorafenib in an orthotopic rat model of hepatocellular carcinoma.
Topics: Animals; Apoptosis; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Movement; Cell Survival; Drug Therapy, Combination; Endothelial Cells; ErbB Receptors; Erlotinib Hydrochloride; Hep G2 Cells; Humans; Liver Neoplasms; Neoplasm Transplantation; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinazolines; Rats; RNA, Messenger; Sorafenib; Vascular Endothelial Growth Factor A | 2012 |
Appropriate management of cutaneous adverse events maximizes compliance with sorafenib treatment: a single-center experience.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Female; Humans; Kidney Neoplasms; Liver Neoplasms; Male; Medication Adherence; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Skin Diseases; Sorafenib | 2012 |
Sorafenib prevents escape from host immunity in liver cirrhosis patients with advanced hepatocellular carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Count; Female; Humans; Immunity; Japan; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; T-Lymphocytes, Regulatory; Th1 Cells; Th2 Cells; Treatment Outcome | 2012 |
Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Dose-Response Relationship, Drug; Humans; Liver Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Retrospective Studies; Sarcopenia; Sorafenib; Survival Analysis | 2012 |
Contrast-enhanced ultrasonography for evaluating antiangiogenic treatment in hepatocellular carcinoma. A long way from research to clinical practice.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Ultrasonography | 2012 |
The different induction mechanisms of growth arrest DNA damage inducible gene 45 β in human hepatoma cell lines.
Topics: Antigens, Differentiation; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Caspases; Cell Line, Tumor; Cell Survival; E2F1 Transcription Factor; Hep G2 Cells; Humans; Liver Neoplasms; NF-kappa B; Niacinamide; Organoplatinum Compounds; Oxaliplatin; Phenylurea Compounds; Pyridines; S-Adenosylmethionine; Sorafenib; Tumor Suppressor Protein p53 | 2012 |
First interim analysis of the GIDEON (Global Investigation of therapeutic decisions in hepatocellular carcinoma and of its treatment with sorafeNib) non-interventional study.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Decision Making; Female; Humans; Liver Neoplasms; Male; Multicenter Studies as Topic; Niacinamide; Phenylurea Compounds; Professional Practice; Pyridines; Randomized Controlled Trials as Topic; Residence Characteristics; Sorafenib; Specialization | 2012 |
[A case of advanced hepatocellular carcinoma with portal vein invasion successfully treated by sorafenib].
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Hepatitis C, Chronic; Humans; Liver Neoplasms; Male; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Portal Vein; Pyridines; Sorafenib | 2012 |
The efficacy of TACE combined sorafenib in advanced stages hepatocellullar carcinoma.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Retrospective Studies; Sorafenib; Treatment Outcome | 2012 |
Genetic predisposition of hand-foot skin reaction after sorafenib therapy in patients with hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Genetic Predisposition to Disease; Hand-Foot Syndrome; Humans; Korea; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Polymorphism, Single Nucleotide; Pyridines; Sorafenib; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A | 2013 |
Drug-induced lung injury associated with sorafenib: analysis of all-patient post-marketing surveillance in Japan.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Cough; Dyspnea; Female; Fever; Humans; Japan; Liver Neoplasms; Lung; Male; Marketing; Middle Aged; Niacinamide; Phenylurea Compounds; Pulmonary Alveoli; Sorafenib | 2013 |
Treatment Response After Unusual Low Dose Sorafenib: Diagnosis with Perfusion CT and Follow-up in a Patient with Recurrent Hepatocellular Carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Liver Neoplasms; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib; Tomography, X-Ray Computed | 2012 |
The role of PI3K/mTOR inhibition in combination with sorafenib in hepatocellular carcinoma treatment.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Growth Processes; Cell Line, Tumor; Female; Furans; Humans; Liver Neoplasms; Mice; Mice, Nude; Niacinamide; Oncogene Protein v-akt; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Pyridines; Pyrimidines; Signal Transduction; Sorafenib; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2012 |
[Relationship between sorafenib-associated hand-food skin reaction and efficacy in treatment of advanced hepatocellular carcinoma].
Topics: Adult; Aged; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Drug Eruptions; Embolization, Therapeutic; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Retrospective Studies; Sorafenib | 2012 |
MCM7 expression predicts post-operative prognosis for hepatocellular carcinoma.
Topics: Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Cycle Proteins; Cell Line, Tumor; Chemotherapy, Adjuvant; DNA-Binding Proteins; Gene Expression Regulation; Hepatitis B; Humans; Immunohistochemistry; Liver Neoplasms; Minichromosome Maintenance Complex Component 7; Multivariate Analysis; Niacinamide; Nuclear Proteins; Phenylurea Compounds; Prognosis; Pyridines; Sorafenib | 2012 |
The monoclonal antibody CH12 enhances the sorafenib-mediated growth inhibition of hepatocellular carcinoma xenografts expressing epidermal growth factor receptor variant III.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; MAP Kinase Signaling System; Mice; Mice, Nude; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyridines; Sorafenib; STAT3 Transcription Factor; Xenograft Model Antitumor Assays | 2012 |
[Influence of body surface area on efficacy and safety of sorafenib in advanced hepatocellular carcinoma].
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Sorafenib | 2012 |
Molecular mechanisms of sorafenib action in liver cancer cells.
Topics: Apoptosis; Benzenesulfonates; Biological Transport; Carcinoma, Hepatocellular; Cell Adhesion; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA Repair; DNA Replication; Gene Expression Profiling; Humans; Liver Neoplasms; Mitogen-Activated Protein Kinases; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Biosynthesis; Protein Kinase Inhibitors; Pyridines; Signal Transduction; Sorafenib; Transcription, Genetic | 2012 |
Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib.
Topics: Animals; Antineoplastic Agents; beta Catenin; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Line, Tumor; Cluster Analysis; Female; Gene Expression Profiling; Genomics; Hep G2 Cells; Humans; Liver Neoplasms; Mice; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Reproducibility of Results; Sorafenib; Transforming Growth Factor beta; Wnt Proteins; Wnt Signaling Pathway | 2012 |
Regression of hepatocellular carcinoma with right atrial extension after sorafenib and transarterial chemoembolization.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Radiography, Abdominal; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Sorafenib combined with locoregional therapy prior to liver transplantation for hepatocellular carcinoma: an update on a previous case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Combined Modality Therapy; Humans; Liver Neoplasms; Liver Transplantation; Niacinamide; Phenylurea Compounds; Sorafenib; Waiting Lists | 2013 |
Sorafenib reduces hepatic infiltrated regulatory T cells in hepatocellular carcinoma patients by suppressing TGF-beta signal.
Topics: Adult; Aged; Antineoplastic Agents; Blotting, Western; Carcinoma, Hepatocellular; Down-Regulation; Female; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; Leukocytes, Mononuclear; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Signal Transduction; Sorafenib; T-Lymphocytes, Regulatory; Transforming Growth Factor beta | 2013 |
Right sided heart mass reveals hepatocellular carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neoplasms; Male; Neoplastic Cells, Circulating; Niacinamide; Phenylurea Compounds; Sorafenib; Thrombosis | 2012 |
Long-term results of sorafenib in advanced-stage hepatocellular carcinoma: what can we learn from routine clinical practice?
Topics: Aged; Aged, 80 and over; alpha-Fetoproteins; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Diarrhea; Disease Progression; Fatigue; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Radiography; Skin Diseases; Sorafenib; Treatment Outcome | 2012 |
Novel antiangiogenic therapies against advanced hepatocellular carcinoma (HCC).
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Carcinoma, Hepatocellular; Clinical Trials, Phase III as Topic; Humans; Liver Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Sorafenib | 2012 |
Sorafenib use in hepatocellular carcinoma in Japan: early experience and impact on clinical practice.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Japan; Liver Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Risk Factors; Sorafenib; Treatment Outcome | 2012 |
Closing remarks.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Drug Approval; Hepatic Artery; Humans; Infusions, Intra-Arterial; Japan; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2012 |
Current status of hepatocellular carcinoma treatment in Japan: case study and discussion-voting system.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Japan; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Practice Guidelines as Topic; Pyridines; Sorafenib; Time Factors | 2012 |
Sorafenib for non-selected patient population with advanced hepatocellular carcinoma: efficacy and safety data according to liver function.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Treatment Outcome | 2013 |
High toxicity of sorafenib for recurrent hepatocellular carcinoma after liver transplantation.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Bone Neoplasms; Calcineurin Inhibitors; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Liver Transplantation; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Recurrence; Retrospective Studies; Sorafenib; TOR Serine-Threonine Kinases; Treatment Outcome | 2012 |
[Efficacy and safety of sorafenib in the prevention and treatment of hepatocellular carcinoma recurrences after liver transplantation].
Topics: Adolescent; Adult; Aged; Carcinoma, Hepatocellular; Cohort Studies; Female; Humans; Liver Neoplasms; Liver Transplantation; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Treatment Outcome; Young Adult | 2012 |
Evaluation of the mRECIST and α-fetoprotein ratio for stratification of the prognosis of advanced-hepatocellular-carcinoma patients treated with sorafenib.
Topics: Adult; Aged; Aged, 80 and over; alpha-Fetoproteins; Antineoplastic Agents; Benzenesulfonates; Biomarkers; Biomarkers, Tumor; Carcinoma, Hepatocellular; Disease Progression; Female; Follow-Up Studies; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Staging; Niacinamide; Outcome Assessment, Health Care; Phenylurea Compounds; Prognosis; Protein Precursors; Prothrombin; Pyridines; Retrospective Studies; Sorafenib; Survival Rate; Tomography, X-Ray Computed | 2012 |
FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; DNA, Neoplasm; Female; Fibroblast Growth Factor 3; Fibroblast Growth Factor 4; Gene Amplification; Gene Expression Regulation, Neoplastic; Humans; In Vitro Techniques; Incidence; Liver Neoplasms; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Transplantation, Heterologous; Treatment Outcome | 2013 |
The effect of sorafenib treatment on the diabetic status of patients with renal cell or hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Comorbidity; Diabetes Mellitus; Humans; Kidney Neoplasms; Liver Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome | 2012 |
Enhanced erythrocyte membrane exposure of phosphatidylserine following sorafenib treatment: an in vivo and in vitro study.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Death; Cell Size; Ceramides; Erythrocytes; Hemolysis; Humans; Liver Neoplasms; Niacinamide; Oxidative Stress; Phenylurea Compounds; Phosphatidylserines; Protein Kinase Inhibitors; Sorafenib | 2012 |
[Hepatocellular carcinoma - long-term treatable disease].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2012 |
Sorafenib down-regulates expression of HTATIP2 to promote invasiveness and metastasis of orthotopic hepatocellular carcinoma tumors in mice.
Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Disease Models, Animal; Down-Regulation; Hep G2 Cells; Humans; Janus Kinases; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Repressor Proteins; Signal Transduction; Sorafenib; STAT3 Transcription Factor; Transplantation, Heterologous; Tumor Suppressor Proteins | 2012 |
RAF-targeted therapy for hepatocellular carcinoma in the regenerating liver.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Fluorescent Antibody Technique; Hepatectomy; Hepatocytes; Humans; Immunohistochemistry; Liver Neoplasms; Liver Neoplasms, Experimental; Liver Regeneration; Molecular Targeted Therapy; Neoplasm Micrometastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; raf Kinases; Rats; Sorafenib | 2013 |
Sorafenib inhibits hypoxia-inducible factor-1α synthesis: implications for antiangiogenic activity in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Liver Neoplasms; Mice; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phosphorylation; Sorafenib; Transplantation, Heterologous; Vascular Endothelial Growth Factor A | 2012 |
Clinicopathological characteristics of hepatocellular carcinoma in Turkey.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alcoholism; alpha-Fetoproteins; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Hepatocellular; Female; Hepatitis B; Hepatitis C; Humans; Liver; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Retrospective Studies; Risk Factors; Sorafenib; Turkey; Young Adult | 2012 |
[Clinic predictors of efficacy and adverse events of sorafenib therapy for advanced hepatocellular carcinoma patients].
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Treatment Outcome; Young Adult | 2012 |
A needle in a haystack: Identifying biomarkers to personalize systemic therapy in patients with hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Fibroblast Growth Factor 3; Fibroblast Growth Factor 4; Gene Amplification; Humans; Liver Neoplasms; Lung Neoplasms; Male; Niacinamide; Phenylurea Compounds; Sorafenib | 2013 |
Differential effects of arsenic trioxide on chemosensitization in human hepatic tumor and stellate cell lines.
Topics: Adult; AMP-Activated Protein Kinases; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Blotting, Western; Carcinoma, Hepatocellular; Cell Line; Cell Proliferation; Cell Survival; Drug Synergism; Enzyme Activation; Fluorouracil; Gene Expression Regulation, Enzymologic; Growth Inhibitors; Hep G2 Cells; Hepatic Stellate Cells; Humans; Inhibitory Concentration 50; Liver Neoplasms; Niacinamide; Oxides; Phenylurea Compounds; Reverse Transcriptase Polymerase Chain Reaction; Sorafenib; Thymidylate Synthase; Time Factors | 2012 |
Sorafenib for the treatment of recurrent hepatocellular carcinoma after liver transplantation?
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Liver Transplantation; Niacinamide; Phenylurea Compounds; Pyridines; Recurrence; Sorafenib | 2012 |
Sorafenib and its derivative SC-49 sensitize hepatocellular carcinoma cells to CS-1008, a humanized anti-TNFRSF10B (DR5) antibody.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Male; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Receptors, TNF-Related Apoptosis-Inducing Ligand; Sorafenib; STAT3 Transcription Factor; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
Influence of the sorafenib patients assistance program on treatment compliance and overall survival of unresectable hepatocellular carcinoma patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Financial Support; Humans; Indonesia; Kaplan-Meier Estimate; Liver Neoplasms; Male; Medication Adherence; Middle Aged; Niacinamide; Phenylurea Compounds; Program Evaluation; Proportional Hazards Models; Prospective Studies; Sorafenib; Young Adult | 2012 |
Hepatic arterial thrombosis: a critical complication during combination therapy of arterial chemoinfusion and sorafenib.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Thrombosis | 2012 |
Synergistic growth inhibition by sorafenib and vitamin K2 in human hepatocellular carcinoma cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Flow Cytometry; Liver Neoplasms; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Time Factors; Treatment Outcome; Vitamin K 2 | 2012 |
Sorafenib-mediated targeting of the AAA⁺ ATPase p97/VCP leads to disruption of the secretory pathway, endoplasmic reticulum stress, and hepatocellular cancer cell death.
Topics: Adenosine Triphosphatases; Antineoplastic Agents; Apoptosis; Autophagy; Carcinoma, Hepatocellular; Cell Line, Tumor; Endoplasmic Reticulum Stress; Hep G2 Cells; Humans; Liver Neoplasms; MAP Kinase Signaling System; Mitogen-Activated Protein Kinases; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Secretory Pathway; Sorafenib | 2012 |
The placental growth factor as a target against hepatocellular carcinoma in a diethylnitrosamine-induced mouse model.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Hepatocellular; Diethylnitrosamine; Disease Models, Animal; Drug Therapy, Combination; Liver Neoplasms; Mice; Mice, Knockout; Mice, Transgenic; Neoplasm Metastasis; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Placenta Growth Factor; Pregnancy Proteins; Sorafenib; Treatment Outcome | 2013 |
Sustained complete remission of metastatic hepatocellular carcinoma with single agent sorafenib.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Remission Induction; Sorafenib; Tomography, X-Ray Computed | 2013 |
Diarrhea is a positive outcome predictor for sorafenib treatment of advanced hepatocellular carcinoma.
Topics: Aged; Aged, 80 and over; Benzenesulfonates; Carcinoma, Hepatocellular; Diarrhea; Female; Follow-Up Studies; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Nausea; Niacinamide; Phenylurea Compounds; Prospective Studies; Pyridines; Skin Diseases; Sorafenib; Survival Rate; Treatment Outcome; Vomiting | 2013 |
Sorafenib modulates the radio sensitivity of hepatocellular carcinoma cells in vitro in a schedule-dependent manner.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Cell Survival; DNA Damage; DNA Repair; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Radiation Tolerance; Radiation-Sensitizing Agents; Sorafenib | 2012 |
Exploring the efficacy and safety of single-agent sorafenib in a cohort of Italian patients with hepatocellular carcinoma.
Topics: Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Cohort Studies; Disease Progression; Female; Humans; Italy; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Treatment Outcome | 2012 |
The anti-viral effect of sorafenib in hepatitis C-related hepatocellular carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Cohort Studies; Female; Hepatitis C; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome; Viral Load | 2013 |
OPA1 downregulation is involved in sorafenib-induced apoptosis in hepatocellular carcinoma.
Topics: Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cytochromes c; Down-Regulation; Gene Knockdown Techniques; GTP Phosphohydrolases; Humans; Liver; Liver Neoplasms; Mice; Mice, SCID; Mitochondria; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; raf Kinases; ras Proteins; RNA, Small Interfering; Signal Transduction; Sorafenib; Xenograft Model Antitumor Assays | 2013 |
Long-term exposure to sorafenib of liver cancer cells induces resistance with epithelial-to-mesenchymal transition, increased invasion and risk of rebound growth.
Topics: Anilides; Antineoplastic Agents; Cadherins; Carcinoma, Hepatocellular; Cell Line, Tumor; Chromones; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gene Expression Regulation, Neoplastic; Humans; Keratin-19; Liver Neoplasms; Morpholines; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-akt; Pyridines; Sorafenib; Vimentin | 2013 |
Sorafenib and TRAIL have synergistic effect on hepatocellular carcinoma.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Cell Proliferation; Drug Synergism; Humans; Hypoxia; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured | 2013 |
Sorafenib potentiates irradiation effect in hepatocellular carcinoma in vitro and in vivo.
Topics: Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Combined Modality Therapy; DNA Damage; DNA Repair; Female; Liver Neoplasms; MAP Kinase Signaling System; Mice; Mice, Inbred BALB C; NF-kappa B; Niacinamide; Phenylurea Compounds; Phosphorylation; Radiation-Sensitizing Agents; Sorafenib; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2013 |
Sorafenib treatment for recurrent hepatocellular carcinoma after liver transplantation.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Retrospective Studies; Sorafenib; Time Factors; Treatment Outcome | 2012 |
Efficacy, safety, and survival factors for sorafenib treatment in Japanese patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Asian People; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Progression; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Pyridines; raf Kinases; Risk Factors; Safety; Sorafenib; Survival Rate | 2013 |
Evaluation of sorafenib for hepatocellular carcinoma by contrast-enhanced ultrasonography: a pilot study.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Contrast Media; Disease Progression; Ferric Compounds; Humans; Iron; Liver Neoplasms; Male; Middle Aged; Niacinamide; Oxides; Phenylurea Compounds; Pilot Projects; Predictive Value of Tests; Protein Kinase Inhibitors; Sorafenib; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Ultrasonography | 2012 |
Effects of low concentrations of regorafenib and sorafenib on human HCC cell AFP, migration, invasion, and growth in vitro.
Topics: alpha-Fetoproteins; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Movement; Cell Proliferation; Dose-Response Relationship, Drug; Hep G2 Cells; Humans; Liver Neoplasms; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Signal Transduction; Sorafenib; Time Factors | 2013 |
The impact of patient and tumour baseline characteristics on the overall survival of patients with advanced hepatocellular carcinoma treated with sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Prognosis; Retrospective Studies; Severity of Illness Index; Sorafenib; Survival Analysis; Treatment Outcome; Young Adult | 2013 |
Successful treatment of renal cell carcinoma with sorafenib after effective but hepatotoxic sunitinib exposure.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Chemical and Drug Induced Liver Injury; Humans; Indoles; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome | 2013 |
In-vitro growth inhibition of chemotherapy and molecular targeted agents in hepatocellular carcinoma.
Topics: Alanine; alpha-Fetoproteins; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carcinoma, Hepatocellular; Cetuximab; Dasatinib; Doxorubicin; Drug Screening Assays, Antitumor; Epothilones; Gefitinib; Humans; Indoles; Inhibitory Concentration 50; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Pyridones; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thiazoles; Triazines | 2013 |
PTEN enhances the sensitivity of human hepatocellular carcinoma cells to sorafenib.
Topics: Antineoplastic Agents; Apoptosis; Benzenesulfonates; Blotting, Western; Carcinoma, Hepatocellular; Case-Control Studies; Cell Proliferation; Drug Resistance; Flow Cytometry; Humans; Immunoenzyme Techniques; Liver; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; PTEN Phosphohydrolase; Pyridines; Sorafenib; Survival Rate; Tumor Cells, Cultured | 2012 |
Sorafenib for the treatment of unresectable hepatocellular carcinoma in HIV-positive patients.
Topics: Adult; Aged; Antineoplastic Agents; Antiretroviral Therapy, Highly Active; Carcinoma, Hepatocellular; Disease Progression; Female; HIV Infections; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Treatment Outcome | 2013 |
Surgical resection improves the survival of selected hepatocellular carcinoma patients in Barcelona clinic liver cancer stage C.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Cohort Studies; Humans; Liver Neoplasms; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Survival Rate; Taiwan; Treatment Outcome | 2013 |
Immune modulation of effector CD4+ and regulatory T cell function by sorafenib in patients with hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Case-Control Studies; CD4-Positive T-Lymphocytes; Coculture Techniques; Cytokines; Dose-Response Relationship, Immunologic; Enzyme-Linked Immunosorbent Assay; Humans; Interleukin-2 Receptor alpha Subunit; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib; T-Lymphocytes, Regulatory | 2013 |
Targeting late SV40 factor: is the achilles heel of hepatocarcinogenesis revealed?
Topics: Animals; Antineoplastic Agents; Benzodioxoles; Carcinoma, Hepatocellular; Cell Death; Clinical Trials as Topic; DNA-Binding Proteins; Humans; Liver Neoplasms; Niacinamide; Oncogenes; Phenotype; Phenylurea Compounds; Promoter Regions, Genetic; Protein Kinase Inhibitors; Quinolones; Sorafenib; Transcription Factors | 2012 |
Quantification of dynamic contrast-enhanced ultrasound in HCC: prediction of response to a new combination therapy of sorafenib and panobinostat in advanced hepatocellular carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Contrast Media; Fatal Outcome; Humans; Hydroxamic Acids; Indoles; Liver Neoplasms; Male; Neoplasm Staging; Niacinamide; Panobinostat; Phenylurea Compounds; Sorafenib; Ultrasonography | 2012 |
Effect of sorafenib combined with cytostatic agents on hepatoblastoma cell lines and xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Survival; Cisplatin; Cytostatic Agents; DNA Adducts; Enzyme Activation; Female; Hepatoblastoma; Humans; Liver Neoplasms; Mice; Mice, Nude; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Sorafenib; Xenograft Model Antitumor Assays | 2013 |
Activating oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor overcomes sorafenib resistance of hepatocellular carcinoma.
Topics: Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Glycolysis; Humans; Liver Neoplasms; Mice; Niacinamide; Oxidative Phosphorylation; Phenylurea Compounds; Protein Serine-Threonine Kinases; Pyruvate Dehydrogenase Acetyl-Transferring Kinase; Sorafenib; Xenograft Model Antitumor Assays | 2013 |
How to improve treatment outcomes for hepatocellular carcinoma of intermediate and advanced stage.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Sorafenib; Yttrium Radioisotopes | 2012 |
Real-life clinical practice with sorafenib in advanced hepatocellular carcinoma: a single-center experience.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Invasiveness; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Severity of Illness Index; Sorafenib; Survival Rate; Time Factors; Treatment Outcome | 2012 |
[A case of hepatocellular carcinoma treated by resection of metachronous rib metastasis after primary hepatectomy].
Topics: Aged; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Hepatocellular; Combined Modality Therapy; Hepatectomy; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Ribs; Sorafenib | 2012 |
[A case of curative resection for advanced hepatocellular carcinoma with portal vein tumor thrombus after hepatic arterial infusion chemotherapy].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Combined Modality Therapy; Female; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Portal Vein; Sorafenib; Venous Thrombosis | 2012 |
[Therapeutic effects of sorafenib combined with transcatheter arterial chemoembolization and microwave ablation on postsurgical recurrent hepatocellular carcinoma].
Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Combined Modality Therapy; Doxorubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Iodized Oil; Liver Neoplasms; Male; Microwaves; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Remission Induction; Sorafenib; Survival Rate | 2012 |
Cost-effectiveness of sorafenib treatment in field practice for patients with hepatocellular carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Drug Costs; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Markov Chains; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Prospective Studies; Quality-Adjusted Life Years; Sorafenib | 2013 |
Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzylidene Compounds; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Survival; Drug Resistance, Neoplasm; Drug Therapy, Combination; Humans; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; NF-kappa B; Niacinamide; Phenylurea Compounds; Piperidones; Sorafenib; Treatment Outcome; Von Hippel-Lindau Tumor Suppressor Protein; Xenograft Model Antitumor Assays | 2013 |
Hepatocellular carcinoma treated with sorafenib: early detection of treatment response and major adverse events by contrast-enhanced US.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Area Under Curve; Carcinoma, Hepatocellular; Contrast Media; Disease-Free Survival; Female; Ferric Compounds; Humans; Iron; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Oxides; Perfusion Imaging; Phenylurea Compounds; Predictive Value of Tests; Prospective Studies; Protein Kinase Inhibitors; Reproducibility of Results; Sorafenib; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Ultrasonography | 2013 |
Sustained remission over 36 months of advanced hepatocellular carcinoma after short-term sorafenib therapy.
Topics: Adult; Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Remission Induction; Sorafenib | 2013 |
Impact of age on toxicity and efficacy of sorafenib-targeted therapy in cirrhotic patients with hepatocellular carcinoma.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Kaplan-Meier Estimate; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib | 2013 |
The noncytotoxic dose of sorafenib sensitizes Bel-7402/5-FU cells to 5-FU by down-regulating 5-FU-induced Nrf2 expression.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Biomarkers, Tumor; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Dose-Response Relationship, Drug; Down-Regulation; Drug Resistance, Neoplasm; Fluorescent Antibody Technique; Fluorouracil; Humans; Liver Neoplasms; Multidrug Resistance-Associated Proteins; NF-E2-Related Factor 2; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Reverse Transcriptase Polymerase Chain Reaction; Sorafenib | 2013 |
αB-crystallin complexes with 14-3-3ζ to induce epithelial-mesenchymal transition and resistance to sorafenib in hepatocellular carcinoma.
Topics: 14-3-3 Proteins; alpha-Crystallin B Chain; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Humans; Liver Neoplasms; MAP Kinase Signaling System; Neoplasm Invasiveness; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Proteomics; Proto-Oncogene Proteins c-fos; Snail Family Transcription Factors; Sorafenib; Transcription Factors | 2013 |
Clinical value of continuous administration of sorafenib in combination with modified transarterial chemoembolization in patients with unresectable hepatocellular carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Disease-Free Survival; Humans; Liver Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib | 2013 |
Mcl-1-dependent activation of Beclin 1 mediates autophagic cell death induced by sorafenib and SC-59 in hepatocellular carcinoma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Beclin-1; Carcinoma, Hepatocellular; Cell Line, Tumor; Down-Regulation; Hep G2 Cells; Humans; Liver Neoplasms; Membrane Proteins; Mice; Mice, Nude; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Proto-Oncogene Proteins c-bcl-2; RNA Interference; RNA, Small Interfering; Sorafenib; STAT3 Transcription Factor; Transplantation, Heterologous | 2013 |
Early increase in α-fetoprotein for predicting unfavorable clinical outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib.
Topics: Adult; Aged; Aged, 80 and over; alpha-Fetoproteins; Antineoplastic Agents; Biomarkers; Biomarkers, Tumor; Carcinoma, Hepatocellular; Disease Progression; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Protein Precursors; Prothrombin; Retrospective Studies; Sorafenib; Survival Analysis; Time Factors; Treatment Outcome | 2013 |
Speeding up cancer-drug development.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Humans; Kidney Neoplasms; Liver Neoplasms; Multiple Myeloma; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Treatment Outcome | 2006 |
Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Cycle; Cell Death; Cell Line, Tumor; Cell Survival; Extracellular Signal-Regulated MAP Kinases; Humans; Liver Neoplasms; MAP Kinase Kinase Kinases; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; raf Kinases; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Transplantation, Heterologous | 2006 |
Yellow skin discoloration associated with sorafenib use for treatment of metastatic renal cell carcinoma.
Topics: Acrodermatitis; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Erythema; Humans; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pigmentation Disorders; Protein Kinase Inhibitors; Pyridines; raf Kinases; Sorafenib; Spinal Neoplasms | 2007 |
[Chronic lymphocytic leukemia and loss of strength in the right arm--not a typical combination].
Topics: Administration, Oral; Aged; Antineoplastic Agents; Arm; Benzenesulfonates; Bone Neoplasms; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Disease Progression; Humans; Hypesthesia; Indoles; Kidney Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell; Liver Neoplasms; Lung Neoplasms; Magnetic Resonance Imaging; Male; Muscle Weakness; Neoplasms, Second Primary; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Radiography, Abdominal; Radiography, Thoracic; Risk; Risk Factors; Sex Factors; Sorafenib; Splenic Neoplasms; Sunitinib; Time Factors; Tomography, X-Ray Computed | 2007 |
Can sorafenib cause hypothyroidism?
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Islet Cell; Female; Humans; Hypothyroidism; Liver Neoplasms; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Pyridines; Sorafenib | 2007 |
Cancer drug trials show modest benefit: drugs target liver, gastric, head and neck cancers.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Cetuximab; Clinical Trials, Phase III as Topic; Drug Combinations; Head and Neck Neoplasms; Humans; Liver Neoplasms; Niacinamide; Oxonic Acid; Phenylurea Compounds; Pyridines; Sorafenib; Stomach Neoplasms; Tegafur | 2007 |
ASCO 2007: plenary top 5.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Carcinoma, Small Cell; Colorectal Neoplasms; Humans; Kidney Neoplasms; Leukemia, Promyelocytic, Acute; Liver Neoplasms; Lung Neoplasms; Medical Oncology; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Societies, Medical; Sorafenib; United States | 2007 |
Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Hepatocellular; Clinical Trials as Topic; ErbB Receptors; Humans; Indoles; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2008 |
[News in digestive oncology].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cardia; Colonic Neoplasms; Combined Modality Therapy; Digestive System Neoplasms; Esophageal Neoplasms; Humans; Liver Neoplasms; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Pyridines; Sorafenib; Stomach Neoplasms | 2008 |
FDA approves sorafenib for patients with inoperable liver cancer.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Drug Approval; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyridines; Randomized Controlled Trials as Topic; Sorafenib; United States; United States Food and Drug Administration | 2008 |
Blocking transforming growth factor-beta up-regulates E-cadherin and reduces migration and invasion of hepatocellular carcinoma cells.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Cadherins; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Survival; Female; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Transforming Growth Factor beta | 2008 |
[Use of sorafenib (Nexavar) in the treatment of hepatocellular carcinoma: PRODIGE AFEF recommendations].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Protocols; Contraindications; Disease-Free Survival; Humans; Liver Neoplasms; Neoadjuvant Therapy; Niacinamide; Palliative Care; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; raf Kinases; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Remission Induction; Sorafenib; Survival Rate | 2008 |
Safety and activity of sorafenib in different histotypes of advanced renal cell carcinoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bone Neoplasms; Carcinoma, Papillary; Carcinoma, Renal Cell; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Remission Induction; Salvage Therapy; Sorafenib; Survival Rate | 2007 |
[Inhibitory effect of sorafenib combined with arsenic trioxide on hepatocellular carcinoma cells].
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Benzenesulfonates; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Flow Cytometry; Humans; Liver Neoplasms; Membrane Potential, Mitochondrial; Niacinamide; Oxides; Phenylurea Compounds; Pyridines; Sorafenib | 2008 |